staurosporine profile

Staurosporine is a potent and selective inhibitor of protein kinases, a class of enzymes that regulate a wide range of cellular processes. It was originally isolated from the bacterium Streptomyces staurosporeus. Staurosporine has been studied extensively for its potential therapeutic applications in cancer, inflammation, and other diseases. Its broad-spectrum kinase inhibitory activity has made it a valuable tool for investigating the role of protein kinases in cellular signaling pathways. Staurosporine exhibits cytotoxic effects by inducing apoptosis (programmed cell death) and inhibiting cell proliferation. However, its clinical use has been limited due to its toxicity and lack of selectivity. Despite this, Staurosporine has played a significant role in the development of more selective and potent kinase inhibitors that are currently in clinical trials. Staurosporine is a complex molecule with a unique chemical structure, and its synthesis has been a challenging task for chemists. The synthesis of staurosporine involves a series of complex chemical reactions, and several different synthetic routes have been developed over the years. Staurosporine's broad-spectrum kinase inhibitory activity has also led to its use as a research tool in the development of new drugs targeting specific kinases.'

staurosporinium : Conjugate acid of staurosporine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	44259
CHEMBL ID	388978
CHEBI ID	15738
SCHEMBL ID	8157
MeSH ID	M0028755
PubMed CID	7048594
CHEBI ID	57491
MeSH ID	M0028755

Synonym
CBIOL_001978
staurosporin, 4
bdbm2579
(2s,3r,4r,6r)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one
chembl388978 ,
staurosporine, 8
c28h26n4o3
BRD-K17953061-001-02-8
gtpl346
(2s,3r,4r,6r)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-16-one
9,13-epoxy-1h,9h-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)-benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9s-(9alpha,10beta,11beta,13alpha)-
BIO1_001242
BIO1_000264
BIO1_000753
QTL1_000078
BSPBIO_001146
staurosporine & tumor necrosis factor (tnf)
9,13-epoxy-1h,9h-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9s,10r,11r,13r)- & tumor necrosis factor (tnf)
staurosporine & tnf
8,12-epoxy-1h,8h-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-
antibiotic 230
9,13-epoxy-1h,9h-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, [9s-(9alpha,10beta,11beta,13alpha)]-
alkaloid am-2282 from streptomyces
cgp 39360
staurosporin
9,13-epoxy-1h,9h-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9s,10r,11r,13r)- (9ci)
antibiotic am 2282
ccris 3272
am-2282 ,
(+)-staurosporine
CHEBI:15738 ,
(5s,6r,7r,9r)-6-methoxy-5-methyl-7-methylamino-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one
2DQ7
1U59
1XBC
1STC
1Q3D
1YHS
1NVR
1XJD
1SM2
DB02010
2GCD
NCGC00162400-02
NCGC00162400-01
MOLMAP_000047
MEGXM0_000307
NCGC00162400-03
dtxsid6041131 ,
HMS1990J07
antibiotic am-2282
NCGC00162400-06
NCGC00162400-04
NCGC00162400-05
BRD-K17953061-001-10-1
BRD-K17953061-001-08-5
h88epa0a3n ,
unii-h88epa0a3n
BCPP000063
BRD-K17953061-001-04-4
BRD-K17953061-001-11-9
BRD-K17953061-001-05-1
S1421
AKOS015897119
(9s,10r,11r,13r)- 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1h,9h-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-1-one
cgp-39360
staurosporine [mi]
CCG-208052
HY-15141
SCHEMBL8157
[9s-(9?,10?,11?,13?)]-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1h,9h-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one
HB0590
HMS3650B17
sr-00000001485
(5s,6r,7r,9r)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-14-one
NCGC00162400-09
EX-A1777
(5s,6r,7r,9r)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one
HKSZLNNOFSGOKW-FYTWVXJKSA-N
Q5957181
109189-95-9
SR-00000001485-4
T4000
nsc755774
nsc-755774
am2282
am 2282
staurosporin and antibiotic am-2282
AC-35765
(2s,3r,4r,6r)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one
staurosporine ,
2Z7R
staurosporinium cation
staurosporinium
(5s,6r,7r,9r)-6-methoxy-n,5-dimethyl-14-oxo-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-aminium
CHEBI:57491
(5s,6r,7r,9r)-6-methoxy-5-methyl-7-methylazaniumyl-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one
3HMO
3A4O
[(2s,3r,4r,6r)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-methylazanium
Q27124730

Excerpt	Reference	Relevance
" In vitro cytotoxic activities against cancerous (human chronic myelogenous leukemia, K562 and murine metastatic melanoma, B16F10) and healthy non-cancerous (murine fibroblasts, L929 and murine melanocytes, Melan-A) cells showed that, compared to free ligands, both of the metal complexes are more active as anticancer agents at low concentration in cancerous cell lines, but also possessed toxic effect at comparatively higher concentration towards the non-cancerous cells."	( Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines. Demicheli, C; Dittz, D; Frézard, F; Ishfaq, M; Islam, A; Marzano, IM; Paz Lopes, MT; Perreira-Maia, EC; Rodrigues, BL, 2016)	0.43
" We examined in primary cultured hippocampal neurons whether the protein kinases PKC, PKA, CaM-II, and cGMP-dependent protein kinase modified the toxic effects of anoxia and NO."	( Protein kinases modulate the sensitivity of hippocampal neurons to nitric oxide toxicity and anoxia. Boniece, IR; Maiese, K; Skurat, K; Wagner, JA, 1993)	0.29
"It has been proposed that arsenic exerts its toxic effects, in part, by perturbing cellular methyl metabolism."	( Folic acid protects SWV/Fnn embryo fibroblasts against arsenic toxicity. Finnell, RH; Peterson, MH; Ruan, Y; Vorce, RL; Waes, JG; Wauson, EM, 2000)	0.31
" Our goal was to see if the assessment of DNA methylation might be a useful tool, when used in conjunction with initial, basic in vitro tests, to provide a more informative preliminary appraisal of the toxic potential of chemicals to prioritize them for further evaluation."	( The value of DNA methylation analysis in basic, initial toxicity assessments. Cockerell, GL; Goodman, JI; McKim, JM; Watson, RE, 2004)	0.32
" Aβ was toxic to clean cells, resulting in necrotic cell damage."	( Neuroprotective effects of Mycoplasma hyorhinis against amyloid-β-peptide toxicity in SH-SY5Y human neuroblastoma cells are mediated by calpastatin upregulation in the mycoplasma-infected cells. Barnoy, S; Elkind, E; Kornspan, JD; Kosower, NS; Rottem, S; Vaisid, T, 2011)	0.37
" STS was the most potent neurotoxin at killing NSC-34D cells with a toxic concentration at which 50% of maximal cell death is achieved (TC(50)=0."	( Neurotoxic injury pathways in differentiated mouse motor neuron-neuroblastoma hybrid (NSC-34D) cells in vitro--limited effect of riluzole on thapsigargin, but not staurosporine, hydrogen peroxide and homocysteine neurotoxicity. Armstrong, EJ; Brooks, BR; Hemendinger, RA; Radio, N, 2012)	0.38
" In addition, the cells exposed to both compounds, Al and SA, showed evident morphological signals of recovery from the toxic state produced in the presence of Al."	( Effect of salicylic acid on the attenuation of aluminum toxicity in Coffea arabica L. suspension cells: A possible protein phosphorylation signaling pathway. Cab-Guillén, Y; Chan-May, A; Hernández-Sotomayor, SM; Muñoz-Sanchez, JA, 2013)	0.39
" Next, the hiPSC-Hep, primary cryopreserved human hepatocytes (cryo-hHep) and the hepatic cell lines HepaRG and Huh7 were treated with staurosporine and acetaminophen, and the toxic responses were compared."	( Critical differences in toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines and primary hepatocytes. Andersson, TB; Brolén, G; Cotgreave, I; Glinghammar, B; Jonebring, A; Li, XQ; Liljevald, M; Sagemark, J; Sjogren, AK, 2014)	0.4
" Dose reduction owing to toxic effects occurred in 56% of the patients; re-escalation to the starting dose was feasible in 32% of those patients."	( Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. Akin, C; Awan, FT; George, TI; Gotlib, J; Hartmann, K; Hermine, O; Hexner, E; Horny, HP; Huntsman Labed, A; Kluin-Nelemans, HC; Mauro, MJ; Reiter, A; Sotlar, K; Stanek, EJ; Sternberg, DW; Valent, P; Villeneuve, M, 2016)	0.43
"Nausea and vomiting are the most frequent nonhematologic adverse events reported with midostaurin; therefore, administer midostaurin with antiemetics, and recommend taking it with food."	( Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis. Coleman, M; Fechter, L; Galinsky, I, 2019)	0.51
"This review discusses the management of common adverse events (AEs) in patients with advSM who participated in phase 2 clinical studies that led to the approval of midostaurin."	( Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Akin, C; Gotlib, J; Hartmann, K; Kluin-Nelemans, HC; Reiter, A; Valent, P, 2021)	0.62
" Therapy adherence and strategies to mitigate adverse events must be pursued."	( The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia. Bagnato, G; Cerchione, C; Giannini, MB; Marconi, G; Martinelli, G; Mosquera Orgueira, A; Musuraca, G; Simonetti, G, 2021)	0.62
" However, the impact of midostaurin and other FLT3 inhibitors (FLT3i) on cardiovascular adverse events (CAEs) has not been studied in patients who underwent allogeneic hematopoietic stem cell transplantation in a real-world setting."	( Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML. Brandts, C; Bug, G; Cremer, A; Cremer, S; Enssle, JC; Kouidri, K; Lang, F; Pfaff, S; Serve, H; Steffen, B; Zeiher, A, 2023)	0.91

Excerpt	Reference	Relevance
" For certain applications, however, the in vivo half-life of PAC-1 could be limiting."	( Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics. Botham, RC; Dirikolu, L; Fan, TM; Hergenrother, PJ; Roth, HS; Schmid, SC, 2015)	0.42
" When simultaneously administered with vinblastine to P388/ADR-bearing mice, NA-382 maintained significantly higher vinblastine levels in the tumour cells for 24 h and gave a larger area under the time-intracellular vinblastine concentration curve (0 to 24 h) than those receiving vinblastine alone, with long retention of the agent in ascitic fluid."	( Antitumour effects and pharmacokinetics of combination of vinblastine with a staurosporine derivative, NA-382, in P388/ADR-bearing mice. Koga, K; Miyamoto, K; Ohshima, T; Takeda, K; Wakusawa, S, 1995)	0.29
" A limited pharmacokinetic study in mice treated and with I demonstrated that the method is appropriate for this purpose."	( High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma. Beijnen, JH; Boven, E; Havik, E; ten Bokkel Huinink, WW; van Gijn, R; van Tellingen, O; Vermorken, JB, 1995)	0.29
" Following initial adsorption, pharmacokinetic studies demonstrated that Stsp had a half-life of 51."	( High-performance liquid chromatographic analysis of staurosporine in vivo. Its translocation and pharmacokinetics in rats. Bradbury, EM; Gurley, LR; Kim, JM; Lehnert, BE; Umbarger, KO, 1998)	0.3
" These pharmacokinetic parameters were dose-independent in mice and rats."	( Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. Akinaga, S; Akiyama, T; Fuse, E; Kobayashi, H; Kobayashi, S; Kurata, N; Kuwabara, T; Tanii, H; Yamaguchi, K, 1999)	0.3
"The pharmacokinetic studies showed that UCN-01 has a high clearance and large distribution volume in various experimental animals, and its disposition is linear over the range of doses tested."	( Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. Akinaga, S; Akiyama, T; Fuse, E; Kobayashi, H; Kobayashi, S; Kurata, N; Kuwabara, T; Tanii, H; Yamaguchi, K, 1999)	0.3
" Pharmacokinetic analysis under conditions assuming rapid equilibrium of protein binding and incorporating the dissociation rate was conducted."	( Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein. Fuse, E; Hashimoto, A; Kobayashi, S; Kuwabara, T; Sato, N; Sugiyama, Y; Tanii, H, 2000)	0.31
" The pharmacokinetics and lack of conventional toxicity indicate that pharmacodynamic measures may be additionally needed to optimize the drug dose and schedule."	( Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. Balkwill, F; Blackie, R; Braybrooke, JP; Caponigro, F; Dutreix, C; Ganesan, TS; Graf, P; Harris, AL; Kaye, SB; Man, A; McDonald, AC; Propper, DJ; Talbot, DC; Thavasu, P; Twelves, C, 2001)	0.31
" Here, we examined the role of protein binding as a determinant of the pharmacokinetic behavior of UCN-01 in patients."	( Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Acharya, MR; Chen, H; Figg, WD; Headlee, D; Kuwabara, T; Messmann, RA; Murgo, AJ; Sausville, EA; Senderowicz, AM; Sparreboom, A; Venzon, DJ, 2004)	0.32
"The results suggest the following: (1) that extensive binding to AAG may explain, in part, the unique pharmacokinetic profile of UCN-01 described previously with a small volume of distribution and slow systemic clearance, and (2) that measurement of total UCN-01 concentrations in plasma is a poor surrogate for that of the pharmacologically active fraction unbound drug."	( Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Acharya, MR; Chen, H; Figg, WD; Headlee, D; Kuwabara, T; Messmann, RA; Murgo, AJ; Sausville, EA; Senderowicz, AM; Sparreboom, A; Venzon, DJ, 2004)	0.32
" Method validation data are presented on three pharmacodynamic assays that will be utilised during this trial."	( Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Cummings, J; Dive, C; Durkin, J; LaCasse, E; Lefebvre, C; Ranson, M; St-Jean, M; Ward, TH, 2005)	0.33
" Median plasma UCN-01 half-life (T(1/2)) was 405 hours."	( Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Beaulieu, B; Beelen, AP; Eastman, A; Ernstoff, MS; Johnston, N; Lewis, LD; Olszanski, AJ; Perez, RP; Rhodes, CH, 2006)	0.33
" The long half-life (292."	( Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Baker, SD; Carducci, MA; Dancey, J; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, DA; Messersmith, WA; Purcell, T; Rudek, MA, 2008)	0.35
" Pharmacokinetic parameters were determined on days 1 and 28 based on the plasma concentrations of midostaurin and its metabolites, CGP62221 and CGP52421."	( Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus. Graf, P; Kisicki, JC; Schran, H; Wang, Y; Yin, OQ, 2008)	0.35
" The purpose of this study was to develop a mechanism-based population pharmacokinetic model to describe the plasma concentration profiles of midostaurin and its metabolites and to characterize the time course of auto-induction."	( A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. Schran, H; Wang, Y; Yin, OQ, 2008)	0.35
"The population pharmacokinetic model that was developed was able to describe the time-dependent pharmacokinetic profiles of midostaurin and its auto-induction mechanism."	( A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. Schran, H; Wang, Y; Yin, OQ, 2008)	0.35
" A simultaneous pharmacokinetic model of parent and active metabolites was initially developed by incorporating data from in vitro, preclinical, and clinical pharmacokinetic studies in healthy volunteers and in patients with AML or advSM."	( Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. Chun, DY; Dutreix, C; Einolf, HJ; Gu, H; He, H; Ouatas, T; Rebello, S; Wang, L, 2018)	0.48

Excerpt	Reference	Relevance
"Our goal was to determine the cytotoxicity of 7-OH-hydroxystaurosporine (UCN-01) as a single agent and in combination with cis-diamminedichloroplatinum(II) (CDDP) in a panel of ovarian carcinoma cells."	( UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status. Aghajanian, C; Husain, A; Rosales, N; Schwartz, GK; Spriggs, DR; Yan, XJ, 1997)	0.3
" The clinical evaluation of UCN-01 combined with 5-fluoropyrimidines may be of interest."	( Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells. Danenberg, KD; Danenberg, PV; Grem, JL; Kao, V; Nguyen, D, 2002)	0.31
"The recommended phase II dose of PKC412 is 150 mg/day when combined with a continuous infusion of 200 mg/m2/day 5-FU."	( A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Campbell, A; Clark, JW; Deluca, P; Eder, JP; Garcia-Carbonero, R; LoRusso, P; Puchalski, TA; Rothermel, J; Ryan, DP; Supko, JG; Wozniak, A, 2004)	0.32
" This dose-finding phase I study was designed to establish the maximum tolerated dose (MTD) of PKC412 when combined with cisplatin-gemcitabine."	( Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Berthaud, P; Faivre, S; Henriksson, R; Le Chevalier, T; Monnerat, C; Novello, S; Raymond, E, 2004)	0.32
" We designed a phase I clinical trial of FU in combination with UCN-01."	( Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. Gonen, M; Ilson, DI; Kaubisch, A; Kelsen, DP; Kemeny, N; Kortmansky, J; Maki, RG; O'reilly, E; Saltz, LB; Schwartz, GK; Shah, MA; Sowers, R; Tong, W; Weyerbacher, A; Yi, S, 2005)	0.33
"We escalated the weekly FU dose to 2,600 mg/m(2) in combination with once a month infusions of UCN-01."	( Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. Gonen, M; Ilson, DI; Kaubisch, A; Kelsen, DP; Kemeny, N; Kortmansky, J; Maki, RG; O'reilly, E; Saltz, LB; Schwartz, GK; Shah, MA; Sowers, R; Tong, W; Weyerbacher, A; Yi, S, 2005)	0.33
" The recommended phase II dose of FU in combination with monthly UCN-01 is 2,600 mg/m(2)."	( Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. Gonen, M; Ilson, DI; Kaubisch, A; Kelsen, DP; Kemeny, N; Kortmansky, J; Maki, RG; O'reilly, E; Saltz, LB; Schwartz, GK; Shah, MA; Sowers, R; Tong, W; Weyerbacher, A; Yi, S, 2005)	0.33
" Therefore, we evaluated a pilot clinical trial of ara-C in combination with UCN-01 in patients with relapsed AML."	( Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Andreeff, M; Cortes, J; Du, M; Estrov, Z; Gandhi, V; Plunkett, W; Sampath, D; Shi, Z, 2006)	0.33
"APC and SN-38 exposure decreased when administered in combination with UCN-01."	( Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Baker, SD; Carducci, MA; Dancey, J; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, DA; Messersmith, WA; Purcell, T; Rudek, MA, 2008)	0.35
" Two different CCMS setups, CCMS technology combined with 1D LC-MS and 2D LC-MS, were compared regarding the total number of kinase identifications."	( Improvement of capture compound mass spectrometry technology (CCMS) for the profiling of human kinases by combination with 2D LC-MS/MS. Baumgart, S; Dreger, M; Fischer, JJ; Glinski, M; Graebner, O; Koester, H, 2011)	0.37
" UCN-01, a non-selective Chk1 inhibitor, combined with irinotecan demonstrated activity in advanced TNBC in our Phase I study."	( A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Bernard, PS; Brenin, CM; Cai, SR; Craig Lockhart, A; Creekmore, AN; Dancey, J; Doyle, LA; Ebbert, M; Ellis, MJ; Fracasso, PM; Guo, Z; Ma, CX; Mwandoro, T; Naughton, MJ; Petroni, GR; Picus, J; Piwnica-Worms, H; Pluard, TJ; Reed, J; Ryan, CE; Watson, M; Yarde, ER, 2013)	0.39
" Here, we address the clinical relevance of CYP3A4-related drug-drug interactions with midostaurin as either a "victim" or "perpetrator."	( Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Dutreix, C; Lorenzo, S; Munarini, F; Roesel, J; Wang, Y, 2013)	0.39
" Although knowledge of drug suppression is vital to avoid efficacy-reducing drug interactions or discover countermeasures for chemical toxins, drug-drug suppression relationships have not been systematically mapped."	( Large-scale identification and analysis of suppressive drug interactions. Akhmedov, M; Cansever, D; Cetiner, S; Cokol, M; Doak, A; Giaever, G; Guvenek, A; Iossifov, I; Li, S; Mutlu, B; Nislow, C; Rodriguez-Esteban, R; Roth, FP; Shoichet, B; Tasan, M; Weinstein, ZB; Yilancioglu, K, 2014)	0.4
" This midostaurin drug-drug interaction study assessed the dynamic response and clinical usefulness of urinary 6β-hydroxycortisol to cortisol ratio (6βCR) and plasma 4β-hydroxycholesterol (4βHC) for monitoring CYP3A4 activity in the presence or absence of rifampicin, a strong CYP3A4 inducer."	( Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. Dutreix, C; Lorenzo, S; Wang, Y, 2014)	0.4
"The ability of Tetra-O-methyl nordihydroguaiaretic acid (M4N) to induce rapid cell death in combination with Etoposide, Rapamycin, or UCN-01 was examined in LNCaP cells, both in cell culture and animal experiments."	( Tetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01. Huang, RC; Kimura, K, 2016)	0.43
" In vitro and clinical drug-drug interaction (DDI) studies indicated that midostaurin and its metabolites are substrates, reversible and time-dependent inhibitors, and inducers of CYP3A4."	( Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. Chun, DY; Dutreix, C; Einolf, HJ; Gu, H; He, H; Ouatas, T; Rebello, S; Wang, L, 2018)	0.48
"To evaluate the efficacy and safety of midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.48
"Clinical trials evaluating the efficacy and safety of midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation were reviewed for the treatment of newly diagnosed FLT3-mutated AML."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.48
" A phase III trial illustrated that midostaurin in combination with standard chemotherapy improved event-free survival, disease-free survival, and overall survival in patients with newly diagnosed FLT3-mutation-positive AML compared with standard chemotherapy alone."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.48
"Midostaurin in combination with standard induction and consolidation is safe and efficacious in newly diagnosed FLT3-mutated AML."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.48
"Cancer therapy with tyrosine kinase inhibitors (TKIs) is a rapidly developing field, and several TKIs have been reported to have an impact on the activities of UDP-glucosyltransferases (UGTs), implying a potential risk for drug-drug interaction (DDI)."	( Inhibition of human UDP-glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug-drug interactions. Cao, J; Feng, Y; Jia, Y; Jiang, L; Liu, Y; Wang, X; Wang, Z; Yin, H, 2020)	0.56
" These targeted therapies could be more tolerable than classical antineoplastics, but potential drug-drug interactions (DDI) are relatively frequent."	( Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Ballesta-López, O; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Solana-Altabella, A, 2020)	0.56
", antifungal azoles) may result in drug-drug interactions."	( Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML). Grosch, K; Ouatas, T; Pathak, D; Sechaud, R; Sinclair, K, 2022)	0.72

Excerpt	Reference	Relevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."	( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011)	0.37
" We report here URMC-099 (1) an orally bioavailable (F = 41%), potent (IC50 = 14 nM) MLK3 inhibitor with excellent brain exposure in mouse PK models and minimal interference with key human CYP450 enzymes or hERG channels."	( Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. Dewhurst, S; Gelbard, HA; Goodfellow, VS; Loweth, CJ; Marker, DF; Nguyen, T; Polesskaya, O; Pollack, S; Ravula, SB; Sheppard, D; Todd, DE; Wiemann, T; Xu, Y, 2013)	0.39
" Pharmacokinetic study with 12b·HCl in rats showed an oral bioavailability of 51% with high systemic exposure (AUC) of 1426 ng × h/mL and maximum plasma concentration (Cmax) of 1620 ng/mL."	( Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/ Jin, CH; Kim, DK; Krishnaiah, M; Lee, HJ; Lee, K; Park, HJ; Park, SJ; Rao, KS; Sheen, YY; Sreenu, D; Subrahmanyam, VB, 2014)	0.4
" Moreover, hERG and BBB-PAMPA assays presented safe cardiotoxicity and high CNS bioavailability profiles for 5x."	( Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction. Elkamhawy, A; Hassan, AHE; Lee, J; Moon, B; Pae, AN; Park, BG; Park, HM; Park, JE; Ra, H; Roh, EJ, 2017)	0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The other therapies like hormonal therapy, surgery, radiotherapy, and immune therapy are in use but showed many side effects like bioavailability issues, non-selectivity, pharmacokinetic-pharmacodynamic problems."	( Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies. Arya, GC; Jaitak, V; Kaur, K, 2021)	0.62
" The AUC value was 15 micrograms min ml-1, giving a value for bioavailability of 13%."	( Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. Hill, DL; Posey, CF; Rose, LM; Tillery, KF, 1994)	0.29
"These data indicate that PKC412 (and possibly PTK787) has appropriate activity and sufficient intraocular bioavailability after oral administration to prevent retinal detachment in models of proliferative retinopathy."	( The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies. Campochiaro, PA; Melia, M; Saishin, Y; Seo, MS; Takahashi, K, 2003)	0.32
" Amongst recently developed tyrosine kinase inhibitors of FLT3, lestaurtinib and midostaurin are two orally bioavailable agents that have shown encouraging activity, both preclinically and in relapsed AML, and are now in phase III clinical trials."	( FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Burnett, A; Lo-Coco, F; Löwenberg, B; Sanz, M, 2009)	0.35

Excerpt	Relevance	Reference
" The dose-response curves to PMA for decreasing the activities of PKC 1 and 2 were shifted to the right by the potent and selective PKC inhibitors, staurosporine and calphostin-C."	( Staurosporine and calphostin-C inhibit the phorbol ester-induced decrease of protein kinase C activity in rat hepatocytes. García-Sáinz, JA; López-Gómez, FJ; Robles-Flores, M, 1992)	0.28
" Depletion of PKC by prolonged incubation with phorbol esters also inhibited phagocytosis, and dose-response curves showed a strong correlation between the extent of PKC depletion and the extent of inhibition of ingestion."	( Immunoglobulin-mediated phagocytosis by human monocytes requires protein kinase C activation. Evidence for protein kinase C translocation to phagosomes. Brown, EJ; Zheleznyak, A, 1992)	0.28
" Dose-response and time-course studies revealed that TPA (10(-8) M) acutely increased GnRH secretion 3-fold at 3-6 h, which then declined to baseline at 24 h, while it progressively decreased GnRH mRNA levels by 50% and 70% at 6 and 24 h, respectively."	( Phorbol ester activation of the protein kinase C pathway inhibits gonadotropin-releasing hormone gene expression. Bruder, JM; Krebs, WD; Nett, TM; Wierman, ME, 1992)	0.28
" Dose-response curves demonstrated that H-7 is the most effective among the inhibitors, and the transepithelial resistance was 70% of control up to 1 h after calcium removal."	( Protein kinase inhibitors prevent junction dissociation induced by low extracellular calcium in MDCK epithelial cells. Citi, S, 1992)	0.28
" Normal functional coupling of m2, m4, alpha 2, and D2 receptors was demonstrated by their ability to inhibit forskolin-stimulated cAMP accumulation with dose-response activities consistent with previous reports for these Gi-coupled receptors."	( A transduction pathway associated with receptors coupled to the inhibitory guanine nucleotide binding protein Gi that amplifies ATP-mediated arachidonic acid release. Axelrod, J; Felder, CC; Williams, HL, 1991)	0.28
" The ED50 value for the dose-response curves to B-HT 920 and St587 were found to be significantly increased after the administration of staurosporine."	( Effects of staurosporine on the pressor responses to alpha-adrenoceptor agonists in pithed rats: a comparison with nifedipine. Tabrizchi, R; Triggle, CR, 1991)	0.28
" PDGF displays a steep dose-response relationship in the 1-5 ng/ml range."	( Activation of signal transduction pathways protects quiescent Balb/c-3T3 fibroblasts against death due to serum deprivation. Kikuchi, T; Tamm, I, 1991)	0.28
"The temporal and dose-response relationships of platelet-activating-factor (PAF)-induced changes in the concentrations of cytosolic Ca2+ ([Ca2+]i), Ins(1,4,5)P3 and 1,2-diacylglycerol (DAG) were examined."	( The relationship between cytosolic Ca2+, sn-1,2-diacylglycerol and inositol 1,4,5-trisphosphate elevation in platelet-activating-factor-stimulated rabbit platelets. Influence of protein kinase C on production of signal molecules. Elmore, M; Kellie, S; Murphy, CT; Westwick, J, 1991)	0.28
" The time course and dose-response for the effect of PMA at 23 degrees C closely correlate with the phosphorylation of a set of relatively "slowly" phosphorylated proteins (P20, P35, P41, P60), but not the rapidly phosphorylated P47 protein."	( Synergistic release of arachidonic acid from platelets by activators of protein kinase C and Ca2+ ionophores. Evidence for the role of protein phosphorylation in the activation of phospholipase A2 and independence from the Na+/H+ exchanger. Banga, HS; Feinstein, MB; Halenda, SP; Lau, LF; Zavoico, GB, 1989)	0.28
" In contrast to the discrepancy in Tyrphostin dose-response curves, titration curves for 5-(N-ethyl-n-isopropyl)amiloride and 5-(N,N-hexamethylene)amiloride are comparable in SF- or GM-CSF-stimulated cells."	( Product of the steel locus suppresses apoptosis in hemopoietic cells. Comparison with pathways activated by granulocyte macrophage colony-stimulating factor. Cáceres-Cortés, J; Dumouchel, J; Haddad, P; Hoang, T; Rajotte, D, 1994)	0.29
" In combined intraperitoneal injection with vinblastine (200 micrograms kg-1) into P388/ADR-bearing mice, NA-382 in a suspension form (10 mg kg-1) prolonged the life-span of the mice near to that of P388/S-bearing mice treated with vinblastine alone, but verapamil even at the maximum tolerated dosage (30 mg kg-1) barely affected the in-vivo antitumour effect of vinblastine."	( Antitumour effects and pharmacokinetics of combination of vinblastine with a staurosporine derivative, NA-382, in P388/ADR-bearing mice. Koga, K; Miyamoto, K; Ohshima, T; Takeda, K; Wakusawa, S, 1995)	0.29
" The dose-response curves defining the TPA-dependent suppression of EROD induction and PKC down-regulation were very similar, as were the initial kinetics of PKC loss and the times of TPA pretreatment required for suppression of EROD induction."	( Suppression of cytochrome P450 Cyp1a-1 induction in murine hepatoma 1c1c7 cells by 12-O-tetradecanoylphorbol-13-acetate and inhibitors of protein kinase C. Bischer, P; Cantu, AR; Pavone, A; Reiners, JJ; Schöller, A, 1993)	0.29
" Those cultured from Stage 11c showed similar dose-response to those cultured from Stage 11b except that the incidence of secondary somites formation was much higher."	( Staurosporine does not prevent adrenergic-induced situs inversus, but causes a unique syndrome of defects in rat embryos grown in culture. Baden, JM; Fujinaga, M; Mirkes, PE; Park, HW; Shepard, TH, 1994)	0.29
" In dose-response experiments, NGFI-A and c-fos gene activation parallels the induction of death in LNCaP cells."	( Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells. Day, ML; Humphrey, PA; Swanson, PE; Wu, S; Zhao, X, 1994)	0.29
" For mice dosed intravenously, subcutaneously, or by oral gavage with this compound, the maximum tolerated doses (MTD) were 20, 10, and > 100 mg/kg, respectively."	( Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. Hill, DL; Posey, CF; Rose, LM; Tillery, KF, 1994)	0.29
"The dose-response curves for the inhibition of equilibrative uridine transport by dilazep, dipyridamole and nitrobenzylthioinosine (NBMPR) in undifferentiated HL-60 cells were biphasic."	( Decrease in equilibrative uridine transport during monocytic differentiation of HL-60 leukaemia: involvement of protein kinase C. Lee, CW, 1994)	0.29
" The dose-response of insulin effect shows a behavior typical of other insulin responses: a maximum in the physiological range (1 nM) and smaller effects at higher and lower hormone concentrations."	( Modulation of the Na-H antiport by insulin: interplay between protein kinase C, tyrosine kinase, and protein phosphatases. Baldini, P; Bellucci, V; Incerpi, S; Luly, P; Zannetti, A, 1994)	0.29
" TPA markedly enhanced both haptotactic response to type-IV collagen and motility on tissue-culture glass substrate of L-10 cells in a dose-response manner quite similar to that of TPA-enhanced invasion of Matrigel."	( TPA-enhanced invasion of Matrigel associated with augmentation of cell motility but not metalloproteinase activity in a highly metastatic variant (L-10) of human rectal adenocarcinoma cell line RCM-1. Hayakawa, T; Inoue, T; Kishi, J; Koita, H; Komada, N; Koono, M; Nabeshima, K, 1993)	0.29
" Staurosporin potentiated Ca(2+)-induced Peth formation by shifting the [Ca2+]cyt dose-response curve to the left."	( The role of cytosolic Ca2+, protein kinase C, and protein kinase A in hormonal stimulation of phospholipase D in rat hepatocytes. Benistant, C; Gustavsson, L; Hoek, JB; Moehren, G; Rubin, R; Torres-Marquez, ME, 1994)	0.29
" In addition, treatment of FLC with staurosporine prevented the induction of IFN-stimulated genes and the establishment of the antiviral state only when this drug was used at high dosage (500 nM)."	( Staurosporine inhibits interferon alpha-induced gene expression in Friend erythroleukemia cells through a PKC independent pathway. Affabris, E; Fiorucci, G; Mangino, G; Marcolin, C; Percario, ZA; Romeo, G, )	0.13
" To gain insight into the mechanism of deoxyadenosine toxicity, we investigated the dose-response and time course of its toxic effects on concanavalin A-stimulated mouse splenic lymphocytes by thymidine incorporation and flow cytometry."	( Deoxyadenosine blockade of G0 to G1 transition in lymphocytes: possible involvement of protein kinases. Chan, TS; Sato, T, 1996)	0.29
" While fMLP exerted similar effects in both populations, dose-response curves for SP1 NKA and the NK2 receptor agonist were shifted leftwards (1, 4 and 3 orders of magnitude, respectively) in sensitized AMs."	( Modulation by protein kinase C of the enhanced responsiveness to tachykinins in ovalbumin-sensitized guinea pig alveolar macrophages. Brunelleschi, S; Fantozzi, R; Guidotto, S; Tonso, E; Viano, I, 1996)	0.29
"Treated with low dosage (5 ng."	( [Protein kinase inhibitor staurosporine enhances cytotoxicity of antitumor drugs to cancer cells]. Fang, M; Wang, RH; Xue, SB; Zhang, HQ, 1996)	0.29
" PDBu did not affect the dose-response relation of NE in Mn-loaded preparations."	( Effects of phorbol-12,13-dibutyrate and protein kinase C inhibitors on Mn(2+)-dependent norepinephrine-induced contractions involving increase in Mn2+ sensitivity in Ca(2+)-depleted vas deferens of the guinea pig. Gomi, Y; Tsunobuchi-Ushijima, H, 1997)	0.3
"Treated with low dosage staurosporine, the normal cell 2 BS were arrested in G 1 phase, but tumor cell BGC-823 were not."	( [Changes of intracellular calcium, calmodulin in normal and tumor cells traggered by staurosporine]. Fang, M; Wang, RH; Xue, SB, 1996)	0.29
" Cytotoxicity was determined from dose-response curves established by the Alamar blue vital dye indicator assay."	( UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status. Aghajanian, C; Husain, A; Rosales, N; Schwartz, GK; Spriggs, DR; Yan, XJ, 1997)	0.3
" Comparison of the dose-response curves between TPA-induced hydrogen (H+) secretion, as measured by aminopyrine (AP) uptake, and the membrane-associated PKC-alpha suggests that translocation of PKC-alpha is not involved in the H+ secretory process in PC."	( Expression and characterization of protein kinase C in isolated rabbit parietal cells. Kim, SW; Levine, RA; Loo, A; Nandi, J, 1999)	0.3
" Thrombin-stimulated platelets contained not only the three major proteins: actin (43 kDa), myosin (200 kDa) and an actin-binding protein (250 kDa), but three additional proteins of Mr56 kDa, 80 kDa and 85 kDa in the cytoskeleton, which were induced in by thrombin dose-response relationship."	( Cytoskeletal changes in platelets induced by thrombin and phorbol myristate acetate (PMA). Chen, R; Liang, N, 1998)	0.3
" We investigated the dose-response relationship for each alcohol and determined that the order of potency was methanol < EtOH << octanol, with EC(50) values of 291 mM, 39."	( Effect of ethanol upon respiratory-related hypoglossal nerve output of neonatal rat brain stem slices. Berger, AJ; Gibson, IC, 2000)	0.31
" However, a longer dosing period of UCN-01 increased the residence time in comparison with the shorter infusion."	( The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs. Imabeppu, S; Kobayashi, H; Kobayashi, S; Kurata, N; Kuwabara, T; Nitoh, M, 2000)	0.31
" MT, like PMA, evoked a leftward shift of the dose-response curve for the STZ-induced [Ca(2)+](i) rise, indicating PKC-dependent sensitization of neutrophils for stimulation by STZ."	( Nutritional lipid emulsions modulate cellular signaling and activation of human neutrophils. Naber, T; van Emst-De Vries, S; Wanten, G; Willems, P, 2001)	0.31
"The features of apoptotic dose responses typically have been evaluated over a broad dose-response continuum to differentiate apoptotic and necrotic responses."	( Apoptosis: biphasic dose responses. Calabrese, EJ, 2001)	0.31
" There is a progressive dose-response relationship with 10(-8), 10(-7), and 10(-6) M RA."	( Retinoic acid causes MEK-dependent RAF phosphorylation through RARalpha plus RXR activation in HL-60 cells. Hong, HY; Varvayanis, S; Yen, A, 2001)	0.31
" Further investigation into flavopiridol as a clinical agent should focus on alternative dosing schedules and the compound's potential use in combination chemotherapeutic regimens."	( Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Howard, OM; Kim, HH; Lin, TS; Neuberg, DS; Shipp, MA, 2002)	0.31
" Rightward shift of the dose-response curves due to coinfusion of inhibitors served to assess contribution of different pathways: trimethoxybenzoate (TMB-8) against Ca2+ mobilization, nifedipine against Ca2+ influx, staurosporine and Ro-318220 against PKC, and Y-27632 and HA-1077 against ROK."	( Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat. Bauer, J; Parekh, N, 2003)	0.32
" They shifted dose-response curves of Ang II, norepinephrine, and AVP to sevenfold and higher values."	( Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat. Bauer, J; Parekh, N, 2003)	0.32
"The model of 6-day dosed heat adaptation was developed on cultured rat H9c2 cardiomyoblasts and mouse C2c12 myoblasts."	( Direct and cross-protective effects of heat adaptation in cultured cells. Andreeva, LV; Duchen, MR; Malyshev, IY; Manukhina, EB; Monastyrskaya, EA, 2003)	0.32
" Complete nutrient deprivation alone and staurosporine independently induced significant apoptosis, the latter in a dose-response way."	( Apoptosis of hippocampal neurons in organotypic slice culture models: direct effect of bacteria revisited. Gianinazzi, C; Grandgirard, D; Imboden, H; Joss, P; Leib, SL; Simon, F; Täuber, MG, 2004)	0.32
"25 mumol/L UCN-01, glucose transport is inhibited 66, 29, and 26% at insulin concentrations of 10, 50, and 100,000 (100K) microunits/mL respectively, thus shifting the dose-response curve to the right."	( 7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Cushman, SW; Kondapaka, SB; Sausville, EA; Yver, DR; Zarnowski, M, 2004)	0.32
" The cumulative dose-response curve of SMA to NE and Ca2+ after shock was shifted to the right."	( The role of calcium desensitization in vascular hyporeactivity and its regulation after hemorrhagic shock in the rat. Liu, L; Xu, J, 2005)	0.33
" Dose-response curves to the Ca(2+) ionophore A-23187 and to the calmodulin/myosin light chain kinase inhibitor W-7 served to study Ca(2+)-dependent pathways."	( Both Ca2+ -dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Bisschops, R; Cassiman, D; Fevery, J; Laleman, W; Nevens, F; Roskams, T; Severi, T; Van Landeghem, L; Van Pelt, J; Vander Elst, I; Zeegers, M, 2007)	0.34
" Cell proliferation was determined from dose-response curves."	( AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation. Jane, EP; Pollack, IF; Premkumar, DR, 2007)	0.34
" Thus it may be useful for designing an appropriate dosage regimen for midostaurin."	( A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. Schran, H; Wang, Y; Yin, OQ, 2008)	0.35
" The 1 mM dosage of homocysteine in staurosporine-differentiated RGC-5 cells also did not induce cell death above control levels, although 18 hr treatment of non-differentiated RGC-5 cells with 5 mM homocysteine decreased survival by 50%."	( Sensitivity of staurosporine-induced differentiated RGC-5 cells to homocysteine. Allen, JB; Bozard, BR; Dun, Y; Duplantier, J; Farooq, A; Ganapathy, PS; Ha, Y; Smith, SB, 2010)	0.36
" Our results suggest that the dosage of chemical autophagy inducers would obviously influence autophagic flux in cells."	( Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells. Chen, Y; Deng, X; Fang, Z; Lin, J; Sheng, F; Wei, Y; Xia, B; Zhong, W; Zhou, C; Zhou, J, 2012)	0.38
" The overall responses to anticancer agents and resulting pharmacological dose-response profiles were not affected by the growth of tumor cells in the presence DRAQ7."	( Real-time cell viability assays using a new anthracycline derivative DRAQ7®. Akagi, J; Darzynkiewicz, Z; Dobrucki, J; Errington, R; Kordon, M; Matuszek, A; Smith, PJ; Takeda, K; Wlodkowic, D; Zhao, H, 2013)	0.39
" However, these inhibitors have yet to prove clinically efficacious, and their toxicity in skin, reflecting activity against wild-type EGFR, may limit dosing required to effectively suppress EGFR T790M in vivo."	( Noncovalent wild-type-sparing inhibitors of EGFR T790M. Chan, E; Heffron, TP; La, H; Lee, HJ; Malek, S; Merchant, M; Pirazzoli, V; Politi, K; Schaefer, G; Settleman, J; Shao, L; Sideris, S; Ubhayakar, S; Yauch, RL; Ye, X, 2013)	0.39
" The results of this study help to understand the earliest mechanisms of apoptosis induction in cells, enabling new methods of drug testing and dose-response analyses."	( High temporal resolution fluorescence measurements of a mitochondrial dye for detection of early stage apoptosis. Iyer, D; Pappas, D; Ray, RD, 2013)	0.39
" Pharmacokinetic data showed that the 25 mg dosing of midostaurin achieved therapeutic levels with no significant interaction between midostaurin and ATRA."	( Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P, 2014)	0.4
" Induction chemotherapy with 7 + 3, the combination of continuous-infusion cytarabine and intermittent dosing of an anthracycline administered over 7 and 3 days, respectively, has remained the standard of care since its introduction in 1973 in the United States."	( Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia. Pollyea, DA; Stansfield, LC, 2017)	0.46
"2 observed ratio) after daily dosing of midostaurin for 4 days."	( Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. Chun, DY; Dutreix, C; Einolf, HJ; Gu, H; He, H; Ouatas, T; Rebello, S; Wang, L, 2018)	0.48
"Multiple cycles of azacitidine and midostaurin were not well-tolerated, but persistent inhibition of FLT3 wild-type phosphorylation suggest intermittent dosing of midostaurin should be considered in future low-intensity regimens for FLT3-mutant AML."	( A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. Cooper, BW; Craig, MD; Gallogly, MM; Kane, DM; Lazarus, HM; Levis, MJ; Metheny, L; Tomlinson, BK; William, BM, 2020)	0.56
" We enumerate the practical issues faced in the use of midostaurin like antifungal prophylaxis, dosage of concomitant chemotherapy agents as well as available data on sequencing of the FLT3 inhibitors."	( Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use. Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC, 2020)	0.56
" Pyroptosis assessment leads to a fast FMF diagnosis while combining pyroptosis and IL-1β dosage renders UCN-01-based assays highly sensitive and specific."	( Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor. Abbas, F; Belot, A; Duquesne, A; Durupt, S; Fauter, M; Georgin-Lavialle, S; Gerfaud-Valentin, M; Giurgea, I; Grateau, G; Henry, T; Hot, A; Jamilloux, Y; Magnotti, F; Malsot, T; Martin, A; Rabilloud, M; Savey, L; Sève, P, 2021)	0.62
" More importantly, the matrix experiment design allowed simultaneous computation of the statistical significance and fitting of the dose-response profiles, which can be combined to enable a more accurate identification of target proteins, as well as reporting binding affinities between the ligand and individual targets."	( Matrix Thermal Shift Assay for Fast Construction of Multidimensional Ligand-Target Space. Lyu, J; Ma, Y; Qu, G; Ruan, C; Shi, C; Wang, Y; Ye, M; Zhang, N; Zhang, X, 2022)	0.72
" Subsequent testing in a rat model of asphyxial cardiac arrest, and in a mouse model of severe TBI, showed that serial dosing of 1 mg/kg of NSC74429 over 3 days improved hippocampal survival in both models."	( PHLPP Inhibitor NSC74429 Is Neuroprotective in Rodent Models of Cardiac Arrest and Traumatic Brain Injury. Dezfulian, C; Jackson, TC; Janesko-Feldman, K; Kochanek, PM; Stezoski, J; Vagni, VA, 2022)	0.72
" Compared with RATIFY, this study extended midostaurin treatment from 14 days to 21 days, substituted anthracyclines (idarubicin or daunorubicin), and introduced variation in standard combination chemotherapy dosing ("7+3" or "5+2" in more fragile patients)."	( Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial. Bengoudifa, BR; Caillot, D; Cluzeau, T; Farkas, F; Gilotti, G; Griskevicius, L; Hodzic, S; Legrand, O; Luppi, M; Minotti, C; Montesinos, P; Rambaldi, A; Sierra, J; Thomas, X; Venditti, A, 2023)	0.91

Role	Description
EC 2.7.11.13 (protein kinase C) inhibitor	An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13).
geroprotector	Any compound that supports healthy aging, slows the biological aging process, or extends lifespan.
bacterial metabolite	Any prokaryotic metabolite produced during a metabolic reaction in bacteria.
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
indolocarbazole alkaloid
organic heterooctacyclic compound
ammonium ion derivative	A derivative of ammonium, NH4(+), in which one (or more) of the hydrogens bonded to the nitrogen have been replaced with univalent organyl groups. The substituting carbon of the organyl group must not itself be directly attached to a heteroatom (thereby excluding protonated amides, hemiaminals, etc).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
5q35 copy number variation	0	12
staurosporine biosynthesis	8	24
Ethanol metabolism resulting in production of ROS by CYP2E1	1	17
Ethanol metabolism production of ROS by CYP2E1	1	17

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	39.8107	0.0032	45.4673	12,589.2998	AID2517
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	35.4813	0.1259	19.1169	125.8920	AID2549
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	50.1187	5.6234	17.2929	31.6228	AID485281
PPM1D protein	Homo sapiens (human)	Potency	0.8289	0.0052	9.4661	32.9993	AID1347411
Microtubule-associated protein tau	Homo sapiens (human)	Potency	6.2292	0.1800	13.5574	39.8107	AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	39.8107	0.0112	12.4002	100.0000	AID1030
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	10.6213	0.5318	15.4358	37.6858	AID504845
dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)	Potency	0.1000	0.1000	0.1000	0.1000	AID1732
epidermal growth factor receptor isoform a precursor	Homo sapiens (human)	Potency	0.1996	0.0008	0.4819	3.5481	AID1726; AID1727; AID1729; AID1731
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	28.1838	0.2512	15.8432	39.8107	AID504327
Interferon beta	Homo sapiens (human)	Potency	0.8289	0.0033	9.1582	39.8107	AID1347411
Type-1A angiotensin II receptor	Rattus norvegicus (Norway rat)	Potency	0.1000	0.1000	0.1000	0.1000	AID1732
Type-1B angiotensin II receptor	Rattus norvegicus (Norway rat)	Potency	0.1000	0.1000	0.1000	0.1000	AID1732
Type-2 angiotensin II receptor	Rattus norvegicus (Norway rat)	Potency	0.1000	0.1000	0.1000	0.1000	AID1732
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Serine/threonine-protein kinase Chk1	Homo sapiens (human)	Ki	0.0078	0.0078	0.0078	0.0078	AID977610
Chain A, Serine/threonine-protein kinase Chk1	Homo sapiens (human)	Ki	0.0078	0.0078	0.0078	0.0078	AID977610
Chain A, Serine/threonine-protein kinase Chk1	Homo sapiens (human)	Ki	0.0078	0.0078	0.0078	0.0078	AID977610
Chain A, Glycogen Synthase Kinase-3 Beta	Homo sapiens (human)	IC50 (µMol)	0.0150	0.0040	0.0137	0.0220	AID977608
Chain B, Glycogen Synthase Kinase-3 Beta	Homo sapiens (human)	IC50 (µMol)	0.0150	0.0040	0.0137	0.0220	AID977608
Chain A, Glycogen Synthase Kinase-3 Beta	Homo sapiens (human)	IC50 (µMol)	0.0150	0.0040	0.0137	0.0220	AID977608
Chain E, Camp-dependent Protein Kinase	Bos taurus (cattle)	Ki	0.0080	0.0080	0.0080	0.0080	AID977610
Chain A, Tyrosine-protein kinase ZAP-70	Homo sapiens (human)	IC50 (µMol)	0.0558	0.0558	0.0558	0.0558	AID977608
Chain A, Tyrosine-protein kinase SYK	Homo sapiens (human)	IC50 (µMol)	0.0120	0.0120	0.0120	0.0120	AID977608
Chain A, Protein kinase C, theta type	Homo sapiens (human)	Ki	0.0003	0.0003	0.0003	0.0003	AID977610
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1	Homo sapiens (human)	IC50 (µMol)	0.0100	0.0100	2.0050	4.0000	AID977608
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1	Homo sapiens (human)	IC50 (µMol)	0.0100	0.0100	2.0050	4.0000	AID977608
Chain X, Proto-oncogene tyrosine-protein kinase Fyn	Homo sapiens (human)	IC50 (µMol)	0.0048	0.0048	0.0048	0.0048	AID977608
Chain A, Serine/threonine-protein kinase TAO2	Rattus norvegicus (Norway rat)	IC50 (µMol)	3.0000	3.0000	3.0000	3.0000	AID977608
epidermal growth factor receptor isoform a precursor	Homo sapiens (human)	IC50 (µMol)	0.4467	0.0010	16.8616	100.0000	AID1742
Serine/threonine-protein kinase Sgk1	Homo sapiens (human)	IC50 (µMol)	0.0100	0.0068	0.8665	3.5700	AID1300791; AID1531875; AID1715176
Cell division cycle 7-related protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0549	0.0034	0.0347	0.1400	AID1531615; AID1715421
Serine/threonine-protein kinase PLK4	Homo sapiens (human)	IC50 (µMol)	0.0083	0.0027	0.4625	3.1000	AID1531858; AID1715190
Serine/threonine-protein kinase PLK4	Homo sapiens (human)	Ki	0.5357	0.0003	0.9559	9.3000	AID1798514
Serine/threonine-protein kinase 25	Homo sapiens (human)	IC50 (µMol)	0.0029	0.0019	0.0029	0.0040	AID1531891; AID1612689; AID1715159
Citron Rho-interacting kinase	Homo sapiens (human)	IC50 (µMol)	0.7490	0.4580	0.8327	1.0400	AID1531889; AID1715160
Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)	IC50 (µMol)	0.9255	0.0010	0.3419	1.3000	AID1531774; AID1715270
Telomerase reverse transcriptase	Homo sapiens (human)	IC50 (µMol)	6.9517	0.0006	2.6948	9.4000	AID1290436; AID1755833; AID1872776; AID630397; AID695574; AID722913
Serine/threonine-protein kinase Chk1	Homo sapiens (human)	IC50 (µMol)	0.1772	0.0001	0.4530	8.8300	AID1300799; AID1350963; AID1531637; AID1715399; AID262367; AID262979; AID350257; AID415639; AID426696; AID457751; AID627129; AID634542
Serine/threonine-protein kinase Chk1	Homo sapiens (human)	Ki	0.0078	0.0005	0.2348	0.6590	AID1797591
Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)	IC50 (µMol)	0.5561	0.0009	0.9781	9.8200	AID1059943; AID1068646; AID1191826; AID1531726; AID1715317; AID241675; AID415643; AID427621; AID590190
Aurora kinase A	Homo sapiens (human)	IC50 (µMol)	0.0084	0.0000	0.4620	8.6000	AID1059942; AID1068649; AID1184498; AID1247617; AID1252492; AID1294629; AID1294634; AID1300805; AID1308932; AID1350955; AID1394681; AID1394737; AID1421400; AID1531588; AID1662790; AID1715446; AID1736660; AID1846770; AID1846788; AID350252; AID427622; AID627131; AID629265
Cyclin-G-associated kinase	Homo sapiens (human)	IC50 (µMol)	0.0110	0.0010	0.2972	1.1000	AID1730898
Serine/threonine-protein kinase DCLK1	Homo sapiens (human)	IC50 (µMol)	0.2670	0.1730	0.4167	0.7160	AID1531657; AID1715382
Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)	IC50 (µMol)	0.1265	0.0390	1.4036	7.4000	AID1531725; AID1715318; AID1778247; AID415642; AID590191
Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.1161	0.0038	0.1161	0.2900	AID1308970; AID1531792; AID1715252
Mitogen-activated protein kinase 13	Homo sapiens (human)	IC50 (µMol)	0.4137	0.0007	0.4595	6.3000	AID127093; AID1531812; AID1715235
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	37.9000	0.2000	5.6774	10.0000	AID1473741
3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0072	0.0025	1.4513	9.0000	AID1300790; AID1410153; AID1797581
Death-associated protein kinase 3	Homo sapiens (human)	IC50 (µMol)	0.0026	0.0018	0.3525	2.3300	AID1531935; AID1715122
Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)	IC50 (µMol)	0.0565	0.0056	0.2470	2.6000	AID1351002; AID1531899; AID1709608; AID1715151; AID350296
Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.3560	0.0010	4.6143	100.0000	AID1531863; AID1715186
Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)	IC50 (µMol)	0.0231	0.0114	0.7859	3.2000	AID1531668; AID1715372
NUAK family SNF1-like kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0030	0.0013	0.2918	5.0900	AID1063051; AID1531586; AID1612690; AID1715449
Cyclin-T1	Homo sapiens (human)	IC50 (µMol)	0.0118	0.0010	0.5585	8.0000	AID1356599; AID1531635; AID1715400; AID1917245; AID415620
Cyclin-T1	Homo sapiens (human)	Ki	0.0070	0.0030	0.2768	0.7900	AID723735
Cyclin-T2	Homo sapiens (human)	IC50 (µMol)	0.0038	0.0038	0.0038	0.0038	AID1531636
Tyrosine-protein kinase JAK2	Homo sapiens (human)	IC50 (µMol)	0.0016	0.0001	0.3722	10.0000	AID1068644; AID1191824; AID1298811; AID1300796; AID1308963; AID1531734; AID1631208; AID1715309; AID350277
Rho-associated protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0045	0.0002	0.5780	10.0000	AID1350027; AID1410110; AID1531867; AID1715183
Serine/threonine-protein kinase ULK1	Homo sapiens (human)	IC50 (µMol)	0.0096	0.0029	0.1421	0.7850	AID1531922; AID1715130
Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)	IC50 (µMol)	0.1246	0.0453	2.2860	9.9390	AID1531689; AID1715352
Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)	IC50 (µMol)	0.0011	0.0004	1.3066	8.3000	AID1300792; AID1531785; AID1715258
Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)	IC50 (µMol)	0.0071	0.0030	1.2851	3.0100	AID1531786; AID1715259
Serine/threonine-protein kinase 16	Homo sapiens (human)	IC50 (µMol)	0.2385	0.2350	0.2385	0.2420	AID1531888; AID1715162
Cyclin-K	Homo sapiens (human)	IC50 (µMol)	0.0948	0.0030	0.2656	1.3700	AID1356598; AID1356600; AID1531634; AID1715402; AID745521
Serine/threonine-protein kinase PAK 3	Homo sapiens (human)	IC50 (µMol)	0.0003	0.0002	0.0263	0.0990	AID1531818; AID1715230
Serine/threonine-protein kinase 17B	Homo sapiens (human)	IC50 (µMol)	0.0258	0.0258	2.2072	6.2000	AID1191827
Serine/threonine-protein kinase 10	Homo sapiens (human)	IC50 (µMol)	0.0080	0.0069	0.2334	1.0000	AID1531750; AID1715293
Serine/threonine-protein kinase D3	Homo sapiens (human)	IC50 (µMol)	0.1446	0.0001	1.1701	10.0000	AID1068655; AID1180278; AID1531845; AID155717; AID164952; AID165147; AID1715203; AID240699
Cyclin-dependent kinase 14	Homo sapiens (human)	IC50 (µMol)	0.1145	0.0198	0.6122	2.2000	AID1531619; AID1715417
G2/mitotic-specific cyclin-B2	Homo sapiens (human)	IC50 (µMol)	0.0107	0.0025	1.8172	10.0000	AID1247622; AID240955; AID512487; AID512718; AID55343
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	18.7000	0.1100	7.1903	10.0000	AID1443980; AID1473738
Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)	IC50 (µMol)	0.2829	0.0908	0.2829	0.4750	AID1531769; AID1715276
Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)	IC50 (µMol)	0.0005	0.0003	1.2552	3.4000	AID1531718; AID1715322
Serine/threonine-protein kinase LATS1	Homo sapiens (human)	IC50 (µMol)	0.0130	0.0128	0.0130	0.0133	AID1531743; AID1715301
Serine/threonine-protein kinase PAK 4	Homo sapiens (human)	IC50 (µMol)	0.0132	0.0010	0.5686	6.9000	AID1444450; AID1531819; AID1646264; AID1715228
Serine/threonine-protein kinase Chk2	Homo sapiens (human)	IC50 (µMol)	2.7191	0.0030	0.3482	3.5000	AID1350964; AID1531638; AID1715398; AID1799260; AID350258; AID426697; AID457749; AID590192; AID627128; AID634543
G1/S-specific cyclin-E2	Homo sapiens (human)	IC50 (µMol)	0.0110	0.0010	1.7394	10.0000	AID1247623; AID240956; AID55363
cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)	IC50 (µMol)	0.0812	0.0020	1.2409	9.0000	AID1795421; AID1795948; AID1797134; AID1797337
Tyrosine-protein kinase ABL1	Homo sapiens (human)	IC50 (µMol)	0.1233	0.0001	0.7128	10.0000	AID1069558; AID1236888; AID1300795; AID1308928; AID1350953; AID1394735; AID1481070; AID1531572; AID1714635; AID1715456; AID1743527; AID1743528; AID228824; AID240823; AID350250; AID629262
Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)	IC50 (µMol)	0.0063	0.0004	0.9151	5.1000	AID1799403
Epidermal growth factor receptor	Homo sapiens (human)	IC50 (µMol)	5.4744	0.0000	0.5369	10.0000	AID1247624; AID1279101; AID1308939; AID1308940; AID1308941; AID1308942; AID1404960; AID1423824; AID1423825; AID1426964; AID1450412; AID1452382; AID1466329; AID1483363; AID1483364; AID1483365; AID1483366; AID1531670; AID1664188; AID1664192; AID1664193; AID1664194; AID1664195; AID1664196; AID1715371; AID1758203; AID1772909; AID1846777; AID1846789; AID350262; AID494402; AID629272; AID70049
RAF proto-oncogene serine/threonine-protein kinase	Homo sapiens (human)	IC50 (µMol)	2.1025	0.0010	0.3349	8.9000	AID1252498; AID1394685; AID164360; AID269869; AID415640
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	IC50 (µMol)	0.0713	0.0001	0.5453	10.0000	AID1308940; AID1308958; AID1404961; AID1426965; AID1531683; AID1664189; AID1664197; AID1715358; AID1855770
High affinity nerve growth factor receptor	Homo sapiens (human)	IC50 (µMol)	125.2103	0.0002	0.5436	10.0000	AID1308984; AID1351004; AID1531912; AID1680242; AID1705873; AID1715139; AID1878047; AID350299
Protein kinase C gamma type	Homo sapiens (human)	IC50 (µMol)	0.1167	0.0001	1.0354	10.0000	AID1068655; AID1180278; AID1481082; AID1531842; AID155717; AID163880; AID163882; AID164020; AID164952; AID165147; AID1715206; AID1797337; AID240699; AID241698; AID262973; AID385590
Platelet-derived growth factor receptor beta	Mus musculus (house mouse)	IC50 (µMol)	0.0020	0.0018	0.7552	9.5000	AID241786
Protein kinase C alpha type	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2327	0.0000	0.2193	1.0000	AID155712; AID164969; AID164979; AID1650882; AID1650883; AID1650884; AID1650885; AID165101; AID165105; AID165106; AID165111; AID165113; AID165122
Protein kinase C beta type	Homo sapiens (human)	IC50 (µMol)	0.0684	0.0001	0.5542	10.0000	AID1068655; AID1180278; AID1531837; AID1531838; AID155717; AID1612691; AID163197; AID163199; AID163335; AID163341; AID163348; AID163361; AID164952; AID165147; AID1715210; AID1715211; AID240699; AID241734; AID241735; AID248521; AID342546; AID82386
Prostaglandin G/H synthase 1	Ovis aries (sheep)	IC50 (µMol)	0.0560	0.0003	2.1774	10.0000	AID427626
Insulin receptor	Homo sapiens (human)	IC50 (µMol)	0.0706	0.0017	0.8479	10.0000	AID1308961; AID1350979; AID1531728; AID1715315; AID350275; AID93077
Tyrosine-protein kinase Lck	Homo sapiens (human)	IC50 (µMol)	0.1784	0.0002	1.3173	10.0000	AID1308966; AID1350983; AID1351006; AID1481076; AID1531745; AID1715300; AID224295; AID342545; AID350280; AID438442; AID627338; AID629396
Tyrosine-protein kinase Fyn	Homo sapiens (human)	IC50 (µMol)	0.0929	0.0002	1.6789	8.6800	AID1308956; AID1531704; AID1715337; AID280400; AID280401; AID280402; AID280403; AID280404; AID280405; AID438441
Retinoblastoma-associated protein	Homo sapiens (human)	IC50 (µMol)	0.0660	0.0660	0.0660	0.0660	AID1452447
Cyclin-dependent kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0075	0.0004	1.3452	10.0000	AID1247622; AID1252493; AID1350960; AID1350961; AID1394682; AID1394738; AID1531617; AID1531618; AID1612681; AID1715418; AID1715419; AID1715420; AID240955; AID262975; AID350255; AID415613; AID426699; AID512487; AID512718; AID53178; AID55343; AID629267; AID745529
Cyclin-dependent kinase 1	Homo sapiens (human)	Ki	0.0020	0.0010	1.2551	5.0000	AID1797592
Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)	IC50 (µMol)	0.0039	0.0015	0.2187	0.7060	AID1308948; AID1531693; AID1715348
Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)	IC50 (µMol)	0.1269	0.0006	0.5676	5.5450	AID1247630; AID1450414; AID1531702; AID1715338; AID1743552; AID1797654; AID629278
Tyrosine-protein kinase Yes	Homo sapiens (human)	IC50 (µMol)	0.0029	0.0004	0.5740	8.9000	AID1308986; AID1481085; AID1531931; AID1715125
Tyrosine-protein kinase Lyn	Homo sapiens (human)	IC50 (µMol)	0.0012	0.0002	0.5594	5.2000	AID1247635; AID1308968; AID1350985; AID1481077; AID1531752; AID1531753; AID1715290; AID1715292; AID1846775; AID350281; AID438440; AID629397
Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)	IC50 (µMol)	0.0021	0.0001	0.3484	3.5970	AID1308978; AID1350998; AID1466334; AID1531862; AID1704864; AID1704865; AID1704866; AID1704867; AID1704868; AID1704869; AID1715187; AID350292
Insulin-like growth factor 1 receptor	Homo sapiens (human)	IC50 (µMol)	0.5534	0.0003	0.4308	8.0000	AID1063046; AID1247632; AID1308960; AID1394745; AID1531724; AID1715319; AID494404; AID591131; AID591132; AID591133; AID591134; AID629392; AID93089
Hepatocyte growth factor receptor	Homo sapiens (human)	IC50 (µMol)	0.1917	0.0004	0.3722	10.0000	AID1063044; AID1247621; AID1303870; AID1308917; AID1350958; AID1352739; AID1394740; AID1466326; AID1531602; AID1667739; AID1684588; AID1715433; AID1846772; AID269864; AID350259; AID627292; AID629270
Tyrosine-protein kinase HCK	Homo sapiens (human)	IC50 (µMol)	0.0025	0.0001	1.2226	7.7000	AID1531717; AID1715324
Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)	IC50 (µMol)	0.0004	0.0001	0.3005	6.7000	AID1247642; AID1308980; AID1531869; AID1715181; AID429341; AID629405
Protein kinase C delta type	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2740	0.0000	0.2585	1.0000	AID164969; AID1650882; AID1650883; AID1650884; AID1650885; AID165101; AID165105; AID165106; AID165111; AID165113; AID165122
Protein kinase C epsilon type	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2740	0.0000	0.2585	1.0000	AID164969; AID1650882; AID1650883; AID1650884; AID1650885; AID165101; AID165105; AID165106; AID165111; AID165113; AID165122
Protein kinase C zeta type	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2740	0.0000	0.2585	1.0000	AID164969; AID1650882; AID1650883; AID1650884; AID1650885; AID165101; AID165105; AID165106; AID165111; AID165113; AID165122
Platelet-derived growth factor receptor beta	Homo sapiens (human)	IC50 (µMol)	1.1042	0.0006	0.8007	8.5000	AID1252497; AID1308973; AID1394684; AID1394747; AID1502062; AID1531825; AID161244; AID1715224; AID1751471; AID1799383
Tyrosine-protein kinase Fgr	Homo sapiens (human)	IC50 (µMol)	0.0009	0.0007	1.1659	8.5000	AID1531698; AID1715343
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	0.0002	0.0000	2.0151	10.0000	AID1531940
Mast/stem cell growth factor receptor Kit	Homo sapiens (human)	IC50 (µMol)	0.0375	0.0007	0.4708	10.0000	AID1247620; AID1308937; AID1394739; AID1466332; AID1531600; AID1715436; AID1846771; AID262370; AID262982; AID269863; AID629269
Breakpoint cluster region protein	Homo sapiens (human)	IC50 (µMol)	0.0945	0.0003	0.6200	10.0000	AID1236888; AID1714635; AID1743527; AID1743528
Calcium/calmodulin-dependent protein kinase type II subunit alpha	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0590	0.0001	0.7109	8.4000	AID1795948
Serine/threonine-protein kinase pim-1	Homo sapiens (human)	IC50 (µMol)	0.0216	0.0004	0.8871	10.0000	AID1063041; AID1285477; AID1350994; AID1359962; AID1410152; AID1531830; AID1700282; AID1715218; AID1796959; AID350288; AID410272; AID417327; AID418377; AID418378; AID418379
Fibroblast growth factor receptor 1	Homo sapiens (human)	IC50 (µMol)	0.0699	0.0002	0.9420	10.0000	AID1308952; AID1531694; AID1715347; AID1732830; AID1751472; AID350267; AID73318
Cyclin-dependent kinase 1	Mus musculus (house mouse)	IC50 (µMol)	0.0080	0.0080	0.0080	0.0080	AID241820
Cyclin-dependent kinase 4	Homo sapiens (human)	IC50 (µMol)	0.0429	0.0006	0.5706	10.0000	AID1481072; AID1531627; AID1531628; AID1715407; AID1715408; AID1758205; AID1795948; AID1917240; AID415616; AID55348; AID55359; AID745525
Cyclin-dependent kinase 4	Homo sapiens (human)	Ki	0.0410	0.0006	0.7369	3.6000	AID1797593
Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)	IC50 (µMol)	0.3642	0.0002	0.5335	10.0000	AID1063039; AID1252500; AID1308981; AID1351005; AID1394686; AID1394749; AID1410149; AID1531603; AID1715434; AID1743550; AID205341; AID205343; AID205488; AID224439; AID262371; AID262983; AID350260; AID498727; AID550458; AID580260; AID627293; AID629271; AID638300; AID718365; AID747368
Acyl-CoA desaturase 1	Mus musculus (house mouse)	IC50 (µMol)	3.4000	0.0010	0.6830	3.4000	AID455588
Insulin receptor-related protein	Homo sapiens (human)	IC50 (µMol)	0.0113	0.0076	0.5198	1.8000	AID1531731; AID1715313
G2/mitotic-specific cyclin-B1	Homo sapiens (human)	IC50 (µMol)	0.0088	0.0013	1.4518	10.0000	AID1247622; AID1350960; AID1394682; AID1394738; AID1531617; AID1612681; AID1715419; AID240955; AID350255; AID415613; AID512487; AID512718; AID55343; AID629267
Dipeptidyl peptidase 4	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0030	0.0023	1.2155	5.0000	AID351489
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	IC50 (µMol)	4.0000	0.0004	0.9086	10.0000	AID55537
Serine/threonine-protein kinase B-raf	Homo sapiens (human)	IC50 (µMol)	0.0107	0.0001	0.2800	7.5890	AID1191825; AID1247618; AID1247619; AID1300797; AID1410142; AID1732378; AID1772937; AID1846766; AID1846767
Insulin receptor	Mus musculus (house mouse)	IC50 (µMol)	0.2000	0.2000	0.2000	0.2000	AID241289
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)	IC50 (µMol)	0.0004	0.0001	0.0667	0.5280	AID1350993; AID1531829; AID159258; AID1715220; AID350287
Platelet-derived growth factor receptor alpha	Homo sapiens (human)	IC50 (µMol)	0.0007	0.0001	0.4912	10.0000	AID1308972; AID1350992; AID1466333; AID1531824; AID161244; AID1715223; AID1758204; AID350286
Tyrosine-protein kinase Fer	Homo sapiens (human)	IC50 (µMol)	0.0008	0.0002	0.0968	0.4900	AID1308947; AID1531692; AID1715349
Protein kinase C alpha type	Homo sapiens (human)	IC50 (µMol)	0.0655	0.0001	0.9720	10.0000	AID1068655; AID1180278; AID1308974; AID1350996; AID1410109; AID1481081; AID1531836; AID155717; AID1612680; AID162839; AID163013; AID164952; AID165147; AID165309; AID1715212; AID240699; AID241697; AID269865; AID350290; AID592893
cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)	IC50 (µMol)	0.0115	0.0009	1.3241	9.0000	AID1061209; AID1247638; AID1309007; AID1481080; AID1531833; AID164478; AID164479; AID164630; AID164652; AID1846292; AID262364; AID262972; AID269862
Vascular endothelial growth factor receptor 1	Homo sapiens (human)	IC50 (µMol)	0.0149	0.0001	0.2914	7.0000	AID1308949; AID1350974; AID1360768; AID1394742; AID1531699; AID1715342; AID350270
Cytochrome P450 11B2, mitochondrial	Homo sapiens (human)	IC50 (µMol)	0.0110	0.0001	0.2738	3.5000	AID1177640
Interferon-induced, double-stranded RNA-activated protein kinase	Homo sapiens (human)	IC50 (µMol)	0.1000	0.1000	2.6782	8.0000	AID606664
Amine oxidase [flavin-containing] B	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0025	0.0004	0.7649	12.5000	AID126782
Casein kinase II subunit alpha'	Homo sapiens (human)	IC50 (µMol)	21.6172	0.0003	1.4320	10.0000	AID1531647; AID1715392; AID262366; AID262978; AID49347
Cyclin-A2	Homo sapiens (human)	IC50 (µMol)	4.1749	0.0004	1.0339	10.0000	AID1157145; AID1191830; AID1300803; AID1350962; AID1531623; AID1691929; AID1715413; AID1715420; AID1731513; AID745528; AID745529; AID745531
Cyclin-A2	Homo sapiens (human)	Ki	0.0026	0.0010	0.7007	5.0000	AID1797592; AID723734
Cannabinoid receptor 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0100	0.0002	0.6609	10.0000	AID417327
Serine/threonine-protein kinase MAK	Homo sapiens (human)	IC50 (µMol)	0.0257	0.0227	0.0257	0.0287	AID1531754; AID1715291
Ephrin type-A receptor 1	Homo sapiens (human)	IC50 (µMol)	0.0947	0.0498	0.2268	0.6300	AID1308943; AID1531671; AID1715369
Fibroblast growth factor receptor 2	Homo sapiens (human)	IC50 (µMol)	0.0504	0.0004	0.3276	8.6200	AID1247627; AID1308953; AID1531695; AID1715346; AID1732832; AID1751472; AID1846773; AID350268; AID629275; AID73318
Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)	IC50 (µMol)	0.0106	0.0001	0.0780	1.0240	AID1308940
Fibroblast growth factor receptor 4	Homo sapiens (human)	IC50 (µMol)	13,900.1457	0.0008	0.6217	8.6200	AID1308955; AID1531697; AID1680243; AID1715344; AID1732831; AID1751472; AID73318
Fibroblast growth factor receptor 3	Homo sapiens (human)	IC50 (µMol)	0.0554	0.0004	0.2863	8.6200	AID1247628; AID1308954; AID1350973; AID1531696; AID1715345; AID1732833; AID1751472; AID350269; AID629276; AID73318
cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)	IC50 (µMol)	0.0137	0.0009	1.5482	9.0000	AID1247638; AID1531835; AID164478; AID164479; AID164630; AID164652; AID1715213; AID1846292; AID262364; AID262972; AID269862
Cyclin-O	Homo sapiens (human)	IC50 (µMol)	0.0015	0.0015	0.0015	0.0017	AID1531625; AID1612678; AID1715409; AID1731528
cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)	IC50 (µMol)	0.0148	0.0006	1.4848	9.0000	AID1247638; AID1531834; AID164478; AID164479; AID164630; AID164652; AID1715214; AID1846292; AID262364; AID262972; AID269862; AID592894
Ribosomal protein S6 kinase beta-1	Homo sapiens (human)	IC50 (µMol)	0.0007	0.0004	0.9046	10.0000	AID1300788; AID1531814; AID1710632; AID1715234
Tyrosine-protein kinase JAK1	Homo sapiens (human)	IC50 (µMol)	0.0040	0.0003	0.2378	7.3000	AID1298810; AID1308962; AID1531733; AID1631207; AID1715311
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0280	0.0007	0.9774	9.7000	AID241697
G1/S-specific cyclin-D1	Homo sapiens (human)	IC50 (µMol)	0.0355	0.0006	0.5479	9.5000	AID1481072; AID1531627; AID1531631; AID1715404; AID1715408; AID1795948; AID1917240; AID1917241; AID415616; AID55348; AID55359; AID745523; AID745525
G1/S-specific cyclin-D1	Homo sapiens (human)	Ki	0.0410	0.0006	0.6654	3.6000	AID1797593
Protein kinase C eta type	Homo sapiens (human)	IC50 (µMol)	0.1165	0.0001	0.7971	10.0000	AID1068655; AID1180278; AID1531841; AID155717; AID163855; AID163859; AID164952; AID165147; AID1715207; AID240699
Cyclin-C	Homo sapiens (human)	IC50 (µMol)	0.0105	0.0050	0.6792	5.9000	AID1356601; AID1439521
G1/S-specific cyclin-E1	Homo sapiens (human)	IC50 (µMol)	0.0108	0.0010	1.0404	10.0000	AID1247623; AID1350961; AID1531618; AID1531624; AID1531626; AID1612686; AID1691913; AID1715410; AID1715411; AID1715418; AID1731527; AID1795948; AID1917243; AID240956; AID55363; AID629268; AID745526
Cyclin-dependent kinase 2	Homo sapiens (human)	IC50 (µMol)	1.6200	0.0004	1.0444	10.0000	AID1157145; AID1191830; AID1247623; AID1300803; AID1308936; AID1350962; AID1531623; AID1531624; AID1531625; AID1531937; AID1612678; AID1691929; AID1715409; AID1715411; AID1715412; AID1715413; AID1731513; AID1731526; AID1731527; AID1731528; AID1795948; AID1917243; AID240956; AID350256; AID415611; AID415614; AID55363; AID629268; AID745527; AID745528; AID745531
Cyclin-dependent kinase 2	Homo sapiens (human)	Ki	0.0026	0.0005	0.6427	5.0000	AID1797592; AID723734
Beta-adrenergic receptor kinase 1	Homo sapiens (human)	IC50 (µMol)	1.1595	0.0420	1.2276	2.5000	AID1531708; AID1715333
Platelet-derived growth factor receptor alpha	Mus musculus (house mouse)	IC50 (µMol)	0.0020	0.0018	0.8572	9.5000	AID241786
Mitogen-activated protein kinase 3	Homo sapiens (human)	IC50 (µMol)	9.0475	0.0025	3.0926	9.5820	AID1059939; AID1247625; AID1252494; AID1350968; AID1531685; AID1715356; AID269867; AID350265; AID415641; AID427624; AID494408
MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)	IC50 (µMol)	0.0004	0.0003	0.6636	3.3330	AID1531760; AID1715285
cAMP-dependent protein kinase catalytic subunit alpha	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0550	0.0180	1.0959	3.1000	AID164615; AID164618; AID164619
Mitogen-activated protein kinase 1	Homo sapiens (human)	IC50 (µMol)	5.5321	0.0003	1.6878	9.2000	AID126782; AID126922; AID1308946; AID1350969; AID1531686; AID1715355; AID262365; AID262976; AID350266; AID629273; AID71178
Ephrin type-A receptor 2	Homo sapiens (human)	IC50 (µMol)	0.1257	0.0008	0.0436	0.2626	AID1308938; AID1531672; AID1715370
Ephrin type-A receptor 3	Homo sapiens (human)	IC50 (µMol)	0.0347	0.0003	0.3341	1.2000	AID1350966; AID1531673; AID1715368; AID350263
Ephrin type-A receptor 8	Homo sapiens (human)	IC50 (µMol)	0.1061	0.0012	0.3033	1.0000	AID1531678; AID1715362
Ephrin type-B receptor 2	Homo sapiens (human)	IC50 (µMol)	0.1191	0.0025	1.5875	8.5000	AID1308945; AID1531680; AID1715361
Leukocyte tyrosine kinase receptor	Homo sapiens (human)	IC50 (µMol)	0.0173	0.0003	0.0140	0.0292	AID1308967; AID1531920; AID1715133
Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)	IC50 (µMol)	0.0137	0.0002	0.2950	4.1000	AID1308985; AID1481084; AID1531940; AID1691932; AID1715132
G1/S-specific cyclin-D3	Homo sapiens (human)	IC50 (µMol)	0.0550	0.0015	0.0862	0.9250	AID1531628; AID1531632; AID1715403; AID1715407; AID1758205; AID415619
Tyrosine-protein kinase receptor UFO	Homo sapiens (human)	IC50 (µMol)	0.0131	0.0007	0.4116	9.1000	AID1063050; AID1308933; AID1529866; AID1531591; AID1715444
RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.1848	0.0002	0.7387	10.0000	AID1061210; AID1063052; AID1068665; AID1069559; AID1191829; AID1247615; AID1252491; AID1300783; AID1308929; AID1350954; AID1394736; AID1410150; AID1481068; AID1531575; AID1687404; AID1715453; AID1797336; AID1846765; AID262358; AID262373; AID262968; AID262985; AID269859; AID350251; AID629263
RAC-beta serine/threonine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.4119	0.0005	0.5013	7.6000	AID1300784; AID1531576; AID1687404; AID1715452; AID1797336; AID262362; AID262970; AID269860
G protein-coupled receptor kinase 4	Homo sapiens (human)	IC50 (µMol)	0.0914	0.0699	0.1476	0.2600	AID1531710; AID1715331
Kinesin-1 heavy chain	Homo sapiens (human)	IC50 (µMol)	0.0015	0.0015	0.1963	0.4000	AID1704869
G protein-coupled receptor kinase 5	Homo sapiens (human)	IC50 (µMol)	0.0489	0.0246	0.2720	0.8300	AID1531711; AID1715330
Hexokinase-4	Homo sapiens (human)	IC50 (µMol)	0.0006	0.0005	0.0006	0.0008	AID1531705; AID1715336
Beta-adrenergic receptor kinase 2	Homo sapiens (human)	IC50 (µMol)	0.8560	0.0470	0.5863	0.8620	AID1531709; AID1715332
Vascular endothelial growth factor receptor 3	Homo sapiens (human)	IC50 (µMol)	0.0146	0.0001	0.2264	4.9000	AID1308951; AID1350976; AID1360770; AID1394743; AID1531701; AID1715340; AID262369; AID262981; AID350272
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	IC50 (µMol)	0.9925	0.0000	0.4830	8.8000	AID1063038; AID1244337; AID1245552; AID1247634; AID1308965; AID1324447; AID1326304; AID1350982; AID1360769; AID1365187; AID1394746; AID1450411; AID1466331; AID1478068; AID1531739; AID1666667; AID1715306; AID1799383; AID1833071; AID1865711; AID216786; AID216916; AID262368; AID262980; AID350279; AID462626; AID614640; AID614641; AID614642; AID614643; AID629395; AID697542
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	Ki	0.0017	0.0000	0.6175	4.1000	AID614644
Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0260	0.0002	0.4653	9.7000	AID1531763; AID1715282
Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)	IC50 (µMol)	0.0014	0.0001	0.3275	9.5480	AID1186611; AID1247629; AID1308950; AID1350975; AID1360758; AID1360780; AID1360781; AID1360782; AID1360783; AID1360784; AID1360785; AID1360786; AID1466330; AID1531700; AID1635582; AID1715341; AID1743551; AID1846774; AID1878045; AID1878046; AID350271; AID629277; AID642585
Bone morphogenetic protein receptor type-1A	Homo sapiens (human)	IC50 (µMol)	4.2880	0.0022	0.5568	4.2880	AID1142608
Activin receptor type-1B	Homo sapiens (human)	IC50 (µMol)	9.1180	0.0130	2.5300	9.6220	AID1142609
TGF-beta receptor type-1	Homo sapiens (human)	IC50 (µMol)	5.7931	0.0010	0.6436	10.0000	AID1142592; AID1799383; AID726369
Serine/threonine-protein kinase receptor R3	Homo sapiens (human)	IC50 (µMol)	0.8500	0.0018	0.1215	0.8500	AID1142606
Tyrosine-protein kinase CSK	Homo sapiens (human)	IC50 (µMol)	0.2071	0.0013	1.3352	5.1800	AID1531653; AID1715388; AID1800263
Protein kinase C iota type	Homo sapiens (human)	IC50 (µMol)	0.1739	0.0001	2.0378	10.0000	AID1068655; AID1180278; AID1531843; AID155717; AID164952; AID165147; AID1715205; AID240699; AID385591
Megakaryocyte-associated tyrosine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.4420	0.3920	0.4420	0.4920	AID1531654; AID1715386
Tyrosine-protein kinase Tec	Homo sapiens (human)	IC50 (µMol)	42.6892	0.0005	0.0631	0.4720	AID1450417; AID1531904; AID1715145
Tyrosine-protein kinase TXK	Homo sapiens (human)	IC50 (µMol)	0.0203	0.0003	0.0821	0.4720	AID1531919; AID1715134
Tyrosine-protein kinase ABL2	Homo sapiens (human)	IC50 (µMol)	0.0505	0.0005	0.1492	1.0000	AID1308931; AID1531573; AID1715455; AID228824
Tyrosine-protein kinase FRK	Homo sapiens (human)	IC50 (µMol)	0.0108	0.0013	0.5514	2.3000	AID1531703; AID1715339
G protein-coupled receptor kinase 6	Homo sapiens (human)	IC50 (µMol)	11.3649	0.0329	3.1789	8.7000	AID1259606; AID1531712; AID1715329
Tyrosine-protein kinase ZAP-70	Homo sapiens (human)	IC50 (µMol)	0.0175	0.0011	1.2309	9.7000	AID1410148; AID1481086; AID1531934; AID1715123; AID1762564; AID342541; AID389369; AID627339
Tyrosine-protein kinase SYK	Homo sapiens (human)	IC50 (µMol)	0.0057	0.0001	0.8260	10.0000	AID1068645; AID1247643; AID1308982; AID1351001; AID1481083; AID1531898; AID1715153; AID1762565; AID1846776; AID350295; AID351489; AID389368; AID629406
Mitogen-activated protein kinase 8	Homo sapiens (human)	IC50 (µMol)	1.1067	0.0020	1.0173	5.4200	AID1481075; AID1531736; AID1612677; AID1715308; AID494405; AID629394
Mitogen-activated protein kinase 9	Homo sapiens (human)	IC50 (µMol)	2.0555	0.0050	0.7475	5.2000	AID1300802; AID1531737; AID1612684; AID1715305
Dual specificity mitogen-activated protein kinase kinase 4	Homo sapiens (human)	IC50 (µMol)	0.8630	0.0010	0.7473	1.6000	AID126758; AID1531772; AID1715273
Phosphorylase b kinase regulatory subunit alpha, liver isoform	Homo sapiens (human)	IC50 (µMol)	0.0005	0.0005	0.0013	0.0017	AID159258
Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform	Homo sapiens (human)	IC50 (µMol)	0.0005	0.0005	0.0013	0.0017	AID159258
Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)	IC50 (µMol)	0.0099	0.0025	4.3899	9.6700	AID1531764; AID1715280
Casein kinase I isoform alpha	Homo sapiens (human)	IC50 (µMol)	3.4120	0.0010	2.2499	10.0000	AID1531639; AID1715397; AID49334; AID494400
Casein kinase I isoform delta	Homo sapiens (human)	IC50 (µMol)	1.4000	0.0040	1.1272	10.0000	AID49334
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)	IC50 (µMol)	9.0000	0.0003	0.6607	10.0000	AID1797363
MAP kinase-activated protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.7350	0.0020	1.1620	6.0000	AID1531755; AID1715289; AID262977; AID455585; AID455586; AID455587; AID455588; AID470606; AID494406; AID699808
Cyclin-dependent kinase 8	Homo sapiens (human)	IC50 (µMol)	0.0105	0.0034	1.0275	5.9000	AID1356601; AID1439521
Casein kinase I isoform epsilon	Homo sapiens (human)	IC50 (µMol)	1.4000	0.0040	1.1150	9.5000	AID49334
Dual specificity protein kinase CLK1	Homo sapiens (human)	IC50 (µMol)	0.0108	0.0074	0.4344	2.1000	AID1531648; AID1715391
Dual specificity protein kinase CLK2	Homo sapiens (human)	IC50 (µMol)	1.8994	0.0005	0.7554	8.0380	AID1531649; AID1715389; AID1779844; AID1799383
Dual specificity protein kinase CLK3	Homo sapiens (human)	IC50 (µMol)	0.9200	0.0410	2.0143	8.7440	AID1531650; AID1715390
Glycogen synthase kinase-3 alpha	Homo sapiens (human)	IC50 (µMol)	0.0103	0.0010	1.2249	9.1000	AID1164096; AID1531714; AID1715327; AID1779845; AID269868
Glycogen synthase kinase-3 beta	Homo sapiens (human)	IC50 (µMol)	0.0435	0.0006	0.8013	10.0000	AID1059946; AID1068647; AID1164097; AID1180279; AID1191822; AID1247631; AID1266906; AID1300804; AID1308957; AID1314089; AID1350977; AID1368766; AID1410151; AID1411917; AID1531715; AID1543545; AID1631074; AID1645916; AID1645921; AID1655555; AID1691931; AID1715326; AID1765289; AID1779846; AID1801382; AID1801812; AID1801940; AID1900714; AID241157; AID269868; AID350273; AID419615; AID427619; AID427626; AID494389; AID629279; AID642586; AID73968; AID74094; AID745520
Glycogen synthase kinase-3 beta	Homo sapiens (human)	Ki	0.0220	0.0020	0.3668	1.6000	AID465436
D(1A) dopamine receptor	Sus scrofa (pig)	IC50 (µMol)	0.0010	0.0010	0.1203	0.3000	AID629406
Cyclin-dependent kinase 7	Homo sapiens (human)	IC50 (µMol)	0.2793	0.0001	0.9106	9.2000	AID1356602; AID1531633; AID1715401; AID1917244; AID745522
Cyclin-dependent kinase 9	Homo sapiens (human)	IC50 (µMol)	0.0474	0.0010	0.6236	8.0000	AID1356599; AID1531634; AID1531635; AID1531636; AID1715400; AID1715402; AID1917245; AID415620; AID745521
Cyclin-dependent kinase 9	Homo sapiens (human)	Ki	0.0070	0.0030	0.2482	0.7900	AID723735
Tyrosine-protein kinase Blk	Homo sapiens (human)	IC50 (µMol)	0.0011	0.0001	0.4357	5.4700	AID1531592; AID1715443
Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0377	0.0160	0.1551	0.3900	AID1531729; AID1715314
Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)	IC50 (µMol)	0.0002	0.0001	0.5372	9.9900	AID1531871; AID1715178; AID627290
Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)	IC50 (µMol)	0.0046	0.0004	0.2336	2.6650	AID1531594; AID1715441
cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)	IC50 (µMol)	0.0014	0.0014	0.0026	0.0050	AID1531859; AID1715189
Cyclin-H	Homo sapiens (human)	IC50 (µMol)	0.2793	0.0005	1.0823	9.2000	AID1356602; AID1531633; AID1715401; AID1917244; AID745522
CDK-activating kinase assembly factor MAT1	Homo sapiens (human)	IC50 (µMol)	0.1216	0.0030	1.6892	9.2000	AID1356602; AID1531633; AID1715401; AID1917244
Serine/threonine-protein kinase Nek2	Homo sapiens (human)	IC50 (µMol)	1.7683	0.1580	2.5160	8.0000	AID1063045; AID1531799; AID1715245
Serine/threonine-protein kinase Nek4	Homo sapiens (human)	IC50 (µMol)	0.0851	0.0742	0.5241	1.4020	AID1531801; AID1715244
Tyrosine-protein kinase JAK3	Homo sapiens (human)	IC50 (µMol)	0.0084	0.0001	0.4193	7.9200	AID1247633; AID1298812; AID1308964; AID1350981; AID1410147; AID1450416; AID1481074; AID1531735; AID1631209; AID1715307; AID1772911; AID292817; AID350278; AID426939; AID629393
Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)	IC50 (µMol)	0.0036	0.0010	0.9798	4.5000	AID126765; AID1531773; AID1715271
Serine/threonine-protein kinase PLK1	Homo sapiens (human)	IC50 (µMol)	17.1642	0.0001	0.7734	9.0000	AID1063042; AID1247639; AID1348850; AID1531855; AID1610355; AID1715192; AID629402; AID725933; AID725934
Serine/threonine-protein kinase PLK1	Homo sapiens (human)	Ki	0.5357	0.0002	1.0608	9.3000	AID1798514
Death-associated protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0101	0.0005	2.2845	10.0000	AID1350965; AID1481669; AID1531655; AID1612679; AID1715385; AID350261
LIM domain kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0026	0.0024	0.3245	1.7783	AID1531747; AID1715296
LIM domain kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0956	0.0080	1.2513	7.9433	AID1531748; AID1715297
Mitogen-activated protein kinase 12	Homo sapiens (human)	IC50 (µMol)	0.4512	0.0007	0.4728	6.3000	AID127093; AID1531813; AID1715236
Mitogen-activated protein kinase 10	Homo sapiens (human)	IC50 (µMol)	0.0731	0.0020	1.7035	10.0000	AID1772912
5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)	IC50 (µMol)	3.0363	0.0010	1.1758	8.0380	AID1799383
Ephrin type-B receptor 3	Homo sapiens (human)	IC50 (µMol)	1.2855	0.0060	2.9942	9.4000	AID1531681; AID1715359
Ephrin type-A receptor 5	Homo sapiens (human)	IC50 (µMol)	0.0159	0.0028	0.0312	0.0900	AID1531675; AID1715367
Ephrin type-B receptor 4	Homo sapiens (human)	IC50 (µMol)	0.1869	0.0002	1.0736	5.1000	AID1350967; AID1531682; AID1715360; AID350264
Ephrin type-B receptor 1	Homo sapiens (human)	IC50 (µMol)	0.0694	0.0200	0.0796	0.1279	AID1308944; AID1531679; AID1715363
Ephrin type-A receptor 4	Homo sapiens (human)	IC50 (µMol)	0.0105	0.0076	0.0247	0.0700	AID1531674; AID1715366
Serine/threonine-protein kinase SIK1	Homo sapiens (human)	IC50 (µMol)	0.0009	0.0005	0.1771	0.9200	AID1531878; AID1715173
Calcium-dependent protein kinase 1	Plasmodium falciparum K1	IC50 (µMol)	0.2400	0.0170	0.1285	0.2400	AID1799368
Protein kinase C gamma type	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2168	0.0000	0.2640	1.1000	AID155712; AID164969; AID164979; AID1650882; AID1650883; AID1650884; AID1650885; AID165101; AID165104; AID165105; AID165106; AID165111; AID165113; AID165122
Casein kinase II subunit beta	Homo sapiens (human)	IC50 (µMol)	35.6000	0.0003	1.4875	10.0000	AID262366; AID262978; AID49347
Casein kinase II subunit alpha	Homo sapiens (human)	IC50 (µMol)	27.6043	0.0005	1.3332	10.0000	AID262366; AID262978; AID49347; AID494401
Protein kinase C beta type	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2029	0.0000	0.2164	1.1000	AID155712; AID164969; AID164979; AID1650882; AID1650883; AID1650884; AID1650885; AID165101; AID165105; AID165106; AID165111; AID165113; AID165122; AID1795401; AID1795420
Protein kinase C beta type	Rattus norvegicus (Norway rat)	Ki	0.0190	0.0053	0.0121	0.0190	AID1799441
SRSF protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.2060	0.1850	2.6040	7.4000	AID1531886; AID1715163
Casein kinase I isoform gamma-2	Homo sapiens (human)	IC50 (µMol)	1.9467	0.0040	3.2634	9.5000	AID1531644; AID1715394; AID49334
Cyclin-A1	Homo sapiens (human)	IC50 (µMol)	0.0013	0.0005	1.4715	10.0000	AID1531937; AID1715412; AID1731526; AID745527
Cyclin-A1	Homo sapiens (human)	Ki	0.0040	0.0040	0.1480	0.2500	AID723734
Mitogen-activated protein kinase kinase kinase 9	Homo sapiens (human)	IC50 (µMol)	0.0044	0.0005	0.2244	2.1000	AID1531777; AID1715267; AID1733104
MO15-related protein kinase Pfmrk	Plasmodium falciparum (malaria parasite P. falciparum)	IC50 (µMol)	4.0000	0.7000	4.3200	7.0000	AID242065; AID55537
Cyclin-dependent kinase 3	Homo sapiens (human)	IC50 (µMol)	0.0118	0.0017	0.2026	2.2000	AID1531626; AID1612686; AID1691913; AID1715410; AID415615; AID745526
Cyclin-dependent kinase 6	Homo sapiens (human)	IC50 (µMol)	0.0395	0.0019	0.8654	7.2000	AID1531631; AID1531632; AID1715403; AID1715404; AID1917241; AID415619; AID745523
Cyclin-dependent-like kinase 5	Homo sapiens (human)	IC50 (µMol)	0.0141	0.0002	1.1832	10.0000	AID1531629; AID1531630; AID1715405; AID1715406; AID415617; AID415618; AID494391; AID745524; AID767307
Cyclin-dependent kinase 16	Homo sapiens (human)	IC50 (µMol)	0.0206	0.0172	0.7471	2.2000	AID1531620; AID1715416
Cyclin-dependent kinase 17	Homo sapiens (human)	IC50 (µMol)	0.0135	0.0107	0.7423	2.2000	AID1531621; AID1715415
Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0480	0.0006	1.5257	10.0000	AID1279101
Epidermal growth factor receptor	Mus musculus (house mouse)	IC50 (µMol)	10.0000	0.0810	0.0905	0.1000	AID241562
Protein kinase C epsilon type	Homo sapiens (human)	IC50 (µMol)	0.0767	0.0001	0.8029	10.0000	AID1059944; AID1068655; AID1180278; AID1191823; AID1531840; AID155717; AID163687; AID163692; AID163706; AID164952; AID165147; AID1715208; AID240699; AID385587; AID385588; AID427620
Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)	IC50 (µMol)	0.2314	0.0002	0.6813	9.7000	AID1059941; AID1063047; AID1247636; AID1252496; AID126618; AID126621; AID1481078; AID1531762; AID164360; AID1715281; AID427623; AID629398
Angiopoietin-1 receptor	Homo sapiens (human)	IC50 (µMol)	9,916.7353	0.0004	0.5553	9.0700	AID1308983; AID1351003; AID1531907; AID1680557; AID1715144; AID350298
Mitogen-activated protein kinase kinase kinase 10	Homo sapiens (human)	IC50 (µMol)	0.1952	0.0020	0.1035	0.5800	AID1531778; AID1715266; AID1733105
Protein kinase C theta type	Homo sapiens (human)	IC50 (µMol)	0.1168	0.0001	0.9897	10.0000	AID1068655; AID1180278; AID1531846; AID155717; AID164952; AID165147; AID1678147; AID1715202; AID240699
Activin receptor type-1	Homo sapiens (human)	IC50 (µMol)	4.1977	0.0010	0.7255	8.0380	AID1142607; AID1799383
Macrophage-stimulating protein receptor	Homo sapiens (human)	IC50 (µMol)	0.2195	0.0012	0.2698	3.3700	AID1247641; AID1308979; AID1531868; AID1715182; AID629404
Focal adhesion kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0780	0.0002	0.5416	8.3000	AID1063048; AID1142794; AID1247626; AID1252495; AID1394741; AID1410141; AID1481073; AID1531691; AID1715350; AID629274
Protein kinase C zeta type	Homo sapiens (human)	IC50 (µMol)	1.0044	0.0001	2.4453	10.0000	AID1068655; AID1180278; AID1308975; AID1531847; AID155717; AID164194; AID164195; AID164952; AID165147; AID1715201; AID1797337; AID240699; AID241300
Protein kinase C delta type	Homo sapiens (human)	IC50 (µMol)	0.1283	0.0001	0.8448	10.0000	AID1068655; AID1180278; AID1410143; AID1531839; AID155717; AID163379; AID163504; AID163520; AID164952; AID165147; AID1715209; AID240699; AID241336; AID262974; AID385589
Tyrosine-protein kinase BTK	Homo sapiens (human)	IC50 (µMol)	2.1676	0.0001	0.2557	7.6000	AID1308935; AID1350957; AID1450413; AID1481071; AID1531599; AID1715438; AID350253
Aldehyde oxidase	Homo sapiens (human)	IC50 (µMol)	0.0023	0.0023	0.6320	3.3000	AID1481085
Tyrosine-protein kinase receptor TYRO3	Homo sapiens (human)	IC50 (µMol)	0.0177	0.0014	0.0573	0.3010	AID1531921; AID1715131; AID494407
Cyclin-dependent kinase 18	Homo sapiens (human)	IC50 (µMol)	0.0587	0.0511	0.7725	2.2000	AID1531622; AID1715414
Activated CDC42 kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0299	0.0027	0.3447	3.1000	AID1531574; AID1715454
Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)	IC50 (µMol)	0.9655	0.0005	0.2657	2.8900	AID1531659; AID1705872; AID1715381
Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)	IC50 (µMol)	5.3379	0.0010	0.3090	5.6500	AID1450415; AID1531732; AID1715310
Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)	Ki	0.0061	0.0022	0.0094	0.0160	AID1798742
Myotonin-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.1735	0.1050	0.4490	1.0000	AID1531662; AID1715377
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	90.4000	0.0009	1.9014	10.0000	AID1704347
Mitogen-activated protein kinase kinase kinase 12	Homo sapiens (human)	IC50 (µMol)	0.0992	0.0184	0.0992	0.1800	AID1531661; AID1715379
Tyrosine-protein kinase Mer	Homo sapiens (human)	IC50 (µMol)	0.0331	0.0005	0.2863	4.9000	AID1304448; AID1531601; AID1715435
Serine/threonine-protein kinase 4	Homo sapiens (human)	IC50 (µMol)	0.0013	0.0010	0.0869	0.1910	AID1531788; AID1715256
Serine/threonine-protein kinase PAK 1	Homo sapiens (human)	IC50 (µMol)	0.0004	0.0002	0.3001	2.5000	AID1350990; AID1531816; AID1715233
Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)	IC50 (µMol)	0.0252	0.0015	0.8199	5.7000	AID1531765; AID1715278
Mitogen-activated protein kinase 7	Homo sapiens (human)	IC50 (µMol)	5.9524	0.0590	1.2818	6.3680	AID1350970; AID1350971; AID1531687; AID1715354
Serine/threonine-protein kinase PAK 2	Homo sapiens (human)	IC50 (µMol)	0.0021	0.0010	0.0281	0.1900	AID1350991; AID1531817; AID1715231; AID350548
Serine/threonine-protein kinase 3	Homo sapiens (human)	IC50 (µMol)	0.0034	0.0004	0.3512	2.2000	AID1350988; AID1531789; AID1715255; AID350283
Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)	IC50 (µMol)	0.4380	0.0980	0.3247	0.4850	AID1531766; AID1715279
cGMP-dependent protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0161	0.0058	0.0161	0.0265	AID1531851; AID1715197
Rho-associated protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0038	0.0004	0.8549	10.0000	AID1252499; AID1300789; AID1350999; AID1531866; AID1715184; AID350293
Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)	IC50 (µMol)	0.0012	0.0006	0.8675	2.6000	AID1531911; AID1715140
Calcium/calmodulin-dependent protein kinase type II subunit beta	Homo sapiens (human)	IC50 (µMol)	0.0018	0.0001	1.0320	10.0000	AID1350959; AID1531609; AID165266; AID1715427; AID350254; AID45962; AID45969
Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)	IC50 (µMol)	0.0026	0.0004	1.0531	10.0000	AID1531611; AID165266; AID1715425; AID45962; AID45969
Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)	IC50 (µMol)	0.0024	0.0000	0.9157	10.0000	AID1531610; AID165266; AID1715426; AID45962; AID45969
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)	IC50 (µMol)	0.0095	0.0031	0.7140	9.0120	AID1420033; AID1531665; AID1715375; AID1764191
Bone morphogenetic protein receptor type-2	Homo sapiens (human)	IC50 (µMol)	1.9400	0.0740	1.6988	3.8450	AID1531593; AID1715442
Protein-tyrosine kinase 6	Homo sapiens (human)	IC50 (µMol)	0.4840	0.0053	0.5770	2.3000	AID1067087; AID1308934; AID1531596; AID1715440
cGMP-dependent protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0027	0.0011	0.0267	0.0980	AID1300793; AID1531849; AID1531850; AID1715198; AID1715199
Cyclin-dependent kinase 13	Homo sapiens (human)	IC50 (µMol)	0.0570	0.0100	0.4404	2.2000	AID1356600
Calcium/calmodulin-dependent protein kinase type 1	Homo sapiens (human)	IC50 (µMol)	0.0032	0.0030	0.0032	0.0033	AID1531604; AID1715432
Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)	IC50 (µMol)	0.0003	0.0002	1.0855	5.1286	AID1531727; AID1715316
Protein-tyrosine kinase 2-beta	Homo sapiens (human)	IC50 (µMol)	0.0095	0.0002	0.1562	1.0000	AID1531860; AID1715188
Maternal embryonic leucine zipper kinase	Homo sapiens (human)	IC50 (µMol)	0.0006	0.0004	0.3577	0.7600	AID1531770; AID1715274
Lysine--tRNA ligase	Homo sapiens (human)	IC50 (µMol)	0.0049	0.0009	0.3073	1.4740	AID1410144; AID342540
Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)	IC50 (µMol)	0.0141	0.0010	1.2898	10.0000	AID1531629; AID1531630; AID1715405; AID1715406; AID415617; AID415618; AID494391; AID745524; AID767307
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)	IC50 (µMol)	0.0005	0.0005	1.8909	9.5000	AID1531826; AID1715221
Serine/threonine-protein kinase D1	Homo sapiens (human)	IC50 (µMol)	0.1448	0.0001	1.2319	10.0000	AID1068655; AID1180278; AID1531844; AID155717; AID164952; AID165147; AID1715204; AID240699
Serine/threonine-protein kinase 38	Homo sapiens (human)	IC50 (µMol)	0.0037	0.0006	0.0037	0.0069	AID1531895; AID1715155
Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)	IC50 (µMol)	0.1830	0.0001	0.1736	2.5900	AID1308940; AID1308959; AID1531684; AID1664190; AID1664198; AID1715357; AID1772910; AID350300
Ribosomal protein S6 kinase alpha-2	Homo sapiens (human)	IC50 (µMol)	0.0002	0.0001	0.3165	2.2000	AID1531872; AID1715179
Ephrin type-A receptor 7	Homo sapiens (human)	IC50 (µMol)	0.0477	0.0392	0.3652	1.0000	AID1531677; AID1715365
Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)	IC50 (µMol)	0.0004	0.0001	0.1861	1.2600	AID1300787; AID1351000; AID1531870; AID1715180; AID350294; AID627289
Dual specificity testis-specific protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.1995	0.1380	0.1995	0.2610	AID1531905; AID1715146
Myosin light chain kinase, smooth muscle	Homo sapiens (human)	IC50 (µMol)	0.0448	0.0220	2.4133	10.0000	AID1531775; AID1715268; AID225703
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1	Homo sapiens (human)	IC50 (µMol)	0.0370	0.0080	0.1471	0.9000	AID1709608; AID350297
Mitogen-activated protein kinase 11	Homo sapiens (human)	IC50 (µMol)	1.0000	0.0007	0.4754	6.3000	AID127093
Serine/threonine-protein kinase STK11	Homo sapiens (human)	IC50 (µMol)	0.0598	0.0487	0.0598	0.0709	AID1531749; AID1715295
Rhodopsin kinase GRK1	Homo sapiens (human)	IC50 (µMol)	0.0680	0.0578	0.1586	0.3400	AID1531707; AID1715334
Coiled-coil domain-containing protein 6	Homo sapiens (human)	IC50 (µMol)	0.0022	0.0003	0.1429	0.8890	AID1704868
NT-3 growth factor receptor	Homo sapiens (human)	IC50 (µMol)	0.0002	0.0001	0.1336	1.1150	AID1531914; AID1715137
Serine/threonine-protein kinase N1	Homo sapiens (human)	IC50 (µMol)	0.0025	0.0010	1.1157	5.8000	AID1063040; AID1308976; AID1531852; AID1715196
Serine/threonine-protein kinase N2	Homo sapiens (human)	IC50 (µMol)	0.0055	0.0020	0.9723	4.8000	AID1308977; AID1531853; AID1612687; AID1715195
Mitogen-activated protein kinase 14	Homo sapiens (human)	IC50 (µMol)	0.5052	0.0001	0.7266	7.8000	AID127093; AID1308971
Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)	IC50 (µMol)	0.1475	0.1380	0.1475	0.1570	AID1531612; AID1715424
Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)	IC50 (µMol)	0.0160	0.0040	0.1021	1.1400	AID1531779; AID1715265; AID1733106
BDNF/NT-3 growth factors receptor	Homo sapiens (human)	IC50 (µMol)	0.0004	0.0001	0.3352	2.9620	AID1531913; AID1715138; AID629407
MAP kinase-activated protein kinase 3	Homo sapiens (human)	IC50 (µMol)	2.7750	0.0530	1.7852	3.5500	AID1531756; AID1715287
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Homo sapiens (human)	IC50 (µMol)	0.0017	0.0005	0.0017	0.0026	AID1531828; AID159258; AID1715219
Discoidin domain-containing receptor 2	Homo sapiens (human)	IC50 (µMol)	0.0008	0.0004	0.3938	9.0000	AID1531660; AID1715380
Thioredoxin reductase 1, cytoplasmic	Homo sapiens (human)	IC50 (µMol)	0.0432	0.0432	2.2655	5.0000	AID1778246
Rho-associated protein kinase 2	Bos taurus (cattle)	IC50 (µMol)	0.0417	0.0012	1.3884	9.0000	AID1797134; AID1797135
Myosin light chain kinase 3	Homo sapiens (human)	IC50 (µMol)	0.1585	0.1290	0.1585	0.1880	AID1531793; AID1715251
Serine/threonine-protein kinase SBK1	Homo sapiens (human)	IC50 (µMol)	0.1464	0.0998	0.1464	0.1930	AID1531874; AID1715175
Mitogen-activated protein kinase kinase kinase 19	Homo sapiens (human)	IC50 (µMol)	0.0087	0.0019	0.0087	0.0156	AID1531932; AID1715124
Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0077	0.0004	0.3943	8.3000	AID1531751; AID1715294; AID756067
Mitogen-activated protein kinase kinase kinase 21	Homo sapiens (human)	IC50 (µMol)	1.1175	0.7650	1.1175	1.4700	AID1531780; AID1715263
Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)	IC50 (µMol)	0.0032	0.0010	0.0032	0.0054	AID1531783; AID1715261
Sigma non-opioid intracellular receptor 1	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.0067	0.0020	2.1233	10.0000	AID1300803; AID1300805
Testis-specific serine/threonine-protein kinase 1	Mus musculus (house mouse)	IC50 (µMol)	0.0003	0.0003	0.0003	0.0003	AID1300794
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0120	0.0100	0.5741	2.8000	AID1765307
Protein kinase C eta type	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2740	0.0000	0.2585	1.0000	AID164969; AID1650882; AID1650883; AID1650884; AID1650885; AID165101; AID165105; AID165106; AID165111; AID165113; AID165122
Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)	IC50 (µMol)	0.0005	0.0002	0.0005	0.0008	AID1531663; AID1715378
Calcium/calmodulin-dependent protein kinase type 1B	Homo sapiens (human)	IC50 (µMol)	0.0044	0.0038	0.0044	0.0050	AID1531605; AID1715431
Serine/threonine-protein kinase Nek5	Homo sapiens (human)	IC50 (µMol)	0.0864	0.0763	0.0864	0.0965	AID1531802; AID1715241
Serine/threonine-protein kinase N3	Homo sapiens (human)	IC50 (µMol)	0.0105	0.0078	0.0105	0.0132	AID1531854; AID1715194
Serine/threonine-protein kinase ULK3	Homo sapiens (human)	IC50 (µMol)	0.0027	0.0012	0.0027	0.0042	AID1531924; AID1715128
Kinase suppressor of Ras 2	Homo sapiens (human)	IC50 (µMol)	5.4000	3.9800	5.4000	6.8200	AID1531742; AID1715302
Dual serine/threonine and tyrosine protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0552	0.0313	0.0552	0.0690	AID1531865; AID1612685; AID1715185
Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)	IC50 (µMol)	0.0416	0.0174	0.0416	0.0658	AID1531690; AID1715351
Serine/threonine-protein kinase MARK2	Homo sapiens (human)	IC50 (µMol)	0.0001	0.0001	0.0001	0.0001	AID1531759; AID1715284
Serine/threonine-protein kinase TAO1	Homo sapiens (human)	IC50 (µMol)	0.0008	0.0005	0.0008	0.0012	AID1531900; AID1715150
Serine/threonine-protein kinase Nek8	Homo sapiens (human)	IC50 (µMol)	0.0263	0.0175	0.0263	0.0351	AID1531805; AID1715242
Serine/threonine-protein kinase tousled-like 2	Homo sapiens (human)	IC50 (µMol)	0.0035	0.0034	0.0035	0.0037	AID1531909; AID1715141
Serine/threonine-protein kinase 32C	Homo sapiens (human)	IC50 (µMol)	0.2320	0.1390	0.2320	0.3250	AID1531893; AID1715156
Serine/threonine-protein kinase pim-3	Homo sapiens (human)	IC50 (µMol)	0.0001	0.0001	0.4198	4.3000	AID1481654; AID1531832; AID1715216
Myosin light chain kinase family member 4	Homo sapiens (human)	IC50 (µMol)	0.0537	0.0529	0.0537	0.0545	AID1531794; AID1715250
Homeodomain-interacting protein kinase 1	Homo sapiens (human)	IC50 (µMol)	2.6390	0.1000	0.6100	2.6390	AID350274
Calcium/calmodulin-dependent protein kinase type 1D	Homo sapiens (human)	IC50 (µMol)	0.0003	0.0002	0.0308	0.0920	AID1531606; AID1715430
Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)	IC50 (µMol)	0.0001	0.0001	0.4858	1.7000	AID1531706; AID1715335
Kinase suppressor of Ras 1	Homo sapiens (human)	IC50 (µMol)	6.2650	4.5900	6.2650	7.9400	AID1531741; AID1715303
Cyclin-dependent kinase-like 3	Homo sapiens (human)	IC50 (µMol)	1.1000	0.0071	2.5268	7.9000	AID1733107
MAP kinase-activated protein kinase 5	Homo sapiens (human)	IC50 (µMol)	0.2120	0.0050	1.1575	3.0100	AID1531757; AID1715288
Serine/threonine-protein kinase BRSK2	Homo sapiens (human)	IC50 (µMol)	0.0028	0.0023	0.2591	1.1000	AID1531598; AID1715437
Serine/threonine-protein kinase NIM1	Homo sapiens (human)	IC50 (µMol)	0.1102	0.0915	0.1102	0.1290	AID1531807; AID1715238
Serine/threonine-protein kinase ULK2	Homo sapiens (human)	IC50 (µMol)	0.0032	0.0011	0.8222	4.5780	AID1531923; AID1715129
Misshapen-like kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0004	0.0002	0.0106	0.0400	AID1350986; AID1531771; AID1715272; AID350282
Serine/threonine-protein kinase DCLK2	Homo sapiens (human)	IC50 (µMol)	0.0890	0.0835	0.0890	0.0944	AID1531658; AID1715383
Calcium/calmodulin-dependent protein kinase kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0359	0.0298	0.0349	0.0420	AID1531613; AID1715423
Casein kinase I isoform alpha-like	Homo sapiens (human)	IC50 (µMol)	1.8400	1.2700	1.8400	2.4100	AID1531640; AID1715396
Cyclin-Y	Homo sapiens (human)	IC50 (µMol)	0.0518	0.0107	0.0483	0.1280	AID1531619; AID1531620; AID1531621; AID1531622; AID1715414; AID1715415; AID1715416; AID1715417
Homeodomain-interacting protein kinase 4	Homo sapiens (human)	IC50 (µMol)	0.2260	0.0030	0.1221	0.3140	AID1531722; AID1715321
Myosin-IIIa	Homo sapiens (human)	IC50 (µMol)	0.0425	0.0402	0.0425	0.0448	AID1531795; AID1715248
Serine/threonine-protein kinase Nek11	Homo sapiens (human)	IC50 (µMol)	0.5210	0.2900	0.5210	0.7520	AID1531798; AID1715246
Protein odd-skipped-related 1	Homo sapiens (human)	IC50 (µMol)	0.0402	0.0191	0.0402	0.0613	AID1531809; AID1715237
Mitogen-activated protein kinase 15	Homo sapiens (human)	IC50 (µMol)	0.0081	0.0073	0.0886	0.3300	AID1350972; AID1531688; AID1715353
Serine/threonine-protein kinase Nek9	Homo sapiens (human)	IC50 (µMol)	0.1010	0.0710	0.1010	0.1310	AID1531806; AID1715240
Serine/threonine-protein kinase BRSK1	Homo sapiens (human)	IC50 (µMol)	0.0007	0.0005	0.0628	0.1870	AID1531597; AID1715439
Serine/threonine-protein kinase haspin	Homo sapiens (human)	IC50 (µMol)	0.0422	0.0020	0.1907	0.7700	AID1531716; AID1612688; AID1715325
Rhodopsin kinase GRK7	Homo sapiens (human)	IC50 (µMol)	0.0053	0.0046	0.0635	0.1800	AID1531713; AID1715328
G2/mitotic-specific cyclin-B3	Homo sapiens (human)	IC50 (µMol)	0.0107	0.0025	1.8172	10.0000	AID1247622; AID240955; AID512487; AID512718; AID55343
Myosin-IIIb	Homo sapiens (human)	IC50 (µMol)	0.0058	0.0052	0.0058	0.0064	AID1531796; AID1715249
Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)	IC50 (µMol)	0.1800	0.0140	0.9744	3.0000	AID1531667; AID1715374
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Phosphorylase b kinase regulatory subunit beta	Homo sapiens (human)	IC50 (µMol)	0.0005	0.0005	0.0013	0.0017	AID159258
Serine/threonine-protein kinase Sgk3	Homo sapiens (human)	IC50 (µMol)	0.0730	0.0696	0.0730	0.0765	AID1531877; AID1715172
Aurora kinase B	Homo sapiens (human)	IC50 (µMol)	0.0070	0.0003	0.9634	9.8000	AID1063049; AID1184499; AID1186610; AID1294630; AID1294635; AID1304187; AID1421401; AID1531589; AID1662791; AID1715447; AID1736661
Lymphokine-activated killer T-cell-originated protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0691	0.0543	0.0691	0.0839	AID1531823; AID1715226
MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)	IC50 (µMol)	0.0001	0.0001	0.4854	1.7700	AID1531761; AID1715283
Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)	IC50 (µMol)	0.0047	0.0040	0.0047	0.0053	AID1531607; AID1715429
Testis-specific serine/threonine-protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0038	0.0033	0.0038	0.0043	AID1531915; AID1715135
Testis-specific serine/threonine-protein kinase 3	Homo sapiens (human)	IC50 (µMol)	0.0051	0.0032	0.0051	0.0070	AID1531916; AID1715136
Serine/threonine-protein kinase Nek1	Homo sapiens (human)	IC50 (µMol)	0.0122	0.0091	0.0122	0.0184	AID1531797; AID1715247; AID1830876
Serine/threonine-protein kinase LMTK3	Homo sapiens (human)	IC50 (µMol)	0.0000	0.0000	1.3156	4.6530	AID1619248; AID1659479
PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0107	0.0055	0.0107	0.0158	AID1531822; AID1715225
Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0246	0.0030	0.4017	2.4500	AID1531614; AID1715422
SRSF protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0337	0.0245	0.2881	0.8900	AID1531885; AID1715165
Mitogen-activated protein kinase kinase kinase 14	Homo sapiens (human)	IC50 (µMol)	2.3000	0.2440	1.2720	2.3000	AID493445
Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)	IC50 (µMol)	0.2150	0.0007	1.1713	7.0000	AID1410111; AID1531587; AID1715448; AID407189; AID407190
Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)	IC50 (µMol)	0.0092	0.0076	0.0092	0.0109	AID1531768; AID1715275
MAP kinase-interacting serine/threonine-protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0531	0.0070	1.1169	3.0100	AID1531781; AID1715264
Testis-specific serine/threonine-protein kinase 6	Homo sapiens (human)	IC50 (µMol)	0.1525	0.1120	0.1525	0.1930	AID1531887; AID1715164
Testis-specific serine/threonine-protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0000	0.0000	0.0077	0.0230	AID1531890; AID1715161
Serine/threonine-protein kinase 33	Homo sapiens (human)	IC50 (µMol)	0.0374	0.0140	0.8971	5.0000	AID1531894; AID1715157
Serine/threonine-protein kinase D2	Homo sapiens (human)	IC50 (µMol)	0.0014	0.0013	0.1682	0.7860	AID1531848; AID1715200
NUAK family SNF1-like kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0018	0.0017	0.5607	2.6000	AID1531882; AID1715168
Serine/threonine-protein kinase SIK2	Homo sapiens (human)	IC50 (µMol)	0.3669	0.0003	1.2465	6.6000	AID1531879; AID1715171; AID1895097
Myosin light chain kinase 2, skeletal/cardiac muscle	Homo sapiens (human)	IC50 (µMol)	0.0147	0.0139	0.2435	0.7010	AID1531776; AID1715269
STE20-like serine/threonine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0142	0.0061	0.2149	1.0000	AID1531881; AID1715169; AID1779842
Serine/threonine-protein kinase TAO3	Homo sapiens (human)	IC50 (µMol)	0.0017	0.0012	0.0017	0.0021	AID1531902; AID1715149
Homeodomain-interacting protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.3655	0.1000	0.5720	3.3000	AID1531720; AID1715323
Tyrosine-protein kinase Srms	Homo sapiens (human)	IC50 (µMol)	6.5000	4.2300	6.5000	8.7700	AID1531884; AID1715167
Homeodomain-interacting protein kinase 3	Homo sapiens (human)	IC50 (µMol)	0.4560	0.0450	0.1608	0.7100	AID1531721; AID1715320
Serine/threonine-protein kinase PLK3	Homo sapiens (human)	IC50 (µMol)	5.1015	0.0020	0.6103	7.2000	AID1348851; AID1531857; AID1610357; AID1715191
Serine/threonine-protein kinase PLK3	Homo sapiens (human)	Ki	0.5357	0.0010	1.2726	9.3000	AID1798514
Inactive tyrosine-protein kinase PEAK1	Homo sapiens (human)	IC50 (µMol)	0.0025	0.0020	0.0025	0.0030	AID1531827; AID1715222
Dual specificity protein kinase CLK4	Homo sapiens (human)	IC50 (µMol)	0.0723	0.0110	1.0694	7.9430	AID1531651; AID1715387
MAP kinase-interacting serine/threonine-protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0221	0.0070	0.9594	6.2700	AID1350987; AID1531782; AID1715262
Serine/threonine-protein kinase Sgk2	Homo sapiens (human)	IC50 (µMol)	0.0159	0.0152	0.0159	0.0165	AID1531876; AID1715174
Serine/threonine-protein kinase Nek6	Homo sapiens (human)	IC50 (µMol)	10.0000	1.0650	2.6475	4.2300	AID1063043
Casein kinase I isoform gamma-1	Homo sapiens (human)	IC50 (µMol)	5.3367	0.0040	4.7163	9.5000	AID1531643; AID1715395; AID49334
NADPH oxidase 4	Homo sapiens (human)	IC50 (µMol)	0.0708	0.0708	0.8788	1.3400	AID1778250
Serine/threonine-protein kinase PAK 6	Homo sapiens (human)	IC50 (µMol)	0.0327	0.0060	0.0221	0.0345	AID1531821; AID1715227
SNF-related serine/threonine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0059	0.0038	0.0059	0.0080	AID1531883; AID1715166
Serine/threonine-protein kinase LATS2	Homo sapiens (human)	IC50 (µMol)	0.0062	0.0038	0.0062	0.0086	AID1531744; AID1715299
Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)	IC50 (µMol)	0.0122	0.0042	0.1052	0.5740	AID1350980; AID1531730; AID1715312; AID350276
Serine/threonine-protein kinase 32B	Homo sapiens (human)	IC50 (µMol)	0.0375	0.0258	0.0375	0.0491	AID1531892; AID1715158
Cyclin-dependent kinase 12	Homo sapiens (human)	IC50 (µMol)	0.0530	0.0070	1.0175	8.5000	AID1356598
Serine/threonine-protein kinase PLK2	Homo sapiens (human)	IC50 (µMol)	0.5460	0.0035	0.2405	0.9572	AID1348849; AID1350997; AID1531856; AID1610356; AID1715193; AID350291
Serine/threonine-protein kinase PLK2	Homo sapiens (human)	Ki	0.5357	0.0010	1.2726	9.3000	AID1798514
Serine/threonine-protein kinase MARK1	Homo sapiens (human)	IC50 (µMol)	0.0003	0.0003	0.0003	0.0004	AID1531758; AID1715286
Serine/threonine-protein kinase pim-2	Homo sapiens (human)	IC50 (µMol)	0.0813	0.0047	0.5214	5.1000	AID1531831; AID1715217; AID327000; AID418384; AID418385
Serine/threonine-protein kinase PAK 5	Homo sapiens (human)	IC50 (µMol)	0.0039	0.0025	0.0195	0.0520	AID1531820; AID1715229
Serine/threonine-protein kinase 26	Homo sapiens (human)	IC50 (µMol)	0.0124	0.0029	0.0676	0.1780	AID1531791; AID1715254
Serine/threonine-protein kinase NLK	Homo sapiens (human)	IC50 (µMol)	0.0666	0.0555	0.3778	1.0000	AID1531808; AID1715239
Ribosomal protein S6 kinase beta-2	Homo sapiens (human)	IC50 (µMol)	0.0015	0.0007	2.5038	10.0000	AID1531815; AID1715232
Protein DBF4 homolog A	Homo sapiens (human)	IC50 (µMol)	0.0549	0.0100	0.0324	0.0634	AID1531615; AID1715421
Serine/threonine-protein kinase 17A	Homo sapiens (human)	IC50 (µMol)	0.0386	0.0100	0.8700	5.8500	AID1531664; AID1715376; AID1911005
STE20/SPS1-related proline-alanine-rich protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0158	0.0144	0.0158	0.0172	AID1531897; AID1715152
Ephrin type-A receptor 6	Homo sapiens (human)	IC50 (µMol)	0.0161	0.0118	0.0984	0.2630	AID1531676; AID1715364
Serine/threonine-protein kinase TBK1	Homo sapiens (human)	IC50 (µMol)	0.0030	0.0022	0.8565	6.2200	AID1531903; AID1715147
Death-associated protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0064	0.0056	1.0276	3.0700	AID1531656; AID1715384
Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)	IC50 (µMol)	0.0001	0.0001	0.3353	2.2000	AID1531873; AID1715177
TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)	IC50 (µMol)	0.0103	0.0003	0.2924	1.0000	AID1531910; AID1715142; AID721047; AID721050
Serine/threonine-protein kinase tousled-like 1	Homo sapiens (human)	IC50 (µMol)	0.0295	0.0217	0.0295	0.0364	AID1531908; AID1612683; AID1715143
Serine/threonine-protein kinase TAO2	Homo sapiens (human)	IC50 (µMol)	0.0076	0.0035	0.0076	0.0117	AID1531901; AID1715148
ALK tyrosine kinase receptor	Homo sapiens (human)	IC50 (µMol)	0.0044	0.0001	0.3107	10.0000	AID1063053; AID1247616; AID1300798; AID1308930; AID1410146; AID1471738; AID1471739; AID1471754; AID1471755; AID1471756; AID1471757; AID1471758; AID1531578; AID1715450; AID1846769; AID627291; AID629264
SRSF protein kinase 3	Homo sapiens (human)	IC50 (µMol)	1.7700	1.5800	1.7700	1.9600	AID1531787; AID1715257
Serine/threonine-protein kinase ICK	Homo sapiens (human)	IC50 (µMol)	0.0443	0.0386	0.0443	0.0533	AID1350984; AID1531746; AID1715298
Aurora kinase C	Homo sapiens (human)	IC50 (µMol)	0.0022	0.0010	0.4137	8.6000	AID1531590; AID1715445
Calcium/calmodulin-dependent protein kinase type II subunit alpha	Homo sapiens (human)	IC50 (µMol)	0.0022	0.0000	1.6395	10.0000	AID1531608; AID165266; AID1715428; AID269866; AID45962; AID45969
Protein kinase C theta type	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.2740	0.0000	0.2585	1.0000	AID164969; AID1650882; AID1650883; AID1650884; AID1650885; AID165101; AID165105; AID165106; AID165111; AID165113; AID165122
RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)	IC50 (µMol)	0.3701	0.0006	0.4743	4.0000	AID1300785; AID1531577; AID1687404; AID1715451; AID1797336; AID262363; AID262971; AID269861; AID415638
Serine/threonine-protein kinase 38-like	Homo sapiens (human)	IC50 (µMol)	0.0012	0.0008	0.0012	0.0015	AID1531896; AID1715154
Serine/threonine-protein kinase SIK3	Homo sapiens (human)	IC50 (µMol)	0.1541	0.0010	2.0134	9.6000	AID1531880; AID1715170; AID1895098
Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0335	0.0235	0.2427	0.6610	AID1531767; AID1715277
Serine/threonine-protein kinase WNK2	Homo sapiens (human)	IC50 (µMol)	1.4550	1.4500	2.2673	3.8920	AID1531929; AID1715126
Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)	IC50 (µMol)	0.0017	0.0010	0.5851	4.4200	AID1531666; AID1715373; AID1764190
5'-AMP-activated protein kinase subunit beta-1	Homo sapiens (human)	IC50 (µMol)	3.0363	0.0010	1.1916	8.0380	AID1799383
Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)	IC50 (µMol)	0.0002	0.0002	0.5080	1.5690	AID1531740; AID1715304
Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)	IC50 (µMol)	0.0027	0.0007	0.3352	1.0000	AID1531784; AID1715260
Serine/threonine-protein kinase 24	Homo sapiens (human)	IC50 (µMol)	0.0065	0.0033	0.0058	0.0118	AID1531790; AID1612682; AID1715253
Casein kinase I isoform gamma-3	Homo sapiens (human)	IC50 (µMol)	2.6750	1.9800	2.6750	3.3700	AID1531645; AID1715393
Chain A, Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)	IC50 (µMol)	0.0003	0.0003	0.0003	0.0003	AID977608
Chain X, Tyrosine-protein kinase Lyn	Homo sapiens (human)	IC50 (µMol)	0.0013	0.0013	0.0013	0.0013	AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Leukotriene C4 synthase	Cavia porcellus (domestic guinea pig)	Kd	3.5000	0.9300	2.5478	5.7000	AID625128
Bone morphogenetic protein receptor type-1B	Homo sapiens (human)	Kd	0.1700	0.0009	1.1413	3.7000	AID624825
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)	Kd	10.0000	0.0033	1.5175	7.6000	AID624974
Serine/threonine-protein kinase PLK4	Homo sapiens (human)	Kd	0.0008	0.0008	1.5144	9.0000	AID256607; AID436044; AID625076
Serine/threonine-protein kinase 25	Homo sapiens (human)	Kd	0.1100	0.0120	2.5734	9.2000	AID435329; AID625059
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)	Kd	10.0000	0.0005	1.0152	5.2000	AID624877
Citron Rho-interacting kinase	Homo sapiens (human)	Kd	0.3400	0.0330	3.0646	48.8760	AID435523; AID625065
Serine/threonine-protein kinase RIO3	Homo sapiens (human)	Kd	0.0769	0.0077	1.4099	9.7000	AID1733813; AID435191; AID624926
Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)	Kd	0.0300	0.0270	1.4471	5.3000	AID624722
Serine/threonine-protein kinase Chk1	Homo sapiens (human)	Kd	0.0032	0.0028	1.4744	8.7000	AID435396; AID624831
Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)	Kd	0.0310	0.0120	1.5827	6.3000	AID624836
Peripheral plasma membrane protein CASK	Homo sapiens (human)	Kd	0.0190	0.0190	0.9330	2.8000	AID624749
Aurora kinase A	Homo sapiens (human)	Kd	0.0477	0.0001	0.7342	9.3000	AID256613; AID435518; AID624919
Cyclin-G-associated kinase	Homo sapiens (human)	Kd	0.0340	0.0003	0.9086	28.6510	AID256612; AID435821; AID625012
Serine/threonine-protein kinase DCLK1	Homo sapiens (human)	Kd	0.1100	0.0049	1.8360	8.1000	AID435284; AID624966
Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)	Kd	0.0058	0.0058	1.5058	5.9000	AID624832
Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)	Kd	0.0860	0.0031	0.6128	4.1000	AID435678; AID625022
Ephrin type-B receptor 6	Homo sapiens (human)	Kd	0.2100	0.0000	1.0768	9.0000	AID624957
Mitogen-activated protein kinase 13	Homo sapiens (human)	Kd	0.2400	0.0001	1.4667	6.6000	AID624892
3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)	Kd	0.0017	0.0017	1.3432	3.5000	AID435189; AID624876
Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)	Kd	0.2100	0.0160	0.9316	5.3000	AID624965
Death-associated protein kinase 3	Homo sapiens (human)	Kd	0.3758	0.0010	1.8241	9.9000	AID256659; AID435155; AID435398; AID624834
Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)	Kd	0.0670	0.0015	1.6660	8.5000	AID624724
Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)	Kd	5.1667	0.0020	1.6212	11.4330	AID256611; AID435935; AID624925
NUAK family SNF1-like kinase 1	Homo sapiens (human)	Kd	0.0044	0.0037	0.5214	5.9000	AID435150; AID625088
Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)	Kd	2.7000	0.0180	2.4890	6.7000	AID624751
Tyrosine-protein kinase JAK2	Homo sapiens (human)	Kd	0.0106	0.0000	0.8851	7.0000	AID256645; AID435658; AID624973
Rho-associated protein kinase 2	Homo sapiens (human)	Kd	0.0002	0.0002	2.7105	56.0660	AID624969
Serine/threonine-protein kinase ULK1	Homo sapiens (human)	Kd	0.0099	0.0008	1.8410	23.2730	AID624916
Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)	Kd	0.0210	0.0057	2.0095	12.2010	AID624835
Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)	Kd	0.3768	0.0170	1.9737	29.9570	AID256648; AID435831; AID436051; AID624736; AID624967
Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)	Kd	1.1600	0.0120	1.6396	7.2000	AID435325; AID435441; AID624806; AID624927
Serine/threonine-protein kinase 16	Homo sapiens (human)	Kd	0.2467	0.0017	1.2483	9.9690	AID256606; AID435692; AID624775
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)	Kd	0.4300	0.0032	1.0024	7.5000	AID624958
Serine/threonine-protein kinase PAK 3	Homo sapiens (human)	Kd	0.0049	0.0005	1.4483	5.7000	AID256625; AID435823; AID624873
Cyclin-dependent kinase-like 5	Homo sapiens (human)	Kd	0.3400	0.0017	1.4788	7.3000	AID624905
Serine/threonine-protein kinase 17B	Homo sapiens (human)	Kd	0.0227	0.0048	2.1982	9.4000	AID256605; AID435401; AID624942
Serine/threonine-protein kinase 10	Homo sapiens (human)	Kd	0.0000	0.0000	2.9234	57.4530	AID256604; AID435677; AID625030
Serine/threonine-protein kinase D3	Homo sapiens (human)	Kd	0.0180	0.0089	2.2738	23.3410	AID435554; AID625024
Cyclin-dependent kinase 14	Homo sapiens (human)	Kd	0.1600	0.0160	0.9920	3.6000	AID435689; AID625070
Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)	Kd	0.2600	0.1700	1.5781	8.0000	AID624962
Serine/threonine-protein kinase OSR1	Homo sapiens (human)	Kd	0.4400	0.0480	2.3498	8.0000	AID624977
Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)	Kd	0.0240	0.0082	2.3645	62.7720	AID435910; AID624756
Serine/threonine-protein kinase LATS1	Homo sapiens (human)	Kd	0.0420	0.0140	1.8393	10.7330	AID435529; AID624963
Serine/threonine-protein kinase PAK 4	Homo sapiens (human)	Kd	0.0069	0.0027	2.5694	30.3710	AID256562; AID435929; AID624811
Serine/threonine-protein kinase Chk2	Homo sapiens (human)	Kd	0.0740	0.0071	1.2729	7.7000	AID624803
Tyrosine-protein kinase ABL1	Homo sapiens (human)	Kd	0.2729	0.0000	1.0411	13.4530	AID256665; AID256666; AID256667; AID256668; AID256669; AID256670; AID256671; AID435146; AID435514; AID435515; AID435644; AID435775; AID435776; AID435897; AID624978; AID624979; AID624980; AID624981; AID624982; AID624983; AID624984; AID624985; AID624986; AID624987; AID624988; AID624989; AID624990; AID624991; AID624992
Epidermal growth factor receptor	Homo sapiens (human)	Kd	0.3906	0.0001	1.3514	20.8270	AID256664; AID435156; AID435157; AID435402; AID435525; AID435652; AID435653; AID435791; AID435792; AID435906; AID435907; AID624996; AID624997; AID624998; AID624999; AID625000; AID625001; AID625002; AID625003; AID625004; AID625005; AID625006; AID625007
RAF proto-oncogene serine/threonine-protein kinase	Homo sapiens (human)	Kd	10.0000	0.0066	1.1467	4.4000	AID435556; AID624897
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	Kd	5.0950	0.0008	1.2931	5.1000	AID435796; AID624804
High affinity nerve growth factor receptor	Homo sapiens (human)	Kd	0.0033	0.0020	1.3484	9.2000	AID256626; AID435201; AID624808
Insulin receptor	Homo sapiens (human)	Kd	0.0977	0.0017	1.0823	7.9060	AID256663; AID435408; AID624784
Tyrosine-protein kinase Lck	Homo sapiens (human)	Kd	0.0267	0.0002	1.1174	24.2210	AID256657; AID435676; AID625013
Tyrosine-protein kinase Fyn	Homo sapiens (human)	Kd	0.0390	0.0008	1.4238	8.4000	AID256630; AID435800; AID624727
Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)	Kd	0.0230	0.0048	1.0986	7.4000	AID435161; AID624852
Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)	Kd	0.0120	0.0006	0.6993	8.1000	AID435280; AID624995
Tyrosine-protein kinase Yes	Homo sapiens (human)	Kd	0.0510	0.0003	1.3708	17.1520	AID256614; AID435328; AID625018
Tyrosine-protein kinase Lyn	Homo sapiens (human)	Kd	0.0967	0.0006	1.0485	5.7000	AID256628; AID435804; AID624862
Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)	Kd	0.0188	0.0007	0.8642	27.5420	AID435323; AID435434; AID625121; AID625122; AID625123; AID625124
Insulin-like growth factor 1 receptor	Homo sapiens (human)	Kd	0.2100	0.0010	1.9211	19.2170	AID435164; AID624800
Hepatocyte growth factor receptor	Homo sapiens (human)	Kd	0.1625	0.0002	1.6297	8.5000	AID435312; AID624794; AID624795; AID624796
Tyrosine-protein kinase HCK	Homo sapiens (human)	Kd	0.0173	0.0003	2.0343	15.9930	AID256629; AID435311; AID624857
Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)	Kd	0.0300	0.0005	1.1741	5.8000	AID435192; AID624899
Platelet-derived growth factor receptor beta	Homo sapiens (human)	Kd	0.0021	0.0001	1.0050	11.1070	AID256661; AID435926; AID624875
Tyrosine-protein kinase Fgr	Homo sapiens (human)	Kd	0.0213	0.0005	1.0721	7.8000	AID256560; AID435798; AID625011
Wee1-like protein kinase 2	Homo sapiens (human)	Kd	10.0000	0.0039	2.1874	9.4000	AID624746
Uncharacterized serine/threonine-protein kinase SBK3	Homo sapiens (human)	Kd	0.0250	0.0250	1.4739	5.8000	AID624747
Mast/stem cell growth factor receptor Kit	Homo sapiens (human)	Kd	0.0192	0.0002	0.8159	9.8000	AID256660; AID435167; AID435410; AID435411; AID435675; AID435802; AID599957; AID599959; AID624786; AID624787; AID624788; AID624789; AID624790; AID624791; AID624792; AID624793
Serine/threonine-protein kinase pim-1	Homo sapiens (human)	Kd	0.0057	0.0010	1.1393	19.3160	AID256650; AID257082; AID435931; AID624878
Fibroblast growth factor receptor 1	Homo sapiens (human)	Kd	0.0800	0.0003	1.5581	6.2000	AID256653; AID435526; AID625132
Myosin light chain kinase, smooth muscle	Gallus gallus (chicken)	Kd	0.1400	0.0020	0.3203	1.7000	AID435413
Cyclin-dependent kinase 4	Homo sapiens (human)	Kd	0.0350	0.0033	1.6050	8.6000	AID624780; AID624781
Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)	Kd	0.0700	0.0002	1.5077	9.6000	AID256676; AID435195; AID498728; AID625016
Insulin receptor-related protein	Homo sapiens (human)	Kd	0.0810	0.0062	1.3814	4.6000	AID435430; AID625075
Serine/threonine-protein kinase B-raf	Homo sapiens (human)	Kd	10.0000	0.0002	1.6258	26.0180	AID435901; AID435902; AID624946; AID624947
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)	Kd	0.0004	0.0001	2.0569	9.5000	AID256618; AID435930; AID624797
Platelet-derived growth factor receptor alpha	Homo sapiens (human)	Kd	0.0100	0.0004	0.7090	8.8000	AID435827; AID625034
Tyrosine-protein kinase Fer	Homo sapiens (human)	Kd	0.0260	0.0014	1.3604	8.8000	AID256603; AID435160; AID625010
Protein kinase C alpha type	Homo sapiens (human)	Kd	0.0500	0.0003	1.7922	21.3520	AID256633
cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)	Kd	0.0190	0.0039	2.9479	23.2450	AID435932; AID624881
Vascular endothelial growth factor receptor 1	Homo sapiens (human)	Kd	0.1500	0.0007	0.9585	9.9000	AID435429; AID624853
Interferon-induced, double-stranded RNA-activated protein kinase	Homo sapiens (human)	Kd	0.3600	0.1200	2.3238	7.4000	AID435555; AID624896
Casein kinase II subunit alpha'	Homo sapiens (human)	Kd	0.1183	0.0010	2.5309	28.8720	AID435789; AID624849
Serine/threonine-protein kinase MAK	Homo sapiens (human)	Kd	2.6000	0.0280	1.3461	2.6000	AID625025
Cyclin-dependent kinase 11B	Homo sapiens (human)	Kd	10.0000	0.0084	0.8679	2.1000	AID435395; AID624708
Ephrin type-A receptor 1	Homo sapiens (human)	Kd	0.3000	0.0041	1.8000	9.8000	AID435793; AID625008
Fibroblast growth factor receptor 2	Homo sapiens (human)	Kd	0.1200	0.0310	1.1579	5.5000	AID256654; AID435290; AID625131
Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)	Kd	10.0000	0.0008	2.2545	9.2000	AID624851
Fibroblast growth factor receptor 4	Homo sapiens (human)	Kd	0.2500	0.1100	2.6773	7.2000	AID435656; AID625130
Fibroblast growth factor receptor 3	Homo sapiens (human)	Kd	0.1812	0.0230	1.2652	6.9000	AID256624; AID435291; AID435527; AID624782; AID624783
cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)	Kd	0.0290	0.0130	0.7408	4.1000	AID435182; AID624882
Ribosomal protein S6 kinase beta-1	Homo sapiens (human)	Kd	0.0013	0.0013	1.1805	4.8000	AID624906
Tyrosine-protein kinase JAK1	Homo sapiens (human)	Kd	6.6687	0.0016	1.2166	7.8000	AID435165; AID624858; AID624859
Protein kinase C eta type	Homo sapiens (human)	Kd	0.0048	0.0004	0.2881	1.8000	AID436034; AID625049
Cyclin-dependent kinase 2	Homo sapiens (human)	Kd	0.0074	0.0070	1.5179	10.4870	AID256632; AID435785; AID624844
Activin receptor type-2A	Homo sapiens (human)	Kd	9.4500	0.0100	2.0789	8.9000	AID436004; AID624838
Mitogen-activated protein kinase 3	Homo sapiens (human)	Kd	8.4000	0.4300	5.2743	9.8000	AID436016; AID624885
MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)	Kd	0.0030	0.0030	3.9689	58.2400	AID435659; AID624863
Mitogen-activated protein kinase 1	Homo sapiens (human)	Kd	7.3000	0.0001	2.7441	7.3000	AID435654; AID624713
Ephrin type-A receptor 2	Homo sapiens (human)	Kd	1.0900	0.0009	1.0752	8.1980	AID256602; AID435908; AID624951
Ephrin type-A receptor 3	Homo sapiens (human)	Kd	0.0363	0.0001	2.1521	8.6000	AID256601; AID435794; AID625009
Ephrin type-A receptor 8	Homo sapiens (human)	Kd	0.2267	0.0002	1.2875	7.7000	AID256600; AID435287; AID625120
Ephrin type-B receptor 2	Homo sapiens (human)	Kd	2.1000	0.0004	3.1536	53.1980	AID435288; AID625105
Leukocyte tyrosine kinase receptor	Homo sapiens (human)	Kd	0.0370	0.0010	2.0631	7.5000	AID435168; AID624743
Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)	Kd	1.0707	0.0009	1.5575	8.7000	AID435444; AID624912; AID624913
Wee1-like protein kinase	Homo sapiens (human)	Kd	1.6000	0.0014	3.5389	65.1580	AID435204; AID624914
Tyrosine-protein kinase receptor UFO	Homo sapiens (human)	Kd	0.0068	0.0001	1.2891	6.3000	AID436007; AID624840
Mitogen-activated protein kinase 4	Homo sapiens (human)	Kd	10.0000	1.1000	3.0556	5.4000	AID436017; AID624886
RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)	EC50 (µMol)	0.4600	0.4600	0.4600	0.4600	AID262372; AID262984
RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)	Kd	0.0200	0.0006	1.0621	4.4000	AID435899; AID624994
RAC-beta serine/threonine-protein kinase	Homo sapiens (human)	Kd	0.0440	0.0021	1.6196	8.7000	AID435517; AID624839
G protein-coupled receptor kinase 4	Homo sapiens (human)	Kd	0.0370	0.0120	1.6852	7.3000	AID624739
Dual specificity protein kinase TTK	Homo sapiens (human)	Kd	0.0740	0.0065	1.6269	8.5000	AID256599; AID435203; AID624910
Prostaglandin G/H synthase 2	Homo sapiens (human)	Kd	0.1300	0.0090	1.8725	8.4000	AID625141
Tyrosine-protein kinase receptor Tie-1	Homo sapiens (human)	Kd	0.0650	0.0003	1.0645	5.7000	AID435198; AID625017
Vascular endothelial growth factor receptor 3	Homo sapiens (human)	Kd	0.0290	0.0015	0.9450	7.2000	AID256631; AID436018; AID624854
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	Kd	0.2367	0.0002	0.8063	5.7000	AID256642; AID435327; AID624860
Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)	Kd	0.0280	0.0039	1.6429	9.6000	AID435169; AID625137
Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)	Kd	0.0023	0.0002	0.9559	9.9000	AID256620; AID435162; AID435310; AID435406; AID435407; AID435799; AID624934; AID624935; AID624936; AID624937; AID624938; AID624939; AID624940; AID775336
Bone morphogenetic protein receptor type-1A	Homo sapiens (human)	Kd	3.7000	0.0600	1.5010	7.0000	AID435276; AID624945
Activin receptor type-1B	Homo sapiens (human)	Kd	0.6800	0.0040	1.5110	15.2580	AID435898; AID624943
TGF-beta receptor type-1	Homo sapiens (human)	Kd	2.0000	0.0050	2.2785	9.6000	AID435938; AID624961
Serine/threonine-protein kinase receptor R3	Homo sapiens (human)	Kd	10.0000	0.0029	1.9936	9.5000	AID435645; AID624778
TGF-beta receptor type-2	Homo sapiens (human)	Kd	10.0000	0.0800	1.8351	6.9000	AID435693; AID624909
Tyrosine-protein kinase CSK	Homo sapiens (human)	Kd	0.3667	0.0010	3.4578	39.5530	AID256649; AID435904; AID624948
Protein kinase C iota type	Homo sapiens (human)	Kd	0.0260	0.0260	9.3316	51.0180	AID624883
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	Kd	9.2000	0.0006	0.8462	7.4000	AID435552; AID436033; AID625036; AID625037; AID625038; AID625039; AID625040; AID625041; AID625042; AID625043; AID625044; AID625045
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)	Kd	10.0000	0.0017	0.8316	6.7000	AID625046
Serine/threonine-protein kinase mTOR	Homo sapiens (human)	Kd	10.0000	0.0001	0.5993	9.2000	AID624972
Megakaryocyte-associated tyrosine-protein kinase	Homo sapiens (human)	Kd	0.2600	0.2600	3.0700	7.7000	AID624864
Tyrosine-protein kinase Tec	Homo sapiens (human)	Kd	1.3000	0.0010	1.0095	8.7000	AID435197; AID624908
Tyrosine-protein kinase TXK	Homo sapiens (human)	Kd	0.2300	0.0006	1.9196	6.0000	AID435443; AID624911
Tyrosine-protein kinase ABL2	Homo sapiens (human)	Kd	0.1267	0.0002	1.1249	14.9240	AID256641; AID435777; AID624993
Tyrosine-protein kinase FRK	Homo sapiens (human)	Kd	0.1167	0.0003	1.2424	10.8370	AID256598; AID436019; AID624855
Tyrosine-protein kinase ZAP-70	Homo sapiens (human)	Kd	0.0440	0.0160	1.6844	4.2000	AID435445; AID624744
Tyrosine-protein kinase SYK	Homo sapiens (human)	Kd	0.0117	0.0070	2.0052	9.2260	AID256647; AID435442; AID624907
Mitogen-activated protein kinase 8	Homo sapiens (human)	Kd	0.3200	0.0110	2.0965	26.0590	AID256622; AID435166; AID624889
Mitogen-activated protein kinase 9	Homo sapiens (human)	Kd	4.0033	0.0020	1.4596	8.1000	AID256637; AID435409; AID624717
Dual specificity mitogen-activated protein kinase kinase 4	Homo sapiens (human)	Kd	0.0700	0.0038	1.6264	9.9000	AID435822; AID624902
Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)	Kd	0.0050	0.0050	2.0462	6.6000	AID436022; AID624894
Casein kinase I isoform alpha	Homo sapiens (human)	Kd	0.9700	0.0010	2.5756	19.3520	AID624846
Casein kinase I isoform delta	Homo sapiens (human)	Kd	2.4000	0.0150	2.2270	18.3960	AID435524; AID624716
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)	Kd	1.8000	0.0026	1.4602	8.4000	AID624879
MAP kinase-activated protein kinase 2	Homo sapiens (human)	Kd	0.8800	0.0003	2.0274	14.7420	AID435180; AID624703
Cyclin-dependent kinase 8	Homo sapiens (human)	Kd	0.5100	0.0014	1.2908	8.0000	AID435903; AID624829
Casein kinase I isoform epsilon	Homo sapiens (human)	Kd	0.2787	0.0130	1.4086	12.4090	AID256644; AID435650; AID624847
Dual specificity protein kinase CLK1	Homo sapiens (human)	Kd	0.0303	0.0020	1.8791	29.8810	AID256597; AID435786; AID624764
Dual specificity protein kinase CLK2	Homo sapiens (human)	Kd	0.0095	0.0070	1.1384	6.5000	AID256596; AID435787; AID624932
Dual specificity protein kinase CLK3	Homo sapiens (human)	Kd	1.7733	0.0100	2.4499	9.0000	AID256595; AID436011; AID624931
Glycogen synthase kinase-3 alpha	Homo sapiens (human)	Kd	0.1400	0.0060	2.4754	22.5430	AID435801; AID625114
Glycogen synthase kinase-3 beta	Homo sapiens (human)	Kd	0.0690	0.0070	1.0057	6.1680	AID435163; AID624856
Cyclin-dependent kinase 7	Homo sapiens (human)	Kd	0.0450	0.0025	1.6783	7.7000	AID435278; AID624845
Cyclin-dependent kinase 9	Homo sapiens (human)	Kd	0.1000	0.0010	1.6166	9.9010	AID435279; AID624830
Tyrosine-protein kinase Blk	Homo sapiens (human)	Kd	0.0150	0.0002	0.8228	7.9000	AID435646; AID624841
Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)	Kd	0.0400	0.0061	1.5252	8.5000	AID624837
Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)	Kd	0.0660	0.0170	2.8896	37.6050	AID256619; AID435558; AID624960
Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)	Kd	0.2500	0.0014	1.5489	7.4000	AID256594; AID435781; AID624842
cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)	Kd	0.0130	0.0072	1.3066	5.8000	AID436047; AID624976
Serine/threonine-protein kinase Nek2	Homo sapiens (human)	Kd	0.7467	0.1100	1.5649	6.5000	AID256593; AID435665; AID624869
Serine/threonine-protein kinase Nek3	Homo sapiens (human)	Kd	10.0000	0.1700	5.9368	38.0880	AID624870
Serine/threonine-protein kinase Nek4	Homo sapiens (human)	Kd	10.0000	0.4600	1.5320	2.7000	AID624904
Tyrosine-protein kinase JAK3	Homo sapiens (human)	Kd	0.0110	0.0002	1.0688	8.7000	AID435674; AID624785
Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)	Kd	0.0034	0.0034	2.3943	6.5000	AID435911; AID624895
Serine/threonine-protein kinase PLK1	Homo sapiens (human)	Kd	0.1900	0.0001	0.5711	5.0000	AID435934; AID624975
Death-associated protein kinase 1	Homo sapiens (human)	Kd	0.0014	0.0014	1.2542	4.7000	AID435283; AID624971
LIM domain kinase 1	Homo sapiens (human)	Kd	0.5500	0.0260	1.7840	21.0890	AID256592; AID435803; AID624861
LIM domain kinase 2	Homo sapiens (human)	Kd	9.2000	0.0570	4.9717	52.0560	AID435294; AID625021
Mitogen-activated protein kinase 12	Homo sapiens (human)	Kd	0.0587	0.0001	2.2138	9.9000	AID256615; AID435438; AID624766
Mitogen-activated protein kinase 10	Homo sapiens (human)	Kd	0.1867	0.0010	1.6354	5.9000	AID256636; AID435293; AID624891
5'-AMP-activated protein kinase catalytic subunit alpha-2	Homo sapiens (human)	Kd	0.0120	0.0120	0.7798	5.0000	AID435149; AID625047
Ephrin type-B receptor 3	Homo sapiens (human)	Kd	10.0000	0.0069	2.1713	6.4100	AID435159; AID624955
Ephrin type-A receptor 5	Homo sapiens (human)	Kd	0.1133	0.0002	1.2100	5.9000	AID256591; AID435158; AID624737
Ephrin type-B receptor 4	Homo sapiens (human)	Kd	6.1000	0.0003	2.1678	26.3990	AID435404; AID624956
Ephrin type-B receptor 1	Homo sapiens (human)	Kd	0.3567	0.0004	1.7216	7.3000	AID256590; AID435403; AID624954
Ephrin type-A receptor 4	Homo sapiens (human)	Kd	0.4300	0.0012	3.1525	43.9420	AID256589; AID435795; AID624952
Hormonally up-regulated neu tumor-associated kinase	Homo sapiens (human)	Kd	0.6200	0.0037	2.5139	9.8000	AID625084
Serine/threonine-protein kinase SIK1	Homo sapiens (human)	Kd	0.0022	0.0022	1.1530	3.2000	AID435560; AID624733
Receptor-interacting serine/threonine-protein kinase 4	Homo sapiens (human)	Kd	0.1100	0.0130	1.5506	9.8000	AID624763
Cell division control protein 2 homolog	Plasmodium falciparum 3D7	Kd	0.8000	0.8000	3.2333	5.6000	AID624760
Calcium-dependent protein kinase 1	Plasmodium falciparum 3D7	Kd	0.0003	0.0003	0.8538	3.3000	AID624759
Tubulin alpha-1A chain	Rattus norvegicus (Norway rat)	Kd	0.7700	0.0210	0.8982	4.9000	AID435797
Casein kinase II subunit alpha	Homo sapiens (human)	Kd	0.4880	0.0006	1.7635	7.5000	AID436012; AID624848
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta	Homo sapiens (human)	Kd	0.0770	0.0170	0.8655	7.8000	AID435828; AID624915
SRSF protein kinase 2	Homo sapiens (human)	Kd	0.0670	0.0150	0.2803	1.1000	AID435196; AID624768
Casein kinase I isoform gamma-2	Homo sapiens (human)	Kd	0.9867	0.0460	1.4506	6.6000	AID256634; AID435282; AID624833
Mitogen-activated protein kinase kinase kinase 9	Homo sapiens (human)	Kd	0.0100	0.0035	2.2093	9.9000	AID435297; AID624706
Serine/threonine-protein kinase PknB	Mycobacterium tuberculosis H37Rv	Kd	0.0880	0.0032	1.2724	5.5000	AID624753
Cyclin-dependent kinase 3	Homo sapiens (human)	Kd	0.0300	0.0080	3.0602	63.6140	AID435277; AID624828
Cyclin-dependent kinase-like 1	Homo sapiens (human)	Kd	0.3300	0.0130	0.7332	2.1000	AID624941
Cyclin-dependent-like kinase 5	Homo sapiens (human)	Kd	0.0857	0.0430	1.3757	8.3000	AID256616; AID436010; AID624970
Cyclin-dependent kinase 16	Homo sapiens (human)	Kd	0.0243	0.0011	1.5855	10.0000	AID256588; AID435925; AID625033
Cyclin-dependent kinase 17	Homo sapiens (human)	Kd	0.0960	0.0010	0.8233	5.6000	AID435688; AID624776
Protein kinase C epsilon type	Homo sapiens (human)	Kd	0.0003	0.0002	0.5849	8.1000	AID435320; AID625014
Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)	Kd	0.0210	0.0002	1.1386	8.7730	AID435808; AID624893
Angiopoietin-1 receptor	Homo sapiens (human)	Kd	0.1733	0.0031	1.3464	6.7000	AID256617; AID435939; AID624799
Mitogen-activated protein kinase kinase kinase 10	Homo sapiens (human)	Kd	0.0520	0.0038	2.1074	6.9000	AID435432; AID624867
Protein kinase C theta type	Homo sapiens (human)	Kd	0.0085	0.0007	1.6140	7.2000	AID435321; AID625051
Activin receptor type-1	Homo sapiens (human)	Kd	0.4700	0.0040	1.4853	16.1210	AID435274; AID624819
Macrophage-stimulating protein receptor	Homo sapiens (human)	Kd	0.4000	0.0030	2.0718	8.4000	AID624868
Focal adhesion kinase 1	Homo sapiens (human)	Kd	0.0653	0.0005	1.2255	13.0390	AID256640; AID435184; AID624729
Protein kinase C delta type	Homo sapiens (human)	Kd	0.0015	0.0002	1.1261	9.2060	AID435553; AID625048
Tyrosine-protein kinase BTK	Homo sapiens (human)	Kd	0.3767	0.0006	1.5299	10.1530	AID256561; AID436008; AID624779
Tyrosine-protein kinase receptor TYRO3	Homo sapiens (human)	Kd	0.2800	0.0020	2.2066	9.3000	AID435326; AID625057
Cyclin-dependent kinase 18	Homo sapiens (human)	Kd	0.2700	0.0140	1.4941	8.4000	AID435826; AID624874
Activated CDC42 kinase 1	Homo sapiens (human)	Kd	0.0163	0.0020	1.7138	9.6000	AID256587; AID435694; AID624807
Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)	Kd	0.0190	0.0002	1.6314	71.4840	AID435400; AID624850
Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)	Kd	0.0190	0.0130	0.8600	5.6000	AID435292; AID625020
Myotonin-protein kinase	Homo sapiens (human)	Kd	0.0035	0.0035	2.0528	7.0000	AID435285; AID624950
Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)	Kd	0.0088	0.0031	1.4681	14.0430	AID624959
Mitogen-activated protein kinase kinase kinase 12	Homo sapiens (human)	Kd	1.5000	0.0220	1.0554	6.3000	AID624762
Tyrosine-protein kinase Mer	Homo sapiens (human)	Kd	0.0064	0.0003	1.7055	6.8000	AID436023; AID624767
Serine/threonine-protein kinase 4	Homo sapiens (human)	Kd	0.0002	0.0002	1.7120	25.9020	AID256586; AID435433; AID625055
5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)	Kd	0.0055	0.0037	1.8913	15.3890	AID256638; AID435148; AID624773
Serine/threonine-protein kinase PAK 1	Homo sapiens (human)	Kd	0.0010	0.0006	1.6206	4.4000	AID256673; AID435318; AID624871
Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)	Kd	0.0029	0.0002	2.6590	65.6770	AID624721
Mitogen-activated protein kinase 7	Homo sapiens (human)	Kd	1.6000	0.0420	2.0073	9.9000	AID435655; AID624888
Serine/threonine-protein kinase PAK 2	Homo sapiens (human)	Kd	0.0031	0.0031	2.3045	6.0000	AID435439; AID624872
Serine/threonine-protein kinase 3	Homo sapiens (human)	Kd	0.0002	0.0002	1.8602	17.5260	AID435662; AID625054
Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)	Kd	0.3500	0.0970	2.5995	12.4730	AID625026
cGMP-dependent protein kinase 2	Homo sapiens (human)	Kd	0.0160	0.0031	0.8310	3.6000	AID435322; AID625053
Rho-associated protein kinase 1	Homo sapiens (human)	Kd	0.0003	0.0003	1.7555	13.4620	AID625015
Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)	Kd	0.0025	0.0018	1.0064	11.2690	AID435833; AID624930
Serine/threonine-protein kinase PRP4 homolog	Homo sapiens (human)	Kd	0.2200	0.0084	1.1899	7.6000	AID624750
Receptor-interacting serine/threonine-protein kinase 1	Homo sapiens (human)	Kd	10.0000	0.0200	1.1487	5.4000	AID435557; AID624924
Calcium/calmodulin-dependent protein kinase type II subunit beta	Homo sapiens (human)	Kd	0.0019	0.0013	1.7221	6.8000	AID256652; AID435394; AID624827
Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)	Kd	0.0005	0.0005	1.0209	7.8000	AID256672; AID435784; AID624731
Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)	Kd	0.0004	0.0003	1.5044	20.3010	AID256635; AID435647; AID624770
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)	Kd	0.0040	0.0001	2.1016	40.2910	AID624712
Activin receptor type-2B	Homo sapiens (human)	Kd	4.6000	0.0076	2.7328	9.9000	AID435147; AID624820
Bone morphogenetic protein receptor type-2	Homo sapiens (human)	Kd	6.1500	0.0190	2.5917	14.3770	AID435780; AID624826
Protein-tyrosine kinase 6	Homo sapiens (human)	Kd	2.3000	0.0043	1.7430	9.0000	AID436049; AID625029
cGMP-dependent protein kinase 1	Homo sapiens (human)	Kd	0.0320	0.0016	0.7072	3.8000	AID435546; AID625052
Cyclin-dependent kinase 13	Homo sapiens (human)	Kd	0.0700	0.0009	1.2571	4.5180	AID624761
Calcium/calmodulin-dependent protein kinase type 1	Homo sapiens (human)	Kd	0.0280	0.0270	2.2925	7.0000	AID256643; AID436009; AID624922
Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)	Kd	0.0051	0.0051	1.1093	8.3000	AID435657; AID625074
Protein-tyrosine kinase 2-beta	Homo sapiens (human)	Kd	0.0035	0.0011	1.9450	30.4140	AID436048; AID624732
Maternal embryonic leucine zipper kinase	Homo sapiens (human)	Kd	0.0330	0.0049	2.2835	29.9330	AID435660; AID625087
Serine/threonine-protein kinase D1	Homo sapiens (human)	Kd	0.0270	0.0140	1.4116	8.4000	AID436045; AID624884
Serine/threonine-protein kinase 38	Homo sapiens (human)	Kd	0.0560	0.0560	1.5651	9.4000	AID625067
Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)	Kd	0.7700	0.0009	1.2548	7.0000	AID624815
Ribosomal protein S6 kinase alpha-2	Homo sapiens (human)	Kd	0.0816	0.0089	2.0421	9.6000	AID256627; AID435830; AID436050; AID624805; AID625127
Ephrin type-A receptor 7	Homo sapiens (human)	Kd	0.6500	0.0025	1.4445	6.5000	AID256585; AID435286; AID624953
Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)	Kd	0.6215	0.0280	2.5286	22.7260	AID435690; AID435829; AID624900; AID624901
Dual specificity testis-specific protein kinase 1	Homo sapiens (human)	Kd	0.3200	0.0330	1.7568	5.6000	AID435937; AID625056
Myosin light chain kinase, smooth muscle	Homo sapiens (human)	Kd	0.0150	0.0030	1.2088	7.9000	AID435664; AID624709
Mitogen-activated protein kinase 11	Homo sapiens (human)	Kd	10.0000	0.0001	0.4610	3.7430	AID435551; AID624890
Serine/threonine-protein kinase STK11	Homo sapiens (human)	Kd	0.0610	0.0030	0.9949	5.9000	AID435909; AID624798
Rhodopsin kinase GRK1	Homo sapiens (human)	Kd	0.0010	0.0010	0.6864	2.2000	AID624898
NT-3 growth factor receptor	Homo sapiens (human)	Kd	0.0170	0.0034	1.2020	8.6000	AID435202; AID624765
Serine/threonine-protein kinase N1	Homo sapiens (human)	Kd	0.0013	0.0013	3.1729	49.8130	AID435319; AID624745
Serine/threonine-protein kinase N2	Homo sapiens (human)	Kd	0.0025	0.0018	1.7527	9.9000	AID435933; AID625050
Mitogen-activated protein kinase 14	Homo sapiens (human)	Kd	10.0000	0.0000	0.5036	8.5000	AID435181; AID624714
Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)	Kd	0.0410	0.0300	1.9215	5.4600	AID435152; AID624843
Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)	Kd	0.0200	0.0110	1.5639	17.9840	AID435414; AID624866; AID775337
BDNF/NT-3 growth factors receptor	Homo sapiens (human)	Kd	0.0038	0.0038	0.7875	7.2000	AID435564; AID625032
Mitogen-activated protein kinase 6	Homo sapiens (human)	Kd	6.5500	0.1700	1.9167	5.5000	AID435289; AID624887
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Homo sapiens (human)	Kd	0.0006	0.0004	1.5589	7.1000	AID256639; AID436042; AID625035
Discoidin domain-containing receptor 2	Homo sapiens (human)	Kd	0.0420	0.0030	1.9888	42.2800	AID435154; AID624777
AP2-associated protein kinase 1	Homo sapiens (human)	Kd	0.0012	0.0012	1.3707	13.7110	AID256609; AID435896; AID625089
Myosin light chain kinase 3	Homo sapiens (human)	Kd	0.1400	0.0020	1.6184	10.4240	AID624738
Serine/threonine-protein kinase ULK3	Mus musculus (house mouse)	Kd	0.0030	0.0030	1.1038	3.8000	AID256563
Serine/threonine-protein kinase SBK1	Homo sapiens (human)	Kd	0.0032	0.0032	0.9048	4.8000	AID624812
Mitogen-activated protein kinase kinase kinase 19	Homo sapiens (human)	Kd	0.0009	0.0005	0.8420	6.4000	AID625136
Serine/threonine-protein kinase TNNI3K	Homo sapiens (human)	Kd	1.0000	0.0110	1.7345	7.2000	AID435200; AID625097
Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)	Kd	0.0017	0.0004	1.2042	9.7000	AID624740; AID624741
Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)	Kd	0.0570	0.0570	4.5547	14.0200	AID436024; AID624920
Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)	Kd	0.0370	0.0370	1.9625	9.5000	AID436013; AID625107
Serine/threonine-protein kinase Nek5	Homo sapiens (human)	Kd	0.8100	0.0130	2.4114	7.3000	AID435534; AID624742
Serine/threonine-protein kinase ULK3	Homo sapiens (human)	Kd	0.0012	0.0012	1.3350	9.9000	AID624818
Dual serine/threonine and tyrosine protein kinase	Homo sapiens (human)	Kd	0.0110	0.0053	1.7337	6.4000	AID624758
Mitogen-activated protein kinase kinase kinase 15	Homo sapiens (human)	Kd	0.0025	0.0025	0.9909	2.8000	AID624801
Serine/threonine-protein kinase MARK2	Homo sapiens (human)	Kd	0.0005	0.0001	1.8425	11.1030	AID256608; AID435296; AID625106
Serine/threonine-protein kinase TAO1	Homo sapiens (human)	Kd	0.0004	0.0004	2.1612	18.7570	AID625126
Serine/threonine-protein kinase tousled-like 2	Homo sapiens (human)	Kd	0.0160	0.0160	0.9012	2.6000	AID436054; AID624771
Serine/threonine-protein kinase 32C	Homo sapiens (human)	Kd	0.3100	0.0550	2.1688	8.0000	AID435834; AID624734
Serine/threonine-protein kinase pim-3	Homo sapiens (human)	Kd	0.0005	0.0005	1.3428	5.8000	AID435679; AID624802
Serine/threonine-protein kinase VRK2	Homo sapiens (human)	Kd	10.0000	0.0630	1.9933	4.0000	AID625058
Myosin light chain kinase family member 4	Homo sapiens (human)	Kd	0.4700	0.0150	0.6659	3.4000	AID435691; AID624809
Homeodomain-interacting protein kinase 1	Homo sapiens (human)	Kd	2.7000	0.0550	1.6626	6.8000	AID624726
Calcium/calmodulin-dependent protein kinase type 1D	Homo sapiens (human)	Kd	0.0014	0.0011	1.8547	5.9000	AID256584; AID435393; AID625118
Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)	Kd	0.0082	0.0051	1.6413	15.4350	AID435295; AID624921
Cyclin-dependent kinase-like 3	Homo sapiens (human)	Kd	5.1000	0.0039	1.4549	5.1000	AID624822
MAP kinase-activated protein kinase 5	Homo sapiens (human)	Kd	5.1350	0.0080	1.1241	3.1180	AID435806; AID624923
Serine/threonine-protein kinase BRSK2	Homo sapiens (human)	Kd	0.0035	0.0035	1.9863	8.9000	AID435783; AID624929
Serine/threonine-protein kinase NIM1	Homo sapiens (human)	Kd	0.1400	0.1400	2.6188	8.7000	AID624728
Serine/threonine-protein kinase ULK2	Homo sapiens (human)	Kd	0.0008	0.0008	1.0884	9.9000	AID625085
Misshapen-like kinase 1	Homo sapiens (human)	Kd	0.0010	0.0010	1.1425	8.9000	AID624813
Serine/threonine-protein kinase DCLK2	Homo sapiens (human)	Kd	0.0730	0.0160	1.6907	4.5000	AID435651; AID624814
Calcium/calmodulin-dependent protein kinase kinase 1	Homo sapiens (human)	Kd	0.0000	0.0000	1.1411	5.1000	AID256583; AID435521; AID625143
Casein kinase I isoform alpha-like	Homo sapiens (human)	Kd	0.2500	0.2500	2.2056	7.1000	AID435281; AID624723
Homeodomain-interacting protein kinase 4	Homo sapiens (human)	Kd	0.3900	0.0005	1.3339	8.1000	AID624720
Myosin-IIIa	Homo sapiens (human)	Kd	0.5000	0.0410	1.6626	6.3000	AID435170; AID625104
Ankyrin repeat and protein kinase domain-containing protein 1	Homo sapiens (human)	Kd	0.2700	0.0320	1.6534	9.4000	AID436005; AID624735
Serine/threonine-protein kinase Nek11	Homo sapiens (human)	Kd	3.1000	0.1700	1.2350	3.1000	AID624725
Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)	Kd	10.0000	0.0940	5.1673	65.3020	AID435516; AID625116
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)	Kd	10.0000	0.0030	2.7522	8.8000	AID625134
Mitogen-activated protein kinase 15	Homo sapiens (human)	Kd	0.0350	0.0049	0.6880	4.5000	AID435405; AID624715
Serine/threonine-protein kinase Nek9	Homo sapiens (human)	Kd	4.3000	0.0160	2.7428	19.6170	AID256582; AID435171; AID624704
Serine/threonine-protein kinase BRSK1	Homo sapiens (human)	Kd	0.0260	0.0140	2.3924	8.4000	AID435782; AID624702
Serine/threonine-protein kinase 35	Homo sapiens (human)	Kd	0.1400	0.0020	0.9706	5.4000	AID624711
Serine/threonine-protein kinase Nek7	Homo sapiens (human)	Kd	4.5000	0.0030	3.6719	8.7000	AID435666; AID624754
Rhodopsin kinase GRK7	Homo sapiens (human)	Kd	0.0009	0.0009	1.2793	7.5000	AID624719
Serine/threonine-protein kinase 32A	Homo sapiens (human)	Kd	0.0130	0.0130	2.2043	5.5000	AID624821
Myosin-IIIb	Homo sapiens (human)	Kd	0.3000	0.0810	2.4155	7.1000	AID436032; AID624817
Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)	Kd	0.2500	0.0220	2.3693	7.6000	AID624918
Cyclin-dependent kinase-like 2	Homo sapiens (human)	Kd	0.5100	0.0005	1.3519	5.9000	AID624928
Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)	Kd	0.0043	0.0010	0.9378	5.5000	AID435431; AID624816
Serine/threonine-protein kinase Sgk3	Homo sapiens (human)	Kd	0.0034	0.0034	1.3561	7.2000	AID625073
Atypical kinase COQ8B, mitochondrial	Homo sapiens (human)	Kd	10.0000	0.0270	2.3213	6.1000	AID435778; AID625135
Aurora kinase B	Homo sapiens (human)	Kd	0.0190	0.0020	1.0614	22.8520	AID435519; AID624772
MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)	Kd	0.0054	0.0054	1.1029	4.9000	AID435924; AID625140
Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)	Kd	0.0330	0.0010	1.9148	6.8000	AID256581; AID435151; AID625119
Serine/threonine-protein kinase Nek1	Homo sapiens (human)	Kd	0.8600	0.1700	2.4294	8.3000	AID435533; AID625068
Cyclin-dependent kinase 15	Homo sapiens (human)	Kd	0.2600	0.0320	1.8886	8.6000	AID624718
Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)	Kd	0.0001	0.0000	3.2331	52.8470	AID256580; AID435648; AID625060
SRSF protein kinase 1	Homo sapiens (human)	Kd	0.0055	0.0055	1.0891	5.2000	AID435936; AID624903
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)	Kd	10.0000	0.0440	0.9285	2.9000	AID436043; AID624757
Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)	Kd	0.1125	0.0700	6.5647	50.5360	AID256579; AID407191; AID435412; AID625028
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha	Homo sapiens (human)	Kd	0.0430	0.0360	1.8381	9.7000	AID435190; AID624824
Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)	Kd	2.8000	0.0060	1.5331	9.9000	AID624865
Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)	Kd	10.0000	0.0580	1.9224	4.8360	AID625080
Serine/threonine-protein kinase RIO1	Homo sapiens (human)	Kd	0.1300	0.0090	1.3195	8.4000	AID435324; AID625141
MAP kinase-interacting serine/threonine-protein kinase 1	Homo sapiens (human)	Kd	0.1700	0.0260	1.9734	7.3000	AID435661; AID624823
Serine/threonine-protein kinase RIO2	Homo sapiens (human)	Kd	0.3900	0.0490	1.7667	9.1000	AID625111
Cyclin-dependent kinase 19	Homo sapiens (human)	Kd	0.1900	0.0015	1.9204	7.2000	AID435522; AID625094
Transient receptor potential cation channel subfamily M member 6	Homo sapiens (human)	Kd	10.0000	0.0079	0.0079	0.0079	AID625110
Testis-specific serine/threonine-protein kinase 1	Homo sapiens (human)	Kd	0.0240	0.0240	2.8577	6.3000	AID435940; AID625142
Serine/threonine-protein kinase 33	Homo sapiens (human)	Kd	0.0018	0.0018	1.3542	4.9000	AID436053; AID625138
Serine/threonine-protein kinase D2	Homo sapiens (human)	Kd	0.0720	0.0081	2.3723	25.0190	AID436046; AID625102
Serine/threonine-protein kinase DCLK3	Homo sapiens (human)	Kd	0.0170	0.0045	1.4011	6.5000	AID435399; AID624707
NUAK family SNF1-like kinase 2	Homo sapiens (human)	Kd	0.0001	0.0001	0.6774	4.6000	AID435559; AID625139
Serine/threonine-protein kinase SIK2	Homo sapiens (human)	Kd	0.0011	0.0011	1.8165	41.7950	AID436052; AID625095
Myosin light chain kinase 2, skeletal/cardiac muscle	Homo sapiens (human)	Kd	0.0773	0.0430	1.1312	5.4000	AID256623; AID435415; AID624705
STE20-like serine/threonine-protein kinase	Homo sapiens (human)	Kd	0.0000	0.0000	3.8573	99.2320	AID256578; AID435832; AID625086
Serine/threonine-protein kinase TAO3	Homo sapiens (human)	Kd	0.0002	0.0002	2.7131	14.1960	AID625101
Homeodomain-interacting protein kinase 2	Homo sapiens (human)	Kd	0.1900	0.0073	1.3739	5.0000	AID625129
Tyrosine-protein kinase Srms	Homo sapiens (human)	Kd	0.7400	0.0130	2.6007	9.8000	AID435561; AID624710
Homeodomain-interacting protein kinase 3	Homo sapiens (human)	Kd	0.0750	0.0040	1.7046	9.7000	AID625023
Serine/threonine-protein kinase PLK3	Homo sapiens (human)	Kd	0.9100	0.0040	2.9056	8.5000	AID435183; AID624933
Dual specificity protein kinase CLK4	Homo sapiens (human)	Kd	0.0114	0.0020	1.4122	8.3000	AID256577; AID435788; AID625125
MAP kinase-interacting serine/threonine-protein kinase 2	Homo sapiens (human)	Kd	0.0187	0.0014	1.4131	5.7000	AID256576; AID435531; AID625108
Serine/threonine-protein kinase Nek6	Homo sapiens (human)	Kd	10.0000	0.0063	1.3385	4.4000	AID435545; AID625079
Casein kinase I isoform gamma-1	Homo sapiens (human)	Kd	6.7500	0.0530	2.0622	5.7000	AID435397; AID625128
Serine/threonine-protein kinase 3	Mus musculus (house mouse)	Kd	0.0002	0.0002	0.3140	1.1000	AID256574
Serine/threonine-protein kinase PAK 6	Homo sapiens (human)	Kd	0.0005	0.0004	1.9194	9.7000	AID256573; AID435188; AID625115
SNF-related serine/threonine-protein kinase	Homo sapiens (human)	Kd	0.0900	0.0900	0.5520	1.5000	AID624752
Serine/threonine-protein kinase LATS2	Homo sapiens (human)	Kd	0.0170	0.0010	1.6879	8.0000	AID436021; AID625083
Serine/threonine-protein kinase 36	Homo sapiens (human)	Kd	5.4333	0.1800	2.7651	8.3000	AID256572; AID435562; AID625096
BMP-2-inducible protein kinase	Homo sapiens (human)	Kd	0.0050	0.0022	2.4097	56.0320	AID256571; AID435275; AID625109
Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)	Kd	0.0017	0.0017	3.4719	34.1450	AID625098
Serine/threonine-protein kinase 32B	Homo sapiens (human)	Kd	0.0980	0.0240	2.7040	6.4000	AID436055; AID625112
Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)	Kd	10.0000	0.0023	1.7034	13.6380	AID435941; AID624755
Serine/threonine-protein kinase PLK2	Homo sapiens (human)	Kd	0.2000	0.0008	1.8083	8.3000	AID625063
Serine/threonine-protein kinase MARK1	Homo sapiens (human)	Kd	0.0040	0.0040	1.2615	4.9000	AID435807; AID625113
Serine/threonine-protein kinase pim-2	Homo sapiens (human)	Kd	0.0026	0.0019	0.8415	5.0000	AID256570; AID435440; AID625064
Serine/threonine-protein kinase PAK 5	Homo sapiens (human)	Kd	0.0018	0.0012	0.8801	3.3000	AID256569; AID435687; AID625117
Serine/threonine-protein kinase 26	Homo sapiens (human)	Kd	0.1400	0.0074	1.7380	8.3000	AID435663; AID625103
eIF-2-alpha kinase GCN2	Homo sapiens (human)	Kd	0.0160	0.0033	1.1828	4.4000	AID436020; AID624810
Serine/threonine-protein kinase NLK	Homo sapiens (human)	Kd	0.2200	0.0060	1.0226	4.4000	AID435667; AID625100
Phosphatidylinositol 4-kinase beta	Homo sapiens (human)	Kd	0.4600	0.0390	1.1982	3.5000	AID624880
Serine/threonine-protein kinase 17A	Homo sapiens (human)	Kd	0.0170	0.0010	1.7218	9.0000	AID256568; AID435790; AID624968
STE20/SPS1-related proline-alanine-rich protein kinase	Homo sapiens (human)	Kd	0.1300	0.1300	0.9879	3.7000	AID625071
Ephrin type-A receptor 6	Homo sapiens (human)	Kd	0.2733	0.0011	1.0255	9.1000	AID256567; AID436015; AID624748
Serine/threonine-protein kinase TBK1	Homo sapiens (human)	Kd	0.0009	0.0009	1.7674	49.6010	AID625072
Death-associated protein kinase 2	Homo sapiens (human)	Kd	0.0021	0.0016	1.1261	9.1000	AID256651; AID435153; AID625077
Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)	Kd	1.6590	0.0040	2.4153	23.7620	AID435193; AID435194; AID625081; AID625082
TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)	Kd	0.0051	0.0047	1.3935	10.0000	AID256566; AID435563; AID625093
Serine/threonine-protein kinase tousled-like 1	Homo sapiens (human)	Kd	0.0270	0.0270	1.0513	4.0000	AID435199; AID625069
Serine/threonine-protein kinase TAO2	Homo sapiens (human)	Kd	0.0120	0.0100	2.0176	12.9420	AID625099
ALK tyrosine kinase receptor	Homo sapiens (human)	Kd	0.0320	0.0005	1.3507	7.7000	AID435779; AID624944
SRSF protein kinase 3	Homo sapiens (human)	Kd	0.0730	0.0120	2.1154	9.3000	AID625078
Serine/threonine-protein kinase ICK	Homo sapiens (human)	Kd	0.0160	0.0007	1.4717	9.3000	AID625090
Cyclin-dependent kinase 11A	Homo sapiens (human)	Kd	10.0000	0.0052	0.6617	1.3000	AID435649; AID625133
Aurora kinase C	Homo sapiens (human)	Kd	0.0190	0.0013	1.0848	8.7000	AID256610; AID436006; AID624769
Calcium/calmodulin-dependent protein kinase type II subunit alpha	Homo sapiens (human)	Kd	0.0001	0.0001	1.6996	9.6000	AID256621; AID435520; AID624730
RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)	Kd	0.1700	0.0025	1.7646	6.2000	AID435900; AID625019
Serine/threonine-protein kinase 38-like	Homo sapiens (human)	Kd	0.0443	0.0280	1.4692	6.9000	AID256677; AID436025; AID625092
Microtubule-associated serine/threonine-protein kinase 1	Homo sapiens (human)	Kd	0.1500	0.0190	1.5420	6.2000	AID625091
Serine/threonine-protein kinase SIK3	Homo sapiens (human)	Kd	0.0005	0.0005	1.5086	10.3180	AID624774
Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)	Kd	0.0024	0.0024	1.3298	6.9000	AID625062
Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)	Kd	0.0280	0.0280	1.8129	9.5000	AID436014; AID624964
Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)	Kd	0.0207	0.0005	1.9494	50.2140	AID256565; AID435805; AID625061
Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)	Kd	0.0420	0.0340	3.6252	50.0050	AID435912; AID625031
Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)	Kd	0.0130	0.0070	1.7137	25.5810	AID435528; AID625066
Serine/threonine-protein kinase 24	Homo sapiens (human)	Kd	0.1200	0.0065	0.8920	4.0840	AID435532; AID624917
Casein kinase I isoform gamma-3	Homo sapiens (human)	Kd	10.0000	0.0970	2.3978	8.7000	AID435905; AID624949
Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)	Kd	1.5333	0.0390	2.3970	8.4000	AID256564; AID435530; AID625027
Chain A, Dual specificity protein kinase TTK	Homo sapiens (human)	Kd	0.0305	0.0305	0.0305	0.0305	AID977611
Chain A, Dual specificity protein kinase TTK	Homo sapiens (human)	Kd	0.0305	0.0305	0.0305	0.0305	AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cAMP-dependent protein kinase catalytic subunit alpha isoform Calpha1	Homo sapiens (human)	AC50	0.1260	0.1260	0.8403	1.5580	AID588629
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of cell growth	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
sodium ion transport	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
long-term memory	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
regulation of blood pressure	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
regulation of cell migration	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
positive regulation of transporter activity	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
regulation of cell population proliferation	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
regulation of apoptotic process	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
regulation of catalytic activity	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
regulation of DNA-binding transcription factor activity	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
regulation of gastric acid secretion	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
renal sodium ion absorption	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
cellular response to aldosterone	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
neuron projection morphogenesis	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
positive regulation of gene expression	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
cartilage condensation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
ovarian cumulus expansion	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
osteoblast differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
eye development	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
chondrocyte development	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
inflammatory response	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
central nervous system neuron differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
proteoglycan biosynthetic process	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of bone mineralization	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
BMP signaling pathway	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
retinal ganglion cell axon guidance	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of chondrocyte differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
ovulation cycle	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of osteoblast differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
retina development in camera-type eye	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
endochondral bone morphogenesis	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of cartilage development	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
cellular response to BMP stimulus	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptors	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
negative regulation of chondrocyte proliferation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
dorsal/ventral pattern formation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
protein phosphorylation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
cellular response to growth factor stimulus	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of cell population proliferation	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of nuclear cell cycle DNA replication	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cell cycle phase transition	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cell division	Cell division cycle 7-related protein kinase	Homo sapiens (human)
peptidyl-serine phosphorylation	Cell division cycle 7-related protein kinase	Homo sapiens (human)
double-strand break repair via break-induced replication	Cell division cycle 7-related protein kinase	Homo sapiens (human)
signal transduction	Cell division cycle 7-related protein kinase	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of cytokine production	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
adaptive immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
respiratory burst involved in defense response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
protein phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
neutrophil chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of neutrophil apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell degranulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
innate immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
neutrophil extravasation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of epithelial tube formation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
positive regulation of centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cilium assembly	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
trophoblast giant cell differentiation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
de novo centriole assembly involved in multi-ciliated epithelial cell differentiation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase 25	Homo sapiens (human)
response to oxidative stress	Serine/threonine-protein kinase 25	Homo sapiens (human)
establishment or maintenance of cell polarity	Serine/threonine-protein kinase 25	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase 25	Homo sapiens (human)
axonogenesis	Serine/threonine-protein kinase 25	Homo sapiens (human)
positive regulation of stress-activated MAPK cascade	Serine/threonine-protein kinase 25	Homo sapiens (human)
cellular response to oxidative stress	Serine/threonine-protein kinase 25	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hydrogen peroxide	Serine/threonine-protein kinase 25	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase 25	Homo sapiens (human)
positive regulation of axonogenesis	Serine/threonine-protein kinase 25	Homo sapiens (human)
Golgi localization	Serine/threonine-protein kinase 25	Homo sapiens (human)
establishment of Golgi localization	Serine/threonine-protein kinase 25	Homo sapiens (human)
Golgi reassembly	Serine/threonine-protein kinase 25	Homo sapiens (human)
biological_process	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cellular response to starvation	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
autophagosome organization	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cell migration	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
mitotic cell cycle	Citron Rho-interacting kinase	Homo sapiens (human)
mitotic cytokinesis	Citron Rho-interacting kinase	Homo sapiens (human)
positive regulation of cytokinesis	Citron Rho-interacting kinase	Homo sapiens (human)
negative regulation of hippo signaling	Citron Rho-interacting kinase	Homo sapiens (human)
generation of neurons	Citron Rho-interacting kinase	Homo sapiens (human)
neuron apoptotic process	Citron Rho-interacting kinase	Homo sapiens (human)
chromosome segregation	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
maturation of SSU-rRNA	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
positive regulation of interferon-beta production	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
negative regulation of MDA-5 signaling pathway	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
innate immune response	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
positive regulation of innate immune response	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
defense response to virus	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
cellular response to dsRNA	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
cellular response to virus	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
cellular response to dsDNA	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
apoptotic process	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
response to osmotic stress	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
signal transduction	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
JNK cascade	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
response to heat	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
response to UV	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
response to wounding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
response to tumor necrosis factor	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of JUN kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of DNA-templated transcription	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of JNK cascade	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
stress-activated MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of telomerase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
cellular response to lipopolysaccharide	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
cellular response to interleukin-1	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
cellular senescence	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
positive regulation of telomere capping	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
regulation of motor neuron apoptotic process	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
telomere maintenance	Telomerase reverse transcriptase	Homo sapiens (human)
RNA-templated transcription	Telomerase reverse transcriptase	Homo sapiens (human)
RNA-templated DNA biosynthetic process	Telomerase reverse transcriptase	Homo sapiens (human)
telomere maintenance via telomerase	Telomerase reverse transcriptase	Homo sapiens (human)
mitochondrion organization	Telomerase reverse transcriptase	Homo sapiens (human)
negative regulation of gene expression	Telomerase reverse transcriptase	Homo sapiens (human)
DNA strand elongation	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of Wnt signaling pathway	Telomerase reverse transcriptase	Homo sapiens (human)
siRNA processing	Telomerase reverse transcriptase	Homo sapiens (human)
regulation of protein stability	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of protein binding	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of hair cycle	Telomerase reverse transcriptase	Homo sapiens (human)
negative regulation of neuron apoptotic process	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of angiogenesis	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of glucose import	Telomerase reverse transcriptase	Homo sapiens (human)
response to cadmium ion	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of nitric-oxide synthase activity	Telomerase reverse transcriptase	Homo sapiens (human)
establishment of protein localization to telomere	Telomerase reverse transcriptase	Homo sapiens (human)
cellular response to hypoxia	Telomerase reverse transcriptase	Homo sapiens (human)
DNA biosynthetic process	Telomerase reverse transcriptase	Homo sapiens (human)
replicative senescence	Telomerase reverse transcriptase	Homo sapiens (human)
siRNA transcription	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of miRNA transcription	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of transdifferentiation	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of protein localization to nucleolus	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migration	Telomerase reverse transcriptase	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Telomerase reverse transcriptase	Homo sapiens (human)
positive regulation of stem cell proliferation	Telomerase reverse transcriptase	Homo sapiens (human)
negative regulation of cellular senescence	Telomerase reverse transcriptase	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Telomerase reverse transcriptase	Homo sapiens (human)
DNA damage checkpoint signaling	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
inner cell mass cell proliferation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
DNA replication	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
DNA repair	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
chromatin remodeling	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleus organization	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of double-strand break repair via homologous recombination	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of cell population proliferation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
signal transduction in response to DNA damage	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
mitotic G2/M transition checkpoint	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
positive regulation of cell cycle	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of mitotic nuclear division	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of mitotic centrosome separation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of G0 to G1 transition	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cellular response to mechanical stimulus	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cellular response to caffeine	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
replicative senescence	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
apoptotic process involved in development	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of DNA biosynthetic process	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
protein phosphorylation	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
inflammatory response	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
canonical NF-kappaB signal transduction	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
response to virus	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
peptidyl-serine phosphorylation	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
cortical actin cytoskeleton organization	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
toll-like receptor 3 signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activity	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
TRIF-dependent toll-like receptor signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
regulation of phosphorylation	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
innate immune response	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
positive regulation of DNA-templated transcription	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
T cell receptor signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
stress-activated MAPK cascade	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
protein maturation	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
cellular response to tumor necrosis factor	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
protein localization to plasma membrane	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
regulation of establishment of endothelial barrier	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
negative regulation of bicellular tight junction assembly	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
regulation of toll-like receptor signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
negative regulation of cell-matrix adhesion	Peripheral plasma membrane protein CASK	Homo sapiens (human)
cell adhesion	Peripheral plasma membrane protein CASK	Homo sapiens (human)
negative regulation of keratinocyte proliferation	Peripheral plasma membrane protein CASK	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Peripheral plasma membrane protein CASK	Homo sapiens (human)
GMP metabolic process	Peripheral plasma membrane protein CASK	Homo sapiens (human)
GDP metabolic process	Peripheral plasma membrane protein CASK	Homo sapiens (human)
establishment of localization in cell	Peripheral plasma membrane protein CASK	Homo sapiens (human)
negative regulation of wound healing	Peripheral plasma membrane protein CASK	Homo sapiens (human)
calcium ion import	Peripheral plasma membrane protein CASK	Homo sapiens (human)
positive regulation of calcium ion import	Peripheral plasma membrane protein CASK	Homo sapiens (human)
negative regulation of cellular response to growth factor stimulus	Peripheral plasma membrane protein CASK	Homo sapiens (human)
regulation of synaptic vesicle exocytosis	Peripheral plasma membrane protein CASK	Homo sapiens (human)
protein localization	Peripheral plasma membrane protein CASK	Homo sapiens (human)
regulation of neurotransmitter secretion	Peripheral plasma membrane protein CASK	Homo sapiens (human)
protein phosphorylation	Aurora kinase A	Homo sapiens (human)
response to wounding	Aurora kinase A	Homo sapiens (human)
liver regeneration	Aurora kinase A	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
chromatin remodeling	Aurora kinase A	Homo sapiens (human)
protein phosphorylation	Aurora kinase A	Homo sapiens (human)
apoptotic process	Aurora kinase A	Homo sapiens (human)
spindle organization	Aurora kinase A	Homo sapiens (human)
spindle assembly involved in female meiosis I	Aurora kinase A	Homo sapiens (human)
mitotic centrosome separation	Aurora kinase A	Homo sapiens (human)
anterior/posterior axis specification	Aurora kinase A	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
negative regulation of gene expression	Aurora kinase A	Homo sapiens (human)
peptidyl-serine phosphorylation	Aurora kinase A	Homo sapiens (human)
regulation of protein stability	Aurora kinase A	Homo sapiens (human)
negative regulation of protein binding	Aurora kinase A	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Aurora kinase A	Homo sapiens (human)
negative regulation of apoptotic process	Aurora kinase A	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Aurora kinase A	Homo sapiens (human)
positive regulation of mitotic nuclear division	Aurora kinase A	Homo sapiens (human)
positive regulation of mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
regulation of centrosome cycle	Aurora kinase A	Homo sapiens (human)
protein autophosphorylation	Aurora kinase A	Homo sapiens (human)
cell division	Aurora kinase A	Homo sapiens (human)
centrosome localization	Aurora kinase A	Homo sapiens (human)
cilium disassembly	Aurora kinase A	Homo sapiens (human)
protein localization to centrosome	Aurora kinase A	Homo sapiens (human)
positive regulation of mitochondrial fission	Aurora kinase A	Homo sapiens (human)
positive regulation of oocyte maturation	Aurora kinase A	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Aurora kinase A	Homo sapiens (human)
neuron projection extension	Aurora kinase A	Homo sapiens (human)
mitotic spindle organization	Aurora kinase A	Homo sapiens (human)
regulation of cytokinesis	Aurora kinase A	Homo sapiens (human)
receptor-mediated endocytosis	Cyclin-G-associated kinase	Homo sapiens (human)
endoplasmic reticulum organization	Cyclin-G-associated kinase	Homo sapiens (human)
Golgi organization	Cyclin-G-associated kinase	Homo sapiens (human)
negative regulation of neuron projection development	Cyclin-G-associated kinase	Homo sapiens (human)
synaptic vesicle uncoating	Cyclin-G-associated kinase	Homo sapiens (human)
protein localization to Golgi apparatus	Cyclin-G-associated kinase	Homo sapiens (human)
intracellular transport	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin coat assembly	Cyclin-G-associated kinase	Homo sapiens (human)
chaperone cofactor-dependent protein refolding	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin coat disassembly	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin-dependent endocytosis	Cyclin-G-associated kinase	Homo sapiens (human)
protein localization to plasma membrane	Cyclin-G-associated kinase	Homo sapiens (human)
Golgi to lysosome transport	Cyclin-G-associated kinase	Homo sapiens (human)
regulation of clathrin coat assembly	Cyclin-G-associated kinase	Homo sapiens (human)
neuron migration	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
nervous system development	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
central nervous system development	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
response to virus	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
endosomal transport	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
central nervous system projection neuron axonogenesis	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
forebrain development	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
protein localization to nucleus	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
axon extension	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
dendrite morphogenesis	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
negative regulation of protein localization to nucleus	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
neuron projection morphogenesis	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
skeletal muscle contraction	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
protein phosphorylation	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
inflammatory response	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
immune response	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
canonical NF-kappaB signal transduction	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
I-kappaB phosphorylation	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
Rho protein signal transduction	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
response to xenobiotic stimulus	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
response to virus	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
response to toxic substance	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
anatomical structure morphogenesis	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
response to acetate	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
response to lipopolysaccharide	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
positive regulation of interferon-alpha production	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
response to hydroperoxide	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
cellular response to reactive oxygen species	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
response to amino acid	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
innate immune response	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
positive regulation of DNA-templated transcription	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
striated muscle cell differentiation	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
response to cholecystokinin	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
cellular response to cadmium ion	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
cellular response to tumor necrosis factor	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
cellular response to virus	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
peptidyl-serine phosphorylation	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
positive regulation of protein phosphorylation	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
neuromuscular junction development	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
memory	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
regulation of synaptic assembly at neuromuscular junction	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
positive regulation of gene expression	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
cell differentiation	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
protein autophosphorylation	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
skeletal muscle acetylcholine-gated channel clustering	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
positive regulation of protein geranylgeranylation	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
multicellular organism development	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
positive regulation of kinase activity	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
positive regulation of neuron projection development	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
protein phosphorylation	Ephrin type-B receptor 6	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-B receptor 6	Homo sapiens (human)
axon guidance	Ephrin type-B receptor 6	Homo sapiens (human)
response to osmotic stress	Mitogen-activated protein kinase 13	Homo sapiens (human)
peptidyl-serine phosphorylation	Mitogen-activated protein kinase 13	Homo sapiens (human)
positive regulation of interleukin-6 production	Mitogen-activated protein kinase 13	Homo sapiens (human)
cellular response to UV	Mitogen-activated protein kinase 13	Homo sapiens (human)
positive regulation of inflammatory response	Mitogen-activated protein kinase 13	Homo sapiens (human)
stress-activated MAPK cascade	Mitogen-activated protein kinase 13	Homo sapiens (human)
cellular response to hydrogen peroxide	Mitogen-activated protein kinase 13	Homo sapiens (human)
cellular response to interleukin-1	Mitogen-activated protein kinase 13	Homo sapiens (human)
cellular response to sorbitol	Mitogen-activated protein kinase 13	Homo sapiens (human)
cellular response to anisomycin	Mitogen-activated protein kinase 13	Homo sapiens (human)
cellular response to sodium arsenite	Mitogen-activated protein kinase 13	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase 13	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
intracellular signal transduction	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
type B pancreatic cell development	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein phosphorylation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
negative regulation of protein kinase activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
hyperosmotic response	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
insulin receptor signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of phospholipase activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cell migration	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
peptidyl-threonine phosphorylation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
calcium-mediated signaling	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
actin cytoskeleton organization	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
T cell costimulation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
activation of protein kinase B activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cellular response to insulin stimulus	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
negative regulation of toll-like receptor signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
regulation of mast cell degranulation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of angiogenesis	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein autophosphorylation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
extrinsic apoptotic signaling pathway	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of sprouting angiogenesis	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
intracellular signal transduction	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
positive regulation of neuron maturation	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
peptidyl-serine phosphorylation	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
positive regulation of JUN kinase activity	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
positive regulation of axon extension	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
protein autophosphorylation	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
stress-activated MAPK cascade	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
positive regulation of neuron projection arborization	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
positive regulation of branching morphogenesis of a nerve	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
chromatin organization	Death-associated protein kinase 3	Homo sapiens (human)
regulation of DNA-templated transcription	Death-associated protein kinase 3	Homo sapiens (human)
protein phosphorylation	Death-associated protein kinase 3	Homo sapiens (human)
apoptotic process	Death-associated protein kinase 3	Homo sapiens (human)
regulation of smooth muscle contraction	Death-associated protein kinase 3	Homo sapiens (human)
regulation of mitotic nuclear division	Death-associated protein kinase 3	Homo sapiens (human)
regulation of mitotic cell cycle	Death-associated protein kinase 3	Homo sapiens (human)
regulation of cell shape	Death-associated protein kinase 3	Homo sapiens (human)
regulation of autophagy	Death-associated protein kinase 3	Homo sapiens (human)
negative regulation of translation	Death-associated protein kinase 3	Homo sapiens (human)
positive regulation of cell migration	Death-associated protein kinase 3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Death-associated protein kinase 3	Homo sapiens (human)
intracellular signal transduction	Death-associated protein kinase 3	Homo sapiens (human)
regulation of apoptotic process	Death-associated protein kinase 3	Homo sapiens (human)
positive regulation of apoptotic process	Death-associated protein kinase 3	Homo sapiens (human)
regulation of myosin II filament organization	Death-associated protein kinase 3	Homo sapiens (human)
protein autophosphorylation	Death-associated protein kinase 3	Homo sapiens (human)
regulation of focal adhesion assembly	Death-associated protein kinase 3	Homo sapiens (human)
cellular response to type II interferon	Death-associated protein kinase 3	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Death-associated protein kinase 3	Homo sapiens (human)
apoptotic signaling pathway	Death-associated protein kinase 3	Homo sapiens (human)
regulation of cell motility	Death-associated protein kinase 3	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
positive regulation of T cell cytokine production	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
chromatin remodeling	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
inflammatory response	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
canonical NF-kappaB signal transduction	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
I-kappaB phosphorylation	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
negative regulation of gene expression	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
positive regulation of macroautophagy	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
positive regulation of interleukin-2 production	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
toll-like receptor 3 signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
TRIF-dependent toll-like receptor signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
p38MAPK cascade	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
interleukin-33-mediated signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
interleukin-17A-mediated signaling pathway	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
defense response to bacterium	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
protein serine/threonine kinase activity	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
calcium channel regulator activity	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
potassium channel regulator activity	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
sodium channel regulator activity	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
chloride channel regulator activity	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
protein serine/threonine kinase activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
transmembrane signaling receptor activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
protein binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
ATP binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
BMP binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
SMAD binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
metal ion binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
BMP receptor activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
transforming growth factor beta receptor activity, type I	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
protein kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein binding	Cell division cycle 7-related protein kinase	Homo sapiens (human)
ATP binding	Cell division cycle 7-related protein kinase	Homo sapiens (human)
kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
metal ion binding	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein serine kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase 25	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 25	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 25	Homo sapiens (human)
protein homodimerization activity	Serine/threonine-protein kinase 25	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase 25	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 25	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 25	Homo sapiens (human)
protein binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
phosphatidylinositol binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
transcription coactivator binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Citron Rho-interacting kinase	Homo sapiens (human)
protein binding	Citron Rho-interacting kinase	Homo sapiens (human)
ATP binding	Citron Rho-interacting kinase	Homo sapiens (human)
SH3 domain binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein kinase binding	Citron Rho-interacting kinase	Homo sapiens (human)
PDZ domain binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein serine/threonine kinase inhibitor activity	Citron Rho-interacting kinase	Homo sapiens (human)
metal ion binding	Citron Rho-interacting kinase	Homo sapiens (human)
scaffold protein binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein serine kinase activity	Citron Rho-interacting kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
caspase binding	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
magnesium ion binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
MAP kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
MAP kinase kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
ATP binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
JUN kinase kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
enzyme binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein kinase binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein phosphatase binding	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
protein serine kinase activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
molecular function activator activity	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
tRNA binding	Telomerase reverse transcriptase	Homo sapiens (human)
transcription coactivator binding	Telomerase reverse transcriptase	Homo sapiens (human)
DNA binding	Telomerase reverse transcriptase	Homo sapiens (human)
telomerase activity	Telomerase reverse transcriptase	Homo sapiens (human)
telomerase RNA reverse transcriptase activity	Telomerase reverse transcriptase	Homo sapiens (human)
RNA binding	Telomerase reverse transcriptase	Homo sapiens (human)
RNA-directed DNA polymerase activity	Telomerase reverse transcriptase	Homo sapiens (human)
RNA-dependent RNA polymerase activity	Telomerase reverse transcriptase	Homo sapiens (human)
protein binding	Telomerase reverse transcriptase	Homo sapiens (human)
identical protein binding	Telomerase reverse transcriptase	Homo sapiens (human)
protein homodimerization activity	Telomerase reverse transcriptase	Homo sapiens (human)
metal ion binding	Telomerase reverse transcriptase	Homo sapiens (human)
protein-folding chaperone binding	Telomerase reverse transcriptase	Homo sapiens (human)
telomerase RNA binding	Telomerase reverse transcriptase	Homo sapiens (human)
template-free RNA nucleotidyltransferase	Telomerase reverse transcriptase	Homo sapiens (human)
telomeric DNA binding	Telomerase reverse transcriptase	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein domain specific binding	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
histone H3T11 kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
protein serine/threonine kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
protein binding	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
ATP binding	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
IkappaB kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
protein kinase binding	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
identical protein binding	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
protein homodimerization activity	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
protein heterodimerization activity	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
scaffold protein binding	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
protein serine kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
transferrin receptor binding	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
guanylate kinase activity	Peripheral plasma membrane protein CASK	Homo sapiens (human)
protein serine/threonine kinase activity	Peripheral plasma membrane protein CASK	Homo sapiens (human)
protein binding	Peripheral plasma membrane protein CASK	Homo sapiens (human)
calmodulin binding	Peripheral plasma membrane protein CASK	Homo sapiens (human)
ATP binding	Peripheral plasma membrane protein CASK	Homo sapiens (human)
neurexin family protein binding	Peripheral plasma membrane protein CASK	Homo sapiens (human)
protein serine kinase activity	Peripheral plasma membrane protein CASK	Homo sapiens (human)
signaling receptor binding	Peripheral plasma membrane protein CASK	Homo sapiens (human)
protein kinase activity	Aurora kinase A	Homo sapiens (human)
protein serine/threonine kinase activity	Aurora kinase A	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Aurora kinase A	Homo sapiens (human)
protein binding	Aurora kinase A	Homo sapiens (human)
ATP binding	Aurora kinase A	Homo sapiens (human)
protein kinase binding	Aurora kinase A	Homo sapiens (human)
ubiquitin protein ligase binding	Aurora kinase A	Homo sapiens (human)
histone H3S10 kinase activity	Aurora kinase A	Homo sapiens (human)
protein heterodimerization activity	Aurora kinase A	Homo sapiens (human)
protein serine kinase activity	Aurora kinase A	Homo sapiens (human)
molecular function activator activity	Aurora kinase A	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-G-associated kinase	Homo sapiens (human)
protein binding	Cyclin-G-associated kinase	Homo sapiens (human)
ATP binding	Cyclin-G-associated kinase	Homo sapiens (human)
cyclin binding	Cyclin-G-associated kinase	Homo sapiens (human)
protein-folding chaperone binding	Cyclin-G-associated kinase	Homo sapiens (human)
protein serine kinase activity	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin binding	Cyclin-G-associated kinase	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
protein kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
protein serine/threonine kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
protein binding	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
ATP binding	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
IkappaB kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
protein homodimerization activity	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
protein-containing complex binding	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
protein heterodimerization activity	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
scaffold protein binding	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
transferrin receptor binding	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
protein tyrosine kinase activity	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
protein binding	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
ATP binding	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
metal ion binding	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
Wnt-protein binding	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
ephrin receptor activity	Ephrin type-B receptor 6	Homo sapiens (human)
protein binding	Ephrin type-B receptor 6	Homo sapiens (human)
ATP binding	Ephrin type-B receptor 6	Homo sapiens (human)
signaling receptor activity	Ephrin type-B receptor 6	Homo sapiens (human)
transmembrane-ephrin receptor activity	Ephrin type-B receptor 6	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase 13	Homo sapiens (human)
MAP kinase activity	Mitogen-activated protein kinase 13	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 13	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 13	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 13	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein serine/threonine kinase activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
3-phosphoinositide-dependent protein kinase activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein binding	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
ATP binding	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
phospholipase activator activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
phospholipase binding	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein serine kinase activity	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
enzyme binding	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
protein kinase binding	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
identical protein binding	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
protein homodimerization activity	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
protein serine/threonine kinase activator activity	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
metal ion binding	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
IkappaB kinase complex binding	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
JUN kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
protein serine/threonine kinase activity	Death-associated protein kinase 3	Homo sapiens (human)
protein binding	Death-associated protein kinase 3	Homo sapiens (human)
ATP binding	Death-associated protein kinase 3	Homo sapiens (human)
cAMP response element binding protein binding	Death-associated protein kinase 3	Homo sapiens (human)
small GTPase binding	Death-associated protein kinase 3	Homo sapiens (human)
identical protein binding	Death-associated protein kinase 3	Homo sapiens (human)
protein homodimerization activity	Death-associated protein kinase 3	Homo sapiens (human)
leucine zipper domain binding	Death-associated protein kinase 3	Homo sapiens (human)
protein serine kinase activity	Death-associated protein kinase 3	Homo sapiens (human)
magnesium ion binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
transcription coactivator binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
MAP kinase activity	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
type II transforming growth factor beta receptor binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
MAP kinase kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
receptor tyrosine kinase binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
ubiquitin protein ligase binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
histone kinase activity	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
identical protein binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
scaffold protein binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
protein serine/threonine kinase binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
DNA-binding transcription factor binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
linear polyubiquitin binding	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
protein serine/threonine kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
signaling receptor binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
ATP binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
LIM domain binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
signaling adaptor activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
identical protein binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein homodimerization activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
CARD domain binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
caspase binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein serine kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
JUN kinase kinase kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
magnesium ion binding	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
protein kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
ATP binding	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
protein serine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
p53 binding	NUAK family SNF1-like kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	NUAK family SNF1-like kinase 1	Homo sapiens (human)
protein binding	NUAK family SNF1-like kinase 1	Homo sapiens (human)
ATP binding	NUAK family SNF1-like kinase 1	Homo sapiens (human)
metal ion binding	NUAK family SNF1-like kinase 1	Homo sapiens (human)
protein serine kinase activity	NUAK family SNF1-like kinase 1	Homo sapiens (human)
protein binding	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activity	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
phosphatidylinositol kinase activity	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
transcription cis-regulatory region binding	Cyclin-T1	Homo sapiens (human)
DNA binding	Cyclin-T1	Homo sapiens (human)
chromatin binding	Cyclin-T1	Homo sapiens (human)
protein binding	Cyclin-T1	Homo sapiens (human)
protein kinase binding	Cyclin-T1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activity	Cyclin-T1	Homo sapiens (human)
RNA polymerase binding	Cyclin-T1	Homo sapiens (human)
7SK snRNA binding	Cyclin-T1	Homo sapiens (human)
DNA-binding transcription factor binding	Cyclin-T1	Homo sapiens (human)
molecular condensate scaffold activity	Cyclin-T1	Homo sapiens (human)
transcription coactivator binding	Cyclin-T2	Homo sapiens (human)
chromatin binding	Cyclin-T2	Homo sapiens (human)
protein binding	Cyclin-T2	Homo sapiens (human)
RNA polymerase binding	Cyclin-T2	Homo sapiens (human)
7SK snRNA binding	Cyclin-T2	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activity	Cyclin-T2	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
growth hormone receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12 receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein kinase binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
heme binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
type 1 angiotensin receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
acetylcholine receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
histone H3Y41 kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
histone binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
insulin receptor substrate binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
peptide hormone receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protease binding	Rho-associated protein kinase 2	Homo sapiens (human)
RNA binding	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
structural molecule activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein binding	Rho-associated protein kinase 2	Homo sapiens (human)
ATP binding	Rho-associated protein kinase 2	Homo sapiens (human)
small GTPase binding	Rho-associated protein kinase 2	Homo sapiens (human)
metal ion binding	Rho-associated protein kinase 2	Homo sapiens (human)
tau protein binding	Rho-associated protein kinase 2	Homo sapiens (human)
tau-protein kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
endopeptidase activator activity	Rho-associated protein kinase 2	Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
small GTPase binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein-containing complex binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
GTPase binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
RNA endonuclease activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
platelet-derived growth factor receptor binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
enzyme binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
Hsp70 protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein homodimerization activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
ADP binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
Hsp90 protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
unfolded protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
magnesium ion binding	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein tyrosine kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
histone H3S10 kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
histone H3S28 kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
histone H2AS1 kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
magnesium ion binding	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
ribosomal protein S6 kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
histone H3S10 kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
histone H3S28 kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Serine/threonine-protein kinase 16	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 16	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 16	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)
phosphatidylinositol binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)
phosphatidylinositol kinase activity	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-K	Homo sapiens (human)
protein binding	Cyclin-K	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-K	Homo sapiens (human)
protein kinase binding	Cyclin-K	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activity	Cyclin-K	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
MAP kinase kinase activity	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
SH3 domain binding	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
small GTPase binding	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase-like 5	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase-like 5	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase-like 5	Homo sapiens (human)
protein binding	Cyclin-dependent kinase-like 5	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase-like 5	Homo sapiens (human)
kinase activity	Cyclin-dependent kinase-like 5	Homo sapiens (human)
small GTPase binding	Cyclin-dependent kinase-like 5	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase-like 5	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase 17B	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 17B	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 17B	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 17B	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 10	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 10	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein homodimerization activity	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 10	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase D3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase D3	Homo sapiens (human)
kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase D3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 14	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 14	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 14	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 14	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 14	Homo sapiens (human)
protein binding	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cadherin binding	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
magnesium ion binding	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
protein kinase binding	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
creatine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
microtubule binding	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
MAP kinase kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein kinase binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
nuclear estrogen receptor binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cadherin binding involved in cell-cell adhesion	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
protein kinase binding	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
ubiquitin protein ligase binding	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
protein homodimerization activity	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
protein binding	G1/S-specific cyclin-E2	Homo sapiens (human)
protein kinase binding	G1/S-specific cyclin-E2	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	G1/S-specific cyclin-E2	Homo sapiens (human)
protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein serine/threonine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
AMP-activated protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein binding	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
ATP binding	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein domain specific binding	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein serine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
supercoiled DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
magnesium ion binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
four-way junction DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
bubble DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
transcription coactivator activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin monomer binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nicotinate-nucleotide adenylyltransferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein kinase C binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
SH3 domain binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
syntaxin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
manganese ion binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuropilin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
nucleoplasm	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
mitochondrion	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
endoplasmic reticulum membrane	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
nuclear speck	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Sgk1	Homo sapiens (human)
plasma membrane	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
dendrite	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
neuronal cell body	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
receptor complex	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
HFE-transferrin receptor complex	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
plasma membrane	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
nucleus	Cell division cycle 7-related protein kinase	Homo sapiens (human)
nucleoplasm	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cytoplasm	Cell division cycle 7-related protein kinase	Homo sapiens (human)
intercellular bridge	Cell division cycle 7-related protein kinase	Homo sapiens (human)
mitotic spindle	Cell division cycle 7-related protein kinase	Homo sapiens (human)
nucleus	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cytoplasm	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
XY body	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cleavage furrow	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
deuterosome	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
procentriole	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
procentriole replication complex	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase 25	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 25	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase 25	Homo sapiens (human)
FAR/SIN/STRIPAK complex	Serine/threonine-protein kinase 25	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 25	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
endoplasmic reticulum	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cytosol	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
endocytic vesicle	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
intracellular membrane-bounded organelle	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cytosol	Citron Rho-interacting kinase	Homo sapiens (human)
membrane	Citron Rho-interacting kinase	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
preribosome, small subunit precursor	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase RIO3	Homo sapiens (human)
nucleus	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
cytoplasm	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
cytosol	Dual specificity mitogen-activated protein kinase kinase 7	Homo sapiens (human)
PML body	Telomerase reverse transcriptase	Homo sapiens (human)
chromosome, telomeric region	Telomerase reverse transcriptase	Homo sapiens (human)
nucleus	Telomerase reverse transcriptase	Homo sapiens (human)
nucleoplasm	Telomerase reverse transcriptase	Homo sapiens (human)
telomerase holoenzyme complex	Telomerase reverse transcriptase	Homo sapiens (human)
nucleolus	Telomerase reverse transcriptase	Homo sapiens (human)
cytosol	Telomerase reverse transcriptase	Homo sapiens (human)
plasma membrane	Telomerase reverse transcriptase	Homo sapiens (human)
nuclear speck	Telomerase reverse transcriptase	Homo sapiens (human)
mitochondrial nucleoid	Telomerase reverse transcriptase	Homo sapiens (human)
TERT-RMRP complex	Telomerase reverse transcriptase	Homo sapiens (human)
telomerase catalytic core complex	Telomerase reverse transcriptase	Homo sapiens (human)
nuclear telomere cap complex	Telomerase reverse transcriptase	Homo sapiens (human)
RNA-directed RNA polymerase complex	Telomerase reverse transcriptase	Homo sapiens (human)
chromosome, telomeric region	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
condensed nuclear chromosome	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
extracellular space	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
replication fork	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
intracellular membrane-bounded organelle	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
chromatin	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein-containing complex	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cytoplasm	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
nucleus	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
cytosol	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
IkappaB kinase complex	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
cytoplasmic side of plasma membrane	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
membrane raft	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
CD40 receptor complex	Inhibitor of nuclear factor kappa-B kinase subunit beta	Homo sapiens (human)
basement membrane	Peripheral plasma membrane protein CASK	Homo sapiens (human)
nuclear lamina	Peripheral plasma membrane protein CASK	Homo sapiens (human)
nucleolus	Peripheral plasma membrane protein CASK	Homo sapiens (human)
cytoplasm	Peripheral plasma membrane protein CASK	Homo sapiens (human)
cytosol	Peripheral plasma membrane protein CASK	Homo sapiens (human)
cell-cell junction	Peripheral plasma membrane protein CASK	Homo sapiens (human)
focal adhesion	Peripheral plasma membrane protein CASK	Homo sapiens (human)
actin cytoskeleton	Peripheral plasma membrane protein CASK	Homo sapiens (human)
nuclear matrix	Peripheral plasma membrane protein CASK	Homo sapiens (human)
vesicle	Peripheral plasma membrane protein CASK	Homo sapiens (human)
presynaptic membrane	Peripheral plasma membrane protein CASK	Homo sapiens (human)
ciliary membrane	Peripheral plasma membrane protein CASK	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Peripheral plasma membrane protein CASK	Homo sapiens (human)
basement membrane	Peripheral plasma membrane protein CASK	Homo sapiens (human)
cell-cell junction	Peripheral plasma membrane protein CASK	Homo sapiens (human)
basolateral plasma membrane	Peripheral plasma membrane protein CASK	Homo sapiens (human)
plasma membrane	Peripheral plasma membrane protein CASK	Homo sapiens (human)
spindle microtubule	Aurora kinase A	Homo sapiens (human)
nucleus	Aurora kinase A	Homo sapiens (human)
nucleoplasm	Aurora kinase A	Homo sapiens (human)
centrosome	Aurora kinase A	Homo sapiens (human)
centriole	Aurora kinase A	Homo sapiens (human)
spindle	Aurora kinase A	Homo sapiens (human)
cytosol	Aurora kinase A	Homo sapiens (human)
postsynaptic density	Aurora kinase A	Homo sapiens (human)
microtubule cytoskeleton	Aurora kinase A	Homo sapiens (human)
basolateral plasma membrane	Aurora kinase A	Homo sapiens (human)
midbody	Aurora kinase A	Homo sapiens (human)
spindle pole centrosome	Aurora kinase A	Homo sapiens (human)
ciliary basal body	Aurora kinase A	Homo sapiens (human)
germinal vesicle	Aurora kinase A	Homo sapiens (human)
axon hillock	Aurora kinase A	Homo sapiens (human)
pronucleus	Aurora kinase A	Homo sapiens (human)
perinuclear region of cytoplasm	Aurora kinase A	Homo sapiens (human)
mitotic spindle	Aurora kinase A	Homo sapiens (human)
meiotic spindle	Aurora kinase A	Homo sapiens (human)
mitotic spindle pole	Aurora kinase A	Homo sapiens (human)
glutamatergic synapse	Aurora kinase A	Homo sapiens (human)
spindle pole centrosome	Aurora kinase A	Homo sapiens (human)
chromosome passenger complex	Aurora kinase A	Homo sapiens (human)
spindle midzone	Aurora kinase A	Homo sapiens (human)
kinetochore	Aurora kinase A	Homo sapiens (human)
Golgi apparatus	Cyclin-G-associated kinase	Homo sapiens (human)
cytosol	Cyclin-G-associated kinase	Homo sapiens (human)
focal adhesion	Cyclin-G-associated kinase	Homo sapiens (human)
membrane	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin-coated vesicle	Cyclin-G-associated kinase	Homo sapiens (human)
vesicle	Cyclin-G-associated kinase	Homo sapiens (human)
intracellular membrane-bounded organelle	Cyclin-G-associated kinase	Homo sapiens (human)
perinuclear region of cytoplasm	Cyclin-G-associated kinase	Homo sapiens (human)
presynapse	Cyclin-G-associated kinase	Homo sapiens (human)
vesicle	Cyclin-G-associated kinase	Homo sapiens (human)
cytoplasm	Cyclin-G-associated kinase	Homo sapiens (human)
intracellular membrane-bounded organelle	Cyclin-G-associated kinase	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
postsynaptic density	Serine/threonine-protein kinase DCLK1	Homo sapiens (human)
nucleoplasm	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
cytoplasm	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
cytosol	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
IkappaB kinase complex	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
cytoplasmic side of plasma membrane	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
CD40 receptor complex	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
cytoplasm	Inhibitor of nuclear factor kappa-B kinase subunit alpha	Homo sapiens (human)
plasma membrane	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
neuromuscular junction	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
postsynaptic membrane	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
receptor complex	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
plasma membrane	Muscle, skeletal receptor tyrosine-protein kinase	Homo sapiens (human)
extracellular region	Ephrin type-B receptor 6	Homo sapiens (human)
cytosol	Ephrin type-B receptor 6	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 6	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 6	Homo sapiens (human)
dendrite	Ephrin type-B receptor 6	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 13	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 13	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 13	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
nucleus	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cytoplasm	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cytosol	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
plasma membrane	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
focal adhesion	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
postsynaptic density	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cytoplasmic vesicle	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cell projection	3-phosphoinositide-dependent protein kinase 1	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
membrane	Mitogen-activated protein kinase kinase kinase 13	Homo sapiens (human)
nucleus	Death-associated protein kinase 3	Homo sapiens (human)
nucleoplasm	Death-associated protein kinase 3	Homo sapiens (human)
cytosol	Death-associated protein kinase 3	Homo sapiens (human)
PML body	Death-associated protein kinase 3	Homo sapiens (human)
nucleus	Death-associated protein kinase 3	Homo sapiens (human)
cytoplasm	Death-associated protein kinase 3	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
plasma membrane	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
endosome membrane	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
ATAC complex	Mitogen-activated protein kinase kinase kinase 7	Homo sapiens (human)
plasma membrane	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytoplasm	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
endoplasmic reticulum	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytosol	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytoskeleton	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
vesicle	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein-containing complex	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
pericentriolar material	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
nucleoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
cytoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
cytosol	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
cytoplasmic stress granule	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
nuclear speck	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
intracellular membrane-bounded organelle	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
cytoskeleton	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
cytoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 3	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha'	Mus musculus (house mouse)
fibrillar center	NUAK family SNF1-like kinase 1	Homo sapiens (human)
nucleus	NUAK family SNF1-like kinase 1	Homo sapiens (human)
nucleoplasm	NUAK family SNF1-like kinase 1	Homo sapiens (human)
cytoplasm	NUAK family SNF1-like kinase 1	Homo sapiens (human)
microtubule cytoskeleton	NUAK family SNF1-like kinase 1	Homo sapiens (human)
phagocytic cup	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
uropod	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
cytosol	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
adherens junction	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
focal adhesion	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
endosome membrane	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
ruffle membrane	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
presynapse	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	Homo sapiens (human)
nucleolus	Cyclin-T1	Homo sapiens (human)
nucleus	Cyclin-T1	Homo sapiens (human)
nucleus	Cyclin-T1	Homo sapiens (human)
nucleoplasm	Cyclin-T1	Homo sapiens (human)
cytosol	Cyclin-T1	Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complex	Cyclin-T1	Homo sapiens (human)
P-TEFb complex	Cyclin-T1	Homo sapiens (human)
nucleus	Cyclin-T2	Homo sapiens (human)
nucleoplasm	Cyclin-T2	Homo sapiens (human)
cytosol	Cyclin-T2	Homo sapiens (human)
plasma membrane	Cyclin-T2	Homo sapiens (human)
perinuclear region of cytoplasm	Cyclin-T2	Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complex	Cyclin-T2	Homo sapiens (human)
nucleus	Cyclin-T2	Homo sapiens (human)
extrinsic component of plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytoskeleton	Tyrosine-protein kinase JAK2	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
caveola	Tyrosine-protein kinase JAK2	Homo sapiens (human)
focal adhesion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
granulocyte macrophage colony-stimulating factor receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
endosome lumen	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12 receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-23 receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
postsynapse	Tyrosine-protein kinase JAK2	Homo sapiens (human)
glutamatergic synapse	Tyrosine-protein kinase JAK2	Homo sapiens (human)
euchromatin	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleus	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome	Rho-associated protein kinase 2	Homo sapiens (human)
cytosol	Rho-associated protein kinase 2	Homo sapiens (human)
plasma membrane	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome	Rho-associated protein kinase 2	Homo sapiens (human)
cytoskeleton	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasm	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
mitochondrial outer membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
endoplasmic reticulum membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
axon	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
recycling endosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
omegasome membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
Atg1/ULK1 kinase complex	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
nuclear inner membrane	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
mitochondrion	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
endoplasmic reticulum	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
endoplasmic reticulum membrane	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
Ire1 complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
AIP1-IRE1 complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
IRE1-TRAF2-ASK1 complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
IRE1-RACK1-PP2A complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
nucleus	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
nucleus	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
cytosol	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
synapse	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase 16	Homo sapiens (human)
Golgi-associated vesicle	Serine/threonine-protein kinase 16	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 16	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase 16	Homo sapiens (human)
perinuclear region of cytoplasm	Serine/threonine-protein kinase 16	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase 16	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 16	Homo sapiens (human)
cytosol	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)
membrane	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	Homo sapiens (human)
cyclin K-CDK12 complex	Cyclin-K	Homo sapiens (human)
cyclin K-CDK13 complex	Cyclin-K	Homo sapiens (human)
nucleoplasm	Cyclin-K	Homo sapiens (human)
nucleus	Cyclin-K	Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complex	Cyclin-K	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
postsynaptic density	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
glutamatergic synapse	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PAK 3	Homo sapiens (human)
ruffle membrane	Cyclin-dependent kinase-like 5	Homo sapiens (human)
glutamatergic synapse	Cyclin-dependent kinase-like 5	Homo sapiens (human)
nucleus	Cyclin-dependent kinase-like 5	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase-like 5	Homo sapiens (human)
centrosome	Cyclin-dependent kinase-like 5	Homo sapiens (human)
dendrite cytoplasm	Cyclin-dependent kinase-like 5	Homo sapiens (human)
ciliary basal body	Cyclin-dependent kinase-like 5	Homo sapiens (human)
dendritic growth cone	Cyclin-dependent kinase-like 5	Homo sapiens (human)
perinuclear region of cytoplasm	Cyclin-dependent kinase-like 5	Homo sapiens (human)
ciliary tip	Cyclin-dependent kinase-like 5	Homo sapiens (human)
postsynaptic density, intracellular component	Cyclin-dependent kinase-like 5	Homo sapiens (human)
nucleus	Cyclin-dependent kinase-like 5	Homo sapiens (human)
dendrite cytoplasm	Cyclin-dependent kinase-like 5	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase 17B	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase 17B	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment	Serine/threonine-protein kinase 17B	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase 17B	Homo sapiens (human)
actin cytoskeleton	Serine/threonine-protein kinase 17B	Homo sapiens (human)
Flemming body	Serine/threonine-protein kinase 17B	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase 17B	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 10	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase 10	Homo sapiens (human)
specific granule membrane	Serine/threonine-protein kinase 10	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase 10	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 10	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase D3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase D3	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase D3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase D3	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 14	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 14	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 14	Homo sapiens (human)
plasma membrane	Cyclin-dependent kinase 14	Homo sapiens (human)
cytoplasmic cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 14	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 14	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 14	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 14	Homo sapiens (human)
centrosome	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cytosol	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
microtubule cytoskeleton	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
membrane	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
centrosome	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cytoplasm	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
nucleus	G2/mitotic-specific cyclin-B2	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase OSR1	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
focal adhesion	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
midbody	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
adherens junction	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
focal adhesion	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
chromosome, telomeric region	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
PML body	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Chk2	Homo sapiens (human)
nucleoplasm	G1/S-specific cyclin-E2	Homo sapiens (human)
cytosol	G1/S-specific cyclin-E2	Homo sapiens (human)
cyclin E2-CDK2 complex	G1/S-specific cyclin-E2	Homo sapiens (human)
nucleus	G1/S-specific cyclin-E2	Homo sapiens (human)
cytoplasm	G1/S-specific cyclin-E2	Homo sapiens (human)
centrosome	G1/S-specific cyclin-E2	Homo sapiens (human)
cyclin E1-CDK2 complex	G1/S-specific cyclin-E2	Homo sapiens (human)
acrosomal vesicle	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
mitochondrion	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
plasma membrane	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
neuromuscular junction	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
sperm flagellum	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
perinuclear region of cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
ruffle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleolus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitochondrion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytosol	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin cytoskeleton	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nuclear body	Tyrosine-protein kinase ABL1	Homo sapiens (human)
dendrite	Tyrosine-protein kinase ABL1	Homo sapiens (human)
growth cone	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nuclear membrane	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuronal cell body	Tyrosine-protein kinase ABL1	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
postsynapse	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein-containing complex	Tyrosine-protein kinase ABL1	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytosol	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
nucleus	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
mitochondrial inner membrane	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
cytoskeleton	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
plasma membrane	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
focal adhesion	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
endosome membrane	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
membrane	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
cell junction	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
perinuclear region of cytoplasm	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
protein-containing complex	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
plasma membrane	Proto-oncogene tyrosine-protein kinase Src	Gallus gallus (chicken)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
ruffle membrane	Epidermal growth factor receptor	Homo sapiens (human)
Golgi membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Epidermal growth factor receptor	Homo sapiens (human)
nucleus	Epidermal growth factor receptor	Homo sapiens (human)
cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
focal adhesion	Epidermal growth factor receptor	Homo sapiens (human)
cell surface	Epidermal growth factor receptor	Homo sapiens (human)
endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane	Epidermal growth factor receptor	Homo sapiens (human)
basolateral plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
apical plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
cell junction	Epidermal growth factor receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Epidermal growth factor receptor	Homo sapiens (human)
early endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
nuclear membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane raft	Epidermal growth factor receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
multivesicular body, internal vesicle lumen	Epidermal growth factor receptor	Homo sapiens (human)
intracellular vesicle	Epidermal growth factor receptor	Homo sapiens (human)
protein-containing complex	Epidermal growth factor receptor	Homo sapiens (human)
receptor complex	Epidermal growth factor receptor	Homo sapiens (human)
Shc-EGFR complex	Epidermal growth factor receptor	Homo sapiens (human)
basal plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
plasma membrane	RAF proto-oncogene serine/threonine-protein kinase	Homo sapiens (human)
nucleus	RAF proto-oncogene serine/threonine-protein kinase	Homo sapiens (human)
cytoplasm	RAF proto-oncogene serine/threonine-protein kinase	Homo sapiens (human)
mitochondrial outer membrane	RAF proto-oncogene serine/threonine-protein kinase	Homo sapiens (human)

Bioassays (4260)

Assay ID	Title	Year	Journal	Article
AID624766	Binding constant for p38-gamma kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624809	Binding constant for MYLK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531869	Inhibition of human ROS using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624801	Binding constant for MAP3K15 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435664	Binding constant for MYLK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1481078	Inhibition of human MEK1 using ERK2 as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID720476	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1365719	Cytotoxicity against human HepG2 cells at 100 uM after 3 days by CellTiter-Glo luminescent cell viability assay	2017	Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21	The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID720329	Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720279	Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462569	Induction of apoptosis in human MFE296 cells assessed as early apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.5 to 2.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1365192	Inhibition of FLT3 (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
AID1350958	Inhibition of cMET (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1715143	Inhibition of human TLK1 using Histone H3 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1732832	Inhibition of FGFR2 (unknown origin)	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
AID625116	Binding constant for ADCK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715180	Inhibition of human RSK1 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531315	Inhibition of human EPHB1 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1680242	Inhibition of human Trk-A using myelin basic protein as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting method	2018	Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21	Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
AID720448	Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624705	Binding constant for MYLK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624972	Binding constant for MTOR kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1285477	Inhibition of Pim1 kinase (unknown origin) using substrate S3 after 50 mins by HTRF assay	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and Pim-1 kinase inhibitors.
AID1531375	Inhibition of human KDR assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1736064	Inhibition of recombinant human PAK4 kinase domain (300 to 591 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate using serine/threonine-20 peptide as substrate at 50 uM incubated for 60 mins in presence of ATP by FRET based Z'	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor.
AID262370	Inhibition of C-KIT using 1.0 mM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID435663	Binding constant for full-length MST4	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1368675	Inhibition of human DAPK1 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1531268	Inhibition of human CDK6/cyclin-D3 assessed as residual activity at 100 uM using RB protein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID262976	Inhibition of ERK2 at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1715249	Inhibition of human MYO3B using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1758204	Inhibition of PDGFRA (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins in presence of ATP by caliper mobility shift assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Ring closure strategy leads to potent RIPK3 inhibitors.
AID601550	Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Metachromins U-W: cytotoxic merosesquiterpenoids from an Australian specimen of the sponge Thorecta reticulata.
AID625110	Binding constant for TRPM6 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720303	Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720254	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1157145	Inhibition of CDK2/cyclin A2 (unknown origin)	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Design and synthesis of pyrimidine molecules endowed with thiazolidin-4-one as new anticancer agents.
AID1183902	Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 3 uM after 18 hrs by inverse MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1715198	Inhibition of human PKG1beta using LRRASLG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256674	Average Binding Constant for PKMYT1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624975	Binding constant for PLK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531874	Inhibition of human SBK1 using LCGRTGRRNSI as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715123	Inhibition of human ZAP70 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID49344	Inhibition of rat brain Casein kinase II	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID1247624	Inhibition of EGFR (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID126618	Inhibition of MEK1 phosphorylation by activated human recombinant Raf	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
AID1074867	Induction of apoptosis in human A2780 cells assessed as cholesterol crystal formation after 24 hrs by acridine orange/propidium iodide staining-based fluorescence microscopy	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID1491367	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 72 hrs by CellTiter Glo luminescent assay	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	2-Substituted-thio-N-(4-substituted-thiazol/1H-imidazol-2-yl)acetamides as BACE1 inhibitors: Synthesis, biological evaluation and docking studies.
AID624866	Binding constant for MLK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1348850	Inhibition human recombinant full length His-tagged Plk1 expressed in baculovirus expression system after 1 hr by FRET-based Z'-Lyte assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold.
AID262977	Inhibition of MAPKAP2 at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1127411	Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	4-Oxo-1,4-dihydro-quinoline-3-carboxamides as BACE-1 inhibitors: synthesis, biological evaluation and docking studies.
AID1531568	Inhibition of human YSK4 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256608	Average Binding Constant for MARK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID426692	Inhibition of CHK1 at 25 nM by alphascreen assay in presence of 0.01% Triton-X100	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Identification of inhibitors of checkpoint kinase 1 through template screening.
AID256656	Average Binding Constant for p38-alpha; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720139	Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531651	Inhibition of human CLK4 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1202435	Inhibition of KIT (unknown origin) at 10 uM after 30 mins by HTRF method	2015	European journal of medicinal chemistry, , Volume: 96	Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents.
AID1715362	Inhibition of human EPHA8 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531704	Inhibition of human FYN using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715345	Inhibition of human FGFR3 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720218	Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID342541	Inhibition of human ZAP70	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
AID1689398	Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxic condition by MTT assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
AID1531531	Inhibition of human STK38 assessed as residual activity at 100 uM using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462586	Induction of apoptosis in human T47D cells assessed as late apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 3 to 13.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531331	Inhibition of human FGFR2 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531333	Inhibition of human FGFR4 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1466331	Inhibition of VEGFR-2 (unknown origin) by HTRF method	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
AID625089	Binding constant for AAK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID281696	Induction of apoptosis in Jurkat cells assessed as PARP cleavage at 1 uM after 30 hrs	2004	Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25	Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.
AID720158	Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1846769	Inhibition of ALK (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID640589	Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity.
AID753283	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological evaluation of N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides as inhibitors of angiogenesis and tumor growth.
AID624759	Binding constant for PFCDPK1(P.falciparum) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1206448	Activation of Caspase 3/7 in human U937 cells assessed as cleavage of Ac-DEVD-AFC at 1 uM after 16 hrs by fluorescence assay relative to control	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.
AID1277435	Induction of apoptosis in mouse B16F10 cells assessed as dead cells at 0.1 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.11%)	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines.
AID1314089	Inhibition of recombinant human N-terminal His-tagged GSK-3beta expressed in Escherichia coli using glycogen synthase-2 as substrate and ATP measured after 30 mins by Kinase-Glo luminescent kinase assay	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity.
AID1624699	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced TNF-alpha level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA	2019	Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6	Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1524570	Antiproliferative activity against human BJ cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Synthesis and Biological Studies of (+)-Liquiditerpenoic Acid A (Abietopinoic Acid) and Representative Analogues: SAR Studies.
AID350283	Inhibition of MST2	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1236888	Inhibition of BCR-ABL1 (unknown origin) assessed as ATP remaining by Kinase-Glo luminescent kinase assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
AID1531629	Inhibition of human CDK5/p25 using histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531657	Inhibition of human DCAMKL1 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1732833	Inhibition of FGFR3 (unknown origin)	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
AID624849	Binding constant for CSNK2A2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715178	Inhibition of human RSK2 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531834	Inhibition of human PKAcb using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID164478	Inhibition of human neutrophil protein kinase A (PKA)	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID1531590	Inhibition of human Aurora C using [H-LRRASLG] as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720204	Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715317	Inhibition of human IKKbeta using KKKKERLLDDRHDSGLDSMKDEE as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256614	Average Binding Constant for YES; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1462545	Induction of apoptosis in human p53-null PC3 cells assessed as early apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.6 to 1.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1466329	Inhibition of EGFR (unknown origin) by HTRF method	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
AID350256	Inhibition of CDK2/cyclinA	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1531456	Inhibition of human PAK5 assessed as residual activity at 100 uM using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID590191	Inhibition of human recombinant IKK-alpha expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	Structure-based design and biological profile of (E)-N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of IκB kinase-β.
AID1900711	Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate preincubated with enzyme for 20 mins followed by substrate addition and measured after 20 mins by Ellman's method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
AID1368684	Inhibition of human ROCK1 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1715166	Inhibition of human SNRK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720464	Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624964	Binding constant for DYRK1B kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462571	Induction of apoptosis in human MFE296 cells assessed as nuclear debris at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.4 to 0.8%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531462	Inhibition of human PDK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624977	Binding constant for OSR1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1889867	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
AID1063043	Inhibition of NEK6 (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID435153	Binding constant for full-length DAPK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531810	Inhibition of human p38alpha using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1678147	Inhibition of PKCtheta (unknown origin) by HTRF assay
AID1462520	Induction of apoptosis in human A2780 cells assessed as viable cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 95 to 96.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531857	Inhibition of human PLK3 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720162	Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720200	Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1381799	Induction of apoptosis in human KOPN8 cells assessed as viable cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 85.2%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1247643	Inhibition of SYK (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1300784	Inhibition of Akt2 (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID415642	Inhibition of IKKalpha	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID1531324	Inhibition of human ERK7 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1164097	Inhibition of human recombinant GSK3beta using CFFKNIVTPRTPPPSQGK-amide substrate after 90 mins incubation by LANCE method	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
AID164952	Inhibition of Protein kinase C	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
AID1715378	Inhibition of human DMPK2 using KKRPQRRYSNVF as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1360770	Inhibition of human FLT4 by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID1245552	Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors.
AID1191823	Inhibition of N-terminal His-tagged recombinant PKC-epsilon (unknown origin) by HTRF assay	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
AID1760632	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID624841	Binding constant for BLK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435659	Binding constant for full-length MARK3	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1298811	Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
AID723735	Inhibition of CDK9/Cyclin T (1 to 330 amino acid residues) (unknown origin) by differential scanning fluorimetry assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
AID1531318	Inhibition of human EPHB4 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531380	Inhibition of human LATS2 assessed as residual activity at 100 uM using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531819	Inhibition of human PAK4 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715340	Inhibition of human FLT4 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID163855	Inhibition of Protein kinase C eta	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID1498025	Antiproliferative activity against human MDA-MB-231 cells at 0.1 uM after 48 hrs in presence of pan-caspase inhibitor Z-VAD-FMK by MTS assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery and Identification of Small Molecules as Methuosis Inducers with in Vivo Antitumor Activities.
AID1772911	Inhibition of JAK3 (unknown origin) incubated for 40 mins in presence of Mg/ATP mix by [gamma p33]-ATP based scintillation counting method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1715417	Inhibition of human CDK14/cyclin-Y using RB protein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531867	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624961	Binding constant for TGFBR1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1730898	Inhibition of tracer 222 binding to GAK (unknown origin) incubated for 1 hr by Lanthascreen TR-FRET assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase.
AID228824	Inhibition of Abl tyrosine kinase	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID256604	Average Binding Constant for STK10; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715359	Inhibition of human EPHB3 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435792	Binding constant for EGFR(S752-I759del) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID625119	Binding constant for CAMK1G kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625019	Binding constant for AKT3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID303330	Inhibition of TRKA at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID624872	Binding constant for PAK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID494408	Inhibition of ERK1	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID1531931	Inhibition of human YES using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID629262	Inhibition of Abl1	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID720128	Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531736	Inhibition of human JNK1 using ATF2 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531865	Inhibition of human RIPK5 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625135	Binding constant for ADCK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715202	Inhibition of human PKCtheta using Histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID462626	Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
AID1727473	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Cytotoxic triterpenoid-safirinium conjugates target the endoplasmic reticulum.
AID1531623	Inhibition of human CDK2/cyclin-A using histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308937	Inhibition of c-Kit (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID601547	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Metachromins U-W: cytotoxic merosesquiterpenoids from an Australian specimen of the sponge Thorecta reticulata.
AID624936	Binding constant for FLT3(D835Y) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531417	Inhibition of human MNK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256586	Average Binding Constant for STK4; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1612678	Inhibition of human CDK2/cyclin-O using histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID350290	Inhibition of PKCalpha	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID625082	Binding constant for RSK4(Kin.Dom.2-C-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID78448	In vitro antiproliferative activity against human carcinoma cell line HCT116 (colon)	2003	Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14	Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
AID1715168	Inhibition of human SNARK using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715390	Inhibition of human CLK3 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1680983	Induction of mitochondrial membrane potential loss in human Jurkat cells assessed as death cells at 200 nM after 4 hrs by MitoSense Red/7-AAD. flow cytometric analysis (Rvb = 0.22%)	2020	Journal of natural products, 08-28, Volume: 83, Issue:8	Total Synthesis of Natural Lembehyne C and Investigation of Its Cytotoxic Properties.
AID1531608	Inhibition of human CAMK2A using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1129876	Induction of late apoptosis in human HepG2 cells assessed as induction of DNA fragmentation at 1 uM after 4 hrs by JC-1 staining relative to control	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Investigation of the cytotoxic, genotoxic, and apoptosis-inducing effects of estragole isolated from fennel (Foeniculum vulgare).
AID1728101	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
AID1715454	Inhibition of human ACK1 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID241093	Inhibition of Protein Kinase A in P19 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID720359	Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1666670	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometric analysis (Rvb = 0.41 %)	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
AID1531777	Inhibition of human MLK1 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1247617	Inhibition of Aurora A (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID435791	Binding constant for EGFR(E746-A750del) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720461	Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624757	Binding constant for PKMYT1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID304247	Inhibition of DNA synthesis in human A549 cells after 24 hrs by [3H]thymidine incorporation assay	2007	Journal of medicinal chemistry, 12-13, Volume: 50, Issue:25	Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy.
AID1715373	Inhibition of human DYRK1B using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID429341	Inhibition of ROS1 by HotSpot assay relative to control	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
AID624770	Binding constant for CAMK2D kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531920	Inhibition of human TYK1 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531544	Inhibition of human TLK1 assessed as residual activity at 100 uM using Histone H3 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531483	Inhibition of human PKCzeta assessed as residual activity at 100 uM using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624718	Binding constant for PFTAIRE2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720044	Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720232	Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531307	Inhibition of human EPHA1 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1484297	Induction of apoptosis in human PC3 cells assessed as viable cells at 30 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 95%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID1531210	Inhibition of human ACK1 assessed as residual activity at 100 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720248	Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462542	Induction of apoptosis in human p53-null PC3 cells assessed as late apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.4 to 1.6%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531422	Inhibition of human MSK2 assessed as residual activity at 100 uM using GRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1247633	Inhibition of Jak3 (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1184499	Inhibition of Aurora B (unknown origin) using [33P]-ATP and 10 uM ATP after 2 hrs	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Click approach to the discovery of 1,2,3-triazolylsalicylamides as potent Aurora kinase inhibitors.
AID435311	Binding constant for HCK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1654676	Induction of DNA damage in human ARN8 cells assessed as gammaH2AX level at 1 uM incubated for 4.5 hrs in presence of pan-caspase inhibitor, Z-VAD-FMK by Western blot analysis	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
AID1531902	Inhibition of human TAOK3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715396	Inhibition of human CK1a1L using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715252	Inhibition of human MUSK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID389366	Solubility in water	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
AID1269230	Cytoprotective activity against H2O2-induced apoptosis in human SH-SY5Y cells assessed as late apoptotic cells at 100 nM preincubated for 24 hrs followed by H2O2 addition measured after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytomet	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	α-Aryl-N-aryl nitrones: Synthesis and screening of a new scaffold for cellular protection against an oxidative toxic stimulus.
AID435198	Binding constant for TIE1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531910	Inhibition of human TNIK using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624886	Binding constant for ERK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1394746	Inhibition of recombinant human KDR expressed in Sf9 insect cells using Ulight-CAGAGAIETDKEYYTVKD as substrate after 60 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID1531237	Inhibition of human c-MER assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720375	Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID257079	Inhibitory activity against PIM1 at 1 uM	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
AID435287	Binding constant for EPHA8 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531512	Inhibition of human SGK2 assessed as residual activity at 100 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531803	Inhibition of human NEK6 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715246	Inhibition of human NEK11 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531452	Inhibition of human PAK1 assessed as residual activity at 100 uM using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1247638	Inhibition of PKA (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1300789	Inhibition of ROCK1 (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID720120	Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435276	Binding constant for BMPR1A kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531539	Inhibition of human TBK1 assessed as residual activity at 100 uM using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531484	Inhibition of human PKD2 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435413	Binding constant for MLCK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715434	Inhibition of human c-SRC using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1169351	Selectivity index, ratio of cytotoxic EC50 against human cells to EC50 for Plasmodium falciparum K1	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID1531454	Inhibition of human PAK3 assessed as residual activity at 100 uM using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531673	Inhibition of human EPHA3 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625137	Binding constant for MEK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1074835	Induction of apoptosis in human A2780 cells assessed as caspase 3 activity at 1 uM after 24 hrs relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID435833	Binding constant for full-length TNK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID601551	Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Metachromins U-W: cytotoxic merosesquiterpenoids from an Australian specimen of the sponge Thorecta reticulata.
AID625056	Binding constant for TESK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715162	Inhibition of human STK16 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720273	Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715228	Inhibition of human PAK4 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531682	Inhibition of human EPHB4 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720373	Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624888	Binding constant for ERK5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1664188	Inhibition of wild type EGFR (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay
AID735916	Inhibition of ERK1 (unknown origin) at 50 uM	2013	Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3	Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment.
AID624811	Binding constant for PAK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715181	Inhibition of human ROS using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715155	Inhibition of human STK38 using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID402476	Potentiation of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay	1997	Journal of natural products, Aug, Volume: 60, Issue:8	Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
AID625105	Binding constant for EPHB2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID614648	Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 after 60 mins by activity based 100 fold dilution assay	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID1531460	Inhibition of human PDGFRalpha assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1481088	Inhibition of PI3Kbeta (unknown origin)	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1715287	Inhibition of human MAPKAPK3 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720370	Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531744	Inhibition of human LATS2 using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1059946	Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli BL21 assessed as phosphate incorporation in CREB	2013	European journal of medicinal chemistry, Oct, Volume: 68	Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
AID720176	Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715207	Inhibition of human PKCeta using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1778247	Inhibition of IKKalpha (unknown origin) by ADP-Glo kinase assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Beyond direct Nrf2 activation; reinvestigating 1,2,4-oxadiazole scaffold as a master key unlocking the antioxidant cellular machinery for cancer therapy.
AID494387	Inhibition of human GSK3-beta assessed as residual activity at 1 uM relative to control	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID624747	Binding constant for SgK110 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1810930	Induction of caspase-mediated apoptosis in human HCC827-Luc cells assessed as reduction in cell viability at 1 uM pretreated with caspase inhibitor Z-VAD-fmk for 1 hr followed by compound addition and measured after 72 hrs by CCK-8 assay	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Synthesis of Fluorescent Probes Targeting Tumor-Suppressor Protein FHIT and Identification of Apoptosis-Inducing FHIT Inhibitors.
AID624950	Binding constant for DMPK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462551	Induction of apoptosis in human p53-null PC3 cells assessed as nuclear debris at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.1 to 0.5%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1655213	Induction of apoptosis in human GCE28 cells assessed as increase in caspase 3/7 activation at 10 uM measured after 48 hrs by CellEvent caspase 3/7 probe based fluorecence analysis	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Development of Pyrazolo[3,4-
AID625095	Binding constant for SIK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435294	Binding constant for full-length LIMK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1771935	Binding affinity to MERTK-AXL mutant (unknown origin) expressed in Escherichia coli Rosetta cells assessed as change in melting temperature by SYPRO orange dye based DSF assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Design and Development of a Chemical Probe for Pseudokinase Ca
AID1779108	Induction of apoptosis in VEGF-stimulated HUVEC cells assessed as increase in Bax/Bcl2 ratio at 250 nM measured after 48 hrs by western blot analysis	2021	Journal of natural products, 06-25, Volume: 84, Issue:6	Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway.
AID1531518	Inhibition of human SNARK assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531580	Inhibition of human ALK2 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531845	Inhibition of human PKCnu using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1666226	Antiproliferative activity against human DND41 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1531685	Inhibition of human ERK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624831	Binding constant for CHEK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531250	Inhibition of human CAMKK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435793	Binding constant for EPHA1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1164096	Inhibition of human recombinant GSK3alpha using CFFKNIVTPRTPPPSQGK-amide substrate after 60 mins incubation by LANCE method	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
AID1481086	Inhibition of human ZAP70 using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1532727	Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells at 1 uM after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry method (Rvb = 3.8%)	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID1531932	Inhibition of human YSK4 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435554	Binding constant for PRKD3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1448905	Inhibition of human C-terminal His-tagged IGF1R (960 to 1367 residues) expressed in baculovirus infected insect cells at 10 uM using KKKSPGEYVNIEFG as substrate in presence of [gamma32P]ATP after 120 mins relative to control	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.
AID49334	Inhibition of Casein kinase I	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID1531503	Inhibition of human ROCK2 assessed as residual activity at 100 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1760630	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID624960	Binding constant for RSK2(Kin.Dom.1-N-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID436047	Binding constant for full-length PRKX	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715177	Inhibition of human RSK4 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715311	Inhibition of human JAK1 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1287708	Induction of apoptosis in human NALM6 cells assessed as viable cells at 0.5 uM measured after 24 hrs by annexin V-propidium iodide staining based flow cytometric analysis (Rvb = 1.7%)	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID1531496	Inhibition of human PYK2 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256625	Average Binding Constant for PAK3; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720137	Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435321	Binding constant for PRKCQ kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531244	Inhibition of human CAMK2A assessed as residual activity at 100 uM using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID350276	Inhibition of IRAK4	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1350982	Inhibition of VEGFR2 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1715361	Inhibition of human EPHB2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435896	Binding constant for AAK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1059942	Inhibition of recombinant aurora kinase A (unknown origin) expressed in Escherichia coli	2013	European journal of medicinal chemistry, Oct, Volume: 68	Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
AID1142774	Antiproliferative activity against human A549 cells after 24 to 48 hrs by CCK-8 assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity.
AID1531807	Inhibition of human NIM1 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1691930	Inhibition of human full length recombinant CDK9/cyclin T1 using KTFCGTPEYLAPE as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1).
AID256618	Average Binding Constant for PHkg2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624907	Binding constant for SYK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720438	Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID629405	Inhibition of ROS	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1531889	Inhibition of human STK21 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435197	Binding constant for TEC kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720133	Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624994	Binding constant for AKT1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720022	Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1770395	Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID1247625	Inhibition of ErK1 (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID624922	Binding constant for CAMK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720168	Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID303329	Inhibition of TIE2 at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID435903	Binding constant for CDK8 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID427626	Inhibition of GST-GSK3beta	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
AID1689702	Induction of apoptosis in human RPMI-8226 cells assessed as Bcl-2 level incubated for 24 hrs by ELISA (Rvb = 4.857 +/- 0.0226 ng/ml)	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
AID720169	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID350267	Inhibition of FGFR1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID624748	Binding constant for EPHA6 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID436018	Binding constant for FLT4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID256567	Average Binding Constant for EPHA6; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID415618	Inhibition of CDK5/P35	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID435929	Binding constant for PAK4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1381811	Induction of apoptosis in human SUP-B15 cells assessed as viable cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 82.8%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1887904	Antiproliferative activity against human Ca-Ski cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
AID624875	Binding constant for PDGFRB kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID366082	Inhibition of PKA in human MCF7 cells by array-based fluorescence assay	2008	Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16	Array-based fluorescence assay for serine/threonine kinases using specific chemical reaction.
AID1394743	Inhibition of recombinant human Flt4 using Ulight-CAGAGAIETDKEYYTVKD as substrate after 90 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID165266	Inhibition of purified mammalian brain calcium calmodulin dependent protein kinase (Ca calmod)	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID427623	Inhibition of recombinant MEK1 expressed in Escherichia coli	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
AID126782	Inhibition of Mitogen-activated protein kinase (MAPK)phosphorylation by activated MEK-1	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
AID1360780	Inhibition of human FLT3 D835Y mutant by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID1531793	Inhibition of human MYLK3 using KKRPQRRYSNVF as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531804	Inhibition of human NEK7 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1421401	Inhibition of Aurora B (unknown origin) using STK S2 as substrate after 30 mins by HTRF assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
AID1715267	Inhibition of human MLK1 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256635	Average Binding Constant for CAMK2D; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715436	Inhibition of human c-KIT using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624899	Binding constant for ROS1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435561	Binding constant for SRMS kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715171	Inhibition of human SIK2 using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1439521	Inhibition of Alexa647 tracer binding to full length recombinant human His-tagged CDK8/Cyclin C expressed in baculovirus expression system preincubated for 20 mins followed by tracer addition measured after 60 mins by TR-FRET based Lanthascreen assay	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
AID1531527	Inhibition of human STK25 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531252	Inhibition of human CDK17/Cyclin-A assessed as residual activity at 100 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625055	Binding constant for MST1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID498018	Inhibition of GST-fused Plasmodium falciparum recombinant CDPK1 expressed in Escherichia coli Rosetta 2 assessed as inhibition of [gamma-33P]ATP incorporation into substrate peptide by scintillation counting	2008	Nature chemical biology, Jun, Volume: 4, Issue:6	Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility.
AID720224	Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID257082	Binding affinity to non phosphorylated PIM1	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
AID262979	Inhibition of Chk1 at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID720079	Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID402479	Cytotoxicity against mouse L929 cells at 1 uM preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining	1997	Journal of natural products, Aug, Volume: 60, Issue:8	Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
AID720217	Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID55504	Inhibitory activity against Cyclin E-cyclin-dependent kinase 2 in enzymatic assay by measuring phosphorylation of RbING; not tested	2003	Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14	Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
AID1531808	Inhibition of human NLK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720340	Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435397	Binding constant for CSNK1G1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435898	Binding constant for ACVR1B kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531362	Inhibition of human IKKbeta assessed as residual activity at 100 uM using KKKKERLLDDRHDSGLDSMKDEE as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1581525	Antiproliferative activity against human HCT116 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay
AID720025	Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1404961	Inhibition of recombinant human N-terminal GST-tagged HER2 (679 to 1255 residues) expressed in baculovirus infected Sf9 cells using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay
AID1531325	Inhibition of human ERN1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID350251	Inhibition of AKT1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1531755	Inhibition of human MAPKAPK2 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435764	Inhibition of V66A-mutated CK2 holoenzyme	2003	The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3	Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID720092	Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720117	Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308957	Inhibition of GSK3beta (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID720404	Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715300	Inhibition of human LCK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435282	Binding constant for full-length CSNK1G2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1142794	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity.
AID435782	Binding constant for BRSK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID256636	Average Binding Constant for JNK3; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID415624	Selectivity ratio of IC50 for CDK4/cyclin D1 to IC50 for human GSK3-beta	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID720046	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID625062	Binding constant for MAP3K2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462564	Induction of apoptosis in human MFE296 cells assessed as viable cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 90.9 to 94.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1462531	Induction of apoptosis in human MCF7 cells assessed as nuclear debris at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.2 to 3%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1715399	Inhibition of human CHK1 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624758	Binding constant for RIPK5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531314	Inhibition of human EPHA8 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625084	Binding constant for HUNK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715134	Inhibition of human TXK using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID280405	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP	2007	Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6	Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes.
AID1715367	Inhibition of human EPHA5 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531712	Inhibition of human GRK6 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624826	Binding constant for BMPR2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435524	Binding constant for full-length CSNK1D	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531284	Inhibition of human CLK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531306	Inhibition of human EGFR assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720245	Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435688	Binding constant for full-length PCTK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531670	Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435167	Binding constant for KIT(V559D) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435293	Binding constant for JNK3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435926	Binding constant for PDGFRB kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID436010	Binding constant for full-length CDK5	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1655555	Inhibition of recombinant full length human N-terminal GST-tagged GSK3beta (1 to 420 end residues) expressed in baculovirus expression system using unphosphorylated peptide as substrate incubated enzyme-substrate mixture for 90 mins in presence of ATP by	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Optimization of Indazole-Based GSK-3 Inhibitors with Mitigated hERG Issue and
AID1715374	Inhibition of human DYRK2 using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1365191	Inhibition of EGFR (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
AID622362	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents.
AID745529	Inhibition of CDK1/Cyclin A (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID1484291	Induction of apoptosis in human PC3 cells assessed as viable cells at 10 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 95%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID1308945	Inhibition of EPHB2 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID720207	Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID730004	Inhibition of VEGFR-2 kinase (unknown origin) using [33P]-ATP at 10 uM after 20 to 40 mins by scintillation counting analysis	2013	European journal of medicinal chemistry, Mar, Volume: 61	Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
AID1715328	Inhibition of human GRK7 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID611846	Inhibition of PDGFR-alpha at 20 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID1531832	Inhibition of human PIM3 using RSRHSSYPAGT as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720100	Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1704864	Inhibition of recombinant wild-type human N-terminal GST-HIS6 fused RET C-terminal domain (H658 to S1114 residues) expressed in Sf9 insect cells using TRK-C-derived peptide as substrate in presence of [33P]-ATP by filter binding assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
AID1531701	Inhibition of human FLT4 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531742	Inhibition of human KSR2 using KRREILSRRPSYR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1581521	Antiproliferative activity against human A549 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay
AID720124	Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720430	Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531450	Inhibition of human p70S6K assessed as residual activity at 100 uM using KKRNRTLTK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1350964	Inhibition of CHK2 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID350266	Inhibition of ERK2	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1252493	Inhibition of human CDK1 by kinase inhibition assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID1531692	Inhibition of human FER using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715200	Inhibition of human PKD2 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1504785	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Platanic acid: A new scaffold for the synthesis of cytotoxic agents.
AID720114	Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1066419	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	2014	European journal of medicinal chemistry, Jan-24, Volume: 72	The chemical and biological potential of C ring modified triterpenoids.
AID1531366	Inhibition of human IRAK4 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531733	Inhibition of human JAK1 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1706574	Inhibition of EPHA2 (unknown origin) assessed as change in melting temperature at 10 uM by DSF assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Selective targeting of the αC and DFG-out pocket in p38 MAPK.
AID435202	Binding constant for TRKC kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID625063	Binding constant for PLK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID351489	Inhibition of recombinant Syk	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
AID1531828	Inhibition of human PHKgamma1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715217	Inhibition of human PIM2 using RSRHSSYPAGT as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID415619	Inhibition of CDK6/cyclin D3	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID624780	Binding constant for CDK4-cyclinD1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720215	Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531225	Inhibition of human Aurora B assessed as residual activity at 100 uM using [H-LRRASLG] as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715199	Inhibition of human PKG1alpha using LRRASLG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435275	Binding constant for BIKE kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624706	Binding constant for MLK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1689703	Induction of apoptosis in human RPMI-8226 cells assessed as PARP-1 level incubated for 24 hrs by ELISA (Rvb = 0.151 +/- 0.0027 ng/ml)	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
AID624751	Binding constant for PIP5K1C kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531247	Inhibition of human CAMK2G assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720221	Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715230	Inhibition of human PAK3 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID342546	Inhibition of PKCbeta2	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
AID1552359	Induction of apoptosis in human Ramos cells assessed as caspase-3 activation at 2.5 uM using AcDEVD-AMC as substrate preincubated for up to 8 hrs followed by substrate addition and measured after 60 mins by spectrophotometric method	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Novel meriolin derivatives as rapid apoptosis inducers.
AID1462540	Induction of apoptosis in human p53-null PC3 cells assessed as viable cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 96.5 to 98.6%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531842	Inhibition of human PKCgamma using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID164652	Inhibition of protein kinase A (PKA)	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID415617	Inhibition of CDK5/P25	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID624951	Binding constant for EPHA2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531603	Inhibition of human c-SRC using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256646	Average Binding Constant for JAK1 (Kin.Dom. 1); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720422	Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531936	Inhibition of human CDK2/cyclin-A1 assessed as residual activity at 100 uM using histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1671730	Antiproliferative activity against hTERT-RPE1 cells assessed as cell viability at 2 uM after 48 hrs by CellTiter96 AQueous assay relative to control	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
AID1631074	Inhibition of His-tagged full length human recombinant GSK3beta using [YRRAAVPPSPSLSRHSSPHQ-(pS)EDEEE] substrate and pre-incubarted for 20 mins before [gamma-33P]ATP addition and measured after 2 hrs by radiometric kinase assay	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	Application of Fragment-Based de Novo Design to the Discovery of Selective Picomolar Inhibitors of Glycogen Synthase Kinase-3 Beta.
AID1691929	Inhibition of full length human recombinant CDK2/Cyclin A using histone H1 as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1).
AID1784932	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Natural inspired piperine-based sulfonamides and carboxylic acids as carbonic anhydrase inhibitors: Design, synthesis and biological evaluation.
AID624924	Binding constant for RIPK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435564	Binding constant for TRKB kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID256624	Average Binding Constant for FGFR3; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435514	Binding constant for ABL1(M351T) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624932	Binding constant for CLK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID695574	Inhibition of telomerase in human HepG2 cells after 24 hrs by TRAP-PCR-ELISA assay	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors.
AID1531797	Inhibition of human NEK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256583	Average Binding Constant for CAMKK1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715338	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624802	Binding constant for PIM3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715272	Inhibition of human MINK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720070	Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID625072	Binding constant for TBK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435286	Binding constant for EPHA7 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID629394	Inhibition of JNK1	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID415625	Selectivity ratio of IC50 for CDK5/P25 to IC50 for human GSK3-beta	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID1350988	Inhibition of STK3 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID624865	Binding constant for MAP3K3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435780	Binding constant for BMPR2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720458	Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715214	Inhibition of human PKAcb using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256568	Average Binding Constant for STK17A; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1055901	Cytotoxicity against human HCT116 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID624782	Binding constant for FGFR3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531799	Inhibition of human NEK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1731528	Inhibition of CDK2/Cyclin-O (unknown origin) using histone H1 as substrate preincubated for 20 mins followed by 33P-ATP addition and measured after 2 hrs by filter binding method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Tetrahydroindazole inhibitors of CDK2/cyclin complexes.
AID624797	Binding constant for PHKG2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720181	Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531877	Inhibition of human SGK3 using GRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1300798	Inhibition of ALK (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1169353	Cytotoxicity against human Raji cells	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID747368	Inhibition of 6xHis-tagged Src catalytic domain (unknown origin) expressed in Escherichia coli using AEEEIYGEFEAKKKK as substrate incubated for 10 mins prior to substrate addition measured after 30 mins by fluorescence intensity assay	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors.
AID640588	Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity.
AID436012	Binding constant for full-length CSNK2A1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720385	Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID410272	Inhibition of human recombinant Pim1 by ATP depletion assay	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.
AID1531588	Inhibition of human Aurora A using [H-LRRASLG] as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID436053	Binding constant for full-length STK33	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715259	Inhibition of human MSK2 using GRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624834	Binding constant for DAPK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715445	Inhibition of human Aurora C using [H-LRRASLG] as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720283	Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1074853	Induction of apoptosis in human A2780 cells assessed as caspase 3 activity at 1 uM after 6 hrs relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID350252	Inhibition of Aurora-A	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1715266	Inhibition of human MLK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID735919	Inhibition of JNK1 (unknown origin) at 50 uM	2013	Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3	Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment.
AID1531411	Inhibition of human MLCK assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625118	Binding constant for CAMK1D kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720140	Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1090419	Antimicrobial activity against Rhizoctonia solani assessed as growth inhibition incubated for 4 to 7 fays	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1531886	Inhibition of human SRPK2 using GRSRSRSRSR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256597	Average Binding Constant for CLK1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256652	Average Binding Constant for CAMK2B; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256592	Average Binding Constant for LIMK1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531441	Inhibition of human NEK8 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531686	Inhibition of human ERK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1808084	Selectivity index, ratio of IC50 for human MCF-10A cells to IC50 for human MDA-MB-231 cells	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer.
AID624861	Binding constant for LIMK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720262	Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624884	Binding constant for PRKD1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID567889	Induction of apoptosis in human MCF7 cells expressing estrogen receptor assessed as increase of PARP cleavage at 10'-5 M after 9 hrs by Western blotting	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Syntheses, antiproliferative activity and theoretical characterization of acitretin-type retinoids with changes in the lipophilic part.
AID1715456	Inhibition of human ABL1 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715276	Inhibition of human MEKK6 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1481080	Inhibition of human PKACA using LCGRTGRRNSI as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1531571	Inhibition of human ZIPK assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1063027	Cytotoxicity against human Jurkat cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Leonurusoleanolides E-J, minor spirocyclic triterpenoids from Leonurus japonicus fruits.
AID625054	Binding constant for MST2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1581520	Antiproliferative activity against human A549 cells measured after 72 hrs under normoxic condition by MTT assay
AID435665	Binding constant for NEK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1381919	Inhibition of Rb phosphorylation in human KOPN8 cells assessed as ratio of phosphorylated Rb to total Rb levels after 3 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1421095	Antiproliferative activity against human MG63 cells assessed as reduction in cell viability at 2.14 uM after 72 hrs by WST8 assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID725934	Inhibition of human recombinant N-terminal GST-tagged Plk1 in presence of 3.12 mM of ATP	2013	Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3	Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
AID1183889	Induction of cell death in human primary monocytes at 3 uM after 4 hrs by LDH release assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1757219	Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors.
AID1612687	Inhibition of human PKN2 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID256628	Average Binding Constant for LYN; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720477	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624839	Binding constant for AKT2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720235	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1732383	Cytotoxicity against human LOX IMVI cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
AID262973	Inhibition of PKCgamma at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID426940	Ratio of IC50 for JAK3 expressing human resting Jurkat cells to IC50 for JAK3 expressing IL2-stimulated human Jurkat cells	2009	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12	Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses.
AID435399	Binding constant for DCAMKL3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531263	Inhibition of human CDK4/cyclin-D1 assessed as residual activity at 100 uM using RB protein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720247	Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1572743	Cytostatic activity against human K562 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1751471	Inhibition of PDGFRbeta (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives.
AID625109	Binding constant for BIKE kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID629392	Inhibition of IGF1R	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID284062	Weight change in human A431 xenografted BALB/c nude mouse at 1 mg/kg, ip after 10 days	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents.
AID493445	Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening.
AID1715426	Inhibition of human CAMK2D using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1462555	Induction of apoptosis in human MFE280 cells assessed as nuclear debris at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.5 to 2.3%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID720032	Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531245	Inhibition of human CAMK2B assessed as residual activity at 100 uM using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624717	Binding constant for JNK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID78415	In vitro antiproliferative activity against human carcinoma cell line H460 (lung); not tested	2003	Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14	Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
AID1664189	Inhibition of HER2 (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay
AID415611	Inhibition of CDK2/Cyclin E	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID624959	Binding constant for MAP4K2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1706571	Inhibition of AURKB (unknown origin) assessed as change in melting temperature at 10 uM by DSF assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Selective targeting of the αC and DFG-out pocket in p38 MAPK.
AID756067	Inhibition of human N-terminal GST-tagged LRRK2 after 1 hr by TR-FRET assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	The development of CNS-active LRRK2 inhibitors using property-directed optimisation.
AID1247627	Inhibition of FGFR2 (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1531397	Inhibition of human MARK4 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID629404	Inhibition of RON	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID624829	Binding constant for CDK8 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID611836	Inhibition of PDGFR-alpha at 50 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID1532744	Induction of apoptosis in human HCT116 cells at 1 uM after 12 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID670626	Induction of caspase 3 activation in human HeLa cells using Ac-DEVD-pNA at 2 uM after 4 hrs by Bradford assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID1402965	Inhibition of recombinant human N-terminal GST-tagged HER2 (679 to 1255 residues) expressed in baculovirus infected Sf9 cells at 100 nM using poly[Glu:Tyr] (4:1) as substrate after 40 mins by Kinase-Glo plus luminescence assay relative to control	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID256619	Average Binding Constant for RPS6KA3 (Kin.Dom. 1); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID269864	Inhibition of Met	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID1705873	Inhibition of human TRKA using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]ATP by scintillation counting method
AID592894	Inhibition of PKA activity using neurogranin as a substrate in presence of 50 uM ATP by mass spectrometry	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	The synthesis and evaluation of indolylureas as PKCα inhibitors.
AID720130	Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715325	Inhibition of human haspin using Histone H3 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625128	Binding constant for CSNK1G1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625048	Binding constant for PRKCD kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720383	Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435326	Binding constant for TYRO3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1543906	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID624833	Binding constant for CSNK1G2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715303	Inhibition of human KSR1 using KRREILSRRPSYR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID303313	Inhibition of ACK at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID350274	Inhibition of HIPK1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID720058	Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715254	Inhibition of human MST4 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256580	Average Binding Constant for CAMKK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1394737	Inhibition of recombinant human Aurora-A expressed in Sf21 insect cells using Ulight-RRRSLLE as substrate after 15 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID1594645	Antiproliferative activity against human HCT116 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1360781	Inhibition of human FLT3 F594_R595insREY mutant by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID1410109	Inhibition of PKCalpha (unknown origin) by HTRF assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Bioactive Indolocarbazoles from the Marine-Derived Streptomyces sp. DT-A61.
AID1715129	Inhibition of human ULK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1612681	Inhibition of human CDK1/cyclinB using Histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID435147	Binding constant for ACVR2B kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435784	Binding constant for CAMK2G kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1462561	Induction of apoptosis in human MFE280 cells assessed as early apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 5.1 to 6.2%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID88220	Compound was tested or HeLa cell cycle inhibition; arrest of G2/M phase	2003	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17	Isolation of bisindole alkaloids that inhibit the cell cycle from Myxomycetes Arcyria ferruginea and Tubifera casparyi.
AID1846771	Inhibition of cKit (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID1531238	Inhibition of human c-MET assessed as residual activity at 100 uM using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624965	Binding constant for LZK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID256668	Average Binding Constant for ABL1(H396P); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID164020	Inhibition of Protein kinase C gamma	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID1770393	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID1531800	Inhibition of human NEK3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308981	Inhibition of SRC (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID435152	Binding constant for CAMK4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1247642	Inhibition of ROS1 (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1059941	Inhibition of recombinant MEK1 (unknown origin) expressed in Escherichia coli	2013	European journal of medicinal chemistry, Oct, Volume: 68	Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
AID389370	Inhibition of IL2 production in PHA-stimulated human PBMC after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
AID435789	Binding constant for full-length CSNK2A2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1360768	Inhibition of human FLT1 by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID1300797	Inhibition of BRAF (unknown origin) after 1 hr by HTRF assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1090400	Phytotoxicity in Phytophthora capsici zoospores suspension infected Capsicum annuum cv. Hanbyul (pepper) at first branch stage pre-exposed to compound spray on stems before fungal infection at 500 ug/mL under greenhouse conditions	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1715174	Inhibition of human SGK2 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625086	Binding constant for SLK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531425	Inhibition of human MST2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435555	Binding constant for PRKR kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID436024	Binding constant for MRCKA kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1462557	Induction of apoptosis in human MFE280 cells assessed as early apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 5.1 to 6.2%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531489	Inhibition of human PKN2 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1666228	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID624846	Binding constant for CSNK1A1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435694	Binding constant for TNK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715253	Inhibition of human MST3 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435934	Binding constant for PLK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531399	Inhibition of human MEK2 assessed as residual activity at 100 uM using ERK2 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1350960	Inhibition of CDK1/cyclin B (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531281	Inhibition of human CK1gamma3 assessed as residual activity at 100 uM using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531347	Inhibition of human GRK5 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID262371	Inhibition of SRC kinase using 1.0 mM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID1462562	Induction of apoptosis in human MFE280 cells assessed as late apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 6 to 7.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID161244	Inhibition of Platelet-derived growth factor receptor	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID1715387	Inhibition of human CLK4 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256587	Average Binding Constant for ACK1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1581522	Antiproliferative activity against human PC3 cells measured after 72 hrs under normoxic condition by MTT assay
AID625047	Binding constant for AMPK-alpha2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID164360	Inhibition of kinase activity of Raf/MEK/ERK kinase cascade in ELISA	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
AID624935	Binding constant for FLT3(D835H) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624962	Binding constant for ASK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1246338	Induction of apoptosis in human triple-negative MDA-MB-231 cells assessed as early apoptotic cells after 12 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 3.1%)	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID1715245	Inhibition of human NEK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID70049	Inhibition of Epidermal growth factor receptor	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID163520	Inhibition of Protein kinase C delta	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID720099	Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1090411	Antimicrobial activity against Magnaporthe grisea assessed as growth inhibition incubated for 4 to 7 fays	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID720156	Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435674	Binding constant for JAK3(Kin.Dom.2/JH1 - catalytic) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID567888	Induction of apoptosis in human MCF7 cells expressing estrogen receptor assessed as increase of PARP cleavage at 10'-5 M after 4 hrs by Western blotting	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Syntheses, antiproliferative activity and theoretical characterization of acitretin-type retinoids with changes in the lipophilic part.
AID1657501	Antiproliferative activity against human PANC1 cells assessed as inhibition of cell growth	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.
AID624784	Binding constant for INSR kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531420	Inhibition of human MRCKbeta assessed as residual activity at 100 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1074861	Induction of apoptosis in human A2780 cells assessed as chromatin condensation at at 1 uM after 24 hrs by acridine orange/propidium iodide staining-based fluorescence microscopy	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID1350997	Inhibition of PLK2 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1733107	Inhibition of CDKL3 (unknown origin) by NanoBRET cellular target engagement assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core.
AID1531719	Inhibition of human HIPK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1203682	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID256650	Average Binding Constant for PIM1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625097	Binding constant for TNNI3K kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462567	Induction of apoptosis in human MFE296 cells assessed as nuclear debris at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.4 to 0.8%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID256609	Average Binding Constant for AAK1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531406	Inhibition of human MELK assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID436049	Binding constant for PTK6 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720291	Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308962	Inhibition of JAK1 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1704682	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	3-Methylthiazolo[3,2-a]benzimidazole-benzenesulfonamide conjugates as novel carbonic anhydrase inhibitors endowed with anticancer activity: Design, synthesis, biological and molecular modeling studies.
AID262970	Inhibition of Akt2 at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1531501	Inhibition of human RIPK5 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531829	Inhibition of human PHKgamma2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625136	Binding constant for YSK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531337	Inhibition of human FLT4 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531301	Inhibition of human DYRK1A assessed as residual activity at 100 uM using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID418424	Selectivity ratio of IC50 for Pim2 to IC50 for Pim1	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.
AID1542196	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors.
AID1715185	Inhibition of human RIPK5 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1666229	Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1715251	Inhibition of human MYLK3 using KKRPQRRYSNVF as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1074843	Induction of apoptosis in human A2780 cells assessed as caspase 9 activity at 1 uM after 12 hrs relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID1348853	Selectivity index, ratio of IC50 for human recombinant GST-tagged Plk3 catalytic domain (58 to 340 residues) expressed in baculovirus expression system to IC50 for human recombinant full length GST-tagged Plk2 expressed in baculovirus expression system	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold.
AID1531847	Inhibition of human PKCzeta using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1350968	Inhibition of ERK1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1572744	Cytostatic activity against human Z138 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1300792	Inhibition of MSK1 (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1368678	Inhibition of human IRAK at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1531923	Inhibition of human ULK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1808082	Antiproliferative activity against HEK293 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer.
AID1090404	Antimicrobial activity against Xanthomonas vesicatoria assessed as growth inhibition incubated for 4 to 7 days	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1531615	Inhibition of human CDC7/DBF4 using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID303314	Inhibition of TYRO3 at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID625003	Binding constant for EGFR(L858R) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID595221	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Maklamicin, an antibacterial polyketide from an endophytic Micromonospora sp.
AID720301	Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435930	Binding constant for PHKG2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531814	Inhibition of human p70S6K using KKRNRTLTK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1142608	Inhibition of ALK3 (unknown origin) by radioisotopic assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/
AID1704865	Inhibition of recombinant human N-terminal GST-HIS6 fused RET M918T mutant C-terminal domain (H658 to S1114 residues) expressed in Sf9 insect cells using TRK-C-derived peptide as substrate in presence of [33P]-ATP by filter binding assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
AID720327	Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715308	Inhibition of human JNK1 using ATF2 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1074844	Induction of apoptosis in human A2780 cells assessed as caspase 3 activity at 1 uM after 12 hrs relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID1715421	Inhibition of human CDC7/DBF4 using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1354793	Induction of apoptosis in human SH-SY5Y cells at 1 uM after 6 hrs by Annexin V-FITC/PI staining based flow cytometry	2018	Journal of natural products, 06-22, Volume: 81, Issue:6	Structures and Activities of Tiahuramides A-C, Cyclic Depsipeptides from a Tahitian Collection of the Marine Cyanobacterium Lyngbya majuscula.
AID624934	Binding constant for FLT3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624795	Binding constant for MET(M1250T) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720429	Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531837	Inhibition of human PKCb1 using Histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435404	Binding constant for EPHB4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID262365	Inhibition of ERK2 using 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID625114	Binding constant for GSK3A kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531574	Inhibition of human ACK1 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID415622	Selectivity ratio of IC50 for CDK2/cyclin A to IC50 for human GSK3-beta	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID1490931	Induction of apoptosis in human U2OS cells assessed as caspase-3/7 cleavage at 250 nM after 16 hrs by caspase-3/7 green reagent based flow cytometry (Rvb = 8.04%)	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Preussilides A-F, Bicyclic Polyketides from the Endophytic Fungus Preussia similis with Antiproliferative Activity.
AID435193	Binding constant for RPS6KA6(Kin.Dom.1 - C-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1308940	Inhibition of EGFR L858R mutant (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID163504	Inhibition of Protein kinase C delta	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID1350985	Inhibition of LYN (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531666	Inhibition of human DYRK1B using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1066418	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	2014	European journal of medicinal chemistry, Jan-24, Volume: 72	The chemical and biological potential of C ring modified triterpenoids.
AID256579	Average Binding Constant for MAP3K5; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531414	Inhibition of human MLK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1680982	Induction of mitochondrial membrane potential loss in human Jurkat cells assessed as stressed cells at 200 nM after 4 hrs by MitoSense Red/7-AAD. flow cytometric analysis (Rvb = 1.12%)	2020	Journal of natural products, 08-28, Volume: 83, Issue:8	Total Synthesis of Natural Lembehyne C and Investigation of Its Cytotoxic Properties.
AID350263	Inhibition of EPHA3	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID614640	Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID1715145	Inhibition of human TEC using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715402	Inhibition of human CDK9/cyclin-K using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID402474	Potentiation of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining	1997	Journal of natural products, Aug, Volume: 60, Issue:8	Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
AID405702	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method	2008	Journal of natural products, Jun, Volume: 71, Issue:6	Cytotoxic staurosporines from the marine ascidian Cystodytes solitus.
AID720222	Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID625028	Binding constant for ASK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1063052	Inhibition of AKT1 (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1715310	Inhibition of human ITK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720252	Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256615	Average Binding Constant for p38-gamma; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1368679	Inhibition of human LCK at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1531463	Inhibition of human PEAK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720453	Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531342	Inhibition of human GLK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1532728	Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells at 1 uM after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry method (Rvb = 5.4%)	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID1308955	Inhibition of FGFR4 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID629278	Inhibition of FMS	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID624893	Binding constant for MEK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID256617	Average Binding Constant for TEK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256622	Average Binding Constant for JNK1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID695572	Antiproliferative activity against human HeLa cells after 48 hrs by MTT method	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors.
AID358177	Inhibition of PKC	1992	Journal of natural products, Nov, Volume: 55, Issue:11	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1530823	Inhibition of human full length N-terminal GST tagged CHK1 assessed as residual activity at 2.00 10'-5M (Rvb = 96.94 to 103.06%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID280403	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP	2007	Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6	Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes.
AID1715256	Inhibition of human MST1 using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435806	Binding constant for MAPKAPK5 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531491	Inhibition of human PLK1 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1478068	Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.
AID1531798	Inhibition of human NEK11 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624709	Binding constant for MYLK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID592893	Inhibition of human PKCalpha activity using kemptide as a substrate in presence of 50 uM ATP by mass spectrometry	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	The synthesis and evaluation of indolylureas as PKCα inhibitors.
AID720155	Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435909	Binding constant for full-length LKB1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1300786	Inhibition of PKA (unknown origin) after 60 mins by Z-LYTE kinase assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1531477	Inhibition of human PKCeta assessed as residual activity at 100 uM using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID269862	Inhibition of PKA	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID350288	Inhibition of PIM1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1068665	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.
AID720278	Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715146	Inhibition of human TESK1 using cofilin as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1760633	Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID164195	Inhibition of Protein kinase C zeta	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID1917245	Inhibition of CDK9/cyclin T1 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors.
AID720085	Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624744	Binding constant for ZAP70 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1771923	Binding affinity to recombinant N-terminal His-tagged CASK (1 to 337 residues) (unknown origin) expressed in Escherichia coli assessed as change in melting temperature by SYPRO orange dye based DSF assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Design and Development of a Chemical Probe for Pseudokinase Ca
AID494404	Inhibition of IGF1R	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID720236	Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720409	Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531740	Inhibition of human KHS using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1183895	Cytotoxicity against human primary monocytes assessed as reduction in cell viability at 3 uM after 2 hrs by inverse MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1715221	Inhibition of human PDK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256660	Average Binding Constant for KIT; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1394739	Inhibition of recombinant human c-KIT using Ulight-TK peptide as substrate after 30 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID720216	Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624999	Binding constant for EGFR(G719S) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624982	Binding constant for ABL1(F317L)-phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715324	Inhibition of human HCK using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625131	Binding constant for FGFR2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720363	Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1142775	Antiproliferative activity against human HeLa cells after 24 to 48 hrs by CCK-8 assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity.
AID256634	Average Binding Constant for CSNK1G2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531653	Inhibition of human CSK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1074832	Induction of apoptosis in human A2780 cells assessed as caspase 9 activity at 1 uM after 24 hrs relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID1715184	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID242065	Inhibition of Plasmodium falciparum cyclin-dependent kinase	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
AID1846774	Inhibition of FLT3 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID1350954	Inhibition of AKT1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1381878	Induction of apoptosis in human KOPN8 cells assessed as effect on Mcl-1 level after 3 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID624874	Binding constant for PCTK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1889870	Antiproliferative activity against human HaCaT cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
AID1872776	Inhibition of telomerase (unknown origin)	2022	European journal of medicinal chemistry, Apr-15, Volume: 234	Recent applications of vinyl sulfone motif in drug design and discovery.
AID1715375	Inhibition of human DYRK1A using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1462587	Induction of apoptosis in human T47D cells assessed as nuclear debris at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.2 to 7.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1895103	Binding affinity to PAK1 (unknown origin) assessed as change in melting temperature by thermal shift based DSF assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors.
AID1350962	Inhibition of CDK2/cyclin A (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531726	Inhibition of human IKKbeta using KKKKERLLDDRHDSGLDSMKDEE as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715451	Inhibition of human AKT3 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID304250	Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 30 nM after 24 hrs by flow cytometry	2007	Journal of medicinal chemistry, 12-13, Volume: 50, Issue:25	Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy.
AID720478	Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308942	Inhibition of EGFR T790M/L858R mutant (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID624713	Binding constant for ERK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531534	Inhibition of human SYK assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531900	Inhibition of human TAOK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531321	Inhibition of human ERK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1484296	Induction of apoptosis in human PC3 cells assessed as necrotic cells at 20 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 2 to 3%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID1090420	Antimicrobial activity against Alternaria mali assessed as growth inhibition incubated for 4 to 7 days	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1664196	Inhibition of recombinant human N-terminal GST-tagged EGFR L858R mutant (669 to 1210 residues) expressed in baculovirus expression system by competitive binding assay
AID163859	Inhibition of Protein kinase C eta	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID1531551	Inhibition of human TSSK2 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531875	Inhibition of human SGK1 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531274	Inhibition of human CHK2 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531885	Inhibition of human SRPK1 using GRSRSRSRSR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531892	Inhibition of human STK32B using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435783	Binding constant for full-length BRSK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1462576	Induction of apoptosis in human T47D cells assessed as viable cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 74.5 to 94.5%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID624835	Binding constant for ERN1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID269863	Inhibition of Kit	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID1350957	Inhibition of BTK (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID625041	Binding constant for PIK3CA(H1047L) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID159258	Inhibition of phosphorylase kinase.	1992	Journal of medicinal chemistry, Jan, Volume: 35, Issue:1	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.
AID1531427	Inhibition of human MST4 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1736573	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay
AID1287695	Induction of apoptosis in human NALM6 cells assessed as cleaved PARP level at 0.5 uM measured after 3 and 6 hrs by immunoblot analysis	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID688349	Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID165105	Inhibition of rat brain protein kinase C(PKC) in 1%DMSO.	1992	Journal of medicinal chemistry, Jan, Volume: 35, Issue:1	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.
AID1531299	Inhibition of human DMPK2 assessed as residual activity at 100 uM using KKRPQRRYSNVF as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625081	Binding constant for RSK4(Kin.Dom.1-N-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1654686	Induction of apoptosis in human ARN8 cells assessed as increase in caspase 3/7 activity at 1 uM incubated for 48 hrs in presence of pan-caspase inhibitor, Z-VAD-FMK by live cell imaging analysis	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
AID1252497	Inhibition of human PDGFRbeta by kinase inhibition assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID720045	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715354	Inhibition of human ERK5 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715393	Inhibition of human CK1gamma3 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1830800	Antiproliferative activity against human BET-sensitive 22Rv1 cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-Glo assay	2021	Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20	Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins.
AID720078	Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720413	Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID163348	Inhibition of Protein kinase C beta 2	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID1531668	Inhibition of human DYRK3 using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1581523	Antiproliferative activity against human PC3 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay
AID624806	Binding constant for RPS6KA4(Kin.Dom.1-N-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435415	Binding constant for MYLK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID152130	Inhibitory activity against Plasmodium falciparum D6	2003	Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18	Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.
AID1252494	Inhibition of human ERK1 by kinase inhibition assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID624781	Binding constant for CDK4-cyclinD3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531509	Inhibition of human RSK4 assessed as residual activity at 100 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720467	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID165309	Inhibition of Protein kinase C alpha	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID1246337	Induction of apoptosis in human triple-negative MDA-MB-231 cells assessed as viable cells after 12 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 93.1%)	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID624726	Binding constant for HIPK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624774	Binding constant for QSK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462546	Induction of apoptosis in human p53-null PC3 cells assessed as late apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.4 to 1.6%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1715131	Inhibition of human TYRO3 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715316	Inhibition of human IKKepsilon using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID680723	TP_TRANSPORTER: increase in Rhodamine 123 intracellular accumulation (R123: 1.66 uM, Staurosporine: 80 uM) in MCF7/Adr cells	1996	British journal of cancer, May, Volume: 73, Issue:9	Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
AID288804	Growth inhibition of Streptomyces 85E at 20 ug/disk by hyphae formation inhibition assay	2007	Journal of natural products, Jun, Volume: 70, Issue:6	Lemnalosides A-D, decalin-type bicyclic diterpene glycosides from the marine soft coral Lemnalia sp.
AID1531706	Inhibition of human GLK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715149	Inhibition of human TAOK3 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531648	Inhibition of human CLK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID93089	Inhibition of Insulin receptor kinase-beta	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID1531320	Inhibition of human ERBB4 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531257	Inhibition of human CDK17/cyclin-Y assessed as residual activity at 100 uM using MBP protein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720343	Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1191822	Inhibition of recombinant GST-tagged GSK-3beta (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 9 peptide substrate by Z'-LYTE kinase assay	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
AID1531724	Inhibition of human IGF1R using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1654683	Induction of apoptosis in human ARN8 cells assessed as increase in caspase 3/7 activity at 1 uM incubated for 48 hrs by live cell imaging analysis	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
AID1911005	Inhibition of human N-terminal His-tagged/ TEV cleavage fused DRAK1 (39 to 369 residues) transfected in HEK293T cells using NanoBRET NanoGlo as substrate incubated for 2 hrs by NanoBRET assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5-
AID624840	Binding constant for AXL kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1350984	Inhibition of ICK (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531224	Inhibition of human Aurora A assessed as residual activity at 100 uM using [H-LRRASLG] as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1069558	Inhibition of ABL (unknown origin) after 30 mins	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III.
AID1481082	Inhibition of human PKCg using histone H1 as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID624756	Binding constant for MAP4K4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531904	Inhibition of human TEC using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720167	Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID292817	Inhibition of JAK3 expressed in Sf21 cells	2007	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2	Simplified staurosporine analogs as potent JAK3 inhibitors.
AID1531475	Inhibition of human PKCdelta assessed as residual activity at 100 uM using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID745522	Inhibition of CDK7/Cyclin H (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID1531578	Inhibition of human ALK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1532717	Induction of apoptosis in human HCT116 cells after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry method	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID624930	Binding constant for TNK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID611841	Inhibition of PI3K-alpha at 50 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID350284	Inhibition of p38-alpha	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1531586	Inhibition of human ARK5 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1751469	Cytotoxicity against human WI-38 cells assessed as cell viability measured by MTT assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives.
AID1655211	Induction of apoptosis in human GIN8 cells assessed as increase in caspase 3/7 activation at 10 uM measured after 48 hrs by CellEvent caspase 3/7 probe based fluorescence analysis	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Development of Pyrazolo[3,4-
AID1450416	Inhibition of human JAK3 using GEEEEYFELVKKKK as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.
AID720320	Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715157	Inhibition of human STK33 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1504783	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Platanic acid: A new scaffold for the synthesis of cytotoxic agents.
AID1531652	Inhibition of human COT1 using MEK1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720068	Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID257080	Inhibitory activity against PIM1 at 10 uM	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
AID1068644	Inhibition of JAK2 (unknown origin)	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.
AID1530830	Inhibition of human full length N-terminal GST tagged CHK1 assessed as residual activity at 1.22 10'-9M (Rvb = 96.94 to 103.06%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID494405	Inhibition of JNK1	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID513192	Antiapoptotic activity against staurosporine-induced cell death in human HeLa cells assessed as caspase 3 activity at 10 uM after 24 hrs	2006	Nature chemical biology, Sep, Volume: 2, Issue:9	Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation.
AID1450412	Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.
AID1846788	Inhibition of Aurora A (unknown origin) using kemptide as substrate incubated for 50 mins in the presence of ATP by ADP-Glo reagent based luminescence assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Aurora kinase inhibitors as potential anticancer agents: Recent advances.
AID1715218	Inhibition of human PIM1 using KKRNRTLTK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1368674	Inhibition of human CK2a1 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1531730	Inhibition of human IRAK4 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435274	Binding constant for ACVR1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID368327	Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Isolation, structure elucidation and cytotoxic evaluation of endiandrin B from the Australian rainforest plant Endiandra anthropophagorum.
AID1882065	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Research progress in pharmacological activities and structure-activity relationships of tetralone scaffolds as pharmacophore and fluorescent skeleton.
AID624799	Binding constant for TIE2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1287706	Induction of apoptosis in human NALM6 cells assessed as early apoptotic cells at 0.5 uM measured after 24 hrs by annexin V-propidium iodide staining based flow cytometric analysis (Rvb = 91.5%)	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID720194	Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1066417	Cytotoxicity against human A549 cells after 96 hrs by SRB assay	2014	European journal of medicinal chemistry, Jan-24, Volume: 72	The chemical and biological potential of C ring modified triterpenoids.
AID435779	Binding constant for ALK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715255	Inhibition of human MST2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715227	Inhibition of human PAK6 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720153	Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720229	Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID405703	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method	2008	Journal of natural products, Jun, Volume: 71, Issue:6	Cytotoxic staurosporines from the marine ascidian Cystodytes solitus.
AID720317	Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720034	Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1610356	Inhibition of recombinant full length human GST-tagged PLK2 expressed in baculovirus expression system using ser/thr 16 as substrate incubated for 1 hr by Z'-LYTE assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
AID256573	Average Binding Constant for PAK6; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435146	Binding constant for ABL1(H396P) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531658	Inhibition of human DCAMKL2 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715124	Inhibition of human YSK4 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531817	Inhibition of human PAK2 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1738917	Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID622361	Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents.
AID1385656	Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2018	Journal of natural products, 08-24, Volume: 81, Issue:8	Staurosporine Derivatives Generated by Pathway Engineering in a Heterologous Host and Their Cytotoxic Selectivity.
AID1531809	Inhibition of human OSR1 using RRHYYYDTHTNTYYLRTFGHNTRR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID590156	Inhibition of Abl2 at 20 uM after 1 hr by luminescence assay	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
AID720203	Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1594648	Antiproliferative activity against human HL60 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID625052	Binding constant for PRKG1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715213	Inhibition of human PKAcg using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1189707	Inhibition of telomerase in human HepG2 cells at 1 uM after 1 day by TRAP-ELISA method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID624754	Binding constant for NEK7 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID262978	Inhibition of CK2 at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1531433	Inhibition of human NEK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1478067	Inhibition of VEGFR2 (unknown origin) at 10 uM using biotin substrate incubated for 1 hr by HTRF method relative to control	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.
AID435169	Binding constant for full-length MEK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID494388	Inhibition of CDK5/p25 assessed as residual activity at 1 uM relative to control	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID1715381	Inhibition of human DDR1 using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720054	Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308930	Inhibition of ALK (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531506	Inhibition of human RSK1 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1191825	Inhibition of BRAF (unknown origin) by HTRF assay	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
AID624911	Binding constant for TXK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1191828	Inhibition of recombinant N-terminal His-tagged PKA (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 1 peptide substrate by Z'-LYTE kinase assay	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
AID241735	Inhibition of human Protein kinase C beta 2 using [gamma-33P]-ATP	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1531505	Inhibition of human ROS assessed as residual activity at 100 uM using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID627293	Inhibition of c-Src using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1531781	Inhibition of human MNK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1169356	Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as inhibition of parasite growth after 72 hrs by cell based assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID1531495	Inhibition of human PRKX assessed as residual activity at 100 uM using LRRASLG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID512487	Inhibition of CDK1/cyclinB	2004	Trends in pharmacological sciences, Sep, Volume: 25, Issue:9	Pharmacological inhibitors of glycogen synthase kinase 3.
AID1738915	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1531346	Inhibition of human GRK4 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715144	Inhibition of human TIE2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1462577	Induction of apoptosis in human T47D cells assessed as early apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.6 to 4.3%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID625120	Binding constant for EPHA8 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1360785	Inhibition of human FLT3 R595_E596 mutant by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID350294	Inhibition of RSK1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1531232	Inhibition of human BRK assessed as residual activity at 100 uM using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435441	Binding constant for RPS6KA4(Kin.Dom.2 - N-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435830	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1484301	Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 40 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 2 to 3%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID629270	Inhibition of cMet	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1462556	Induction of apoptosis in human MFE280 cells assessed as viable cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 84.9 to 87.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531387	Inhibition of human LRRK2 assessed as residual activity at 100 uM using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435925	Binding constant for PCTK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720187	Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308935	Inhibition of BTK (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1700282	Inhibition of recombinant human GST-tagged PIM1 by ELISA	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
AID720355	Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID625010	Binding constant for FER kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624867	Binding constant for MLK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID426939	Inhibition of JAK3 expressed in insect Sf21 cells assessed as inhibition of biotinylated substrate phosphorylation	2009	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12	Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses.
AID624787	Binding constant for KIT(A829P) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID436039	Inhibition of I174A-mutated CK2 holoenzyme	2003	The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3	Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID720166	Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531600	Inhibition of human c-KIT using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624915	Binding constant for PIP5K2B kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715306	Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1895100	Binding affinity to MST2 (unknown origin) assessed as change in melting temperature by thermal shift based DSF assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors.
AID1531715	Inhibition of human GSK3B using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1666671	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometric analysis (Rvb = 1.56 %)	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
AID1531241	Inhibition of human CAMK1B assessed as residual activity at 100 uM using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID657570	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
AID720426	Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1917240	Inhibition of CDK4/cyclin D1 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors.
AID1671732	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability at 2 uM after 48 hrs by CellTiter96 AQueous assay relative to control	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
AID269878	Activity against AKT-mediated S6RP S235/236P phosphorylation in human DOV13 cell line	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID67963	Effective concentration for 50% inhibition of plasminogen activator activity relative to control by beta-PDBu stimulation	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID720325	Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1309157	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 1 uM by ELISA	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthetic sulfoglycolipids targeting the serine-threonine protein kinase Akt.
AID624755	Binding constant for ZAK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1351002	Inhibition of TAK1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531635	Inhibition of human CDK9/cyclin-T1 using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715337	Inhibition of human FYN using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1770392	Antiproliferative activity against human DND41 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID435290	Binding constant for FGFR2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1187631	Induction of apoptosis in human HL60 cells assessed as early apoptosis level at 0.2 uM after 24 hrs by Annexin V-PE and 7-AAD staining based flow cytometry (Rvb = 3.3%)	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Cytotoxic activity of butane type of 1,7-seco-2,7'-cyclolignanes and apoptosis induction by Caspase 9 and 3.
AID1484300	Induction of apoptosis in human PC3 cells assessed as viable cells at 40 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 95%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID1531294	Inhibition of human DCAMKL2 assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531780	Inhibition of human MLK4 using MEK1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435325	Binding constant for RPS6KA4(Kin.Dom.1 - C-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID625044	Binding constant for PIK3CA(M1043I) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID415616	Inhibition of CDK4/Cyclin D1	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID1779099	Induction of apoptosis in VEGF-stimulated HUVEC cells assessed as increase in late apoptotic cells at 250 nM measured after 48 hrs by AnnexinV-FITC/PI staining based flow cytometry	2021	Journal of natural products, 06-25, Volume: 84, Issue:6	Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway.
AID1246329	Cell cycle arrest in human triple-negative MDA-MB-231 cells assessed as accumulation at S phase at 2.5 uM after 12 hrs by propidium iodide staining-based flow cytometry (Rvb = 31.23%)	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID1846775	Inhibition of Lyn (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID1423831	Inhibition of EGFR 19D/T790M/C797S mutant (unknown origin) expressed in mouse BAF3 cells assessed as reduction in EGF-induced receptor phosphorylation at 1 to 3 uM preincubated for 2 hrs followed by EGF stimulation for 15 mins by Western blot analysis
AID1531672	Inhibition of human EPHA2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID53923	Antiproliferative activity against human colon cancer cell line (DLD-1 cells) using MTT assay	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Synthesis and biological evaluation of novel bisindolylmaleimides that inhibit vascular endothelial cell proliferation.
AID625076	Binding constant for PLK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1365187	Inhibition of VEGFR2 (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
AID624898	Binding constant for GRK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624988	Binding constant for ABL1(T315I)-non phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720087	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID350296	Inhibition of TAK1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID624938	Binding constant for FLT3(K663Q) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID627290	Inhibition of RSK2 using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID494406	Inhibition of MAPKAPK2	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID241397	Inhibition of Protein kinase C epsilon	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1247629	Inhibition of FLT3 (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID599231	Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Cytotoxic and NF-κB inhibitory constituents of the stems of Cratoxylum cochinchinense and their semisynthetic analogues.
AID624807	Binding constant for TNK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624776	Binding constant for PCTK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1524568	Antiproliferative activity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Synthesis and Biological Studies of (+)-Liquiditerpenoic Acid A (Abietopinoic Acid) and Representative Analogues: SAR Studies.
AID1531743	Inhibition of human LATS1 using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435654	Binding constant for full-length ERK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1646264	Inhibition of PAK4 (unknown origin) by HTRF assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	PB-10, a thiazolo[4,5-d] pyrimidine derivative, targets p21-activated kinase 4 in human colorectal cancer cells.
AID1531654	Inhibition of human CTK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720027	Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435405	Binding constant for ERK8 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624791	Binding constant for KIT(V559D) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1269229	Cytoprotective activity against H2O2-induced apoptosis in human SH-SY5Y cells assessed as dead cells at 100 nM preincubated for 24 hrs followed by H2O2 addition measured after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analys	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	α-Aryl-N-aryl nitrones: Synthesis and screening of a new scaffold for cellular protection against an oxidative toxic stimulus.
AID720443	Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531519	Inhibition of human SNRK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435520	Binding constant for CAMK2A kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID262363	Inhibition of Akt3 using 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID720171	Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715351	Inhibition of human ERN2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID614653	Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 assessed as dissociation half life after 60 mins by ligand displacement based enzyme-inhibitor dilution assay	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID1779846	Inhibition of GSK3beta (unknown origin) assessed as transfer of radiolabelled phosphate group from ATP by reaction biology method	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold.
AID1531792	Inhibition of human MUSK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1090410	Antimicrobial activity against Ilyonectria radicicola assessed as growth inhibition incubated for 4 to 7 days	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID256598	Average Binding Constant for FRK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435322	Binding constant for PRKG2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID688350	Cytotoxicity against human G361 cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID720084	Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1186610	Inhibition of Aurora B (unknown origin) using HLRRASLG substrate	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
AID624730	Binding constant for CAMK2A kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435924	Binding constant for MARK4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID725404	Ratio of IC50 for TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells to IC50 for TNIK (unknown origin)	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors.
AID720460	Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID303323	Inhibition of Met kinase at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID435161	Binding constant for FES kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1142606	Inhibition of ALK1 (unknown origin) by radioisotopic assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/
AID1252496	Inhibition of human MEK1 by kinase inhibition assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID256664	Average Binding Constant for EGFR; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID334305	Inhibition of pig tubulin polymerization at 6 to 32 ug/ml by turbidity assay
AID436042	Binding constant for full-length PHKG1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1350026	Cytotoxicity against human HCT116 cells by sulforhodamine B assay	2018	Journal of natural products, 02-23, Volume: 81, Issue:2	Cyclizidine-Type Alkaloids from Streptomyces sp. HNA39.
AID720214	Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1287707	Effect on cell cycle in human SEM cells assessed as accumulation at G0/G1 phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb = 45.75%)	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID1410108	Cytotoxicity against human PC3 cells after 72 hrs by SRB assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Bioactive Indolocarbazoles from the Marine-Derived Streptomyces sp. DT-A61.
AID1666223	Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID599959	Binding affinity to human KIT D816V mutant incubated for 1 hr by kinase binding assay	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
AID1381812	Induction of apoptosis in human SUP-B15 cells assessed as necrotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 9.2%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID720462	Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID164979	In vitro inhibition of [32P] incorporation into histones by rat brain partially purified Protein kinase C in the presence of PMA, [Ca2+] and phosphatidylserine.	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	Substituted 2-(aminomethyl)piperidines: a novel class of selective protein kinase C inhibitors.
AID1650885	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated TNFalpha release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by ELISA	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Variegatic acid from the edible mushroom Tylopilus ballouii inhibits TNF-α production and PKCβ1 activity in leukemia cells.
AID1531794	Inhibition of human MYLK4 using KKRPQRRYSNVF as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1383797	Inhibition of PLK1 (unknown origin) at 10 uM using Ser/Thr-16 peptide substrate after 60 mins by Z'-LYTE assay relative to control	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
AID1308983	Inhibition of TIE2 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID720471	Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256666	Average Binding Constant for ABL1(Q252H); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID725935	Ratio of IC50 for human recombinant N-terminal GST-tagged Plk1 in presence of 3.12 mM of ATP to IC50 for human recombinant N-terminal GST-tagged Plk1 in presence of 62.5 uM of ATP	2013	Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3	Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
AID720150	Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID740397	Inhibition of EGFR tyrosine kinase (unknown origin) using poly (Glu,Tyr) as substrate at 0.5 uM after 40 mins by Kinase-Glo Plus luminescence kinase assay	2013	European journal of medicinal chemistry, Mar, Volume: 61	Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
AID1706569	Inhibition of p38beta (unknown origin) assessed as change in melting temperature at 10 uM by DSF assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Selective targeting of the αC and DFG-out pocket in p38 MAPK.
AID1722642	Selective index, difference between deltaTm for CLK3 A319V mutant (unknown origin) expressed in Escherichia coli to deltaTm for recombinant wild type CLK3 (R134 to T484 residues) (unknown origin) expressed in Escherichia coli	2020	Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18	DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID624771	Binding constant for TLK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1779110	Induction of apoptosis in VEGF-stimulated HUVEC cells assessed as increase in cleaved caspase-9 protein expression at 250 nM measured after 48 hrs by western blot analysis	2021	Journal of natural products, 06-25, Volume: 84, Issue:6	Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway.
AID284061	Antitumor activity against human A431 xenograft in BALB/c nude mouse at 1 mg/kg, ip after 10 days relative control	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents.
AID729552	Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells at 5 uM by TR-FRET based binding assay	2013	European journal of medicinal chemistry, Mar, Volume: 61	Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
AID1900714	Inhibition of GSK3-beta (unknown origin) incubated for 60 mins by ATP-Glo luminescent assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
AID625121	Binding constant for RET kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID241336	Inhibition of Protein kinase C delta	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1394748	Inhibition of recombinant human PKA expressed in Escherichia coli using Ulight-RRRSLLE as substrate after 10 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID1531825	Inhibition of human PDGFRbeta using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715406	Inhibition of human CDK5/p25 using histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625046	Binding constant for PIK3CB kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID284068	Weight change in human A431 xenografted BALB/c nude mouse at 1 mg/kg, po after 18 days	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents.
AID1381809	Induction of apoptosis in human SUP-B15 cells assessed as early apoptotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.1%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID624910	Binding constant for TTK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1350979	Inhibition of IR (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID625091	Binding constant for MAST1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625077	Binding constant for DAPK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID241894	Inhibition of Vascular endothelial growth factor receptor in P19 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1531292	Inhibition of human DAPK2 assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435403	Binding constant for EPHB1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720199	Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1351023	Inhibition of LCK (unknown origin) assessed as remaining activity at 3.05 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 89.74%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1169354	Cytotoxicity against human BJ cells	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID256574	Average Binding Constant for STK3_m; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624976	Binding constant for PRKX kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715428	Inhibition of human CAMK2A using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1394681	Inhibition of recombinant human Aurora-A using Ulight-RRRSLLE as substrate measured after 15 mins by LANCE assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
AID1531695	Inhibition of human FGFR2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1381798	Induction of apoptosis in human KOPN8 cells assessed as late apoptotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 9.5%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID436044	Binding constant for PLK4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531779	Inhibition of human MLK3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID614650	Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 assessed as dissociation half life after 60 mins by activity based 100 fold dilution assay	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID720037	Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID625016	Binding constant for SRC kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1351021	Inhibition of LCK (unknown origin) assessed as remaining activity at 4.88 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 89.74%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID697542	Inhibition of VEGFR2 after 60 mins by electrophoretic mobility shift assay	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Predicting new indications for approved drugs using a proteochemometric method.
AID1351019	Inhibition of LCK (unknown origin) assessed as remaining activity at 7.81 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 89.74%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID720095	Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531352	Inhibition of human haspin assessed as residual activity at 100 uM using Histone H3 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531919	Inhibition of human TXK using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID219826	Inhibition of cAMP dependent protein kinase catalytic subunit of bovine heart	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID1715355	Inhibition of human ERK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435156	Binding constant for EGFR kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531547	Inhibition of human TNK1 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1689468	Antiproliferative activity against human MCF7 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
AID1531354	Inhibition of human HGK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715360	Inhibition of human EPHB4 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435778	Binding constant for full-length ADCK4	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID625042	Binding constant for PIK3CA(H1047Y) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID627291	Inhibition of ALK using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1394684	Inhibition of recombinant human PDGFRbeta using Ulight-Poly GAT[EAY(1:1:1)]n as substrate measured after 30 mins by LANCE assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
AID1483365	Inhibition of recombinant human GST-tagged EGFR L858R/T790M double mutant cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
AID624822	Binding constant for CDKL3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531394	Inhibition of human MARK1 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256584	Average Binding Constant for CAMK1D; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1875875	Activation of caspase-3/7 activity in human 518A2 cells at 1 uM preincubated for 6 hrs followed by caspase-3/7 fluorogenic substrate addition and measured after 60 mins by fluorescence assay
AID1531766	Inhibition of human MEKK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715196	Inhibition of human PKN1 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435394	Binding constant for CAMK2B kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531801	Inhibition of human NEK4 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715167	Inhibition of human SRMS using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720423	Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715280	Inhibition of human MEK3 using p38alpha as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531687	Inhibition of human ERK5 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715349	Inhibition of human FER using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1277438	Induction of apoptosis in mouse B16F10 cells assessed as early apoptotic cells at 0.1 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.087%)	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines.
AID1394735	Inhibition of recombinant human ABL expressed in insect cells using Ulight-TK peptide as substrate after 60 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID1727487	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Cytotoxic triterpenoid-safirinium conjugates target the endoplasmic reticulum.
AID1715322	Inhibition of human HGK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625049	Binding constant for PRKCH kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1191826	Inhibition of N-terminal His-tagged recombinant IKK2 (unknown origin) by HTRF assay	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
AID256613	Average Binding Constant for Aurora2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID640587	Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity.
AID624928	Binding constant for CDKL2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624881	Binding constant for PKAC-alpha kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624953	Binding constant for EPHA7 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1063040	Inhibition of PRK1 (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1846773	Inhibition of FGFR2 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID1462529	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 2 to 2.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID471625	Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 80 ug/disk after 72 hrs at 37 degreeC by disc diffusion method	2009	Journal of natural products, Aug, Volume: 72, Issue:8	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp.
AID624974	Binding constant for PIK3CD kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720396	Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624728	Binding constant for NIM1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1900709	Inhibition of equine serum BChE at 50 uM using butyrylthiocholine iodide as substrate preincubated with enzyme for 20 mins followed by substrate addition and measured after 20 mins by Ellman's method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
AID1531266	Inhibition of human CDK5/p35 assessed as residual activity at 100 uM using histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531408	Inhibition of human MKK4 assessed as residual activity at 100 uM using JNK1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531595	Inhibition of human BRAF using MEK1 (K97R) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531516	Inhibition of human SIK3 assessed as residual activity at 100 uM using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1830876	Inhibition of human NEK1 using myelin basic protein as substrate assessed as residual activity in presence of [gamma-33P]-ATP by radiometric hotspot kinase assay relative to control	2021	Bioorganic & medicinal chemistry letters, 12-01, Volume: 53	Design, synthesis and biological evaluation of novel aminopyrazole- and 7-azaindole-based Nek1 inhibitors and their effects on zebrafish kidney development.
AID624901	Binding constant for RSK1(Kin.Dom.2-C-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462537	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 2 to 2.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1351044	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.05 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID435180	Binding constant for MAPKAPK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1330920	Induction of apoptosis in Brugia malayi microfilariae isolated from peritoneal cavity of infected Meriones unguiculatus after 48 hrs by acridine orange/ethidium bromide dual staining based epifluorescence microscopy	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Sulfonamide chalcones: Synthesis and in vitro exploration for therapeutic potential against Brugia malayi.
AID1715425	Inhibition of human CAMK2G using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1462535	Induction of apoptosis in human MCF7 cells assessed as nuclear debris at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.2 to 3%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1246353	Induction of apoptosis in human triple-negative MDA-MB-231 cells at 2.5 uM after 6 to 48 hrs by microscopic analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID1715388	Inhibition of human CSK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720362	Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1502657	Antiproliferative activity against human MCF7 cells after 5 days by WST-1 assay	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Oxidation of the Meroterpenoid (-)-Terreumol C from the Mushroom Tricholoma terreum: Discovery of Cytotoxic Analogues.
AID435677	Binding constant for LOK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1666225	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID624851	Binding constant for ERBB3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1377586	Downregulation of P-gp expression in human MDR KBV1 cells after 24 hrs relative to control	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer.
AID350259	Inhibition of c-Met	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID624946	Binding constant for BRAF kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1308933	Inhibition of AXL (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531521	Inhibition of human SRPK1 assessed as residual activity at 100 uM using GRSRSRSRSR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1502062	Inhibition of PDGFRbeta (unknown origin) using ATP and enzyme substrate by kinase-glo Plus luminescence kinase assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer.
AID625087	Binding constant for MELK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720483	Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID164615	Inhibition of cAMP-dependent kinase PKA(Protein kinase A) catalytic subunit at 100 uM	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	Substituted 2-(aminomethyl)piperidines: a novel class of selective protein kinase C inhibitors.
AID624941	Binding constant for CDKL1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID256677	Average Binding Constant for STK38L; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435140	Relative inhibition of I174A-mutated CK2 holoenzyme compared to wild-type	2003	The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3	Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1765289	Inhibition of human full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by ADP-Glo kinase assay	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
AID435329	Binding constant for YSK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID453815	Antibacterial activity against Bacillus anthracis deltaANR after 14 hrs by microplate alamar blue assay	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	Natural product leads for drug discovery: isolation, synthesis and biological evaluation of 6-cyano-5-methoxyindolo[2,3-a]carbazole based ligands as antibacterial agents.
AID1715260	Inhibition of human MRCKbeta using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720064	Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256601	Average Binding Constant for EPHA3; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435907	Binding constant for EGFR(L861Q) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435560	Binding constant for SNF1LK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1169350	Selectivity index, ratio of cytotoxic EC50 against human cells to EC50 for Plasmodium falciparum 3D7	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID625122	Binding constant for RET(M918T) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1063053	Inhibition of ALK (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1715135	Inhibition of human TSSK2 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624995	Binding constant for CSF1R kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID155717	In vitro inhibition of protein kinase C (PKC)	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	New dermatological agents for the treatment of psoriasis.
AID269872	Activity against AKT-mediated PRAS40 T246P phosphorylation in human DOV13 cell line	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID1308975	Inhibition of PKCzeta (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531607	Inhibition of human CAMK1G using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID238873	Inhibition of [3H]astemizole binding to Potassium channel HERG; Not determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID624762	Binding constant for DLK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720445	Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1887946	Inhibition of full length FLAG/HA/Strep-tagged TLK2 (unknown origin) transfected in HEK293T cells at 50 uM using GST-ASF1 as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins in presence of ATP by Western blot an	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of bisindole derivatives as anticancer agents against Tousled-like kinases.
AID262982	Inhibition of C-KIT at 1.0 mM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID127093	Inhibition of Mitogen-activated protein kinase p38	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID1450415	Inhibition of human ITK using myelin basic protein as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1531253	Inhibition of human CDK1/cyclinB assessed as residual activity at 100 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720073	Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID642586	Inhibition of GSK3-beta by colorimetric analysis	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Design and combinatorial synthesis of a novel kinase-focused library using click chemistry-based fragment assembly.
AID1715158	Inhibition of human STK32B using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715392	Inhibition of human CK2A2 using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531326	Inhibition of human ERN2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715170	Inhibition of human SIK3 using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1308964	Inhibition of JAK3 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID622360	Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents.
AID1531830	Inhibition of human PIM1 using KKRNRTLTK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID775221	Inhibition of EGFR (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	2013	European journal of medicinal chemistry, Nov, Volume: 69	Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II.
AID1531633	Inhibition of human CDK7/cyclin-H/MNAT1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID55358	Inhibitory activity against Cyclin D1-cyclin-dependent kinase 4 in enzymatic assay by measuring phosphorylation of Rb21; not tested	2003	Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14	Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
AID624798	Binding constant for LKB1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531339	Inhibition of human FRK assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1481079	Inhibition of human mTOR/FRAP1 using 4EBP1 as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1531767	Inhibition of human MEKK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435168	Binding constant for LTK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1704869	Inhibition of KIF5B-RET fusion protein (unknown origin) by radiometric assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
AID241300	Inhibition of Protein kinase C zeta	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID350278	Inhibition of JAK3	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID435401	Binding constant for full-length DRAK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715130	Inhibition of human ULK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720326	Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715302	Inhibition of human KSR2 using KRREILSRRPSYR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID720024	Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1351005	Inhibition of c-SRC (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1706568	Inhibition of p38alpha (unknown origin) assessed as change in melting temperature at 10 uM by DSF assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Selective targeting of the αC and DFG-out pocket in p38 MAPK.
AID1531772	Inhibition of human MKK4 using JNK1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1350959	Inhibition of CAMK2b (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID720193	Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308917	Inhibition of c-Met (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1381879	Induction of apoptosis in human KOPN8 cells assessed as effect on Mcl-1 level after 24 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1063025	Cytotoxicity against human MCF7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Leonurusoleanolides E-J, minor spirocyclic triterpenoids from Leonurus japonicus fruits.
AID1189695	Inhibition of telomerase in human HepG2 cells at 2 uM after 2 days by TRAP-ELISA method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID623566	Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay	2011	Journal of natural products, Oct-28, Volume: 74, Issue:10	Bioassay-guided isolation of constituents of Piper sarmentosum using a mitochondrial transmembrane potential assay.
AID1715377	Inhibition of human DMPK using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720374	Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715242	Inhibition of human NEK8 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625012	Binding constant for GAK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531365	Inhibition of human IRAK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1779845	Inhibition of GSK3alpha (unknown origin) assessed as transfer of radiolabelled phosphate group from ATP by reaction biology method	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold.
AID1531552	Inhibition of human TSSK3 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435826	Binding constant for full-length PCTK3	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID764617	Induction of apoptosis in rat PC12 cells assessed as procaspase-3 activation at 1 uM after 24 hrs by fluorometric assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and initial in vitro biological evaluation of two new zinc-chelating compounds: comparison with TPEN and PAC-1.
AID1531348	Inhibition of human GRK6 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435157	Binding constant for EGFR(G719C) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531583	Inhibition of human ALK5 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625090	Binding constant for ICK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531543	Inhibition of human TIE2 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1351015	Inhibition of LCK (unknown origin) assessed as remaining activity at 2 x 10'-5 M after 120 mins in presence of 33P-ATP (Rvb = 89.74%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1743551	Inhibition of FLT3 (unknown origin) in presence of ATP	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
AID1531369	Inhibition of human JAK1 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624765	Binding constant for TRKC kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1247616	Inhibition of ALK (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1715176	Inhibition of human SGK1 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625143	Binding constant for CAMKK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID767334	Inhibition of ABL1 (unknown origin) at 50 uM after 1 hr by luminescence assay relative to control	2013	Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18	Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
AID720310	Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID385591	Inhibition of human PKCiota	2007	The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45	Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID435796	Binding constant for ERBB2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1063042	Inhibition of PLK1 (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1531688	Inhibition of human ERK7 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID303325	Inhibition of KIT at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID327393	Induction of cytochrome c release in mitochondrial fraction of human BJ cell expressing TERT, LT, ST and RAS G12V mutant genes at 1 uM	2007	Nature, Jun-14, Volume: 447, Issue:7146	RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels.
AID720321	Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531890	Inhibition of human STK22D using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435444	Binding constant for TYK2(Kin.Dom.2/JH1 - catalytic) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID627129	Inhibition of CHK1 using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID735918	Inhibition of Raf1 (unknown origin) at 50 uM	2013	Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3	Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment.
AID1531400	Inhibition of human MEK3 assessed as residual activity at 100 uM using p38alpha as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720118	Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1381830	Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G0/G1 phase at 2.5 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 70.47%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1090417	Antimicrobial activity against Colletotrichum orbiculare assessed as growth inhibition incubated for 4 to 7 days	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1381823	Cell cycle arrest in human KOPN8 cells assessed as accumulation at S phase at 2 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 66.56%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1671733	Antiproliferative activity against human SH-SY5Y cells assessed as cell viability at 2 uM after 48 hrs by CellTiter96 AQueous assay relative to control	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
AID624913	Binding constant for TYK2(JH2domain-pseudokinase) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID350271	Inhibition of FLT3	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1531754	Inhibition of human MAK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531481	Inhibition of human PKCnu assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531564	Inhibition of human WNK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462544	Induction of apoptosis in human p53-null PC3 cells assessed as viable cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 96.5 to 98.6%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1462547	Induction of apoptosis in human p53-null PC3 cells assessed as nuclear debris at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.1 to 0.5%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1715334	Inhibition of human GRK1 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID753284	Inhibition of EGFR (unknown origin) at 10 uM after 30 mins by fluorescence assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological evaluation of N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides as inhibitors of angiogenesis and tumor growth.
AID624778	Binding constant for ACVRL1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531758	Inhibition of human MARK1 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624916	Binding constant for ULK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720053	Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1439517	Inhibition of Alexa647 tracer binding to full length recombinant human His-tagged CDK8/Cyclin C expressed in baculovirus expression system at 5 uM preincubated for 20 mins followed by tracer addition measured after 60 mins by TR-FRET based Lanthascreen as	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
AID1183912	Induction of apoptosis in human primary monocytes assessed as apoptotic bodies formation at 3 uM after 3 hrs by light microscopy	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1715209	Inhibition of human PKCdelta using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625102	Binding constant for PRKD2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531507	Inhibition of human RSK2 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624860	Binding constant for VEGFR2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1471754	Inhibition of recombinant human ALK C1156Y mutant (1093 to 1411 residues) expressed in baculovirus expression system using 5'FAM-KKSRGDYMTMQIG-CONH as substrate preincubated for 15 mins followed by addition of ATP measured after 1 hr by microfluidic mobil	2017	Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.
AID1324448	Inhibition of BRAF (unknown origin) using FAM-labeled peptide as substrate after 1 hr by Lanthascreen assay
AID164969	Inhibition of rat brain Protein kinase C	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID624729	Binding constant for FAK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531929	Inhibition of human WNK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715275	Inhibition of human MEKK3 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625039	Binding constant for PIK3CA(E545A) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID256602	Average Binding Constant for EPHA2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1411917	Inhibition of GSK3beta (unknown origin)	2017	MedChemComm, Nov-01, Volume: 8, Issue:11	Benzisoxazole: a privileged scaffold for medicinal chemistry.
AID455588	Displacement of [8-3H]ATP from human recombinant MK2 (41-364) by scintillation proximity assay	2010	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1	2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
AID720265	Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1294629	Inhibition of human Aurora A using H-LRRASLG as substrate after 2 hrs by HotSpot assay in presence of 33P-ATP and 10 uM ATP	2016	Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9	Design, synthesis, and evaluation of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives as Aurora kinase inhibitors.
AID1394685	Inhibition of recombinant human RAF1	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
AID1300791	Inhibition of SGK (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID435832	Binding constant for SLK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531924	Inhibition of human ULK3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1650884	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of anti-DNP IgE-stimulated TNFalpha release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by ELISA	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Variegatic acid from the edible mushroom Tylopilus ballouii inhibits TNF-α production and PKCβ1 activity in leukemia cells.
AID1715455	Inhibition of human ABL2 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID240699	Inhibition of Protein Kinase C activity	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
AID1404981	Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells at 1 uM using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay relati
AID720315	Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID417327	Inhibition of human recombinant Pim1 expressed in insect cells by HTRF	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors.
AID1715339	Inhibition of human FRK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1351039	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.13 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1732830	Inhibition of FGFR1 (unknown origin)	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
AID435159	Binding constant for EPHB3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1855770	Inhibition of recombinant human HER2 incubated for 40 to 45 mins and measured after 15 mins by Kinase-Glo Max assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
AID624854	Binding constant for FLT4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1481074	Inhibition of human JAK3 using GEEEEYFELVKKKK as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1531234	Inhibition of human BRSK2 assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531696	Inhibition of human FGFR3 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720041	Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID426696	Inhibition of CHK1 assessed as CDC25C peptide phosphorylation by DELFIA assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Identification of inhibitors of checkpoint kinase 1 through template screening.
AID350291	Inhibition of PLK2	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1531208	Inhibition of human ABL1 assessed as residual activity at 100 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625050	Binding constant for PKN2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1300804	Inhibition of GSK3beta (unknown origin) after 60 mins by Z-LYTE kinase assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1531871	Inhibition of human RSK2 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531373	Inhibition of human JNK2 assessed as residual activity at 100 uM using ATF2 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715268	Inhibition of human MLCK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531374	Inhibition of human JNK3 assessed as residual activity at 100 uM using ATF2 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715226	Inhibition of human PBK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624828	Binding constant for CDK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1308956	Inhibition of FYN (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531811	Inhibition of human p38beta using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1818408	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors.
AID1531678	Inhibition of human EPHA8 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID164619	Inhibition of rat brain protein kinase A(PKA) in 10%DMSO.	1992	Journal of medicinal chemistry, Jan, Volume: 35, Issue:1	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.
AID435911	Binding constant for MEK6 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1308946	Inhibition of ERK2 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1715449	Inhibition of human ARK5 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720023	Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715368	Inhibition of human EPHA3 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1770398	Cytotoxicity against human REC1 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID629402	Inhibition of PLK1	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1715248	Inhibition of human MYO3A using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256600	Average Binding Constant for EPHA8; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531558	Inhibition of human ULK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531372	Inhibition of human JNK1 assessed as residual activity at 100 uM using ATF2 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1452382	Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate measured after 10 mins by mobility shift assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
AID240823	Inhibition of c-Abl tyrosine kinase activity	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
AID1623697	Induction of apoptosis in human SUP-B15 cells assessed as late apoptotic cells level at 2 uM after 24 hrs by Annexin V and propidium iodide staining based flow cytometry (Rvb = 13.5%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID436025	Binding constant for NDR2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1471738	Inhibition of human wild type ALK using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition after 2 hrs by filter binding assay	2017	Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.
AID1715125	Inhibition of human YES using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID729996	Partition coefficient, log P of the compound	2013	European journal of medicinal chemistry, Mar, Volume: 61	Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
AID1715442	Inhibition of human BMPR2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435908	Binding constant for EPHA2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531838	Inhibition of human PKCb2 using Histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID591134	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 60 mins by time resolved-fluorescent assay	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.
AID720227	Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435188	Binding constant for PAK6 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720356	Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531508	Inhibition of human RSK3 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715239	Inhibition of human NLK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID627289	Inhibition of RSK1 using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1531702	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1063026	Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Leonurusoleanolides E-J, minor spirocyclic triterpenoids from Leonurus japonicus fruits.
AID435162	Binding constant for FLT3(N841I) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531861	Inhibition of human RAF1 using MEK1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1738918	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID624752	Binding constant for SNRK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435525	Binding constant for EGFR(L858R) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720364	Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1657498	Antiproliferative activity against human U87MG cells assessed as inhibition of cell growth	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.
AID1450417	Inhibition of human TEC using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.
AID600820	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Marianins A and B, prenylated phenylpropanoids from Mariannaea camptospora.
AID1715265	Inhibition of human MLK3 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435190	Binding constant for full-length PIP5K1A	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID88219	Compound was tested for HeLa cell cycle inhibition; arrest of G1 phase	2003	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17	Isolation of bisindole alkaloids that inhibit the cell cycle from Myxomycetes Arcyria ferruginea and Tubifera casparyi.
AID1090416	Antimicrobial activity against Botryotinia fuckeliana assessed as growth inhibition incubated for 4 to 7 fays	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1846768	Inhibition of CDK1/cyclinB (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID720135	Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID45969	Inhibition of Calcium/calmodulin-dependent protein kinase type II	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID435834	Binding constant for YANK3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720269	Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462579	Induction of apoptosis in human T47D cells assessed as nuclear debris at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.2 to 7.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID624710	Binding constant for SRMS kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720401	Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531880	Inhibition of human SIK3 using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID73828	Glycogen synthase activity of HEK293 cells, inhibition of GSK3-beta (Not determined)	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID625104	Binding constant for MYO3A kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531888	Inhibition of human STK16 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256629	Average Binding Constant for HCK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531714	Inhibition of human GSK3A using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625068	Binding constant for NEK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720433	Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462548	Induction of apoptosis in human p53-null PC3 cells assessed as viable cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 96.5 to 98.6%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID625017	Binding constant for TIE1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1368672	Inhibition of human CK1a1 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1531312	Inhibition of human EPHA6 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720408	Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715224	Inhibition of human PDGFRbeta using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715346	Inhibition of human FGFR2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720039	Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1657500	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.
AID1715409	Inhibition of human CDK2/cyclin-O using histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435530	Binding constant for MAP3K4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624830	Binding constant for CDK9 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1779842	Inhibition of SLK (unknown origin) assessed as transfer of radiolabelled phosphate group from ATP by reaction biology method	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold.
AID1715298	Inhibition of human LCK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625018	Binding constant for YES kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720205	Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720367	Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1356600	Inhibition of N-terminal FLAG-tagged human full-length CDK13 (1 to 1512 residues)/N-terminal His-tagged CycK (1 to 580 residues) expressed in Sf9 cells assessed as reduction in ATP-dependent ULight-4E-BP1 (Thr37/Thr46) substrate peptide phosphorylation pr	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
AID358178	Inhibition of human neutrophil PTK	1992	Journal of natural products, Nov, Volume: 55, Issue:11	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID745528	Inhibition of CDK2/Cyclin A (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID435939	Binding constant for TIE2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435204	Binding constant for WEE1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1484289	Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 5 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 2 to 3%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID1090418	Antimicrobial activity against Phytophthora capsici assessed as growth inhibition incubated for 4 to 7 fays	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID624734	Binding constant for YANK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625026	Binding constant for MAP3K1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1183901	Cytotoxicity against human primary monocytes assessed as reduction in cell viability at 3 uM after 18 hrs by inverse MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID624855	Binding constant for FRK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1846765	Inhibition of AKT1 (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID625005	Binding constant for EGFR(L861Q) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625015	Binding constant for ROCK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720056	Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID201187	Antiproliferative activity against burkit lymphoma cell line (ST-486 cells) using MTT assay	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Synthesis and biological evaluation of novel bisindolylmaleimides that inhibit vascular endothelial cell proliferation.
AID1715133	Inhibition of human TYK1 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID436011	Binding constant for full-length CLK3	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID745520	Inhibition of GSK3beta (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID720322	Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID269871	Activity against AKT-mediated GSK3 S9P phosphorylation in human DOV13 cell line	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID625125	Binding constant for CLK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531442	Inhibition of human NEK9 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID55343	Inhibition of Cyclin B-cyclin-dependent kinase 1	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
AID1308979	Inhibition of RON (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID720035	Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720341	Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531410	Inhibition of human MKK7 assessed as residual activity at 100 uM using JNK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720019	Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720285	Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531445	Inhibition of human OSR1 assessed as residual activity at 100 uM using RRHYYYDTHTNTYYLRTFGHNTRR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531659	Inhibition of human DDR1 using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720403	Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720057	Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720243	Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531407	Inhibition of human MINK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1398546	Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Cytotoxic and NF-κB and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from Syzygium corticosum and their semi-synthetic derivatives.
AID498728	Binding affinity to wild type cSrc by fluorescence based binding assay	2009	Nature chemical biology, Jun, Volume: 5, Issue:6	A new screening assay for allosteric inhibitors of cSrc.
AID625029	Binding constant for BRK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1612691	Inhibition of human PKCb2 using Histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID1350972	Inhibition of MAPK15 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1068649	Inhibition of Aurora A (unknown origin)	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.
AID625141	Binding constant for RIOK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1068655	Inhibition of PKC (unknown origin)	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.
AID45954	Inhibition of calcium/calmodulin-dependent protein kinase	1992	Journal of medicinal chemistry, Jan, Volume: 35, Issue:1	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.
AID435900	Binding constant for AKT3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1524566	Antiproliferative activity against mouse leukemia cells overexpressing BCR/ABL after 72 hrs by CellTiter-Glo luminescent cell viability assay	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Synthesis and Biological Studies of (+)-Liquiditerpenoic Acid A (Abietopinoic Acid) and Representative Analogues: SAR Studies.
AID1351022	Inhibition of LCK (unknown origin) assessed as remaining activity at 1.22 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 89.74%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID350292	Inhibition of RET	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID720052	Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720481	Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1594646	Antiproliferative activity against human NCI-H460 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1423830	Inhibition of EGFR T790M/L858R/C797S mutant (unknown origin) expressed in mouse BAF3 cells assessed as reduction in EGF-induced receptor phosphorylation at 1 to 3 uM preincubated for 2 hrs followed by EGF stimulation for 15 mins by Western blot analysis
AID1846789	Inhibition of EGFR (unknown origin) using Poly(Gly,Tyr) as substrate incubated for 45 mins in the presence of ATP by ADP-Glo reagent based luminescence assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Aurora kinase inhibitors as potential anticancer agents: Recent advances.
AID1061209	Inhibition of PKAalpha (unknown origin) using serine/threonine 01 peptide as substrate after 1 hr by FRET based Z'-LYTE assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Preparation and evaluation of deconstruction analogues of 7-deoxykalafungin as AKT kinase inhibitors.
AID1531870	Inhibition of human RSK1 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720296	Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531419	Inhibition of human MRCKalpha assessed as residual activity at 100 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID164948	Inhibition of human platelet protein kinase C (PKC)	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID256657	Average Binding Constant for LCK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715236	Inhibition of human p38gamma using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720479	Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1758203	Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins in presence of ATP by caliper mobility shift assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Ring closure strategy leads to potent RIPK3 inhibitors.
AID1846292	Inhibition of PKA (unknown origin)	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Recent advances in development of hetero-bivalent kinase inhibitors.
AID1308965	Inhibition of KDR (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531681	Inhibition of human EPHB3 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715282	Inhibition of human MEK2 using ERK2 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715382	Inhibition of human DCAMKL1 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625079	Binding constant for NEK6 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID163335	Inhibition of Protein kinase C beta 1	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID269867	Inhibition of ERK1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID1531357	Inhibition of human HIPK3 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715283	Inhibition of human MARK4 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715288	Inhibition of human MAPKAPK5 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1300796	Inhibition of JAK2 (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID407189	Inhibition of ASK1 by fluorescence correlation spectroscopy	2008	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13	Development of a novel fluorescent probe for fluorescence correlation spectroscopic detection of kinase inhibitors.
AID624943	Binding constant for ACVR1B kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1722641	Selective index, difference between deltaTm for recombinant wild type CLK1 (H148 to I484 residues) (unknown origin) expressed in Escherichia coli to deltaTm for recombinant CLK1 V324A mutant (unknown origin) expressed in Escherichia coli	2020	Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18	DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1531640	Inhibition of human CK1a1L using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1169349	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite growth after 72 hrs by cell based assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID720040	Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531790	Inhibition of human MST3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531338	Inhibition of human FMS assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531935	Inhibition of human ZIPK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715203	Inhibition of human PKCnu using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1059939	Inhibition of recombinant ERK1 (unknown origin) expressed in Escherichia coli	2013	European journal of medicinal chemistry, Oct, Volume: 68	Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
AID1715173	Inhibition of human SIK1 using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720472	Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1610359	Selectivity index, ratio of IC50 for recombinant human GST-tagged PLK3 (58 to 340 residues) expressed in baculovirus expression system to IC50 for recombinant full length human His-tagged PLK1 expressed in baculovirus expression system	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
AID435666	Binding constant for full-length NEK7	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1360786	Inhibition of human FLT3 Y591-V592 mutant by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID753282	Inhibition of ABL (unknown origin) at 10 uM after 30 mins by fluorescence assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological evaluation of N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides as inhibitors of angiogenesis and tumor growth.
AID1715423	Inhibition of human CAMKK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531313	Inhibition of human EPHA7 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624984	Binding constant for ABL1(H396P)-phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715270	Inhibition of human MKK7 using JNK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624711	Binding constant for STK35 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531535	Inhibition of human TAK1 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID455587	Displacement of [8-3H]ATP from human recombinant MK2 (36-400) by scintillation proximity assay	2010	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1	2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
AID1917244	Inhibition of CDK7/cyclin H/MAT1 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors.
AID256564	Average Binding Constant for MAP3K4; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531379	Inhibition of human LATS1 assessed as residual activity at 100 uM using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435790	Binding constant for DRAK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1308958	Inhibition of HER2 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID513248	Antiapoptotic activity against staurosporine-induced cell death in human HeLa cells assessed as caspase 7 activity at 10 uM after 24 hrs	2006	Nature chemical biology, Sep, Volume: 2, Issue:9	Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation.
AID720323	Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720399	Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1063047	Inhibition of wild type MEK1 (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID624708	Binding constant for CDC2L1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID536057	Activation of EGF-induced MEK5 activity in HEK293 cells assessed as phosphorylated ERK5 level at 10 uM after 1 hr by Western blotting relative to control	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Structure-activity relationships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5 signaling pathway.
AID256651	Average Binding Constant for DAPK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1308952	Inhibition of FGFR1 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID512717	Inhibition of protein kinase C	2006	The AAPS journal, Mar-24, Volume: 8, Issue:1	Selectivity and potency of cyclin-dependent kinase inhibitors.
AID1055896	Cytotoxicity against human MDA-MB-231 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID1726215	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay	2020	ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12	Staurosporine Analogs Via C-H Borylation.
AID262366	Inhibition of CK2 using 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID1252492	Inhibition of human AurA kinase by kinase inhibition assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID1481071	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1531469	Inhibition of human PKA assessed as residual activity at 100 uM using LCGRTGRRNSI as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715148	Inhibition of human TAOK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625006	Binding constant for EGFR(S752-I759del) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720381	Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715307	Inhibition of human JAK3 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID269869	Inhibition of RAF1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID1531610	Inhibition of human CAMK2D using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID436051	Binding constant for RPS6KA5(Kin.Dom.2 - N-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720307	Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715433	Inhibition of human c-MET using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID280401	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP	2007	Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6	Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes.
AID1531939	Inhibition of human TYK2 assessed as residual activity at 100 uM using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462568	Induction of apoptosis in human MFE296 cells assessed as viable cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 90.9 to 94.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1381822	Cell cycle arrest in human KOPN8 cells assessed as accumulation at G2/M phase at 2 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 9.67%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID457751	Inhibition of CHK1 by DELFIA assay	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
AID720382	Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1895102	Binding affinity to MST4 (unknown origin) assessed as change in melting temperature by thermal shift based DSF assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors.
AID1481669	Inhibition of human DAPK1 using KKLNRTLSFAEPG as substrate in presence of [gamma-33P]-ATP
AID284058	Weight change in intratumorally dosed BALB/c nude mouse bearing human A431 cells at 1 mg/kg after 17 days	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents.
AID1404960	Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay
AID720020	Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462534	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 1 to 2.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531593	Inhibition of human BMPR2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1732379	Inhibition of p38 alpha (unknown origin) using Ser/Thr 15 as substrate incubated for 1 hr in presence of ATP by Z'-Lyte assay
AID1531592	Inhibition of human BLK using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID457749	Inhibition of CHK2 by DELFIA assay	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
AID1743550	Inhibition of c-Src (unknown origin) in presence of ATP	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
AID1833071	Inhibition of VEGFR2 (unknown origin)	2021	Bioorganic & medicinal chemistry, 11-15, Volume: 50	Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
AID436046	Binding constant for PRKD2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531849	Inhibition of human PKG1alpha using LRRASLG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308949	Inhibition of FLT1 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531661	Inhibition of human DLK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID269861	Inhibition of AKT3	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID1531222	Inhibition of human ARK5 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID241734	Inhibition of human Protein kinase C beta 1 using [gamma-33P]-ATP	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID720089	Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1543545	Inhibition of GSK-3beta (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by caliper assay	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease.
AID435182	Binding constant for full-length PKAC-beta	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1309144	Inhibition of N-terminal his-tagged full length human recombinant BTK PH domain expressed in baculovirus infected Sf9 insect cells at 100 uM by ADP-glo luminescence assay	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthetic sulfoglycolipids targeting the serine-threonine protein kinase Akt.
AID624971	Binding constant for DAPK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1714635	Inhibition of BCR (unknown origin)/recombinant human N-terminal His-tagged ABL1 (27 to end residues) expressed in baculovirus infected Sf9 cells using ABLtide as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr in	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.
AID1247628	Inhibition of FGFR3 (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID45083	Inhibition of purified mammalian brain calcium [Ca(2+)]/Calmodulin dependent kinase	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID1351041	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.95 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1462573	Induction of apoptosis in human MFE296 cells assessed as early apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.5 to 2.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID720398	Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720225	Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID494391	Inhibition of CDK5/p25	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID624824	Binding constant for PIP5K1A kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1304187	Inhibition of Aurora B (unknown origin) using myelin protein as substrate assessed as ADP generation after 60 mins by ADP-glo assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors.
AID1368673	Inhibition of human CK1g1 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1308977	Inhibition of PKN2 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID720131	Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720333	Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1770389	Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID1531279	Inhibition of human CK1gamma1 assessed as residual activity at 100 uM using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1183915	Induction of apoptosis in human primary monocytes at 3 uM by PE Annexin V and 7-aminoactinomycin staining based flow cytometry	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID407190	Inhibition of ASK1 by luciferase assay	2008	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13	Development of a novel fluorescent probe for fluorescence correlation spectroscopic detection of kinase inhibitors.
AID720389	Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531818	Inhibition of human PAK3 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720266	Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1183892	Cytotoxicity against human HeLa cells at 0.001 to 1 uM after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1624700	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced IL-4 level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA	2019	Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6	Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1531844	Inhibition of human PKCmu using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID350264	Inhibition of EPHB4	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID205341	Inhibition of Src protein tyrosine kinase	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID1300794	Inhibition of mouse TSSK1 by luminescent ADP-Glo assay kit	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID219830	Inhibition of Bovine heart cAMP-dependent protein kinase	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID350258	Inhibition of CHK2	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1531576	Inhibition of human AKT2 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1247639	Inhibition of PLK1 (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID256563	Average Binding Constant for ULK3 m; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1066415	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	2014	European journal of medicinal chemistry, Jan-24, Volume: 72	The chemical and biological potential of C ring modified triterpenoids.
AID1624709	Competitive inhibition of human LYN expressed in baculovirus infected Sf9 insect cells using p-nitrophenol at 10 uM after 10 mins by Lineweaver-Burk plot analysis	2019	Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6	Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1899695	Time dependent inhibition of wild type N-terminal GST tagged BLK (unknown origin) (1 to 505 residues) expressed in sf21 insect cell using TK as substrate in presence of ATP by HTRF assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK).
AID470606	Inhibition of GST-tagged MAPKAPK2 assessed as [33P] incorporation after 40 mins by scintillation proximity assay	2009	Journal of natural products, Sep, Volume: 72, Issue:9	Guttiferones O and P, prenylated benzophenone MAPKAPK-2 inhibitors from Garcinia solomonensis.
AID1090406	Antimicrobial activity against Pectobacterium carotovorum assessed as growth inhibition incubated for 4 to 7 days	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1350025	Cytotoxicity against human PC3 cells by sulforhodamine B assay	2018	Journal of natural products, 02-23, Volume: 81, Issue:2	Cyclizidine-Type Alkaloids from Streptomyces sp. HNA39.
AID619954	Inhibition of PKCzeta in human U937 cells assessed as inhibition of TNF-alpha-induced NF-kB activation at 1 uM by luciferase reporter gene assay	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	4-benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCζ.
AID629267	Inhibition of CDK1/Cyclin B	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID629407	Inhibition of TRKB	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1351001	Inhibition of SYK (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID451370	Inhibition of PKA assessed as [gamma-32P]ATP labeling of kemptide by liquid scintillation counting	2009	Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17	Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling.
AID1524567	Antiproliferative activity against human KOPN8 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Synthesis and Biological Studies of (+)-Liquiditerpenoic Acid A (Abietopinoic Acid) and Representative Analogues: SAR Studies.
AID1624701	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced beta-hexosaminidase release preincubated for 15 mins followed by calcium ionophore-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta	2019	Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6	Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID435200	Binding constant for full-length TNNI3K	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1484299	Induction of apoptosis in human PC3 cells assessed as necrotic cells at 30 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 2 to 3%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID1531395	Inhibition of human MARK2 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID695573	Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors.
AID1300787	Inhibition of RSK1 (unknown origin) by Z-LYTE kinase assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1531628	Inhibition of human CDK4/cyclin-D3 using RB-CTF as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256673	Average Binding Constant for PAK1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625080	Binding constant for EIF2AK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID550458	Inhibition of c-Src after 60 mins	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Click chemistry inspired one-pot synthesis of 1,4-disubstituted 1,2,3-triazoles and their Src kinase inhibitory activity.
AID1531660	Inhibition of human DDR2 using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1612680	Inhibition of human PKCalpha using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID241157	Inhibition of human Glycogen synthase kinase-3 beta	2004	Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16	Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
AID1287696	Induction of apoptosis in human NALM6 cells assessed as cleaved PARP level at 0.5 uM measured after 12 hrs by immunoblot analysis	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID1878045	Inhibition of recombinant N-terminal GST/His6-tagged human FLT3 ITD mutant (571 to 993 residues) expressed in insect cells by LanthaScreen assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
AID262367	Inhibition of Chk1 using 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID625073	Binding constant for SGK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1612683	Inhibition of human TLK1 using Histone H3 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID163882	Inhibition of Protein kinase C gamma	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID1715386	Inhibition of human CTK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435649	Binding constant for CDC2L2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID629393	Inhibition of JAK3	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID624733	Binding constant for SIK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1368676	Inhibition of human GSK3beta at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID165101	Inhibition of protein kinase C (PKC) of rat brain	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID1531391	Inhibition of human MAPKAPK2 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1203683	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID1531368	Inhibition of human ITK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531332	Inhibition of human FGFR3 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1481081	Inhibition of human PKCa using histone H1 as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1715284	Inhibition of human MARK2 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1352739	Inhibition of c-Met (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Identification of novel N
AID1531557	Inhibition of human TYRO3 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531909	Inhibition of human TLK2 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435546	Binding constant for PRKG1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1350999	Inhibition of ROCK1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531587	Inhibition of human ASK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256566	Average Binding Constant for TNIK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1666667	Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
AID435438	Binding constant for full-length p38-gamma	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1917243	Inhibition of CDK2/cyclin E1 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors.
AID256663	Average Binding Constant for INSR; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531745	Inhibition of human LCK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1350990	Inhibition of PAK1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID720028	Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531881	Inhibition of human SLK using Histone H3 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720108	Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715323	Inhibition of human HIPK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256662	Average Binding Constant for ERBB2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID49345	Inhibition of rat liver casein kinase II	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID720154	Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531291	Inhibition of human DAPK1 assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624980	Binding constant for ABL1(F317I)-phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531759	Inhibition of human MARK2 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624880	Binding constant for PIK4CB kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1532718	Induction of apoptosis in human MCF10A cells after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry method	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID624983	Binding constant for ABL1(H396P)-non phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531350	Inhibition of human GSK3A assessed as residual activity at 100 uM using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531548	Inhibition of human TRKA assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625024	Binding constant for PRKD3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1055902	Cytotoxicity against human A375 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1531295	Inhibition of human DDR1 assessed as residual activity at 100 uM using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531725	Inhibition of human IKKalpha using KKKKERLLDDRHDSGLDSMKDEE as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531751	Inhibition of human LRRK2 using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624739	Binding constant for GRK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID284490	Cytotoxicity against human U937 cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	In vitro cytotoxicity evaluation of some substituted isatin derivatives.
AID1531897	Inhibition of human STK39 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531235	Inhibition of human BTK assessed as residual activity at 100 uM using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435938	Binding constant for TGFBR1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1654692	Induction of apoptosis in human ARN8 cells assessed as increase in YOYO3 positive cells at 1 uM incubated for 48 hrs in presence of caspase inhibitor, Z-VAD-FMK measured every 2 hrs by YOYO-3 staining based live cell imaging analysis	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
AID49347	Inhibition of Casein kinase II	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID73968	Inhibitory activity against human glycogen synthase kinase-3beta (GSK3-beta) at 100 uM ATP	2003	Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15	Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors.
AID1715415	Inhibition of human CDK17/cyclin-Y using MBP protein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1247630	Inhibition of FMS (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1531310	Inhibition of human EPHA4 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID163199	Inhibition of Protein kinase C beta 1	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID612258	Inhibition of SRC at 50 uM after 1 hr	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.
AID1531517	Inhibition of human SLK assessed as residual activity at 100 uM using Histone H3 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720134	Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1426964	Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design, synthesis and biological evaluation of quinazoline-phosphoramidate mustard conjugates as anticancer drugs.
AID621707	Binding affinity to TPL2 immobilized on a sensor chip surface by biacore-based competitive binding assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors.
AID624869	Binding constant for NEK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715289	Inhibition of human MAPKAPK2 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID629406	Inhibition of SYK	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID256632	Average Binding Constant for CDK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625075	Binding constant for INSRR kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1770388	Antiproliferative activity against human HAP1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID720081	Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531680	Inhibition of human EPHB2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720160	Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1186611	Inhibition of FLT3 (unknown origin) using EAIYAAPFAKKK substrate	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
AID435667	Binding constant for full-length NLK	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1060709	Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis, molecular modeling and biological evaluation of N-benzylidene-2-((5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)thio)acetohydrazide derivatives as potential anticancer agents.
AID624864	Binding constant for CTK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531895	Inhibition of human STK38 using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1666666	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by MTT assay	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
AID624767	Binding constant for MERTK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531879	Inhibition of human SIK2 using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720043	Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1185519	Cytotoxicity against human HCT116 cells at 0.2 uM after 48 hrs by MTT assay relative to untreated control	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	β-amino-alcohol tethered 4-aminoquinoline-isatin conjugates: synthesis and antimalarial evaluation.
AID1483363	Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
AID1531330	Inhibition of human FGFR1 assessed as residual activity at 100 uM using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531727	Inhibition of human IKKepsilon using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1743527	Inhibition of wild type BCR-ABL (unknown origin) incubated for 40 mins in presence of [gamma33P]ATP by scintillation method	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
AID720097	Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531833	Inhibition of human PKA using LCGRTGRRNSI as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531236	Inhibition of human c-KIT assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1466330	Inhibition of FLT3 (unknown origin) by HTRF method	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
AID624992	Binding constant for ABL1-phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1543902	Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID1531873	Inhibition of human RSK4 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID269859	Inhibition of AKT1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID303326	Inhibition of PDGFRalpha at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID1471758	Inhibition of recombinant human ALK G1202R mutant (1093 to 1411 residues) expressed in baculovirus expression system using 5'FAM-KKSRGDYMTMQIG-CONH as substrate preincubated for 15 mins followed by addition of ATP measured after 1 hr by microfluidic mobil	2017	Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.
AID629275	Inhibition of FGFR2	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1531689	Inhibition of human ERN1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1624702	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced TNF-alpha level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA	2019	Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6	Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1846777	Inhibition of EGFR (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID624949	Binding constant for CSNK1G3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435285	Binding constant for DMPK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1060710	Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Synthesis, molecular modeling and biological evaluation of N-benzylidene-2-((5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)thio)acetohydrazide derivatives as potential anticancer agents.
AID436007	Binding constant for AXL kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720129	Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1762563	Inhibition of N-terminal GST-fused human recombinant full length ZAP70 (1 to 619 residues) expressed in baculovirus-infected Sf21 cells using FAM-22 peptide as substrate at 1 uM preincubated with enzyme for 10 mins followed by substrate addition for 30 mi	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.
AID720346	Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435148	Binding constant for AMPK-alpha1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624785	Binding constant for JAK3(JH1domain-catalytic) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531775	Inhibition of human MLCK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256653	Average Binding Constant for FGFR1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435519	Binding constant for AURKB kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1365189	Inhibition of CRAF (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
AID1530827	Inhibition of human full length N-terminal GST tagged CHK1 assessed as residual activity at 7.81 10'-8M (Rvb = 96.94 to 103.06%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531474	Inhibition of human PKCb2 assessed as residual activity at 100 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID303322	Inhibition of JAK3 at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID256596	Average Binding Constant for CLK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID262981	Inhibition of FLt4 at 1.0 mM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1704685	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	3-Methylthiazolo[3,2-a]benzimidazole-benzenesulfonamide conjugates as novel carbonic anhydrase inhibitors endowed with anticancer activity: Design, synthesis, biological and molecular modeling studies.
AID1462558	Induction of apoptosis in human MFE280 cells assessed as late apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 6 to 7.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID720065	Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1733104	Inhibition of MLK1 (unknown origin) by NanoBRET cellular target engagement assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core.
AID1654689	Induction of apoptosis in human ARN8 cells assessed as increase in YOYO3 positive cells at 1 uM incubated for 48 hrs measured every 2 hrs by YOYO-3 staining based live cell imaging analysis	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
AID1715407	Inhibition of human CDK4/cyclin-D3 using RB-CTF as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531560	Inhibition of human ULK3 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1189697	Inhibition of telomerase in human HepG2 cells at 4 uM after 1 day by TRAP-ELISA method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID350295	Inhibition of SYK	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1715370	Inhibition of human EPHA2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531705	Inhibition of human GCK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435803	Binding constant for full-length LIMK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1417227	Cytotoxicity against human HeLa cells assessed as cell viability at 1 uM by XTT assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
AID1704347	Inhibition of human ERG	2020	European journal of medicinal chemistry, Oct-01, Volume: 203	Design and synthesis of 1H-indazole-3-carboxamide derivatives as potent and selective PAK1 inhibitors with anti-tumour migration and invasion activities.
AID435442	Binding constant for SYK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531260	Inhibition of human CDK2/cyclin-E assessed as residual activity at 100 uM using histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625069	Binding constant for TLK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID634543	Competitive inhibition of human CHK2 using ATP as substrate by DELFIA	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
AID1531273	Inhibition of human CHK1 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1156597	Inhibition of CDK6/cyclin D1 (unknown origin) at 1 uM after 20 to 30 mins by scintillation counting analysis relative to control	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antitumor activity of pyrido [2,3-d]pyrimidine and pyrido[2,3-d] [1,2,4]triazolo[4,3-a]pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest.
AID350287	Inhibition of PHKgamma2	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1715383	Inhibition of human DCAMKL2 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624805	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531677	Inhibition of human EPHA7 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID426699	Inhibition of CDK1 assessed as Rb (ser780) biotinylated peptide phosphorylation by DELFIA assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Identification of inhibitors of checkpoint kinase 1 through template screening.
AID1531887	Inhibition of human SSTK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1381887	Inhibition of RNA polymerase 2 C-terminal domain phosphorylation at Ser2 residue in human KOPN8 cells after 3 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1246321	Cell cycle arrest in human triple-negative MDA-MB-231 cells assessed as accumulation at G0/G1 phase at 2.5 uM after 12 hrs by propidium iodide staining-based flow cytometry (Rvb = 48.36%)	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID415613	Inhibition of CDK1/Cyclin B	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID256643	Average Binding Constant for CAMK1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624773	Binding constant for AMPK-alpha1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720213	Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531921	Inhibition of human TYRO3 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720098	Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531650	Inhibition of human CLK3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1247623	Inhibition of CDK2/cyclin E (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID624844	Binding constant for CDK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624737	Binding constant for EPHA5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1887905	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
AID1532741	Induction of apoptosis in human MCF10A cells assessed as necrotic cells at 1 uM after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry method (Rvb = 0.57%)	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID256599	Average Binding Constant for TTK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531631	Inhibition of human CDK6/cyclin-D1 using RB protein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720432	Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531785	Inhibition of human MSK1 using GRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID45092	Inhibition of human adenocarcinoma cell line Caco-2 proliferation (Not tested)	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
AID720151	Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720411	Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720220	Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435676	Binding constant for LCK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531905	Inhibition of human TESK1 using cofilin as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID93077	Inhibition of Insulin receptor	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID624761	Binding constant for CDC2L5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531853	Inhibition of human PKN2 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1659479	Inhibition of LMTK3 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9	Discovery of cyclic guanidine-linked sulfonamides as inhibitors of LMTK3 kinase.
AID1246325	Cell cycle arrest in human triple-negative MDA-MB-231 cells assessed as accumulation at G2/M phase at 2.5 uM after 12 hrs by propidium iodide staining-based flow cytometry (Rvb = 20.40%)	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID1531589	Inhibition of human Aurora B using [H-LRRASLG] as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID126922	Inhibition of Mitogen-activated protein kinase 1	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID256589	Average Binding Constant for EPHA4; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID55348	Inhibitory activity against Cyclin D1-cyclin-dependent kinase 4 by measuring the phosphorylation of RbING	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
AID624703	Binding constant for MAPKAPK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID164204	Inhibition of Protein kinase C zeta at 1 uM	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID611840	Inhibition of ABL-1 at 50 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID624850	Binding constant for DDR1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1180279	Inhibition of GSK3beta (unknown origin) assessed as luminescence intensity by luminometry	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Syntheses, neural protective activities, and inhibition of glycogen synthase kinase-3β of substituted quinolines.
AID1531691	Inhibition of human FAK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256621	Average Binding Constant for CAMK2A; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1247632	Inhibition of IGF1R (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1531528	Inhibition of human STK32B assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715229	Inhibition of human PAK5 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1452447	Inhibition of retinoblastoma protein phosphorylation in human MDA-MB-231 cells after 16 hrs by Hoechst 33342 staining based fluorescence assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors.
AID1715189	Inhibition of human PRKX using LRRASLG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID701520	Induction of cell death in mouse MEF cells containing Bax/Bak double knock out at 1 uM by Annexin V and propidium iodide staining based FACS method	2012	European journal of medicinal chemistry, Nov, Volume: 57	Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID1531843	Inhibition of human PKCiota using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531316	Inhibition of human EPHB2 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308934	Inhibition of BRK (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID435899	Binding constant for AKT1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624810	Binding constant for GCN2(Kin.Dom.2,S808G) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720466	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1770387	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID720469	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624779	Binding constant for BTK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435553	Binding constant for PRKCD kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720271	Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531647	Inhibition of human CK2A2 using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256654	Average Binding Constant for FGFR2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID436022	Binding constant for full-length MEK3	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720145	Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1704866	Inhibition of recombinant human N-terminal GST-HIS6 fused RET V804L mutant C-terminal domain (H658 to S1114 residues) expressed in Sf9 insect cells using TRK-C-derived peptide as substrate in presence of [33P]-ATP by filter binding assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
AID625066	Binding constant for IRAK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1755833	Inhibition of telomerase in human SGC-7901 cell extract by TRAP assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective.
AID1715194	Inhibition of human PKN3 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625030	Binding constant for LOK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435434	Binding constant for RET kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720308	Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID67965	Effective dose against plasminogen activator activity stimulated by phorbol ester in endothelial cells	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID1830799	Antiproliferative activity against human BET-sensitive MV4-11 cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-Glo assay	2021	Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20	Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins.
AID256603	Average Binding Constant for FER; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID165111	Inhibition of protein kinase C	1997	Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19	Fused pyrrolo[2,3-c]carbazol-6-ones: novel immunostimulants that enhance human interferon-gamma activity.
AID418379	Inhibition of Pim1 after 15 mins by scintillation counting-based competition assay in presence of 100 uM [gamma33P]ATP	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.
AID1142592	Inhibition of human recombinant ALK5 expressed in insect Sf9 cells using casein as substrate by radioisotopic assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/
AID1308954	Inhibition of FGFR3 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1715264	Inhibition of human MNK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID350273	Inhibition of GSK3B	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID624790	Binding constant for KIT(L576P) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1247635	Inhibition of Lyn (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID435393	Binding constant for CAMK1D kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1394741	Inhibition of recombinant human FAK expressed in Sf9 insect cells using Ulight-TK peptide as substrate after 60 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID1531309	Inhibition of human EPHA3 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624878	Binding constant for PIM1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1731513	Inhibition of human N-terminal GST-tagged CDK2 (1 to 298 residues)/Cyclin A (174 to 432 residues) expressed in Escherichia coli Turner (DE3) cells assessed as reduction in ADP formation using PKTPKKAKKL as substrate by resorufin dye based fluorescence ass	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Tetrahydroindazole inhibitors of CDK2/cyclin complexes.
AID1524565	Antiproliferative activity against human NALM6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Synthesis and Biological Studies of (+)-Liquiditerpenoic Acid A (Abietopinoic Acid) and Representative Analogues: SAR Studies.
AID1531716	Inhibition of human haspin using Histone H3 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720280	Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531389	Inhibition of human LYN-B assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715142	Inhibition of human TNIK using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715366	Inhibition of human EPHA4 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID55359	Inhibitory activity against Cyclin D1-cyclin-dependent kinase 4 in enzymatic assay by measuring phosphorylation of RbING	2003	Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14	Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
AID1350961	Inhibition of CDK1/cyclin E (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID720219	Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1895098	Inhibition of full length N-terminal nanoLuc-tagged human SIK3 expressed in HEK293 cells using NanoBRET NanoGlo substrate incubated for 2 hrs in presence of tracer K10 by NanoBRET assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors.
AID720075	Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID453816	Antitubercular activity against Mycobacterium tuberculosis H37Rv after 16 to 24 hrs by microplate alamar blue assay	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	Natural product leads for drug discovery: isolation, synthesis and biological evaluation of 6-cyano-5-methoxyindolo[2,3-a]carbazole based ligands as antibacterial agents.
AID1462533	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 2 to 2.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID435151	Binding constant for CAMK1G kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720209	Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531302	Inhibition of human DYRK1B assessed as residual activity at 100 uM using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624750	Binding constant for PRP4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1351043	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.22 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1410143	Inhibition of PKCdelta (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID1531664	Inhibition of human DRAK1 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624813	Binding constant for MINK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531750	Inhibition of human LOK using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1727481	Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Cytotoxic triterpenoid-safirinium conjugates target the endoplasmic reticulum.
AID1543901	Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID435292	Binding constant for ITK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1650883	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated beta-hexosaminidase release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Variegatic acid from the edible mushroom Tylopilus ballouii inhibits TNF-α production and PKCβ1 activity in leukemia cells.
AID1531492	Inhibition of human PLK2 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1895101	Binding affinity to MST3 (unknown origin) assessed as change in melting temperature by thermal shift based DSF assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors.
AID1191829	Inhibition of recombinant N-terminal His-tagged AKT1 (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 6 peptide substrate by Z'-LYTE kinase assay	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
AID1830801	Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-Glo assay	2021	Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20	Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins.
AID629274	Inhibition of FAK	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1531907	Inhibition of human TIE2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531624	Inhibition of human CDK2/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462528	Induction of apoptosis in human MCF7 cells assessed as viable cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 92.6 to 96.8%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531866	Inhibition of human ROCK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720202	Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624720	Binding constant for HIPK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1294634	Inhibition of human Aurora A using H-LRRASLG as substrate after 2 hrs by HotSpot assay in presence of 33P-ATP and 1 uM ATP	2016	Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9	Design, synthesis, and evaluation of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives as Aurora kinase inhibitors.
AID1483366	Inhibition of recombinant human N-terminally GST-tagged EGFR L858R/T790M/C797S triple mutant expressed in baculovirus in Sf9 insect cells preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
AID435552	Binding constant for PIK3CA(E545K) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID764619	Induction of apoptosis in rat PC12 cells assessed as procaspase-3 activation at 0.5 uM after 24 hrs by fluorometric assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and initial in vitro biological evaluation of two new zinc-chelating compounds: comparison with TPEN and PAC-1.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1531915	Inhibition of human TSSK2 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1758205	Inhibition of CDK4/Cyclin D3 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins in presence of ATP by caliper mobility shift assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Ring closure strategy leads to potent RIPK3 inhibitors.
AID256630	Average Binding Constant for FYN; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1202431	Inhibition of KDR (unknown origin) at 10 uM after 30 mins by HTRF method	2015	European journal of medicinal chemistry, , Volume: 96	Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents.
AID1531370	Inhibition of human JAK2 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715172	Inhibition of human SGK3 using GRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531738	Inhibition of human JNK3 using ATF2 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1421400	Inhibition of Aurora A (unknown origin) using STK S2 as substrate after 40 mins by HTRF assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
AID1461683	Cytotoxic activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 10-01, Volume: 25, Issue:19	Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
AID625057	Binding constant for TYRO3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720071	Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720125	Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624723	Binding constant for CSNK1A1L kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720402	Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1666224	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID435280	Binding constant for CSF1R kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531319	Inhibition of human ERBB2 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID723734	Inhibition of CDK2/Cyclin A (174 to 432 amino acid residues) (unknown origin) by differential scanning fluorimetry assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
AID1715313	Inhibition of human IRR using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID427621	Inhibition of recombinant IKK2 expressed in Bac-to Bac baculovirus system	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
AID1531773	Inhibition of human MKK6 using p38alpha as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1189699	Inhibition of telomerase in human HepG2 cells at 4 uM after 3 days by TRAP-ELISA method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID436013	Binding constant for DMPK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715343	Inhibition of human FGR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435439	Binding constant for PAK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID629264	Inhibition of Alk	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1715371	Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624753	Binding constant for PKNB(M.tuberculosis) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531934	Inhibition of human ZAP70 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID611838	Inhibition of VEGFR-1 at 50 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID720067	Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720272	Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1484294	Induction of apoptosis in human PC3 cells assessed as viable cells at 20 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 95%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID247966	Concentration required for growth inhibition of human colon carcinoma cell line HCT116	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
AID1808083	Antiproliferative activity against human MCF-10A cells assessed as inhibition rate incubated for 72 hrs by MTT assay	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer.
AID498730	Binding affinity to p38alpha	2009	Nature chemical biology, Jun, Volume: 5, Issue:6	A new screening assay for allosteric inhibitors of cSrc.
AID720288	Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531458	Inhibition of human PASK assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID627338	Inhibition of LCK using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1715350	Inhibition of human FAK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1308936	Inhibition of CDK2 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID256665	Average Binding Constant for ABL1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531426	Inhibition of human MST3 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531894	Inhibition of human STK33 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308950	Inhibition of FLT3 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531700	Inhibition of human FLT3 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531717	Inhibition of human HCK using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715416	Inhibition of human CDK16/cyclin-Y using RB protein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624863	Binding constant for MARK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1350974	Inhibition of VEGFR1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID337238	Inhibition of mouse EGFR by liquid scintillation counting
AID435521	Binding constant for CAMKK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID745525	Inhibition of CDK4/Cyclin D1 (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID1410144	Inhibition of SYK (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID1715261	Inhibition of human MRCKalpha using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531884	Inhibition of human SRMS using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1350987	Inhibition of MNK2 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID720378	Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715234	Inhibition of human p70S6K using KKRNRTLTK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1394749	Inhibition of recombinant human Src expressed in insect cells using Ulight-Poly GAT[EAY(1:1:1)]n as substrate after 10 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID1655212	Induction of apoptosis in human GIN28 cells assessed as increase in caspase 3/7 activation at 10 uM measured after 48 hrs by CellEvent caspase 3/7 probe based fluorescence analysis	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Development of Pyrazolo[3,4-
AID1351004	Inhibition of TRKA (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531693	Inhibition of human FES using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720159	Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531806	Inhibition of human NEK9 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1569121	Cytotoxicity against human HEK293 cells assessed as cell viability incubated for 72 hrs by cell titer-glo luminescent cell viability assay (Rvb = > 100 uM)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of carbazole derivatives as novel allosteric MEK inhibitors by pharmacophore modeling and virtual screening.
AID1715353	Inhibition of human ERK7 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1654670	Induction of DNA damage in human ARN8 cells assessed as increase in p53 phosphorylation at Ser15 at 1 uM incubated for 4.5 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8	Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
AID624740	Binding constant for LRRK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624789	Binding constant for KIT(D816V) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1848363	Cytotoxicity against human OKF6 cells assessed as reduction in cell viability at 10 uM by Annexin V-FITC/PI staining based flow cytometric analysis
AID256561	Average Binding Constant for BTK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715271	Inhibition of human MKK6 using p38alpha as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435171	Binding constant for NEK9 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1635587	Antiproliferative activity against human WI38 cells after 72 hrs by SRB assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
AID745521	Inhibition of CDK9/Cyclin K (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID1531757	Inhibition of human MAPKAPK5 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1733106	Inhibition of MLK3 (unknown origin) by NanoBRET cellular target engagement assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core.
AID1308986	Inhibition of YES (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID775220	Inhibition of ALK (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	2013	European journal of medicinal chemistry, Nov, Volume: 69	Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II.
AID624858	Binding constant for JAK1(JH2domain-pseudokinase) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1709608	Inhibition of recombinant human full-length His-tagged TAK1-TAB1 fusion protein (437 to 504 residues) expressed in baculovirus expression system using fluorescein-MAP2K1 as substrate preincubated for 30 mins followed by substrate addition and measured aft	2021	ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4	Discovery of 2,4-1
AID1524569	Antiproliferative activity against human UOCB1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Synthesis and Biological Studies of (+)-Liquiditerpenoic Acid A (Abietopinoic Acid) and Representative Analogues: SAR Studies.
AID435398	Binding constant for DAPK3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624890	Binding constant for p38-beta kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531429	Inhibition of human MYLK3 assessed as residual activity at 100 uM using KKRPQRRYSNVF as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID415626	Selectivity ratio of IC50 for CDK5/P35 to IC50 for human GSK3-beta	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID1350970	Inhibition of MAPK7 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531783	Inhibition of human MRCKalpha using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1350983	Inhibition of LCK (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID720103	Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435901	Binding constant for BRAF kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624968	Binding constant for DRAK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID262980	Inhibition of KDR at 1.0 mM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID350548	Inhibition of PAK2	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1350955	Inhibition of Aurora A (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1308976	Inhibition of PKN1 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID256576	Average Binding Constant for MKNK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1298812	Inhibition of human recombinant JAK3 assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
AID625083	Binding constant for LATS2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1689701	Induction of apoptosis in human RPMI-8226 cells assessed as BAX level incubated for 24 hrs by ELISA (Rvb = 56 +/- 1.31 pg/ml)	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
AID435196	Binding constant for full-length SRPK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715269	Inhibition of human MLCK2 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID498727	Inhibition of wild type cSrc	2009	Nature chemical biology, Jun, Volume: 5, Issue:6	A new screening assay for allosteric inhibitors of cSrc.
AID1298808	Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation at 10 uM pre-incubated before substrate addition and measured after 60 mins by LANCE detection method	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
AID1531756	Inhibition of human MAPKAPK3 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715191	Inhibition of human PLK3 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624981	Binding constant for ABL1(F317L)-non phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715318	Inhibition of human IKKalpha using KKKKERLLDDRHDSGLDSMKDEE as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624842	Binding constant for BMX kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720086	Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720412	Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID303324	Inhibition of FLT3	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID1356601	Inhibition of GST-tagged human CDK8/CycC (04 to 109 residues) using kinase tracer 236 probe incubated for 60 mins by TR-FRET assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
AID1536864	Inhibition of kinase tracer 236 binding to recombinant full length His-tagged human CDK8/CycC expressed in baculovirus expression system at 10 uM preincubated for 20 mins followed by tracer addition and measured after 2 hrs by FRET-based LanthaScreen Eu k	2019	Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4	Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.
AID415641	Inhibition of ERK1	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID624732	Binding constant for PYK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720390	Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID745526	Inhibition of CDK3/Cyclin E (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID1531638	Inhibition of human CHK2 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID55537	Inhibitory activity against Plasmodium falciparum cyclin dependent protein kinase, Pfmrk	2003	Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18	Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.
AID624856	Binding constant for GSK3B kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1394742	Inhibition of recombinant human Flt1 expressed in Sf9 insect cells using Ulight-TK peptide as substrate after 15 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID1491366	Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	2-Substituted-thio-N-(4-substituted-thiazol/1H-imidazol-2-yl)acetamides as BACE1 inhibitors: Synthesis, biological evaluation and docking studies.
AID256667	Average Binding Constant for ABL1(E255K); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256658	Average Binding Constant for p38-beta; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1067087	Inhibition of PTK6 (unknown origin) phosphorylation using Z'-LYTE-Tyr 1 peptide substrate after 1 hr by fluorescence assay	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors.
AID625130	Binding constant for FGFR4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715363	Inhibition of human EPHB1 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256569	Average Binding Constant for PAK7/PAK5; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531211	Inhibition of human AKT1 assessed as residual activity at 100 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531616	Inhibition of human CDK17/Cyclin-A using Histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1704683	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	3-Methylthiazolo[3,2-a]benzimidazole-benzenesulfonamide conjugates as novel carbonic anhydrase inhibitors endowed with anticancer activity: Design, synthesis, biological and molecular modeling studies.
AID1531762	Inhibition of human MEK1 using ERK2 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID241562	Inhibition of Epidermal growth factor receptor in P19 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1350966	Inhibition of EPHA3 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1715182	Inhibition of human RON using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720387	Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624870	Binding constant for NEK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462539	Induction of apoptosis in human MCF7 cells assessed as nuclear debris at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.2 to 3%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1368683	Inhibition of human PAK1 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1462521	Induction of apoptosis in human A2780 cells assessed as early apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.7 to 2.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID415620	Inhibition of CDK9/cyclin T1	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID720309	Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID625092	Binding constant for NDR2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531860	Inhibition of human PYK2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID630397	Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay	2011	Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21	Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents.
AID1531614	Inhibition of human CAMKK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715197	Inhibition of human PKG2 using LRRASLG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720255	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624978	Binding constant for ABL1(E255K)-phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1484293	Induction of apoptosis in human PC3 cells assessed as necrotic cells at 10 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 2 to 3%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID164479	Inhibition of Protein kinase A	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
AID1531360	Inhibition of human IGF1R assessed as residual activity at 100 uM using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID611839	Inhibition of VEGFR-2 at 50 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID1074863	Induction of apoptosis in human A2780 cells assessed as cell shrinkage at at 1 uM after 24 hrs by acridine orange/propidium iodide staining-based fluorescence microscopy	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID1531398	Inhibition of human MEK1 assessed as residual activity at 100 uM using ERK2 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531358	Inhibition of human HIPK4 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531529	Inhibition of human STK32C assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531567	Inhibition of human YES assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1055899	Cytotoxicity against human HepG2 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID720330	Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720082	Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720192	Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720350	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720417	Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1772909	Inhibition of EGFR (unknown origin) incubated for 40 mins in presence of Mg/ATP mix by [gamma p33]-ATP based scintillation counting method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1715258	Inhibition of human MSK1 using GRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720354	Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720281	Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462530	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 1 to 2.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1462519	Induction of apoptosis in human A2780 cells assessed as nuclear debris at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.3 to 1.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1247615	Inhibition of AKT1 (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID284067	Antitumor activity against human A431 xenograft in BALB/c nude mouse at 1 mg/kg, po after 18 days relative control	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents.
AID1055889	Cytotoxicity against human LN18 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID155712	Inhibition of protein kinase C was evaluated as Inhibitory concentration	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID435445	Binding constant for ZAP70 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715444	Inhibition of human AXL using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720173	Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715380	Inhibition of human DDR2 using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID216916	Inhibition of Vascular endothelial growth factor receptor 2	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID720126	Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1410141	Inhibition of FAK (unknown origin) by Lanthascreen assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID721047	Inhibition of TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells by beta-lactamase reporter gene assay	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors.
AID720305	Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435297	Binding constant for MLK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID262975	Inhibition of CDK1 at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1481070	Inhibition of human ABL1 using EAIYAAPFAKKK as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1531771	Inhibition of human MINK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435323	Binding constant for RET(M918T) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1462574	Induction of apoptosis in human MFE296 cells assessed as late apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 3.6 to 6.6%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID262374	Antiproliferative activity against MiaPaCa-2 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID1531412	Inhibition of human MLCK2 assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624903	Binding constant for SRPK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1247618	Inhibition of BRAF (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1715223	Inhibition of human PDGFRalpha using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531622	Inhibition of human CDK18/cyclin-Y using RB protein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531523	Inhibition of human SSTK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624985	Binding constant for ABL1(M351T)-phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531671	Inhibition of human EPHA1 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625053	Binding constant for PRKG2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID342545	Inhibition of Lck	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
AID1531401	Inhibition of human MEK5 assessed as residual activity at 100 uM using ERK5 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531435	Inhibition of human NEK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531914	Inhibition of human TRKC using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625051	Binding constant for PRKCQ kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531618	Inhibition of human CDK1/cyclinE using RB protein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531637	Inhibition of human CHK1 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435912	Binding constant for MRCKB kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624768	Binding constant for SRPK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531448	Inhibition of human p38delta assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624991	Binding constant for ABL1-non phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720152	Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531270	Inhibition of human CDK9/cyclin-K assessed as residual activity at 100 uM using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1069559	Inhibition of AKT1 (unknown origin) after 30 mins	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III.
AID1664194	Inhibition of EGFR ex19del mutant (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay
AID624947	Binding constant for BRAF(V600E) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462584	Induction of apoptosis in human T47D cells assessed as viable cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 74.5 to 94.5%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1738914	Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID625022	Binding constant for MUSK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID629269	Inhibition of cKIT	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID350282	Inhibition of MINK	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1462582	Induction of apoptosis in human T47D cells assessed as late apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 3 to 13.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID435931	Binding constant for PIM1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715161	Inhibition of human STK22D using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1183891	Cytotoxicity against human primary monocytes at 0.001 to 1 uM after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID455585	Displacement of [8-3H]ATP from human recombinant phospho-MK2 (36-400) by scintillation proximity assay	2010	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1	2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
AID1164145	Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level at 1 uM by autoradiography	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
AID624800	Binding constant for IGF1R kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1691931	Inhibition of human recombinant GSK3 beta H350L mutant using YRRAAVPPSPSLSR as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1).
AID720242	Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435661	Binding constant for full-length MKNK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531255	Inhibition of human CDK14/cyclin-Y assessed as residual activity at 100 uM using RB protein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1063028	Cytotoxicity against human KE-97 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Leonurusoleanolides E-J, minor spirocyclic triterpenoids from Leonurus japonicus fruits.
AID256565	Average Binding Constant for MAP4K5; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1351038	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.25 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID164194	Inhibition of Protein kinase C zeta	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID1879140	Cytotoxicity in human HeLa cells assessed as reduction in cell viability at 0.2 to 50 uM incubated for 24 hrs by MTT assay	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Development of dihydropyrrolopyridinone-based PKN2/PRK2 chemical tools to enable drug discovery.
AID624763	Binding constant for RIPK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531852	Inhibition of human PKN1 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720069	Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715344	Inhibition of human FGFR4 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID418377	Inhibition of Pim1 in presence of 1 uM ATP	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.
AID350289	Inhibition of PKA	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID720088	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531536	Inhibition of human TAOK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1252498	Inhibition of human RAF1 by kinase inhibition assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID435804	Binding constant for LYN kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435184	Binding constant for PTK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435904	Binding constant for full-length CSK	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435678	Binding constant for MUSK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435788	Binding constant for CLK4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID241289	Inhibition of Insulin receptor kinase in P19 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1531269	Inhibition of human CDK7/cyclin-H/MNAT1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1678146	Inhibition of PKCtheta (unknown origin) at 2.5 ug/ml by HTRF assay relative to control
AID720031	Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1461684	Cytotoxic activity against human BT549 cells incubated for 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 10-01, Volume: 25, Issue:19	Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
AID1531734	Inhibition of human JAK2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID241675	Inhibitory activity against recombinant human I-kappa-B-kinase beta	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: Improvement of in vitro activity.
AID165147	Inhibition Protein kinase C (PKC)	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID152141	Inhibitory activity against Plasmodium falciparum W2	2003	Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18	Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.
AID1715237	Inhibition of human OSR1 using RRHYYYDTHTNTYYLRTFGHNTRR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720178	Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715151	Inhibition of human TAK1 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720294	Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1738923	Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human FaDu cells incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID625127	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1308938	Inhibition of ECK (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531242	Inhibition of human CAMK1D assessed as residual activity at 100 uM using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715140	Inhibition of human TNK1 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531343	Inhibition of human GRK1 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625117	Binding constant for PAK7 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435158	Binding constant for EPHA5 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID625071	Binding constant for STK39 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462522	Induction of apoptosis in human A2780 cells assessed as late apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.2 to 2.2%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID720026	Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531795	Inhibition of human MYO3A using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID350300	Inhibition of ERBB4	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID624804	Binding constant for ERBB2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1180278	Inhibition of PKC (unknown origin) using C1 peptide substrate	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Syntheses, neural protective activities, and inhibition of glycogen synthase kinase-3β of substituted quinolines.
AID1531303	Inhibition of human DYRK2 assessed as residual activity at 100 uM using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID53178	Inhibition of Cyclin-dependent kinase 1	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID1063029	Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Leonurusoleanolides E-J, minor spirocyclic triterpenoids from Leonurus japonicus fruits.
AID730003	Inhibition of c-MET tyrosine kinase (unknown origin) using [33P]-ATP at 10 uM after 20 to 40 mins by scintillation counting analysis	2013	European journal of medicinal chemistry, Mar, Volume: 61	Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
AID1531289	Inhibition of human CSK assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID377264	Inhibition of PKC	2000	Journal of natural products, Sep, Volume: 63, Issue:9	Bioactive compounds from Psorothamnus junceus.
AID406987	Induction of apoptosis in HDMEC at 2.1 uM after 5 hrs	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.
AID1350963	Inhibition of CHK1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531327	Inhibition of human FAK assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1631209	Inhibition of human recombinant JAK3 using Ulight-CAGAGAIETDKEYYTVKD as substrate by LANCE assay	2016	ACS medicinal chemistry letters, Oct-13, Volume: 7, Issue:10	Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1
AID1466332	Inhibition of KIT (unknown origin) by HTRF method	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
AID1531504	Inhibition of human RON assessed as residual activity at 100 uM using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715304	Inhibition of human KHS using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID670612	Induction of apoptosis in human HeLa cells assessed as DNA fragmentation at 2 uM after 48 hrs by agarose gel electrophoresis	2012	European journal of medicinal chemistry, Aug, Volume: 54	Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID720198	Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1350976	Inhibition of VEGFR3 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID435794	Binding constant for EPHA3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715235	Inhibition of human p38delta using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531437	Inhibition of human NEK4 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1736661	Inhibition of Aurora B (unknown origin) incubated for 1 hrs by HTRF assay	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition.
AID1462525	Induction of apoptosis in human A2780 cells assessed as early apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.7 to 2.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1594644	Antiproliferative activity against human HAP1 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1300803	Inhibition of CDK2/cyclin A (unknown origin) after 60 mins by Z-LYTE kinase assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID435203	Binding constant for TTK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID625040	Binding constant for PIK3CA(E545K) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625011	Binding constant for FGR kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531764	Inhibition of human MEK3 using p38alpha as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715247	Inhibition of human NEK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720298	Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720368	Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436032	Binding constant for MYO3B kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1285290	Inhibition of human recombinant VEGFR-2 at 1 uM after 50 mins by microtiter plate based luciferase reporter gene assay	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors.
AID1531812	Inhibition of human p38delta using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID165104	Inhibition of rat brain protein kinase C (PKC) with ATP and histone as substrates	1992	Journal of medicinal chemistry, Jan, Volume: 35, Issue:1	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.
AID435515	Binding constant for ABL1(Q252H) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531699	Inhibition of human FLT1 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID241062	Inhibition of Casein kinase 1 in P19 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID262358	Inhibition of Akt1 using 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID1531308	Inhibition of human EPHA2 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625043	Binding constant for PIK3CA(I800L) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1594647	Antiproliferative activity against human DND41 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID720312	Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID753280	Inhibition of ALK (unknown origin) at 10 uM after 30 mins by fluorescence assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological evaluation of N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides as inhibitors of angiogenesis and tumor growth.
AID720440	Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435786	Binding constant for full-length CLK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID436005	Binding constant for ANKK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720474	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1185520	Cytotoxicity against human HCT116 cells at 2 uM after 48 hrs by MTT assay relative to untreated control	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	β-amino-alcohol tethered 4-aminoquinoline-isatin conjugates: synthesis and antimalarial evaluation.
AID1531911	Inhibition of human TNK1 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531778	Inhibition of human MLK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308970	Inhibition of MUSK (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1572742	Cytostatic activity against human HL60 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1531858	Inhibition of human PLK4 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256644	Average Binding Constant for CSNK1E; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531471	Inhibition of human PKAcg assessed as residual activity at 100 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID350279	Inhibition of KDR	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID435559	Binding constant for SNARK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720352	Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715327	Inhibition of human GSK3A using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1063039	Inhibition of SRC (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID435518	Binding constant for AURKA kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435527	Binding constant for FGFR3(G697C) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531739	Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715408	Inhibition of human CDK4/cyclin-D1 using RB protein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1645916	Inhibition of Glycogen synthase kinase-3 beta (unknown origin)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review.
AID1846770	Inhibition of Aurora A(unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID1715278	Inhibition of human MEK5 using ERK5 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1183911	Induction of apoptosis in human primary monocytes assessed as nuclear fragmentation at 3 uM after 3 hrs by light microscopy	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1350994	Inhibition of PIM1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID629272	Inhibition EGFR	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID720170	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1177640	Inhibition of human aldosterone synthase expressed in V79 MZ cells assessed as inhibition of aldosterone synthesis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
AID625126	Binding constant for TAOK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720256	Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1736660	Inhibition of Aurora A (unknown origin) incubated for 1 hrs by HTRF assay	2020	European journal of medicinal chemistry, Mar-15, Volume: 190	Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition.
AID624788	Binding constant for KIT(D816H) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1664193	Inhibition of EGFR L858R/T790M mutant (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay
AID1351016	Inhibition of LCK (unknown origin) assessed as remaining activity at 5 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 89.74%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID625060	Binding constant for CAMKK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID262971	Inhibition of Akt3 at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1531883	Inhibition of human SNRK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435181	Binding constant for full-length p38-alpha	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531415	Inhibition of human MLK3 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715187	Inhibition of human RET using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID591133	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 30 mins by time resolved-fluorescent assay	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.
AID1462554	Induction of apoptosis in human MFE280 cells assessed as late apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 6 to 7.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID435652	Binding constant for EGFR(L747-E749del, A750P) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID436008	Binding constant for full-length BTK	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720147	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462572	Induction of apoptosis in human MFE296 cells assessed as viable cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 90.9 to 94.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1715241	Inhibition of human NEK5 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715294	Inhibition of human LRRK2 using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531597	Inhibition of human BRSK1 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625138	Binding constant for STK33 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1631208	Inhibition of human recombinant JAK2 using Ulight-CAGAGAIETDKEYYTVKD as substrate by LANCE assay	2016	ACS medicinal chemistry letters, Oct-13, Volume: 7, Issue:10	Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1
AID455586	Inhibition of human recombinant phospho-MK2 (36-400) by HTRF assay	2010	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1	2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
AID1715395	Inhibition of human CK1gamma1 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715193	Inhibition of human PLK2 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625037	Binding constant for PIK3CA(C420R) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID614644	Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 after 10 mins by Global fit analysis	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID1680557	Inhibition of human TIE2 using myelin basic protein as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting method	2018	Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21	Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
AID624868	Binding constant for MST1R kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624883	Binding constant for PRKCI kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531272	Inhibition of human CDK9/cyclin-T2 assessed as residual activity at 100 uM using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID280404	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP	2007	Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6	Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes.
AID1531786	Inhibition of human MSK2 using GRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715192	Inhibition of human PLK1 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1350971	Inhibition of MAPK7 catalytic domain (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531831	Inhibition of human PIM2 using RSRHSSYPAGT as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1731526	Inhibition of CDK2/Cyclin A1 (unknown origin) using histone H1 as substrate preincubated for 20 mins followed by 33P-ATP addition and measured after 2 hrs by filter binding method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Tetrahydroindazole inhibitors of CDK2/cyclin complexes.
AID1300802	Inhibition of JNK2 (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1715132	Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1779109	Induction of apoptosis in VEGF-stimulated HUVEC cells assessed as increase in cleaved caspase-3 protein expression at 250 nM measured after 48 hrs by western blot analysis	2021	Journal of natural products, 06-25, Volume: 84, Issue:6	Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway.
AID720406	Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID262984	Activity against GSK3 phosphorylation in FL5.12-Akt1 cells	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID624707	Binding constant for DCAMKL3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715277	Inhibition of human MEKK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID695570	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors.
AID1462581	Induction of apoptosis in human T47D cells assessed as early apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.6 to 4.3%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID256642	Average Binding Constant for VEGFR2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624847	Binding constant for CSNK1E kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID256672	Average Binding Constant for CAMK2G; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715397	Inhibition of human CK1a1 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1308972	Inhibition of PDGFRalpha (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531328	Inhibition of human FER assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531384	Inhibition of human LIMK2 assessed as residual activity at 100 uM using cofilin as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1055894	Cytotoxicity against human NCI-H69 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID1689704	Induction of apoptosis in human RPMI-8226 cells assessed as Caspase-3 level incubated for 24 hrs by ELISA (Rvb = 35.3 pg/ml)	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
AID695571	Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors.
AID269868	Inhibition of GSK3	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID435777	Binding constant for ABL2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531882	Inhibition of human SNARK using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID600821	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Marianins A and B, prenylated phenylpropanoids from Mariannaea camptospora.
AID720074	Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID303312	Inhibition of Abl kinase at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID629276	Inhibition of FGFR3	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1531787	Inhibition of human MSSK1 using GRSRSRSRSR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720180	Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720437	Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531322	Inhibition of human ERK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531675	Inhibition of human EPHA5 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256670	Average Binding Constant for ABL1(T315I); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624825	Binding constant for BMPR1B kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435828	Binding constant for full-length PIP5K2B	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435657	Binding constant for full-length IKK-epsilon	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID688344	Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID624956	Binding constant for EPHB4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1461682	Cytotoxic activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 10-01, Volume: 25, Issue:19	Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
AID1531896	Inhibition of human STK38L using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531550	Inhibition of human TRKC assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531646	Inhibition of human CK2A using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720345	Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435192	Binding constant for ROS1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1439518	Inhibition of Alexa647 tracer binding to full length recombinant human His-tagged CDK8/Cyclin C expressed in baculovirus expression system at 0.5 uM preincubated for 20 mins followed by tracer addition measured after 60 mins by TR-FRET based Lanthascreen	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
AID1481083	Inhibition of human SYK using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1531612	Inhibition of human CAMK4 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715424	Inhibition of human CAMK4 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1191824	Inhibition of N-terminal His-tagged recombinant JAK2 (unknown origin) by HTRF assay	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
AID720018	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID595222	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Maklamicin, an antibacterial polyketide from an endophytic Micromonospora sp.
AID629398	Inhibition of MEK1	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID720379	Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308963	Inhibition of JAK2 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1715127	Inhibition of human WNK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435432	Binding constant for MLK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID256611	Average Binding Constant for RIPK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID303318	Inhibition of EphB4 at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID625100	Binding constant for NLK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1738920	Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human HT29 cells incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1572738	Cytostatic activity against human Capan1 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID435656	Binding constant for FGFR4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720347	Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1191827	Inhibition of Drak2 (unknown origin) by ADP-GLO kinase assay	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
AID1531468	Inhibition of human PIM3 assessed as residual activity at 100 uM using RSRHSSYPAGT as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531788	Inhibition of human MST1 using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1760628	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID427619	Inhibition of recombinant GST-GSK3beta expressed in Escherichia coli BL21 (DE3)	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
AID624891	Binding constant for JNK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID767307	Inhibition of CDK5/p25 (unknown origin)-mediated incorporation of gamma33P into substrate after 20 mins by scintillation counting analysis in presence of 33P-ATP	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Potential neuroprotective flavonoid-based inhibitors of CDK5/p25 from Rhus parviflora.
AID1308984	Inhibition of TRKA (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1715257	Inhibition of human MSSK1 using GRSRSRSRSR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435310	Binding constant for FLT3(ITD) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531707	Inhibition of human GRK1 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720358	Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435523	Binding constant for CIT kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID634151	Cytotoxicity against rat PC12 cells assessed as cell viability at 1 uM after 24 hrs by MTT assay	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	C-terminal tetrapeptides inhibit Aβ42-induced neurotoxicity primarily through specific interaction at the N-terminus of Aβ42.
AID624843	Binding constant for CAMK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624792	Binding constant for KIT(V559D,T670I) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531423	Inhibition of human MSSK1 assessed as residual activity at 100 uM using GRSRSRSRSR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435802	Binding constant for KIT(V559D,V654A) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531824	Inhibition of human PDGFRalpha using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1450413	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.
AID1277454	Induction of apoptosis in mouse B16F10 cells at 0.1 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines.
AID1531283	Inhibition of human CK2A2 assessed as residual activity at 100 uM using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625007	Binding constant for EGFR(T790M) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720361	Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID614643	Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID1531323	Inhibition of human ERK5 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1612690	Inhibition of human ARK5 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID435533	Binding constant for NEK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531486	Inhibition of human PKG1beta assessed as residual activity at 100 uM using LRRASLG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1247626	Inhibition of FAK (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID720424	Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1252646	Induction of apoptosis in human U251MG cells assessed as PARP level at 0.5 to 10 nM after 24 to 48 hrs by immunoblot analysis	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma.
AID1531293	Inhibition of human DCAMKL1 assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531908	Inhibition of human TLK1 using Histone H3 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1063051	Inhibition of ARK5 (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1531243	Inhibition of human CAMK1G assessed as residual activity at 100 uM using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531382	Inhibition of human LCK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256649	Average Binding Constant for CSK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531760	Inhibition of human MARK3 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715291	Inhibition of human MAK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435937	Binding constant for TESK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID591131	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 5 mins by time resolved-fluorescent assay	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.
AID350257	Inhibition of CHK1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID436006	Binding constant for full-length AURKC	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1689706	Induction of apoptosis in human RPMI-8226 cells assessed as Caspase-9 level incubated for 24 hrs by ELISA (Rvb = 1.63 +/- 0.102 ng/ml)	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
AID435689	Binding constant for full-length PFTK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720292	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID494389	Inhibition of human GSK3-beta	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID1531753	Inhibition of human LYN-B using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531256	Inhibition of human CDK16/cyclin-Y assessed as residual activity at 100 uM using RB protein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1689469	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under normoxic condition by MTT assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
AID1770390	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID625032	Binding constant for TRKB kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1351045	Inhibition of FMS (unknown origin) assessed as remaining activity at 7.63 x 10'-11 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID720136	Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531813	Inhibition of human p38gamma using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1185521	Cytotoxicity against human HCT116 cells at 20 uM after 48 hrs by MTT assay relative to untreated control	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	β-amino-alcohol tethered 4-aminoquinoline-isatin conjugates: synthesis and antimalarial evaluation.
AID1531626	Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256572	Average Binding Constant for STK36; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1687404	Inhibition of human AKT assessed as inhibition of substrate phosphorylation using AKTide-2T as substrate
AID1865708	Inhibition of human VEGFR2 in HUVEC cells assessed as reduction in VEGFR2 phosphorylation at 10 uM incubated for 30 mins by anti-phospho VEGF Tyr 1175 antibody based assay relative to control	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks.
AID699808	Inhibition of MAPKAP-K2 using KKLNRTLSVA as substrate and [33P]-gamma-ATP after 30 mins by liquid scintillation counter	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach.
AID1531639	Inhibition of human CK1a1 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435941	Binding constant for ZAK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1351020	Inhibition of LCK (unknown origin) assessed as remaining activity at 1.95 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 89.74%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID435660	Binding constant for full-length MELK	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1308932	Inhibition of Aurora A (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531926	Inhibition of human VRK2 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1846776	Inhibition of SYK (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID720148	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720110	Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531493	Inhibition of human PLK3 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720080	Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720090	Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1410151	Inhibition of GSK3b (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID1664191	Selectivity index, ratio of IC50 for wild type EGFR (unknown origin) to IC50 for HER4 (unknown origin) by radioisotope filter binding assay
AID1610357	Inhibition of recombinant human GST-tagged PLK3 (58 to 340 residues) expressed in baculovirus expression system using ser/thr 16 as substrate incubated for 1 hr by Z'-LYTE assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
AID624775	Binding constant for STK16 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1394682	Inhibition of recombinant human CDK1/Cyclin B using Ulight-CFFKNIVTPRTPPPSQGK-amide as substrate measured after 15 mins by LANCE assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
AID720115	Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1368766	Inhibition of human GSK-3beta using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Discovery of new GSK-3β inhibitors through structure-based virtual screening.
AID327000	Inhibition of Pim2 kinase	2008	Journal of natural products, Mar, Volume: 71, Issue:3	Pim2 inhibitors from the Papua New Guinean plant Cupaniopsis macropetala.
AID624796	Binding constant for MET(Y1235D) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435170	Binding constant for MYO3A kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624735	Binding constant for ANKK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720234	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531855	Inhibition of human PLK1 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624783	Binding constant for FGFR3(G697C) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1252500	Inhibition of human Src kinase by kinase inhibition assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID126621	Inhibition of Mitogen activated protein kinase kinase 1	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID1531737	Inhibition of human JNK2 using ATF2 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720439	Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720189	Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531645	Inhibition of human CK1gamma3 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715410	Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1287705	Cytotoxicity in human SEM cells assessed as cell death at 1 uM after 24 hrs	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID1531212	Inhibition of human AKT2 assessed as residual activity at 100 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308941	Inhibition of EGFR T790M mutant (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1680243	Inhibition of human FGFR4 using using myelin basic protein as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting method	2018	Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21	Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
AID435693	Binding constant for TGFBR2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531912	Inhibition of human TRKA using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624958	Binding constant for PIK3C2G kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531455	Inhibition of human PAK4 assessed as residual activity at 100 uM using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435551	Binding constant for full-length p38-beta	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1902781	Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability by MTT assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Discovery of new carbonic anhydrase IX inhibitors as anticancer agents by toning the hydrophobic and hydrophilic rims of the active site to encounter the dual-tail approach.
AID624993	Binding constant for ABL2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720332	Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531859	Inhibition of human PRKX using LRRASLG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531572	Inhibition of human ABL1 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624857	Binding constant for HCK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1543905	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID720293	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1351037	Inhibition of FMS (unknown origin) assessed as remaining activity at 5 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1462565	Induction of apoptosis in human MFE296 cells assessed as early apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.5 to 2.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID614641	Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID435289	Binding constant for ERK3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720132	Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624793	Binding constant for KIT(V559D,V654A) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID445087	Displacement of N,N'-(2,2'-(3,3'-disulfanediylbis(2,5-dioxopyrrolidine-3,1-diyl))bis(ethane-2,1-diyl))bis(2-(3-(3-tert-butyl-5-(3-naphthalen-1-ylureido)-1H-pyrazol-1-yl)phenylamino)acetamide) from inactive form of p38alpha expressed in Escherichia coli BL	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Displacement assay for the detection of stabilizers of inactive kinase conformations.
AID1732378	Inhibition of BRAF V600E mutant (unknown origin) using Ser/Thr 03 as substrate after 1 hr in presence of ATP by Z'-LYTE assay
AID435429	Binding constant for FLT1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1408884	Cytotoxicity against human HeLa cells assessed as cell viability at 1 uM after 3 days by XTT assay relative to control	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
AID625088	Binding constant for ARK5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720191	Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1055891	Cytotoxicity against human NCI-N87 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID350268	Inhibition of FGFR2	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1531918	Inhibition of human TTBK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1410146	Inhibition of ALK (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID720419	Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720463	Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1381810	Induction of apoptosis in human SUP-B15 cells assessed as late apoptotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.2%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID625099	Binding constant for TAOK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435324	Binding constant for full-length RIOK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720339	Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624803	Binding constant for CHEK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID256606	Average Binding Constant for STK16; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435775	Binding constant for ABL1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531784	Inhibition of human MRCKbeta using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531782	Inhibition of human MNK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625085	Binding constant for ULK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462524	Induction of apoptosis in human A2780 cells assessed as viable cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 95 to 96.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1530828	Inhibition of human full length N-terminal GST tagged CHK1 assessed as residual activity at 1.95 10'-8M (Rvb = 96.94 to 103.06%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435191	Binding constant for full-length RIOK3	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1381821	Cell cycle arrest in human KOPN8 cells assessed as accumulation at G0/G1 phase at 2 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 24.77%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID720328	Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID664020	Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis, biological evaluation and molecular docking studies of novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone derivatives.
AID720185	Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID625107	Binding constant for DMPK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531732	Inhibition of human ITK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720146	Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531846	Inhibition of human PKCtheta using Histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1532730	Induction of apoptosis in human HCT116 cells assessed as viable cells at 1 uM after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry method (Rvb = 86.0%)	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID1294630	Inhibition of human Aurora B using H-LRRASLG as substrate after 2 hrs by HotSpot assay in presence of 33P-ATP and 10 uM ATP	2016	Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9	Design, synthesis, and evaluation of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives as Aurora kinase inhibitors.
AID1531906	Inhibition of human TGFBR2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID745527	Inhibition of CDK2/Cyclin A1 (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID1484288	Induction of apoptosis in human PC3 cells assessed as viable cells at 5 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 95%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID1531405	Inhibition of human MEKK6 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID436033	Binding constant for PIK3CA kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID436045	Binding constant for PRKD1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531722	Inhibition of human HIPK4 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256659	Average Binding Constant for DAPK3; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435829	Binding constant for RPS6KA1(Kin.Dom.2 - C-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531594	Inhibition of human BMX using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1350993	Inhibition of PHKg2 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1715437	Inhibition of human BRSK2 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1308948	Inhibition of FES (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1500587	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 2 days by cell-titer-glo luminescent assay	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	The antitrypanosomal and antitubercular activity of some nitro(triazole/imidazole)-based aromatic amines.
AID1736066	Inhibition of recombinant human PAK4 kinase domain (300 to 591 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate using serine/threonine-20 peptide as substrate at 0.5 uM incubated for 60 mins in presence of ATP by FRET based Z	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor.
AID1715210	Inhibition of human PKCb2 using Histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1846286	Inhibition of PKC (unknown origin)	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Recent advances in development of hetero-bivalent kinase inhibitors.
AID1531413	Inhibition of human MLK1 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720059	Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435396	Binding constant for CHEK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435822	Binding constant for MEK4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715315	Inhibition of human IR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1266906	Competitive inhibition of glycogen synthase kinase-3 beta (unknown origin) using GS-1 as substrate after 30 mins by scintillation counting analysis in presence of [gamma-32P]-ATP	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
AID435412	Binding constant for MAP3K5 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID303327	Inhibition of SYK at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID1531667	Inhibition of human DYRK2 using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720174	Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720282	Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID164947	Inhibition of human neutrophil protein kinase C (PKC)	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID1300790	Inhibition of PDK1 (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1623700	Induction of apoptosis in human KOPN8 cells assessed as late apoptotic cells level at 2 uM after 24 hrs by Annexin V and propidium iodide staining based flow cytometry (Rvb = 96.4%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID435516	Binding constant for ADCK3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531364	Inhibition of human IR assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715156	Inhibition of human STK32C using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1471757	Inhibition of recombinant human ALK L1152R mutant (1093 to 1411 residues) expressed in baculovirus expression system using 5'FAM-KKSRGDYMTMQIG-CONH as substrate preincubated for 15 mins followed by addition of ATP measured after 1 hr by microfluidic mobil	2017	Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.
AID720042	Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531317	Inhibition of human EPHB3 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715450	Inhibition of human ALK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID415623	Selectivity ratio of IC50 for CDK3/cyclin E to IC50 for human GSK3-beta	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID1531511	Inhibition of human SGK1 assessed as residual activity at 100 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531464	Inhibition of human PHKgamma1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID657571	Inhibition of bovine brain FAK after 20 mins by turbidimetry	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
AID720066	Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1279101	Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by addition of substrate by mobility shift assay	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors.
AID1531240	Inhibition of human CAMK1A assessed as residual activity at 100 uM using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID280402	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP	2007	Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6	Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes.
AID1846772	Inhibition of c-MET (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID1368680	Inhibition of human MAPKAPK2 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1865711	Inhibition of human VEGFR2 in HUVEC cells assessed as reduction in VEGFR2 phosphorylation incubated for 30 mins by anti-phospho VEGF Tyr 1175 antibody based assay	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks.
AID435400	Binding constant for DDR1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624814	Binding constant for DCAMKL2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID350253	Inhibition of BTK	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1531641	Inhibition of human CK1D using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1572740	Cytostatic activity against human NCI-H460 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1631207	Inhibition of human recombinant JAK1 using Ulight-CAGAGAIETDKEYYTVKD as substrate by LANCE assay	2016	ACS medicinal chemistry letters, Oct-13, Volume: 7, Issue:10	Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1
AID1531287	Inhibition of human CLK4 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531494	Inhibition of human PLK4 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720407	Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID262364	Inhibition of PKA using 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID256612	Average Binding Constant for GAK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715312	Inhibition of human IRAK4 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID640590	Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity.
AID1055898	Cytotoxicity against human U937 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID720449	Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1356598	Inhibition of N-terminal FLAG-tagged human full-length CDK12 (1 to 1490 residues)/N-terminal His-tagged CycK (1 to 580 residues) expressed in Sf9 cells assessed as reduction in ATP-dependent ULight-4E-BP1 (Thr37/Thr46) substrate peptide phosphorylation pr	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
AID1531851	Inhibition of human PKG2 using LRRASLG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625036	Binding constant for PIK3CA kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720414	Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1572741	Cytostatic activity against human DND41 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID624969	Binding constant for ROCK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720372	Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715153	Inhibition of human SYK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID612259	Inhibition of VEGFR2 at 50 uM after 1 hr	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.
AID1531490	Inhibition of human PKN3 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1666673	Induction of apoptosis in human MCF7 cells assessed as up regulation of caspase 9 expression by measuring caspase 9 level by ELISA (Rvb = 1.223 ng/ml)	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
AID1612682	Inhibition of human MST3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID720420	Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531581	Inhibition of human ALK3 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435395	Binding constant for CDC2L1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1394736	Inhibition of recombinant human AKT1 expressed in insect cells using CREBtide as substrate after 60 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID624852	Binding constant for FES kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625094	Binding constant for CDK11 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624942	Binding constant for DRAK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID629271	Inhibition cSRC	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1324447	Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay
AID256575	Average Binding Constant for NEK6; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531749	Inhibition of human LKB1 using LSNLYHQGKFLQTFCGSPLYRRR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435821	Binding constant for GAK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID256605	Average Binding Constant for STK17B; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1351006	Inhibition of LCK (unknown origin) after 120 mins in presence of 33P-ATP	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID256647	Average Binding Constant for SYK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID438441	Inhibition of Fyn	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Structural basis for the inhibitor recognition of human Lyn kinase domain.
AID1481085	Inhibition of human YES/YES1 using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1504784	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Platanic acid: A new scaffold for the synthesis of cytotoxic agents.
AID417303	Cytotoxicity against mouse MC3T3-E1 cells assessed as increase in apoptosis treated for 3 hrs measured after 22 hrs by caspase 3 colorimetric assay	2009	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5	Small molecules with potent osteogenic-inducing activity in osteoblast cells.
AID1068656	Inhibition of BRAF1 (unknown origin)	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.
AID720048	Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462527	Induction of apoptosis in human A2780 cells assessed as nuclear debris at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.3 to 1.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531226	Inhibition of human Aurora C assessed as residual activity at 100 uM using [H-LRRASLG] as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715297	Inhibition of human LIMK2 using cofilin as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531473	Inhibition of human PKCb1 assessed as residual activity at 100 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531457	Inhibition of human PAK6 assessed as residual activity at 100 uM using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624979	Binding constant for ABL1(F317I)-non phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720480	Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID629273	Inhibition of ERK2	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1715165	Inhibition of human SRPK1 using GRSRSRSRSR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1736065	Inhibition of recombinant human PAK4 kinase domain (300 to 591 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate using serine/threonine-20 peptide as substrate at 5 uM incubated for 60 mins in presence of ATP by FRET based Z'-	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor.
AID1287698	Induction of apoptosis in human SEM cells assessed as activated caspase3 levels at 0.5 uM after 6 hrs by immunoblot analysis	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID1538680	Induction of mitochondrial membrane potential loss in human DU145 cells after 2 hrs by JC1 staining based fluorescence assay	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Caspase-Dependent Apoptosis in Prostate Cancer Cells and Zebrafish by Corchorusoside C from Streptocaulon juventas.
AID1531791	Inhibition of human MST4 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1368670	Inhibition of human CDK2 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID436034	Binding constant for PRKCH kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531656	Inhibition of human DAPK2 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625134	Binding constant for PIP5K2C kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1252648	Induction of apoptosis in human U251MG cells assessed as cleaved caspase 3 level at 0.5 to 10 nM after 24 to 48 hrs by immunoblot analysis	2015	Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19	Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma.
AID262974	Inhibition of PKCdelta at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID625096	Binding constant for STK36 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1285291	Inhibition of human recombinant EGFR at 1 uM after 50 mins by microtiter plate based luciferase reporter gene assay	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors.
AID1704868	Inhibition of human N-terminal GST-HIS6 fused CCDC6-RET fusion protein (Met1 to Ser503 residues) expressed in Sf9 insect cells using TRK-C-derived peptide as substrate in presence of [33P]-ATP by filter binding assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
AID1531821	Inhibition of human PAK6 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1385654	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2018	Journal of natural products, 08-24, Volume: 81, Issue:8	Staurosporine Derivatives Generated by Pathway Engineering in a Heterologous Host and Their Cytotoxic Selectivity.
AID1350986	Inhibition of MINK1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1704867	Inhibition of recombinant human N-terminal GST-HIS6 fused RET V804M mutant C-terminal domain (H658 to S1114 residues) expressed in Sf9 insect cells using TRK-C-derived peptide as substrate in presence of [33P]-ATP by filter binding assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
AID720231	Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1691932	Inhibition of human recombinant TYK2 (875 to end residues) using GGMEDIYFEFMGG as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1).
AID720190	Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256638	Average Binding Constant for PRKAA1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720164	Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID767336	Inhibition of VEGFR2 (unknown origin) at 50 uM after 1 hr by luminescence assay relative to control	2013	Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18	Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
AID1764190	Inhibition of DYRK1B (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors.
AID256645	Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1889869	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
AID720353	Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715305	Inhibition of human JNK2 using ATF2 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1635582	Inhibition of human N-terminal GST-tagged FLT3 (564 to 993 residues) expressed in baculovirus expression system using peptide FAM-P2 as substrate incubated for 10 mins followed by substrate addition by mobility shift assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
AID1481072	Inhibition of human CDK4/cyclinD1 using RB-CTF as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID436014	Binding constant for full-length DYRK1B	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID256559	Average Binding Constant for EPHB4; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435805	Binding constant for MAP4K5 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID269860	Inhibition of AKT2	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID624997	Binding constant for EGFR(E746-A750del) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715205	Inhibition of human PKCiota using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID721050	Inhibition of TNIK (unknown origin) by ADP glo luminescent assay	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors.
AID624721	Binding constant for MEK5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1394745	Inhibition of recombinant human IGF1R using Ulight-TK peptide as substrate after 60 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID435414	Binding constant for MLK3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1287691	Induction of apoptosis in human NALM6 cells assessed as activated caspase3 level at 0.5 uM after 3 hrs by immunoblot analysis	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID435528	Binding constant for IRAK3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720276	Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720371	Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715335	Inhibition of human GLK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435328	Binding constant for YES kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1090403	Antioomycete activity against Phytophthora capsici zoospores suspension infected in pepper plants (cv. Hanbyul) at first branch stage pre-exposed to compound spray on stems before fungal infection assessed as reduction in Phyophthora blight disease severi	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1187632	Induction of apoptosis in human HL60 cells assessed as late apoptosis level at 0.2 uM after 24 hrs by Annexin V-PE and 7-AAD staining based flow cytometry (Rvb = 3.3%)	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Cytotoxic activity of butane type of 1,7-seco-2,7'-cyclolignanes and apoptosis induction by Caspase 9 and 3.
AID262373	Antiproliferative activity against FL5.12-Akt1 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID1061210	Inhibition of recombinant AKT1 (unknown origin) using serine/threonine 06 peptide as substrate after 1 hr by FRET based Z'-LYTE assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Preparation and evaluation of deconstruction analogues of 7-deoxykalafungin as AKT kinase inhibitors.
AID1846287	Inhibition of CaMKII (unknown origin)	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Recent advances in development of hetero-bivalent kinase inhibitors.
AID1531403	Inhibition of human MEKK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531233	Inhibition of human BRSK1 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1889866	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
AID102199	Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Synthesis and biological evaluation of novel bisindolylmaleimides that inhibit vascular endothelial cell proliferation.
AID1502655	Antiproliferative activity against mouse L929 cells after 5 days by WST-1 assay	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Oxidation of the Meroterpenoid (-)-Terreumol C from the Mushroom Tricholoma terreum: Discovery of Cytotoxic Analogues.
AID1348852	Selectivity index, ratio of IC50 for human recombinant full length His-tagged Plk1 expressed in baculovirus expression system to IC50 for human recombinant full length GST-tagged Plk2 expressed in baculovirus expression system	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold.
AID1531598	Inhibition of human BRSK2 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624714	Binding constant for p38-alpha kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435658	Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID303319	Inhibition of FAK at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID1531416	Inhibition of human MLK4 assessed as residual activity at 100 uM using MEK1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1594643	Antiproliferative activity against human Capan1 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1531385	Inhibition of human LKB1 assessed as residual activity at 100 uM using LSNLYHQGKFLQTFCGSPLYRRR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1727475	Cytotoxicity against human A-375 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Cytotoxic triterpenoid-safirinium conjugates target the endoplasmic reticulum.
AID625034	Binding constant for PDGFRA kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715188	Inhibition of human PYK2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531340	Inhibition of human FYN assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531582	Inhibition of human ALK4 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1471755	Inhibition of recombinant human ALK F1174L mutant (1093 to 1411 residues) expressed in baculovirus expression system using 5'FAM-KKSRGDYMTMQIG-CONH as substrate preincubated for 15 mins followed by addition of ATP measured after 1 hr by microfluidic mobil	2017	Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.
AID435283	Binding constant for DAPK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715356	Inhibition of human ERK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID224439	Inhibition of human p60 c-src	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID1760625	Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID435440	Binding constant for PIM2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715439	Inhibition of human BRSK1 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1356599	Inhibition of GST-tagged human CDK9/CycT1 (04 to 110 residues) assessed as reduction in ATP-dependent ULight-4E-BP1 (Thr37/Thr46) substrate peptide phosphorylation pre-incubated for 60 mins by LANCE Ultra assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
AID1770394	Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID625001	Binding constant for EGFR(L747-S752del, P753S) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720253	Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256627	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435798	Binding constant for FGR kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531864	Inhibition of human RIPK3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1189700	Inhibition of telomerase in human HepG2 cells at 1 to 4 uM after 1 to 3 days by TRAP-ELISA method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID435823	Binding constant for full-length PAK3	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1063048	Inhibition of FAK (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1247622	Inhibition of CDK1/cyclin B (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1063049	Inhibition of aurora-B (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID256607	Average Binding Constant for STK18; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715163	Inhibition of human SRPK2 using GRSRSRSRSR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435650	Binding constant for full-length CSNK1E	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1462552	Induction of apoptosis in human MFE280 cells assessed as viable cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 84.9 to 87.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID729551	Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells at 10 uM by TR-FRET based binding assay	2013	European journal of medicinal chemistry, Mar, Volume: 61	Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
AID1531933	Inhibition of human ZAK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435522	Binding constant for CDK11 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624923	Binding constant for MAPKAPK5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715347	Inhibition of human FGFR1 using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624827	Binding constant for CAMK2B kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715219	Inhibition of human PHKgamma1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1287685	Induction of apoptosis in human NALM6 cells assessed as necrotic cells at 0.5 uM measured after 24 hrs by annexin V-propidium iodide staining based flow cytometric analysis (Rvb = 0.0%)	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID435150	Binding constant for ARK5 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715285	Inhibition of human MARK3 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531669	Inhibition of human DYRK4 using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID165106	Inhibition of rat brain protein kinase C(PKC) in 10%DMSO.	1992	Journal of medicinal chemistry, Jan, Volume: 35, Issue:1	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.
AID720290	Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1090412	Antimicrobial activity against Fusarium oxysporum f. sp. lycopersici assessed as growth inhibition incubated for 4 to 7 days	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID606032	Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Resorcylic acid lactones with cytotoxic and NF-κB inhibitory activities and their structure-activity relationships.
AID1531525	Inhibition of human STK21 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531708	Inhibition of human GRK2 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720287	Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720107	Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531275	Inhibition of human CK1a1 assessed as residual activity at 100 uM using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308968	Inhibition of LYNA (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1484292	Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 10 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 2 to 3%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID720336	Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624742	Binding constant for NEK5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531239	Inhibition of human c-SRC assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435443	Binding constant for TXK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1491365	Binding affinity to BACE1 (unknown origin) by SPR method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	2-Substituted-thio-N-(4-substituted-thiazol/1H-imidazol-2-yl)acetamides as BACE1 inhibitors: Synthesis, biological evaluation and docking studies.
AID624743	Binding constant for LTK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1368671	Inhibition of human CHK1 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID262983	Inhibition of SRC kinase at 1.0 mM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1183916	Induction of necrosis in human primary monocytes at 3 uM by PE Annexin V and 7-aminoactinomycin staining based flow cytometry	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID494407	Inhibition of TYRO3/SKY	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID622358	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents.
AID1402961	Inhibition of recombinant human C-terminal His/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells at 100 nM using biotin-labeled poly[Glu:Tyr] (4:1) as substrate after 30 mins by Kinase-Glo plus luminescence assa	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID624716	Binding constant for CSNK1D kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID664021	Inhibition of bovine brain FAK after 20 mins by turbidimetry	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis, biological evaluation and molecular docking studies of novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone derivatives.
AID720349	Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID385590	Inhibition of human PKCgamma	2007	The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45	Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID625074	Binding constant for IKK-epsilon kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1466334	Inhibition of RET (unknown origin) by HTRF method	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
AID350286	Inhibition of PDGFRalpha	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1715398	Inhibition of human CHK2 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1770391	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID1680981	Induction of mitochondrial membrane potential loss in human Jurkat cells assessed as alife cells at 200 nM after 4 hrs by MitoSense Red/7-AAD. flow cytometric analysis (Rvb = 98.47%)	2020	Journal of natural products, 08-28, Volume: 83, Issue:8	Total Synthesis of Natural Lembehyne C and Investigation of Its Cytotoxic Properties.
AID1531436	Inhibition of human NEK3 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1055890	Cytotoxicity against human 786-O cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID720435	Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1671731	Antiproliferative activity against human HCT116 cells assessed as cell viability at 2 uM after 48 hrs by CellTiter96 AQueous assay relative to control	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
AID1715206	Inhibition of human PKCgamma using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256570	Average Binding Constant for PIM2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID350299	Inhibition of Trk-A	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID280400	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP	2007	Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6	Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes.
AID720179	Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID389371	Inhibition of IL2 production in PHA-stimulated human whole blood after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
AID1066420	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	2014	European journal of medicinal chemistry, Jan-24, Volume: 72	The chemical and biological potential of C ring modified triterpenoids.
AID723732	Stabilization of CDK2/Cyclin A (174 to 432 amino acid residues) (unknown origin) assessed as change in melting temperature at 20 uM by differential scanning fluorimetry assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
AID1543903	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID350255	Inhibition of CDK1/cyclinB	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID720418	Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531776	Inhibition of human MLCK2 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531940	Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720157	Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715281	Inhibition of human MEK1 using ERK2 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID303328	Inhibition of TEC at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID1531611	Inhibition of human CAMK2G using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624745	Binding constant for PKN1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720391	Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715295	Inhibition of human LKB1 using LSNLYHQGKFLQTFCGSPLYRRR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID611837	Inhibition of PDGFR-beta at 50 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID126765	Inhibition of Mitogen activated protein kinase kinase 6	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID1368685	Inhibition of human TAK1 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID205343	Inhibition of Src protein tyrosine kinase	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID1531524	Inhibition of human STK16 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715150	Inhibition of human TAOK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1156594	Inhibition of CDK4/cyclin D1 (unknown origin) at 1 uM after 20 to 30 mins by scintillation counting analysis relative to control	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antitumor activity of pyrido [2,3-d]pyrimidine and pyrido[2,3-d] [1,2,4]triazolo[4,3-a]pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest.
AID1531541	Inhibition of human TESK1 assessed as residual activity at 100 uM using cofilin as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624845	Binding constant for CDK7 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462570	Induction of apoptosis in human MFE296 cells assessed as late apoptotic cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 3.6 to 6.6%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531363	Inhibition of human IKKepsilon assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1612688	Inhibition of human haspin using Histone H3 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID536058	Inhibition of EGF-induced MEK5 activity in HEK293 cells assessed as phosphorylated ERK5 level at 10 uM after 1 hr by Western blotting relative to control	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Structure-activity relationships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5 signaling pathway.
AID1715440	Inhibition of human BRK using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID262985	Antiproliferative activity against Akt1 overexpressing murine FL5.12-Akt1 cell	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1889868	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
AID256661	Average Binding Constant for PDGFRB; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531835	Inhibition of human PKAcg using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1365700	Cytotoxicity against African green monkey Vero cells after 2 days by CellTiter-Glo luminescent cell viability assay	2017	Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21	The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID536056	Inhibition of EGF-induced MEK1/2 activity in HEK293 cells assessed as phosphorylated ERK1/2 level at 10 uM after 1 hr by Western blotting relative to control	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Structure-activity relationships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5 signaling pathway.
AID720101	Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1481654	Inhibition of human PIM3 using RSRHSSYPAGT as substrate in presence of [gamma-33P]-ATP
AID1715385	Inhibition of human DAPK1 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1887906	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
AID1531683	Inhibition of human ERBB2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308974	Inhibition of PKCalpha (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1462553	Induction of apoptosis in human MFE280 cells assessed as early apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 5.1 to 6.2%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531311	Inhibition of human EPHA5 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID163687	Inhibition of Protein kinase C epsilon	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID775337	Binding affinity to human MLK3	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
AID624794	Binding constant for MET kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715422	Inhibition of human CAMKK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435558	Binding constant for RPS6KA3(Kin.Dom.1 - N-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435897	Binding constant for ABL1(T315I) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720410	Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531393	Inhibition of human MAPKAPK5 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715204	Inhibition of human PKCmu using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1287715	Induction of apoptosis in human SEM cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by annexin V-propidium iodide staining based flow cytometric analysis (Rvb = 85.3%)	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID624879	Binding constant for PIK3CG kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1066421	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	2014	European journal of medicinal chemistry, Jan-24, Volume: 72	The chemical and biological potential of C ring modified triterpenoids.
AID435545	Binding constant for NEK6 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1300785	Inhibition of Akt3 (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1368668	Inhibition of human Aurora A at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID435932	Binding constant for PKAC-alpha kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID494400	Inhibition of CK1alpha1	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID1531444	Inhibition of human NLK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID611913	Inhibition of PDGFR-beta at 20 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID720392	Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID163706	Inhibition of Protein kinase C epsilon	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID1298809	Inhibition of human recombinant JAK3 assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation at 10 uM pre-incubated before substrate addition and measured after 60 mins by LANCE detection method	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
AID720400	Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715141	Inhibition of human TLK2 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1287686	Induction of apoptosis in human NALM6 cells assessed as late apoptotic cells at 0.5 uM measured after 24 hrs by annexin V-propidium iodide staining based flow cytometric analysis (Rvb = 4.3%)	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID1531694	Inhibition of human FGFR1 using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1394738	Inhibition of recombinant human CDK1/Cyclin B expressed in insect cells using Ulight-CFFKNIVTPRTPPPSQGK-amide as substrate after 15 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID624832	Binding constant for IKK-alpha kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID627292	Inhibition of c-Met using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1531530	Inhibition of human STK33 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID71178	Inhibition of Extracellular signal-regulated kinase 2 (Erk2)	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID1531376	Inhibition of human KHS assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID418378	Inhibition of Pim1	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.
AID1612677	Inhibition of human JNK1 using ATF2 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID1715414	Inhibition of human CDK18/cyclin-Y using RB protein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435691	Binding constant for SgK085 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531214	Inhibition of human ALK assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID627128	Inhibition of CHK2 using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1531927	Inhibition of human WEE1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID415627	Selectivity ratio of IC50 for CDK6/cyclin D3 to IC50 for human GSK3-beta	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID1715152	Inhibition of human STK39 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID163361	Inhibition of Protein kinase C beta 2	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID624998	Binding constant for EGFR(G719C) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720196	Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435906	Binding constant for EGFR(L747-T751del,Sins) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1727479	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Cytotoxic triterpenoid-safirinium conjugates target the endoplasmic reticulum.
AID1778250	Inhibition of human NADPH oxidase 4 by quantitative sandwich enzyme immunoassay technique	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Beyond direct Nrf2 activation; reinvestigating 1,2,4-oxadiazole scaffold as a master key unlocking the antioxidant cellular machinery for cancer therapy.
AID1715215	Inhibition of human PKA using LCGRTGRRNSI as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715413	Inhibition of human CDK2/cyclin-A using histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531351	Inhibition of human GSK3B assessed as residual activity at 100 uM using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1359962	Inhibition of recombinant human Pim1 expressed in bacterial expression system using histone H1 as substrate after 30 mins by ADP-Glo reagent based luminescence assay	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.
AID1760629	Antiproliferative activity against human DND41 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID625124	Binding constant for RET(V804M) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID164630	Inhibition of Protein kinase A	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID625112	Binding constant for YANK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1725214	Cytotoxicity against hTERT-immortalized human OKF6 cells assessed as small and rounded cell morphology at 8 uM incubated for 24 hrs by trypan blue dye based light inverted microscopic analysis
AID1531713	Inhibition of human GRK7 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308943	Inhibition of EPHA1 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1715379	Inhibition of human DLK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624948	Binding constant for CSK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435529	Binding constant for LATS1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720468	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531752	Inhibition of human LYN using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462532	Induction of apoptosis in human MCF7 cells assessed as viable cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 92.6 to 96.8%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1865712	Inhibition of cell migration in HUVEC cells at 10 uM after 8 hrs by wound healing assay	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks.
AID1308985	Inhibition of TYK2 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID435154	Binding constant for DDR2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720475	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1760626	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID435149	Binding constant for AMPK-alpha2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1368669	Inhibition of human CAMK4 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID340323	Inhibition of protein kinase C	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID1350975	Inhibition of FLT3 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID720182	Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720442	Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531731	Inhibition of human IRR using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720244	Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1169352	Cytotoxicity against human HepG2 cells	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID1662790	Inhibition of human Aurora A using [H-LRRASLG] as substrate in presence of [gamma-33P]-ATP incubated for 2 hrs by hotspot kinase assay
AID1715372	Inhibition of human DYRK3 using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531300	Inhibition of human DRAK1 assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720306	Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1354792	Induction of cell death in human SH-SY5Y cells at 0.5 uM pretreated with caspase inhibitor ZVAD-FMK for 24 hrs followed by compound addition measured after 6 hrs by MTT assay	2018	Journal of natural products, 06-22, Volume: 81, Issue:6	Structures and Activities of Tiahuramides A-C, Cyclic Depsipeptides from a Tahitian Collection of the Marine Cyanobacterium Lyngbya majuscula.
AID720377	Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID629279	Inhibition of GSK3-beta	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1531898	Inhibition of human SYK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308967	Inhibition of LTK (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID435183	Binding constant for PLK3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID241063	Inhibition of Casein kinase 2 of P19 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID435662	Binding constant for MST2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531862	Inhibition of human RET using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID718909	Inhibition of LCK	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Purpuroines A-J, halogenated alkaloids from the sponge Iotrochota purpurea with antibiotic activity and regulation of tyrosine kinases.
AID1715175	Inhibition of human SBK1 using LCGRTGRRNSI as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID241786	Inhibition of Platelet-derived growth factor receptor in P19 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1689481	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
AID1732831	Inhibition of FGFR4 (unknown origin)	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
AID625132	Binding constant for FGFR1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624848	Binding constant for CSNK2A1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID592895	Ratio of IC50 for human PKCalpha to IC50 for PKA	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	The synthesis and evaluation of indolylureas as PKCα inhibitors.
AID256675	Average Binding Constant for PTK6; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720366	Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531627	Inhibition of human CDK4/cyclin-D1 using RB protein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531555	Inhibition of human TXK assessed as residual activity at 100 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531763	Inhibition of human MEK2 using ERK2 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720275	Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624906	Binding constant for S6K1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID262972	Inhibition of PKA at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1531620	Inhibition of human CDK16/cyclin-Y using RB protein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1055892	Cytotoxicity against human PC3 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID720263	Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1183896	Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 3 uM after 2 hrs by inverse MTT assay	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID590190	Inhibition of human recombinant IKK-beta expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	Structure-based design and biological profile of (E)-N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of IκB kinase-β.
AID1531515	Inhibition of human SIK2 assessed as residual activity at 100 uM using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1762565	Inhibition of N-terminal GST-fused human recombinant full length SYK (1 to 635 residues) expressed in baculovirus-infected Sf21 cells using FAM-22 peptide as substrate preincubated with enzyme for 10 mins followed by substrate addition for 30 mins in pres	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.
AID427624	Inhibition of recombinant ERK1 expressed in Escherichia coli	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
AID1350977	Inhibition of GSK3beta (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID580260	Inhibition of GST-fussed c-SRC after 30 mins	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
AID1715342	Inhibition of human FLT1 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720258	Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1368682	Inhibition of human p38alpha at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1277437	Induction of apoptosis in mouse B16F10 cells assessed as viable cells at 0.1 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 98.4%)	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines.
AID1624703	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced IL-4 level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA	2019	Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6	Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1252499	Inhibition of human ROCK1 by kinase inhibition assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID1300795	Inhibition of ABL (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1462559	Induction of apoptosis in human MFE280 cells assessed as nuclear debris at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.5 to 2.3%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531546	Inhibition of human TNIK assessed as residual activity at 100 uM using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531451	Inhibition of human p70S6Kb assessed as residual activity at 100 uM using KKRNRTLTK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625004	Binding constant for EGFR(L858R,T790M) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531769	Inhibition of human MEKK6 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720388	Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715453	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1300799	Inhibition of N-terminal GST tagged recombinant full-length human CHK1 expressed in baculovirus Sf9 insect cells after 10 mins by luminescent ADP-Glo assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID1394686	Inhibition of recombinant human Src using Ulight-Poly GAT[EAY(1:1:1)]n as substrate measured after 10 mins by LANCE assay	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
AID262968	Inhibition of Akt1 at 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID624731	Binding constant for CAMK2G kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1308939	Inhibition of EGFR (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID624895	Binding constant for MEK6 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID436050	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1581524	Antiproliferative activity against human HCT116 cells measured after 72 hrs under normoxic condition by MTT assay
AID1410149	Inhibition of SRC (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID256669	Average Binding Constant for ABL1(M351T); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID415628	Selectivity ratio of IC50 for CDK9/cyclin T1 to IC50 for human GSK3-beta	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID720384	Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1404982	Inhibition of recombinant human N-terminal GST-tagged HER2 (679 to 1255 residues) expressed in baculovirus infected Sf9 cells at 1 uM using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay relative to control
AID1572739	Cytostatic activity against human HAP1 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1350992	Inhibition of PDGFRalpha (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID435933	Binding constant for PKN2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720267	Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531248	Inhibition of human CAMK4 assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720405	Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531356	Inhibition of human HIPK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624871	Binding constant for PAK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720348	Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531613	Inhibition of human CAMKK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID471626	Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 80 ug/disk after 72 hrs at 25 degreeC by disc diffusion method	2009	Journal of natural products, Aug, Volume: 72, Issue:8	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp.
AID1715159	Inhibition of human STK25 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624836	Binding constant for IKK-beta kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720351	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1738922	Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human A2780 cells incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1462538	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 1 to 2.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID165140	Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells	1998	Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19	Novel protein kinase C inhibitors: alpha-terthiophene derivatives.
AID629397	Inhibition of LYN	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1531526	Inhibition of human STK22D assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531868	Inhibition of human RON using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1068645	Inhibition of SYK (unknown origin)	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.
AID720061	Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1450411	Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.
AID1715292	Inhibition of human LYN using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531499	Inhibition of human RIPK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720457	Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720484	Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1532746	Induction of reactive oxygen species generation in human HCT116 cells assessed as increase in mitochondrial superoxide generation at 1 uM after 12 hrs by MitoSOX red dye-based fluorescence microscopic analysis	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID256655	Average Binding Constant for CSNK1G1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435160	Binding constant for FER kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID74094	Inhibition of Glycogen synthase kinase-3 beta	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID1531815	Inhibition of human p70S6Kb using KKRNRTLTK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625033	Binding constant for PCTK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531223	Inhibition of human ASK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID405701	Cytotoxicity against human HT29 cells after 72 hrs by sulforhodamine B method	2008	Journal of natural products, Jun, Volume: 71, Issue:6	Cytotoxic staurosporines from the marine ascidian Cystodytes solitus.
AID1715139	Inhibition of human TRKA using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1532748	Induction of mitochondrial membrane depolarization in human HCT116 cells at 1 uM after 12 hrs by JC-1 staining based fluorescence microscopic analysis	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID1715290	Inhibition of human LYN-B using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625021	Binding constant for LIMK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1387464	Cytotoxicity in HEK293 cells expressing human VMAT2 assessed as reduction in cell viability at 3 uM incubated for 24 hrs by MTT assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID256562	Average Binding Constant for PAK4; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID591132	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 10 mins by time resolved-fluorescent assay	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.
AID624764	Binding constant for CLK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624741	Binding constant for LRRK2(G2019S) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1247634	Inhibition of VEGFR2 (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1895099	Binding affinity to MST1 (unknown origin) assessed as change in melting temperature by thermal shift based DSF assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors.
AID1715201	Inhibition of human PKCzeta using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720096	Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531434	Inhibition of human NEK11 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624816	Binding constant for HPK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1202433	Inhibition of FLT3 (unknown origin) at 10 uM after 30 mins by HTRF method	2015	European journal of medicinal chemistry, , Volume: 96	Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents.
AID435645	Binding constant for ACVRL1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531430	Inhibition of human MYLK4 assessed as residual activity at 100 uM using KKRPQRRYSNVF as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1063041	Inhibition of PIM1 (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1531230	Inhibition of human BMX assessed as residual activity at 100 uM using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID415612	Selectivity ratio of IC50 for CDK2/Cyclin E to IC50 for human GSK3-beta	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID1531381	Inhibition of human LCK assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720376	Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462517	Induction of apoptosis in human A2780 cells assessed as early apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.7 to 2.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID436015	Binding constant for EPHA6 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624966	Binding constant for DCAMKL1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID205488	Inhibition of src kinase	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID720365	Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715137	Inhibition of human TRKC using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435557	Binding constant for RIPK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720223	Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1090401	Antioomycete activity against Phytophthora capsici zoospores suspension infected in pepper plants (cv. Hanbyul) at first branch stage pre-exposed to compound spray on stems before fungal infection assessed as reduction in Phyophthora blight disease severi	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID638300	Inhibition of His6-tagged c-Src kinase domain using AEEEIYGEFEAKKKK as substrate pre-incubated for 10 mins before substrate addition measured after 30 mins by Transcreener ADP2 FI Assay	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities.
AID1715384	Inhibition of human DAPK2 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624887	Binding constant for ERK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531459	Inhibition of human PBK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435195	Binding constant for SRC kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1202432	Inhibition of PDGFR-beta (unknown origin) at 10 uM after 30 mins by HTRF method	2015	European journal of medicinal chemistry, , Volume: 96	Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents.
AID1715244	Inhibition of human NEK4 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715279	Inhibition of human MEKK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531710	Inhibition of human GRK4 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531304	Inhibition of human DYRK3 assessed as residual activity at 100 uM using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID274366	Inhibition of human SIRT1	2006	Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25	Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
AID624749	Binding constant for CASK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1247641	Inhibition of RON (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID720357	Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715332	Inhibition of human GRK3 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1450414	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.
AID1532739	Induction of apoptosis in human MCF10A cells assessed as early apoptotic cells at 1 uM after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry method (Rvb = 0.20%)	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID622359	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents.
AID1381888	Inhibition of RNA polymerase 2 C-terminal domain phosphorylation at Ser2 residue in human KOPN8 cells after 24 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1531711	Inhibition of human GRK5 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1287714	Induction of apoptosis in human SEM cells assessed as late apoptotic cells at 1 uM measured after 24 hrs by annexin V-propidium iodide staining based flow cytometric analysis (Rvb = 7.2%)	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID1531585	Inhibition of human ARAF using MEK1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624746	Binding constant for WEE2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID775219	Inhibition of ABL (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	2013	European journal of medicinal chemistry, Nov, Volume: 69	Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II.
AID1090415	Antimicrobial activity against Cladosporium cucumerinum assessed as growth inhibition incubated for 4 to 7 days	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID624823	Binding constant for MKNK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624873	Binding constant for PAK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462566	Induction of apoptosis in human MFE296 cells assessed as late apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 3.6 to 6.6%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1715441	Inhibition of human BMX using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID216786	Inhibition of Vascular endothelial growth factor receptor 2	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID435690	Binding constant for RPS6KA1(Kin.Dom.1 - N-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID726369	Inhibition of human ALK5 in presence of 1 microM ATP	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	Synthesis and biological evaluation of 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1,2,3-triazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
AID1531872	Inhibition of human RSK3 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715262	Inhibition of human MNK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715273	Inhibition of human MKK4 using JNK1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531449	Inhibition of human p38gamma assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1063038	Inhibition of VEGFR2 (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID625065	Binding constant for CIT kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1351024	Inhibition of LCK (unknown origin) assessed as remaining activity at 7.63 x 10'-11 M after 120 mins in presence of 33P-ATP (Rvb = 89.74%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1878047	Inhibition of recombinant His-tagged human TrKA expressed in baculovirus expression system by LanthaScreen assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
AID402482	Cytotoxicity against mouse L929 cells at 1 uM preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay	1997	Journal of natural products, Aug, Volume: 60, Issue:8	Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
AID1757218	Antiproliferative activity against human MDA-MB-231 cells incubated for 2 days by MTT assay	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors.
AID1360789	Binding affinity to human FLT3 ITD/F691L double mutant expressed in bacterial expression system by Kinomescan method	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID84798	Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Synthesis and biological evaluation of novel bisindolylmaleimides that inhibit vascular endothelial cell proliferation.
AID1394747	Inhibition of recombinant human PDGFRbeta expressed in insect cells using Ulight-Poly GAT[EAY(1:1:1)]n as substrate after 30 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID1727477	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Cytotoxic triterpenoid-safirinium conjugates target the endoplasmic reticulum.
AID625098	Binding constant for IRAK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID242106	Inhibition of Calcium/calmodulin-dependent protein kinase type II in P19 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID624772	Binding constant for AURKB kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720030	Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435288	Binding constant for EPHB2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720055	Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435164	Binding constant for IGF1R kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715358	Inhibition of human ERBB2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435567	Selectivity for PRKCH as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID599957	Binding affinity to human KIT incubated for 1 hr by kinase binding assay	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
AID1531591	Inhibition of human AXL using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1164144	Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level at 10 uM by autoradiography	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
AID1438358	Cytotoxicity against mouse Neuro2a cells assessed as cell viability at 10 uM after 72 hrs by MTT assay relative to control	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction.
AID1531286	Inhibition of human CLK3 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531684	Inhibition of human ERBB4 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1189694	Inhibition of telomerase in human HepG2 cells at 2 uM after 1 day by TRAP-ELISA method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID625139	Binding constant for SNARK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1484302	Induction of apoptosis in human PC3 cells assessed as necrotic cells at 40 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 2 to 3%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID435787	Binding constant for CLK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID436019	Binding constant for FRK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1074866	Induction of apoptosis in human A2780 cells assessed as cholesterol crystal formation at 1 uM by acridine orange/propidium iodide staining-based fluorescence microscopy	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID1300793	Inhibition of PRKG1 (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID624925	Binding constant for RIPK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531768	Inhibition of human MEKK3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720455	Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715447	Inhibition of human Aurora B using [H-LRRASLG] as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624819	Binding constant for ACVR1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1420033	Inhibition of DYRK1A (unknown origin)	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
AID163013	Inhibition of Protein kinase C alpha	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID1531703	Inhibition of human FRK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID436004	Binding constant for ACVR2A kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1481084	Inhibition of human TYK2 using KKSRGDYMTMQIG as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID426697	Inhibition of CHK2 assessed as CDC25C peptide phosphorylation by DELFIA assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Identification of inhibitors of checkpoint kinase 1 through template screening.
AID720313	Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1624711	Inhibition of human LYN expressed in baculovirus infected Sf9 insect cells using p-nitrophenol at 10 uM after 10 mins by Lineweaver-Burk plot analysis	2019	Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6	Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID426938	Antiproliferative activity against JAK3 expressing IL2-stimulated human Jurkat cells	2009	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12	Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses.
AID418384	Inhibition of Pim2 in presence of 1 uM ATP	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.
AID720386	Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435517	Binding constant for AKT2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624944	Binding constant for ALK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1727484	Cytotoxicity against human FaDu cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Cytotoxic triterpenoid-safirinium conjugates target the endoplasmic reticulum.
AID624876	Binding constant for PDPK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624909	Binding constant for TGFBR2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531470	Inhibition of human PKAcb assessed as residual activity at 100 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715331	Inhibition of human GRK4 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1308931	Inhibition of ARG (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID720104	Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435278	Binding constant for full-length CDK7	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1462516	Induction of apoptosis in human A2780 cells assessed as viable cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 95 to 96.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID720465	Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID625142	Binding constant for TSSK1B kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1612685	Inhibition of human RIPK5 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID1715419	Inhibition of human CDK1/cyclinB using Histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID358170	Inhibition of Rous sarcoma virus p60 v-src	1992	Journal of natural products, Nov, Volume: 55, Issue:11	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID625064	Binding constant for PIM2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531438	Inhibition of human NEK5 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531443	Inhibition of human NIM1 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531421	Inhibition of human MSK1 assessed as residual activity at 100 uM using GRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720238	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256626	Average Binding Constant for NTRK1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720184	Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1646266	Antiproliferative activity against human COLO205 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	PB-10, a thiazolo[4,5-d] pyrimidine derivative, targets p21-activated kinase 4 in human colorectal cancer cells.
AID1531747	Inhibition of human LIMK1 using cofilin as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531789	Inhibition of human MST2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720050	Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531913	Inhibition of human TRKB using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1650882	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of mouse anti-DNP IgE-stimulated beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-bet	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Variegatic acid from the edible mushroom Tylopilus ballouii inhibits TNF-α production and PKCβ1 activity in leukemia cells.
AID1502656	Antiproliferative activity against human KB-3-1 cells after 5 days by WST-1 assay	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Oxidation of the Meroterpenoid (-)-Terreumol C from the Mushroom Tricholoma terreum: Discovery of Cytotoxic Analogues.
AID1715420	Inhibition of human CDK1/Cyclin-A using Histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID334306	Inhibition of pig microtubule assembly at 6 to 32 ug/ml by turbidity assay
AID624897	Binding constant for RAF1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435781	Binding constant for full-length BMX	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1381831	Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2/M phase at 2.5 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 9.38%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1308980	Inhibition of ROS (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID625002	Binding constant for EGFR(L747-T751del,Sins) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID262986	Antiproliferative activity against human MiaPaCa-2 cells	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID624931	Binding constant for CLK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720324	Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531575	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715391	Inhibition of human CLK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531390	Inhibition of human MAK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1612684	Inhibition of human JNK2 using ATF2 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID1531472	Inhibition of human PKCalpha assessed as residual activity at 100 uM using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1612689	Inhibition of human STK25 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID720111	Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531265	Inhibition of human CDK5/p25 assessed as residual activity at 100 uM using histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624719	Binding constant for GRK7 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720451	Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720434	Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720284	Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1360783	Inhibition of human FLT3 ITD-NPOS mutant by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID1531697	Inhibition of human FGFR4 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1287713	Induction of apoptosis in human SEM cells assessed as necrotic cells at 1 uM measured after 24 hrs by annexin V-propidium iodide staining based flow cytometric analysis (Rvb = 0.0%)	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID1531655	Inhibition of human DAPK1 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720456	Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720427	Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531663	Inhibition of human DMPK2 using KKRPQRRYSNVF as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462583	Induction of apoptosis in human T47D cells assessed as nuclear debris at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.2 to 7.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID720318	Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1055893	Cytotoxicity against human NCI-H1115 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID720102	Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624724	Binding constant for TAK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720344	Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308966	Inhibition of LCK (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID625000	Binding constant for EGFR(L747-E749del, A750P) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1308951	Inhibition of FLT4 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1715293	Inhibition of human LOK using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531899	Inhibition of human TAK1 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625113	Binding constant for MARK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1387463	Cytotoxicity in HEK293 cells expressing human VMAT2 assessed as reduction in cell viability at 1 uM incubated for 24 hrs by MTT assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID269866	Inhibition of CamK2alpha	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID720138	Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720277	Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720036	Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435640	Inhibition of wild-type CK2 holoenzyme	2003	The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3	Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1410110	Inhibition of ROCK2 (unknown origin) by HTRF assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Bioactive Indolocarbazoles from the Marine-Derived Streptomyces sp. DT-A61.
AID1531605	Inhibition of human CAMK1B using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1423195	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability at 5 uM after 24 hrs by cellTiter-Glo reagent based assay	2018	Journal of natural products, 11-26, Volume: 81, Issue:11	Azaphilone Derivatives from the Fungus Coniella fragariae Inhibit NF-κB Activation and Reduce Tumor Cell Migration.
AID720197	Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID627131	Inhibition of Aurora A using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID1531487	Inhibition of human PKG2 assessed as residual activity at 100 uM using LRRASLG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720083	Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID541030	Induction of apoptosis in bovine BL3 cells assessed as late apoptotic cells after 24 hrs by annexin V/propidium iodide staining-based FACS analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Theileria apicoplast as a target for chemotherapy.
AID730005	Inhibition of EGFR tyrosine kinase (unknown origin) using [33P]-ATP at 10 uM after 20 to 40 mins by scintillation counting analysis	2013	European journal of medicinal chemistry, Mar, Volume: 61	Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
AID624882	Binding constant for PKAC-beta kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID165113	Inhibition of purified rat brain protein kinase C (RB-PKC)	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID418385	Inhibition of Pim2 in presence of 100 uM ATP	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.
AID625070	Binding constant for PFTK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720274	Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624955	Binding constant for EPHB3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID688347	Cytotoxicity against human K562 cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID720421	Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1246335	Induction of apoptosis in human triple-negative MDA-MB-231 cells assessed as necrotic cells after 12 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.1%)	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID1247621	Inhibition of c-MET (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID627339	Inhibition of ZAP70 using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.
AID767337	Inhibition of ERK2 (unknown origin) at 50 uM after 1 hr by luminescence assay relative to control	2013	Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18	Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
AID720127	Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435430	Binding constant for INSRR kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1426965	Inhibition of recombinant human His-tagged HER2 cytoplasmic domain (676 to 1255 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design, synthesis and biological evaluation of quinazoline-phosphoramidate mustard conjugates as anticancer drugs.
AID1531642	Inhibition of human CK1E using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1277436	Induction of apoptosis in mouse B16F10 cells assessed as late apoptotic cells at 0.1 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.450%)	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines.
AID1531280	Inhibition of human CK1gamma2 assessed as residual activity at 100 uM using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531559	Inhibition of human ULK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720116	Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720459	Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531839	Inhibition of human PKCdelta using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720183	Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1738913	Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID611845	Inhibition of EGFR at 20 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID1531630	Inhibition of human CDK5/p35 using histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435409	Binding constant for full-length JNK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID225703	Inhibition of myosin light chain kinase (MLCK) from turkey gizzard	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID720165	Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624933	Binding constant for PLK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID415638	Inhibition of AKT3	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID436055	Binding constant for full-length YANK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715138	Inhibition of human TRKB using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1667739	Inhibition of cMET (unknown origin) using FAM-labeled peptide as substrate pre-incubated for 5 to 10 mins followed by substrate addition and measured after 30 to 60 mins by mobility shift assay	2020	Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9	Design, synthesis and biological evaluation of 4-(pyridin-4-yloxy)benzamide derivatives bearing a 5-methylpyridazin-3(2H)-one fragment.
AID1715212	Inhibition of human PKCalpha using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715232	Inhibition of human p70S6Kb using KKRNRTLTK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID350281	Inhibition of LYN	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1059944	Inhibition of recombinant PKCE (unknown origin) expressed in baculovirus expression system	2013	European journal of medicinal chemistry, Oct, Volume: 68	Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
AID1623696	Induction of apoptosis in human SUP-B15 cells assessed as late apoptotic cells level at 2 uM after 24 hrs by Annexin V and propidium iodide staining based flow cytometry (Rvb = 83%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1706573	Inhibition of STK10 (unknown origin) assessed as change in melting temperature at 10 uM by DSF assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Selective targeting of the αC and DFG-out pocket in p38 MAPK.
AID1381800	Induction of apoptosis in human KOPN8 cells assessed as necrotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.2%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1531540	Inhibition of human TEC assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID163341	Inhibition of Protein kinase C beta 2	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID1090409	Antimicrobial activity against Candida albicans assessed as growth inhibition incubated for 4 to 7 fays	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1715376	Inhibition of human DRAK1 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID162839	Inhibition of Protein kinase C alpha	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID1360784	Inhibition of human FLT3 ITD-W51 mutant by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID1504786	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Platanic acid: A new scaffold for the synthesis of cytotoxic agents.
AID1715412	Inhibition of human CDK2/cyclin-A1 using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624727	Binding constant for FYN kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624905	Binding constant for CDKL5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1203681	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID624820	Binding constant for ACVR2B kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435408	Binding constant for INSR kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID436021	Binding constant for LATS2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1244337	Inhibition of human KDR using and Ulight-CAGAGAIETDKEYYTVKD as substrate after 1 hr by FRET assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model.
AID1383798	Inhibition of PLK1 (unknown origin) at 1 uM using Ser/Thr-16 peptide substrate after 60 mins by Z'-LYTE assay relative to control	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
AID1504787	Cytotoxicity against human A549 cells after 96 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Platanic acid: A new scaffold for the synthesis of cytotoxic agents.
AID720201	Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715319	Inhibition of human IGF1R using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1763643	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 3 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition.
AID1462575	Induction of apoptosis in human MFE296 cells assessed as nuclear debris at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.4 to 0.8%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1532742	Induction of apoptosis in human MCF10A cells assessed as viable cells at 1 uM after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry method (Rvb = 95.4%)	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID1530831	Inhibition of human full length N-terminal GST tagged CHK1 assessed as residual activity at 3.05 10'-10M (Rvb = 96.94 to 103.06%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID664019	Cytotoxicity against human MCF7 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis, biological evaluation and molecular docking studies of novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone derivatives.
AID1531718	Inhibition of human HGK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1726216	Cytotoxicity against human HMLE cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay	2020	ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12	Staurosporine Analogs Via C-H Borylation.
AID1502658	Antiproliferative activity against human FS4-LTM cells after 24 hrs by WST-1 assay	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Oxidation of the Meroterpenoid (-)-Terreumol C from the Mushroom Tricholoma terreum: Discovery of Cytotoxic Analogues.
AID1715211	Inhibition of human PKCb1 using Histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715411	Inhibition of human CDK2/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1572737	Cytostatic activity against human hTERT-RPE1 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1715238	Inhibition of human NIM1 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435644	Binding constant for ABL1(E255K) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531409	Inhibition of human MKK6 assessed as residual activity at 100 uM using p38alpha as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435940	Binding constant for full-length TSSK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID303315	Inhibition of CSK at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID435646	Binding constant for BLK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1704684	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	3-Methylthiazolo[3,2-a]benzimidazole-benzenesulfonamide conjugates as novel carbonic anhydrase inhibitors endowed with anticancer activity: Design, synthesis, biological and molecular modeling studies.
AID720393	Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1059943	Inhibition of recombinant IKK2 (unknown origin) expressed in baculovirus expression system	2013	European journal of medicinal chemistry, Oct, Volume: 68	Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
AID1068646	Inhibition of IKKbeta (unknown origin)	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.
AID1560818	Covalent inhibition of full-length human recombinant BTK assessed as reduction in enzyme recovery at 10-fold molar excess concentration using FITC-Ahx-TSELKKVVALYDYMPMNAND-biotin-NH2 as substrate preincubated for 1 hr followed by enzyme-compound mixture d	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID435795	Binding constant for EPHA4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720314	Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720335	Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624967	Binding constant for RPS6KA5(Kin.Dom.2-C-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID256616	Average Binding Constant for CDK5; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625101	Binding constant for TAOK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715405	Inhibition of human CDK5/p35 using histone H1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531513	Inhibition of human SGK3 assessed as residual activity at 100 uM using GRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID415615	Inhibition of CDK3/Cyclin E	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID720261	Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531498	Inhibition of human RET assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531721	Inhibition of human HIPK3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531251	Inhibition of human CDC7/DBF4 assessed as residual activity at 100 uM using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625045	Binding constant for PIK3CA(Q546K) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID235786	Concentration for 50% cell death determined by lysosomal staining in the neutral red viability assay.	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID625111	Binding constant for RIOK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1532729	Induction of apoptosis in human HCT116 cells assessed as necrotic cells at 1 uM after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry method (Rvb = 4.8%)	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID1532740	Induction of apoptosis in human MCF10A cells assessed as late apoptotic cells at 1 uM after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry method (Rvb = 3.81%)	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
AID720431	Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID126758	Inhibition of Mitogen activated protein kinase kinase 4	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID337241	Inhibition of protein kinase C
AID1691913	Inhibition of full length human recombinant CDK3/Cyclin E using histone H1 as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1).
AID625078	Binding constant for SRPK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624970	Binding constant for CDK5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID342543	Suppression of IL2 production in human whole blood after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
AID625129	Binding constant for HIPK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1664192	Inhibition of EGFR L858R mutant (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay
AID720123	Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531827	Inhibition of human PEAK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1689705	Induction of apoptosis in human RPMI-8226 cells assessed as Caspase-7 level incubated for 24 hrs by ELISA (Rvb = 0.359 +/- 0.016 ng/ml)	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
AID643483	Competitive inhibition of human Myt1 by TR-FRET assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	In vitro and in silico studies on substrate recognition and acceptance of human PKMYT1, a Cdk1 inhibitory kinase.
AID1308960	Inhibition of IGF-1R (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531532	Inhibition of human STK38L assessed as residual activity at 100 uM using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531596	Inhibition of human BRK using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715231	Inhibition of human PAK2 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715263	Inhibition of human MLK4 using MEK1 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID241698	Inhibition of human Protein kinase C gamma using [gamma-33P]-ATP	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID435888	Relative inhibition of V66A-mutated CK2 holoenzyme compared to wild-type	2003	The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3	Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1063045	Inhibition of NEK2 (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1308929	Inhibition of AKT1 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1531467	Inhibition of human PIM2 assessed as residual activity at 100 uM using RSRHSSYPAGT as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID262372	Activity against GSK3 in FL5.12-Akt1 cells	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID740396	Inhibition of EGFR tyrosine kinase (unknown origin) using poly (Glu,Tyr) as substrate at 1 uM after 40 mins by Kinase-Glo Plus luminescence kinase assay	2013	European journal of medicinal chemistry, Mar, Volume: 61	Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
AID1531723	Inhibition of human HPK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435166	Binding constant for full-length JNK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715418	Inhibition of human CDK1/cyclinE using RB protein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID541031	Induction of apoptosis in bovine BL3 cells assessed as necrotic after 24 hrs by annexin V/propidium iodide staining-based FACS analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Theileria apicoplast as a target for chemotherapy.
AID1715401	Inhibition of human CDK7/cyclin-H using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531258	Inhibition of human CDK18/cyclin-Y assessed as residual activity at 100 uM using RB protein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1664190	Inhibition of HER4 (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay
AID720237	Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1180280	Selectivity index, ratio of IC50 for PKC (unknown origin) to GSK3beta (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Syntheses, neural protective activities, and inhibition of glycogen synthase kinase-3β of substituted quinolines.
AID1733105	Inhibition of MLK2 (unknown origin) by NanoBRET cellular target engagement assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core.
AID435201	Binding constant for TRKA kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624838	Binding constant for ACVR2A kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715250	Inhibition of human MYLK4 using KKRPQRRYSNVF as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624919	Binding constant for AURKA kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID337242	Inhibition of phosphatidylinositol kinase
AID1715286	Inhibition of human MARK1 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID436048	Binding constant for full-length PTK2B	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435319	Binding constant for PKN1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435155	Binding constant for full-length DLK	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID513247	Antiapoptotic activity against staurosporine-induced cell death in human H1299 cells assessed as caspase 7 activity at 10 uM after 24 hrs	2006	Nature chemical biology, Sep, Volume: 2, Issue:9	Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation.
AID1481073	Inhibition of human FAK/PTK2 using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID358676	Induction of REST/NRSF-coupled repression of luciferase tagged rat RE1/NRSE BDNF promoter activity expressed in ST14A cells at 10 nM assessed as increase in luciferase activity	2007	The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34	Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators.
AID625106	Binding constant for MARK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625133	Binding constant for CDC2L2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531361	Inhibition of human IKKalpha assessed as residual activity at 100 uM using KKKKERLLDDRHDSGLDSMKDEE as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435675	Binding constant for KIT(V559D,T670I) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624704	Binding constant for NEK9 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624908	Binding constant for TEC kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715122	Inhibition of human ZIPK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531213	Inhibition of human AKT3 assessed as residual activity at 100 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715243	Inhibition of human NEK3 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624996	Binding constant for EGFR kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1360788	Binding affinity to human FLT3 ITD/D835V double mutant expressed in bacterial expression system by Kinomescan method	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID1385655	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2018	Journal of natural products, 08-24, Volume: 81, Issue:8	Staurosporine Derivatives Generated by Pathway Engineering in a Heterologous Host and Their Cytotoxic Selectivity.
AID1900710	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated with enzyme for 20 mins followed by substrate addition and measured after 20 mins by Ellman's method	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
AID334303	Cytotoxicity against mouse P388 cells
AID1481077	Inhibition of human LYN using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID625061	Binding constant for MAP4K5 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624702	Binding constant for BRSK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625058	Binding constant for VRK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435407	Binding constant for FLT3(D835Y) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID719247	Inhibition of gamma secretase in human H4 cells expressing APP695 assessed as inhibition of Abeta42 production after 20 to 24 hrs by liquid phase electrochemiluminescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3.
AID435655	Binding constant for ERK5 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1779106	Induction of apoptosis in VEGF-stimulated HUVEC cells assessed as mitochondrial membrane potential alteration at 250 nM measured after 48 hrs by JC-1 staining based flow cytometry	2021	Journal of natural products, 06-25, Volume: 84, Issue:6	Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway.
AID1760627	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1484290	Induction of apoptosis in human PC3 cells assessed as necrotic cells at 5 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 2 to 3%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID541029	Induction of apoptosis in bovine BL3 cells assessed as viable cells after 24 hrs by annexin V/propidium iodide staining-based FACS analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Theileria apicoplast as a target for chemotherapy.
AID624712	Binding constant for DYRK1A kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1612679	Inhibition of human DAPK1 using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID465436	Inhibition of GSK3-beta assessed as NADH level after 10 mins by pyruvate kinase/lactate dehydrogenase coupled spectrophotometric assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta.
AID1538563	Cell cycle arrest in human KOPN8 cells assessed as increase in accumulation at S phase at 2 uM incubated for 24 hrs by propidium iodide staining based flow cytometric analysis	2019	Journal of natural products, 05-24, Volume: 82, Issue:5	Studies of Jatrogossone A as a Reactive Oxygen Species Inducer in Cancer Cellular Models.
AID1531816	Inhibition of human PAK1 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715195	Inhibition of human PKN2 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1466326	Inhibition of recombinant c-MET (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 45 mins by ELISA	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
AID1846766	Inhibition of BRAF (unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID1715431	Inhibition of human CAMK1B using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720454	Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1189693	Inhibition of telomerase in human HepG2 cells at 1 uM after 3 days by TRAP-ELISA method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID1715164	Inhibition of human SSTK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1348849	Inhibition human recombinant full length GST-tagged Plk2 expressed in baculovirus expression system after 1 hr by FRET-based Z'-Lyte assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold.
AID1772937	Inhibition of BRAF V600E mutant (unknown origin) incubated for 40 mins in presence of Mg/ATP mix by [gamma p33]-ATP based scintillation counting method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1438359	Cytotoxicity against mouse Neuro2a cells assessed as cell viability after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction.
AID624896	Binding constant for PRKR kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531261	Inhibition of human CDK2/cyclin-O assessed as residual activity at 100 uM using histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531893	Inhibition of human STK32C using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1309007	Inhibition of PKACalpha (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1705872	Inhibition of human DDR1 using KKSRGDYMTMQIG as substrate in presence of [gamma-33P]ATP by scintillation counting method
AID256641	Average Binding Constant for ABL2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531674	Inhibition of human EPHA4 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435563	Binding constant for TNIK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID274369	Inhibition of human recombinant SIRT2 at 50 uM	2006	Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25	Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
AID624929	Binding constant for BRSK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID269870	Antiproliferative activity against human DOV13 cell line	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID720017	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1068647	Inhibition of GSK3beta (unknown origin)	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.
AID241820	Inhibition of Cyclin-dependent kinase 1 in P19 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1483364	Inhibition of recombinant human GST-tagged EGFR L858R mutant cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
AID1531264	Inhibition of human CDK4/cyclin-D3 assessed as residual activity at 100 uM using RB-CTF as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531878	Inhibition of human SIK1 using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624817	Binding constant for MYO3B kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531537	Inhibition of human TAOK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531625	Inhibition of human CDK2/cyclin-O using histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624957	Binding constant for EPHB6 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1351040	Inhibition of FMS (unknown origin) assessed as remaining activity at 7.81 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531662	Inhibition of human DMPK using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID438442	Inhibition of Lck	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Structural basis for the inhibitor recognition of human Lyn kinase domain.
AID350250	Inhibition of ABL1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID601549	Cytotoxicity against human H460 cells after 48 hrs by SRB assay	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Metachromins U-W: cytotoxic merosesquiterpenoids from an Australian specimen of the sponge Thorecta reticulata.
AID624885	Binding constant for ERK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531271	Inhibition of human CDK9/cyclin-T1 assessed as residual activity at 100 uM using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531461	Inhibition of human PDGFRbeta assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531632	Inhibition of human CDK6/cyclin-D3 using RB protein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1191830	Inhibition of CDK2/CycA2 (unknown origin) using Ser/Thr 12 peptide substrate by Z'-LYTE kinase assay	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
AID1664198	Inhibition of recombinant human N-terminal GST-tagged HER4 (676 to 1308 residues) expressed in baculovirus expression system by competitive binding assay
AID1404897	Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells at 10 uM using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay relat
AID102192	Inhibition of human adenocarcinoma cell line LoVo proliferation (Not tested)	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
AID1360769	Inhibition of human KDR by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID1715220	Inhibition of human PHKgamma2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625123	Binding constant for RET(V804L) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1247620	Inhibition of c-Kit (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID720249	Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID625038	Binding constant for PIK3CA(E542K) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435653	Binding constant for EGFR(L747-S752del, P753S) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531840	Inhibition of human PKCepsilon using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1664197	Inhibition of recombinant human N-terminal His-tagged HER2 (676 to 1255 residues) expressed in baculovirus expression system by competitive binding assay
AID256671	Average Binding Constant for ABL1(Y253F); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID614649	Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 after 60 mins by ligand displacement based enzyme-inhibitor dilution assay	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID1531396	Inhibition of human MARK3 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531606	Inhibition of human CAMK1D using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1351000	Inhibition of RSK1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID342540	Inhibition of human Syk	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
AID256560	Average Binding Constant for FGR; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531690	Inhibition of human ERN2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531805	Inhibition of human NEK8 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1063046	Inhibition of IGF1R (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID303316	Inhibition of EGFR at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID1351018	Inhibition of LCK (unknown origin) assessed as remaining activity at 3.13 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 89.74%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531488	Inhibition of human PKN1 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715128	Inhibition of human ULK3 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435402	Binding constant for EGFR(G719S) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720447	Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624914	Binding constant for WEE1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720177	Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720241	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624986	Binding constant for ABL1(Q252H)-non phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1308928	Inhibition of ABL (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531698	Inhibition of human FGR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720210	Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1779844	Inhibition of CLK2 (unknown origin) assessed as transfer of radiolabelled phosphate group from ATP by reaction biology method	2021	Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18	Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold.
AID720436	Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531386	Inhibition of human LOK assessed as residual activity at 100 uM using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715336	Inhibition of human GCK using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID445088	Inhibition of p38alpha active form expressed in Escherichia coli BL21(DE3) cells by HTRF assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Displacement assay for the detection of stabilizers of inactive kinase conformations.
AID1531573	Inhibition of human ABL2 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435189	Binding constant for full-length PDPK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531901	Inhibition of human TAOK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531259	Inhibition of human CDK2/cyclin-A assessed as residual activity at 100 uM using histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID688351	Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID720331	Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1765307	Inhibition of rat recombinant DYRK1A expressed in Escherichia coli using RRRFRPASPLRGPPK as substrate by ADP-Glo kinase assay	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
AID541028	Induction of apoptosis in bovine BL3 cells assessed as early apoptotic cells after 24 hrs by annexin V/propidium iodide staining-based FACS analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Theileria apicoplast as a target for chemotherapy.
AID224295	Inhibition of human p56 lck	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID82386	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID1531296	Inhibition of human DDR2 assessed as residual activity at 100 uM using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID164618	Inhibition of rat brain protein kinase A(PKA) in 1%DMSO.	1992	Journal of medicinal chemistry, Jan, Volume: 35, Issue:1	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.
AID1068648	Inhibition of Drak (unknown origin)	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.
AID415639	Inhibition of CHK1	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID350275	Inhibition of IR	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID624912	Binding constant for TYK2(JH1domain-catalytic) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435291	Binding constant for FGFR3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1743552	Inhibition of FMS (unknown origin) in presence of ATP	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
AID629277	Inhibition of FLT3	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1063044	Inhibition of wild type MET (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID1252491	Inhibition of human Akt1 by kinase inhibition assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID415640	Inhibition of cRAF	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID624812	Binding constant for SBK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID155568	Inhibition of protein kinase A was evaluated as Inhibitory concentration	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID1666672	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometric analysis (Rvb = 0.3 %)	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
AID1531262	Inhibition of human CDK3/cyclin-E assessed as residual activity at 100 uM using histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531761	Inhibition of human MARK4 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624818	Binding constant for ULK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1381832	Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at 2.5 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 20.15%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1531822	Inhibition of human PASK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720212	Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308959	Inhibition of HER4 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID435902	Binding constant for BRAF(V600E) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720257	Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531841	Inhibition of human PKCeta using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID745524	Inhibition of CDK5/P25 (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID1350027	Inhibition of ROCK2 (unknown origin) using SKT S2 as substrate measured after 30 mins by HTRF assay	2018	Journal of natural products, 02-23, Volume: 81, Issue:2	Cyclizidine-Type Alkaloids from Streptomyces sp. HNA39.
AID720063	Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531377	Inhibition of human KSR1 assessed as residual activity at 100 uM using KRREILSRRPSYR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435163	Binding constant for full-length GSK3B	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624973	Binding constant for JAK2(JH1domain-catalytic) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID256593	Average Binding Constant for NEK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715438	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531209	Inhibition of human ABL2 assessed as residual activity at 100 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID303320	Inhibition of FGFR1 at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID624920	Binding constant for MRCKA kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435910	Binding constant for MAP4K4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1760631	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID625115	Binding constant for PAK6 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1751472	Inhibition of FGFR (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives.
AID720208	Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531891	Inhibition of human STK25 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID719380	Inhibition of human recombinant FLT3 expressed in insect cells using Ulight-CAGAGAIETDKEYYTVKD as substrate at 10 uM after 90 mins by LANCE method relative to staurosporine	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3.
AID1531428	Inhibition of human MUSK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1771924	Binding affinity to CSNK1E (unknown origin) assessed as change in melting temperature by SYPRO orange dye based DSF assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Design and Development of a Chemical Probe for Pseudokinase Ca
AID1531599	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715341	Inhibition of human FLT3 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624952	Binding constant for EPHA4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1738921	Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human MCF7 cells incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID435692	Binding constant for STK16 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1090408	Antimicrobial activity against Saccharomyces cerevisiae assessed as growth inhibition incubated for 4 to 7 fays	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1664195	Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system by competitive binding assay
AID1531876	Inhibition of human SGK2 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID498019	Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay	2008	Nature chemical biology, Jun, Volume: 4, Issue:6	Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility.
AID624937	Binding constant for FLT3(ITD) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID436009	Binding constant for full-length CAMK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID436016	Binding constant for full-length ERK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1646263	Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	PB-10, a thiazolo[4,5-d] pyrimidine derivative, targets p21-activated kinase 4 in human colorectal cancer cells.
AID1623701	Induction of apoptosis in human KOPN8 cells assessed as late apoptotic cells level at 2 uM after 24 hrs by Annexin V and propidium iodide staining based flow cytometry (Rvb = 2%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID720228	Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512485	Inhibition of GSK3	2004	Trends in pharmacological sciences, Sep, Volume: 25, Issue:9	Pharmacological inhibitors of glycogen synthase kinase 3.
AID720446	Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531850	Inhibition of human PKG1beta using LRRASLG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720240	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531297	Inhibition of human DLK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435556	Binding constant for RAF1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID720342	Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531579	Inhibition of human ALK1 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462518	Induction of apoptosis in human A2780 cells assessed as late apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.2 to 2.2%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1666222	Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1368677	Inhibition of human IKKbeta at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID325559	Inhibition of PKG	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID256620	Average Binding Constant for FLT3; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531290	Inhibition of human CTK assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625013	Binding constant for LCK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531349	Inhibition of human GRK7 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1269231	Cytoprotective activity against H2O2-induced apoptosis in human SH-SY5Y cells assessed as early apoptotic cells at 100 nM preincubated for 24 hrs followed by H2O2 addition measured after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytome	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	α-Aryl-N-aryl nitrones: Synthesis and screening of a new scaffold for cellular protection against an oxidative toxic stimulus.
AID1471756	Inhibition of recombinant human ALK G1269A mutant (1093 to 1411 residues) expressed in baculovirus expression system using 5'FAM-KKSRGDYMTMQIG-CONH as substrate preincubated for 15 mins followed by addition of ATP measured after 1 hr by microfluidic mobil	2017	Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.
AID611914	Inhibition of VEGFR-2 at 20 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID624904	Binding constant for NEK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624892	Binding constant for p38-delta kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720051	Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531602	Inhibition of human c-MET using KKKSPGEYVNIEFG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531345	Inhibition of human GRK3 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531476	Inhibition of human PKCepsilon assessed as residual activity at 100 uM using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID269865	Inhibition of PKCa	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
AID1531482	Inhibition of human PKCtheta assessed as residual activity at 100 uM using Histone H1 as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624760	Binding constant for PFPK5(P.falciparum) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531720	Inhibition of human HIPK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462543	Induction of apoptosis in human p53-null PC3 cells assessed as nuclear debris at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.1 to 0.5%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531903	Inhibition of human TBK1 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1298810	Inhibition of human recombinant JAK1 assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
AID1308961	Inhibition of INSR (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID745523	Inhibition of CDK6/Cyclin D1 (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured after 90 mins by P33-radiolabeled assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID1715443	Inhibition of human BLK using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435679	Binding constant for PIM3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID625108	Binding constant for MKNK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531334	Inhibition of human FGR assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531267	Inhibition of human CDK6/cyclin-D1 assessed as residual activity at 100 uM using RB protein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1348851	Inhibition human recombinant GST-tagged Plk3 catalytic domain (58 to 340 residues) expressed in baculovirus expression system after 1 hr by FRET-based Z'-Lyte assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold.
AID720106	Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID415643	Inhibition of IKK-beta	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID720186	Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID614651	Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 assessed as dissociation half life after 60 mins by ligand displacement based enzyme-inhibitor dilution assay	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID1055900	Cytotoxicity against human HT-29 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID1715429	Inhibition of human CAMK1G using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256590	Average Binding Constant for EPHB1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624715	Binding constant for ERK8 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID256595	Average Binding Constant for CLK3; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1736574	Cytotoxicity against human T47D cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay
AID1715190	Inhibition of human PLK4 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1530829	Inhibition of human full length N-terminal GST tagged CHK1 assessed as residual activity at 4.88 10'-9M (Rvb = 96.94 to 103.06%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1350981	Inhibition of JAK3 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1715309	Inhibition of human JAK2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625020	Binding constant for ITK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720338	Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720093	Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531336	Inhibition of human FLT3 assessed as residual activity at 100 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531636	Inhibition of human CDK9/cyclin-T2 using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720142	Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1202434	Inhibition of EGFR (unknown origin) at 10 uM after 30 mins by HTRF method	2015	European journal of medicinal chemistry, , Volume: 96	Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents.
AID720295	Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720175	Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID248102	Tested for TNF-alpha-induced RANTES production in A549 cells using ELISA assay; ND is Not done	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: Improvement of in vitro activity.
AID625014	Binding constant for PRKCE kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1751468	Cytotoxicity against human A549 cells assessed as cell viability measured by MTT assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives.
AID720021	Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720311	Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID303332	Inhibition of Src at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID1365190	Inhibition of c-MET (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
AID1381797	Induction of apoptosis in human KOPN8 cells assessed as early apoptotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.1%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID718908	Inhibition of CDK2	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Purpuroines A-J, halogenated alkaloids from the sponge Iotrochota purpurea with antibiotic activity and regulation of tyrosine kinases.
AID720233	Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID163379	Inhibition of Protein kinase C delta	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID1247619	Inhibition of BRAF V599E mutant (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1710632	Inhibition of human S6K1 using KKRNRTLTK peptide substrate by radiometric assay	2020	RSC medicinal chemistry, May-01, Volume: 11, Issue:5	Computer-aided discovery of phenylpyrazole based amides as potent S6K1 inhibitors.
AID624859	Binding constant for JAK1(JH1domain-catalytic) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1462580	Induction of apoptosis in human T47D cells assessed as viable cells at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 74.5 to 94.5%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1066416	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	2014	European journal of medicinal chemistry, Jan-24, Volume: 72	The chemical and biological potential of C ring modified triterpenoids.
AID1531298	Inhibition of human DMPK assessed as residual activity at 100 uM using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715352	Inhibition of human ERN1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID634542	Competitive inhibition of human CHK1 using ATP as substrate by DELFIA	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
AID1715299	Inhibition of human LATS2 using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID256581	Average Binding Constant for CAMK1G; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715400	Inhibition of human CDK9/cyclin-T1 using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1142609	Inhibition of ALK4 (unknown origin) by radioisotopic assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/
AID1481087	Inhibition of PI3Kalpha (unknown origin)	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID242696	Inhibition of Glycogen synthase kinase-3 beta dependent Tau protein serine-396 phosphorylation in human SY5Y cells; NT= not tested	2004	Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16	Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
AID1531485	Inhibition of human PKG1alpha assessed as residual activity at 100 uM using LRRASLG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720211	Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720302	Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID723733	Stabilization of CDK9/Cyclin T (1 to 330 amino acid residues) (unknown origin) assessed as change in melting temperature at 20 uM by differential scanning fluorimetry assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
AID1715179	Inhibition of human RSK3 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715430	Inhibition of human CAMK1D using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720334	Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID389368	Inhibition of human Syk expressed in Sf9 cells	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
AID624889	Binding constant for JNK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720450	Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1771925	Binding affinity to MERTK (571 to 864 residue) (unknown origin) expressed in Escherichia coli Rosetta cells assessed as change in melting temperature by SYPRO orange dye based DSF assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Design and Development of a Chemical Probe for Pseudokinase Ca
AID435785	Binding constant for full-length CDK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624853	Binding constant for FLT1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531478	Inhibition of human PKCgamma assessed as residual activity at 100 uM using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID513191	Antiapoptotic activity against staurosporine-induced cell death in human H1299 cells assessed as caspase 3 activity at 10 uM after 24 hrs	2006	Nature chemical biology, Sep, Volume: 2, Issue:9	Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation.
AID1531796	Inhibition of human MYO3B using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID73318	Inhibition of Fibroblast growth factor receptor	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID720047	Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1184498	Inhibition of Aurora A (unknown origin) using [33P]-ATP and 10 uM ATP after 2 hrs	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Click approach to the discovery of 1,2,3-triazolylsalicylamides as potent Aurora kinase inhibitors.
AID1772910	Inhibition of ErbB4 (unknown origin) incubated for 40 mins in presence of Mg/ATP mix by [gamma p33]-ATP based scintillation counting method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1770396	Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID1778246	Inhibition of TrxR1 (unknown origin) assessed as reduction in DTNB to TNB by colorimetric assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Beyond direct Nrf2 activation; reinvestigating 1,2,4-oxadiazole scaffold as a master key unlocking the antioxidant cellular machinery for cancer therapy.
AID718907	Inhibition of PLK1	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Purpuroines A-J, halogenated alkaloids from the sponge Iotrochota purpurea with antibiotic activity and regulation of tyrosine kinases.
AID1762564	Inhibition of N-terminal GST-fused human recombinant full length ZAP70 (1 to 619 residues) expressed in baculovirus-infected Sf21 cells using FAM-22 peptide as substrate preincubated with enzyme for 10 mins followed by substrate addition for 30 mins in pr	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.
AID256582	Average Binding Constant for NEK9; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625031	Binding constant for MRCKB kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720076	Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720188	Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1303870	Inhibition of cMET (unknown origin) using TK substrate-biotin as substrate preincubated with compound followed by substrate addition for 40 mins measured after 1 hr by HTRF assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives.
AID1531601	Inhibition of human c-MER using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435687	Binding constant for PAK7/PAK5 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531728	Inhibition of human IR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID327394	Induction of cytochrome c release in cytosolic fraction of human BJ cell expressing TERT, LT, ST and RAS G12V mutant genes at 1 uM	2007	Nature, Jun-14, Volume: 447, Issue:7146	RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels.
AID720141	Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531856	Inhibition of human PLK2 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID240956	Inhibition of Cyclin-dependent kinase 2-cyclin E	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
AID303321	Inhibition of IGF1R at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID1846767	Inhibition of BRAF V599E mutant(unknown origin)	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID1531649	Inhibition of human CLK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720206	Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308944	Inhibition of EPHB1 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID720268	Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531848	Inhibition of human PKD2 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462549	Induction of apoptosis in human p53-null PC3 cells assessed as early apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.6 to 1.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531770	Inhibition of human MELK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID436043	Binding constant for PKMYT1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715403	Inhibition of human CDK6/cyclin-D3 using RB protein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID722913	Inhibition of telomerase in human HepG2 cells after 48 hrs by TRAP-PCR-ELISA	2013	European journal of medicinal chemistry, Feb, Volume: 60	Synthesis, molecular modeling and biological evaluation of 2-aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3H)-thione quinolone derivatives as novel anticancer agent.
AID720112	Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720304	Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435312	Binding constant for MET kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1819633	Binding affinity to human STK17B assessed as thermal stability by measuring melting temperature at 10 uM by differential scanning fluorimetry	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.
AID720038	Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435800	Binding constant for FYN kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1368681	Inhibition of human MINK at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID1531341	Inhibition of human GCK assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435277	Binding constant for full-length CDK3	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1247631	Inhibition of GSK3b (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID350280	Inhibition of LCK	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1662791	Inhibition of human Aurora B using [H-LRRASLG] as substrate in presence of [gamma-33P]-ATP incubated for 2 hrs by hotspot kinase assay
AID1531392	Inhibition of human MAPKAPK3 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID657569	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
AID1743528	Inhibition of BCR-ABL T315I mutant (unknown origin) incubated for 40 mins in presence of [gamma33P]ATP by scintillation method	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
AID1462585	Induction of apoptosis in human T47D cells assessed as early apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.6 to 4.3%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1531676	Inhibition of human EPHA6 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462563	Induction of apoptosis in human MFE280 cells assessed as nuclear debris at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.5 to 2.3%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1715301	Inhibition of human LATS1 using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1772912	Inhibition of JNK3 (unknown origin) incubated for 40 mins in presence of Mg/ATP mix by [gamma p33]-ATP based scintillation counting method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1715314	Inhibition of human IRAK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625008	Binding constant for EPHA1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1738916	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis.
AID1531510	Inhibition of human SBK1 assessed as residual activity at 100 uM using LCGRTGRRNSI as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID625093	Binding constant for TNIK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID303331	Inhibition of KDR at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID720072	Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531634	Inhibition of human CDK9/cyclin-K using KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1246336	Induction of apoptosis in human triple-negative MDA-MB-231 cells assessed as late apoptotic cells after 12 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 3.7%)	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID720470	Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1360782	Inhibition of human FLT3 F594_R595insR mutant by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID1531854	Inhibition of human PKN3 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1594649	Antiproliferative activity against human K562 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID242177	Inhibition of Mitogen-activated protein kinase/extracellular signal-regulated kinase 2 in P19 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1252495	Inhibition of human FAK by kinase inhibition assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID1531538	Inhibition of human TAOK3 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256571	Average Binding Constant for BIKE; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531922	Inhibition of human ULK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720289	Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624917	Binding constant for MST3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1247636	Inhibition of MEK1 (unknown origin) after 40 mins by scintillation counting analysis	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
AID1531285	Inhibition of human CLK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1865713	Inhibition of angiogenesis in HUVEC cells assessed as reduction in capillary tube formation at 10 uM after 48 hrs by capillary tube formation assay	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks.
AID625140	Binding constant for MARK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1350953	Inhibition of ABL1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID625027	Binding constant for MAP3K4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID350270	Inhibition of FLT1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID435807	Binding constant for MARK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID590159	Inhibition of Abl1 at 20 uM after 1 hr by luminescence assay	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
AID435831	Binding constant for RPS6KA5(Kin.Dom.1 - C-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531367	Inhibition of human IRR assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531344	Inhibition of human GRK2 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720260	Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531404	Inhibition of human MEKK3 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1610358	Selectivity index, ratio of IC50 for recombinant full length human GST-tagged PLK2 expressed in baculovirus expression system to IC50 for recombinant full length human His-tagged PLK1 expressed in baculovirus expression system	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
AID1917242	Inhibition of CDK1/cyclin B (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors.
AID1624698	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-be	2019	Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6	Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1715369	Inhibition of human EPHA1 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1421096	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability at 2.14 uM after 72 hrs by WST8 assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID426937	Antiproliferative activity against JAK3 expressing human resting Jurkat cells	2009	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12	Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses.
AID1531556	Inhibition of human TYK1 assessed as residual activity at 100 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435562	Binding constant for STK36 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1594650	Antiproliferative activity against human Z138 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1531465	Inhibition of human PHKgamma2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720397	Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531514	Inhibition of human SIK1 assessed as residual activity at 100 uM using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624808	Binding constant for TRKA kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1865710	Cytotoxicity against HUVEC cells assessed as reduction in cell viability after 96 hrs by MTT assay	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks.
AID303317	Inhibition of EphA2 at 10 nM	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
AID1635586	Antiproliferative activity against FLT3-deficient human K562 cells after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
AID720094	Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1530826	Inhibition of human full length N-terminal GST tagged CHK1 assessed as residual activity at 3.13 10'-7M (Rvb = 96.94 to 103.06%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531228	Inhibition of human BLK assessed as residual activity at 100 uM using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1770397	Cytotoxicity against human MV4-11cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
AID1657499	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth	2020	Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10	4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.
AID720297	Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462550	Induction of apoptosis in human p53-null PC3 cells assessed as late apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.4 to 1.6%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1530832	Inhibition of human full length N-terminal GST tagged CHK1 assessed as residual activity at 7.63 10'-11M (Rvb = 96.94 to 103.06%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID350293	Inhibition of ROCK1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID735917	Inhibition of ERK2 (unknown origin) at 50 uM	2013	Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3	Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment.
AID1715365	Inhibition of human EPHA7 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1499134	Inhibition of recombinant human His-tagged PLK1 expressed in baculovirus expression system at 1 uM using Ser/Thr 16 prptide after 60 mins by Z'LYTE assay relative to control	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
AID256676	Average Binding Constant for SRC; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435827	Binding constant for PDGFRA kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531917	Inhibition of human TTBK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID325541	Inhibition of PKC	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624921	Binding constant for MAP4K3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531577	Inhibition of human AKT3 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435534	Binding constant for NEK5 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1287716	Induction of apoptosis in human SEM cells assessed as viable cells at 1 uM measured after 24 hrs by annexin V-propidium iodide staining based flow cytometric analysis (Rvb = 1.5%)	2016	European journal of medicinal chemistry, May-04, Volume: 113	Anti-proliferative evaluation of monoterpene derivatives against leukemia.
AID1462541	Induction of apoptosis in human p53-null PC3 cells assessed as early apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.6 to 1.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID435295	Binding constant for MAP4K3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1381894	Effect on c-Myc expression in human KOPN8 cells after 24 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1715274	Inhibition of human MELK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1410111	Inhibition of ASK1 (unknown origin) by HTRF assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Bioactive Indolocarbazoles from the Marine-Derived Streptomyces sp. DT-A61.
AID1530825	Inhibition of human full length N-terminal GST tagged CHK1 assessed as residual activity at 1.25 10'-6M (Rvb = 96.94 to 103.06%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531665	Inhibition of human DYRK1A using RRRFRPASPLRGPPK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720250	Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID350297	Inhibition of TAB1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID720161	Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1765288	Inhibition of human recombinant full length GSK3beta expressed in baculovirus in Sf9 insect cells using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate at 10 uM by ADP-Glo kinase assay relative to control	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
AID1350969	Inhibition of MAPK1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID720452	Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256640	Average Binding Constant for PTK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID389369	Inhibition of human ZAP70 expressed in Sf9 cells	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
AID163692	Inhibition of Protein kinase C epsilon	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID624990	Binding constant for ABL1(Y253F)-phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID614652	Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 assessed as dissociation half life after 60 mins by activity based 100 fold dilution assay	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID1055897	Cytotoxicity against human Jurkat E6-1 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID606664	Inhibition of human recombinant PKR autophosphorylation using poly[I:C] after 10 mins by luminescent assay	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Identification of new inhibitors of protein kinase R guided by statistical modeling.
AID256631	Average Binding Constant for FLT4; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531453	Inhibition of human PAK2 assessed as residual activity at 100 uM using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531916	Inhibition of human TSSK3 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715225	Inhibition of human PASK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720060	Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID614642	Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
AID427622	Inhibition of recombinant Aurora A expressed in Escherichia coli	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
AID350261	Inhibition of DAPK1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID415621	Selectivity ratio of IC50 for CDK1/cyclin B to IC50 for human GSK3-beta	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID629263	Inhibition of AKT1	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID325540	Inhibition of PKA	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1531549	Inhibition of human TRKB assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435165	Binding constant for JAK1(Kin.Dom.1/JH2 - pseudokinase) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID385587	Inhibition of human PKCepsilon	2007	The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45	Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID1531802	Inhibition of human NEK5 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715329	Inhibition of human GRK6 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1074834	Induction of apoptosis in human A2780 cells assessed as caspase 8 activity at 1 uM after 24 hrs relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID1531741	Inhibition of human KSR1 using KRREILSRRPSYR as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720149	Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435801	Binding constant for full-length GSK3A	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID256610	Average Binding Constant for Aurora3; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1360787	Binding affinity to human FLT3 D835Y mutant (Q580 to Y969 residues) expressed in bacterial expression system by Kinomescan method	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID667487	Inhibition of protein kinase in human HuH7 cells assessed as increase in ATP level at 0.5 uM after 72 hrs by Kinase-Glo assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(β-D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells.
AID1531424	Inhibition of human MST1 assessed as residual activity at 100 uM using KKSRGDYMTMQIG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435433	Binding constant for full-length MST1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531533	Inhibition of human STK39 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1504788	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Platanic acid: A new scaffold for the synthesis of cytotoxic agents.
AID624769	Binding constant for AURKC kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1706572	Inhibition of SLK (unknown origin) assessed as change in melting temperature at 10 uM by DSF assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Selective targeting of the αC and DFG-out pocket in p38 MAPK.
AID350272	Inhibition of FLT4	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1878046	Inhibition of recombinant His-tagged human FLT3 D835Y mutant (564 to 958 residues) expressed in baculovirus expression system by LanthaScreen assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
AID720195	Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID601548	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Metachromins U-W: cytotoxic merosesquiterpenoids from an Australian specimen of the sponge Thorecta reticulata.
AID1350996	Inhibition of PKCalpha (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID625035	Binding constant for PHKG1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435410	Binding constant for KIT kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID389367	Apparent permeability across human Caco-2 cells	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
AID1410150	Inhibition of AKT1 (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID435935	Binding constant for RIPK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID427620	Inhibition of recombinant PKCE expressed in Bac-to Bac baculovirus system	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
AID1612686	Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
AID1531820	Inhibition of human PAK5 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1462536	Induction of apoptosis in human MCF7 cells assessed as viable cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 92.6 to 96.8%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID350265	Inhibition of ERK1	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1531748	Inhibition of human LIMK2 using cofilin as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308978	Inhibition of RET (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1074842	Induction of apoptosis in human A2780 cells assessed as caspase 8 activity at 1 uM after 12 hrs relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID720395	Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1466333	Inhibition of PDGFRalpha (unknown origin) by HTRF method	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
AID1481068	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID1646265	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	PB-10, a thiazolo[4,5-d] pyrimidine derivative, targets p21-activated kinase 4 in human colorectal cancer cells.
AID624902	Binding constant for MEK4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715333	Inhibition of human GRK2 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720444	Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1917241	Inhibition of CDK6/cyclin D1 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors.
AID350260	Inhibition of cSRC	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1381920	Inhibition of Rb phosphorylation in human KOPN8 cells assessed as ratio of phosphorylated Rb to total Rb levels after 24 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1484298	Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 30 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 2 to 3%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID1531826	Inhibition of human PDK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720428	Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436023	Binding constant for MERTK kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531418	Inhibition of human MNK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID165122	Inhibition of protein kinase C	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives.
AID775218	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	2013	European journal of medicinal chemistry, Nov, Volume: 69	Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II.
AID1715404	Inhibition of human CDK6/cyclin-D1 using RB protein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720109	Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1404898	Inhibition of recombinant human N-terminal GST-tagged HER2 (679 to 1255 residues) expressed in baculovirus infected Sf9 cells at 10 uM using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay relative to control
AID1350980	Inhibition of IRAK4 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID624926	Binding constant for RIOK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531863	Inhibition of human RIPK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID629396	Inhibition of LCK	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID256588	Average Binding Constant for PCTK1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID415614	Inhibition of CDK2/Cyclin A	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
AID1350973	Inhibition of FGFR3 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID624939	Binding constant for FLT3(N841I) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715183	Inhibition of human ROCK2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID350254	Inhibition of CAMK2B	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID240698	Inhibition of Protein Kinase A activity	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
AID1063050	Inhibition of AXL (unknown origin)	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
AID624927	Binding constant for RPS6KA4(Kin.Dom.2-C-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715448	Inhibition of human ASK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1351017	Inhibition of LCK (unknown origin) assessed as remaining activity at 1.25 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 89.74%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID735920	Inhibition of p38-alpha (unknown origin) at 50 uM	2013	Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3	Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment.
AID624821	Binding constant for YANK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1715233	Inhibition of human PAK1 using RRRLSFAEPG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID487002	Cytotoxicity against human Caco-2 cells assessed as induction of DNA fragmentation under oxic condition at 10 uM after 24 hrs using ethidium bromide staining by agarose gel electrophoresis	2010	Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12	Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation.
AID720033	Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1351036	Inhibition of FMS (unknown origin) assessed as remaining activity at 2 x 10'-5 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID642585	Inhibition of FLT3 by colorimetric analysis	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Design and combinatorial synthesis of a novel kinase-focused library using click chemistry-based fragment assembly.
AID1189692	Inhibition of telomerase in human HepG2 cells at 1 uM after 2 days by TRAP-ELISA method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID1715154	Inhibition of human STK38L using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715321	Inhibition of human HIPK4 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID436017	Binding constant for ERK4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID327392	Induction of mitochondrial structural integrity loss in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes cells at 1 uM after 5 hrs	2007	Nature, Jun-14, Volume: 447, Issue:7146	RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels.
AID435797	Binding constant for ERBB4 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531709	Inhibition of human GRK3 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1529866	Inhibition of N-terminal His-tagged recombinant human AXL (473 to end amino acids) expressed by baculovirus in Sf9 cells using axltide substrate and ATP by ADP-Glo luminescence assay	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors.
AID49346	Inhibition of purified rat brain casein kinase II	2003	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
AID702297	Cytotoxicity against human BJeLR cells expressing RAS G12V mutant at 1 uM after 24 hrs by trypan blue staining	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Design and synthesis of Pictet-Spengler condensation products that exhibit oncogenic-RAS synthetic lethality and induce non-apoptotic cell death.
AID1471739	Inhibition of human ALK L1196M mutant using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition after 2 hrs by filter binding assay	2017	Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.
AID494402	Inhibition of EGFR	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID159255	Inhibition of rabbit muscle phosphorylase kinase (PhK)	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID1762566	Inhibition of N-terminal GST-fused human recombinant full length SYK (1 to 635 residues) expressed in baculovirus-infected Sf21 cells using FAM-22 peptide as substrate at 1 uM preincubated with enzyme for 10 mins followed by substrate addition for 30 mins	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.
AID1462523	Induction of apoptosis in human A2780 cells assessed as nuclear debris at 300 nM by 7-AAD/Annexin staining-based assay (Rvb = 0.3 to 1.1%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID435320	Binding constant for PRKCE kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1444450	Inhibition of recombinant human N-terminal GST-fused PAK4 (1 to 591 residues) expressed in baculovirus expression system using S2 as substrate measured after 40 mins by HTRF assay	2017	European journal of medicinal chemistry, May-05, Volume: 131	Development of 2, 4-diaminoquinazoline derivatives as potent PAK4 inhibitors by the core refinement strategy.
AID262369	Inhibition of FLT4 using 1.0 mM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID337240	Inhibition of protein kinase A
AID1350998	Inhibition of RET (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1531565	Inhibition of human WNK2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1360758	Inhibition of human FLT3 by Hotspot assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Discovery of the selective and efficacious inhibitors of FLT3 mutations.
AID1531522	Inhibition of human SRPK2 assessed as residual activity at 100 uM using GRSRSRSRSR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1300788	Inhibition of P70S6K (unknown origin) by mobility shift assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID625023	Binding constant for HIPK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531353	Inhibition of human HCK assessed as residual activity at 100 uM using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435532	Binding constant for MST3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID262368	Inhibition of KDR using 1.0 mM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID1715208	Inhibition of human PKCepsilon using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720226	Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID624989	Binding constant for ABL1(T315I)-phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1385653	Cytotoxicity against human Huh7.5 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2018	Journal of natural products, 08-24, Volume: 81, Issue:8	Staurosporine Derivatives Generated by Pathway Engineering in a Heterologous Host and Their Cytotoxic Selectivity.
AID720062	Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720415	Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID407191	Binding affinity to ASK1	2008	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13	Development of a novel fluorescent probe for fluorescence correlation spectroscopic detection of kinase inhibitors.
AID1350965	Inhibition of DAPK1 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1351003	Inhibition of TIE2 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1090405	Antimicrobial activity against Ralstonia solanacearum assessed as growth inhibition incubated for 4 to 7 fays	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1531836	Inhibition of human PKCalpha using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256594	Average Binding Constant for BMX; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531584	Inhibition of human ALK6 using casein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720049	Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720143	Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720113	Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1169355	Cytotoxicity against HEK293 cells	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID1760634	Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1308953	Inhibition of FGFR2 (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID368408	Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Isolation, structure elucidation and cytotoxic evaluation of endiandrin B from the Australian rainforest plant Endiandra anthropophagorum.
AID1499133	Inhibition of recombinant human His-tagged PLK1 expressed in baculovirus expression system at 10 uM using Ser/Thr 16 prptide after 60 mins by Z'LYTE assay relative to control	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
AID73970	Inhibition of Glycogen synthase kinase-3 beta (Not determined)	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
AID720286	Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715432	Inhibition of human CAMK1A using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720270	Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1308973	Inhibition of PDGFRbeta (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1530824	Inhibition of human full length N-terminal GST tagged CHK1 assessed as residual activity at 5.00 10'-6M (Rvb = 96.94 to 103.06%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715147	Inhibition of human TBK1 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID45962	Inhibition of Calcium/calmodulin-dependent protein kinase type II	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
AID248521	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID1326304	Inhibition of VEGFR2 (unknown origin) by mobility shift/LanthaScreen assay
AID1381896	Effect on c-Myc expression in human KOPN8 cells after 3 hrs by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Novel vitexin-inspired scaffold against leukemia.
AID1304448	Inhibition of MERTK (unknown origin) using EFPIYDFLPAKKK-CONH2 as substrate and ATP after 180 mins by microfluidic capillary electrophoresis method	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Synthesis, biological evaluation, and physicochemical property assessment of 4-substituted 2-phenylaminoquinazolines as Mer tyrosine kinase inhibitors.
AID1350967	Inhibition of EPHB4 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1671734	Antiproliferative activity against human U2OS cells assessed as cell viability at 2 uM after 48 hrs by CellTiter96 AQueous assay relative to control	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
AID1410152	Inhibition of PIM1 (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID625103	Binding constant for MST4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID241697	Inhibition of human Protein kinase C alpha using [gamma-33P]-ATP	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
AID436020	Binding constant for GCN2(Kin.Dom.2,S808G) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715364	Inhibition of human EPHA6 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531480	Inhibition of human PKCmu assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531604	Inhibition of human CAMK1A using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1368667	Inhibition of human AKT1 at 10 uM by ADP-Glo kinase assay	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Small molecule inhibitors of anthrax edema factor.
AID720299	Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531729	Inhibition of human IRAK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435296	Binding constant for MARK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID256591	Average Binding Constant for EPHA5; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID350269	Inhibition of FGFR3	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1731527	Inhibition of CDK2/Cyclin E (unknown origin) using histone H1 as substrate preincubated for 20 mins followed by 33P-ATP addition and measured after 2 hrs by filter binding method	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Tetrahydroindazole inhibitors of CDK2/cyclin complexes.
AID720105	Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720119	Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435431	Binding constant for MAP4K1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435647	Binding constant for CAMK2D kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID629265	Inhibition of Aurora-A	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID624877	Binding constant for PIK3C2B kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1810928	Induction of apoptosis in human HCC827-Luc cells assessed as increase in caspase 3/7 activity at 1 uM measured after 24 hrs by confocal fluorescence microscopic analysis	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Synthesis of Fluorescent Probes Targeting Tumor-Suppressor Protein FHIT and Identification of Apoptosis-Inducing FHIT Inhibitors.
AID1300805	Inhibition of Aurora A (unknown origin) after 1 hr by HTRF assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID720319	Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435411	Binding constant for KIT(D816V) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435318	Binding constant for PAK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531928	Inhibition of human WNK1 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1350995	Inhibition of PKA (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID342542	Suppression of IL2 production in human PBMC after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
AID624837	Binding constant for IRAK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531643	Inhibition of human CK1gamma1 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531383	Inhibition of human LIMK1 assessed as residual activity at 100 uM using cofilin as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1365188	Inhibition of BRAF (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
AID1715446	Inhibition of human Aurora A using [H-LRRASLG] as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1290436	Inhibition of telomerase in human MGC-803 cells after 24 hrs by TRAP-PCR-ELISA assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Dihydropyrazole derivatives as telomerase inhibitors: Structure-based design, synthesis, SAR and anticancer evaluation in vitro and in vivo.
AID1531570	Inhibition of human ZAP70 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID240955	Inhibition of Cyclin-dependent kinase 1-cyclin B	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
AID1706570	Inhibition of BRAF (unknown origin) assessed as change in melting temperature at 10 uM by DSF assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Selective targeting of the αC and DFG-out pocket in p38 MAPK.
AID1090413	Antimicrobial activity against Stagonosporopsis cucurbitacearum assessed as growth inhibition incubated for 4 to 7 days	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1531378	Inhibition of human KSR2 assessed as residual activity at 100 uM using KRREILSRRPSYR as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531335	Inhibition of human FLT1 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435651	Binding constant for DCAMKL2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1410147	Inhibition of JAK3 (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID624786	Binding constant for KIT kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435808	Binding constant for full-length MEK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435199	Binding constant for TLK1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531246	Inhibition of human CAMK2D assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531432	Inhibition of human MYO3B assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531735	Inhibition of human JAK3 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720360	Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID745531	Inhibition of human CDK2/Cyclin A2 using PKTPKKAKKL as substrate by fluorescence assay	2013	Journal of medicinal chemistry, May-23, Volume: 56, Issue:10	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
AID498021	Inhibition of GST-fused Plasmodium falciparum recombinant CDPK1 expressed in Escherichia coli Rosetta 2 assessed as inhibition of [gamma-33P]ATP incorporation into substrate peptide at 0.5 uM by scintillation counting	2008	Nature chemical biology, Jun, Volume: 4, Issue:6	Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility.
AID1715169	Inhibition of human SLK using Histone H3 as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID688348	Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID720394	Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1236889	Antitumor activity against human K562 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
AID1462560	Induction of apoptosis in human MFE280 cells assessed as viable cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 84.9 to 87.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1715126	Inhibition of human WNK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720337	Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720473	Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID385589	Inhibition of human PKCdelta	2007	The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45	Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID624894	Binding constant for MEK3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720230	Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1462578	Induction of apoptosis in human T47D cells assessed as late apoptotic cells at 1000 nM by 7-AAD/Annexin staining-based assay (Rvb = 3 to 13.4%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID1074851	Induction of apoptosis in human A2780 cells assessed as caspase 9 activity at 1 uM after 6 hrs relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID435799	Binding constant for FLT3 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435936	Binding constant for full-length SRPK1	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531431	Inhibition of human MYO3A assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720369	Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720441	Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1410145	Inhibition of PKA (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID1715136	Inhibition of human TSSK3 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID775336	Binding affinity to human FLT3	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
AID720172	Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531249	Inhibition of human CAMKK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID55363	Inhibition of Cyclin E-cyclin-dependent kinase 2	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
AID256633	Average Binding Constant for PRKACA; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435776	Binding constant for ABL1(Y253F) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435648	Binding constant for CAMKK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1300783	Inhibition of Akt1 (unknown origin) after 1 hr by HTRF assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.
AID611835	Inhibition of EGFR at 50 uM after 1 hrs by luminescence assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID629395	Inhibition of KDR	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1142607	Inhibition of ALK2 (unknown origin) by radioisotopic assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/
AID720091	Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715389	Inhibition of human CLK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1715160	Inhibition of human STK21 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1543904	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID494401	Inhibition of CK2alpha	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
AID1189698	Inhibition of telomerase in human HepG2 cells at 4 uM after 2 days by TRAP-ELISA method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID720380	Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1055895	Cytotoxicity against human K562 cells at 10 uM after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, , Volume: 70	Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
AID1610355	Inhibition of recombinant full length human His-tagged PLK1 expressed in baculovirus expression system using ser/thr 16 as substrate incubated for 1 hr by Z'-LYTE assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
AID720077	Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1635585	Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD mutant after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
AID436054	Binding constant for TLK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624940	Binding constant for FLT3(R834Q) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720239	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531823	Inhibition of human PBK using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531388	Inhibition of human LYN assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1846310	Inhibition of v-Src (unknown origin)	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Recent advances in development of hetero-bivalent kinase inhibitors.
AID1715452	Inhibition of human AKT2 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435284	Binding constant for DCAMKL1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID702148	Cytotoxicity against human BJeH cells expressing wild type RAS at 1 uM after 24 hrs by trypan blue staining	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Design and synthesis of Pictet-Spengler condensation products that exhibit oncogenic-RAS synthetic lethality and induce non-apoptotic cell death.
AID720121	Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID725933	Inhibition of human recombinant N-terminal GST-tagged Plk1 in presence of 62.5 uM of ATP	2013	Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3	Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
AID1394740	Inhibition of recombinant human c-MET expressed in insect cells using Ulight-CAGAGAIETDKEYYTVKD as substrate after 60 mins by LANCE method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
AID1531466	Inhibition of human PIM1 assessed as residual activity at 100 uM using KKRNRTLTK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308947	Inhibition of FER (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID720259	Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID262362	Inhibition of Akt2 using 10 uM ATP	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
AID590192	Inhibition of human CHK2 kinase expressed in insect Sf21 cells using phospho-CREBtide as substrate at 30 uM	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	Structure-based design and biological profile of (E)-N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of IκB kinase-β.
AID1645921	Inhibition of Glycogen synthase kinase-3 beta (unknown origin) after 30 mins by Kinase-Glo assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review.
AID1715435	Inhibition of human c-MER using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID471920	Induction of apoptosis in human HT-29 cells assessed as change in mitochondrial transmembrane potential after 2 hrs by JC1 staining based fluorescence assay	2009	Journal of natural products, Jun, Volume: 72, Issue:6	Bioactive 5,6-dihydro-alpha-pyrone derivatives from Hyptis brevipes.
AID1531520	Inhibition of human SRMS assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID435531	Binding constant for MKNK2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715240	Inhibition of human NEK9 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1779098	Induction of apoptosis in VEGF-stimulated HUVEC cells assessed as increase in early apoptotic cells at 250 nM measured after 48 hrs by AnnexinV-FITC/PI staining based flow cytometry	2021	Journal of natural products, 06-25, Volume: 84, Issue:6	Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway.
AID1531479	Inhibition of human PKCiota assessed as residual activity at 100 uM using ERMRPRKRQGSVRRRV as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1298807	Inhibition of human recombinant JAK1 assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation at 10 uM pre-incubated before substrate addition and measured after 60 mins by LANCE detection method	2016	Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12	Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
AID1715330	Inhibition of human GRK5 using casein as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720029	Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1715394	Inhibition of human CK1gamma2 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID512718	Inhibition of CDK1/cyclin B	2006	The AAPS journal, Mar-24, Volume: 8, Issue:1	Selectivity and potency of cyclin-dependent kinase inhibitors.
AID435194	Binding constant for RPS6KA6(Kin.Dom.2 - N-terminal) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1715216	Inhibition of human PIM3 using RSRHSSYPAGT as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1531254	Inhibition of human CDK1/cyclinE assessed as residual activity at 100 uM using RB protein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624963	Binding constant for LATS1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720264	Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256639	Average Binding Constant for PHkg1; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1531644	Inhibition of human CK1gamma2 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1680980	Induction of mitochondrial membrane potential loss in human Jurkat cells at 200 nM after 4 hrs by MitoSense Red/7-AAD. flow cytometric analysis	2020	Journal of natural products, 08-28, Volume: 83, Issue:8	Total Synthesis of Natural Lembehyne C and Investigation of Its Cytotoxic Properties.
AID625067	Binding constant for NDR1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531937	Inhibition of human CDK2/cyclin-A1 using histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID256637	Average Binding Constant for JNK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624777	Binding constant for DDR2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID256585	Average Binding Constant for EPHA7; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435281	Binding constant for full-length CSNK1A1L	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1531402	Inhibition of human MEKK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720251	Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID350277	Inhibition of JAK2	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID624945	Binding constant for BMPR1A kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625059	Binding constant for YSK1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1244857	Inhibition of CDK2 (unknown origin) at 10 uM	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
AID334304	Cytotoxicity against human KB cells
AID1715222	Inhibition of human PEAK1 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720163	Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531229	Inhibition of human BMPR2 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID624918	Binding constant for DYRK2 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1410153	Inhibition of PDK1 (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID1481076	Inhibition of human LCK using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID720300	Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256577	Average Binding Constant for CLK4; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1350991	Inhibition of PAK2 (unknown origin)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID1764191	Inhibition of DYRK1A (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors.
AID1715320	Inhibition of human HIPK3 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624862	Binding constant for LYN kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID536055	Activation of EGF-induced MEK1/2 activity in HEK293 cells assessed as phosphorylated ERK1/2 level at 10 uM after 1 hr by Western blotting relative to control	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Structure-activity relationships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5 signaling pathway.
AID1462526	Induction of apoptosis in human A2780 cells assessed as late apoptotic cells at 100 nM by 7-AAD/Annexin staining-based assay (Rvb = 1.2 to 2.2%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID624725	Binding constant for NEK11 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID624900	Binding constant for RSK1(Kin.Dom.1-N-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID623565	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	2011	Journal of natural products, Oct-28, Volume: 74, Issue:10	Bioassay-guided isolation of constituents of Piper sarmentosum using a mitochondrial transmembrane potential assay.
AID720416	Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1356602	Inhibition of GST-tagged human GST-tagged CDK7/CycH/MAT1 (04 to 108 residues) using kinase tracer 236 probe incubated for 60 mins by TR-FRET assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
AID1715357	Inhibition of human ERBB4 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624736	Binding constant for RPS6KA5(Kin.Dom.1-N-terminal) kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID435406	Binding constant for FLT3(D835H) kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1725208	Cytotoxicity against hTERT-immortalized human OKF6 cells assessed as reduction in cell density at 8 uM incubated for 24 hrs by trypan blue dye based light inverted microscopic analysis
AID1684588	Inhibition of c-Met (unknown origin) by mobility shift assay	2021	Bioorganic & medicinal chemistry letters, 02-01, Volume: 33	Design, synthesis and biological evaluation of novel 4-(pyrrolo[2,3-d]pyrimidine-4-yloxy)benzamide derivatives as potential antitumor agents.
AID435905	Binding constant for full-length CSNK1G3	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID718365	Inhibition of GST-tagged c-Src preincubated for 30 mins measured after 60 mins	2012	Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23	O-Aryl α,β-d-ribofuranosides: synthesis & highly efficient biocatalytic separation of anomers and evaluation of their Src kinase inhibitory activity.
AID385588	Inhibition of human PKCepsilon type M486A mutant	2007	The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45	Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID1531502	Inhibition of human ROCK1 assessed as residual activity at 100 uM using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1531619	Inhibition of human CDK14/cyclin-Y using RB protein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720122	Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID256648	Average Binding Constant for RPS6KA5 (Kin.Dom 1); NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID419615	Inhibition of human GSK3-beta	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
AID720425	Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531746	Inhibition of human LCK2 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID629268	Inhibition of CDK2/Cyclin E	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
AID1715186	Inhibition of human RIPK2 using MBP as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624987	Binding constant for ABL1(Q252H)-phosphorylated kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1351042	Inhibition of FMS (unknown origin) assessed as remaining activity at 4.88 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
AID624738	Binding constant for MLCK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID720316	Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531765	Inhibition of human MEK5 using ERK5 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID720482	Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID350298	Inhibition of TIE2/TEK	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1308982	Inhibition of SYK (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID1531609	Inhibition of human CAMK2B using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1410148	Inhibition of ZAP70 (unknown origin) by mobility shift assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID1531276	Inhibition of human CK1a1L assessed as residual activity at 100 uM using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1090414	Antimicrobial activity against Sclerotinia sclerotiorum assessed as growth inhibition incubated for 4 to 7 fays	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1630200	Induction of apoptosis in human A375 cells assessed as cells with active caspase-3 at 1 uM after 12 hrs by flow cytometry (Rvb = 4.16%)	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells.
AID1423825	Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) T790M/L858R/C797S mutant using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA
AID1189696	Inhibition of telomerase in human HepG2 cells at 2 uM after 3 days by TRAP-ELISA method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.
AID1531930	Inhibition of human WNK3 using MBP as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID426691	Inhibition of CHK1 at 25 nM by alphascreen assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Identification of inhibitors of checkpoint kinase 1 through template screening.
AID1715348	Inhibition of human FES using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1074852	Induction of apoptosis in human A2780 cells assessed as caspase 8 activity at 1 uM after 6 hrs relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Membrane damaging activity of a maslinic acid analog.
AID1531679	Inhibition of human EPHB1 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1308971	Inhibition of p38alpha (unknown origin) incubated for 1 hr by spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.
AID624815	Binding constant for ERBB4 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531774	Inhibition of human MKK7 using JNK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1481075	Inhibition of human JNK1 using ATF2 as substrate in presence of [gamma-32P]ATP	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
AID163197	Inhibition of Protein kinase C beta 1	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID163880	Inhibition of Protein kinase C gamma	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
AID256623	Average Binding Constant for MYLK2; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1715296	Inhibition of human LIMK1 using cofilin as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID720246	Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531329	Inhibition of human FES assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID438440	Inhibition of human Lyn	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Structural basis for the inhibitor recognition of human Lyn kinase domain.
AID436052	Binding constant for full-length SNF1LK2	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID435526	Binding constant for FGFR1 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1666227	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID435327	Binding constant for VEGFR2 kinase domain	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID624954	Binding constant for EPHB1 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID625025	Binding constant for MAK kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1895097	Inhibition of full length N-terminal nanoLuc-tagged human SIK2 expressed in HEK293 cells using NanoBRET NanoGlo substrate incubated for 2 hrs in presence of tracer K10 by NanoBRET assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors.
AID1410142	Inhibition of BRAF (unknown origin) by Lanthascreen assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.
AID625009	Binding constant for EPHA3 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531925	Inhibition of human VRK1 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID304248	Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 30 nM after 24 hrs by flow cytometry	2007	Journal of medicinal chemistry, 12-13, Volume: 50, Issue:25	Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy.
AID256578	Average Binding Constant for SLK; NA=Not Active at 10 uM	2005	Nature biotechnology, Mar, Volume: 23, Issue:3	A small molecule-kinase interaction map for clinical kinase inhibitors.
AID720144	Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1531617	Inhibition of human CDK1/cyclinB using Histone H1 as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID350262	Inhibition of EGFR	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1294635	Inhibition of human Aurora B using H-LRRASLG as substrate after 2 hrs by HotSpot assay in presence of 33P-ATP and 1 uM ATP	2016	Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9	Design, synthesis, and evaluation of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives as Aurora kinase inhibitors.
AID1484295	Induction of apoptosis in human PC3 cells assessed as apoptotic cells at 20 uM after 16 hrs by F2N12S orange and SYTOX green double staining based flow cytometry (Rvb = 2 to 3%)	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
AID1531621	Inhibition of human CDK17/cyclin-Y using MBP protein as substrate by [gamma-33P]-ATP assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1715427	Inhibition of human CAMK2B using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID304249	Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 30 nM after 24 hrs by flow cytometry	2007	Journal of medicinal chemistry, 12-13, Volume: 50, Issue:25	Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy.
AID1715326	Inhibition of human GSK3B using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate by [gamma-33P]-ATP assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID624722	Binding constant for MKK7 kinase domain	2011	Nature biotechnology, Oct-30, Volume: 29, Issue:11	Comprehensive analysis of kinase inhibitor selectivity.
AID1531545	Inhibition of human TLK2 assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID1423824	Inhibition of recombinant human EGFR T790M/L858R double mutant using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA
AID1531227	Inhibition of human AXL assessed as residual activity at 100 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
AID164627	Inhibition of Protein kinase A (Histone) (not tested)	2003	Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14	Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
AID435279	Binding constant for full-length CDK9	2008	Nature biotechnology, Jan, Volume: 26, Issue:1	A quantitative analysis of kinase inhibitor selectivity.
AID1090407	Antimicrobial activity against Bacillus subtilis subsp. subtilis assessed as growth inhibition incubated for 4 to 7 days	2006	Journal of agricultural and food chemistry, Apr-19, Volume: 54, Issue:8	Isolation and antifungal and antioomycete activities of staurosporine from Streptomyces roseoflavus strain LS-A24.
AID1801940	GSK-3β activity assay from Article 10.1016/j.bioorg.2016.07.007: \\Synthesis of pyrimidin-4-one-1,2,3-triazole conjugates as glycogen synthase kinase-3u00DF inhibitors with anti-depressant activity.\\	2016	Bioorganic chemistry, 10, Volume: 68	Synthesis of pyrimidin-4-one-1,2,3-triazole conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity.
AID1801382	Kinase Assay from Article 10.1111/cbdd.12546: \\Synthesis and Evaluation of 3-(furo[2,3-b]pyridin-3-yl)-4-(1H-indol-3-yl)-maleimides as Novel GSK-3u00DF Inhibitors and Anti-Ischemic Agents.\\	2015	Chemical biology & drug design, Oct, Volume: 86, Issue:4	Synthesis and Evaluation of 3-(furo[2,3-b]pyridin-3-yl)-4-(1H-indol-3-yl)-maleimides as Novel GSK-3β Inhibitors and Anti-Ischemic Agents.
AID1797134	Kinase Activity Assay from Article 10.1074/jbc.M512374200: \\Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.\\	2006	The Journal of biological chemistry, Aug-25, Volume: 281, Issue:34	Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.
AID1795401	PKC assay from Article 10.1021/jm00079a024: \\Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.\\	1992	Journal of medicinal chemistry, Jan, Volume: 35, Issue:1	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.
AID1798514	PLK Kinase Assay from Article 10.1021/bi7008745: \\Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.\\	2007	Biochemistry, Aug-21, Volume: 46, Issue:33	Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
AID1795420	PKC assay from Article 10.1021/jm00053a003: \\Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.\\	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID1795948	CDK Kinase Inhibition Assay from Article 10.1016/s0960-894x(03)00461-x: \\Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.\\	2003	Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14	Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
AID1799368	Scintillation Proximity Assay from Article 10.1038/nchembio.87: \\Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility.\\	2008	Nature chemical biology, Jun, Volume: 4, Issue:6	Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility.
AID1799403	Tyrosine Kinase Inhibition Assay from Article 10.1038/nchembio.162: \\A new screening assay for allosteric inhibitors of cSrc.\\	2009	Nature chemical biology, Jun, Volume: 5, Issue:6	A new screening assay for allosteric inhibitors of cSrc.
AID1797337	PKA/PKC Kinase Assay from Article 10.1016/j.bmcl.2005.12.065: \\Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.\\	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1799383	in vitro Kinase Assay from Article 10.1021/cb9002865: \\In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.\\	2010	ACS chemical biology, Feb-19, Volume: 5, Issue:2	In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.
AID1797336	Akt Kinase Assay from Article 10.1016/j.bmcl.2005.12.065: \\Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.\\	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
AID1797592	CDK Activity Assay. from Article 10.1074/jbc.M201233200: \\Structural basis for Chk1 inhibition by UCN-01.\\	2002	The Journal of biological chemistry, Nov-29, Volume: 277, Issue:48	Structural basis for Chk1 inhibition by UCN-01.
AID1797591	Chk1 Enzymatic Assay from Article 10.1074/jbc.M201233200: \\Structural basis for Chk1 inhibition by UCN-01.\\	2002	The Journal of biological chemistry, Nov-29, Volume: 277, Issue:48	Structural basis for Chk1 inhibition by UCN-01.
AID1797654	cFMs Autophosphorylation Fluorescence Polarization End Point Assay. from Article 10.1074/jbc.M608182200: \\Protein engineering of the colony-stimulating factor-1 receptor kinase domain for structural studies.\\	2007	The Journal of biological chemistry, Feb-09, Volume: 282, Issue:6	Protein engineering of the colony-stimulating factor-1 receptor kinase domain for structural studies.
AID1797593	CDK4 Activity Assay from Article 10.1074/jbc.M201233200: \\Structural basis for Chk1 inhibition by UCN-01.\\	2002	The Journal of biological chemistry, Nov-29, Volume: 277, Issue:48	Structural basis for Chk1 inhibition by UCN-01.
AID1797581	PDK1 Kinase Activity Assay from Article 10.1042/BJ20031119: \\Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition.\\	2003	The Biochemical journal, Oct-15, Volume: 375, Issue:Pt 2	Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition.
AID1799442	Inhibition Assay from Article 10.1016/1074-5521(95)90124-8: \\Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol.\\	1995	Chemistry & biology, Sep, Volume: 2, Issue:9	Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol.
AID1795421	PKA assay from Article 10.1021/jm00053a003: \\Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.\\	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.
AID1797363	Fluorescence Assays for Determination of Binding Affinity. from Article 10.1016/s1097-2765(05)00089-4: \\Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine.\\	2000	Molecular cell, Oct, Volume: 6, Issue:4	Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine.
AID1801812	Kinase-Glo Assay from Article 10.1111/cbdd.12724: \\Synthesis of Novel Oxazolo[4,5-b]pyridine-2-one based 1,2,3-triazoles as Glycogen Synthase Kinase-3u00DF Inhibitors with Anti-inflammatory Potential.\\	2016	Chemical biology & drug design, 06, Volume: 87, Issue:6	Synthesis of Novel Oxazolo[4,5-b]pyridine-2-one based 1,2,3-triazoles as Glycogen Synthase Kinase-3β Inhibitors with Anti-inflammatory Potential.
AID1796959	Kinase Assay from Article 10.1074/jbc.M413155200: \\Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002.\\	2005	The Journal of biological chemistry, Apr-08, Volume: 280, Issue:14	Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002.
AID1798742	Radiometric Kinase Assay from Article 10.1074/jbc.M400031200: \\Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.\\	2004	The Journal of biological chemistry, Apr-30, Volume: 279, Issue:18	Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.
AID1799260	In Vitro Protein Kinase Assay from Article 10.1124/mol.107.035832: \\Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.\\	2007	Molecular pharmacology, Oct, Volume: 72, Issue:4	Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.
AID1797135	Kinase Inhibition Assay from Article 10.1074/jbc.M512374200: \\Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.\\	2006	The Journal of biological chemistry, Aug-25, Volume: 281, Issue:34	Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.
AID1800263	c-Src Kinase Inhibitory Activity Assay from Article 10.1016/j.bioorg.2014.02.001: \\Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives.\\	2014	Bioorganic chemistry, Apr, Volume: 53	Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives.
AID1799441	Inhibition Assay from Article 10.1016/1074-5521(95)90124-8: \\Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol.\\	1995	Chemistry & biology, Sep, Volume: 2, Issue:9	Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2003	Journal of molecular biology, Oct-17, Volume: 333, Issue:2	Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.
AID1811	Experimentally measured binding affinity data derived from PDB	2003	Journal of molecular biology, Oct-17, Volume: 333, Issue:2	Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.
AID1811	Experimentally measured binding affinity data derived from PDB	2004	The Journal of biological chemistry, Dec-31, Volume: 279, Issue:53	A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2004	The Journal of biological chemistry, Dec-31, Volume: 279, Issue:53	A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
AID1811	Experimentally measured binding affinity data derived from PDB	2004	The Journal of biological chemistry, Oct-08, Volume: 279, Issue:41	The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: implications for the design of selective inhibitors.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2004	The Journal of biological chemistry, Oct-08, Volume: 279, Issue:41	The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: implications for the design of selective inhibitors.
AID1811	Experimentally measured binding affinity data derived from PDB	2005	The Journal of biological chemistry, Apr-08, Volume: 280, Issue:14	Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2005	The Journal of biological chemistry, Apr-08, Volume: 280, Issue:14	Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002.
AID1345403	Human protein kinase C iota (Iota subfamily)	2007	The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45	Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.
AID1345720	Human mitogen-activated protein kinase kinase 6 (STE7 family)	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID1345465	Human M4 receptor (Acetylcholine receptors (muscarinic))	2000	Molecular pharmacology, Jul, Volume: 58, Issue:1	Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site.
AID1345708	Human mitogen-activated protein kinase kinase 4 (STE7 family)	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
AID1345620	Human homeodomain interacting protein kinase 1 (HIPK subfamily)	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1345912	Human serine/threonine kinase 3 (MST subfamily)	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1345365	Human protein kinase N1 (Protein kinase N (PKN) family)	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1345346	Human calcium/calmodulin-dependent protein kinase II beta subunit (CAMK2 family)	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1345377	Human protein kinase, cAMP-dependent, catalytic, beta subunit (Protein kinase A)	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	The synthesis and evaluation of indolylureas as PKCα inhibitors.
AID1345286	Human M1 receptor (Acetylcholine receptors (muscarinic))	2000	Molecular pharmacology, Jul, Volume: 58, Issue:1	Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site.
AID1345742	Human phosphorylase kinase catalytic subunit gamma 2 (Phosphorylase kinase (PHK) family)	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1345771	Human p21 (RAC1) activated kinase 2 (PAKA subfamily)	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1345326	Human M2 receptor (Acetylcholine receptors (muscarinic))	2000	Molecular pharmacology, Jul, Volume: 58, Issue:1	Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site.
AID1345641	Human death associated protein kinase 1 (Death-associated kinase (DAPK) family)	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1345878	Human TRAF2 and NCK interacting kinase (MSN subfamily)	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	1997	Structure (London, England : 1993), Dec-15, Volume: 5, Issue:12	Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2006	Biochemical and biophysical research communications, Aug-04, Volume: 346, Issue:3	Structure of human Fyn kinase domain complexed with staurosporine.
AID1811	Experimentally measured binding affinity data derived from PDB	2006	Biochemical and biophysical research communications, Aug-04, Volume: 346, Issue:3	Structure of human Fyn kinase domain complexed with staurosporine.
AID1811	Experimentally measured binding affinity data derived from PDB	2006	Acta biochimica et biophysica Sinica, Jun, Volume: 38, Issue:6	Crystal structure of the MAP3K TAO2 kinase domain bound by an inhibitor staurosporine.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2006	Acta biochimica et biophysica Sinica, Jun, Volume: 38, Issue:6	Crystal structure of the MAP3K TAO2 kinase domain bound by an inhibitor staurosporine.
AID1811	Experimentally measured binding affinity data derived from PDB	2004	The Journal of biological chemistry, Nov-26, Volume: 279, Issue:48	Catalytic domain crystal structure of protein kinase C-theta (PKCtheta).
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2004	The Journal of biological chemistry, Nov-26, Volume: 279, Issue:48	Catalytic domain crystal structure of protein kinase C-theta (PKCtheta).
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2002	The Journal of biological chemistry, Nov-29, Volume: 277, Issue:48	Structural basis for Chk1 inhibition by UCN-01.
AID1811	Experimentally measured binding affinity data derived from PDB	2002	The Journal of biological chemistry, Nov-29, Volume: 277, Issue:48	Structural basis for Chk1 inhibition by UCN-01.
AID602156	Novartis GNF Liver Stage Dataset: Malariabox Annotation	2011	Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061	Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2007	Protein science : a publication of the Protein Society, Dec, Volume: 16, Issue:12	Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Structural basis for the inhibitor recognition of human Lyn kinase domain.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2010	Biochemistry, Mar-02, Volume: 49, Issue:8	Biophysical and X-ray crystallographic analysis of Mps1 kinase inhibitor complexes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	97 (1.50)	18.7374
1990's	2777 (42.80)	18.2507
2000's	2191 (33.77)	29.6817
2010's	1158 (17.85)	24.3611
2020's	265 (4.08)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	58 (0.92%)	5.53%
Reviews	15 (3.61%)	6.00%
Reviews	158 (2.52%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	35 (0.56%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	3 (0.05%)	0.25%
Other	401 (96.39%)	84.16%
Other	6,018 (95.95%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia [NCT01174888]	Phase 1	34 participants (Actual)	Interventional	2010-08-31	Completed
"A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial" [NCT03092674]	Phase 2/Phase 3	78 participants (Actual)	Interventional	2018-02-02	Active, not recruiting
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML [NCT02115295]	Phase 2	458 participants (Anticipated)	Interventional	2014-05-19	Recruiting
An Open-Label Extension Study of Post-Transplant Maintenance Midostaurin (PKC412) in Elderly Patients (Age ≥ 60 Years) With FLT3-ITD/TKD Mutated AML Who Previously Received Midostaurin and Decitabine as Part of Study HEMAML0022 / CPKC412AUS27T [NCT02723435]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to Logistical and administrative issues)
An Open-label, Parallel Group, Phase I Study to Assess the Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function. [NCT01429337]	Phase 1	43 participants (Actual)	Interventional	2011-03-07	Completed
A Phase 2 Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly Patients With Newly Diagnosed FLT3-ITD/TKD Positive Acute Myeloid Leukemia [NCT01846624]	Phase 2	13 participants (Actual)	Interventional	2013-06-30	Terminated(stopped due to Accrual factor)
A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation [NCT02634827]	Phase 2	1 participants (Actual)	Interventional	2015-12-30	Terminated
MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) [NCT04385290]	Phase 1/Phase 2	214 participants (Anticipated)	Interventional	2020-09-04	Recruiting
A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia. [NCT01093573]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2009-07-31	Completed
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia [NCT03900949]	Phase 1	18 participants (Anticipated)	Interventional	2019-03-13	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial	Outcome
NCT01093573 (5) [back to overview]	Duration of Response
NCT01093573 (5) [back to overview]	Maximum Tolerated Dose of Midostaurin in Combination With Azacitidine in Patients With Acute Myelogenous Leukemia (Phase I)
NCT01093573 (5) [back to overview]	Number of Participants With Hematologic Improvement (Phase I)
NCT01093573 (5) [back to overview]	Overall Survival (Phase II)
NCT01093573 (5) [back to overview]	Toxicity Profile (Phase II)
NCT01846624 (5) [back to overview]	Complete Remission (CR) Rate
NCT01846624 (5) [back to overview]	Median Duration of Response (DoR)
NCT01846624 (5) [back to overview]	Overall Response Rate (ORR)
NCT01846624 (5) [back to overview]	Overall Survival (OS)
NCT01846624 (5) [back to overview]	Progression-free Survival (PFS)

Intervention	days (Median)
Dose Level 3	252

Intervention	mg/bid (Number)
Midostaurin Dose Escalation	75

Intervention	Participants (Count of Participants)
Dose Level 1	0
Dose Level 2	0
Dose Level 3	2

Intervention	days (Median)
Dose Level 3	244

Intervention	Participants (Count of Participants)
Dose Level 3	24

Intervention	Participants (Count of Participants)
Decitabine, Then Midostaurin	8

Intervention	weeks (Median)
Decitabine, Then Midostaurin	24

Intervention	Participants (Count of Participants)
Decitabine, Then Midostaurin	10

Intervention	Participants (Count of Participants)
Decitabine, Then Midostaurin	2

Intervention	Participants (Count of Participants)
Decitabine, Then Midostaurin	0

Substance	Relationship Strength	Studies	Trials	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.44	2	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
4-hydroxybenzoic acid 4-hydroxybenzoic acid : A monohydroxybenzoic acid that is benzoic acid carrying a hydroxy substituent at C-4 of the benzene ring.	3.08	1	0	monohydroxybenzoic acid	algal metabolite; plant metabolite
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	2.46	2	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
aminooxyacetic acid Aminooxyacetic Acid: A compound that inhibits aminobutyrate aminotransferase activity in vivo, thereby raising the level of gamma-aminobutyric acid in tissues.. (aminooxy)acetic acid : A member of the class of hydroxylamines that is acetic acid substituted at postion 2 by an aminooxy group. It is a compound which inhibits aminobutyrate aminotransferase activity in vivo, resulting in increased levels of gamma-aminobutyric acid in tissues.	2.05	1	0	amino acid; hydroxylamines; monocarboxylic acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor; EC 4.2.1.22 (cystathionine beta-synthase) inhibitor; nootropic agent
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	2.05	1	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
melatonin [no description available]	2.46	2	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.03	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	2.08	1	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
8-hydroxy-2-(di-n-propylamino)tetralin 8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively	2.04	1	0	phenols; tertiary amino compound; tetralins	serotonergic antagonist
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.	2.06	1	0	non-proteinogenic alpha-amino acid
gallopamil Gallopamil: Coronary vasodilator that is an analog of iproveratril (VERAPAMIL) with one more methoxy group on the benzene ring.	2.04	1	0	benzenes; organic amino compound
1,3-dipropyl-8-cyclopentylxanthine DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.	2.46	2	0	oxopurine	adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
1-(3-chlorophenyl)piperazine 1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.	2.08	1	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
pd 173074 [no description available]	2.03	1	0	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
hoe 33342 BXI-72: structure in first source	2.05	1	0	bibenzimidazole; N-methylpiperazine	fluorochrome
3,4-dichloroisocoumarin 3,4-dichloroisocoumarin : A member of the class of isocoumarins that is isocoumarin substituted by chloro groups at positions 3 and 4. It is a serine protease inhibitor.	2.04	1	0	isocoumarins; organochlorine compound	geroprotector; serine protease inhibitor
3-nitropropionic acid 3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE. 3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.	2.03	1	0	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin
nsc-267703 [no description available]	2.06	1	0	anthracycline
4,5,6,7-tetrabromo-2-azabenzimidazole 4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor	3.84	3	0
phenytoin [no description available]	2.49	2	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
7,8-dihydroxyflavone 7,8-dihydroxyflavone : A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A naturally occurring flavonoid produced by several plants, including the weed Tridax procumbens (coalbuttons or tridax daisy) and the tree Godmania aesculifolia, In animal models, it has shown efficacy against several diseases of the nervous system, including Alzheimer's, Parkinson's, and Huntington's.	3.08	1	0	dihydroxyflavone	antidepressant; antineoplastic agent; antioxidant; plant metabolite; tropomyosin-related kinase B receptor agonist
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	3.9	3	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
N-(2-aminoethyl)-5-chloro-1-naphthalenesulfonamide [no description available]	2.03	1	0	naphthalenes; sulfonic acid derivative
acebutolol Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.	2.05	1	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.76	3	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	4.98	10	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohydroxamic acid acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.	2.05	1	0	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
dactinomycin [no description available]	2.06	1	0	cyclodepsipeptide
tyrphostin ag 1024 tyrphostin AG 1024: modulates radiosensitivity in human breast cancer cells; also an IGF1 receptor inhibitor	2.08	1	0	alkylbenzene
ag 1295 [no description available]	2.46	2	0	quinoxaline derivative	geroprotector
ag-1296 6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase	2.08	1	0	quinoxaline derivative
rtki cpd [no description available]	2.49	2	0	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector
tyrphostin a23 tyrphostin A23: inhibits EGF-stimulated thymidine incorporation as well as EGF-stimulated receptor autophosphorylation & tyrosine phosphorylation & cell proliferation; structure given in first source	2.03	1	0	catechols
tyrphostin a1 [no description available]	2.08	1	0	methoxybenzenes	geroprotector
1-aminoindan-1,5-dicarboxylic acid 1-aminoindan-1,5-dicarboxylic acid: structure given in first source	2.06	1	0
albendazole [no description available]	2.53	2	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	2.47	2	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	2.5	2	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	2.05	1	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.47	2	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
diatrizoic acid Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.	2.08	1	0	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.47	2	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
theophylline [no description available]	3.19	5	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.76	3	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
dan 2163 [no description available]	2.08	1	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	2.76	3	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.08	1	0	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	2.47	2	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amodiaquine Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.	2.06	1	0	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.	2.08	1	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	2.47	2	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole [no description available]	2.08	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
anthralin Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.	2.08	1	0	anthracenes	antipsoriatic
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	2.47	2	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
aprindine Aprindine: A class Ib anti-arrhythmia agent used to manage ventricular and supraventricular arrhythmias.	2.05	1	0	indanes
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	2.76	3	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.75	3	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	3.19	5	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	2.76	3	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
baclofen [no description available]	2.08	1	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	2.47	2	0	1-benzofurans; aromatic ketone	uricosuric drug
benzocaine Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.	2.08	1	0	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
bepridil Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.	2.05	1	0	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
berberine [no description available]	2.06	1	0	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.08	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
bay h 4502 bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1.	2.08	1	0	biphenyls; imidazoles
bisacodyl Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)	2.08	1	0	diarylmethane
bisbenzimidazole Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.	2.05	1	0	bibenzimidazole; N-methylpiperazine	anthelminthic drug; fluorochrome
bisindolylmaleimide i bisindolylmaleimide I: a bis(indolyl)maleimide	4.93	11	0
2-(1-(2-(1-methylpyrrolidino)ethyl)-1h-indol-3-yl)maleimide bisindolylmaleimide II: protein kinase C inhibitor; see also bisindolylmaleimide I	2.03	1	0
bisindolylmaleimide iv [no description available]	3.12	5	0	indoles; maleimides
bisindolylmaleimide v bisindolylmaleimide V: used as a negative control compound for protein kinase C inhibition; structure in first source;	2.4	2	0	indoles
ro 31-7549 Ro 31-7549: structure	2.4	2	0
ro 31-8425 [no description available]	1.98	1	0
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	2.05	1	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bohemine bohemine : Purine substituted on C-2, C-6 and N-9 with (3-hydroxypropyl)amino, benzylamino and isopropyl groups respectively; a synthetic, cell-permeable, cyclin-dependent kinase (CDK) inhibitor that is structurally similar to olomoucine and roscovitine.	2.46	2	0	purines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bretylium bretylium: RN given refers to parent cpd. bretylium : A quaternary ammonium cation having 2-bromobenzyl, ethyl and two methyl groups attached to the nitrogen. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.	2.05	1	0	quaternary ammonium ion	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent
bromhexine Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).	2.05	1	0	organobromine compound; substituted aniline; tertiary amino compound	mucolytic
bromopride bromopride: RN given refers to parent cpd; structure	2.08	1	0	benzamides
bronopol [no description available]	2.08	1	0	nitro compound
bumetanide [no description available]	2.76	3	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
busulfan [no description available]	2.47	2	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
caffeine [no description available]	2.8	3	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	4.83	9	0	aromatic ether; nitrile; polyether; tertiary amino compound
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	3.02	4	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.47	2	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carprofen carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.	2.08	1	0	carbazoles; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent
carteolol Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.	2.05	1	0	quinolone; secondary alcohol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
carvedilol [no description available]	2.08	1	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
carbonyl cyanide m-chlorophenyl hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.	2.1	1	0	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
celecoxib [no description available]	2.48	2	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	2.46	2	0	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.79	3	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlordiazepoxide Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.	2.76	3	0	benzodiazepine
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	3.56	8	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	2.47	2	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.76	3	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	2.76	3	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.	2.47	2	0	isoindoles; monochlorobenzenes; sulfonamide
chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.	2.08	1	0	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
cifenline [no description available]	2.08	1	0	diarylmethane
ciclopirox [no description available]	2.08	1	0	cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone	antibacterial agent; antiseborrheic
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	2.47	2	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
cilostazol [no description available]	2.08	1	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	2.97	4	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
aricine [no description available]	2.06	1	0	cinchona alkaloid
ciprofibrate [no description available]	2.47	2	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	3	4	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
cisapride Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed). cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.	2.1	1	0	benzamides
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	2.47	2	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
cl 387785 CL 387785: structure in first source. N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.	2.11	1	0	bromobenzenes; quinazolines; secondary carboxamide; ynamide	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
clenbuterol Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.. clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.05	1	0	amino alcohol; dichlorobenzene; ethanolamines; primary arylamine; secondary amino compound; substituted aniline	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	2.79	3	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clobazam Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.. clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.	2.08	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator
clofazimine Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.	2.47	2	0	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	2.76	3	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clofilium clofilium: RN given refers to parent cpd; structure	2.06	1	0	benzenes; organic amino compound
clomiphene [no description available]	2.08	1	0	tertiary amine	estrogen antagonist; estrogen receptor modulator
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	2.76	3	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	2.82	3	0	clonidine; imidazoline
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide [no description available]	2.47	2	0	sulfonamide
chlorazepate clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.	2.05	1	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
clotrimazole [no description available]	2.06	1	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
damnacanthal damnacanthal: structure given in first source; isolated from the stem bark and roots of Morinda lucida; a selective inhibitor of p56(lck) tyrosine kinase activity	2.03	1	0	aldehyde; monohydroxyanthraquinone
dapsone [no description available]	2.76	3	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
debrisoquin Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.	2.05	1	0	carboxamidine; isoquinolines	adrenergic agent; antihypertensive agent; human metabolite; sympatholytic agent
dequalinium Dequalinium: A topical bacteriostat that is available as various salts. It is used in wound dressings and mouth infections and may also have antifungal action, but may cause skin ulceration.. dequalinium : A quinolinium ion comprising decane in which one methyl hydrogen at each end of the molecule has been replaced by a 4-amino-2-methylquinolin-1-yl group.	2.06	1	0	quinolinium ion	antifungal agent; antineoplastic agent; antiseptic drug; mitochondrial NADH:ubiquinone reductase inhibitor
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	2.76	3	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
r 59022 R 59022: diacylglycerol kinase inhibitor; structure given in first source; platelet activator factor antagonist	2.03	1	0	diarylmethane
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	3.15	5	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	2.76	3	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	2.45	2	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
3,4-dihydroxybenzohydroxamic acid [no description available]	2.05	1	0	benzoic acids
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	2.05	1	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
dimercaprol Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.	2.05	1	0	dithiol; primary alcohol	chelator
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	2.05	1	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	2.08	1	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	2.47	2	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
disulfiram [no description available]	2.08	1	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
n(6),n(6)-dimethyladenine N(6),N(6)-dimethyladenine : A tertiary amine that is adenine substituted at N-6 by geminal methyl groups.	2.03	1	0	tertiary amine
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.47	2	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	4.22	4	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
doxepin Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.	2.47	2	0	dibenzooxepine; tertiary amino compound	antidepressant
e 4031 E 4031: class III anti-arrhythmia agent; structure given in UD	2.86	3	0	sulfonamide
ebastine [no description available]	2.08	1	0	organic molecular entity
nsc-526417 [no description available]	2.06	1	0
ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.	2.49	2	0	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite
emodin Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.	3.5	2	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
enoxacin Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.	2.55	2	0	1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
ethacrynic acid Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.	2.47	2	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
ethosuximide Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.	2.47	2	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
ethyl loflazepate ethyl loflazepate: structure given in first source	2.05	1	0	organic molecular entity
brl 42810 [no description available]	2.08	1	0	2-aminopurines; acetate ester	antiviral drug; prodrug
carbonyl cyanide p-trifluoromethoxyphenylhydrazone Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.	2.21	1	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
4-biphenylylacetic acid biphenyl-4-ylacetic acid : A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis.	2.08	1	0	biphenyls; monocarboxylic acid	non-steroidal anti-inflammatory drug
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	2.47	2	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	2.47	2	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.05	1	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.05	1	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	2.05	1	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fleroxacin Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.	2.08	1	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	3.65	2	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	2.08	1	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
fluphenazine [no description available]	2.05	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	2.47	2	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
flunitrazepam Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.	2.03	1	0	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
fluorescite fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.	2.47	2	0	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	5.46	18	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.99	4	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	2.05	1	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	2.76	3	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
furafylline [no description available]	2.11	1	0	oxopurine
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.76	3	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
vanoxerine vanoxerine: structure given in first source. vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.	2.04	1	0	ether; N-alkylpiperazine; organofluorine compound; tertiary amino compound	dopamine uptake inhibitor
gemfibrozil [no description available]	2.47	2	0	aromatic ether	antilipemic drug
gentian violet crystal violet cation : An iminium ion that is malachite green cation in which the hydrogen at the para- psition of the monosubstituted phenyl group is replaced by a dimethylamino group.	2.06	1	0	iminium ion	antibacterial agent; antifungal agent
gliclazide Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.	2.08	1	0	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger
glimepiride glimepiride: structure given in first source	2.47	2	0	sulfonamide
glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.	2.47	2	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glutethimide Glutethimide: A hypnotic and sedative. Its use has been largely superseded by other drugs.	2.05	1	0	piperidines
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	2.47	2	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
gö6983 [no description available]	2.57	2	0	indoles; maleimides
go 6976 [no description available]	2.96	4	0	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
guanethidine Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.	2.05	1	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
guanfacine Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.	2.47	2	0	acetamides
ha 1004 N-(2-guanidinoethyl)-5-isoquinolinesulfonamide: structure given in first source	2.03	1	0	isoquinolines
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	4.27	5	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.78	3	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	2.21	1	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
hexahydrosiladifenidol [no description available]	2.06	1	0
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	2.47	2	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroflumethiazide Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.	2.08	1	0	benzothiadiazine; thiazide	antihypertensive agent; diuretic
hydroxyurea [no description available]	2.8	3	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	2.05	1	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.46	2	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
phenelzine Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.	2.05	1	0	primary amine
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.99	4	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifosfamide [no description available]	2.08	1	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.76	3	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	2.76	3	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
incadronate [no description available]	2.05	1	0	1,1-bis(phosphonic acid)
indapamide Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.	2.76	3	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
indirubin-3'-monoxime indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	4.84	10	0
indirubin-5-sulfonate [no description available]	3.13	1	0
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.76	3	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	2.08	1	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iproniazid [no description available]	2.47	2	0	carbohydrazide; pyridines
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	2.08	1	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.35	6	0	carbohydrazide	antitubercular agent; drug allergen
isradipine Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.	2.08	1	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
itraconazole [no description available]	2.47	2	0	piperazines
whi p154 WHI P154: an anti-leukemic agent; structure in first source	2.08	1	0
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone ZM39923: structure in first source	2.08	1	0	naphthalenes
1-(2-naphthalenyl)-2-propen-1-one [no description available]	2.03	1	0	naphthalenes
staurosporine aglycone staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor	2.43	2	0
nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).	4.64	8	0	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.76	3	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	3.17	5	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	3.17	5	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.05	1	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketotifen Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.	2.05	1	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	2.05	1	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lamotrigine [no description available]	2.08	1	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	2.76	3	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
lavendustin a lavendustin A: from Streptomyces griseolavendus; structure given in first source	3.5	2	0	aromatic amine
lavendustin b [no description available]	3.08	1	0
2-hydroxy-5-(2,5-dihydrobenzyl)aminobenzoic acid [no description available]	2.44	2	0	aromatic amine
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.08	1	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	3.65	2	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lofepramine Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.	2.47	2	0	aromatic ketone; dibenzoazepine; monochlorobenzenes; tertiary amino compound	antidepressant
lomustine [no description available]	2.47	2	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	2.08	1	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
lorazepam Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.	2.05	1	0	benzodiazepine
ly 303511 LY 303511: inhibitor of phosphatidylinositol 3-kinase	2.08	1	0	N-arylpiperazine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	3.75	10	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
maprotiline Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.	2.76	3	0	anthracenes
mazindol Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.	2.05	1	0	organic molecular entity
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	2.48	2	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.	2.05	1	0	nitrogen mustard; organochlorine compound	alkylating agent
mefenamic acid Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.	2.08	1	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
mefloquine hydrochloride [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.	2.73	3	0	organofluorine compound; piperidines; quinolines; secondary alcohol
vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.	2.58	2	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	2.05	1	0	imidazolidine-2,4-dione	anticonvulsant
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.47	2	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methoxyamine methoxyamine: analytical reagent for aldehydes and ketones; strong irritant, can probably produce methemoglobinemia; RN given refers to parent cpd; structure	2.05	1	0	organooxygen compound
methoxyflurane Methoxyflurane: An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with NITROUS OXIDE to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180). methoxyflurane : An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl.	2.05	1	0	ether; organochlorine compound; organofluorine compound	hepatotoxic agent; inhalation anaesthetic; nephrotoxic agent; non-narcotic analgesic
methyl methanesulfonate [no description available]	2.03	1	0	methanesulfonate ester	alkylating agent; apoptosis inducer; carcinogenic agent; genotoxin; mutagen
methylphenidate Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.	2.05	1	0	beta-amino acid ester; methyl ester; piperidines
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	2.76	3	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	2.8	3	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	4.32	5	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
metyrapone Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.	2.1	1	0	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	2.47	2	0	aromatic ether; primary amino compound	anti-arrhythmia drug
mianserin Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.	2.05	1	0	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	2.47	2	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
milrinone [no description available]	2.04	1	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	2.76	3	0	dialkylarylamine; tertiary amino compound
mirtazapine Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.	2.08	1	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.05	1	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
ml 9 [no description available]	2.03	1	0	naphthalenes; sulfonic acid derivative
moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.	2.76	3	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
n-acetyl-4-nitrophenylserinol N-acetyl-4-nitrophenylserinol: RN given refers to cpd without isomeric designation; structure	2.06	1	0
acecainide Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.	2.47	2	0	acetamides; benzamides	anti-arrhythmia drug
clorgyline Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.. clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.	2.04	1	0	aromatic ether; dichlorobenzene; terminal acetylenic compound; tertiary amino compound	antidepressant; EC 1.4.3.4 (monoamine oxidase) inhibitor
nabumetone Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.	2.05	1	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
nadolol [no description available]	2.47	2	0	tetralins
nalidixic acid [no description available]	2.08	1	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
nefazodone nefazodone: may be useful as an opiate adjunct	2.47	2	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nefopam Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.	2.47	2	0	benzoxazocine; tertiary amino compound
neostigmine Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.	2.47	2	0	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.47	2	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	2.47	2	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	2.47	2	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	2.08	1	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	2.47	2	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nisoldipine Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.	2.08	1	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrazepam Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).	2.47	2	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.76	3	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	2.05	1	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	2.05	1	0	isoquinolines	dopamine uptake inhibitor
masoprocol nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)	1.99	1	0	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	3.9	3	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	2.76	3	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
ns 2028 NS 2028: structure in first source	2.04	1	0
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source. NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.	2.48	2	0	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor
nu6102 NU6102: structure in first source	3.58	2	0
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	2.55	2	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	4.22	5	0	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	2.76	3	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	2.47	2	0	carbazoles
oxaprozin Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.	2.08	1	0	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
oxatomide oxatomide: structure; an anti-allergic & an anti-asthmatic. oxatomide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug.	2.05	1	0	benzimidazoles; diarylmethane; N-alkylpiperazine	anti-allergic agent; anti-inflammatory agent; geroprotector; H1-receptor antagonist; serotonergic antagonist
oxazepam Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.	2.05	1	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
oxiracetam oxiracetam: structure in first source	2.06	1	0	organonitrogen compound; organooxygen compound
oxprenolol Oxprenolol: A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.	2.05	1	0	aromatic ether
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	2.47	2	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
oxyphenbutazone Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.	2.05	1	0	phenols; pyrazolidines	antimicrobial agent; antineoplastic agent; antipyretic; drug metabolite; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic metabolite
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	2.05	1	0	aminobenzoic acid; phenols	antitubercular agent
pamidronate [no description available]	2.05	1	0	phosphonoacetic acid
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	2.05	1	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	2.76	3	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pd 153035 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source. PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.	4.42	6	0	aromatic amine; aromatic ether; bromobenzenes; quinazolines; secondary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
pd 158780 [no description available]	2.08	1	0	aromatic amine; bromobenzenes; diamine; pyridopyrimidine; secondary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
pd 169316 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor	2.46	2	0	imidazoles
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.95	4	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pemoline Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.	2.08	1	0	1,3-oxazoles	central nervous system stimulant
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.98	4	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentoxifylline [no description available]	2.47	2	0	oxopurine
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	2.76	3	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.76	3	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenindione Phenindione: An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)	2.05	1	0	aromatic ketone; beta-diketone	anticoagulant
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	2.05	1	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phentermine Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.	2.05	1	0	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.	2.05	1	0	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
pifithrin pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source	2.03	1	0	aromatic ketone
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	2.47	2	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.47	2	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piracetam Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.	2.52	2	0	organonitrogen compound; organooxygen compound
pirenzepine Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.	2.04	1	0	pyridobenzodiazepine	anti-ulcer drug; antispasmodic drug; muscarinic antagonist
piribedil Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.	2.08	1	0	N-arylpiperazine
1-NA-PP1 [no description available]	2.44	2	0	pyrazolopyrimidine	tyrosine kinase inhibitor
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	4.68	8	0	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine [no description available]	2.08	1	0	pyrazoles; ring assembly
ono 1078 pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist	2.08	1	0	chromones
pyranoprofen pyranoprofen: RN given refers to unlabled parent cpd; structure given in first source	2.08	1	0	pyridochromene
praziquantel azinox: Russian drug	2.08	1	0	isoquinolines
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	2.75	3	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	2.76	3	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
primidone Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.	2.08	1	0	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	2.08	1	0	benzoic acids; sulfonamide	uricosuric drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	2.76	3	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
procaine Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).. procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.	2.05	1	0	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
procarbazine Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	2.05	1	0	benzamides; hydrazines	antineoplastic agent
prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.	2.47	2	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
procyclidine Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.	2.08	1	0	pyrrolidines; tertiary alcohol	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	2.76	3	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
pronethalol pronethalol: was heading 1964-94 (Prov 1964-66); NAPHTHYLISOPROTERENOL was see PRONETHALOL 1977-94; use ETHANOLAMINES to search PRONETHALOL 1966-94	2.06	1	0	naphthalenes
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	2.48	2	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.99	4	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protriptyline Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.	2.04	1	0	carbotricyclic compound	antidepressant
pyrilamine Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.	2.04	1	0	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
pyrimethamine Maloprim: contains above 2 cpds	2.46	2	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rabeprazole Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.	2.05	1	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one [no description available]	2.15	1	0	indoles
ranitidine [no description available]	2.47	2	0	aralkylamine
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.08	1	0	benzothiazoles
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	2.47	2	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
ro 31-8220 Ro 31-8220: a protein kinase C inhibitor	4.54	7	0	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
ro 31-8830 Ro 31-8830: structure given in first source; derivative of Ro 31-8425 with in vivo anti-inflammatory activity	1.98	1	0
rofecoxib [no description available]	2.47	2	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
rolipram [no description available]	2.04	1	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
sanguinarine benzophenanthridine alkaloid : A specific group of isoquinoline alkaloids that occur only in higher plants and are constituents mainly of the Papaveraceae family.	3.25	1	0	alkaloid antibiotic; benzophenanthridine alkaloid; botanical anti-fungal agent
sb 220025 SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.	2.46	2	0	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 239063 SB 239063: structure in first source. SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.	2.03	1	0	imidazoles
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	5.24	11	0	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
scriptaid scriptide: provokes translocation of GLUT4 to increase glucose uptake; structure in first source	2.06	1	0	isoquinolines
sulfadiazine Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.	2.47	2	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
sk&f 86002 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase	2.47	2	0	imidazoles
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	2.5	2	0	pyridines
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	2.47	2	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
sq 22536 9-(tetrahydrofuryl)adenine : A nucleoside analogue that is adenine in which the nitrogen at position 9 has been substituted by a tetrahydrofuran-2-yl group. It is an adenylate cyclase inhibitor.	2.04	1	0	nucleoside analogue; oxolanes	EC 4.6.1.1 (adenylate cyclase) inhibitor
imatinib [no description available]	5.75	19	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.01	4	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	2.47	2	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfanilamide [no description available]	3.41	1	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfanitran [no description available]	2.08	1	0	sulfonamide
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.47	2	0
sulfisoxazole Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.	2.47	2	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
sulforaphane sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.	2.05	1	0	isothiocyanate; sulfoxide	antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite
sumatriptan Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.	2.47	2	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	2.44	2	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.08	1	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.	2.08	1	0	acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane	keratolytic drug; prodrug; teratogenic agent
temozolomide [no description available]	2.08	1	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terazosin Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia	2.08	1	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terbutaline Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.76	3	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.74	3	0	diarylmethane
thioridazine Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.	2.53	2	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	2.47	2	0	aziridines
tiapride [no description available]	2.08	1	0	benzamides
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	2.05	1	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tilorone Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.	2.47	2	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.	2.08	1	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
tizanidine tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.	2.47	2	0	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
nikethamide Nikethamide: A central nervous system stimulant. It was formerly used in the treatment of barbiturate overdose but is now considered to be of no value for such purposes and may be dangerous. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1229)	2.08	1	0	pyridinecarboxamide
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	2.76	3	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
tolnaftate [no description available]	2.08	1	0	monothiocarbamic ester	antifungal drug
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine: a zinc ion chelating agent; structure given in first source. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine : An N-substituted diamine that is ethylenediamine in which the four amino hydrogens are replaced by 2-pyridylmethyl groups.	2.08	1	0	N-substituted diamine; pyridines; tertiary amino compound	apoptosis inducer; chelator; copper chelator
trazodone Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.	2.47	2	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	2.76	3	0	pteridines	diuretic; sodium channel blocker
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	2.05	1	0	triazolobenzodiazepine	sedative
triclosan [no description available]	2.05	1	0	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
trifluoperazine [no description available]	2.7	3	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trimethadione Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.	2.05	1	0	oxazolidinone	anticonvulsant; geroprotector
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.76	3	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.47	2	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
thenoyltrifluoroacetone Thenoyltrifluoroacetone: Chelating agent and inhibitor of cellular respiration.	2.08	1	0
undecylenic acid undecylenic acid: a fatty acid with a terminal double bond. 10-undecenoic acid : An undecenoic acid having its double bond in the 10-position. It is derived from castor oil and is used for the treatment of skin problems.. undecenoic acid : A C11, straight-chain fatty acid carrying a C=C double bond at any position.	2.08	1	0	undecenoic acid	antifungal drug; plant metabolite
urapidil [no description available]	2.47	2	0	piperazines
6,18,30-trimethyl-3,9,12,15,21,24,27,33,36-nona(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone [no description available]	2.06	1	0	cyclodepsipeptide
venlafaxine venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.	2.47	2	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
vigabatrin [no description available]	2.08	1	0	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
whi p180 [no description available]	2.43	2	0
pirinixic acid pirinixic acid: structure	2.47	2	0	aryl sulfide; organochlorine compound; pyrimidines
ici 204,219 zafirlukast: a leukotriene D4 receptor antagonist	2.08	1	0	carbamate ester; indoles; N-sulfonylcarboxamide	anti-asthmatic agent; leukotriene antagonist
zaleplon zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.	2.08	1	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
zm 336372 N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source	2.03	1	0	benzamides
zolpidem Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.	2.03	1	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
zonisamide Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.	2.47	2	0	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
zopiclone zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.	2.47	2	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2.03	1	0	mitomycin	alkylating agent; antineoplastic agent
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	2.47	2	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	4.29	5	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
penicillamine Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.	2.08	1	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	2.25	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
paramethasone Paramethasone: A glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than HYDROCORTISONE with supplementary FLUDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p737)	2.05	1	0	fluorinated steroid
dichlororibofuranosylbenzimidazole Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.	2.73	3	0
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	3.63	2	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.47	2	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	4.66	4	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
cetrimonium bromide cetyltrimethylammonium bromide : The organic bromide salt that is the bromide salt of cetyltrimethylammonium; one of the components of the topical antiseptic cetrimide.	2.05	1	0	organic bromide salt; quaternary ammonium salt	detergent; surfactant
vincristine [no description available]	2.15	1	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.08	1	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
tubocurarine Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.	2.47	2	0	bisbenzylisoquinoline alkaloid	drug allergen; muscle relaxant; nicotinic antagonist
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.47	2	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	2.47	2	0	kanamycins	bacterial metabolite
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.47	2	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	2.21	1	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	3.53	2	0	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	5.3	9	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	3.19	5	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
fluocinolone acetonide Fluocinolone Acetonide: A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluocinolone acetonide : A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders.	2.05	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; glucocorticoid; organic heteropentacyclic compound; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
triamcinolone diacetate triamcinolone diacetate: lysyl oxidase antagonist; Polcortolon may also refers to triamcinolone	2.08	1	0	corticosteroid hormone
norethindrone Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.	2.05	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	3.64	2	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
mannitol [no description available]	2.05	1	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine [no description available]	2.75	3	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
phenacyl bromide phenacyl bromide: structure. phenacyl bromide : An alpha-bromoketone that is acetophenone substituted by a bromo group at position 2.	3.23	1	0	acetophenones; alpha-bromoketone	metabolite
medroxyprogesterone acetate [no description available]	2.08	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
veratridine [no description available]	2.04	1	0	steroid	sodium channel modulator
sulfobromophthalein sodium bromosulfophthalein sodium : An organic sodium salt that is the disodium salt of bromosulfophthalein.. bromosulfophthalein : An organosulfonic acid that consists of phthalide bearing four bromo substituents at positions 4, 5, 6 and 7 as well as two 4-hydroxy-3-sulfophenyl groups both located at position 1.	2.05	1	0	organic sodium salt	dye
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	2.08	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
rhodamine b rhodamine B: RN & N1 from 9th CI Form Index; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7973; TETRAETHYLRHODAMINE was see RHODAMINES 1975-93; use RHODAMINES to search TETRAETHYLRHODAMINE 1975-93. rhodamine B : An organic chloride salt having N-[9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethylethanaminium as the counterion. An amphoteric dye commonly used as a fluorochrome.	2.31	1	0	organic chloride salt; xanthene dye	fluorescent probe; fluorochrome; histological dye
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.76	3	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.08	1	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
phanquinone phanquinone: structure. phanquone : An orthoquinone that is the 5,6-diketo derivative of 4,7-phenanthroline.	2.06	1	0	orthoquinones
5-bromoisatin [no description available]	2.03	1	0	indoles	anticoronaviral agent
pseudoephedrine Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.	2.05	1	0	phenylethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; bronchodilator agent; central nervous system drug; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
isatin tribulin: endogenous MONOAMINE OXIDASE inhibitory activity extractable into ethyl acetate found in brain and many mammalian tissues and fluids; ISATIN is a major component; produced in excess following alcohol withdrawal;	2.44	2	0	indoledione	EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
proflavine Proflavine: Topical antiseptic used mainly in wound dressings.. 3,6-diaminoacridine : An aminoacridine that is acridine that is substituted by amino groups at positions 3 and 6. A slow-acting bacteriostat that is effective against many Gram-positive bacteria (but ineffective against spores), its salts were formerly used for treatment of burns and infected wounds.	2.05	1	0	aminoacridines	antibacterial agent; antiseptic drug; carcinogenic agent; chromophore; intercalator
thiophene-2-carboxaldehyde thiophene-2-carboxaldehyde: structure in first source. formylthiophene : An aldehyde that is thiophene substituted by a formyl group at position 2.	1.99	1	0	aldehyde; thiophenes	metabolite
4-bromophenacyl bromide 4-bromophenacyl bromide: phospholipidase A(2) inhibitor; structure	3.23	1	0
2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester [no description available]	2.55	2	0	piperidines
diphenan [no description available]	2.06	1	0	diarylmethane
2-phenylacetamide 2-phenylacetamide: structure. 2-phenylacetamide : A monocarboxylic acid amide that is acetamide substituted by a phenyl group at position 2.	2.06	1	0	monocarboxylic acid amide	mouse metabolite
neostigmine bromide neostigmine bromide : The bromide salt of neostigmine.	2.04	1	0	bromide salt
phenformin Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.	2.76	3	0	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	2.45	2	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
1-hydroxyanthraquinone [no description available]	3.08	1	0	monohydroxyanthraquinone
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.96	4	0	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
1,4-naphthoquinone naphthoquinone : A polycyclic aromatic ketone metabolite of naphthalene.. 1,4-naphthoquinone : The parent structure of the family of 1,4-naphthoquinones, in which the oxo groups of the quinone moiety are at positions 1 and 4 of the naphthalene ring. Derivatives have pharmacological properties.	2.46	2	0	1,4-naphthoquinones
syringaldehyde syringaldehyde: isolated from nonfermented fiber fractions of oat hulls and cottonseed hulls. syringaldehyde : A hydroxybenzaldehyde that is 4-hydroxybenzaldehyde substituted by methoxy groups at positions 3 and 5. Isolated from Pisonia aculeata and Panax japonicus var. major, it exhibits hypoglycemic activity.	2.17	1	0	dimethoxybenzene; hydroxybenzaldehyde	hypoglycemic agent; plant metabolite
estragole estragole : A phenylpropanoid that is chavicol in which the hydroxy group is replaced by a methoxy group.	2.1	1	0	alkenylbenzene; monomethoxybenzene; phenylpropanoid	carcinogenic agent; flavouring agent; genotoxin; insect attractant; plant metabolite
sterogenol hexadecylpyridinium bromide: structure in first source. cetylpyridinium bromide : A pyridinium salt that has N-hexadecylpyridinium as the cation and bromide as the anion.	2.05	1	0	bromide salt; pyridinium salt	antiseptic drug; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; surfactant
tetraphenylborate Tetraphenylborate: An anionic compound that is used as a reagent for determination of potassium, ammonium, rubidium, and cesium ions. It also uncouples oxidative phosphorylation and forms complexes with biological materials, and is used in biological assays.	2.06	1	0
yohimbine Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.	2.04	1	0	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
cycloguanil hydrochloride cycloguanil hydrochloride : The hydrochloride salt of cycloguanil.	2.06	1	0	hydrochloride; organic molecular entity
cycloguanil cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source. cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil.	2.46	2	0	triazines	antifolate; antiinfective agent; antimalarial; antiparasitic agent; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
triphenyltetrazolium triphenyltetrazolium: RN given refers to parent cpd. 2,3,5-triphenyltetrazolium : An organic cation that is tetrazole carrying three phenyl substituents at positions 2, 3 and 5.	2.06	1	0	organic cation
2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-: Proposed catecholamine depletor.	2.17	1	0
aminophylline Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.	2.08	1	0	mixture	bronchodilator agent; cardiotonic drug
galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.	2.76	3	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
procarbazine hydrochloride procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	2.08	1	0	hydrochloride	antineoplastic agent
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	2.76	3	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
lithocholic acid Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid.	3.41	1	0	bile acid; C24-steroid; monohydroxy-5beta-cholanic acid	geroprotector; human metabolite; mouse metabolite
dextropropoxyphene Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.	2.05	1	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
berbamine [no description available]	2.06	1	0	phenylpropanoid
indirubin [no description available]	3.64	2	0
plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.	3.62	2	0	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.98	4	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
osthol osthol: from Cnidium monnieri and Angelica pubescens (both Apiaceae); structure given in first source	2.11	1	0	botanical anti-fungal agent; coumarins	metabolite
bicuculline Bicuculline: An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.. bicuculline : A benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.	2.03	1	0	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin
melarsoprol Melarsoprol: Arsenical used in trypanosomiases. It may cause fatal encephalopathy and other undesirable side effects.	2.15	1	0	triazines
benzohydroxamic acid [no description available]	2.05	1	0
oleanolic acid [no description available]	4.2	4	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
abietic acid abietic acid : An abietane diterpenoid that is abieta-7,13-diene substituted by a carboxy group at position 18.	2.11	1	0	abietane diterpenoid; monocarboxylic acid	plant metabolite
medroxyprogesterone [no description available]	2.05	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
physcione physcione: structure. physcion : A dihydroxyanthraquinone that is 9,10-anthraquinone bearing hydroxy substituents at positions 1 and 8, a methoxy group at position 3, and a methyl group at position 6. It has been widely isolated and characterised from both terrestrial and marine sources.	3.08	1	0	dihydroxyanthraquinone	anti-inflammatory agent; antibacterial agent; antifungal agent; antineoplastic agent; apoptosis inducer; hepatoprotective agent; metabolite
dequalinium chloride dequalinium chloride : An organic chloride salt that is the dichloride salt of dequalinium.	2.06	1	0	organic chloride salt	antifungal agent; antineoplastic agent; antiseptic drug; mitochondrial NADH:ubiquinone reductase inhibitor
dimenhydrinate gravinol: has antioxidant and ant-inflammatory activities; structure in first source	2.08	1	0	diarylmethane
flavone flavone: RN given refers to unlabeled cpd; structure given in first source. flavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2.	3.08	1	0	flavones	metabolite; nematicide
1-naphthylisothiocyanate 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.	2.47	2	0	isothiocyanate	insecticide
4-acetylbenzoic acid 4-acetylbenzoic acid: structure in first source	2.13	1	0
megestrol acetate [no description available]	2.47	2	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
Berberine chloride (TN) [no description available]	2.06	1	0	organic molecular entity
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.47	2	0	cyclic ketone; erythromycin
hydroxychloroquine sulfate [no description available]	2.08	1	0
9,10-dimethylanthracene 9,10-dimethylanthracene: RN given refers to parent ion	2.06	1	0
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	2.08	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
vinblastine [no description available]	2.46	2	0
adenosine 5'-tetraphosphate adenosine 5'-(pentahydrogen tetraphosphate) : A purine ribonucleoside 5'-tetraphosphate having adenine as the nucleobase.	3.08	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-tetraphosphate
ethambutol hydrochloride ethambutol dihydrochloride : The dihydrchloride salt of ethambutol. A bacteriostatic antimycobacterial drug, it is effective against Mycobacterium tuberculosis and some other mycobacteria. It is used in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol dihydrochloride is used alone.	2.08	1	0	hydrochloride	antitubercular agent
c 137 C 137: RN given refers to parent cpd	2.06	1	0
ethidium bromide [no description available]	2.48	2	0	organic bromide salt	geroprotector; intercalator; trypanocidal drug
antimycin a [no description available]	2.47	2	0	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide
pregnenolone carbonitrile Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage.	2.08	1	0	aliphatic nitrile
metylperon metylperon: RN given refers to parent cpd	2.08	1	0	aromatic ketone
n-methylisatin N-methylisatin: structure given in first source	2.03	1	0
glaucine glaucine: RN given refers to (+-)-isomer	3.25	1	0	aporphine alkaloid; organic heterotetracyclic compound; polyether; tertiary amino compound	antibacterial agent; antineoplastic agent; antitussive; muscle relaxant; NF-kappaB inhibitor; plant metabolite; platelet aggregation inhibitor; rat metabolite
sulfadoxine Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.	2.05	1	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
acetophenazine acetophenazine: major descriptor (73-85); minor descriptor (64-72); on-line search PHENOTHIAZINES (64-85); Index Medicus search PHENOTHIAZINES (64-72); ACETOPHENAZINE (73-85); RN given refers to parent cpd. acetophenazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the nitogen atom and an acetyl group at position 2.	2.05	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; phenothiazines	phenothiazine antipsychotic drug
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	2.08	1	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
dicloxacillin Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.	2.47	2	0	dichlorobenzene; penicillin	antibacterial drug
palmatine burasaine: structure in first source	2.06	1	0	berberine alkaloid; organic heterotetracyclic compound	plant metabolite
4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine 4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine: structure in first source	2.06	1	0
cladribine [no description available]	2.08	1	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
beclomethasone [no description available]	2.05	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug
pyrodifenium bromide pyrodifenium bromide: was heading 1976-94 (see under PYRROLIDINES 1976-90); PRIFINIUM BROMIDE was see PYRODIFENIUM BROMIDE 1976-94: use PYRROLIDINES to search PYRODIFENIUM BROMIDE 1976-94; quaternary ammonium anticholinergic agent more specific for the gastrointestinal tract than atropine	2.05	1	0	organic molecular entity
metocurine metocurine: from Chinese herb Cyclea hainanensis Mrr	2.47	2	0	isoquinolines
buquinolate [no description available]	2.06	1	0
diadenosine tetraphosphate P(1),P(4)-bis(5'-adenosyl) tetraphosphate : A diadenosyl tetraphosphate compound having the two 5'-adenosyl residues attached at the P(1)- and P(4)-positions.	3.53	2	0	diadenosyl tetraphosphate	Escherichia coli metabolite; mouse metabolite
etidronate disodium etidronate disodium : An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions.	2.08	1	0	organic sodium salt	antineoplastic agent; bone density conservation agent; chelator
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.08	1	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	3.5	7	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
amopyroquine amopyroquine: RN given refers to parent cpd; structure	2.05	1	0
mafenide acetate [no description available]	2.08	1	0	carboxylic acid
diacerein diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;	2.08	1	0	anthraquinone
xipamide Xipamide: A sulfamoylbenzamide analog of CLOPAMIDE. It is diuretic and saluretic with antihypertensive activity. It is bound to PLASMA PROTEINS, thus has a delayed onset and prolonged action.	2.05	1	0	benzamides
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	2.04	1	0	selegiline; terminal acetylenic compound	geroprotector
selegiline hydrochloride, (r)-isomer [no description available]	2.47	2	0	hydrochloride; terminal acetylenic compound	antiparkinson drug; dopaminergic agent; EC 1.4.3.4 (monoamine oxidase) inhibitor
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.05	1	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
thiamphenicol [no description available]	2.08	1	0	monocarboxylic acid amide; sulfone	antimicrobial agent; immunosuppressive agent
pancuronium bromide pancuronium bromide : A bromide salt consisting of two bromide ions and one pancuronium dication.	2.08	1	0	bromide salt	cholinergic antagonist; muscle relaxant; nicotinic antagonist
ornidazole Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.	2.08	1	0	C-nitro compound; imidazoles; organochlorine compound; secondary alcohol	antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	2.47	2	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
fludarabine phosphate fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.	2.08	1	0	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	2.05	1	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.	2.05	1	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2.78	3	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
halazepam halazepam: structure	2.05	1	0	organic molecular entity
dexchlorpheniramine dexchlorpheniramine: RN given refers to parent cpd(S)-isomer	2.05	1	0	chlorphenamine
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	3.65	2	0	penicillin allergen; penicillin	antibacterial drug
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	2.76	3	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
indoramin Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.	2.47	2	0	tryptamines
oxcarbazepine Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.	2.08	1	0	cyclic ketone; dibenzoazepine	anticonvulsant; drug allergen
carbidopa carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.	2.08	1	0	catechols; hydrazines; monocarboxylic acid	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
amineptin amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.	2.05	1	0	amino acid; carbocyclic fatty acid; carbotricyclic compound; secondary amino compound	antidepressant; dopamine uptake inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.08	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
feprazone Feprazone: A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)	2.08	1	0	organic molecular entity
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	2.08	1	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	5.35	16	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.73	9	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
propranolol glycol propranolol glycol: propranolol metabolite; potent anticonvulsant against strychnine induced convulsions	2.06	1	0
halofantrine halofantrine: used in treatment of mild to moderate acute malaria	2.05	1	0	phenanthrenes
butaclamol [no description available]	2.04	1	0	amino alcohol; organic heteropentacyclic compound; tertiary alcohol; tertiary amino compound	dopaminergic antagonist
ribavirin Rebetron: Rebetron is tradename	2.08	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	2.47	2	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
hydroxymaprotilin hydroxymaprotilin: RN given refers to cpd without isomeric designation	2.05	1	0
5-Methoxyisatin [no description available]	2.03	1	0	indoles	anticoronaviral agent
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	2.05	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
tocainide Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.	2.05	1	0	monocarboxylic acid amide	anti-arrhythmia drug; local anaesthetic; sodium channel blocker
sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.	2.05	1	0
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	2.76	3	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
vecuronium bromide Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.	2.08	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent; nicotinic antagonist
pinazepam pinazepam: structure	2.05	1	0	benzodiazepine
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [no description available]	2.21	1	0	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
butibufen butibufen: RN given refers to parent cpd	2.05	1	0	monoterpenoid
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	2.08	1	0	benzamides; carboxylic ester
acarbose [no description available]	3.65	2	0	tetrasaccharide derivative	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; geroprotector; hypoglycemic agent
naphthoxybutanolcyclohexylamine naphthoxybutanolcyclohexylamine: structure	2.06	1	0
metalaxyl metalaxyl: RN given refers to (DL-Ala)-isomer. metalaxyl : A racemate comprising equal amounts of (R)- and (S)-metalaxyl. A systemic fungicide, it is active against phytopathogens of the order Peronosporales and is used to conrtrol Pythium in a number of vegetable crops.. methyl N-(2,6-dimethylphenyl)-N-(methoxyacetyl)alaninate : An alanine derivative that is methyl alaninate in which one of the hydrogens attached to the nitrogen is substituted by a methoxyacetyl group, while the other is substituted by a 2,6-dimethylphenyl group.	2.03	1	0	alanine derivative; aromatic amide; carboxamide; ether; methyl ester
lorcainide [no description available]	2.47	2	0	acetamides
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	2.05	1	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	2.75	3	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
foscarnet sodium trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	2.08	1	0	one-carbon compound; organic sodium salt	antiviral drug
atracurium besylate atracurium besylate : The bisbenzenesulfonate salt of atracurium.	2.08	1	0	organosulfonate salt; quaternary ammonium salt	muscle relaxant; nicotinic antagonist
nicorandil Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.	2.08	1	0	nitrate ester; pyridinecarboxamide	potassium channel opener; vasodilator agent
pergolide mesylate pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	2.08	1	0	methanesulfonate salt	antiparkinson drug; dopamine agonist; geroprotector
cefadroxil anhydrous Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.08	1	0	cephalosporin	antibacterial drug
talniflumate talniflumate: an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma	2.08	1	0	benzofurans
fenoldopam mesylate [no description available]	2.08	1	0	benzazepine
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.08	1	0	cephalosporin	antibacterial drug; drug allergen
pefloxacin Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.	2.47	2	0	fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; antiinfective agent; DNA synthesis inhibitor
alfentanil Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.	2.46	2	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
cefotetan Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.	2.47	2	0
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	2.08	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	2.47	2	0	aminopyridine
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.08	1	0	aromatic ketone
stepronin [no description available]	2.08	1	0	N-acyl-amino acid
piritrexim piritrexim: RN given refers to parent cpd; structure given in first source	2.05	1	0
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.78	3	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
idazoxan Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.	2.47	2	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
remoxipride Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.	2.47	2	0	dimethoxybenzene
cabergoline Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.	2.08	1	0	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist
bambuterol bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.	2.05	1	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
atomoxetine hydrochloride Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.. atomoxetine hydrochloride : The hydrochloride salt of atomoxetine.	2.08	1	0	hydrochloride	adrenergic uptake inhibitor; antidepressant
quinapril Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.	2.08	1	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	2.08	1	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
salmeterol xinafoate Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.	2.47	2	0	naphthoic acid
brequinar brequinar : A quinolinemonocarboxylic acid that is quinoline substituted by 2'-fluoro[1,1'-biphenyl]-4-yl, methyl, carboxy and fluoro groups at positions 2, 3, 4, and 6, respectively. It is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis. The compound exhibits antineoplastic and antiviral properties.	2.25	1	0	biphenyls; monocarboxylic acid; monofluorobenzenes; quinolinemonocarboxylic acid	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	2.47	2	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.	2.08	1	0	imidazoquinoline	antineoplastic agent; interferon inducer
fadrozole Fadrozole: A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer.	2.1	1	0	imidazopyridine
sertindole sertindole : A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.	2.08	1	0	heteroarylpiperidine; imidazolidinone; organochlorine compound; organofluorine compound; phenylindole	alpha-adrenergic antagonist; H1-receptor antagonist; second generation antipsychotic; serotonergic antagonist
adapalene Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.	2.08	1	0	adamantanes; monocarboxylic acid; naphthoic acid	dermatologic drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; non-steroidal anti-inflammatory drug
aromasil [no description available]	2.08	1	0	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic
sparfloxacin [no description available]	2.08	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone
zileuton [no description available]	2.08	1	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	2.53	2	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	2.05	1	0	tetralins	T-type calcium channel blocker
bromfenac bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.	2.08	1	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
gemcitabine hydrochloride [no description available]	2.08	1	0	hydrochloride; organofluorine compound	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral drug; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; immunosuppressive agent; radiosensitizing agent
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.59	2	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	2.08	1	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
atorvastatin calcium anhydrous [no description available]	2.08	1	0	organic calcium salt
lamivudine [no description available]	2.08	1	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
duloxetine hydrochloride Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.	2.08	1	0	duloxetine hydrochloride	antidepressant
irinotecan [no description available]	2.06	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	2.08	1	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	2.05	1	0
zolmitriptan zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.	2.08	1	0	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
adefovir dipivoxil bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.	2.08	1	0	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
emtricitabine Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.	2.08	1	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
dehydroabietylamine dehydroabietylamine: has antimalarial activity; structure in first source	2.11	1	0	diterpenoid
paroxetine hydrochloride paroxetine hydrochloride : The hydrochloride salt of paroxetine. It is an antidepressant drug.	2.08	1	0	hydrochloride	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
bupropion hydrochloride [no description available]	2.08	1	0	aromatic ketone
trazodone hydrochloride Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.	2.08	1	0	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	2.05	1	0
doxazosin mesylate Cardura: Trade name in United States.	2.08	1	0	methanesulfonate salt	geroprotector
ciprofloxacin hydrochloride anhydrous [no description available]	2.05	1	0	hydrochloride	antibacterial drug; antiinfective agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.08	1	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	2.47	2	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	2.08	1	0	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
bupivacaine hydrochloride bupivacaine hydrochloride (anhydrous) : A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride : A hydrochloride obtained by combining 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with one molar equivalent of hydrochloric acid.	2.08	1	0	hydrochloride; racemate	adrenergic antagonist; amphiphile; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; local anaesthetic
ursolic acid [no description available]	2.83	3	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
propamidine propamidine: structure given in first source. propamidine : A polyether that is the bis(4-guanidinophenyl) ether of propane-1,3-diol. Used (as its isethionate salt) for the treatment of minor eye or eyelid infections, such as conjunctivitis and blepharitis.	2.46	2	0	aromatic ether; guanidines; polyether	antimicrobial agent; antiseptic drug
betulinic acid [no description available]	2.59	2	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
platanic acid platanic acid: inhibits HIV replication; isolated from Syzigium claviflorum; structure in first source. platanic acid : A pentacyclic triterpenoid that is 30-norlupan-28-oic acid substituted by a 3beta-hydroxy and an oxo group at position 20. It is isolated from the leaves of Syzygium claviflorum and exhibits anti-HIV activity.	2.17	1	0	hydroxy monocarboxylic acid; methyl ketone; pentacyclic triterpenoid	anti-HIV agent; metabolite
arctigenin arctigenin: precursor to catechols; in many plants	2.03	1	0	lignan
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	2.08	1	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
amprenavir [no description available]	2.47	2	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.27	1	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
alpha-terthienyl [no description available]	1.99	1	0	terthiophene
salvin salvin: a biocyclic diterpenoid; from sage and rosemary (Lamiaceae)	2.11	1	0	abietane diterpenoid; carbotricyclic compound; catechols; monocarboxylic acid	angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; food preservative; HIV protease inhibitor; plant metabolite
neocuproine neocuproine: Spectrophotometric determination of copper and ultramicro blood sugar determinations; structure; RN given refers to parent cpd. neocuproine : A member of the class of phenanthrolines that is 1,10-phenanthroline bearing two methyl substituents at positions 2 and 9.	2.06	1	0	phenanthrolines	chelator; copper chelator
ticlopidine hydrochloride [no description available]	2.08	1	0	hydrochloride
epirubicin hydrochloride [no description available]	2.08	1	0
triciribine [no description available]	2.08	1	0	nucleoside analogue	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
taleranol taleranol: a metabolite of ZEARALENONE which is a non-steroidal estrogenic lactone used as an anabolic compound in animal feed; a stereoisomer of ZERANOL (alpha-zearalanol)	2.06	1	0	macrolide
sinefungin [no description available]	2.05	1	0	adenosines; non-proteinogenic alpha-amino acid	antifungal agent; antimicrobial agent
mespirenone mespirenone: structure given in first source	2.1	1	0
droxicam droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.	2.05	1	0	organic heterotricyclic compound; pyridines	cyclooxygenase 1 inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; prodrug
etofibrate etofibrate: analog of clofibrate with nicotinic acid substituted on the 2-carbon of the ethyl ester group; structure; RN given refers to parent cpd	2.05	1	0	monocarboxylic acid
pazufloxacin [no description available]	2.08	1	0	quinolines
repaglinide [no description available]	2.08	1	0	piperidines
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	2.47	2	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
dexfenfluramine Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.	2.05	1	0	fenfluramine	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
toxoflavin toxoflavin: azapteridine antibiotic; structure. toxoflavin : A pyrimidotriazine that is 1,6-dimethyl-1,5,6,7-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 7.	2.06	1	0	carbonyl compound; pyrimidotriazine	antibacterial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; toxin; virulence factor; Wnt signalling inhibitor
2-bromo-4'-nitroacetophenone [no description available]	3.23	1	0
synthalin a synthalin A: RN given refers to parent cpd; structure. synthalin : A hydrochloride resulting from the reaction of decamethylenediguanidine with 2 mol eq. of hydrogen chloride.. synthalin A : A member of the class of guanidines that is decane having guanidino groups at the 1- and 10-positions.	2.05	1	0	guanidines	hepatotoxic agent; hypoglycemic agent; nephrotoxin
pinocembrin pinocembrin : A dihydroxyflavanone in which the two hydroxy groups are located at positions 5 and 7. A natural product found in Piper sarmentosum and Cryptocarya chartacea.	3.79	3	0	(2S)-flavan-4-one; dihydroxyflavanone	antineoplastic agent; antioxidant; metabolite; neuroprotective agent; vasodilator agent
harmol harmol: harmol is oxidized form of alkaloid harmolol; RN given refers to parent cpd; structure	3.27	1	0	harmala alkaloid
miconazole nitrate miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.08	1	0
ibopamine ibopamine: structure given in UD 31;67a & in 2nd source	2.05	1	0	benzoate ester; phenols
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	3	4	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
talinolol [no description available]	2.15	1	0	ureas
pirlindole pirlindole: RN given refers to parent cpd; synonym pyrazidol refers to mono-HCl; structure in Negwer, 5th ed, #2812	2.05	1	0	carbazoles
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.08	1	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
plasmenylserine plasmenylserine: RN given refers to (L)-isomer. O-phospho-L-serine : The L-enantiomer of O-phosphoserine.. O-phosphoserine : A serine derivative that is serine substituted at the oxygen atom by a phosphono group.	2.06	1	0	O-phosphoserine	EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor; EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor; EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
brinzolamide brinzolamide: an antiglaucoma agent	2.08	1	0	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor
drospirenone drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source	2.08	1	0	3-oxo-Delta(4) steroid; steroid lactone	aldosterone antagonist; contraceptive drug; progestin
artemether Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.47	2	0	artemisinin derivative; cyclic acetal; organic peroxide; semisynthetic derivative; sesquiterpenoid	antimalarial
quinocide quinocide: Russian drug; RN given refers to parent cpd; structure	2.06	1	0
2,2',2''-terpyridine 2,2',2''-terpyridine: RN given refers to parent cpd. 2,2':6',2''-terpyridine : A tridentate heterocyclic ligand that binds metals at three meridional sites giving two adjacent 5-membered MN2C2 chelate rings.	2.06	1	0	terpyridines	chelator
6-amino-1-hydroxyhexane-1,1-diphosphonate 6-amino-1-hydroxyhexane-1,1-diphosphonate: used for therapy of Paget's disease of bone & malignant hypercalcaemia	2.05	1	0	1,1-bis(phosphonic acid)
uk 68798 [no description available]	2.08	1	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
hp 873 iloperidone: an atypical, negative symptom antipsychotic agent. iloperidone : A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia.	2.08	1	0	1,2-benzoxazoles; aromatic ether; aromatic ketone; methyl ketone; monoamine; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
clobetasone butyrate [no description available]	2.06	1	0	organic molecular entity
loxapine succinate [no description available]	2.08	1	0	succinate salt	geroprotector
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	2.08	1	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
betamipron [no description available]	2.47	2	0	organonitrogen compound; organooxygen compound
rexigen clobenzorex: RN given refers to (+)-isomer; structure	2.05	1	0
uroxatral [no description available]	2.08	1	0	hydrochloride
aceclofenac [no description available]	2.47	2	0	amino acid; carboxylic ester; dichlorobenzene; monocarboxylic acid; secondary amino compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
secnidazole [no description available]	3.41	1	0	C-nitro compound; imidazoles; secondary alcohol	epitope
clociguanil clociguanil: RN given refers to parent cpd; structure	2.05	1	0
cletoquine [no description available]	2.06	1	0
tebuquine [no description available]	2.05	1	0
thiocolchicoside [no description available]	2.08	1	0	glycoside
7-hydroxystaurosporine [no description available]	7.42	2	0
epicatechin (-)-epicatechin : A catechin with (2R,3R)-configuration.	1.99	1	0	catechin; polyphenol	antioxidant
hesperetin [no description available]	1.99	1	0	3'-hydroxyflavanones; 4'-methoxyflavanones; monomethoxyflavanone; trihydroxyflavanone	antineoplastic agent; antioxidant; plant metabolite
chelerythrine chloride [no description available]	2.03	1	0
jatrorrhizine jatrorrhizine: isolated from bark of Enantia chlorantha (Annonaceae); structure given in first source	2.06	1	0	alkaloid
betulin betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.	2.63	2	0	diol; pentacyclic triterpenoid	analgesic; anti-inflammatory agent; antineoplastic agent; antiviral agent; metabolite
narciclasine narciclasine: antitumor alkaloid from bulbs of Narcissus species	2.07	1	0	phenanthridines	metabolite
lycorine lycorine: from bulbs of LYCORIS & other plants; RN given refers to (1 alpha,2 beta)-isomer; structure in Merck Index, 9th ed, #5444. lycorine : An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity.	2.47	2	0	indolizidine alkaloid	anticoronaviral agent; antimalarial; plant metabolite; protein synthesis inhibitor
bathophenanthroline 4,7-diphenyl-1,10-phenanthroline : A member of the class of phenanthrolines that is 1,10-phenanthroline bearing two phenyl substituents at positions 4 and 7.	2.06	1	0	benzenes; phenanthrolines	chelator
fascaplysine fascaplysine: from tropic sea sponges	2.03	1	0
LSM-4272 [no description available]	2.48	2	0	beta-carbolines
hederagenin [no description available]	2.21	1	0	dihydroxy monocarboxylic acid; pentacyclic triterpenoid; sapogenin	plant metabolite
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	2.08	1	0	carbapenems
tryptanthrine tryptanthrine: minor constituent of traditional Chinese medicine qing dai	3.6	2	0	alkaloid antibiotic; organic heterotetracyclic compound; organonitrogen heterocyclic compound
maslinic acid (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria	2.5	2	0	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	2.05	1	0	hydroxy-1,2-naphthoquinone
rosiglitazone [no description available]	2.47	2	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
tamiflu [no description available]	2.08	1	0	phosphate salt
cryptolepine cryptolepine: fused indole-quinoline; structure in first source; from CRYPTOLEPIS sanguinolenta. cryptolepine : An organic heterotetracyclic compound that is 5H-indolo[3,2-b]quinoline in which the hydrogen at position N-5 is replaced by a methyl group.	2.05	1	0	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound	anti-inflammatory agent; antimalarial; antineoplastic agent; cysteine protease inhibitor; plant metabolite
bexarotene [no description available]	2.54	2	0	benzoic acids; naphthalenes; retinoid	antineoplastic agent
s20098 [no description available]	2.08	1	0	acetamides
flunisolide flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones	2.08	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent
ketorolac tromethamine Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.	2.08	1	0	organoammonium salt	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	2.08	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
ethylhydrocupreine ethylhydrocupreine: structure; RN given refers to parent cpd. optochin : A cinchona alkaloid consisting of 10,11-dihydrocinchonan bearing hydroxy and ethoxy substituents at positions 9 and 6' respectively.	2.06	1	0	aromatic ether; cinchona alkaloid	EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
5-iodoisatin 5-iodoisatin: structure in first source	2.03	1	0	indoles	anticoronaviral agent
2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine 2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine: RN given refers to parent cpd; structure given in first source	2.06	1	0
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.47	2	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
cinchonine [no description available]	2.46	2	0	(8xi)-cinchonan-9-ol; cinchona alkaloid	metabolite
matrine [no description available]	3.25	1	0	alkaloid
gliquidone gliquidone: structure; RN given refers to parent cpd	2.08	1	0	isoquinolines
n-hexadecyl-n,n-dimethyl-3-ammonio-1-propanesulfonate [no description available]	2.05	1	0
lopinavir [no description available]	2.47	2	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
uvaol uvaol: from Vauquelinia corymbosa (Rosaceae)	2.17	1	0	triterpenoid	metabolite
dehydroabietic acid dehydroabietic acid: major aquatic toxicant in effluent of pulp and paper mills. dehydroabietic acid : An abietane diterpenoid that is abieta-8,11,13-triene substituted at position 18 by a carboxy group.. dehydroabietate : A monocarboxylic acid anion that is the conjugate base of dehydroabietic acid, obtained by deprotonation of the carboxy group.	2.54	2	0	abietane diterpenoid; carbotricyclic compound; monocarboxylic acid	allergen; metabolite
7-chloro-4-aminoquinoline 7-chloro-4-aminoquinoline: structure given in first source	2.06	1	0	aminoquinoline
desethylchloroquine desethylchloroquine: metabolite of chloroquine	2.05	1	0	aminoquinoline
6-bromoisatin 6-bromoisatin: anticancer compound from Dicathais orbita; structure in first source	2.03	1	0
mmv665852 MMV665852: an antischistosomal agent	2.06	1	0
1,3,4,10-Tetrahydro-9(2H)-acridinone [no description available]	2.06	1	0	acridines
5-iodotubercidin 7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase	2.49	2	0	organoiodine compound
adenosine-5'-carboxylic acid [no description available]	3.61	2	0	purine nucleoside
wr 158122 WR 158122: structure	2.06	1	0
loliolide loliolide: RN given refers to (6S-cis)-isomer	2.17	1	0	benzofurans	metabolite
wr 159412 [no description available]	2.05	1	0
10-deazaaminopterin [no description available]	2.06	1	0
moxifloxacin hydrochloride moxifloxacin hydrochloride : A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.	2.08	1	0	hydrochloride	antibacterial drug
lobeline (-)-lobeline : An optically active piperidine alkaloid having a 2-oxo-2-phenylethyl substituent at the 2-position and a 2-hydroxy-2-phenylethyl group at the 6-position.	2.17	1	0	aromatic ketone; piperidine alkaloid; tertiary amine	nicotinic acetylcholine receptor agonist
cinchonidine cinchonidine: has antimalarial activity; diastereoisomer of cinchonine with distinct physiochemical properties; RN given refers to parent cpd(8alpha,9R)-isomer. cinchonidine : 8-epi-Cinchonan in which a hydrogen at position 9 is substituted by hydroxy (R configuration). A diasteroisomer of cinchonine, it occurs in the bark of most varieties of Cinchona shrubs, and is frequently used for directing chirality in asymmetric synthesis.	2.05	1	0	(8xi)-cinchonan-9-ol; cinchona alkaloid	metabolite
erythrodiol [no description available]	2.17	1	0	diol; pentacyclic triterpenoid; primary alcohol; secondary alcohol	plant metabolite
benzyloxyamine benzyloxyamine: RN given refers to parent cpd	2.05	1	0
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	2.55	2	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
mizoribine [no description available]	2.08	1	0	imidazoles	anticoronaviral agent
sr141716 [no description available]	2.08	1	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	2.47	2	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
dihydroergocristine Dihydroergocristine: A 9,10alpha-dihydro derivative of ERGOTAMINE that contains an isopropyl sidechain at the 2' position of the molecule.. dihydroergocristine : Ergocristine in which a single bond replaces the double bond between positions 9 and 10. It is used as the mesylate salt for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease.	2.06	1	0	ergot alkaloid	adrenergic antagonist; vasodilator agent
racecadotril racecadotril: parenterally active enkephalinase inhibitor	2.08	1	0	N-acyl-amino acid
methoctramine methoctramine: structure given in first source. methoctramine : A tetramine that is N,N'-bis(6-aminohexyl)octane-1,8-diamine where the primary amino groups both carry 2-methoxybenzyl substituents.. methoctramine tetrahydrochloride : A hydrochloride obtained by combining methoctramine with four molar equivalents of hydrochloric acid.	2.04	1	0	hydrochloride	muscarinic antagonist
pyronaridine [no description available]	2.05	1	0	aminoquinoline
Zearalanone [no description available]	2.06	1	0	macrolide; resorcinols
benzamil [no description available]	2.06	1	0	guanidines; pyrazines
ecteinascidin 743 [no description available]	3.25	1	0	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
kt 5823 KT 5823: indolocarbazole; activates human neutrophils & fails to inhibit cGMP-dependent protein kinase phosphorylation of vimentin. KT 5823 : An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of methyl (3R)-3-methoxy-2-methyltetrahydrofuran-3-carboxylate (the 2S,3R,5R product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1-methyl-1,5-dihydro-2H-pyrrol-2-one.	2	1	0	gamma-lactam; hemiaminal; indolocarbazole; methyl ester; organic heterooctacyclic compound	EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor
tadalafil [no description available]	2.08	1	0	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
3',4'-dichlorobenzamil 3',4'-dichlorobenzamil: inhibits Na-Ca exchange in membrane vesicle & papillary muscle preparations from guinea pig heart	2.06	1	0	guanidines; pyrazines
tafenoquine tafenoquine : A racemate comprising equimolar amounts of (R)- and (S)-tafenoquine.. N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine : An aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group.	2.05	1	0	(trifluoromethyl)benzenes; aminoquinoline; aromatic ether; primary amino compound; secondary amino compound
plavix [no description available]	2.08	1	0	azaheterocycle sulfate salt; organoammonium sulfate salt	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
clofarabine [no description available]	2.08	1	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
arg-3-hyp-7-phe-bradykinin NPC 567: bradykinin receptor antagonist. NPC-567 : A ten-membered oligopeptide comprising D-arginyl, L-arginyl, L-prolyl, (4R)-4-hydroxy-L-prolyl, glycyl, L-phenylalanyl, L-seryl, D-phenylalanyl, L-phenylalanyl and L-arginine residues joined in sequence.	2.04	1	0	oligopeptide	bradykinin receptor antagonist
cleistanthin b cleistanthin B: toxic constituent of Cleistanthus collinus. cleistanthin B : A member of the class of cleistanthins that is cleistanthin A in which the 3,4-di-O-methyl-D-xylopyranosyl group is replaced by a beta-D-glucopyranosyl group.	2.06	1	0	beta-D-glucoside; cleistanthins; monosaccharide derivative	alpha-adrenergic antagonist; antihypertensive agent; diuretic
pramipexole Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.	2.08	1	0	benzothiazoles; diamine	antidyskinesia agent; antiparkinson drug; dopamine agonist; radical scavenger
valdecoxib [no description available]	2.08	1	0	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
n-acetyltyramine N-acetyltyramine: structure given in first source. N-acetyltyramine : A member of the class of tyramines that is tyramine in which one of the hydrogens of the amino group is replaced by an acetyl group.	2.06	1	0	acetamides; tyramines	animal metabolite; Aspergillus metabolite; bacterial metabolite; marine metabolite; quorum sensing inhibitor
desethylamodiaquine desethylamodiaquine: metabolite of amodiaquine	2.05	1	0
saccharolactone saccharolactone: used as index for assessing induction of hepatic enzymes by anticonvulsants; RN given refers to cpd without isomeric designation. D-glucaro-1,4-lactone : A delta-lactone that is D-glucono-1,4-lactone in which the hydroxy group at position 6 has been oxidised to the corresponding carboxylic acid.	3.41	1	0	aldarolactone; delta-lactone
1,3-di(4-imidazolinophenoxyl)propane 1,3-di(4-imidazolinophenoxyl)propane: structure given in first source	2.06	1	0
n,n-dideethylchloroquine [no description available]	2.05	1	0
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.48	2	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
mk 0663 [no description available]	2.47	2	0	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
gefitinib [no description available]	5.66	17	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.	2.04	1	0	adenosines; monocarboxylic acid amide; organoiodine compound	adenosine A3 receptor agonist
1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine 1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine: structure given in first source. 1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine : A tertiary amino compound that consists of cyclohexane having piperidin-1-yl and benzothiophen-2-yl groups attached at position 1. A potent dopamine re-uptake inhibitor with a behavioral profile different from that of phencyclidine (PCP) and similar to that of cocaine.	2.04	1	0	1-benzothiophenes; piperidines; tertiary amino compound	dopamine uptake inhibitor
dihydrotetrabenazine dihydrotetrabenazine: RN given refers to cpd without isomeric designation	2.17	1	0	isoquinolines
desloratadine desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.	2.08	1	0	benzocycloheptapyridine	anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist
w 7 [no description available]	2	1	0
4'-amino-6-hydroxyflavone 4'-amino-6-hydroxyflavone: a p53/56(lyn) inhibitor; structure given in first source	3.08	1	0	flavones
lestaurtinib [no description available]	2.81	3	0	indolocarbazole
methotrexate [no description available]	2.8	3	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
3,6-diamino-9-(4-(methylsulfonyl)aminophenyl)aminoacridine [no description available]	2.05	1	0
ne 58051 NE 58051: inhibits tumor cell adhesion to extracellular matrices; structure in first source	2.05	1	0
(hydroxy-2-naphthalenylmethyl)phosphonic acid (hydroxy-2-naphthalenylmethyl)phosphonic acid: a protein-tyrosine kinase inhibitor; structure given in first source	3.08	1	0
sulbactam [no description available]	2.08	1	0	penicillanic acids
7h-pyrido(4,3-c)carbazole 7H-pyrido(4,3-c)carbazole: structure given in first source	2.06	1	0
olmesartan medoxomil Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.	2.08	1	0	biphenyls
omega-n-methylarginine omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.	2.49	2	0	amino acid zwitterion; arginine derivative; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid
abiraterone [no description available]	2.08	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; pyridines	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
5'-(sulfonylbenzoyl)adenosine 5'-(sulfonylbenzoyl)adenosine: covalently binds to platelet membrane	4.35	3	0
imiloxan [no description available]	2.06	1	0	benzodioxine
wr 242511 WR 242511: RN given refers to parent cpd	2.05	1	0
cl 246738 3,6-bis(2-piperidinoethoxy)acridine trihydrochloride: immunomodulator; structure given in first source; RN given for tri-HCl	2.06	1	0
febuxostat Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.	2.08	1	0	1,3-thiazolemonocarboxylic acid; aromatic ether; nitrile	EC 1.17.3.2 (xanthine oxidase) inhibitor
lexapro Lexapro: Trade name of escitalopram, the active S-enantiomer of the racemic citalopram.	2.08	1	0
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	4.7	7	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
perifosine [no description available]	2.13	1	0	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	2.81	3	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
9-(2-hydroxy-3-nonyl)adenine (2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase.	2.04	1	0	EHNA	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor
ezetimibe Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).	2.08	1	0	azetidines; beta-lactam; organofluorine compound	anticholesteremic drug; antilipemic drug; antimetabolite
cox 189 lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.	2.08	1	0	amino acid; monocarboxylic acid; organochlorine compound; organofluorine compound; secondary amino compound	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
vatalanib [no description available]	4.82	7	0	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
evodiamine [no description available]	2.31	1	0	beta-carbolines
vx 497 N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic acid tetrahydrofuran-3-yl ester: structure in first source	3.1	1	0
ruboxistaurin ruboxistaurin: inhibits protein kinase C beta; structure in first source	4.93	8	0
xamoterol Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.	2.08	1	0	morpholines
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	2.76	3	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
canertinib dihydrochloride [no description available]	2.06	1	0
canertinib [no description available]	4.7	6	0	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
birb 796 [no description available]	4.95	8	0	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
telbivudine [no description available]	2.08	1	0	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
celastrol methyl ester celastrol methyl ester: isolated from Tripterygium wilfordii; potent inhibitory activity on both Kir2.1 and ERG1 potassium channels, leading to LONG QT SYNDROME	2.06	1	0	carboxylic ester
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	7	13	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
homolycorine homolycorine: irritant isolated from daffodils (Narcissus pseudonarcissus L., Amaryllidaceae); structure given in first source	2.07	1	0
isosakuranetin isosakuranetin: structure in first source. 4'-methoxy-5,7-dihydroxyflavanone : A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7 and a methoxy group at position 4' (the 2S stereoisomer).	1.99	1	0	(2S)-flavan-4-one; 4'-methoxyflavanones; dihydroxyflavanone; monomethoxyflavanone	plant metabolite
epiberberine epiberberine: isolated in plants of Coptis from China	2.06	1	0
2-phenyl-4-oxohydroquinoline 2-phenyl-4-oxohydroquinoline: structure given in first source	2.06	1	0
sclareol sclareol: structure given in first source. sclareol : A labdane diterpenoid that is labd-14-ene substituted by hydroxy groups at positions 8 and 13. It has been isolated from Salvia sclarea.	2.11	1	0	labdane diterpenoid	antifungal agent; antimicrobial agent; apoptosis inducer; fragrance; plant metabolite
frenolicin b frenolicin B: produced by Streptomyces roseofulvus strain AM 3867; structure	2.1	1	0	benzoisochromanequinone; p-quinones	metabolite
diadenosine triphosphate [no description available]	2.31	1	0	diadenosyl triphosphate	mouse metabolite
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.99	4	0
cypripedin cypripedin: sensitizing agent for contact dermatitis from Lady Slipper (Cypripedium calceolus); structure	2.06	1	0	phenanthrol
sb 203580 [no description available]	4.94	8	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
sb 216763 [no description available]	4.75	5	0	indoles; maleimides
enzastaurin [no description available]	2.44	2	0	indoles; maleimides
erlotinib [no description available]	7.03	13	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
dichamanetin dichamanetin: structure in first source	2.06	1	0	diarylheptanoid	metabolite
4',6-dihydroxyflavone 4',6-dihydroxyflavone : A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 4' and 6.	3.08	1	0	dihydroxyflavone
deflazacort deflazacort: structure	2.05	1	0	corticosteroid hormone
respinomycin d respinomycin D: structure given in first source; isolated from Streptomyces xanthocidicus	2.06	1	0
olpadronic acid [no description available]	2.05	1	0
ramelteon ramelteon: melatonin MT1/MT2 receptor agonist	2.08	1	0	indanes
lapatinib [no description available]	5.42	13	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
deferasirox Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.	2.08	1	0	benzoic acids; monocarboxylic acid; phenols; triazoles	iron chelator
bms204352 BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source	2.47	2	0
tbc-11251 sitaxsentan: endothelin A receptor antagonist; structure in first source	2.08	1	0	benzodioxoles
tolvaptan [no description available]	2.08	1	0	benzazepine; benzenedicarboxamide	aquaretic; vasopressin receptor antagonist
sorafenib [no description available]	6.16	28	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide [no description available]	2.08	1	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
lacosamide Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.	2.08	1	0	N-acyl-amino acid
pimaric acid pimaric acid: RN given refers to (D)-isomer; structure	2.11	1	0	diterpenoid
4'-hydroxyflavone 4'-hydroxyflavone: structure in first source	3.08	1	0
acetoxycycloheximide acetoxycycloheximide: structure	2.06	1	0
(R)-Roemerine [no description available]	2.06	1	0	isoquinoline alkaloid
5-Fluoroisatin [no description available]	2.03	1	0	indoles	anticoronaviral agent
vincaleukoblastine [no description available]	3.04	4	0	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite
vincristine sulfate [no description available]	2.08	1	0	organic sulfate salt	antineoplastic agent; geroprotector
estramustine Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.	2.05	1	0	17beta-hydroxy steroid; carbamate ester; organochlorine compound	alkylating agent; antineoplastic agent; radiation protective agent
lupeol [no description available]	2.05	1	0	pentacyclic triterpenoid; secondary alcohol	anti-inflammatory drug; plant metabolite
u-104 SLC-0111: a carbonic anhydrase inhibitor; structure in first source	2.76	2	0
wortmannin [no description available]	8.14	5	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
pifithrin mu 2-phenylacetylenesulfonamide: induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia cells; also inhibits Hsp70 and autophagy	2.03	1	0	benzenes
rocaglamide rocaglamide: RN refers to (1alpha,2alpha,3beta,3abeta,8bbeta)-isomer; isolated from stems of Aglaia elliptifolia; structure given in first source. rocaglamide : An organic heterotricyclic compound that is 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan substituted by hydroxy groups at positions 1 and 8b, methoxy groups at positions 6 and 8, a 4-methoxyphenyl group at position 3a, a phenyl group at position 3 and a N,N-dimethylcarbamoyl group at position 1. Isolated from Aglaia odorata and Aglaia duperreana, it exhibits antineoplastic activity.	3.19	5	0	monocarboxylic acid amide; monomethoxybenzene; organic heterotricyclic compound	antileishmanial agent; antineoplastic agent; metabolite
3',4',5'-trimethoxyflavone 3',4',5'-trimethoxyflavone: structure in first source	3.08	1	0	ether; flavonoids
2-guanidine-4-methylquinazoline 2-guanidine-4-methylquinazoline: structure given in first source	2.06	1	0
1,3(2h,4h)-isoquinolinedione 1,3(2H,4H)-isoquinolinedione: structure in first source	2.05	1	0
paullone paullone: structure in first source. paullone : An indolobenzazepine that is 5,6,7,12-tetrahydroindolo[3,2-d][1]benzazepine carrying an oxo substituent at position 6.	3.57	2	0	indolobenzazepine; lactam	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
bortezomib [no description available]	3.37	6	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
neocryptolepine neocryptolepine: isolated from the roots of the African plant Cryptolepis sanguinolenta; structure in first source	2.05	1	0
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.47	2	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
fti 276 FTI 276: a ras CAAX (C - Cys; A - aliphatic amino acid; X - Ser or Met) peptidomimetic; inhibits farnesyltransferase; FTI-277 is the methyl ester derivative of FTI-276	2.01	1	0	methionine derivative
4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride 4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride: structure in first source	2.15	1	0
meridianin g meridianin G: from the tunicate Aplidium meridianum; structure in first source	2.05	1	0
5-iodoindirubin-3'-monoxime 5-iodoindirubin-3'-monoxime: inhibits GSK-3beta	2.44	2	0
mensacarcin mensacarcin: structure in first source	2.06	1	0
1-hydroxypentane-1,1-bisphosphonate [no description available]	2.05	1	0
cimadronate cimadronate: increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity; structure given in first source	2.05	1	0
1,1-hydroxyoctanodiphosphonate [no description available]	2.05	1	0
lithium chloride Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.	2.66	2	0	inorganic chloride; lithium salt	antimanic drug; geroprotector
2H-pyrazolo[4,3-b]quinoxalin-3-amine [no description available]	2.75	3	0	quinoxaline derivative
5'-methylthioadenosine 5'-methylthioadenosine: structure. 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group.	2.07	1	0	thioadenosine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
naringenin (S)-naringenin : The (S)-enantiomer of naringenin.	3.49	2	0	(2S)-flavan-4-one; naringenin	expectorant; plant metabolite
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	2.05	1	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
bekanamycin bekanamycin: kanendomycin is the sulfate of bekanamycin; RN given refers to parent cpd; structure	3.41	1	0	kanamycins
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	2.04	1	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
puromycin [no description available]	2.06	1	0	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
taxifolin (+)-taxifolin : A taxifolin that has (2R,3R)-configuration.	3.49	2	0	taxifolin	metabolite
pentostatin Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.	2.08	1	0	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor
monoiodotyrosine Monoiodotyrosine: A product from the iodination of tyrosine. In the biosynthesis of thyroid hormones (THYROXINE and TRIIODOTHYRONINE), tyrosine is first iodized to monoiodotyrosine.. iodotyrosine : A tyrosine derivative which has at least one iodo-substituent on the benzyl moiety.. monoiodotyrosine : An iodotyrosine carrying a single iodo substituent.. 3-iodo-L-tyrosine : The monoiodotyrosine that is L-tyrosine carrying an iodo-substituent at position C-3 of the benzyl group.	2.04	1	0	amino acid zwitterion; L-tyrosine derivative; monoiodotyrosine; non-proteinogenic L-alpha-amino acid	EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor; human metabolite; mouse metabolite
eriodictyol eriodictyol: structure. eriodictyol : A tetrahydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5, 7, 3' and 4' respectively.	1.99	1	0	3'-hydroxyflavanones; tetrahydroxyflavanone
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	4.43	6	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	2.08	1	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.47	2	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	2.47	2	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
perindopril erbumine [no description available]	2.08	1	0	addition compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol [no description available]	2.08	1	0	piperidines
rocuronium bromide rocuronium bromide : The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.08	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent
erythromycin estolate Erythromycin Estolate: A macrolide antibiotic, produced by Streptomyces erythreus. It is the lauryl sulfate salt of the propionic ester of erythromycin. This erythromycin salt acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.	2.05	1	0	aminoglycoside sulfate salt; erythromycin derivative	enzyme inhibitor
linezolid [no description available]	2.08	1	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
canaline canaline: structure	2.05	1	0	amino acid zwitterion; non-proteinogenic L-alpha-amino acid	antimetabolite; antineoplastic agent; phytogenic insecticide; plant metabolite
pancratistatin pancratistatin: an isocarbostyril from Amaryllidaceae	2.07	1	0	citraconoyl group
carnosol carnosol: isolated from Lepechinia hastata	2.11	1	0	diterpenoid
ferruginol ferruginol: structure in first source. ferruginol : An abietane diterpenoid that is abieta-8,11,13-triene substituted by a hydroxy group at positions 12.	2.82	3	0	abietane diterpenoid; carbotricyclic compound; meroterpenoid; phenols	antibacterial agent; antineoplastic agent; plant metabolite; protective agent
cephaelin cephaelin: do not confuse with cephalin of brain; after emetine this is the most important alkaloid of ipecac; protein synthesis inhibitor. cephaeline : A pyridoisoquinoline comprising emetam having a hydroxy group at the 6'-position and methoxy substituents at the 7'-, 10- and 11-positions.	2.06	1	0	pyridoisoquinoline
picrotoxinin [no description available]	2.04	1	0	epoxide; gamma-lactone; organic heteropentacyclic compound; picrotoxane sesquiterpenoid; tertiary alcohol	GABA antagonist; plant metabolite; serotonergic antagonist
ononin [no description available]	2.31	1	0	4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; monosaccharide derivative	plant metabolite
devazepide Devazepide: A derivative of benzodiazepine that acts on the cholecystokinin A (CCKA) receptor to antagonize CCK-8's (SINCALIDE) physiological and behavioral effects, such as pancreatic stimulation and inhibition of feeding.. devazepide : An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders.	2.04	1	0	1,4-benzodiazepinone; indolecarboxamide	antineoplastic agent; apoptosis inducer; cholecystokinin antagonist; gastrointestinal drug
pemirolast potassium salt [no description available]	2.08	1	0
eplerenone Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.	2.49	2	0	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
vinpocetine vinpocetine: whole issue of Arzneim Forsch (23 articles) discuss this drug; Arzneim Forsch 26(10a);1976; RN given refers to parent cpd with unspecified isomeric designation	2.17	1	0	alkaloid	geroprotector
ao 128 AO 128: alpha-glucosidase inhibitor; structure given in first source	2.08	1	0	organic molecular entity
loteprednol etabonate Loteprednol Etabonate: An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.	2.08	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; etabonate ester; organochlorine compound; steroid acid ester; steroid ester	anti-inflammatory drug
fluticasone propionate fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.	2.08	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester	adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.76	3	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.8	3	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
phosphoramidon phosphoramidon: a membrane metallo-endopeptidase & endothelin-converting enzyme inhibitor; thermolysin inhibitor from culture filtrate of Streptomyces tanashiensis; structure. phosphoramidon : A dipeptide isolated from the cultures of Streptomyces tanashiensis.	2.04	1	0	deoxyaldohexose phosphate; dipeptide	bacterial metabolite; EC 3.4.24.11 (neprilysin) inhibitor; EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	2.08	1	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
ferulic acid ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.	3.53	2	0	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.17	1	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
mupirocin Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.	2.08	1	0	alpha,beta-unsaturated carboxylic ester; epoxide; monocarboxylic acid; oxanes; secondary alcohol; triol	antibacterial drug; bacterial metabolite; protein synthesis inhibitor
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	2.05	1	0
brivudine brivudine: anti-herpes agent	3.78	2	0
1-(3-tert-butyl-1-methylpyrazol-5-yl)-3-(4-chlorophenyl)urea 1-(3-tert-butyl-1-methylpyrazol-5-yl)-3-(4-chlorophenyl)urea : A member of the class of phenylureas that is urea which is substituted at position 1 by a 3-tert-butyl-1-methylpyrazol-5-yl group and at position 3 by a p-chlorophenyl group.	2.05	1	0	monochlorobenzenes; phenylureas; pyrazoles	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.08	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
pd 173955 PD 173955: inhibits src family-selective tyrosine kinase; structure in first source	2.48	2	0	aryl sulfide; dichlorobenzene; methyl sulfide; pyridopyrimidine	tyrosine kinase inhibitor
hts 466284 HTS 466284: a TGFbeta-RI inhibitor; structure in first source	2.08	1	0	pyrazoles; pyridines; quinolines	TGFbeta receptor antagonist
epothilone b [no description available]	2.5	2	0	epothilone; epoxide	antineoplastic agent; apoptosis inducer; microtubule-stabilising agent
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source	4.68	8	0
y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.	2.74	3	0	aromatic amide
h 1152 (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane : A member of the class of isoquinolines that is the sulfonamide formed by the formal condensation of the sulfo group of 4-methylisoquinoline-5-sulfonic acid with the 1-amino group of (S)-2-methyl-1,4-diazepane.	2.96	4	0	isoquinolines; N-sulfonyldiazepane	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
adenosine-5'-(n-ethylcarboxamide) Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.	2.04	1	0	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
diethylstilbestrol Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.	2.15	1	0	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine [no description available]	3.83	3	0
6-bromoindirubin-3'-oxime 6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	4.25	5	0
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	2.76	3	0	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
afimoxifene afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.	3.41	1	0	phenols; tertiary amino compound	antineoplastic agent; estrogen receptor antagonist; metabolite
decitabine [no description available]	2.08	1	0	2'-deoxyribonucleoside
teniposide [no description available]	2.08	1	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
kt 5720 KT 5720: indolocarbazole; synthetic derivative of K 252a. KT 5720 : An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of hexyl (3S)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2R,3S,5S product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.	2.03	1	0	carboxylic ester; gamma-lactam; hemiaminal; indolocarbazole; organic heterooctacyclic compound; semisynthetic derivative; tertiary alcohol	EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
valrubicin [no description available]	2.08	1	0	anthracycline; trifluoroacetamide
pa 824 pretomanid: nitroimidazopyran derived from 5-nitroimidazoles; a prodrug that requires activation by a bacterial F420-depedent glucose-6-phosphate dehydrogenase (Fgd) and nitroreductase to activate components that then inhibit bacterial mycolic acid and protein synthesis; structure in first source	2.15	1	0
ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.	4.04	3	0	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	4.25	5	0	purvalanol
wr-142,490 (+)-(11R,2'S)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (+)-(11R,2'S)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.	2.06	1	0	[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol	antimalarial
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.77	3	0	actinomycin	mutagen
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.47	2	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione [no description available]	2.06	1	0	pyrimidotriazine
posaconazole [no description available]	2.08	1	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
rubitecan rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor. rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.	2.08	1	0	C-nitro compound; delta-lactone; pyranoindolizinoquinoline; semisynthetic derivative; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione [no description available]	2.46	2	0	aminotoluene
N-ethylharmine N-ethylharmine : A member of the class of beta-carbolines that is 9H-beta-carboline substituted by a ethyl group at position 9, methoxy group at position 7 and a methyl group at position 1. It is semisynthetic derivative of harmine and has been shown to exhibit significant anti-HIV activity.	3.27	1	0	aromatic ether; beta-carbolines; semisynthetic derivative	anti-HIV agent
evp 4593 EVP 4593: an NF-kappaB pathway inhibitor; structure in first source	2.08	1	0
jp-1302 [no description available]	2.06	1	0
Tetrahydropiperine [no description available]	2.05	1	0	benzodioxoles
carbenoxolone [no description available]	2.05	1	0
methyl ursolate methyl ursolate: structure in first source	2.1	1	0
7-hydroxy-2-methoxy-1,4-phenanthrenedione 7-hydroxy-2-methoxy-1,4-phenanthrenedione: structure in first source; from Dendrobium densiflorum	2.06	1	0
trans-4-coumaric acid hydroxycinnamic acid : Any member of the class of cinnamic acids carrying one or more hydroxy substituents.. trans-4-coumaric acid : The trans-isomer of 4-coumaric acid.. 4-coumaric acid : A coumaric acid in which the hydroxy substituent is located at C-4 of the phenyl ring.	3.08	1	0	4-coumaric acid	food component; mouse metabolite; plant metabolite
chalcone trans-chalcone : The trans-isomer of chalcone.	2.11	1	0	chalcone	EC 3.2.1.1 (alpha-amylase) inhibitor
piperine piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.	3.59	2	0	benzodioxoles; N-acylpiperidine; piperidine alkaloid; tertiary carboxamide	food component; human blood serum metabolite; NF-kappaB inhibitor; plant metabolite
antofine antofine: structure in first source. (-)-antofine : An organic heteropentacyclic compound that is (13aR)-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline substituted at positions 2, 3 and 6 by methoxy groups. It is an alkaloid produced by relatives of the milkweed family and exhibits antiviral, anti-inflammatory, antiadipogenic and antitumorigenic activities.	3.25	1	0	alkaloid antibiotic; alkaloid; aromatic ether; organic heteropentacyclic compound	angiogenesis inhibitor; anti-inflammatory agent; antimicrobial agent; antineoplastic agent; antiviral agent; phytotoxin; plant metabolite
ilepcimide ilepcimide: structure given in first source; RN given refers to compound with no isomeric designation	2.05	1	0	benzodioxoles
4'-methoxychalcone 4'-methoxychalcone: RN given refers to compound with no isomeric designation	2.11	1	0	chalcones
discodermolide [no description available]	3.25	1	0	diterpenoid
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	2.08	1	0	vasopressin	cardiovascular drug; hematologic agent; mitogen
cgp 60474 [no description available]	3.54	2	0	substituted aniline
s 1033 [no description available]	2.06	1	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
3-(4-pyridyl)-1h-indole 3-(4-pyridyl)-1H-indole: structure in first source	2.08	1	0	indoles
trilostane trilostane: inhibits conversion of pregnenolone to progesterone; adrenal blocking agent used in treatment of Cushing's syndrome. trilostane : An epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions.	2.08	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; androstanoid; epoxy steroid; nitrile	abortifacient; antineoplastic agent; EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
tiamulin tiamulin: 81723 HFU and tiamutin are for fumarate salt; prevents senescence in ascomycete; pleuromutilin derivative; RN given refers to ((3aS-(3aalpha,4beta,5alpha,6alpha,8beta,9alpha,9abeta,10S*))-isomer. tiamulin : A carbotricyclic compound that is pleuromutilin in which the hydroxyacetate group is replaced by a 2-{[2-(diethylamino)ethyl]sulfanyl}acetate group. An antibacterial drug, tiamulin is used in veterinary medicine (generally as its hydrogen fumarate salt) for the treatment of swine dysentery caused by Serpulina hyodysenteriae.	3.25	1	0	carbotricyclic compound; carboxylic ester; cyclic ketone; organic sulfide; secondary alcohol; semisynthetic derivative; tertiary amino compound; tetracyclic diterpenoid	antibacterial drug
leuprolide acetate leuprolide acetate : An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.08	1	0	acetate salt	antineoplastic agent; gonadotropin releasing hormone agonist
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.05	1	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
octotropine methylbromide octotropine methylbromide: minor descriptor (65-86); on line & INDEX MEDICUS search TROPANES (69-86); RN given refers to endo-isomer. anisotropine methylbromide : A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide.	2.05	1	0
(1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol [no description available]	2.06	1	0	alkylbenzene
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	2.08	1	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
ipratropium bromide anhydrous [no description available]	2.05	1	0
r 59949 R 59949: diacylglycerol kinase inhibitor	2.46	2	0	diarylmethane
2-[2-hydroxy-6,7-dimethoxy-4-(4-morpholinyl)-1-naphthalenyl]-N-phenylacetamide [no description available]	2.06	1	0	naphthols
2-amino-3-cyano-7-(dimethylamino)-4-(3-methoxy-4,5-methylenedioxyphenyl)-4h-chromene 2-amino-3-cyano-7-(dimethylamino)-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene: induces apoptosis; structure in first source	2.02	1	0
4,9-dimethyl-3-(2H-tetrazol-5-ylmethoxy)-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-6-one [no description available]	2.31	1	0	coumarins
etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.	2.1	1	0	ethyl ester; imidazoles	intravenous anaesthetic; sedative
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.48	2	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
ag-213 tyrphostin 47: inhibits protein-tyrosine kinase activity of EGF-R both in vitro and in living cells;	4.53	4	0
3,3',4,5'-tetrahydroxystilbene 3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.	4.03	4	0	catechols; polyphenol; resorcinols; stilbenol	antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor
bemesetron [no description available]	2.04	1	0
3,4-methylenedioxy-beta-nitrostyrene 3,4-methylenedioxy-beta-nitrostyrene: tyrosine kinase inhibitor that prevents platelet glycoprotein IIb/IIIa activation; structure in first source	2.08	1	0
7,8,3'-trihydroxyflavone 7,8,3'-trihydroxyflavone: a potent small molecule TrkB receptor agonist that protects spiral ganglion neurons from degeneration both in vitro and in vivo	3.08	1	0
levosulpiride (S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).	2.08	1	0	sulpiride	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
dehydrovomifoliol dehydrovomifoliol: isolated from Litsea sessilis; structure in first source. (6S)-dehydrovomifoliol : A dehydrovomifoliol that has S-configuration at the chiral centre.. dehydrovomifoliol : A fenchane monoterpenoid that is substituted by methyl groups at positions 3, 5, and 5, and by both a hydroxy group and a 3-oxobut-1-en-1-yl group at position 4.	2.17	1	0	dehydrovomifoliol	plant metabolite
(2S)-7-hydroxyflavanone [no description available]	3.08	1	0	7-hydroxyflavanone
caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid.	3.08	1	0	caffeic acid	geroprotector; mouse metabolite
isatin beta-thiosemicarbazone isatin beta-thiosemicarbazone: isatizon believed to be Russian synonym	2.49	2	0
N4-(3-chlorophenyl)-6-methyl-N2-(phenylmethyl)pyrimidine-2,4-diamine [no description available]	2.06	1	0	aralkylamine
nitrofurylacrylic acid [no description available]	3.41	1	0
n-(4-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine N-(4-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine: calcium-activated small conductance potassium channels inhibitor; structure in first source	2.06	1	0
2,6-bis(benzimidazol-2-yl)pyridine 2,6-bis(benzimidazol-2-yl)pyridine: structure in first source	2.06	1	0	benzimidazoles
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol [no description available]	2.08	1	0	substituted aniline
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide [no description available]	2.08	1	0	naphthalenecarboxamide
n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine: an SK channel inhibitor	2.06	1	0
N-[4-(1-azepanyl)phenyl]-2-chloroacetamide [no description available]	2.06	1	0	anilide
N-(4-methylphenyl)carbamic acid (cyclopentylideneamino) ester [no description available]	2.06	1	0	toluenes
(2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine) [no description available]	2.06	1	0	benzimidazoles
1,4,8-trimethyl-12-quinolino[2,3-b]quinolinamine [no description available]	2.06	1	0	aminoquinoline
oncrasin-1 oncrasin-1: an antineoplastic agent; structure in first source. oncrasin-1 : A member of the class of indoles that is 1H-indole substituted by 4-chlorobenzyl and formyl groups at positions 1 and 3, respectively. It is an anti-cancer agent that is active against lung cancer cells with K-Ras mutations.	2.11	1	0	arenecarbaldehyde; indoles; monochlorobenzenes	antineoplastic agent; apoptosis inducer
flunarizine Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.	2.05	1	0	diarylmethane
eszopiclone Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.	2.08	1	0	zopiclone	central nervous system depressant; sedative
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	4	3	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide [no description available]	2.08	1	0	dimethoxybenzene
2-furanyl-(4,4,8-trimethyl-1-sulfanylidene-5-dithiolo[3,4-c]quinolinyl)methanone [no description available]	2.06	1	0	aromatic amide; heteroarene
1-(6-methoxy-2,2,4-trimethyl-1-quinolinyl)-2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone [no description available]	2.06	1	0	quinolines
3-cyano-4-phenyl-6-(3-bromo-6-hydroxyphenyl)-2-pyridone 3-cyano-4-phenyl-6-(3-bromo-6-hydroxyphenyl)-2-pyridone : A member of the class of pyridones that is 2-pyridone carrying cyano, phenyl and 3-bromo-6-hydroxyphenyl substituents at positions 3, 4 and 6 respectively	2.05	1	0	bromophenol; nitrile; pyridone
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	2.08	1	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
stk295900 [no description available]	2.06	1	0
Src Inhibitor-1 Src Inhibitor-1 : A member of the class of quinazolines that is quinazoline which is substituted at position 4 by a p-phenoxyanilino group and at positions 6 and 7 by methoxy groups. It is a potent, competitive dual site (both the ATP- and peptide-binding) Src kinase inhibitor. Src Inhibitor-1 is one of the 'gold standards' for Src kinase inhibition that has been shown to use PP1 or PP2 in parallel with Src-I1 to inhbit Src family kinases.	2.08	1	0	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
6-(4-methyl-1-piperazinyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazole [no description available]	2.06	1	0	benzimidazoles
cinnarizine Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.	2.47	2	0	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	2.76	3	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
epalrestat epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.	2.08	1	0	monocarboxylic acid; thiazolidines	EC 1.1.1.21 (aldehyde reductase) inhibitor
drotaverin drotaverin: Hungarian drug; RN given refers to parent cpd; structure	2.47	2	0	isoquinolines
tg 003 TG 003: a Clk inhibitor; structure in first source	3.87	3	0
N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine [no description available]	2.06	1	0	aromatic ether
N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline [no description available]	2.48	2	0	benzimidazoles
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.03	1	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.83	3	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
tamoxifen [no description available]	4.33	5	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
4-(1-adamantyl)-2-methyl-1,3-thiazole [no description available]	2.06	1	0	thiazoles
ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.	2.05	1	0	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
2-amino-6-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]pyridine-3,5-dicarbonitrile [no description available]	2.06	1	0	piperazines; pyridines
cgp 74514a [no description available]	2.48	2	0
sc 514 SC 514: inhibits IkappaB kinase-2; structure in first source	2.06	1	0	ring assembly; thiophenes
1-(4-fluorophenyl)-3-[4-(4-fluorophenyl)-2-methyl-5-(trifluoromethyl)-3-pyrazolyl]urea [no description available]	2.06	1	0	pyrazoles; ring assembly
3,3-dimethyl-5-oxo-5-[(3-phenyl-1H-pyrazol-5-yl)amino]pentanoic acid [no description available]	2.17	1	0	pyrazoles; ring assembly
sirtinol [no description available]	2.03	1	0	aldimine; benzamides; naphthols	anti-inflammatory agent; EC 3.5.1.98 (histone deacetylase) inhibitor; Sir2 inhibitor
2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine [no description available]	2.06	1	0	quinazolines
polysulfide rubber [no description available]	2.06	1	0
lch-7749944 LCH-7749944: potent p21-activated kinase 4 inhibitor, structure in first source	2.5	2	0
4-(4-nitrophenyl)-N-prop-2-enyl-1-piperazinecarbothioamide [no description available]	2.06	1	0	piperazines
zeranol Zeranol: A non-steroidal estrogen analog.	2.06	1	0	macrolide
fusidic acid Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.	2.47	2	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
artemotil artemotil: structure given in first source; RN given refers to cpd without isomeric designation	2.05	1	0	artemisinin derivative
valinomycin Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.	2.77	3	0	cyclodepsipeptide; macrocycle	antimicrobial agent; antiviral agent; bacterial metabolite; potassium ionophore
ranitidine Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.	2.51	2	0	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
hmr 3647 [no description available]	2.47	2	0
latoconazole latoconazole: RN refers to cpd without isomeric designation; latoconazole is (E)-isomer; structure given in first source	2.08	1	0	conazole antifungal drug; imidazole antifungal drug
maraviroc [no description available]	2.08	1	0	tropane alkaloid
1,4-dimethoxy-10H-acridine-9-thione [no description available]	2.08	1	0	acridines
toremifene citrate [no description available]	2.08	1	0	stilbenoid	anticoronaviral agent
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	3.31	6	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	2.08	1	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
4-diphenylacetoxy-n-methylpiperidine methiodide 4-DAMP methiodide : A quaternary ammonium salt obtained by combining equimolar amounts of 4-diphenylacetoxy-N-methylpiperidine and iodomethane.	2.04	1	0	iodide salt; quaternary ammonium salt	cholinergic antagonist; muscarinic antagonist
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	4.54	5	0	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
gestodene Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer	2.47	2	0	steroid	estrogen
glucametacin glucametacin: indomethacin analog; structure	2.05	1	0
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	2.08	1	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine [no description available]	2.76	3	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
sf 2370 SF 2370: indolocarbazole isolated from Actinomadura sp. SF-2370; structure given in first source. K-252a : A organic heterooctacyclic compound that is a potent inhibitor of protein kinase C and is isolated from Nocardiopsis sp K-252a	3.12	5	0	bridged compound; gamma-lactam; methyl ester; organic heterooctacyclic compound	antimicrobial agent; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; tropomyosin-related kinase B receptor antagonist
u-50488 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer: A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21). U50488 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of 3,4-dichlorophenylacetic acid and the secondary amino group of (1R,2R)-N-methyl-2-(pyrrolidin-1-yl)cyclohexanamine	2.04	1	0	dichlorobenzene; monocarboxylic acid amide; N-alkylpyrrolidine	analgesic; antitussive; calcium channel blocker; diuretic; kappa-opioid receptor agonist
c,n-diphenylnitrone C,N-diphenylnitrone: structure in first source	2.13	1	0
sch 23390 SCH 23390: a selective D1-receptor antagonist. SCH 23390 : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 7 and a hydroxy substituent at position 8.	2.04	1	0	benzazepine
tandutinib [no description available]	4.82	7	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745 [no description available]	4.53	5	0	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
azilect [no description available]	2.08	1	0
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	5.32	12	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
zd 6474 CH 331: structure in first source	6.28	10	0	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
sideroxylin sideroxylin: from Hydrastis canadensis; structure in first source. sideroxylin : A monomethoxyflavone that is flavone substituted by a methoxy group at position 7, hydroxy groups at positions 5 and 4' and methyl groups at positions 6 and 8. It has been isolated from Hydrastis canadensis and Eucalyptus species.	2.17	1	0	dihydroxyflavone; monomethoxyflavone	plant metabolite
aldisine [no description available]	2.01	1	0
5-bromo-1-(1-oxopropyl)-N,N-dipropyl-2,3-dihydroindole-7-sulfonamide [no description available]	2.06	1	0	indoles
N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide [no description available]	2.06	1	0	aromatic amide; heteroarene
gtp 14564 [no description available]	2.46	2	0	pyrazoles; ring assembly
sb 218078 [no description available]	2.46	2	0	indolocarbazole
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	2.13	1	0	organic sodium salt	detergent; protein denaturant
sto 609 STO 609: structure in first source	2.48	2	0	naphthoic acid
7-butyl-6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine [no description available]	2.08	1	0	pyrroles
ML162 ML162 : A monochlorobenzene that is benzene substituted by (chloroacetyl){2-oxo-2-[(2-phenylethyl)amino]-1-(thiophen-2-yl)ethyl}amino, chloro and methoxy groups at positions 1, 3 and 4, respectively. It is a covalent inhibitor of glutathione peroxidase 4 (GPX4) that induces ferroptosis in cells.	2.07	1	0	monochlorobenzenes; monomethoxybenzene; organochlorine compound; secondary carboxamide; tertiary carboxamide; thiophenes	EC 1.11.1.9 (glutathione peroxidase) inhibitor; ferroptosis inducer
2-[(3-ethyl-7-methyl-4-oxo-6,8-dihydro-5H-pyrido[2,3]thieno[2,4-b]pyrimidin-2-yl)thio]-N-(2-phenylethyl)acetamide [no description available]	2.06	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor. TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease.	3.84	3	0	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sb 415286 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source	4.25	5	0	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	2.47	2	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	4.13	3	0	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	2.47	2	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
5-Nitroisatin [no description available]	2.43	2	0	indoles	anticoronaviral agent
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	5.78	11	0	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
imd 0354 N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source	2.31	1	0	benzamides
4,5,6,7-tetrabromobenzimidazole 4,5,6,7-tetrabromobenzimidazole: structure in first source	3.27	1	0
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-ylemine [no description available]	2.08	1	0	pyrazolopyrimidine	tyrosine kinase inhibitor
ku 55933 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source	2.08	1	0
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	1.97	1	0	sphing-4-enine	human metabolite; mouse metabolite
quercetin [no description available]	9.92	11	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
biochanin a [no description available]	3.5	2	0	4'-methoxyisoflavones; 7-hydroxyisoflavones	antineoplastic agent; EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
vitexin [no description available]	2.17	1	0	C-glycosyl compound; trihydroxyflavone	antineoplastic agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite; platelet aggregation inhibitor
acacetin 5,7-dihydroxy-4'-methoxyflavone : A monomethoxyflavone that is the 4'-methyl ether derivative of apigenin.	3.08	1	0	dihydroxyflavone; monomethoxyflavone	anticonvulsant; plant metabolite
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	4.36	6	0	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	3.79	3	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	3.54	2	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
quercitrin [no description available]	2.04	1	0	alpha-L-rhamnoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	antileishmanial agent; antioxidant; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; plant metabolite
vomifoliol blumenol A: a phytotoxin isolated from Oryza sativa Awaakamai; structure in first source. vomifoliol : A fenchane monoterpenoid that is 3,5,5-trimethylcyclohex-2-en-1-one substituted by a hydroxy and a (1E)-3-hydroxybut-1-en-1-yl group at position 4.. (6S,9R)-vomifoliol : A (6S)-vomifoliol with a R configuration for the hydroxy group at position 9.	2.17	1	0	(6S)-vomifoliol	metabolite; phytotoxin
daphnetin [no description available]	2.03	1	0	hydroxycoumarin
alprostadil [no description available]	2.47	2	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	2.08	1	0	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	1.99	1	0	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
kaempferol [no description available]	3.79	3	0	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
harmine Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.	4.25	4	0	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
genistein [no description available]	4.38	6	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.47	2	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	2.08	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
oxymetholone Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed). oxymetholone : A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.	2.08	1	0
eprosartan eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.	2.47	2	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
brompheniramine maleate brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.08	1	0	maleate salt	anti-allergic agent
dexchlorpheniramine maleate [no description available]	2.08	1	0	organic molecular entity
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	2.08	1	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
entacapone entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.	2.08	1	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
aureusidin aureusidin: structure in first source. aureusidin : A hydroxyaurone that is aurone substituted by hydroxy groups at positions 4, 6, 3' and 4' respectively.	2.08	1	0	hydroxyaurone	plant metabolite
sulfuretin sulfuretin: the chalcone C ring closes into a 5 instead of the more typical 6 membered ring leaving a phenyl methane at the 2 position instead of the typical phenyl	2.08	1	0	1-benzofurans
genistin genistin: glycoside of soy bean isoflavone, gentistein	3.08	1	0	7-hydroxyisoflavones 7-O-beta-D-glucoside
usambarensine usambarensine: structure given in first source	2.05	1	0	harmala alkaloid
zearalenone Zearalenone: (S-(E))-3,4,5,6,8,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione. One of a group of compounds known under the general designation of resorcylic acid lactones. Cis, trans, dextro and levo forms have been isolated from the fungus Gibberella zeae (formerly Fusarium graminearum). They have estrogenic activity, cause toxicity in livestock as feed contaminant, and have been used as anabolic or estrogen substitutes.. zearalenone : A macrolide comprising a fourteen-membered lactone fused to 1,3-dihydroxybenzene; a potent estrogenic metabolite produced by some Giberella species.	2.06	1	0	macrolide; resorcinols	fungal metabolite; mycoestrogen
baicalein [no description available]	2.47	2	0	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	3.79	3	0	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
cupressuflavone cupressuflavone: from Cupressus macrocarpa; structure in first source. cupressuflavone : A biflavonoid that is obtained by oxidative coupling of two molecules of apigenin resulting in a bond between positions C-8 of the two chromene rings respectively. Isolated from Cupressus sempervirens and Juniperus occidentalis, it exhibits free radical scavenging and antielastase activities.	2.08	1	0	biflavonoid; hydroxyflavone; ring assembly	EC 3.4.21.37 (leukocyte elastase) inhibitor; metabolite; radical scavenger
fisetin [no description available]	3.5	2	0	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
galangin 5,7-dihydroxyflavonol: antimicrobial from the twigs of Populus nigra x Populus deltoides; structure in first source. galangin : A 7-hydroxyflavonol with additional hydroxy groups at positions 3 and 5 respectively; a growth inhibitor of breast tumor cells.	3.49	2	0	7-hydroxyflavonol; trihydroxyflavone	antimicrobial agent; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; plant metabolite
genkwanin genkwanin: structure. genkwanin : A monomethoxyflavone that is apigenin in which the hydroxy group at position 7 is methylated.	3.08	1	0	dihydroxyflavone; monomethoxyflavone	metabolite
hyperoside quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity.	2.08	1	0	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	2.06	1	0	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
kaempferide kaempferide: structure in first source. kaempferide : A monomethoxyflavone that is the 4'-O-methyl derivative of kaempferol.	1.99	1	0	7-hydroxyflavonol; monomethoxyflavone; trihydroxyflavone	antihypertensive agent; metabolite
morin morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.	1.99	1	0	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
myricetin [no description available]	9.2	5	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
quercetagetin quercetagetin: structure given in first source; inhibits aldose reductase in rat lens. quercetagetin : A hexahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 5, 6, 7, 3' and 4' respectively.	2.45	2	0	flavonols; hexahydroxyflavone	antioxidant; antiviral agent; plant metabolite
daidzein [no description available]	3.08	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
cynarine cynarine: active principle of the artichoke; functions primarily as a cholagogue and choleretic and also as antilipemic agent	2.05	1	0	alkyl caffeate ester; quinic acid	plant metabolite
rosmarinic acid rosmarinic acid: RN given refers to parent cpd; promote OT project. (R)-rosmarinic acid : A stereoisomer of rosmarinic acid having (R)-configuration.. rosmarinic acid : The 1-carboxy-2-(2,4-dihydroxyphenyl)ethyl ester of trans-caffeic acid.	2.03	1	0	rosmarinic acid	geroprotector; plant metabolite
orobol orobol: from Aspergillus niger or Streptomyces neyagawaensis; potent inhibitor of phosphatidylinositol kinase. orobol : A member of the class of 7-hydroxyisoflavones which consists of isoflavone substituted by hydroxy groups at positions 5, 7, 3' and 4'. It has been isolated from the mycelia of Cordyceps sinensis.	3.08	1	0	7-hydroxyisoflavones	anti-inflammatory agent; fungal metabolite; plant metabolite; radical scavenger
prunetin prunetin: reduces herpes virus-1 plaque formation. prunetin : A hydroxyisoflavone that is genistein in which the hydroxy group at position 7 is replaced by a methoxy group.	3.08	1	0	7-methoxyisoflavones; hydroxyisoflavone	anti-inflammatory agent; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor; metabolite
wedelolactone wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source. wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3.	2.03	1	0	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite
rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.	2.03	1	0	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
3,3',4-o-trimethylellagic acid 3,7,8-tri-O-methylellagic acid: structure given in first source	2.17	1	0	tannin
l 660,711 [no description available]	2.47	2	0	quinolines
7-hydroxyflavone 7-hydroxyflavone : A hydroxyflavonoid in which the flavone nucleus is substituted at position 7 by a hydroxy group.	3.08	1	0	hydroxyflavonoid
syringetin [no description available]	3.08	1	0	3',5'-dimethoxyflavone; 3'-methoxyflavones; 7-hydroxyflavonol; dimethoxyflavone; tetrahydroxyflavone	metabolite; platelet aggregation inhibitor
4',7-dihydroxyflavone 4',7-dihydroxyflavone: inducer of nod gene. 4',7-dihydroxyflavone : A dihydroxyflavone in which the two hydroxy substituents are located at positions 4' and 7.	3.08	1	0	dihydroxyflavone	metabolite
travoprost Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.. travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.	2.08	1	0	(trifluoromethyl)benzenes; isopropyl ester; prostaglandins Falpha	antiglaucoma drug; antihypertensive agent; ophthalmology drug; prodrug; prostaglandin receptor agonist
tranilast tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group.	2.08	1	0	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent
imipenem [no description available]	2.08	1	0	carbapenems
etretinate retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.	2.08	1	0	enoate ester; ethyl ester; retinoid	keratolytic drug
isotretinoin Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.	2.08	1	0	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
ketotifen fumarate ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug.	2.08	1	0	organoammonium salt	anti-asthmatic drug; H1-receptor antagonist
dinoprost tromethamine [no description available]	2.08	1	0	organic molecular entity
triprolidine Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.	2.05	1	0	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
rosuvastatin calcium S 4522: structure in first source	2.08	1	0	N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine; organic calcium salt	anti-inflammatory agent; cardioprotective agent; CETP inhibitor
terbinafine hydrochloride terbinafine hydrochloride : A hydrochloride obtained by reaction of terbinafine with one molar equivalent of hydrogen chloride.	2.08	1	0	allylamine antifungal drug; hydrochloride	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor
codeine [no description available]	2.05	1	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.78	3	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
natamycin [no description available]	2.08	1	0	antibiotic antifungal drug; dicarboxylic acid monoester; epoxide; macrolide antibiotic; monosaccharide derivative; polyene antibiotic	antifungal agrochemical; antimicrobial food preservative; apoptosis inducer; bacterial metabolite; ophthalmology drug
acitretin Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.	2.48	2	0	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug
dihydrocodeine dihydrocodeine: RN refers to parent cpd(5alpha,6alpha)-isomer	2.05	1	0	morphinane alkaloid
levetiracetam Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.	2.08	1	0	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic
ly 163892 loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.	2.05	1	0	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
nalmefene nalmefene: RN given refers to 5-alpha isomer	2.08	1	0	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	2.76	3	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.83	3	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	2.08	1	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
trichomonacid trichomonacid: RN given refers to phosphate (1:3) salt	2.06	1	0
ophiocordin azepinostatin: isolated from Fusarium merismoides; structure in first source; RN assigned by CAS - 63590-19-2 (ophiocordin; azepinostatin is not the same as ophiocordin)	1.98	1	0
as 604850 [no description available]	2.08	1	0
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	6.65	9	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
geldanamycin [no description available]	2.03	1	0	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor
calcipotriene [no description available]	3.1	1	0	cyclopropanes; hydroxy seco-steroid; seco-cholestane; secondary alcohol; triol	antipsoriatic; drug allergen
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.46	2	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
demycarosylturimycin h [no description available]	2.08	1	0
su 9516 [no description available]	4.75	5	0
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine [no description available]	2.06	1	0	triazolopyrimidines
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-methoxyethyl)-3-oxo-1H-isoindole-4-carboxamide [no description available]	2.06	1	0	isoindoles
acipimox acipimox: lipolysis inhibitor	2.08	1	0	pyrazinecarboxylic acid
atosiban [no description available]	2.08	1	0	oligopeptide
bimatoprost Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.	2.08	1	0	monocarboxylic acid amide	antiglaucoma drug; antihypertensive agent
fr 173657 FR 173657: structure given in first source	2.31	1	0
fr 190997 FR 190997: structure given in first source	2.31	1	0
lacidipine [no description available]	2.05	1	0	cinnamate ester; tert-butyl ester
latanoprost Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.	2.08	1	0	isopropyl ester; prostaglandins Falpha; triol	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor; prodrug
nateglinide Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.	2.08	1	0	phenylalanine derivative
pd 166285 [no description available]	2.48	2	0
vinorelbine [no description available]	2.05	1	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide [no description available]	2.08	1	0	pyrimidines
cgp 71683 a [no description available]	2.06	1	0	naphthalenes; sulfonic acid derivative
kn 93 KN 93: reduces dopamine content in PC12h cells. KN-93 : A sulfonamide resulting from the formal condensation of p-methoxybenzenesulfonic acid with the anilino nitrogen of 2-(aminomethyl)-N-(2-hydroxyethyl)aniline in which the hydrogens of the primary amino group have been replaced by methyl and p-chlorocinnamyl groups. KN-93 is a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II.	2.46	2	0	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector
kn 62 KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II	2.08	1	0	piperazines
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.46	2	0
fustin fustin : A dihydroflavonol that is the 2,3-dihydro derivative of fisetin.. tetrahydroxyflavanone : A hydroxyflavanone with atleast four hydroxy substituents.	3.08	1	0
licochalcone a licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer	2.05	1	0	chalcones
granulatimide granulatimide: minor alkaloids of the Brazilian ascidian Didemnum; structure in first source	2.01	1	0
casein kinase ii Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.	3.27	1	0
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)- 1H-pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-: structure in first source	1.98	1	0
arcyriaflavin a arcyriaflavin A: from marine ascidian, Eudistoma sp.; structure given in first source	2.42	2	0	indolocarbazole
erbstatin erbstatin: from actinomycetes; an inhibitor of EGF-receptor kinase & other protein-tyrosine kinases; structure in first source	3.08	1	0
ag 538 AG 538: an IGF-1 receptor kinase inhibitor; structure in first source	3.08	1	0
ag 99 tyrphostin A46: epidermal growth factor-urogastrone receptor antagonist	3.08	1	0
tyrphostin ag 555 [no description available]	3.08	1	0
tyrphostin ag-494 AG 494: tyrphostin that blocks Cdk2 activation; structure in first source	3.5	2	0
ag-490 [no description available]	4.54	4	0	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
alpha-cyano-4-hydroxycinnamic acid alpha-cyano-4-hydroxycinnamic acid : A monohydroxycinnamic acid that is 4-hydroxycinnamic acid in which the hydrogen alpha- to the carboxy group is replaced by a cyano group. It is used as a matrix in matrix-assisted laser desorption/ionization (MALDI) mass spectrometry for the analysis of peptides and oligonucleotides.	3.08	1	0	monohydroxycinnamic acid; nitrile; phenols	MALDI matrix material
ag 30 AG 30: structure given in first source; do not confuse with AG-30 antimicrobial peptide	3.08	1	0
ag 112 [no description available]	3.51	2	0
ag 183 AG 183: structure given in first source	3.08	1	0
bosutinib 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile: a Src kinase inhibitor; structure in first source	2.06	1	0	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	3.01	4	0	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
su 11248 [no description available]	5.65	17	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
su 11652 SU 11652: a tyrosine kinase inhibitor; amino acid sequence in first source. SU11652 : A member of the class of pyrrolecarboxamides obtained by formal condensation of the carboxy group of 5-[(Z)-(5-chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethylpyrrole-3-carboxylic acid with the primary amino group of N(1),N(1)-diethylethane-1,2-diamine.	2.46	2	0	olefinic compound; organochlorine compound; oxindoles; pyrrolecarboxamide; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor
n,n'-dimethyl-n,n'-bis(mercaptoacetyl)hydrazine N,N'-dimethyl-N,N'-bis(mercaptoacetyl)hydrazine: used to reduce disulfide bonds; structure in first source	2.05	1	0
6-(4-methoxyphenyl)-3-(3-thiophenyl)pyrazolo[1,5-a]pyrimidine [no description available]	2.08	1	0	pyrimidines
palbociclib [no description available]	2.76	2	0	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621 [no description available]	4.36	4	0	sulfonamide
mitoguazone Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.	2.03	1	0	guanidines; hydrazone	antineoplastic agent; apoptosis inducer; EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
stilbamidine stilbamidine: RN given refers to parent cpd	2.05	1	0
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.08	1	0	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
2-(dimethylaminostyryl)-1-ethylpyridinium 2-(dimethylaminostyryl)-1-ethylpyridinium: fluorescent monitor for energetic state of isolated brown- adipose-tissue mitochondria; RN given refers to parent cpd; synonym DASPEI refers to iodide	2.06	1	0	pyridinium ion
methyl 2,5-dihydroxycinnamate methyl 2,5-dihydroxycinnamate: structure given in first source. 2,5-dihydroxycinnamic acid methyl ester : A cinnamate ester that is the methyl ester of 2,5-dihydroxycinnamic acid.	3.5	2	0	cinnamate ester; hydroquinones; methyl ester	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; geroprotector; human urinary metabolite; plant metabolite
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.	2.47	2	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
molsidomine [no description available]	2.08	1	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
psi-tectorigenin psi-tectorigenin: structure given in first source; isolated from Streptomyces	3.08	1	0
flavokawain a flavokawain A: from kava extract, induces apoptosis in bladder cancer cells; structure in first source	3.27	1	0	chalcones
4'-acetamidochalcone [no description available]	2.02	1	0
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	2.15	1	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
butorphanol Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.	2.47	2	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
cefixime [no description available]	2.47	2	0	cephalosporin	antibacterial drug; drug allergen
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	2.08	1	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ramipril Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.	2.08	1	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	2.47	2	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
piperic acid piperinic acid: from Piper longum; structure in first source. (E,E)-piperic acid : A monocarboxylic acid that is (E)-penta-2,4-dienoic acid substituted by a 1,3-benzodioxol-5-yl group at position 5. It has been isolated from black pepper (Piper nigrum).	2.05	1	0	alpha,beta-unsaturated monocarboxylic acid; benzodioxoles	plant metabolite
5-(4-methoxybenzylidene)thiazolidine-2,4-dione 5-(4-methoxybenzylidene)thiazolidine-2,4-dione: used to treat concanavalin A-induced liver injury; structure in first source	2.05	1	0
sorbicillin sorbicillin: RN given for (E,E)-isomer; structure in first source	2.21	1	0	phenols
enalapril maleate enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.	2.08	1	0	maleate salt	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
k00135 [no description available]	2.48	2	0
enkephalin, ala(2)-mephe(4)-gly(5)- [no description available]	2.04	1	0	peptide
enalaprilat anhydrous Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.	2.08	1	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
gamma-mangostin gamma-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3, 6 and 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antitumour activity.	2.06	1	0	phenols; xanthones	antineoplastic agent; plant metabolite; protein kinase inhibitor
bakuchiol bakuchiol: chief component of Psoralea corylifolia Linn; structure	2.13	1	0
pepstatin pepstatin: inhibits the aspartic protease endothiapepsin	2.04	1	0	pentapeptide; secondary carboxamide	bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor
trandolapril trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.	2.08	1	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
pregabalin Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.	2.08	1	0	gamma-amino acid	anticonvulsant; calcium channel blocker
alvimopan anhydrous alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain	2.08	1	0	peptide
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one: a janus-activated kinase inhibitor. 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one : An organic heterotetracyclic compound that is 1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one bearing additional tert-butyl and fluoro substituents at positions 2 and 9 respectively.	2.46	2	0	organic heterotetracyclic compound; organofluorine compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
vx680 [no description available]	4.69	6	0	N-arylpiperazine
hydrocortisone acetate, (11beta)-isomer [no description available]	2.06	1	0
famotidine [no description available]	2.47	2	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
xib 4035 XIB 4035: a GFRalpha-1 agonist; structure in first source	2.06	1	0
10-hydroxy-3-methyl-8-pentyl-2,4-dihydro-1H-[1]benzopyrano[3,4-c]pyridin-5-one [no description available]	2.06	1	0	pyridochromene
gw-5074 [no description available]	2.94	3	0
st 638 [no description available]	3.5	2	0
su 1498 SU 1498: structure in first source. SU1498 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2E)-2-cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]prop-2-enoic acid with the amino group of 3-phenylpropylamine.	2.03	1	0	enamide; monocarboxylic acid amide; nitrile; phenols; secondary carboxamide	vascular endothelial growth factor receptor antagonist
proguanil Proguanil: A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.. proguanil : A biguanide compound which has isopropyl and p-chlorophenyl substituents on the terminal N atoms. A prophylactic antimalarial drug, it works by inhibiting the enzyme dihydrofolate reductase, which is involved in the reproduction of the malaria parasites Plasmodium falciparum and P. vivax within the red blood cells.	2.05	1	0	biguanides; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
oroidin oroidin: from marine sponges of the genus Agelas; structure in first source	2.01	1	0	pyrroles; secondary carboxamide	metabolite
cci 15641 [no description available]	2.08	1	0	cephalosporin
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	2.03	1	0	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
saralasin Saralasin: An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION.	2.04	1	0	oligopeptide
jatrophone jatrophone: RN refers to (2R-(2R,3aR,9E,12Z))-isomer; structure	2.21	1	0	oxolanes
diacetyldiphenylurea bisguanylhydrazone diacetyldiphenylurea bisguanylhydrazone: antineoplastic agent particularly effective as an antileukemic agent; has been shown to be active against leukemia L1210 in mice; minor descriptor (75-86); on-line & INDEX MEDICUS search CARBANILIDES (75-86); RN given refers to parent cpd	2.03	1	0
tenofovir disoproxil fumarate tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.	2.08	1	0	fumarate salt	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug
ml 3403 [no description available]	2.46	2	0
d 4476 [no description available]	2.78	3	0	imidazoles
GSK3-XIII GSK3-XIII : A member of the class of aromatic amines that is ammonia with two of the hydrogens replaced by 5-methylpyrazol-3-yl and 2-phenylquinazolin-4-yl groups.	2.75	3	0	aromatic amine; pyrazoles; quinazolines; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
dexbrompheniramine maleate dexbrompheniramine maleate : The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.08	1	0	brompheniramine maleate	anti-allergic agent; H1-receptor antagonist
rifaximin [no description available]	2.08	1	0	acetate ester; cyclic ketal; lactam; macrocycle; organic heterohexacyclic compound; rifamycins; semisynthetic derivative	antimicrobial agent; gastrointestinal drug; orphan drug
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	2.11	1	0	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
herbimycin [no description available]	3.51	2	0
lumefantrine Lumefantrine: A fluorene derivative that is used in combination with ARTEMETHER for the treatment of MALARIA (see ARTEMETHER-LUMEFANTRINE DRUG COMBINATION).. lumefantrine : A member of the class of fluorenes that is 9-(p-chlorobenzylidene)-9H-fluorene which is substitutec by chlorine at positions 2 and 7, and by a 2-(dibutylamino)-1-hydroxyethyl group at position 4. An antimalarial drug used in combination with artemether for the treatment of multi-drug resistant strains of falciparum malaria.	2.06	1	0	fluorenes; monochlorobenzenes; secondary alcohol; tertiary amine	antimalarial
st 271 [no description available]	3.08	1	0
1,2-dihydroxy-4-(nitroethenyl)benzene 1,2-dihydroxy-4-(nitroethenyl)benzene: isolated from Streptomyces lavendulae	3.08	1	0
everolimus [no description available]	2.08	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
ekb 569 EKB 569: an EGF receptor kinase inhibitor	4.53	5	0	aminoquinoline; monocarboxylic acid amide; monochlorobenzenes; nitrile	protein kinase inhibitor
axitinib [no description available]	2.77	3	0	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
su 4312 SU4312 : A member of the class of oxindoles that is 3-methyleneoxindole in which one of the hydrogens of the methylene group has been replaced by a p-(dimethylamino)phenyl group. SU 4312 is a vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 and platelet derived growth factor (PDGF) receptor inhibitor. It also inhibits the neuronal nitric oxide synthase (NOS) and exhibits neuroprotection against NO-mediated neurotoxicity.	2.46	2	0
nifuroxime 5-nitro-2-furaldehyde oxime: structure in first source	2.05	1	0
cefpodoxime proxetil cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.	2.08	1	0	carboxylic acid; carboxylic ester; cephalosporin	antibacterial drug; prodrug
1-azakenpaullone 1-azakenpaullone : An organic heterotetracyclic compound that is 7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indole substituted at positions 6 and 9 by oxo and bromo groups respectively.	3.12	1	0	lactam; organic heterotetracyclic compound; organobromine compound; organonitrogen heterocyclic compound	EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole [no description available]	3.83	3	0	aryl sulfide
gdp 366 GDP 366: an antineoplastic agent; structure in first source	2.03	1	0
1-methyl-d-lysergic acid butanolamide [no description available]	2.05	1	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
fluphenazine [no description available]	2.08	1	0
b 43 RK-24466 : A member of the class of pyrrolopyrimidines that is 7H-pyrrolo[2,3-d]pyrimidine substituted by amino, 4-phenoxyphenyl, and cyclopentyl groups at positions 4, 5 and 7, respectively. It is a potent inhibitor of Lck that inhibits Lck (64-509) and LckCD isoforms (IC50 of less than 1 and 2 nM, respectively).	2.08	1	0	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
nitrofurantoin Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.	2.08	1	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
aminopurvalanol a aminopurvalanol A: casein kinase I alpha inhibitor; structure in first source	2.46	2	0	monochlorobenzenes; purvalanol	protein kinase inhibitor
cgk 733 [no description available]	2.08	1	0	diarylmethane
cgp 53353 4,5-bis(4-fluoroanilino)phthalimide: structure in first source	2.08	1	0	phthalimides
4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone: structure	2.05	1	0
nifurtimox Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.	2.05	1	0	nitrofuran antibiotic
butylscopolammonium bromide Butylscopolammonium Bromide: Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.	2.05	1	0
roxithromycin (E)-roxithromycin : A major geometrical isomer of roxithromycin.	2.47	2	0	roxithromycin	environmental contaminant; xenobiotic
cefdinir [no description available]	2.08	1	0	cephalosporin; ketoxime	antibacterial drug
bisoprolol, fumarate (1:1) salt [no description available]	2.08	1	0
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.47	2	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
edatrexate edatrexate: structure given in first source	2.06	1	0	glutamic acid derivative
etoposide phosphate [no description available]	2.08	1	0	furonaphthodioxole
ciclesonide ciclesonide: nasal spray approved for seasonal and perennial allergic rhinitis	2.08	1	0	organic molecular entity
temsirolimus [no description available]	2.08	1	0	macrolide lactam
dutasteride Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.	2.08	1	0	(trifluoromethyl)benzenes; aza-steroid; delta-lactam	antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
cvt 313 CVT 313: a potent inhibitor of CDK2 that prevents neointimal proliferation; structure given in first source	2.46	2	0
tekturna [no description available]	2.08	1	0	fumarate salt	antihypertensive agent
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.06	1	0	aminobenzoic acid
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	2.03	1	0	substituted aniline
vildagliptin [no description available]	2.08	1	0	amino acid amide
sl 327 SL 327: a MEK inhibitor. SL-327 : A nitrile that is acrylonitrile in which the hydrogen attached to the same carbon as the cyano group has been replaced by an o-(trifluoromethyl)phenyl group, while the remaining hydrogens of the ethenyl group have been replaced by amino and (4-aminophenyl)sulfanyl groups. The configuration of the double bond is not specified. It is an inhibitor of MEK1 and MEK2.	2.03	1	0
tws 119 [no description available]	4.77	5	0	pyrroles
krn 633 N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea: a VEGF receptor-2 tyrosine kinase inhibitor; structure in first source	2.03	1	0
((3z)-n-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1h-pyrrol-2-yl)methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide) [no description available]	2.03	1	0	sulfonamide
c 1368 [no description available]	2.75	3	0
pq 401 PQ 401: an IGF receptor type I antagonist; structure in first source	2.46	2	0	quinolines
sgd 301-76 [no description available]	2.08	1	0	conazole antifungal drug; imidazole antifungal drug; organic nitrate salt	antiinfective agent
fluvoxamine maleate [no description available]	2.08	1	0	(trifluoromethyl)benzenes
thioacetazone Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.	2.47	2	0
chlorproguanil chlorproguanil: dichloro-derivative of chloroguanide; RN given refers to parent cpd; structure	2.05	1	0	dichlorobenzene
3-aminopyridine-2-carboxaldehyde thiosemicarbazone 3-aminopyridine-2-carboxaldehyde thiosemicarbazone: a neuroprotective agent; structure given in first source	2.05	1	0
dexlansoprazole Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.	2.08	1	0	benzimidazoles; sulfoxide
gemifloxacin mesylate gemifloxacin mesylate : The mesylate salt of gemifloxacin.	2.08	1	0	methanesulfonate salt	antimicrobial agent; topoisomerase IV inhibitor
jnj 10198409 [no description available]	2.46	2	0
cp 547632 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source	2.03	1	0
bms345541 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline: structure in first source	2.06	1	0	quinoxaline derivative
lenvatinib lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.	2.17	1	0	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist
gw843682x [no description available]	2.03	1	0	(trifluoromethyl)benzenes
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	4.97	8	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
gambogic acid gambogic acid: RN given refers to (1R-(1alpha,1(Z),3abeta,5alpha,11beta,14aS*))-isomer	2.49	2	0	pyranoxanthones	metabolite
sb-505124 SB 505124 : A member of the class of imidazoles carrying tert-butyl, 1,3-benzodioxol-5-yl and 6-methylpyridin-2-yl substituents at positions 2, 4 and 5 respectively.	2.49	2	0	benzodioxole; imidazoles; methylpyridines	TGFbeta receptor antagonist
ic 86621 1-(2-hydroxy-4-morpholin-4-ylphenyl)ethanone: a DNA-dependent protein kinase inhibitor	2.08	1	0	aromatic ketone
nu 7026 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source	2.46	2	0	organic heterotricyclic compound; organooxygen compound
fr 148083 5Z-7-oxozeaenol : A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB.	2.53	2	0	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor
LL-Z1640-1 [no description available]	2.06	1	0	macrolide; resorcinols	metabolite
ki 20227 [no description available]	2.06	1	0
scio-469 SCIO-469: a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor for potential oral therapy for inflammatory disorders; in phase lib clinical trials for rheumatoid arthritis 4/2004. talmapimod : An indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties.	2.05	1	0	aromatic amide; aromatic ketone; chloroindole; dicarboxylic acid diamide; indolecarboxamide; monofluorobenzenes; N-acylpiperazine; N-alkylpiperazine	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
cp 724714 2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide: CP-724714 is the ((2E)-isomer, 1:1.5 succinate); structure in first source	4.13	3	0	2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; hepatotoxic agent
rivaroxaban Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.	2.08	1	0	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	5.25	11	0	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
y 27632, dihydrochloride, (4(r)-trans)-isomer [no description available]	2.03	1	0
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide: an IKK-2 kinase inhibitor; structure in first source	2.48	2	0	aromatic amide; thiophenes
norketotifen norketotifen: Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy; structure in first source	2.06	1	0	organosulfur heterocyclic compound
n1-phenyl-3,5-dinitro-n4,n4-di-n-propylsulfanilamide N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide: a potent, selective antimitotic agent against kinetoplastid parasites; structure in first source	2.05	1	0
tivozanib N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source	2.08	1	0	aromatic ether
hki 272 [no description available]	2.78	3	0	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor
3,9-bis((ethylthio)methyl)-k-252a 3,9-bis((ethylthio)methyl)-K-252a: RN given for (9S-(9alpha,10beta,12alpha))-isomer; mixed lineage kinase inhibitor, neuroprotective agent, and neurotrophic agent derived from K-252a; structure in first source	2.08	1	0
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	6.06	8	0	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bibr 1532 [no description available]	2.13	1	0
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide [no description available]	2.06	1	0
hypothemycin hypothemycin: a resorcylic acid lactone antibiotic; antifungal metabolite from Hypomyces trichothecoides. hypothemycin : A macrolide that is isolated from the cultured broth of Hypomyces subiculosus and shows antifungal activity and inhibits the growth of some human cancer cells.	2.06	1	0	aromatic ether; diol; enone; epoxide; macrolide; phenols; polyketide; secondary alpha-hydroxy ketone	antifungal agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; fungal metabolite
cediranib [no description available]	2.06	1	0	aromatic ether
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- [no description available]	2.15	1	0	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
chir 99021 Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.	3.12	1	0	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
ly2090314 LY-2090314 : A member of the class of diazepinoindoles that is 1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indole substituted by piperidin-1-ylcarbonyl, 4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl and fluoro groups at position 2, 7 and 9, respectively. It is a potent ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3alpha and GSK-3beta. The drug is in clinical development for the treatment of advanced/metastatic cancer.	2.44	2	0	diazepinoindole; imidazopyridine; maleimides; monofluorobenzenes; piperidinecarboxamide; ureas	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator
masitinib [no description available]	2.06	1	0	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor
ly-2157299 LY-2157299: an orally active transforming growth factor beta receptor (TGF-beraR) kinase inhibitor. LY-2157299 : A pyrrolopyrazole that is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole which is substituted at positions 2 and 3 by 6-methylpyridin-2-yl and 6-(aminocarbonyl)quinolin-4-yl groups, respectively. A Transforming growth factor-betaRI (TGF-betaRI) kinase inhibitor, it blocks TGF-beta-mediated tumor growth in glioblastoma.	2.1	1	0	aromatic amide; methylpyridines; monocarboxylic acid amide; pyrrolopyrazole; quinolines	antineoplastic agent; TGFbeta receptor antagonist
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	5.07	9	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
azd 6244 AZD 6244: a MEK inhibitor	2.06	1	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
su 14813 5-((5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide: has both antineoplastic and antiangiogenic activities; structure in first source	4.35	4	0
bibw 2992 [no description available]	3.23	5	0	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
nu 6140 4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide: a cyclin-dependent kinase inhibitor; structure in first source	2.78	3	0
artenimol artenimol: derivative of antimalarial drug artemisinin (quinghaosu)	2.05	1	0
4-phenoxyphenoxyethyl thiocyanate 4-phenoxyphenoxyethyl thiocyanate: has antiparasitic activity; structure in first source	2.05	1	0
aee 788 AEE 788: structure in first source	2.06	1	0	6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist; trypanocidal drug
crenolanib [no description available]	2.41	1	0	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
tg100-115 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol: for treatment of ischemia reperfusion injury; structure in first source	2.06	1	0	pteridines
(S)-Isosclerone [no description available]	3.51	1	0	tetralins
pha 665752 [no description available]	2.53	2	0	dichlorobenzene; enamide; indolones; N-acylpyrrolidine; pyrrolecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide	antineoplastic agent; c-Met tyrosine kinase inhibitor
amg 009 AMG 009: an anti-inflammatory agent; structure in first source	2.08	1	0
ly 338522 LY 338522: des-methyl metabolite of LY333531; structure in first source	1.99	1	0
cefotaxime sodium [no description available]	2.08	1	0	organic sodium salt
PDGF receptor tyrosine kinase inhibitor III PDGF receptor tyrosine kinase inhibitor III : An N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a (4-phenoxyphenyl)aminocarbonyl group, while the hydrogen attached to the nitrogen at position 4 is replaced by a 6,7-dimethoxyquinazolin-4-yl group. It is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT.	2.08	1	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; quinazolines; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ucn 1028 c calphostin C: structure given in first source; isolated from Cladosporium cladosporioides	2.05	1	0
oleanderolide oleanderolide: oleanane-type triterpene from Nerium oleander; structure in first source	2.1	1	0
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one [no description available]	2.76	3	0	methoxybenzenes; substituted aniline
erastin erastin: an antineoplastic agent; structure in first source. erastin : A member of the class of quinazolines that is quinazolin-4(3H)-one in which the hydrogens at positions 2 and 3 are replaced by 1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl and 2-ethoxyphenyl groups, respectively. It is an inhibitor of voltage-dependent anion-selective channels (VDAC2 and VDAC3) and a potent ferroptosis inducer.	2.46	2	0	aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide	antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor
abt-737 [no description available]	2.07	1	0	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
brivanib [no description available]	2.06	1	0	aromatic ether; diether; fluoroindole; pyrrolotriazine; secondary alcohol	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; drug metabolite; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
icg 001 [no description available]	2.08	1	0	peptide
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	2.15	1	0	nystatins
np 031112 tideglusib: an NSAID and neuroprotective agent. tideglusib : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a naphthalen-1-yl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. Currently under clinical investigation for the treatment of Alzheimer's disease and progressive supranuclear palsy.	2.17	1	0	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
at 7519 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide : A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine.	2.06	1	0	dichlorobenzene; piperidines; pyrazoles; secondary carboxamide	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bi 2536 [no description available]	3.36	6	0
bisorbicillinol bisorbicillinol: structure in first source	2.21	1	0
4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide [no description available]	2.08	1	0	biphenyls
nvp-ast487 NVP-AST487: antineoplastic; a RET kinase inhibitor that blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells	4.55	5	0
kw 2449 KW 2449: has both multikinase inhibitory activity and antineoplastic activity; structure in first source	2.48	2	0
nutlin-3a nutlin 3: an MDM2 antagonist; structure in first source	2.25	1	0	stilbenoid
danusertib [no description available]	2.25	1	0	piperazines
nvp-aew541 [no description available]	2.17	1	0
abt 869 [no description available]	4.35	4	0	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
fr 180204 FR 180204: structure in first source	2.46	2	0	pyrazoles; ring assembly
azd 1152 AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.	2.13	1	0	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug
dorsomorphin dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.	2.99	4	0	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
2,5-dimethylcelecoxib 2,5-dimethylcelecoxib: non-COX-2 inhibitory structural analog of celecoxib	2.07	1	0
ki11502 Ki11502: a multitargeted receptor tyrosine kinase inhibitor that induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo; structure in first source. Ki11502 : A member of the class of quinolines that acts as a receptor tyrosine kinase inhibitor and apoptosis inducer with potential for use in treatment of leukemia and colorectal cancer.	2.08	1	0	aromatic ether; benzamides; quinolines; thioureas	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
gw 2580 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source	4.69	6	0
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	2.5	2	0	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cgp 57380 CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1	2.48	2	0	pyrazolopyrimidine
chir-265 [no description available]	4.54	5	0	aromatic ether
motesanib [no description available]	4.35	4	0	pyridinecarboxamide
in 1130 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide: an activin receptor-like kinase-5 inhibitor; structure in first source	2.1	1	0
jnj 28312141 [no description available]	2.06	1	0
mln8054 [no description available]	4.55	5	0	benzazepine
pha 767491 PHA 767491: a Cdc7 inhibitor; structure in first source	2.41	1	0	pyrrolopyridine
GDC-0879 [no description available]	2.06	1	0	indanes; ketoxime; primary alcohol; pyrazoles; pyridines	antineoplastic agent; B-Raf inhibitor
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	2.08	1	0
silvestrol silvestrol: isolated from the fruit and twig of Aglaia silvestris. silvestrol : An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.	2.06	1	0	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite
diflucortolone Diflucortolone: A topical glucocorticoid used in various DERMATOSES. It is absorbed through the skin, bound to plasma albumin, and may cause adrenal suppression. It is also administered as the valerate.	2.05	1	0	21-hydroxy steroid
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.08	1	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
crinamine crinamine: RN given for (3alpha,5alpha,11R,13beta,19alpha)-isomer; structure in first source	2.07	1	0
2alpha,3beta-dihydroxy-20(29)-lupen-28-oic acid alphitolic acid: from the aerial parts of Gouania longipetala; structure in first source. 2alpha,3beta-dihydroxy-20(29)-lupen-28-oic acid : A pentacyclic triterpenoid that is betulinic acid carrying an additional alpha-hydroxy group at position 2. It has been isolated from Breynia fruticosa.	2.17	1	0	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
tomaymycin tomaymycin: structure. tomaymycin : A pyrrolobenzodiazepine that is (11aS)-2,3,5,10,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine which is substituted at positions 2,5,7,8 and 11R by ethylidene, oxo, methoxy, hydroxy and methoxy groups, respectively. It is a natural product of Streptomyces achromogenes that binds covalently with guanine in the minor groove of DNA. It is an antitumoral compound which is active in ovarian, plasmacytoma, and leukemia cancer cell lines at nanomolar concentrations.. (Z)-tomaymycin : The (Z)-isomer of tomaymycin.	2.06	1	0	tomaymycin
deoxoartemisinin deoxoartemisinin: structure given in first source	2.05	1	0
rabeprazole sodium [no description available]	2.08	1	0	organic sodium salt
2,3-dihydrowithaferin A 2,3-dihydrowithaferin A : A withanolide that is the 2,3-dihydro derivative of withaferin A. It has been isolated from the aerial parts of Physalis longifolia.	2.07	1	0	27-hydroxy steroid; 4-hydroxy steroid; delta-lactone; epoxy steroid; ergostanoid; primary alcohol; secondary alcohol; withanolide	plant metabolite
dehydroabietinol dehydroabietinol: Isolated from Hyptis suaveolens; structure in first source	2.17	1	0	abietane diterpenoid; carbotricyclic compound
gsk 461364 GSK 461364: an antineoplastic agent that inhibits polo-like kinase 1	2.06	1	0	(trifluoromethyl)benzenes
azd 1152-hqpa AZD2811: has antineoplastic activity; structure in first source	4.54	5	0	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor
nvp-tae684 [no description available]	2.79	3	0	piperidines
enmd 2076 ENMD 2076: an antiangiogenic agent with aurora kinase inhibitory and antineoplastic activities	2.61	2	0
amodiaquine hydrochloride [no description available]	2.05	1	0
e 7050 [no description available]	2.69	2	0	aromatic ether
pf-00562271 [no description available]	2.17	1	0
bivalirudin bivalirudin: designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition. bivalirudin : A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.	2.08	1	0	polypeptide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor
somatostatin [no description available]	2.46	2	0	heterodetic cyclic peptide; peptide hormone
nociceptin [no description available]	2.04	1	0	organic molecular entity; polypeptide	human metabolite; rat metabolite
gramicidin a Gramicidin: A group of peptide antibiotics from BACILLUS brevis. Gramicidin C or S is a cyclic, ten-amino acid polypeptide and gramicidins A, B, D are linear. Gramicidin is one of the two principal components of TYROTHRICIN.	2.06	1	0
ly-146032 [no description available]	2.08	1	0	heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide	antibacterial drug; bacterial metabolite; calcium-dependent antibiotics
N-methyl-3-[5-(3-phenylpropyl)-1,3,4-oxadiazol-2-yl]-N-(3-thiophenylmethyl)propanamide [no description available]	2.06	1	0	benzenes
warfarin sodium warfarin sodium : A racemate comprising equal amounts of (R)- and (S)-warfarin sodium. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.	2.08	1	0
tg101209 [no description available]	2.15	1	0	N-alkylpiperazine; N-arylpiperazine; pyrimidines; secondary amino compound; sulfonamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
fedratinib fedratinib: a selective small-molecule inhibitor of JAK2	2.06	1	0	sulfonamide
gsk690693 [no description available]	2.06	1	0	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024 [no description available]	2.17	1	0	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor
endiandrin a endiandrin A: a potent glucocorticoid receptor binder isolated from the Australian plant Endiandra anthropophagorum; structure in first source	2.05	1	0
sipholenol a sipholenol A: reverses ABCB1-mediated multidrug resistance in cancer cells; structure in first source	2.1	1	0
pravastatin sodium pravastatin sodium : An organic sodium salt that is the sodium salt of pravastatin. A reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), it is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	2.08	1	0	organic sodium salt; statin (semi-synthetic)	anticholesteremic drug
alendronate sodium [no description available]	2.08	1	0
(e)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid: casein kinase II inhibitor	2.48	2	0
valproate sodium Epilim: oral sodium valproate used as antidepressive agent. sodium valproate : The sodium salt of valproic acid.. valproate : A branched-chain saturated fatty acid anion that is the conjugate base of valproic acid.	2.05	1	0	organic sodium salt	geroprotector
gdc 0941 pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.	2.06	1	0	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
sl 80.0750 [no description available]	2.08	1	0
stf-118804 [no description available]	2.21	1	0
mesna Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.	2.08	1	0	organosulfonic acid
clavulanate potassium potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.	2.08	1	0	potassium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
piperacillin sodium [no description available]	2.08	1	0	organic sodium salt
oxacillin sodium [no description available]	2.08	1	0	organic sodium salt
cefazolin sodium cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.	2.08	1	0	organic sodium salt
azlocillin sodium [no description available]	2.08	1	0	organic sodium salt
olaparib [no description available]	2.31	1	0	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
plx 4720 PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source	2.06	1	0	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
mk 5108 [no description available]	2.13	1	0	aromatic ether
cx 4945 [no description available]	4.24	2	0
purfalcamine purfalcamine: a PfCDPK-1 inhibitor; structure in first source	2.04	1	0
sgx 523 [no description available]	2.49	2	0	aryl sulfide; biaryl; pyrazoles; quinolines; triazolopyridazine	c-Met tyrosine kinase inhibitor; nephrotoxic agent
bms 754807 BMS 754807: an IGR-1R kinase inhibitor; structure in first source	2.25	1	0	pyrazoles; pyridines; pyrrolidines; pyrrolotriazine	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
bms 777607 N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: a Met kinase inhibitor; structure in first source	2.15	1	0	aromatic amide
sgi 1776 SGI 1776: a Pim kinase inhibitor; structure in first source	2.13	1	0	imidazoles
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	2.69	2	0	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
cink4 CINK4: cyclin-dependent kinase 4 inhibitor; may have tumor suppression activity; structure in first source	3.13	1	0	indoles
ponatinib [no description available]	2.41	1	0	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor
mk-1775 adavosertib: a Wee1 kinase inhibitor; structure in first source	2.21	1	0	piperazines
quizartinib [no description available]	3.06	4	0	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor
az 505 AZ 505: an SMYD2 inhibitor; structure in first source	2.41	1	0
dcc-2036 rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent	2.41	1	0	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor
neurotensin neurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91	2.04	1	0	peptide hormone	human metabolite; mitogen; neurotransmitter; vulnerary
cabozantinib cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.	3.1	4	0	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
incb-018424 [no description available]	2.79	3	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
entrectinib entrectinib: inhibits TRK, ROS1, and ALK receptor tyrosine kinases; structure in first source. entrectinib : A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours.	2.72	2	0	benzamides; difluorobenzene; indazoles; N-methylpiperazine; oxanes; secondary amino compound; secondary carboxamide	antibacterial agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
gsk 1838705a [no description available]	2.06	1	0	organonitrogen compound; organooxygen compound
ldn 193189 LDN 193189: inhibits bone morphogenetic protein signaling	2.51	2	0	pyrimidines
1-[3-methoxy-4-[[4-(2-propan-2-ylsulfonylanilino)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]phenyl]-4-piperidinol [no description available]	2.15	1	0	piperidines
pf 3758309 PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first source	2.9	3	0	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
plx4032 [no description available]	2.51	2	0	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
gsk 1363089 GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source	3.03	4	0	aromatic ether
INDY INDY : A member of the class of benzothiazoles that is 2,3-dihydro-1,3-benzothiazole substituted by 2-oxopropylidene, ethyl, and hydroxy groups at positions 2, 3 and 5, respectively. It is an ATP-competitive inhibitor of Dyrk1A and Dyrk1B (IC50 of 0.24 muM and 0.23 muM, respectively).	3.27	1	0	benzothiazoles; enone; organic hydroxy compound	antineoplastic agent; drug metabolite; EC 2.7.12.1 (dual-specificity kinase) inhibitor
mk 2461 [no description available]	2.06	1	0
osilodrostat Osilodrostat: an orally active aldosterone-synthase inhibitor	2.1	1	0
pretubulysin pretubulysin: from myxobacteria; structure in first source	2.1	1	0
sar 020106 SAR 020106: a CHK1 inhibitor; structure in first source	2.06	1	0
baricitinib [no description available]	2.13	1	0	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
endothelins [no description available]	2.04	1	0
bisvertinolone bisvertinolone: structure in first source	2.21	1	0
thiopental sodium [no description available]	2.57	2	0	organochlorine compound; piperazines; pyrimidines	antineoplastic agent; tyrosine kinase inhibitor
pf 3644022 [no description available]	2.07	1	0
ribociclib ribociclib: inhibits both CDK4 and CDK6	2.63	2	0
1-(4-methyl-1-piperazinyl)-2-[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]ethanone [no description available]	2.25	1	0	amino acid amide
lrrk2-in1 LRRK2-IN1: inhibits leucine-rich repeat kinase 2; structure in first source	2.49	2	0	aromatic amine; aromatic ether; N-acylpiperidine; N-alkylpiperazine; pyrimidobenzodiazepine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
jq1 compound [no description available]	2.57	2	0	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
jnj38877605 [no description available]	2.13	1	0	quinolines
dinaciclib [no description available]	2.08	1	0	pyrazolopyrimidine
gsk525762a molibresib: mimicks acetylated histones; structure in first source	2.57	2	0	benzodiazepine
alectinib [no description available]	2.15	1	0	aromatic ketone; morpholines; nitrile; organic heterotetracyclic compound; piperidines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
nimorazole [no description available]	2.07	1	0
DMH1 DMH1 : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine bearing quinolin-4-yl and 4-isopropyloxyphenyl substituents at positions 3 and 6 respectively.	2.05	1	0	aromatic ether; pyrazolopyrimidine; quinolines	antineoplastic agent; bone morphogenetic protein receptor antagonist; protein kinase inhibitor
3-(5-methoxy-2-methyl-1h-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one [no description available]	2.17	1	0
gsk2141795 GSK2141795: an Akt inhibitor with antineoplastic activity; structure in first source	2.13	1	0
butyrolactone i butyrolactone I: selective inhibitor of cdk2 & cdc2 kinase; structure given in first source	3.82	3	0	butenolide
armillaridin armillaridin: isolated from Armillaria mellea mycelium I; structure given in first source	2.1	1	0	benzoate ester; sesquiterpenoid
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.52	2	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	2.76	3	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	2.05	1	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	2.05	1	0
piroxicam [no description available]	2.8	3	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
roquinimex roquinimex: structure in first source	2.08	1	0	aromatic amide
lfm a13 LFM-A13 : An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties.	2.03	1	0	aromatic amide; dibromobenzene; enamide; enol; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 2.7.11.21 (polo kinase) inhibitor; geroprotector; platelet aggregation inhibitor
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	2.08	1	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.	2.76	3	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
isoxicam isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.	2.08	1	0	benzothiazine; isoxazoles; monocarboxylic acid amide	antirheumatic drug; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.15	1	0	benzenes; hydroxycoumarin; methyl ketone
rolitetracycline Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.	2.05	1	0
teriflunomide [no description available]	3.1	1	0	(trifluoromethyl)benzenes; aromatic amide; enamide; enol; nitrile; secondary carboxamide	drug metabolite; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; hepatotoxic agent; non-steroidal anti-inflammatory drug; tyrosine kinase inhibitor
minocycline hydrochloride [no description available]	2.08	1	0
tigecycline [no description available]	2.08	1	0
lornoxicam lornoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.	2.08	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; organochlorine compound; pyridines; thienothiazine	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
tetracycline hydrochloride Actisite: tradename; fiber for periodontal use	2.06	1	0
urmc-099 URMC-099: inhibits mixed lineage kinase 3	2.08	1	0
ew-7197 vactosertib: a TGF-beta type I receptor kinase inhibitor with antifibrotic and antineoplastic activities; structure in first source	2.1	1	0
byl719 [no description available]	2.31	1	0	proline derivative
ceritinib ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.	2.15	1	0	aminopyrimidine; aromatic ether; organochlorine compound; piperidines; secondary amino compound; sulfone	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
chr-6494 [no description available]	3.41	1	0
vernolide-a vernolide-A: antineoplastic from the plant Vernonia cinerea L. (Asteraceae); structure in first source	2.11	1	0
stemofoline stemofoline: RN given for (2S-(2alpha,3beta,4beta,5alpha,5abeta,6beta,8abeta,9S*))-isomer; structure in first source	3.25	1	0
acp-196 acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity. acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.	2.25	1	0	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
osimertinib osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.	2.57	2	0	acrylamides; aminopyrimidine; biaryl; indoles; monomethoxybenzene; secondary amino compound; secondary carboxamide; substituted aniline; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
hg-9-91-01 HG-9-91-01: inhibits salt-inducible kinases; structure in first source. HG-9-91-01 : A member of the class of phenylureas that is a potent inhibitor of salt-inducible kinase 2, a potential target protein for therapy in ovarian cancer.	2.31	1	0	aminopyrimidine; dimethoxybenzene; N-alkylpiperazine; N-arylpiperazine; phenylureas; secondary amino compound	antineoplastic agent; salt-inducible kinase 2 inhibitor
lly-507 LLY-507: inhibits methyltransferase SMYD2; structure in first source. LLY-507 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-cyano-2'-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}[biphenyl]-3-carboxylic acid with the amino group of 3-(pyrrolidin-1-yl)propan-1-amine. It is a potent and selective inhibitor of SMYD2 and inhibits the ability of SMYD2 to methylate p53. It serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.	2.41	1	0
THZ531 THZ531: inhibits both CDK12 and CDK13; structure in first source. THZ531 : A member of the class of indoles that is 5-chloro-4-(1H-indol-3-yl)-N-[(3R)-piperidin-3-yl]pyrimidin-2-amine in which the piperidine NH group is substituted by a 4-{[(2E)-4-(dimethylamino)but-2-enoyl]amino}benzoyl group. It is a first-in-class CDK12 and CDK13 covalent kinase inhibitor with IC50 of 158 nM and 69 nM, respectively.	2.17	1	0	aminopyrimidine; enamide; indoles; N-acylpiperidine; organochlorine compound; secondary amino compound; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
MZ1 [no description available]	2.31	1	0	organic molecular entity
at 9283 [no description available]	2.31	1	0
akt-i-1,2 compound Akt-I-1,2 compound: an aminopeptidase P inhibitor; structure in first source	2.08	1	0
entecavir entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.	2.08	1	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
chir 258 [no description available]	4.53	5	0
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	4.14	4	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
can 508 CAN 508: has antiangiogenic activity; structure in first source. CAN-508 : A member of the class of pyrazoles that is 1H-pyrazole substituted by amino, (4-hydroxyphenyl)diazenyl, and amino groups at positions 3, 4 and 5, respectively. It is a CDK9 inhibitor (IC50 = 0.35 muM) with 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes.	2.54	2	0	aromatic amine; monoazo compound; phenols; pyrazoles	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
diguanosine tetraphosphate P(1),P(4)-bis(5'-guanosyl) tetraphosphate : A purine ribonucleoside 5'-tetraphosphate compound having 5'-guanosyl residues at the P(1)- and P(4)-positions.	3.08	1	0	guanosine 5'-phosphate; purine ribonucleoside 5'-tetraphosphate	Escherichia coli metabolite; mouse metabolite
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.59	8	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.76	3	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.08	1	0	dacarbazine
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	2.08	1	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	2.79	3	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
valtrex [no description available]	2.08	1	0	organic molecular entity
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	2.08	1	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.21	1	0	2-aminopurines; propane-1,3-diols	antiviral drug
raltitrexed [no description available]	2.08	1	0	N-acyl-amino acid
1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea [no description available]	2.06	1	0	quinazolines
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.47	2	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
citrovorum factor [no description available]	2.08	1	0	tetrahydrofolic acid
rifapentine rifapentine: cyclopentyl derivative of rifampicin	2.08	1	0	N-alkylpiperazine; N-iminopiperazine; rifamycins	antitubercular agent; leprostatic drug
thiolactomycin thiolactomycin: from actinomycetes; structure given in first source	2.05	1	0
3,4,5-trihydroxybenzamidoxime 3,4,5-trihydroxybenzamidoxime: structure given in first source	2.05	1	0	benzenetriol
sildenafil citrate Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.	2.08	1	0	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	2.08	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
tegaserod maleate [no description available]	2.08	1	0	maleate salt	serotonergic agonist
hymenialdisine [no description available]	4.9	6	0
rifabutin [no description available]	2.47	2	0
isogranulatimide isogranulatimide: G2 checkpoint inhibitor; structure in first source	2.75	3	0
2-carboxyarabinitol 1-phosphate [no description available]	2.79	3	0
nintedanib nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.	2.79	3	0
9-(4-hydroxybutyl)guanine [no description available]	2.21	1	0
6-bromoindirubin-3'-acetoxime 6-bromoindirubin-3'-acetoxime: a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, protects cells from varicella infection	2.08	1	0
debromohymenialdisine [no description available]	2.72	3	0
ver 52296 luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.	2.11	1	0	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile 2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile: structure in first source. AZD1080 : A member of the class of hydroxyindoles that is 1H-indole substituted by hydroxy, 5-(morpholin-4-ylmethyl)pyridin-2-yl, and cyano groups at positions 2, 3 and 5, respectively. It is a potent, brain permeable inhibitor of human GSK3alpha and GSK3beta with Ki of 6.9 nM and 31 nM, respectively. The drug was being developed by AstraZeneca for the treatment of Alzheimer's disease (clinical trial now discontinued).	2.25	1	0	hydroxyindoles; morpholines; nitrile; pyridines; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; tau aggregation inhibitor
pp242 torkinib : A member of the class of pyrazolopyrimidines that is 1H-pyrazolo[3,4-d]pyrimidine substituted by isopropyl, 5-hydroxyindol-2-yl and amino groups at positions 1, 3 and 4 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	2.06	1	0	aromatic amine; biaryl; hydroxyindoles; phenols; primary amino compound; pyrazolopyrimidine	antineoplastic agent; mTOR inhibitor
dinitrochlorobenzene Dinitrochlorobenzene: A skin irritant that may cause dermatitis of both primary and allergic types. Contact sensitization with DNCB has been used as a measure of cellular immunity. DNCB is also used as a reagent for the detection and determination of pyridine compounds.. 1-chloro-2,4-dinitrobenzene : A C-nitro compound that is chlorobenzene carrying a nitro substituent at each of the 2- and 4-positions.	1.98	1	0	C-nitro compound; monochlorobenzenes	allergen; epitope; sensitiser
2,3-diphosphoglycerate 2,3-Diphosphoglycerate: A highly anionic organic phosphate which is present in human red blood cells at about the same molar ratio as hemoglobin. It binds to deoxyhemoglobin but not the oxygenated form, therefore diminishing the oxygen affinity of hemoglobin. This is essential in enabling hemoglobin to unload oxygen in tissue capillaries. It is also an intermediate in the conversion of 3-phosphoglycerate to 2-phosphoglycerate by phosphoglycerate mutase (EC 5.4.2.1). (From Stryer Biochemistry, 4th ed, p160; Enzyme Nomenclature, 1992, p508). 2,3-bisphosphoglyceric acid : A bisphosphoglyceric acid that is glyceric acid carrying two phospho substituents at positions 2 and 3.	1.99	1	0	bisphosphoglyceric acid; tetronic acid derivative	human metabolite
phosphoserine Phosphoserine: The phosphoric acid ester of serine.	4.52	24	0	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	4.25	18	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
acetic acid Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.	2.25	1	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
acetone methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).	2.44	2	0	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
adenine [no description available]	4.97	12	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
agmatine Agmatine: Decarboxylated arginine, isolated from several plant and animal sources, e.g., pollen, ergot, herring sperm, octopus muscle.	2.43	2	0	guanidines; primary amino compound	Escherichia coli metabolite; mouse metabolite
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	4	14	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
beta-alanine [no description available]	2	1	0	amino acid zwitterion; beta-amino acid	agonist; fundamental metabolite; human metabolite; inhibitor; neurotransmitter
benzoic acid Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.	2.03	1	0	benzoic acids	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
bromide Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)	2.06	1	0	halide anion; monoatomic bromine
1-butanol 1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1.. butan-1-ol : A primary alcohol that is butane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It it produced in small amounts in humans by the gut microbes.	3.38	7	0	alkyl alcohol; primary alcohol; short-chain primary fatty alcohol	human metabolite; mouse metabolite; protic solvent
butyric acid Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.	3.6	3	0	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite
cadaverine [no description available]	3.09	5	0	alkane-alpha,omega-diamine	Daphnia magna metabolite; Escherichia coli metabolite; mouse metabolite; plant metabolite
carbamates [no description available]	2.9	4	0	amino-acid anion
carbon monoxide Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed). carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.	2.39	2	0	carbon oxide; gas molecular entity; one-carbon compound	biomarker; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; human metabolite; ligand; metabolite; mitochondrial respiratory-chain inhibitor; mouse metabolite; neurotoxin; neurotransmitter; P450 inhibitor; probe; signalling molecule; vasodilator agent
formic acid formic acid: RN given refers to parent cpd. formic acid : The simplest carboxylic acid, containing a single carbon. Occurs naturally in various sources including the venom of bee and ant stings, and is a useful organic synthetic reagent. Principally used as a preservative and antibacterial agent in livestock feed. Induces severe metabolic acidosis and ocular injury in human subjects.	1.97	1	0	monocarboxylic acid	antibacterial agent; astringent; metabolite; protic solvent; solvent
carnitine [no description available]	2.69	3	0	amino-acid betaine	human metabolite; mouse metabolite
methane Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed). methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).	2.06	1	0	alkane; gas molecular entity; mononuclear parent hydride; one-carbon compound	bacterial metabolite; fossil fuel; greenhouse gas
choline [no description available]	4.51	24	0	cholines	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	6.25	55	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	3.26	6	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
phloroglucinol Phloroglucinol: A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent.. phloroglucinol : A benzenetriol with hydroxy groups at position 1, 3 and 5.	2.01	1	0	benzenetriol; phenolic donor	algal metabolite
gallic acid gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.	4.24	18	0	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite
guaiacol Guaiacol: An agent thought to have disinfectant properties and used as an expectorant. (From Martindale, The Extra Pharmacopoeia, 30th ed, p747). methylcatechol : Any member of the class of catechols carrying one or more methyl substituents.. guaiacol : A monomethoxybenzene that consists of phenol with a methoxy substituent at the ortho position.	2.03	1	0	guaiacols	disinfectant; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; expectorant; plant metabolite
2-aminoadipic acid 2-Aminoadipic Acid: A metabolite in the principal biochemical pathway of lysine. It antagonizes neuroexcitatory activity modulated by the glutamate receptor, N-METHYL-D-ASPARTATE; (NMDA).. 2-aminoadipic acid : An alpha-amino acid that is adipic acid bearing a single amino substituent at position 2. An intermediate in the formation of lysine.	1.99	1	0	amino dicarboxylic acid; dicarboxylic fatty acid; non-proteinogenic alpha-amino acid	Caenorhabditis elegans metabolite; mammalian metabolite
2-keto-4-methylthiobutyric acid 2-keto-4-methylthiobutyric acid: RN given refers to parent cpd; structure. 4-methylthio-2-oxobutanoic acid : A 2-oxo monocarboxylic acid derived from L-methionine via the action of methionine transaminase.	2.08	1	0	omega-(methylthio)-2-oxocarboxylic acid
phosphonoacetic acid Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.. phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.	2.01	1	0	monocarboxylic acid; phosphonic acids	antiviral agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
cytosine [no description available]	4.33	3	0	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	3.63	9	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
diacetyl butane-2,3-dione : An alpha-diketone that is butane substituted by oxo groups at positions 2 and 3. It is a metabolite produced during the malolactic fermentation.	3.1	5	0	alpha-diketone	Escherichia coli metabolite; Saccharomyces cerevisiae metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	4.44	22	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
ethanolamine [no description available]	2.9	4	0	ethanolamines; primary alcohol; primary amine	Escherichia coli metabolite; human metabolite; mouse metabolite
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	2.71	3	0	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycine [no description available]	6.67	22	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
glyceraldehyde Glyceraldehyde: An aldotriose containing the propionaldehyde structure with hydroxy groups at the 2- and 3-positions. It is involved in the formation of ADVANCED GLYCOSYLATION END PRODUCTS.. glyceraldehyde : An aldotriose comprising propanal having hydroxy groups at the 2- and 3-positions. It plays role in the formation of advanced glycation end-products (AGEs), a deleterious accompaniment to ageing.. aldose : Aldehydic parent sugars (polyhydroxy aldehydes H[CH(OH)]nC(=O)H, n >= 2) and their intramolecular hemiacetals.	1.98	1	0	aldotriose	fundamental metabolite
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	2.9	4	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
hydrogen carbonate Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.	3.5	8	0	carbon oxoanion	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
histamine [no description available]	9.98	39	0	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
hydrogen Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.	3.37	7	0	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
hydroquinone [no description available]	1.99	1	0	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
indole [no description available]	2.02	1	0	indole; polycyclic heteroarene	Escherichia coli metabolite
indoleacetic acid indoleacetic acid: RN given refers to unlabeled parent cpd; structure in Merck Index, 9th ed, #4841. auxin : Any of a group of compounds, both naturally occurring and synthetic, that induce cell elongation in plant stems (from Greek alphaupsilonxialphanuomega, "to grow").. indole-3-acetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by a 1H-indol-3-yl group.	3.51	2	0	indole-3-acetic acids; monocarboxylic acid	auxin; human metabolite; mouse metabolite; plant hormone; plant metabolite
dihydroxyphenylalanine Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.. dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.	1.97	1	0	hydroxyphenylalanine; non-proteinogenic alpha-amino acid; tyrosine derivative	human metabolite
pipecolic acid pipecolic acid: RN given refers to cpd without isomeric designation. pipecolic acid : A piperidinemonocarboxylic acid in which the carboxy group is located at position C-2.. pipecolate : A piperidinecarboxylate that is the conjugate base of pipecolic acid.	2.39	2	0	piperidinemonocarboxylic acid
thioctic acid Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.	2.47	2	0	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2	1	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	5.03	13	0	cyclitol; hexol
melatonin [no description available]	4.73	9	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
croton oil [no description available]	1.99	1	0	N-acyl-hexosamine
naphthalene [no description available]	2.25	1	0	naphthalenes; ortho-fused bicyclic arene	apoptosis inhibitor; carcinogenic agent; environmental contaminant; mouse metabolite; plant metabolite; volatile oil component
nickel Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.. nickel ion : A nickel atom having a net electric charge.. nickel atom : Chemical element (nickel group element atom) with atomic number 28.	3.51	8	0	metal allergen; nickel group element atom	epitope; micronutrient
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	7.28	21	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	2.93	4	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	3.51	8	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
1-octanol 1-Octanol: A colorless, slightly viscous liquid used as a defoaming or wetting agent. It is also used as a solvent for protective coatings, waxes, and oils, and as a raw material for plasticizers. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). octan-1-ol : An octanol carrying the hydroxy group at position 1.	1.98	1	0	octanol; primary alcohol	antifungal agent; bacterial metabolite; fuel additive; kairomone; plant metabolite
4-aminobenzoic acid 4-Aminobenzoic Acid: An aminobenzoic acid isomer that combines with pteridine and GLUTAMIC ACID to form FOLIC ACID. The fact that 4-aminobenzoic acid absorbs light throughout the UVB range has also resulted in its use as an ingredient in SUNSCREENS.. 4-ammoniobenzoate : A zwitterion obtained by transfer of a proton from the carboxy to the amino group of 4-aminobenzoic acid.. 4-aminobenzoic acid : An aminobenzoic acid in which the amino group is para to the carboxy group.	2	1	0	aminobenzoic acid; aromatic amino-acid zwitterion	allergen; Escherichia coli metabolite; plant metabolite
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	2.7	3	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
pentachlorophenol PENTA: structure given in first source	2.03	1	0	aromatic fungicide; chlorophenol; organochlorine pesticide; pentachlorobenzenes	human xenobiotic metabolite
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	6.26	13	1	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
phosphorylethanolamine phosphorylethanolamine: RN given refers to parent cpd; structure. O-phosphoethanolamine : The ethanolamine mono-ester of phosphoric acid, and a metabolite of phospholipid metabolism. This phosphomonoester shows strong structural similarity to the inhibitory neurotransmitter GABA, and is decreased in post-mortem Alzheimer's disease brain.	1.98	1	0	phosphoethanolamine; primary amino compound	algal metabolite; human metabolite; mouse metabolite
picolinic acid picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206. picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.	1.99	1	0	pyridinemonocarboxylic acid	human metabolite; MALDI matrix material
propionic acid propionic acid : A short-chain saturated fatty acid comprising ethane attached to the carbon of a carboxy group.	2	1	0	saturated fatty acid; short-chain fatty acid	antifungal drug
pteridines [no description available]	2.47	2	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; pteridines
putrescine [no description available]	2.9	4	0	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
pyridoxal phosphate Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).. pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.	2.04	1	0	methylpyridines; monohydroxypyridine; pyridinecarbaldehyde; vitamin B6 phosphate	coenzyme; cofactor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
pyruvic acid Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.	2.7	3	0	2-oxo monocarboxylic acid	cofactor; fundamental metabolite
quinolinic acid Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.. pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.. quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.	2.96	4	0	pyridinedicarboxylic acid	Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist
dithionite Dithionite: Dithionite. The dithionous acid ion and its salts.	1.98	1	0	sulfur oxide; sulfur oxoanion
sarcosine cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis	1.98	1	0	N-alkylglycine zwitterion; N-alkylglycine; N-methyl-amino acid; N-methylglycines	Escherichia coli metabolite; glycine receptor agonist; glycine transporter 1 inhibitor; human metabolite; mouse metabolite
spermidine [no description available]	2.39	2	0	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermine [no description available]	3.5	8	0	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
succinic acid Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851). succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.	2.01	1	0	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
taurine [no description available]	3.08	5	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
toluene methylbenzene : Any alkylbenzene that is benzene substituted with one or more methyl groups.	3.64	3	0	methylbenzene; toluenes; volatile organic compound	cholinergic antagonist; fuel additive; neurotoxin; non-polar solvent
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	1.98	1	0	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
uric acid Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.	2.69	3	0	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	4.92	11	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
xanthine 7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.. 9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.	2.92	4	0	xanthine	Saccharomyces cerevisiae metabolite
2-amino-5-phosphonovalerate 2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.	3.38	7	0	non-proteinogenic alpha-amino acid	NMDA receptor antagonist
8-hydroxy-2-(di-n-propylamino)tetralin 8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively	2.01	1	0	phenols; tertiary amino compound; tetralins	serotonergic antagonist
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.	3.87	12	0	non-proteinogenic alpha-amino acid
4-iodo-2,5-dimethoxyphenylisopropylamine 4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist. 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.	2.38	2	0	amphetamines; dimethoxybenzene; organoiodine compound
ibotenic acid Ibotenic Acid: A neurotoxic isoxazole (similar to KAINIC ACID and MUSCIMOL) found in AMANITA mushrooms. It causes motor depression, ataxia, and changes in mood, perceptions and feelings, and is a potent excitatory amino acid agonist.	2.89	4	0	non-proteinogenic alpha-amino acid	neurotoxin
gallopamil Gallopamil: Coronary vasodilator that is an analog of iproveratril (VERAPAMIL) with one more methoxy group on the benzene ring.	2.92	4	0	benzenes; organic amino compound
sk&f-38393 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.. 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.. SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393	2.68	3	0	benzazepine; catechols; secondary amino compound
huperzine a huperzine A: RN given refers to 5R-(5alpha,9beta,11E)-isomer; structure given in first source. huperzine A : A sesquiterpene alkaloid isolated from a club moss Huperzia serrata that has been shown to exhibit neuroprotective activity. It is also an effective inhibitor of acetylcholinesterase and has attracted interest as a therapeutic candidate for Alzheimer's disease.	7.43	2	0	quinolone
(alpha-carboxycyclopropyl)glycine (alpha-carboxycyclopropyl)glycine: structure given in first source; glutamate receptor agonist	1.99	1	0	alpha-amino acid
1,10-phenanthroline 1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases	8.24	6	0	phenanthroline	EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
1,2-didecanoylglycerol 1,2-didecanoylglycerol: functions as bioregulator of protein kinase C in human platelets; RN given refers to cpd without isomeric designation	2.4	2	0	1,2-diglyceride; decanoate ester
1,2-dioctanoylglycerol 1,2-dioctanoylglycerol: functions as bioregulator of protein kinase C in human platelets	5	40	0
1,3-dipropyl-8-cyclopentylxanthine DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.	2	1	0	oxopurine	adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	2.69	3	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
1-(5-isoquinolinylsulfonyl)-3-methylpiperazine 1-(5-isoquinolinylsulfonyl)-3-methylpiperazine: a positional isomer of H-7; inhibits protein kinase and cAMP-dependent protein kinase	3.09	5	0
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	1.97	1	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
1-o-hexadecyl-2-o-methylglycerol [no description available]	2.38	2	0
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.	2.05	1	0	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
edelfosine edelfosine: RN given refers to parent cpd. edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.. 1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.	3.08	5	0	glycerophosphocholine
pd 173074 [no description available]	2.07	1	0	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
n-(3-(aminomethyl)benzyl)acetamidine N-(3-(aminomethyl)benzyl)acetamidine: structure in first source. N-[3-(aminomethyl)benzyl]acetamidine : An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase.	2	1	0	aralkylamine; carboxamidine; primary amino compound	angiogenesis inhibitor; EC 1.14.13.39 (nitric oxide synthase) inhibitor; geroprotector
17-octadecynoic acid octadec-17-ynoic acid : An acetylenic fatty acid that is octadecanoi acid (stearic acid) which has been doubly dehydrogenated at positions 17 and 18 to give the corresponding alkynoic acid.	2.41	2	0	acetylenic fatty acid; long-chain fatty acid; monounsaturated fatty acid; terminal acetylenic compound	EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitor; EC 1.14.15.3 (alkane 1-monooxygenase) inhibitor; P450 inhibitor
2,4-dichlorophenoxyacetic acid 2,4-Dichlorophenoxyacetic Acid: An herbicide with irritant effects on the eye and the gastrointestinal system.. 2,4-D : A chlorophenoxyacetic acid that is phenoxyacetic acid in which the ring hydrogens at postions 2 and 4 are substituted by chlorines.	2.42	2	0	chlorophenoxyacetic acid; dichlorobenzene	agrochemical; defoliant; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; environmental contaminant; phenoxy herbicide; synthetic auxin
2,4-dinitrophenol 2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed). dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.. 2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.	2.4	2	0	dinitrophenol	allergen; antiseptic drug; bacterial xenobiotic metabolite; geroprotector; oxidative phosphorylation inhibitor
mercaptoethanol Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.	2.4	2	0	alkanethiol; primary alcohol	geroprotector
2-methyl-5-ht 2-methyl-5-HT: M-receptor agonist	1.97	1	0	tryptamines	serotonergic agonist
2-nitro-4-carboxyphenyl-n,n-diphenylcarbamate 2-nitro-4-carboxyphenyl-N,N-diphenylcarbamate: inhibits phospholipase C and serine esterases; structure in first source	2.9	4	0
2-aminoethoxydiphenyl borate 2-aminoethoxydiphenyl borate: is a novel membrane-penetrable modulator and transient receptor potential channel blocker; structure in first source; do not confuse with 2-APB cpd. 2-aminoethoxydiphenylborane : An organoboron compound that is diphenylborane in which the borane hydrogen is replaced by a 2-aminoethoxy group.	3.44	7	0	organoboron compound; primary amino compound	calcium channel blocker; IP3 receptor antagonist; potassium channel opener
3,4-dichloroisocoumarin 3,4-dichloroisocoumarin : A member of the class of isocoumarins that is isocoumarin substituted by chloro groups at positions 3 and 4. It is a serine protease inhibitor.	2	1	0	isocoumarins; organochlorine compound	geroprotector; serine protease inhibitor
zopolrestat zopolrestat: structure given in first source	2	1	0
3-aminobenzamide [no description available]	3.26	6	0	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
aminopropionitrile Aminopropionitrile: Reagent used as an intermediate in the manufacture of beta-alanine and pantothenic acid.	2.21	1	0	aminopropionitrile	antineoplastic agent; antirheumatic drug; collagen cross-linking inhibitor; plant metabolite
3-methylcholanthrene Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.	1.97	1	0	ortho- and peri-fused polycyclic arene	aryl hydrocarbon receptor agonist; carcinogenic agent
3-nitropropionic acid 3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE. 3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.	3.29	6	0	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin
ro 5-4864 4'-chlorodiazepam: selectively binds peripheral benzodiazepine receptor	1.97	1	0
4,5,6,7-tetrabromo-2-azabenzimidazole 4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor	2.42	2	0
cgp 52411 4,5-dianilinophthalimide: structure given in first source. 4,5-dianilinophthalimide : Phthalimide substituted at the 4- and 5-positions by anilino groups.	6.98	1	0	phthalimides	geroprotector; tyrosine kinase inhibitor
4-(2-aminoethyl)benzenesulfonylfluoride [no description available]	2.03	1	0
4-aminopyridine [no description available]	4.26	18	0	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
5,5-dimethyl-1-pyrroline-1-oxide 5,5-dimethyl-1-pyrroline-1-oxide: do not confuse with DMPO (4',5'-dihydroxy-7-methoxy-4-phenyl-5,2'-oxidocoumarin). 5,5-dimethyl-1-pyrroline N-oxide : A member of the class of 1-pyrroline nitrones (1-pyrroline N-oxides) resulting from the formal N-oxidation of 5,5-dimethyl-1-pyrroline. Used as a spin trap for the study of radicals formed by enzymatic acetaldehyde oxidation.	1.98	1	0	1-pyrroline nitrones	neuroprotective agent; spin trapping reagent
5,8,11,14-eicosatetraynoic acid 5,8,11,14-Eicosatetraynoic Acid: A 20-carbon unsaturated fatty acid containing 4 alkyne bonds. It inhibits the enzymatic conversion of arachidonic acid to prostaglandins E(2) and F(2a).	1.98	1	0	long-chain fatty acid
5-dimethylamiloride 5-dimethylamiloride: has anti-HIV-1 activity	2.89	4	0
5-(n,n-hexamethylene)amiloride 5-(N,N-hexamethylene)amiloride: inhibitor of Na+-H+ exchange; has anti-HIV-1 activity. 5-(N,N-hexamethylene)amiloride : A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring.	2.69	3	0	aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines	antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker
ethylisopropylamiloride ethylisopropylamiloride: structure in first source. ethylisopropylamiloride : A member of the class of pyrazines that is amiloride in which the amino substitutent of the pyrazine ring that is adjacent to the chloro substituent has been substituted by an ethyl group and by an isopropyl group.	3.7	10	0	aromatic amine; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines; tertiary amino compound	anti-arrhythmia drug; neuroprotective agent; sodium channel blocker
5-hydroxydecanoate 5-hydroxydecanoic acid: Potassium Channel Blocker; RN refers to parent cpd	2.93	4	0	medium-chain fatty acid
7-nitroindazole 7-nitroindazole: an inhibitor of nitric oxide synthase; exhibits anti-nociceptive activity without increasing blood pressure	2.01	1	0
8-(4-sulfophenyl)theophylline 8-(4-sulfophenyl)theophylline: adenosine antagonist	2.41	2	0
8-cyclopentyl-1,3-dimethylxanthine 8-cyclopentyl-1,3-dimethylxanthine: prolongs epileptic seizures in rats	1.99	1	0	oxopurine
oxyquinoline Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.	2.6	1	0	monohydroxyquinoline	antibacterial agent; antifungal agrochemical; antiseptic drug; iron chelator
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	8.79	3	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
aa 861 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone: structure given in first source. docebenone : A member of the class of benzoquinones that is p-benzoquinone in which the hydrogens are substituted by three methyl groups and a 12-hydroxydodeca-5,10-diyn-1-yl group.	1.99	1	0	1,4-benzoquinones; acetylenic compound; primary alcohol	EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor
2,2'-azobis(2-amidinopropane) 2,2'-azobis(2-amidinopropane): water-soluble free-radical initiator	1.99	1	0	monoazo compound
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	7.46	2	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
tyrphostin ag 1024 tyrphostin AG 1024: modulates radiosensitivity in human breast cancer cells; also an IGF1 receptor inhibitor	2.01	1	0	alkylbenzene
ag-1296 6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase	3.27	6	0	quinoxaline derivative
tyrphostin a23 tyrphostin A23: inhibits EGF-stimulated thymidine incorporation as well as EGF-stimulated receptor autophosphorylation & tyrosine phosphorylation & cell proliferation; structure given in first source	3.25	6	0	catechols
tyrphostin 25 [no description available]	3.24	6	0	benzenetriol
1-aminoindan-1,5-dicarboxylic acid 1-aminoindan-1,5-dicarboxylic acid: structure given in first source	2.03	1	0
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	2	1	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alpha-methylserotonin alpha-methylserotonin: potent agonist at M & D receptors of serotonin; RN given refers to parent cpd	2.42	2	0	tryptamines	serotonergic agonist
aluminum fluoride [no description available]	2.67	3	0	aluminium coordination entity
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.02	1	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
pimagedine pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.	2.41	2	0	guanidines; one-carbon compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 1.4.3.4 (monoamine oxidase) inhibitor
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	3.25	6	0	N-acylglycine	Daphnia magna metabolite
theophylline [no description available]	8.6	9	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.48	2	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	1.97	1	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anthralin Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.	1.97	1	0	anthracenes	antipsoriatic
2-amino-4-phosphonobutyric acid 2-amino-4-phosphonobutyric acid: glutamate antagonist in locust muscle; structure; do not confuse with L-AP4, which is the propionic acid version	2.39	2	0
acetovanillone apocynin : An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3.	2.7	3	0	acetophenones; aromatic ketone; methyl ketone	antirheumatic drug; EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug; plant metabolite
arecoline Arecoline: An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.. arecoline : A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine.	2.94	4	0	enoate ester; methyl ester; pyridine alkaloid; tetrahydropyridine	metabolite; muscarinic agonist
aristolochic acid i aristolochic acid I: phospholipase A inhibitor. aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.	2.69	3	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	4.01	14	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	2.7	3	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate: a glutamate agonist	2	1	0	alpha-amino acid
aurintricarboxylic acid Aurintricarboxylic Acid: A dye which inhibits protein biosynthesis at the initial stages. The ammonium salt (aluminon) is a reagent for the colorimetric estimation of aluminum in water, foods, and tissues.. aurintricarboxylic acid : A member of the class of quinomethanes that is 3-methylidene-6-oxocyclohexa-1,4-diene-1-carboxylic acid in which the methylidene hydrogens are replaced by 4-carboxy-3-hydroxyphenyl groups. The trisodium salt is the biological stain 'chrome violet CG' while the triammonium salt is 'aluminon'.	2.69	3	0	monohydroxybenzoic acid; quinomethanes; tricarboxylic acid	fluorochrome; histological dye; insulin-like growth factor receptor 1 antagonist
bay-k-8644 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.. Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644. methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6.	4.43	22	0	(trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester
benzamidine benzamidine: RN given refers to parent cpd. benzamidine : A carboxamidine that is benzene carrying an amidino group.	2.02	1	0	benzenes; carboxamidine	serine protease inhibitor
benzo(a)pyrene Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke.. benzo[a]pyrene : An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings.	2.69	3	0	ortho- and peri-fused polycyclic arene	carcinogenic agent; mouse metabolite
beta-naphthoflavone beta-Naphthoflavone: A polyaromatic hydrocarbon inducer of P4501A1 and P4501A2 cytochromes. (Proc Soc Exp Biol Med 1994 Dec:207(3):302-308). beta-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the f side of flavone.	2.39	2	0	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist
2,5-di-tert-butylhydroquinone 2,5-di-tert-butylbenzene-1,4-diol : A member of the class of hydroquinones that is benzene-1,4-diol substituted by tert-butyl groups at position 2 and 5.	2.4	2	0	hydroquinones
bisbenzimidazole Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.	3.4	7	0	bibenzimidazole; N-methylpiperazine	anthelminthic drug; fluorochrome
bisindolylmaleimide i bisindolylmaleimide I: a bis(indolyl)maleimide	11.84	83	0
2-(1-(2-(1-methylpyrrolidino)ethyl)-1h-indol-3-yl)maleimide bisindolylmaleimide II: protein kinase C inhibitor; see also bisindolylmaleimide I	2.03	1	0
bisindolylmaleimide v bisindolylmaleimide V: used as a negative control compound for protein kinase C inhibition; structure in first source;	2	1	0	indoles
ro 31-7549 Ro 31-7549: structure	8.78	11	0
bumetanide [no description available]	4.01	14	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin bunazosin: structure	2.02	1	0	quinazolines
butacaine butacaine: was MH 1965-92; BUTAPROBENZ & BUTOCAIN were see BUTACAINE 1978-92; use 4-AMINOBENZOIC ACID to search BUTACAINE 1966-92	2	1	0	benzoate ester
cacodylic acid dimethylarsinic acid : The organoarsenic compound that is arsenic acid substituted on the central arsenic atom with two methyl groups.	2	1	0	organoarsenic compound	xenobiotic metabolite
caffeine [no description available]	6.94	39	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	5.71	32	0	aromatic ether; nitrile; polyether; tertiary amino compound
calmidazolium calmidazolium: powerful inhibitor of or red blood cell Ca++-ATPase & Ca++ transport into inside-out red blood cell vesicles; RN refers to chloride; structure in first source; an antagonist of calmodulin. calmidazolium : An imidazolium ion that is imidazolium cation substituted by a bis(4-chlorophenyl)methyl group at position 1 and a 2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl group at position 3. It acts as an antagonist of calmodulin, a calcium binding messenger protein.	4.19	17	0	imidazolium ion	apoptosis inducer; calmodulin antagonist
candesartan candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.	2	1	0	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	2.07	1	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	1.99	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carbonyl cyanide m-chlorophenyl hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.	3.72	10	0	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
celecoxib [no description available]	7.46	2	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cgp 12177 CGP 12177 : A benzimidazole that is benzimidazol-2-one substituted at position 4 by a 3-(tert-butylamino)-2-hydroxypropoxy group.	1.98	1	0	aromatic ether; benzimidazoles; secondary alcohol; secondary amino compound	beta-adrenergic antagonist
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	5.87	95	0	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.71	3	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	3.87	12	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	1.98	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	1.97	1	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	2.92	4	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cirazoline cirazoline: posseses agonist properties at alpha-adrenoreceptor sites; RN given refers to parent cpd	2.4	2	0	aromatic ether
clenbuterol Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.. clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.93	1	0	amino alcohol; dichlorobenzene; ethanolamines; primary arylamine; secondary amino compound; substituted aniline	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	2.39	2	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	3.24	6	0	clonidine; imidazoline
clotrimazole [no description available]	2.07	1	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
cycloleucine Cycloleucine: An amino acid formed by cyclization of leucine. It has cytostatic, immunosuppressive and antineoplastic activities.. 1-aminocyclopentanecarboxylic acid : A non-proteinogenic alpha-amino acid that is cyclopentane substituted at position 1 by amino and carboxy groups.	3.49	8	0	non-proteinogenic alpha-amino acid	EC 2.5.1.6 (methionine adenosyltransferase) inhibitor
cypermethrin cypermethrin : A carboxylic ester resulting from the formal condensation between 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid and the alcoholic hydroxy group of hydroxy(3-phenoxyphenyl)acetonitrile.. zeta-cypermethrin : A diastereoisomeric mixture comprising the isomeric pair (1R)-cis-(alphaS)- and (1S)-trans-(alphaR)-cypermethrin together with the isomeric pair (1S)-cis-(alphaS)- and (1S)-trans-(alphaS)-cypermethrin where the ratio between the isomeric pairs lies in the range 45:55 to 55:45.	2	1	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organochlorine compound	agrochemical; molluscicide; pyrethroid ester acaricide; pyrethroid ester insecticide
cystamine [no description available]	2.08	1	0	organic disulfide; primary amino compound	EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor
damnacanthal damnacanthal: structure given in first source; isolated from the stem bark and roots of Morinda lucida; a selective inhibitor of p56(lck) tyrosine kinase activity	4.01	4	0	aldehyde; monohydroxyanthraquinone
dantrolene Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.. dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.	2.72	3	0	hydrazone; imidazolidine-2,4-dione	muscle relaxant; neuroprotective agent; ryanodine receptor antagonist
dapi DAPI: RN given refers to parent cpd.	3.53	8	0	indoles	fluorochrome
2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone 2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone: ubiquinol analog. 6-decylubiquinone : A member of the class of 1,4-benzoquinones that is 2,3-dimethoxybenzoquinone which has been substituted at positions 5 and 6 by decyl and methyl groups.	2.02	1	0	1,4-benzoquinones	cofactor
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	2.91	4	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	2	1	0	primary amine
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	2.68	3	0	alpha-amino acid; fluoroamino acid	trypanocidal drug
r 59022 R 59022: diacylglycerol kinase inhibitor; structure given in first source; platelet activator factor antagonist	3.68	10	0	diarylmethane
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.42	2	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	2.72	3	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
dibucaine Dibucaine: A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006). cinchocaine : A monocarboxylic acid amide that is the 2-(diethylamino)ethyl amide of 2-butoxyquinoline-4-carboxylic acid. One of the most potent and toxic of the long-acting local anesthetics, its parenteral use was restricted to spinal anesthesia. It is now generally only used (usually as the hydrochloride) in creams and ointments and in suppositories for temporary relief of pain and itching associated with skin and anorectal conditions.	3.09	5	0	aromatic ether; monocarboxylic acid amide; tertiary amino compound	topical anaesthetic
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	1.97	1	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
diethylcarbamazine Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.	1.99	1	0	N-carbamoylpiperazine; N-methylpiperazine
dihydrocytochalasin b dihydrocytochalasin B: inhibits cell motility in many eucaryotic cells	1.99	1	0
dilazep Dilazep: Coronary vasodilator with some antiarrhythmic activity.. dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.	1.98	1	0	benzoate ester; diazepane; diester; methoxybenzenes	cardioprotective agent; platelet aggregation inhibitor; vasodilator agent
diphenyleneiodonium diphenyleneiodonium: structure in first source; NADPH oxidase inhibitor. dibenziodolium : An organic cation that is fluorene in which the methylene group is replaced by a positively charged iodine.	3.62	9	0	organic cation
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	2.38	2	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disulfiram [no description available]	2.03	1	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
diuron Diuron: A pre-emergent herbicide.. diuron : A member of the class of 3-(3,4-substituted-phenyl)-1,1-dimethylureas that is urea in which both of the hydrogens attached to one nitrogen are substituted by methyl groups, and one of the hydrogens attached to the other nitrogen is substituted by a 3,4-dichlorophenyl group.	2.01	1	0	3-(3,4-substituted-phenyl)-1,1-dimethylurea; dichlorobenzene	environmental contaminant; mitochondrial respiratory-chain inhibitor; photosystem-II inhibitor; urea herbicide; xenobiotic
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	8.15	5	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
thiorphan Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.	2.02	1	0	N-acyl-amino acid
n(6),n(6)-dimethyladenine N(6),N(6)-dimethyladenine : A tertiary amine that is adenine substituted at N-6 by geminal methyl groups.	2.91	4	0	tertiary amine
2,3-dimethoxy-1,4-naphthoquinone 2,3-dimethoxynaphthalene-1,4-dione : A naphthoquinone that is 1,4-naphthoquinone bearing two methoxy substituents at positions 2 and 3. Redox-cycling agent that induces intracellular superoxide anion formation and, depending on the concentration, induces cell proliferation, apoptosis or necrosis. Used to study the role of ROS in cell toxicity, apoptosis, and necrosis.	2.41	2	0	1,4-naphthoquinones
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	1.98	1	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	7.01	1	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
dsp 4 DSP 4: RN given refers to parent cpd	2	1	0
ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.	2	1	0	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
econazole Econazole: An imidazole derivative that is commonly used as a topical antifungal agent.. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.. 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group.	2.39	2	0	dichlorobenzene; ether; imidazoles; monochlorobenzenes
embelin embelin: from Embelia fruit (Myrsinaceae). embelin : A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease.	2.11	1	0	dihydroxy-1,4-benzoquinones	antimicrobial agent; antineoplastic agent; hepatitis C protease inhibitor; plant metabolite
emodin Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.	2.73	3	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
endosulfan Endosulfan: A polychlorinated compound used for controlling a variety of insects. It is practically water-insoluble, but readily adheres to clay particles and persists in soil and water for several years. Its mode of action involves repetitive nerve-discharges positively correlated to increase in temperature. This compound is extremely toxic to most fish. (From Comp Biochem Physiol (C) 1993 Jul;105(3):347-61). endosulfan : A cyclic sulfite ester that is 1,5,5a,6,9,9a-hexahydro-6,9-methano-2,4,3-benzodioxathiepine 3-oxide substituted by chloro groups at positions 6, 7, 8, 9, 10 and 10.	2.03	1	0	cyclic sulfite ester; cyclodiene organochlorine insecticide	acaricide; agrochemical; GABA-gated chloride channel antagonist; persistent organic pollutant
endothall endothall: minor descriptor (72-82); online & Index Medicus search DICARBOXYLIC ACIDS (72-82)	2.7	3	0
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	4.15	16	0
ether Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes.. ether : An organooxygen compound with formula ROR, where R is not hydrogen.. diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups.	1.98	1	0	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant
etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.	2	1	0	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
carbonyl cyanide p-trifluoromethoxyphenylhydrazone Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.	3.51	8	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	2.4	2	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	2.03	1	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
fenoldopam Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.	2.41	2	0	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
fleroxacin Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.	1.98	1	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
fluphenazine [no description available]	2.05	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flunitrazepam Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.	1.99	1	0	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	6.27	19	2	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.02	1	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	2.02	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
fomepizole Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL.. fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.	2.01	1	0	pyrazoles	antidote; EC 1.1.1.1 (alcohol dehydrogenase) inhibitor; protective agent
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	3.26	6	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	2.92	4	0
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	3.59	9	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
gö6983 [no description available]	2.02	1	0	indoles; maleimides
go 6976 [no description available]	4.88	34	0	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	7.9	4	0
gyki 52466 GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source	1.99	1	0	benzodiazepine
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide [no description available]	4.93	37	0	isoquinolines; sulfonamide
1-(5-isoquinolinesulfonyl)-2-methylpiperazine 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.	8.44	424	0	isoquinolines; N-sulfonylpiperazine	EC 2.7.11.13 (protein kinase C) inhibitor
n-(2-aminoethyl)-5-isoquinolinesulfonamide [no description available]	2.67	3	0
1-(5-isoquinolinesulfonyl)piperazine [no description available]	2.38	2	0	isoquinolines
ha 1004 N-(2-guanidinoethyl)-5-isoquinolinesulfonamide: structure given in first source	5.02	41	0	isoquinolines
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	3.11	5	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
ha14-1 ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia	2.01	1	0	1-benzopyran
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.41	2	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
halothane [no description available]	2.91	4	0	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	2.73	3	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
hexamethylene bisacetamide N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208	2.4	2	0	acetamides
ethidium Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.	2.69	3	0	phenanthridines	fluorochrome; intercalator
hydroxyurea [no description available]	4.72	9	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hypericin [no description available]	3.09	5	0
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	3.83	4	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.92	4	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
idebenone [no description available]	2.41	2	0	1,4-benzoquinones; primary alcohol	antioxidant; ferroptosis inhibitor
ifenprodil ifenprodil: NMDA receptor antagonist	2.92	4	0	piperidines
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2	1	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	10.08	43	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iodoacetamide [no description available]	2.42	2	0
irsogladine irsogladine: RN given refers to parent cpd; MN 1695 refers to maleate salt	1.98	1	0	dichlorobenzene
1-methyl-3-isobutylxanthine 1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.	4.93	37	0	3-isobutyl-1-methylxanthine
isoflurane Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.	4.66	6	0	organofluorine compound	inhalation anaesthetic
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	2.42	2	0	carbohydrazide	antitubercular agent; drug allergen
2-propanol 2-Propanol: An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.. propan-2-ol : A secondary alcohol that is propane in which one of the hydrogens attached to the central carbon is substituted by a hydroxy group.	2.38	2	0	secondary alcohol; secondary fatty alcohol	protic solvent
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	4.66	28	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
isradipine Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.	2.68	3	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
staurosporine aglycone staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor	8.15	105	0
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.03	1	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.74	3	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	4.13	3	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketotifen Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.	6.98	1	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
khellin Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024). khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.	2.41	2	0	furanochromone; organic heterotricyclic compound; oxacycle	anti-asthmatic agent; bronchodilator agent; cardiovascular drug; vasodilator agent
kinetin Kinetin: A furanyl adenine found in PLANTS and FUNGI. It has plant growth regulation effects.. cytokinin : A phytohormone that promote cell division, or cytokinesis, in plant roots and shoots.. kinetin : A member of the class of 6-aminopurines that is adenine carrying a (furan-2-ylmethyl) substituent at the exocyclic amino group.	5.65	10	0	6-aminopurines; furans	cytokinin; geroprotector
kynurenic acid Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.	1.98	1	0	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite
2-amino-3-phosphonopropionic acid 2-amino-3-phosphonopropionic acid: metabotropic glutamate receptor antagonist; do not confuse AP-3 used as an abbreviation for this with enhancer-binding protein AP-3 (a trans-activator) or clathrin assembly protein AP-3. 2-amino-3-phosphonopropanoic acid : A non-proteinogenc alpha-amino acid that is alanine in which one of the hydrogens of the terminal methyl group has been replaced by a dihydroxy(oxido)-lambda(5)-phosphanyl group.	2.68	3	0	alanine derivative; non-proteinogenic alpha-amino acid; phosphonic acids	human metabolite; metabotropic glutamate receptor antagonist
mimosine Mimosine: 3-Hydroxy-4-oxo-1(4H)-pyridinealanine. An antineoplastic alanine-substituted pyridine derivative isolated from Leucena glauca.	2.41	2	0	alpha-amino acid
lamotrigine [no description available]	2.07	1	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lavendustin a lavendustin A: from Streptomyces griseolavendus; structure given in first source	4.19	17	0	aromatic amine
lavendustin b [no description available]	2	1	0
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.03	1	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
tetramisole 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole : An imidazothiazole that is imidazo[2,1-b][1,3]thiazole in which the double bonds at the 2-3 and 5-6 positions have been reduced to single bonds and in which one of the hydrogens at position 6 is replaced by a phenyl group.. tetramisole : A racemate comprising equimolar amounts of levamisole and dexamisole.	2	1	0	imidazothiazole	environmental contaminant; xenobiotic
qx-314 QX-314: triethyl analog of lidocaine; RN & NM refer to ion	2	1	0	monocarboxylic acid amide	local anaesthetic
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	2.05	1	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
lorglumide lorglumide: RN given refers to (+-)-isomer. lorglumide : A racemate comprising equal amounts of (R)- and (S)-lorglumide.. N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-(3,4-dichlorobenzoyl)glutamic acid with the amino group of dipentylamine.	1.98	1	0	benzamides; dicarboxylic acid monoamide; dichlorobenzene; glutamic acid derivative
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	3.79	11	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
ly 171883 LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity.	2	1	0	acetophenones; aromatic ether; phenols; tetrazoles	anti-asthmatic drug; leukotriene antagonist
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	5.09	42	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
6-anilino-5,8-quinolinedione 6-anilino-5,8-quinolinedione: structure given in first source; SRS-A & guanylate cyclase antagonist. 6-anilino-5,8-quinolinedione : A quinolone that is quinoline-5,8-dione in which the hydrogen at position 6 is replaced by an anilino group.	2.4	2	0	aminoquinoline; aromatic amine; p-quinones; quinolone	antineoplastic agent; EC 4.6.1.2 (guanylate cyclase) inhibitor
mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.	2.38	2	0	nitrogen mustard; organochlorine compound	alkylating agent
memantine [no description available]	3.86	4	0	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.	2.05	1	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.13	1	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methomyl Methomyl: A carbamate insecticide with anticholinesterase activity.. methomyl : A carbamate ester obtained by the formal condensation of methylcarbamic acid with the hydroxy group of 1-(methylsulfanyl)acetaldoxime.	1.99	1	0	aliphatic sulfide; carbamate ester	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; nematicide; xenobiotic
nocodazole [no description available]	9.86	34	0	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
methyl methanesulfonate [no description available]	2.71	3	0	methanesulfonate ester	alkylating agent; apoptosis inducer; carcinogenic agent; genotoxin; mutagen
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	2	1	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	2.01	1	0	aromatic ether; primary amino compound	anti-arrhythmia drug
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	3.91	2	1	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
minaprine minaprine: Agr 1240 refers to di-HCl; short-acting type A MAO inhibitor (MAOI) of mild potency; structure	1.98	1	0	morpholines; pyridazines; secondary amine	antidepressant; antiparkinson drug; cholinergic drug; dopamine uptake inhibitor; serotonin uptake inhibitor
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	1.98	1	0	dialkylarylamine; tertiary amino compound
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	4.34	7	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
ml 7 ML-7 : An N-sulfonyldiazepane resullting from the formal condensation of 5-iodo-1-naphthylsulfonic acid with one of the nitrogens of 1,4-diazepane. It is a selective inhibitor of myosin light chain kinase (EC 2.7.11.18).	3.09	5	0	N-sulfonyldiazepane; organoiodine compound	EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
molsidomine Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.. molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.	3.39	7	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
monodansylcadaverine monodansylcadaverine: inhibits cross linkage of fibrin. monodansylcadaverine : A sulfonamide obtained by formal condensation of the sulfo group of 5-(dimethylamino)naphthalene-1-sulfonic acid with one of the amino groups of cadaverine.	3.09	5	0	aminonaphthalene; primary amino compound; sulfonamide; tertiary amino compound	EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor; fluorochrome; protective agent
entinostat [no description available]	2.49	2	0	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide: calmodulin antagonist; structure given in first source. N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide : A sulfonamide that is 5-chloronaphthalene-2-sulfonamide in which one of the hydrogens of the nitrogen atom is substituted by a 4-aminobutyl group.	2.7	3	0	naphthalenes; organochlorine compound; primary amino compound; sulfonamide
n-(6-aminohexyl)-1-naphthalenesulfonamide N-(6-aminohexyl)-1-naphthalenesulfonamide: calmodulin antagonist; RN given refers to parent cpd	2.39	2	0	naphthalenes; sulfonic acid derivative
ethylmaleimide Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.	9.3	19	0	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
nafamostat nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic	2.13	1	0	benzoic acids; guanidines
activins Activins: Activins are produced in the pituitary, gonads, and other tissues. By acting locally, they stimulate pituitary FSH secretion and have diverse effects on cell differentiation and embryonic development. Activins are glycoproteins that are hetero- or homodimers of INHIBIN-BETA SUBUNITS.	3.09	5	0
neostigmine Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.	1.98	1	0	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	3.08	5	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	11.51	45	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
niflumic acid Niflumic Acid: An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.	2.92	4	0	aromatic carboxylic acid; pyridines
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	2	1	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	3.09	5	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nipecotic acid nipecotic acid: RN given refers to cpd without isomeric designation. nipecotic acid : A piperidinemonocarboxylic acid that is piperidine in which one of the hydrogens at position 3 is substituted by a carboxylic acid group.	2.39	2	0	beta-amino acid; piperidinemonocarboxylic acid
nisoldipine Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.	2.4	2	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	8.59	9	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	2.68	3	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
npc 15437 NPC 15437: interacts with th C1 doamin of protein kinase C	2.67	3	0
5-nitro-2-(3-phenylpropylamino)benzoic acid 5-nitro-2-(3-phenylpropylamino)benzoic acid: structure given in first source; chloride channel antagonist	3.42	7	0	nitrobenzoic acid
ns 2028 NS 2028: structure in first source	2	1	0
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source. NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.	2.73	3	0	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor
nu2058 NU2058: structure in first source	2.03	1	0
nu6102 NU6102: structure in first source	2.03	1	0
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	2.39	2	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	5.55	9	0	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).	2.96	4	0	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
oxotremorine Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.	2.39	2	0	N-alkylpyrrolidine
oxymetazoline Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251). oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.	1.98	1	0	carboxamidine; imidazolines; phenols	alpha-adrenergic agonist; nasal decongestant; sympathomimetic agent; vasoconstrictor agent
quinone benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups.. 1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene.. quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).	1.99	1	0	1,4-benzoquinones	cofactor; human xenobiotic metabolite; mouse metabolite
4-iodoclonidine 4-iodoclonidine: structure given in first source	1.98	1	0
palmidrol palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.	1.99	1	0	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	2.4	2	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pd 169316 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor	2	1	0	imidazoles
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	5.75	83	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	1.97	1	0	barbiturates	GABAA receptor agonist
pentoxifylline [no description available]	8.5	8	0	oxopurine
perhexiline Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	2.05	1	0	piperidines	cardiovascular drug
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	2.39	2	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phenoxybenzamine Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.	1.98	1	0	aromatic amine
oxophenylarsine oxophenylarsine: inhibits protein-tyrosine-phosphatase. phenylarsine oxide : An arsine oxide derived from phenylarsine.	3.09	5	0	arsine oxides	antineoplastic agent; apoptosis inducer; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
phenylmethylsulfonyl fluoride Phenylmethylsulfonyl Fluoride: An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex.. phenylmethanesulfonyl fluoride : An acyl fluoride with phenylmethanesulfonyl as the acyl group.	2.13	1	0	acyl fluoride	serine proteinase inhibitor
phloretin [no description available]	2.9	4	0	dihydrochalcones	antineoplastic agent; plant metabolite
pifithrin pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source	8.64	3	0	aromatic ketone
pinacidil Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)	2.41	2	0	pyridines
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.02	1	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piperazine [no description available]	2.43	2	0	azacycloalkane; piperazines; saturated organic heteromonocyclic parent	anthelminthic drug
pirenzepine Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.	2.38	2	0	pyridobenzodiazepine	anti-ulcer drug; antispasmodic drug; muscarinic antagonist
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	5.17	47	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
4-aminobenzoic acid para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.. 4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.	2.41	2	0	aminobenzoate; aromatic amino-acid anion	Escherichia coli metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	3.28	6	0	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert. 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.	2.04	1	0	arenesulfonic acid; azobenzenes; methylpyridines; monohydroxypyridine; organic phosphate; pyridinecarbaldehyde	purinergic receptor P2X antagonist
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	3.69	10	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	1.99	1	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
proadifen Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.	2.4	2	0	diarylmethane
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	1.99	1	0	benzoic acids; sulfonamide	uricosuric drug
proglumide Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.. proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.. N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.	1.98	1	0	benzamides; dicarboxylic acid monoamide; glutamine derivative; racemate	anti-ulcer drug; cholecystokinin antagonist; cholinergic antagonist; delta-opioid receptor agonist; drug metabolite; gastrointestinal drug; opioid analgesic; xenobiotic metabolite
propidium Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.	4.22	17	0	phenanthridines; quaternary ammonium ion	fluorochrome; intercalator
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	2.73	3	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	4.43	22	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protoporphyrin ix protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685. protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.	2.42	2	0
pyrilamine Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.	2.43	2	0	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1h-inden-5-yl)oxy)acetic acid ((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy)acetic acid: an anion channel blocker	2.43	2	0
1,6-bis(cyclohexyloximinocarbonyl)hexane 1,6-bis(cyclohexyloximinocarbonyl)hexane: selective inhibitor of canine platelet diglyceride lipase	2.67	3	0	carbamate ester; organonitrogen compound
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	7.07	1	0	benzothiazoles
ro 31-8220 Ro 31-8220: a protein kinase C inhibitor	5.52	67	0	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.	1.98	1	0	methoxybenzenes
rolipram [no description available]	7.91	4	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
4-bromotetramisole 4-bromotetramisole: available in levo & dextro form; L-form potent inhibitor of non specific alkaline phosphatase; RN given refers to cpd without isomeric designation	2	1	0
sb 206553 SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source	2.02	1	0	pyrroloindole
sb 239063 SB 239063: structure in first source. SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.	2.03	1	0	imidazoles
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	2.93	4	0	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sc-10 N-(m-heptyl)-5-chloro-1-naphthalenesulfonamide: protein kinase C activator	1.98	1	0	naphthalenes; sulfonic acid derivative
linsidomine linsidomine: RN given refers to parent cpd; structure	3.39	7	0	morpholines
sodium fluoride [no description available]	9.43	22	0	fluoride salt	mutagen
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	2	1	0	pyridines
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.58	2	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
sulfobromophthalein Sulfobromophthalein: A phenolphthalein that is used as a diagnostic aid in hepatic function determination.	1.99	1	0	2-benzofurans; organobromine compound; organosulfonic acid; phenols	dye
sulforaphane sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.	2.02	1	0	isothiocyanate; sulfoxide	antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	5.62	14	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
talipexole talipexole: dopamine receptor agonist; structure given in first source	1.97	1	0	azepine
temozolomide [no description available]	2.44	2	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.05	1	0	diarylmethane
tetracaine Tetracaine: A potent local anesthetic of the ester type used for surface and spinal anesthesia.. tetracaine : A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.	2.01	1	0	benzoate ester; tertiary amino compound	local anaesthetic
tetraethylammonium Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)	4.79	12	0	quaternary ammonium ion
tetrahydropapaverine tetrahydropapaverine: RN given refers to parent cpd. 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline : A benzylisoquinoline alkaloid that is norlaudanosoline in which the four phenolic hydrogens have been replaced by methyl groups.	2.11	1	0	aromatic ether; benzylisoquinoline alkaloid; benzyltetrahydroisoquinoline; polyether; secondary amino compound
3-hydroxyaspartic acid 3-hydroxyaspartic acid: RN given refers to cpd without isomeric designation. 3-hydroxyaspartic acid : A hydroxy-amino acid that is aspartic acid in which one of the methylene hydrogens has been replaced by a hydroxy group.	2.42	2	0	amino dicarboxylic acid; aspartic acid derivative; C4-dicarboxylic acid; hydroxy-amino acid
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	3.83	3	0	phthalimides; piperidones
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	2	1	0	aziridines
thymeleatoxin thymeleatoxin: causes translocation & down-regulation of multiple protein kinase C isozymes	3.5	8	0
tilorone Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.	6.97	1	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate: intracellular calcium antagonist; RN given refers to parent cpd	4.24	18	0	trihydroxybenzoic acid
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	1.97	1	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine: a zinc ion chelating agent; structure given in first source. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine : An N-substituted diamine that is ethylenediamine in which the four amino hydrogens are replaced by 2-pyridylmethyl groups.	2.7	3	0	N-substituted diamine; pyridines; tertiary amino compound	apoptosis inducer; chelator; copper chelator
triclosan [no description available]	2.11	1	0	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
trifluoperazine [no description available]	4.66	28	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trimetrexate Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.	2.39	2	0
tyramine [no description available]	2.02	1	0	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
tyrphostin a9 [no description available]	2.02	1	0	alkylbenzene	geroprotector
undecylenic acid undecylenic acid: a fatty acid with a terminal double bond. 10-undecenoic acid : An undecenoic acid having its double bond in the 10-position. It is derived from castor oil and is used for the treatment of skin problems.. undecenoic acid : A C11, straight-chain fatty acid carrying a C=C double bond at any position.	2.52	2	0	undecenoic acid	antifungal drug; plant metabolite
5-methylurapidil [no description available]	2	1	0
w 7 W 7: RN given refers to parent cpd; structure; calmodulin antagonist	5.15	46	0
wb 4101 N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine bearing a [(2',6'-dimethoxyphenoxy)ethylamino]methyl group at position 2. An alpha1A-adrenergic selective antagonist.	2.4	2	0	aromatic ether; benzodioxine; secondary amino compound	alpha-adrenergic antagonist
pirinixic acid pirinixic acid: structure	2.43	2	0	aryl sulfide; organochlorine compound; pyrimidines
zinc chloride zinc chloride: RN given refers to parent cpd. zinc dichloride : A compound of zinc and chloride ions in the ratio 1:2. It exists in four crystalline forms, in each of which the Zn(2+) ions are trigonal planar coordinated to four chloride ions.	7.39	2	0	inorganic chloride; zinc molecular entity	astringent; disinfectant; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; Lewis acid
zonisamide Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.	2.05	1	0	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	5.12	14	0	mitomycin	alkylating agent; antineoplastic agent
corticosterone [no description available]	2.68	3	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	2.39	2	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	1.98	1	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
phentolamine Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.	3.09	5	0	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).	8.72	10	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
thymidine [no description available]	4.66	28	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.	2.92	4	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	3.79	3	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
carbachol Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.	5.72	83	0	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.	2.41	2	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
aldosterone [no description available]	3.93	13	0	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
penicillamine Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.	3.88	12	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	4.11	3	1	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	7.92	4	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
dehydroepiandrosterone Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.	2.94	4	0	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
dichlororibofuranosylbenzimidazole Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.	2.42	2	0
2-acetylaminofluorene 2-Acetylaminofluorene: A hepatic carcinogen whose mechanism of activation involves N-hydroxylation to the aryl hydroxamic acid followed by enzymatic sulfonation to sulfoxyfluorenylacetamide. It is used to study the carcinogenicity and mutagenicity of aromatic amines.	1.98	1	0	2-acetamidofluorenes	antimitotic; carcinogenic agent; epitope; mutagen
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2	1	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
idoxuridine [no description available]	1.97	1	0	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor
dimethylphenylpiperazinium iodide Dimethylphenylpiperazinium Iodide: A selective nicotinic cholinergic agonist used as a research tool. DMPP activates nicotinic receptors in autonomic ganglia but has little effect at the neuromuscular junction.	1.98	1	0	N-arylpiperazine; organic iodide salt; piperazinium salt; quaternary ammonium salt	nicotinic acetylcholine receptor agonist
amifampridine Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.	2.01	1	0	aminopyridine
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	1.97	1	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
diethylnitrosamine Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.	1.97	1	0	nitrosamine	carcinogenic agent; hepatotoxic agent; mutagen
isoflurophate Isoflurophate: A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.	1.98	1	0	dialkyl phosphate
cantharidin Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.. cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.	3.39	7	0	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	3.7	10	0	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	6.29	57	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	1.99	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	4.41	21	0	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	3.61	3	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	3.13	5	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cyanides Cyanides: Inorganic salts of HYDROGEN CYANIDE containing the -CN radical. The concept also includes isocyanides. It is distinguished from NITRILES, which denotes organic compounds containing the -CN radical.. cyanides : Salts and C-organyl derivatives of hydrogen cyanide, HC#N.. isocyanide : The isomer HN(+)#C(-) of hydrocyanic acid, HC#N, and its hydrocarbyl derivatives RNC (RN(+)#C(-)).. cyanide : A pseudohalide anion that is the conjugate base of hydrogen cyanide.	2.91	1	0	pseudohalide anion	EC 1.9.3.1 (cytochrome c oxidase) inhibitor
physostigmine Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.	1.99	1	0	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	2.41	2	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
tubocurarine Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.	1.98	1	0	bisbenzylisoquinoline alkaloid	drug allergen; muscle relaxant; nicotinic antagonist
9,10-dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.	2.38	2	0	ortho-fused polycyclic arene; tetraphenes	carcinogenic agent
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.01	1	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
aminopyrine Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.	2.69	3	0	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	4.53	24	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
triphenylethylene [no description available]	2	1	0	stilbenoid
2,3,4,6-tetrachlorophenol 2,3,4,6-tetrachlorophenol: RN given refers to parent cpd; see also record for tetrachlorophenol with locants for chloro groups not specified. 2,3,4,6-tetrachlorophenol : A tetrachlorophenol in which the chlorines are located at positions 2, 3, 4, and 6.	2.01	1	0	tetrachlorophenol	xenobiotic metabolite
uridine [no description available]	2.9	4	0	uridines	drug metabolite; fundamental metabolite; human metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	3.97	13	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
galactose galactopyranose : The pyranose form of galactose.	1.97	1	0	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	3.64	9	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	4.52	24	0	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2	1	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	4.3	19	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
p-dimethylaminoazobenzene p-Dimethylaminoazobenzene: A reagent used mainly to induce experimental liver cancer. According to the Fourth Annual Report on Carcinogens (NTP 85-002, p. 89) published in 1985, this compound may reasonably be anticipated to be a carcinogen. (Merck, 11th ed)	2.1	1	0	azobenzenes
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	8.41	101	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
phlorhizin [no description available]	1.99	1	0	aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative	antioxidant; plant metabolite
methoxamine Methoxamine: An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.. methoxamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group and the phenyl ring is 2- and 5-substituted with methoxy groups. It is an antihypotensive agent (pressor), an agonist acting directly at alpha-adrenoceptors with selectivity for the alpha-1 adrenoceptor subtype similar to phenylephrine .	2.92	4	0	amphetamines	alpha-adrenergic agonist; antihypotensive agent
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	2.39	2	0	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
methylene blue Methylene Blue: A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN.. methylene blue : An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties.	4.04	4	0	organic chloride salt	acid-base indicator; antidepressant; antimalarial; antimicrobial agent; antioxidant; cardioprotective agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 4.6.1.2 (guanylate cyclase) inhibitor; fluorochrome; histological dye; neuroprotective agent; physical tracer
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	3.26	6	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
aniline [no description available]	1.99	1	0	anilines; primary arylamine
2-aminoisobutyric acid 2-aminoisobutyric acid: RN given refers to unlabeled cpd. 2-aminoisobutyric acid : A rare, non-protein amino acid and end-product of pyrimidine metabolism, excreted in urine and found in some antibiotics of fungal origin. With the exception of a few bacteria, it is non-metabolisable, and therefore used in bioassays.	2.39	2	0	2,2-dialkylglycine zwitterion; 2,2-dialkylglycine
androstenedione Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.	2.4	2	0	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
cytidine monophosphate Cytidine Monophosphate: Cytidine (dihydrogen phosphate). A cytosine nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. cytidine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having cytosine as the nucleobase.	1.99	1	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
uridine triphosphate Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.	3.5	8	0	pyrimidine ribonucleoside 5'-triphosphate; uridine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
lactose Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.	2.04	1	0	lactose
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.93	4	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	4.63	8	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
desoxycorticosterone Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE	3.11	5	0	20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	9.71	29	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
strophanthidin Strophanthidin: 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide. The aglycone cardioactive agent isolated from Strophanthus Kombe, S. gratus and other species; it is a very toxic material formerly used as digitalis. Synonyms: Apocymarin; Corchorin; Cynotoxin; Corchorgenin.	2.68	3	0	14beta-hydroxy steroid; 19-oxo steroid; 3beta-hydroxy steroid; 5beta-hydroxy steroid; cardenolides; steroid aldehyde
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	8.84	156	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
egtazic acid Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.. ethylene glycol bis(2-aminoethyl)tetraacetic acid : A diether that is ethylene glycol in which the hydrogens of the hydroxy groups have been replaced by 2-[bis(carboxymethyl)amino]ethyl group respectively.	5.93	102	0	diether; tertiary amino compound; tetracarboxylic acid	chelator
dimethylformamide Dimethylformamide: A formamide in which the amino hydrogens are replaced by methyl groups.. N,N-dimethylformamide : A member of the class of formamides that is formamide in which the amino hydrogens are replaced by methyl groups.	3.1	1	0	formamides; volatile organic compound	geroprotector; hepatotoxic agent; polar aprotic solvent
17-alpha-hydroxyprogesterone 17alpha-hydroxyprogesterone : A 17alpha-hydroxy steroid that is the 17alpha-hydroxy derivative of progesterone.	2	1	0	17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; tertiary alpha-hydroxy ketone	human metabolite; metabolite; mouse metabolite; progestin
mannitol [no description available]	4.07	15	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine [no description available]	18.59	46	6	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
asparagine Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group.	2	1	0	amino acid zwitterion; asparagine; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
histidine Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.	1.98	1	0	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
threonine Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.	10.49	25	0	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	4.23	5	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
isoleucine Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine.	2.05	1	0	aspartate family amino acid; isoleucine; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	3.87	12	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
ethylene Plastipore: high density polyethylene sponge biocompatible material; used as posts in dental bridges	3.11	5	0	alkene; gas molecular entity	plant hormone; refrigerant
acetylene [no description available]	2.01	1	0	alkyne; gas molecular entity; terminal acetylenic compound
methylamine methyl group : An alkyl group that is the univalent group derived from methane by removal of a hydrogen atom.	2.44	2	0	methylamines; one-carbon compound; primary aliphatic amine	mouse metabolite
tert-butyl alcohol tert-Butyl Alcohol: An isomer of butanol that contains a tertiary butyl group that consists of three methyl groups, each separately attached to a central (tertiary) carbon.. tert-butanol : A tertiary alcohol alcohol that is isobutane substituted by a hydroxy group at position 2.	2.01	1	0	tertiary alcohol	human xenobiotic metabolite
tert-butylhydroperoxide tert-Butylhydroperoxide: A direct-acting oxidative stress-inducing agent used to examine the effects of oxidant stress on Ca(2+)-dependent signal transduction in vascular endothelial cells. It is also used as a catalyst in polymerization reactions and to introduce peroxy groups into organic molecules.. tert-butyl hydroperoxide : An alkyl hydroperoxide in which the alkyl group is tert-butyl. It is widely used in a variety of oxidation processes.	2.93	4	0	alkyl hydroperoxide	antibacterial agent; oxidising agent
gibberellic acid gibberellic acid: RN given refers to (1alpha,2beta,4aalpha,4bbeta,10beta)-isomer; structure. gibberellin A3 : A C19-gibberellin that is a pentacyclic diterpenoid responsible for promoting growth and elongation of cells in plants. Initially identified in Gibberella fujikuroi,it differs from gibberellin A1 in the presence of a double bond between C-3 and C-4.	2	1	0	C19-gibberellin; gibberellin monocarboxylic acid; lactone; organic heteropentacyclic compound	mouse metabolite; plant metabolite
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.4	2	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
acrylamide [no description available]	2.46	2	0	acrylamides; N-acylammonia; primary carboxamide	alkylating agent; carcinogenic agent; Maillard reaction product; mutagen; neurotoxin
chloroacetamide [no description available]	2.1	1	0
pantothenic acid Pantothenic Acid: A butyryl-beta-alanine that can also be viewed as pantoic acid complexed with BETA ALANINE. It is incorporated into COENZYME A and protects cells against peroxidative damage by increasing the level of GLUTATHIONE.. pantothenic acid : A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.. vitamin B5 : Any member of a group of vitamers that belong to the chemical structural class called pantothenic acids that exhibit biological activity against vitamin B5 deficiency. Deficiency of vitamin B5 is rare due to its widespread distribution in whole grain cereals, legumes and meat. Symptoms associated with vitamin B5 deficiency are difficult to asses since they are subtle and resemble those of other B vitamin deficiencies. The vitamers include (R)-pantothenic acid and its ionized and salt forms.. (R)-pantothenate : A pantothenate that is the conjugate base of (R)-pantothenic acid, obtained by deprotonation of the carboxy group.. (R)-pantothenic acid : A pantothenic acid having R-configuration.	1.99	1	0	pantothenic acid; vitamin B5	antidote to curare poisoning; geroprotector; human blood serum metabolite
bisphenol a 4,4'-isopropylidene diphenol: stimulates proliferative responses and cytokine productions of murine spleen cells and thymus cells in vitro. bisphenol : By usage, the methylenediphenols, HOC6H4CH2C6H4OH, commonly p,p-methylenediphenol, and their substitution products (generally derived from condensation of two equivalent amounts of a phenol with an aldehyde or ketone). The term also includes analogues in the the methylene (or substituted methylene) group has been replaced by a heteroatom.. bisphenol A : A bisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups.	7.01	1	0	bisphenol	endocrine disruptor; environmental contaminant; xenobiotic; xenoestrogen
cumene hydroperoxide cumene hydroperoxide: RN given refers to parent cpd. cumene hydroperoxide : A peroxol that is cumene in which the alpha-hydrogen is replaced by a hydroperoxy group.	2.15	1	0	peroxol	environmental contaminant; Mycoplasma genitalium metabolite; oxidising agent
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.52	2	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	4.24	17	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
xanthone xanthone : The parent compound of the xanthone class consisting of xanthene bearing a single oxo substituent at position 9.	2.1	1	0	xanthones	insecticide
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	3.1	5	0	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
2-naphthylamine 2-Naphthylamine: A naphthalene derivative with carcinogenic action.. 2-naphthylamine : A naphthylamine carrying the amino group at position 2.	1.97	1	0	naphthylamine	carcinogenic agent
tolonium chloride Tolonium Chloride: A phenothiazine that has been used as a hemostatic, a biological stain, and a dye for wool and silk. Tolonium chloride has also been used as a diagnostic aid for oral and gastric neoplasms and in the identification of the parathyroid gland in thyroid surgery.. tolonium chloride : An organic chloride salt having 3-amino-7-(dimethylamino)-2-methylphenothiazin-5-ium (tolonium) as the counterion. It is a blue nuclear counterstain that can be used to demonstrate Nissl substance and is also useful for staining mast cell granules, both in metachromatic and orthochromatic techniques.	1.98	1	0
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	3.73	10	0	xanthene
1-phenylpropanol 1-phenylpropanol: structure in first source	2.07	1	0	organic molecular entity
2-methylindole 2-methylindole: SKATOLE refers to 3-methylindole; RN given refers to parent cpd; structure. 2-methyl-1H-indole : A methylindole that is 1H-indole substituted by a methyl group at position 2.	2.06	1	0	methylindole
4-butyrolactone 4-Butyrolactone: One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.. tetrahydrofuranone : Any oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.. gamma-butyrolactone : A butan-4-olide that is tetrahydrofuran substituted by an oxo group at position 2.	3.81	3	0	butan-4-olide	metabolite; neurotoxin
furaldehyde Furaldehyde: A heterocyclic compound consisting of a furan where the hydrogen at position 2 is substituted by a formyl group.. furfural : An aldehyde that is furan with the hydrogen at position 2 substituted by a formyl group.	2.41	1	0	aldehyde; furans	Maillard reaction product; metabolite
4-bromophenacyl bromide 4-bromophenacyl bromide: phospholipidase A(2) inhibitor; structure	3.69	10	0
phenylhydrazine [no description available]	1.98	1	0	phenylhydrazines	xenobiotic
quinuclidines Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.	2.06	1	0	quinuclidines; saturated organic heterobicyclic parent
pyridostigmine bromide Pyridostigmine Bromide: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.	2.6	1	0	pyridinium salt
diisopropyl ether [no description available]	1.98	1	0
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	9.72	70	0	pyrrole; secondary amine
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	3.82	11	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
piperidine [no description available]	2.05	1	0	azacycloalkane; piperidines; saturated organic heteromonocyclic parent; secondary amine	base; catalyst; human metabolite; non-polar solvent; plant metabolite; protic solvent; reagent
diethylenetriamine diethylenetriamine: RN given refers to parent cpd	1.98	1	0	polyazaalkane; triamine
undecanal undecanal : A saturated fatty aldehyde formally arising from reduction of the carboxylic acid group of undecanoic acid. It is a component of essential oils from citrus plants like Citrus reticulata.	2.13	1	0	medium-chain fatty aldehyde; n-alkanal; saturated fatty aldehyde	antimycobacterial drug; plant metabolite; volatile oil component
diethylhexyl phthalate Diethylhexyl Phthalate: An ester of phthalic acid. It appears as a light-colored, odorless liquid and is used as a plasticizer for many resins and elastomers.. bis(2-ethylhexyl) phthalate : A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.	2	1	0	diester; phthalate ester	androstane receptor agonist; apoptosis inhibitor; plasticiser
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	4.43	22	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
3-nitrobenzoic acid 3-nitrobenzoic acid: RN given refers to parent cpd	2.05	1	0
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	3.3	6	0	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
meglumine Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.	1.99	1	0	hexosamine; secondary amino compound
2-naphthol 2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.	2.69	3	0	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
shikimic acid Shikimic Acid: A tri-hydroxy cyclohexene carboxylic acid important in biosynthesis of so many compounds that the shikimate pathway is named after it.. shikimic acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid substituted by hydroxy groups at positions 3, 4 and 5 (the 3R,4S,5R stereoisomer). It is an intermediate metabolite in plants and microorganisms.	3.1	1	0	alpha,beta-unsaturated monocarboxylic acid; cyclohexenecarboxylic acid; hydroxy monocarboxylic acid	Escherichia coli metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
protocatechualdehyde protocatechualdehyde: found in wheat grains, wheat seedlings, & other plants; RN given refers to parent cpd; see also rancinamycins; structure	1.98	1	0	dihydroxybenzaldehyde
pregnenolone [no description available]	2.92	4	0	20-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; C21-steroid	human metabolite; mouse metabolite
yohimbine Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.	3.24	6	0	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
3-o-methylglucose 3-O-Methylglucose: A non-metabolizable glucose analogue that is not phosphorylated by hexokinase. 3-O-Methylglucose is used as a marker to assess glucose transport by evaluating its uptake within various cells and organ systems. (J Neurochem 1993;60(4):1498-504). 3-O-methyl-D-glucose : A D-aldohexose that is D-glucose in which the hydrogen of the hydroxy group at position 3 has been substituted by a methyl group. It is a non-metabolisable glucose analogue that is not phosphorylated by hexokinase and is used as a marker to assess glucose transport by evaluating its uptake within various cells and organ systems.	2.68	3	0	D-aldohexose derivative
2-chloroadenosine 5-chloroformycin A: structure given in first source	2.91	4	0	purine nucleoside
ditiocarb Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.	2.68	3	0	dithiocarbamic acids	chelator; copper chelator
potassium cyanide [no description available]	2.45	2	0	cyanide salt; one-carbon compound; potassium salt	EC 1.15.1.1 (superoxide dismutase) inhibitor; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; neurotoxin
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	2.48	2	0	catechin	antioxidant; plant metabolite
perylene Perylene: A 20-carbon dibenz(de,kl)anthracene that can be viewed as a naphthalene fused to a phenalene or as dinaphthalene. It is used as fluorescent lipid probe in the cytochemistry of membranes and is a polycyclic hydrocarbon pollutant in soil and water. Derivatives may be carcinogenic.. perylene : An ortho- and peri-fused polycyclic arene comprising of five benzene rings that is anthracene in which the d,e and k,l sides are fused to benzene rings.	3.09	5	0	ortho- and peri-fused polycyclic arene; perylenes
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	8.38	26	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
acridines Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.	2.01	1	0	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	5.28	9	0	indazole
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	3.14	5	0	1,3-benzoxazoles; mancude organic heterobicyclic parent
triethylenediamine triethylenediamine: RN given refers to parent cpd. triethylenediamine : An organic heterobicylic compound that is piperazine with an ethane-1,2-diyl group forming a bridge between N1 and N4. It is typically used as a catalyst in polymerization reactions.	2.03	1	0	bridged compound; diamine; saturated organic heterobicyclic parent; tertiary amino compound	antioxidant; catalyst; reagent
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	4.08	15	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	2.72	3	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	7.11	65	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	8.08	65	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrimidine pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.	2.03	1	0	diazine; pyrimidines	Daphnia magna metabolite
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	9.07	27	0	diazine; pyrazines	Daphnia magna metabolite
nitroblue tetrazolium Nitroblue Tetrazolium: Colorless to yellow dye that is reducible to blue or black formazan crystals by certain cells; formerly used to distinguish between nonbacterial and bacterial diseases, the latter causing neutrophils to reduce the dye; used to confirm diagnosis of chronic granulomatous disease.	3.24	6	0	organic cation
methylphenazonium methosulfate Methylphenazonium Methosulfate: Used as an electron carrier in place of the flavine enzyme of Warburg in the hexosemonophosphate system and also in the preparation of SUCCINIC DEHYDROGENASE.	2	1	0	azaheterocycle sulfate salt; phenazines
muscarine Muscarine: A toxic alkaloid found in Amanita muscaria (fly fungus) and other fungi of the Inocybe species. It is the first parasympathomimetic substance ever studied and causes profound parasympathetic activation that may end in convulsions and death. The specific antidote is atropine.	1.97	1	0	monosaccharide
hydrazine diamine : Any polyamine that contains two amino groups.	2.7	3	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
paraoxon [no description available]	2.03	1	0	aryl dialkyl phosphate; organophosphate insecticide	EC 3.1.1.7 (acetylcholinesterase) inhibitor; mouse metabolite
hemicholinium 3 Hemicholinium 3: A potent inhibitor of the high affinity uptake system for CHOLINE. It has less effect on the low affinity uptake system. Since choline is one of the components of ACETYLCHOLINE, treatment with hemicholinium can deplete acetylcholine from cholinergic terminals. Hemicholinium 3 is commonly used as a research tool in animal and in vitro experiments.	2.41	2	0
monocrotaline Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.	2.01	1	0	pyrrolizidine alkaloid
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	10.08	16	4	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
aminoimidazole carboxamide Aminoimidazole Carboxamide: An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases.. 5-aminoimidazole-4-carboxamide : An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.	2.42	2	0	aminoimidazole; monocarboxylic acid amide	mouse metabolite
methysergide Methysergide: An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.. methysergide : A synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD and used prophylactically to reduce the frequency and intensity of severe vascular headaches.	1.98	1	0	ergoline alkaloid
lithocholic acid Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid.	2.03	1	0	bile acid; C24-steroid; monohydroxy-5beta-cholanic acid	geroprotector; human metabolite; mouse metabolite
nandrolone Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.. nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.	2.38	2	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid	human metabolite
2-aminopurine 2-Aminopurine: A purine that is an isomer of ADENINE (6-aminopurine).. aminopurine : Any purine having at least one amino substituent.. 2-aminopurine : The parent compound of the 2-aminopurines, comprising a purine core carrying an amino substituent at the 2-position.	8.09	5	0	2-aminopurines; nucleobase analogue	antimetabolite
4-methylcatechol [no description available]	1.98	1	0	methylcatechol	antioxidant; carcinogenic agent; hapten; human metabolite; plant metabolite
hydantoins Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.	2.02	1	0	imidazolidine-2,4-dione
homocystine [no description available]	2	1	0	amino acid zwitterion; homocystines	human metabolite
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	1.98	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
fusarium Fusarium: A mitosporic Hypocreales fungal genus, various species of which are important parasitic pathogens of plants and a variety of vertebrates. Teleomorphs include GIBBERELLA.	2.1	1	0
rhein [no description available]	2.08	1	0	dihydroxyanthraquinone
indirubin [no description available]	9.03	4	0
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	3.11	5	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
bicuculline Bicuculline: An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.. bicuculline : A benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.	3.12	5	0	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin
kainic acid Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.	4.4	21	0	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
salicylaldehyde isonicotinoyl hydrazone salicylaldehyde isonicotinoyl hydrazone: structure in first source	2.05	1	0
butenolide butenolide: inhibits experimental allergic encephalomyelitis in rats. butenolide : A gamma-lactone that consists of a 2-furanone skeleton and its substituted derivatives.	2.05	1	0	butenolide
isomaltose [no description available]	2.02	1	0
dipicolinic acid dipicolinic acid : A pyridinedicarboxylic acid carrying two carboxy groups at positions 2 and 6.	2	1	0	pyridinedicarboxylic acid	bacterial metabolite
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	6.2	9	0
thiazolidines Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.	3.52	8	0	thiazolidine
cyanogen bromide Cyanogen Bromide: Cyanogen bromide (CNBr). A compound used in molecular biology to digest some proteins and as a coupling reagent for phosphoroamidate or pyrophosphate internucleotide bonds in DNA duplexes.	2.39	2	0
oleanolic acid [no description available]	2.47	2	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
androstenediol Androstenediol: An intermediate in TESTOSTERONE biosynthesis, found in the TESTIS or the ADRENAL GLANDS. Androstenediol, derived from DEHYDROEPIANDROSTERONE by the reduction of the 17-keto group (17-HYDROXYSTEROID DEHYDROGENASES), is converted to TESTOSTERONE by the oxidation of the 3-beta hydroxyl group to a 3-keto group (3-HYDROXYSTEROID DEHYDROGENASES).. androst-5-ene-3beta,17beta-diol : A 3beta-hydroxy-Delta(5)-steroid that is 3beta-hydroxyandrost-5-ene carrying an additional hydroxy group at position 17beta.	2	1	0	17beta-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid	androgen; human metabolite; mouse metabolite; radiation protective agent
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	2.46	2	0	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
luminol Luminol: 5-Amino-2,3-dihydro-1,4-phthalazinedione. Substance that emits light on oxidation. It is used in chemical determinations.	2.39	2	0
copper gluconate Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.	2.02	1	0	organic molecular entity
tropic acid tropic acid: acid moiety of ester alkaloids hyoscyamine & scopolamine; RN given refers to parent cpd with unspecified isomeric designation; structure. tropic acid : A 3-hydroxy monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a phenyl group, and one of the methyl hydrogens is substituted by a hydroxy group.	3.1	1	0	3-hydroxy monocarboxylic acid	human xenobiotic metabolite
methoxyhydroxyphenylglycol Methoxyhydroxyphenylglycol: Synthesized from endogenous epinephrine and norepinephrine in vivo. It is found in brain, blood, CSF, and urine, where its concentrations are used to measure catecholamine turnover.	2.43	2	0	methoxybenzenes; phenols
perillyl alcohol perillyl alcohol: inhibits geranylgeranyl transferase; structure in first source. perillyl alcohol : A limonene monoterpenoid consists of a cyclohexene ring substituted by a hydroxymethyl and a prop-1-en-2-yl group at positions 1 and 4 respectively. It is a constituent of a variety of essential oils including lavender.	2.01	1	0	limonene monoterpenoid	plant metabolite; volatile oil component
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	7.02	1	0	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
uranyl acetate uranyl acetate: used after fixation in uranaffin procedure; RN given refers to parent cpd	1.99	1	0
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.03	1	0	dialdehyde	biomarker
myristic acid Myristic Acid: A saturated 14-carbon fatty acid occurring in most animal and vegetable fats, particularly butterfat and coconut, palm, and nutmeg oils. It is used to synthesize flavor and as an ingredient in soaps and cosmetics. (From Dorland, 28th ed). tetradecanoic acid : A straight-chain, fourteen-carbon, long-chain saturated fatty acid mostly found in milk fat.. tetradecanoate : A long-chain fatty acid anion that is the conjugate base of myristic acid; major species at pH 7.3.	3.37	7	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite
trinitrobenzenesulfonic acid Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.	2	1	0	arenesulfonic acid; C-nitro compound	epitope; explosive; reagent
violacein [no description available]	2.05	1	0
gentian violet Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.	2.57	2	0	organic chloride salt	anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye
resazurin resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure	2.47	2	0	phenoxazine
neutral red Neutral Red: A vital dye used as an indicator and biological stain. Various adverse effects have been observed in biological systems.. neutral red : A hydrochloride obtained by combining the free base of neutral red with one equivalent of hydrochloric acid. Neutral red acts as a pH indicator, changing from red to yellow between pH 6.8 and 8.0.	2.7	3	0	hydrochloride	acid-base indicator; dye; two-colour indicator
4-chloromercuribenzenesulfonate 4-Chloromercuribenzenesulfonate: A cytotoxic sulfhydryl reagent that inhibits several subcellular metabolic systems and is used as a tool in cellular physiology.	1.97	1	0	arenesulfonic acid; arylmercury compound
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	2.42	2	0	flavonols; monohydroxyflavone
allyl sulfide allyl sulfide: essence of garlic; inhibits CYP2E1	2.08	1	0	organic sulfide
alpha-naphthoflavone alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).	1.98	1	0	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist; aryl hydrocarbon receptor antagonist; EC 1.14.14.14 (aromatase) inhibitor
2-hydroxyphenylacetic acid 2-hydroxyphenylacetic acid: structure. (2-hydroxyphenyl)acetic acid : A hydroxy monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 2-hydroxyphenyl group. It is a metabolite of phenylalanine and is excreted in the urine of patients suffering from diseases like phenylketonuria.	1.98	1	0	hydroxy monocarboxylic acid; phenols	human metabolite; mouse metabolite
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	6.05	37	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
c.i. 42510 Rosaniline Dyes: Compounds that contain the triphenylmethane aniline structure found in rosaniline. Many of them have a characteristic magenta color and are used as COLORING AGENTS.. basic fuchsin : A four-component mixture of chemically related dyes comprising pararosanilin, rosanilin, magenta II and new fuchsin in varying amounts. rosanilin : A hydrochloride that is the monohydrochloride of 4-[(4-aminophenyl)(4-iminocyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline. One of the major constituents of Basic fuchsin, together with pararosanilin, magenta II and new fuchsin.	1.98	1	0
dehydroepiandrosterone sulfate Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.	2.72	3	0	17-oxo steroid; steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite
homoserine homoserine : An alpha-amino acid that is glycine substituted at the alpha-position by a 2-hydroxyethyl group.. L-homoserine : The L-enantiomer of homoserine.	2.05	1	0	amino acid zwitterion; homoserine	algal metabolite; Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
2-piperidone 2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.	2	1	0	delta-lactam; piperidones	EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
dibutyldichlorotin [no description available]	2.07	1	0
methylnitrosourea Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.	2	1	0	N-nitrosoureas	alkylating agent; carcinogenic agent; mutagen; teratogenic agent
diphenyliodonium diphenyliodonium: RN given refers to the parent coumpound; inhibitor of neutrophil superoxide generating oxidase; structure has been determined	2.4	2	0
chloracizine chloracizine: RN given refers to parent cpd; structure	2.39	2	0
deoxycytidine [no description available]	10.02	9	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxyuridine [no description available]	2.06	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytidine diphosphate choline Cytidine Diphosphate Choline: Donor of choline in biosynthesis of choline-containing phosphoglycerides.	2.01	1	0	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite
rhodamine 6g rhodamine 6G: RN given refers to HCl	2	1	0
pyrrolnitrin Pyrrolnitrin: 3-Chloro-4-(3-chloro-2-nitrophenyl)pyrrole. Antifungal antibiotic isolated from Pseudomonas pyrrocinia. It is effective mainly against Trichophyton, Microsporium, Epidermophyton, and Penicillium.. pyrrolnitrin : A member of the class of pyrroles carrying chloro and 3-chloro-2-nitrophenyl substituents at positions 3 and 4 respectively.	3.1	1	0	alkaloid; C-nitro compound; monochlorobenzenes; pyrroles	antifungal drug; bacterial metabolite
arsenic trioxide Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.	4.12	4	0
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	2.1	1	0	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
nsc 65346 sangivamycin: RN given refers to parent cpd. sangivamycin : A nucleoside analogue that is adenosine in which the nitrogen at position 7 is replaced by a carbamoyl-substituted carbon. It is a potent inhibitor of protein kinase C.	3.36	7	0	nucleoside analogue	protein kinase inhibitor
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	3.95	13	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
selenomethionine [no description available]	2.01	1	0	selenoamino acid; selenomethionines	plant metabolite
digoxigenin Digoxigenin: 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide. A cardenolide which is the aglycon of digoxin. Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh.. digoxigenin : A hydroxy steroid that consists of 5beta-cardanolide having a double bond at the 20(22)-position as well as hydroxy groups at the 3beta-, 12beta- and 14beta-positions. It has been isolated from the plant species of the genus Digitalis.	2.1	1	0	12beta-hydroxy steroid; 14beta-hydroxy steroid; 3beta-hydroxy steroid; 3beta-sterol	hapten; plant metabolite
paraquat Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.	3.1	5	0	organic cation	geroprotector; herbicide
pristane pristane: structure. pristane : A norterpene that is an acyclic saturated hydrocarbon derived from phytane by loss of its C-16 terminal methyl group.	2.21	1	0	long-chain alkane; norterpene	biomarker; immunological adjuvant
2'-deoxyadenosine triphosphate 2'-deoxyadenosine triphosphate: RN given refers to unlabeled parent cpd	2.69	3	0	2'-deoxyadenosine 5'-phosphate; purine 2'-deoxyribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite
2-tert-butylhydroquinone 2-tert-butylhydroquinone: an anticarcinogenic and chemopreventive agent. 2-tert-butylhydroquinone : A member of the class of hydroquinones in which one of the ring hydrogens of hydroquinone is replaced by a tert-butyl group.	2.71	3	0	hydroquinones	food antioxidant
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	5.08	43	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
fluorescein Fluorescein: A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium such as the aqueous humor.. fluorescein (lactone form) : A xanthene dye that is highly fluorescent, detectable even when present in minute quantities. Used forensically to detect traces of blood, in analytical chemistry as an indicator in silver nitrate titrations and in microscopy.	2.7	3	0	2-benzofurans; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; polyphenol; xanthene dye	fluorescent dye; radioopaque medium
fucose Fucose: A six-member ring deoxysugar with the chemical formula C6H12O5. It lacks a hydroxyl group on the carbon at position 6 of the molecule.. L-fucopyranose : The pyranose form of L-fucose.. fucose : Any deoxygalactose that is deoxygenated at the 6-position.	1.98	1	0	fucopyranose; L-fucose	Escherichia coli metabolite; mouse metabolite
tetrapentylammonium tetrapentylammonium: RN given refers to parent cpd	2.43	2	0	quaternary ammonium ion
2-amino-3-chloro-1,4-naphthoquinone 2-amino-3-chloro-1,4-naphthoquinone: has antineoplastic activity; structure in first source	1.99	1	0	1,4-naphthoquinones
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	2.05	1	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
tetrahydropapaveroline Tetrahydropapaveroline: A leukomaine (animal alkaloid) formed in brain and liver from dopamine and L-dopa; it may be implicated in psychiatric problems.	2.38	2	0	benzylisoquinoline alkaloid; benzyltetrahydroisoquinoline; isoquinolinol	human metabolite
fluorescein-5-isothiocyanate Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.	3.79	11	0	fluorescein isothiocyanate
mannose mannopyranose : The pyranose form of mannose.	2.4	2	0	D-aldohexose; D-mannose; mannopyranose	metabolite
dithiothreitol 1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.	3.38	7	0	1,4-dimercaptobutane-2,3-diol; butanediols; dithiol; glycol; thiol	chelator; human metabolite; reducing agent
Brilliant Blue brilliant blue: coal tar derivative food dye; used as the di-NH4 or di-Na salts; RN given refers to parent cpd	2.05	1	0	organic molecular entity
l 451167 L 451167: structure given in first source	1.98	1	0
dideoxyadenosine Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.	3.1	5	0	adenosines; purine 2',3'-dideoxyribonucleoside	EC 3.5.4.4 (adenosine deaminase) inhibitor; EC 4.6.1.1 (adenylate cyclase) inhibitor
cladribine [no description available]	7.7	7	1	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
mono-(2-ethylhexyl)phthalate mono-(2-ethylhexyl)phthalate: RN given refers to parent cpd. mono(2-ethylhexyl) phthalate : The mono(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.	2	1	0	phthalic acid monoester
buthionine sulfoximine Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.	2.92	4	0	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	3.52	8	0	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
4-(4-dimethylaminophenylazo)benzoic acid 4-(4-dimethylaminophenylazo)benzoic acid: structure given in first source	2.1	1	0
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	6.05	45	0	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
hepes [no description available]	2	1	0	HEPES; organosulfonic acid
lanthanum [no description available]	3.6	9	0	f-block element atom; lanthanoid atom; scandium group element atom
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	4.39	21	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
mercury Mercury: A silver metallic element that exists as a liquid at room temperature. It has the atomic symbol Hg (from hydrargyrum, liquid silver), atomic number 80, and atomic weight 200.59. Mercury is used in many industrial applications and its salts have been employed therapeutically as purgatives, antisyphilitics, disinfectants, and astringents. It can be absorbed through the skin and mucous membranes which leads to MERCURY POISONING. Because of its toxicity, the clinical use of mercury and mercurials is diminishing.. mercury(0) : Elemental mercury of oxidation state zero.	2.02	1	0	elemental mercury; zinc group element atom	neurotoxin
molybdenum Molybdenum: A metallic element with the atomic symbol Mo, atomic number 42, and atomic weight 95.95. It is an essential trace element, being a component of the enzymes xanthine oxidase, aldehyde oxidase, and nitrate reductase.	1.98	1	0	chromium group element atom	micronutrient
ruthenium Ruthenium: A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM.	2.72	3	0	iron group element atom; platinum group metal atom
titanium Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.	2.02	1	0	titanium group element atom
argon Argon: A noble gas with the atomic symbol Ar, atomic number 18, and atomic weight 39.948. It is used in fluorescent tubes and wherever an inert atmosphere is desired and nitrogen cannot be used.	2.08	1	0	monoatomic argon; noble gas atom; p-block element atom	food packaging gas; neuroprotective agent
cadmium Cadmium: An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.. elemental cadmium : An element in the zinc group of the periodic table with atomic number 48, atomic mass 112, M.P. 321degreeC, and B.P. 765degreeC). An odourless, tasteless, and highly poisonous soft, ductile, lustrous metal with electropositive properties. It has eight stable isotopes: (106)Cd, (108)Cd,(110)Cd, (111)Cd, (112)Cd, (113)Cd, (114)Cd and (116)Cd, with (112)Cd and (114)Cd being the most common.	3.61	9	0	cadmium molecular entity; zinc group element atom
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	4.61	10	0	f-block element atom; lanthanoid atom
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.77	3	0	copper group element atom; elemental gold
uranium Uranium: A radioactive element of the actinide series of metals. It has an atomic symbol U, atomic number 92, and atomic weight 238.03. U-235 is used as the fissionable fuel in nuclear weapons and as fuel in nuclear power reactors.	1.99	1	0	actinoid atom; f-block element atom; monoatomic uranium
xenon Xenon: A noble gas with the atomic symbol Xe, atomic number 54, and atomic weight 131.30. It is found in the earth's atmosphere and has been used as an anesthetic.	2.08	1	0	monoatomic xenon; noble gas atom; p-block element atom
aluminum chloride Aluminum Chloride: A compound with the chemical formula AlCl3; the anhydrous salt is used as a catalyst in organic chemical synthesis, and hydrated salts are used topically as antiperspirants, and for the management of HYPERHYDROSIS.	1.97	1	0	aluminium coordination entity	Lewis acid
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.42	2	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
magnesium sulfate Magnesium Sulfate: A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083). magnesium sulfate : A magnesium salt having sulfate as the counterion.	1.98	1	0	magnesium salt; metal sulfate; organic magnesium salt	anaesthetic; analgesic; anti-arrhythmia drug; anticonvulsant; calcium channel blocker; cardiovascular drug; fertilizer; tocolytic agent
mercuric chloride Mercuric Chloride: Mercury chloride (HgCl2). A highly toxic compound that volatizes slightly at ordinary temperature and appreciably at 100 degrees C. It is corrosive to mucous membranes and used as a topical antiseptic and disinfectant.. mercury dichloride : A mercury coordination entity made up of linear triatomic molecules in which a mercury atom is bonded to two chlorines. Water-soluble, it is highly toxic. Once used in a wide variety of applications, including preserving wood and anatomical specimens, embalming and disinfecting, as an intensifier in photography, as a mordant for rabbit and beaver furs, and freeing gold from lead, its use has markedly declined as less toxic alternatives have been developed.	2.4	2	0	mercury coordination entity	sensitiser
acetylglucosamine Acetylglucosamine: The N-acetyl derivative of glucosamine.. N-acetyl-beta-D-glucosamine : An N-acetyl-D-glucosamine having beta-configuration at the anomeric centre.	1.98	1	0	N-acetyl-D-glucosamine	epitope
galactosamine 2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.	2.03	1	0	D-galactosamine; primary amino compound	toxin
cesium chloride cesium chloride: RN given refers to unlabeled cpd. caesium chloride : The inorganic chloride salt of caesium; each caesium ion is coordinated by eight chlorine ions.	2.05	1	0	inorganic caesium salt; inorganic chloride	phase-transfer catalyst; vasoconstrictor agent
hypochlorous acid Hypochlorous Acid: An oxyacid of chlorine (HClO) containing monovalent chlorine that acts as an oxidizing or reducing agent.. hypochlorous acid : A chlorine oxoacid with formula HOCl; a weak, unstable acid, it is the active form of chlorine in water.	2.49	2	0	chlorine oxoacid; reactive oxygen species	EC 2.5.1.18 (glutathione transferase) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; human metabolite
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	9.93	72	3	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
ferric chloride ferric chloride: RN given refers to cpd with MF of Fe-Cl3; used to induce experimental arterial thrombosis to evaluate antithrombotic agents	2	1	0	iron coordination entity	astringent; Lewis acid
nickel chloride nickel chloride: RN given refers to cpd with MF of Ni-Cl2. nickel dichloride : A compound of nickel and chloride in which the ratio of nickel (in the +2 oxidation state) to chloride is 1:2.	2.9	4	0	nickel coordination entity	calcium channel blocker; hapten
ferrous sulfate ferrous sulfate: Ferro-Gradumet is ferrous sulfate in controlled release form; RN given refers to Fe(+2)[1:1] salt. iron(2+) sulfate (anhydrous) : A compound of iron and sulfate in which the ratio of iron(2+) to sulfate ions is 1:1. Various hydrates occur naturally - most commonly the heptahydrate, which loses water to form the tetrahydrate at 57degreeC and the monohydrate at 65degreeC.	2.93	4	0	iron molecular entity; metal sulfate	reducing agent
sodium pyrophosphate sodium pyrophosphate: RN refers to diphosphoric acid, tetra-Na salt; structure. sodium diphosphate : An inorganic sodium salt comprised of a diphosphate(4-) anion and four sodium(1+) cations. More commonly known as tetrasodium pyrophosphate, it finds much use in the food industry as an emulsifier and in dental hygiene as a calcium-chelating salt.	1.98	1	0	inorganic sodium salt	chelator; food emulsifier; food thickening agent
isopentenyladenosine Isopentenyladenosine: N(6)-[delta(3)-isopentenyl]adenosine. Isopentenyl derivative of adenosine which is a member of the cytokinin family of plant growth regulators.. N(6)-(Delta(2)-isopentenyl)adenosine : A nucleoside analogue in which adenosine has been modified by substitution at the 6-amino nitrogen by a Delta(2)-isopentenyl group.	3.1	1	0	N-ribosyl-N(6)-isopentenyladenine; nucleoside analogue	antineoplastic agent; plant growth regulator; plant metabolite
zinc sulfate Zinc Sulfate: A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995). zinc sulfate : A metal sulfate compound having zinc(2+) as the counterion.	2.4	2	0	metal sulfate; zinc molecular entity	fertilizer
chromates Chromates: Salts of chromic acid containing the CrO(2-)4 radical.. chromate(2-) : A chromium oxoanion resulting from the removal of two protons from chromic acid.	1.98	1	0	chromium oxoanion; divalent inorganic anion	oxidising agent
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	2.04	1	0	dihydrogen
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	2.68	3	0	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
chlorine Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.	8.12	5	0	diatomic chlorine; gas molecular entity	bleaching agent
molybdate ion molybdate : A divalent inorganic anion obtained by removal of both protons from molybdic acid	1.98	1	0	divalent inorganic anion; molybdenum oxoanion	Escherichia coli metabolite
calcium pyrophosphate Calcium Pyrophosphate: An inorganic pyrophosphate which affects calcium metabolism in mammals. Abnormalities in its metabolism occur in some human diseases, notably HYPOPHOSPHATASIA and pseudogout (CHONDROCALCINOSIS).	1.97	1	0	calcium phosphate
galactose aldohexose : A hexose with a (potential) aldehyde group at one end.	2.4	2	0
cadmium chloride Cadmium Chloride: A cadmium halide in the form of colorless crystals, soluble in water, methanol, and ethanol. It is used in photography, in dyeing, and calico printing, and as a solution to precipitate sulfides. (McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). cadmium dichloride : A cadmium coordination entity in which cadmium(2+) and Cl(-) ions are present in the ratio 2:1. Although considered to be ionic, it has considerable covalent character to its bonding.	2	1	0	cadmium coordination entity
4-chloro-7-nitrobenzofurazan 4-Chloro-7-nitrobenzofurazan: A benzofuran derivative used as a protein reagent since the terminal N-NBD-protein conjugate possesses interesting fluorescence and spectral properties. It has also been used as a covalent inhibitor of both beef heart mitochondrial ATPase and bacterial ATPase.. 4-chloro-7-nitrobenzofurazan : A benzoxadiazole that is 2,1,3-benzoxadiazole which is substituted at position 4 by chlorine and at position 7 by a nitro group.	2.42	2	0	benzoxadiazole; C-nitro compound; organochlorine compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.6.1.3 (adenosinetriphosphatase) inhibitor; fluorescent probe; fluorochrome
barium chloride barium chloride: RN given refers to parent cpd. barium chloride : The inorganic dichloride salt of barium.	2.68	3	0	barium salt; inorganic chloride	potassium channel blocker
trolamine salicylate Arthritis: Acute or chronic inflammation of JOINTS.	1.98	1	0
rhamnose [no description available]	2.02	1	0	L-rhamnose
clodronic acid Clodronic Acid: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.. clodronic acid : An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.	2	1	0	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent
chloramine [no description available]	2.76	3	0	halide
ammonium chloride Ammonium Chloride: An acidifying agent that has expectorant and diuretic effects. Also used in etching and batteries and as a flux in electroplating.. ammonium chloride : An inorganic chloride having ammonium as the counterion.	3.38	7	0	ammonium salt; inorganic chloride	ferroptosis inhibitor
arabinofuranosylcytosine triphosphate Arabinofuranosylcytosine Triphosphate: A triphosphate nucleotide analog which is the biologically active form of CYTARABINE. It inhibits nuclear DNA synthesis.	1.98	1	0
tiletamine hydrochloride Cyclohexanones: Cyclohexane ring substituted by one or more ketones in any position.. cyclohexanones : Any alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.	2.67	3	0
etorphine Etorphine: A narcotic analgesic morphinan used as a sedative in veterinary practice.	2.39	2	0
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.01	1	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
cromolyn sodium Cromolyn Sodium: A chromone complex that acts by inhibiting the release of chemical mediators from sensitized MAST CELLS. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.. disodium cromoglycate : An organic sodium salt that is the disodium salt of cromoglycic acid.	2.69	3	0	organic sodium salt	anti-asthmatic drug; drug allergen
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	11.38	1,145	0	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
ethephon (2-chloroethyl)phosphonic acid: structure in first source. (2-chloroethyl)phosphonic acid : A phosphonic acid compound having a 2-chloroethyl substituent attached to the P-atom.	2.41	2	0	phosphonic acids	plant growth regulator
fluorides [no description available]	3.86	12	0	halide anion; monoatomic fluorine
iodine [no description available]	2.67	3	0	halide anion; monoatomic iodine	human metabolite
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	17.68	31	6	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
razoxane Razoxane: An antimitotic agent with immunosuppressive properties.	2	1	0	N-alkylpiperazine
fludarabine phosphate fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.	4.37	1	1	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
phosphotyrosine Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.. O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.	7.62	55	1	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine	Escherichia coli metabolite; immunogen
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	3.12	5	0	benzenes; phenyl acetates
4-ethylphenol 4-ethylphenol: RN given refers to parent cpd. 4-ethylphenol : A member of the class of phenols carrying an ethyl substituent at position 4.	2.03	1	0	phenols	fungal xenobiotic metabolite
pyrrolidine [no description available]	2.44	2	0	azacycloalkane; pyrrolidines; saturated organic heteromonocyclic parent
triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.	2.05	1	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
ursodeoxycholic acid Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	1.98	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
pregnanolone Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.	2.44	2	0	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
8-bromo cyclic adenosine monophosphate 8-Bromo Cyclic Adenosine Monophosphate: A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.. 8-Br-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP bearing an additional bromo substituent at position 8 on the adenine ring. An activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.	5.08	43	0	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; organobromine compound	antidepressant; protein kinase agonist
transferrin Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.	2.39	2	0
tridemorph tridemorph: RN given refers to cpd with unspecified isomeric designation; structure. tridemorph : A mixture of 4-alkyl-2,6-dimethylmorpholines, where 'alkyl' is a mixture of C11 to C14 homologues of which 60-70% is tridecyl. A systemic fungicide, it is no longer approved for use within the European Union.. 2,6-dimethyl-4-tridecylmorpholine : A member of the class of morpholines that is 2,6-dimethylmorpholine in which the hydrogen attached to the nitrogen is replaced by a tridecyl group. The configuration at positions 2 and 6 is unknown or unspecified.	2	1	0	morpholines; tertiary amino compound	antifungal agrochemical
alkenes [no description available]	2.91	4	0
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	5.44	61	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
adenylyl imidodiphosphate Adenylyl Imidodiphosphate: 5'-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation.	4.59	8	0	adenosine 5'-phosphate
sodium azide Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).	8.11	5	0	inorganic sodium salt	antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	3.78	11	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
adenosine diphosphate ribose Adenosine Diphosphate Ribose: An ester formed between the aldehydic carbon of RIBOSE and the terminal phosphate of ADENOSINE DIPHOSPHATE. It is produced by the hydrolysis of nicotinamide-adenine dinucleotide (NAD) by a variety of enzymes, some of which transfer an ADP-ribosyl group to target proteins.	3.24	6	0	ADP-sugar	Escherichia coli metabolite; mouse metabolite
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	1.99	1	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
nicergoline Nicergoline: An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It may ameliorate cognitive deficits in CEREBROVASCULAR DISORDERS.	2	1	0	organic heterotetracyclic compound; organonitrogen heterocyclic compound
nigericin Nigericin: A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed). nigericin : A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus.	7.9	4	0	polycyclic ether	antibacterial agent; antimicrobial agent; bacterial metabolite; potassium ionophore
vidarabine phosphate Vidarabine Phosphate: An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties.	4.37	1	1
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	10.79	28	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	7.36	166	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
substance p [no description available]	4.07	15	0	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
iprodione iprodione : An imidazolidine-2,4-dione in which the nitrogen at position 1 is substituted by an N-(isopropyl)carboxamide group while that at position 3 is substituted by a 3,5-dichlorophenyl group. A contact fungicide, it blocks the growth of the fungal mycelium and inhibits the germination of fungal spores. It is used on fruit and vegetable crops affected by various fungal diseases. It is also used as a nematicide.	2.02	1	0	benzenes; dichlorophenyl dicarboximide fungicide; imidazole fungicide; imidazolidine-2,4-dione; ureas	antifungal agrochemical; nematicide
ribavirin Rebetron: Rebetron is tradename	2	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
phorbol 12,13-dibutyrate Phorbol 12,13-Dibutyrate: A phorbol ester found in CROTON OIL which, in addition to being a potent skin tumor promoter, is also an effective activator of calcium-activated, phospholipid-dependent protein kinase (protein kinase C). Due to its activation of this enzyme, phorbol 12,13-dibutyrate profoundly affects many different biological systems.	7.51	200	0	butyrate ester; phorbol ester; tertiary alpha-hydroxy ketone
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	3.49	8	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
nimustine Nimustine: Antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. The drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.. nimustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-amino-2-methylpyrimidin-5-ylmethyl] group. An antineoplastic agent especially effective against malignant brain tumors.	2	1	0	aminopyrimidine; N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
1-methyl-4-phenylpyridinium 1-Methyl-4-phenylpyridinium: An active neurotoxic metabolite of 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE. The compound reduces dopamine levels, inhibits the biosynthesis of catecholamines, depletes cardiac norepinephrine and inactivates tyrosine hydroxylase. These and other toxic effects lead to cessation of oxidative phosphorylation, ATP depletion, and cell death. The compound, which is related to PARAQUAT, has also been used as an herbicide.. N-methyl-4-phenylpyridinium : A pyridinium ion that is N-methylpyridinium having a phenyl substituent at the 4-position.	3.53	8	0	pyridinium ion	apoptosis inducer; herbicide; human xenobiotic metabolite; neurotoxin
lonidamine lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.	2.05	1	0	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	4.02	14	0	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
quisqualic acid Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis.	3.78	11	0	non-proteinogenic alpha-amino acid
decamethrin decamethrin: pyrethroid insecticide; RN given refers to cpd without isomeric designation; structure	1.99	1	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organobromine compound	agrochemical; antifeedant; calcium channel agonist; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; pyrethroid ester insecticide
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [no description available]	2.7	3	0	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide: 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity.	2.01	1	0	epoxide	intercalator
enkephalin, methionine Enkephalin, Methionine: One of the endogenous pentapeptides with morphine-like activity. It differs from LEU-ENKEPHALIN by the amino acid METHIONINE in position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.	2.02	1	0
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	4.24	3	1	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	3.33	2	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ethylcholine aziridinium ethylcholine aziridinium: causes passive avoidance deficits	2.41	2	0
4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone: structure; from tobacco smoke	2.74	3	0	nitrosamine; pyridines
nicorandil Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.	1.99	1	0	nitrate ester; pyridinecarboxamide	potassium channel opener; vasodilator agent
bw-755c 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine: A dual inhibitor of both cyclooxygenase and lipoxygenase pathways. It exerts an anti-inflammatory effect by inhibiting the formation of prostaglandins and leukotrienes. The drug also enhances pulmonary hypoxic vasoconstriction and has a protective effect after myocardial ischemia.	7.67	3	0
colforsin Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.	7.06	127	0	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
buserelin Buserelin: A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications.	2.68	3	0	oligopeptide
amonafide xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor	2.04	1	0	isoquinolines
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	2.71	3	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
quinpirole Quinpirole: A dopamine D2/D3 receptor agonist.. quinpirole : A pyrazoloquinoline that is (4aR,8aR)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]quinoline substituted by a propyl group at position 5. It acts as a dopamine agonist.	2.67	3	0	pyrazoloquinoline	dopamine agonist
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	2	1	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
ilmofosine ilmofosine: used in treatment of colonic adenocarcinoma in rats; structure given in first source; RN given refers to hydroxide inner salt	2.39	2	0
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	3.26	6	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
cilazapril, anhydrous Cilazapril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors) used for hypertension. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat.. cilazapril : A pyridazinodiazepine resulting from the formal condensation of the carboxy group of cilazaprilat with ethanol. It is a drug used in the treatment of hypertension and heart failure.	2	1	0	dicarboxylic acid monoester; ethyl ester; pyridazinodiazepine	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
fura-2 Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.	4.93	37	0
eticlopride eticlopride: blocks dopamine-D2 binding sites; structure given in first source; RN given refers to (S)-isomer	1.99	1	0	salicylamides
n-(8-aminohexyl)-5-iodonaphthalene-1-sulfonamide N-(8-aminohexyl)-5-iodonaphthalene-1-sulfonamide: calmodulin antagonist	1.98	1	0
zileuton [no description available]	2	1	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	2.02	1	0	tetralins	T-type calcium channel blocker
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	5.67	10	2	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	4.92	8	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
irinotecan [no description available]	8.58	17	3	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
pobilukast pobilukast: a leukotriene receptor antagonist; an antiasthmatic agent; structure in first source; RN refers to (R-(R,S)-isomer	1.97	1	0
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	9.56	25	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
gadolinium chloride gadolinium chloride: a macrophage inhibitor; reduces pulmonary injury and inflammatory mediator production induced by inhaled ozone	2.69	3	0	gadolinium coordination entity	TRP channel blocker
vanadates Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects.. vanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms.	10.53	68	0	trivalent inorganic anion; vanadium oxoanion	EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
acridine orange Acridine Orange: A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.. acridine orange : Fluorescent dye useful for cell cycle determination. It is cell-permeable, and interacts with DNA and RNA by intercalation or electrostatic attractions respectively.. acridine orange free base : A member of the class of aminoacridines that is acridine carrying two dimethylamino substituents at positions 3 and 6. The hydrochloride salt is the fluorescent dye 'acridine orange', used for cell cycle determination.	3.26	6	0	aminoacridines; aromatic amine; tertiary amino compound	fluorochrome; histological dye
benzylaminopurine benzylaminopurine: a plant growth regulator. N-benzyladenine : A member of the class of 6-aminopurines that is adenine in which one of the hydrogens of the amino group is replaced by a benzyl group.	2.05	1	0	6-aminopurines	cytokinin; plant metabolite
rolofylline rolofylline: selective antagonist for adenosine receptors; a cardiovascular agent	2	1	0	oxopurine
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	5.76	28	0	D-glucopyranose	epitope; mouse metabolite
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	2.02	1	0	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
lanthanum chloride lanthanum chloride: RN given refers to parent cpd	2.9	4	0
cilazaprilat cilazaprilat: InChIKey: UVAUYSRYXACKSC-ULQDDVLXSA-N	2	1	0	non-proteinogenic alpha-amino acid
2',7'-dichlorofluorescein 2',7'-dichlorofluorescein: RN given refers to parent cpd	2.02	1	0	2-benzofurans	fluorochrome
ursolic acid [no description available]	2.07	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	4.1	15	0	organic bromide salt	colorimetric reagent; dye
ro 5-3335 Ro 5-3335: inhibits gene expression by HIV-1 at the level of transcriptional trans-activation by Tat. Ro 5-3335 : A 1,4-benzodiazepinone that is nordazepam in which the phenyl substituent has been replaced by a 1H-pyrrol-2-yl group. It inhibits gene expression in HIV-1 at the transcriptional level through interference with Tat-mediated transactivation.	1.99	1	0	1,4-benzodiazepinone; organochlorine compound; pyrroles	anti-HIV-1 agent; antineoplastic agent; HIV-1 Tat inhibitor; RUNX1 inhibitor
diacetylfluorescein [no description available]	1.99	1	0
methylthymidine methylthymidine: RN given refers to N-3-methylthymidine	1.99	1	0
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.48	2	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
fluorexon fluorexon: structure	2.04	1	0	xanthene dye	fluorochrome
gallocatechol gallocatechol: structure give in first source; RN given for (trans-(+-))-omer; inhibits DNA-dependent DNA & RNA polymerases. (+)-gallocatechin : A gallocatechin that has (2R,3S)-configuration. It is found in green tea and bananas.. gallocatechin : A catechin that is a flavan substituted by hydroxy groups at positions 3, 3', 4', 5, 5' and 7 (the trans isomer). It is isolated from Acacia mearnsii.	2.08	1	0	gallocatechin	antioxidant; metabolite; radical scavenger
25-hydroxycholesterol [no description available]	2.39	2	0	25-hydroxy steroid; oxysterol	human metabolite
aica ribonucleotide AICA ribonucleotide: purine precursor that has antineoplastic activity. AICA ribonucleotide : A 1-(phosphoribosyl)imidazolecarboxamide that is acadesine in which the hydroxy group at the 5' position has been converted to its monophosphate derivative.	2.02	1	0	1-(phosphoribosyl)imidazolecarboxamide; aminoimidazole	cardiovascular drug; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
2',5'-dideoxyadenosine [no description available]	2.39	2	0	deoxyribonucleoside
nile red nile red : An organic heterotetracyclic compound that is 5H-benzo[a]phenoxazin-5-one substituted at position 9 by a diethylamino group.	2.07	1	0	aromatic amine; cyclic ketone; organic heterotetracyclic compound; tertiary amino compound	fluorochrome; histological dye
lissamine rhodamine b lissamine rhodamine B: RN given refers to parent cpd; Lissamine Rhodamine B refers to Na salt	2.03	1	0
rhodamine 110 rhodamine 110: RN given refers to chloride	2	1	0
pyrrolidine dithiocarbamate pyrrolidine dithiocarbamic acid: spelled pyrolidine in J Nutr 1979 reference; RN given refers to parent cpd. pyrrolidine dithiocarbamate : A member of the class of dithiocarbamic acids that is the N-dithiocarboxy derivative of pyrrolidine.	2.69	3	0	dithiocarbamic acids; pyrrolidines	anticonvulsant; antineoplastic agent; geroprotector; neuroprotective agent; NF-kappaB inhibitor; radical scavenger
glutathione disulfide Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.	2.43	2	0	glutathione derivative; organic disulfide	Escherichia coli metabolite; mouse metabolite
4-nitrobenzylthioinosine 4-nitrobenzylthioinosine: inhibitor of nucleoside transport; acts on ENT1	1.98	1	0	purine nucleoside
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	2.1	1	0	cephalosporin	fungal metabolite
tiflucarbine tiflucarbine: structure given in first source; calmodulin antagonist	2.67	3	0
web 2086 WEB 2086: structure given in first source; PAF antagonist	2.67	3	0	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
methacycline [no description available]	4.23	18	0	1,2-diglyceride
naphthalimides Naphthalimides: Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.	2.04	1	0
1,7-phenanthroline [no description available]	3.24	6	0	phenanthroline
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	5.9	18	0	1,2,3-triazole
isocoumarins Isocoumarins: Compounds that differ from COUMARINS in having the positions of the ring and ketone oxygens reversed so the keto oxygen is at the 1-position of the molecule.. isocoumarin : The simplest member of the class of isocoumarins that is 1H-isochromene which is substituted by an oxo group at position 1.	2	1	0	isocoumarins
medetomidine Medetomidine: An agonist of RECEPTORS, ADRENERGIC ALPHA-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of DEXMEDETOMIDINE.	2.4	2	0	imidazoles
selfotel selfotel: a N-methyl-D-aspartate (NMDA) antagonist; used to treat stroke-induced impairment	1.98	1	0	non-proteinogenic alpha-amino acid
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.01	1	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
tianeptine tianeptine: structure given in first source. tianeptine : A racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs).. 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid : A member of the class of dibenzothiazepines that is 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide substituted by a (6-carboxyhexyl)amino group at position 11.. (S)-tianeptine : The S-enantiomer of tianeptine.	2.1	1	0	dibenzothiazepine; monocarboxylic acid; organochlorine compound
1,4-anthraquinone 1,4-anthraquinone: structure in first source	2.02	1	0
dipropylacetamide dipropylacetamide: structure. valpromide : A fatty amide derived from valproic acid.	2.08	1	0	fatty amide	geroprotector; metabolite; teratogenic agent
n-methylscopolamine N-Methylscopolamine: A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.	2	1	0
cromakalim Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352)	3.82	4	0
posatirelin posatirelin: stimulates oxygen consumption	2.05	1	0	oligopeptide
masoprocol Masoprocol: A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.. masoprocol : The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase.	3.86	12	0	nordihydroguaiaretic acid	antineoplastic agent; hypoglycemic agent; lipoxygenase inhibitor; metabolite
ubenimex ubenimex: growth inhibitor	2.42	2	0
7-hydroxystaurosporine [no description available]	18.11	300	20
4-o-methyl-12-o-tetradecanoylphorbol 13-acetate [no description available]	2.94	4	0
phorbol-12,13-diacetate phorbol-12,13-diacetate: RN given refers to (1aR-(1a alpha,1b beta,4a beta,7a alpha,7b alpha,8 alpha,9 beta,9a alpha))-isomer	3.12	5	0
phorbol-12,13-dibenzoate [no description available]	1.97	1	0
honokiol [no description available]	2.04	1	0	biphenyls
lycorine lycorine: from bulbs of LYCORIS & other plants; RN given refers to (1 alpha,2 beta)-isomer; structure in Merck Index, 9th ed, #5444. lycorine : An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity.	2	1	0	indolizidine alkaloid	anticoronaviral agent; antimalarial; plant metabolite; protein synthesis inhibitor
teleocidin b-4 teleocidins: structure; RN given refers to teleocidin	2.89	4	0
leupeptin [no description available]	1.98	1	0	aldehyde; tripeptide	bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor
tosyllysine chloromethyl ketone Tosyllysine Chloromethyl Ketone: An inhibitor of SERINE ENDOPEPTIDASES. Acts as an alkylating agent and is known to interfere with the translation process.	2	1	0	sulfonic acid derivative
rebeccamycin rebeccamycin: from actinomycete strain C-38,383; structure given in first source. rebeccamycin : An N-glycosyl compound consisting of a heteropolycyclic ring system with a glucosyl group attached to one of the indolic nitrogens.	5.58	13	0	indolocarbazole; N-glycosyl compound; organic heterohexacyclic compound; organochlorine compound
fascaplysine fascaplysine: from tropic sea sponges	3.18	1	0
5-(n-methyl-n-isobutyl)amiloride 5-(N-methyl-N-isobutyl)amiloride: inhibitor of the Na+-H+ antiporter	2.38	2	0
calpeptin [no description available]	2.01	1	0	amino acid amide
bilobalide [no description available]	2	1	0	sesquiterpene lactone
maslinic acid (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria	2.07	1	0	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite
tetrahexylammonium tetrahexylammonium: RN given refers to parent cpd	2	1	0
tri-n-butylmethylammonium tri-n-butylmethylammonium: RN given refers to iodide	1.98	1	0
6-carboxyfluorescein 6-carboxyfluorescein: originally sold as 6-carboxyfluorescein, but commercial product is a mixture of two isomers; correct name is 5(6)-carboxyfluorescein	2	1	0	monocarboxylic acid
benzoyltyrosine ethyl ester ethyl N-benzoyl-L-tyrosinate : An L-tyrosine derivative that is the ethyl ester of N-benzoyltyrosine.	1.98	1	0	benzamides; ethyl ester; L-tyrosine derivative; phenols	chromogenic compound
bendamustine hydrochloride [no description available]	3.11	1	0
monomethyl succinate monomethyl succinate: RN given refers to parent cpd. monomethyl succinate : A dicarboxylic acid monoester that is succinic acid in which one of the carboxy groups has been converted to its methyl ester.	1.98	1	0	dicarboxylic acid monoester; hemisuccinate
rosiglitazone [no description available]	2.06	1	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
cholest-5-ene-3,4-diol cholest-5-ene-3,4-diol: RN given refers to (3beta,4beta)-isomer	3.92	2	1
kg 501 naphthol AS-E phosphate: structure in first source	2.03	1	0
coenzyme a [no description available]	1.97	1	0	adenosine 3',5'-bisphosphate	coenzyme; Escherichia coli metabolite; mouse metabolite
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	4.2	17	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	3.24	6	0	iditol	fungal metabolite
moexipril [no description available]	2	1	0	peptide
equol Equol: A non-steroidal ESTROGEN generated when soybean products are metabolized by certain bacteria in the intestines.	2.03	1	0	hydroxyisoflavans
7-ketocholesterol 7-ketocholesterol: inhibits uptake of cholesterol in rabbit aorta. 7-ketocholesterol : A cholestanoid that consists of cholesterol bearing an oxo substituent at position 7.	7.01	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; 7-oxo steroid; cholestanoid	neuroprotective agent
cadmium telluride cadmium telluride: used in radiation monitoring device	2.21	1	0
3,4-dihydroxyphenylglycol 3,4-dihydroxyphenylglycol: noradrenaline metabolite in mouse brain; RN given refers to cpd without isomeric designation. 3,4-dihydroxyphenylethyleneglycol : A tetrol composed of ethyleneglycol having a 3,4-dihydroxyphenyl group at the 1-position.	2.43	2	0	catechols; tetrol	metabolite; mouse metabolite
5'-adenylyl (beta,gamma-methylene)diphosphonate 5'-adenylyl (beta,gamma-methylene)diphosphonate: do not confuse with alpha,beta-methyleneadenosine 5'-triphosphate	2.42	2	0	nucleoside triphosphate analogue
homocysteine Homocysteine: A thiol-containing amino acid formed by a demethylation of METHIONINE.. homocysteine : A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain.. L-homocysteine : A homocysteine that has L configuration.	3.52	8	0	amino acid zwitterion; homocysteine; serine family amino acid	fundamental metabolite; mouse metabolite
alpha,beta-methyleneadenosine 5'-triphosphate alpha,beta-methyleneadenosine 5'-triphosphate: do not confuse with beta,gamma-methylene ATP; RN given refers to parent cpd	2.94	4	0	nucleoside triphosphate analogue
salsolinol salsolinol: RN given refers to cpd without isomeric designation; EP to SALSOLINE ALKALOIDS (78-82); on-line search SALSOLINE ALKALOIDS (78-82); Index Medicus search ISOQUINOLINES (78-82). (S)-salsolinol : A 1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol that has S-configuration.	2.05	1	0	1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol	human urinary metabolite
8-((4-chlorophenyl)thio)cyclic-3',5'-amp 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP: lowers cAMP in heart & fat cells; cAMP-dependent kinase inhibitor. 8-(4-chlorophenylthio)-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the hydrogen at position 2 on the purine fragment is replaced by a 4-chlorophenylthio group.	3.23	6	0	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; aryl sulfide; organochlorine compound	protein kinase agonist
phospho-l-arginine phospho-L-arginine: inhibits pyruvate kinase. N(omega)-phospho-L-arginine : An arginine derivative that is L-arginine substituted by a phosphono group at N(omega)-position.	2.03	1	0	L-arginine derivative; non-proteinogenic L-alpha-amino acid; phosphagen; phosphoamino acid	animal metabolite
n(6)-(delta(2)-isopentenyl)adenine N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group.	3.1	1	0	6-isopentenylaminopurine	cytokinin
n-(4,4-diphenyl-3-butenyl)nipecotic acid N-(4,4-diphenyl-3-butenyl)nipecotic acid: structure given in first source	2	1	0	diarylmethane
aluminum maltolate aluminum maltolate: aluminum cpd, not an aluminum salt	2.03	1	0
mci 9038 [no description available]	1.98	1	0	peptide
tyrphostin 8 tyrphostin 8: a tyrosine kinase inhibitor (a tyrphostin)	1.98	1	0	phenols
norcantharidin norcantharidin: structure given in first source; RN given refers to cpds without isomeric designation	2.02	1	0	furofuran
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.41	2	0
glycylsarcosine glycylsarcosine : A dipeptide obtained by formal condensation of the carboxy group of glycine with the amino group of sarcosine.	1.98	1	0	dipeptide zwitterion; dipeptide
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	2.02	1	0	D-glucuronic acid	algal metabolite
2-methylglutamic acid 2-methylglutamic acid: RN given refers to parent cpd without isomeric designation	1.99	1	0
septacidin septacidin: structure	3.08	1	0
1,3,4-oxadiazole 1,3,4-oxadiazole: structure in first source	2.82	2	0
s-(2,4-dinitrophenyl)glutathione S-(2,4-dinitrophenyl)glutathione : A glutathione conjugate in which the thiol hydrogen of glutathione has been replaced by a 2,4-dinitrophenyl group.	2.67	3	0	glutathione conjugate
2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine 2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine: anorectic; CNS stimulant; synonym G 130 refers to HCl; RN given refers to parent cpd; structure	2	1	0
diosgenin [no description available]	2.02	1	0	3beta-sterol; hexacyclic triterpenoid; sapogenin; spiroketal	antineoplastic agent; antiviral agent; apoptosis inducer; metabolite
phorbolol myristate acetate [no description available]	2.94	4	0
kemptide [no description available]	1.98	1	0
8-chloro-cyclic adenosine monophosphate [no description available]	2.39	2	0
2'-chloro-2'-deoxyadenosine [no description available]	2.01	1	0
diphenylditelluride [no description available]	2.06	1	0
tetrahydrodeoxycorticosterone tetrahydrodeoxycorticosterone: RN given refers to (3alpha,5beta)-isomer	2.43	2	0	21-hydroxy steroid
cobalt Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.	3.28	6	0	cobalt group element atom; metal allergen	micronutrient
p-methoxy-n-methylphenethylamine p-Methoxy-N-methylphenethylamine: A potent mast cell degranulator. It is involved in histamine release.. N,O-dimethyltyramine : A secondary amino compound that is tyramine in which the hydrogen of the phenolic hydroxy group has been replaced by a methyl group.	3.37	7	0	aromatic ether; secondary amino compound	metabolite
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	2.71	3	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
mafosfamide mafosfamide: RN given refers to cis-(+-)-isomer	2.02	1	0
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid: structure in first source	4.7	29	0	polyamino carboxylic acid; tetracarboxylic acid	chelator
1-amino-1,3-dicarboxycyclopentane 1-amino-1,3-dicarboxycyclopentane: RN given refers to (cis)-isomer	3.49	8	0
enkephalin, d-penicillamine (2,5)- Enkephalin, D-Penicillamine (2,5)-: A disulfide opioid pentapeptide that selectively binds to the DELTA OPIOID RECEPTOR. It possesses antinociceptive activity.. DPDPE : A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.	1.99	1	0	heterodetic cyclic peptide	delta-opioid receptor agonist
u 73122 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione: structure given in first source. U-73122 : An aza-steroid that is 3-O-methyl-17beta-estradiol in which the 17beta-hydroxy group is replaced by a 6-(maleimid-1-yl)hexylamino group. An inibitor of phospholipase C.	5.17	46	0	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
arginyl-glycyl-aspartic acid arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system	3.09	5	0	oligopeptide
1,4-dihydropyridine [no description available]	2.68	3	0
quin2 Quin2: fluorescent highly selective Ca indicator, binding Ca 1:1; structure given in first source	2.89	4	0
s-nitrosoglutathione [no description available]	7.94	4	0	glutathione derivative; nitrosothio compound	bronchodilator agent; nitric oxide donor; platelet aggregation inhibitor; signalling molecule
acrylodan [no description available]	1.97	1	0
diacetyldichlorofluorescein diacetyldichlorofluorescein: stable storage form of dichlorofluorescein	2.15	1	0
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole: inhibits platelet aggregation & Ca2+ entry into platelets. SKF-96365 free base : An ether that is 2-(1H-imidazol-1-yl)-1-(4-methoxyphenyl)ethanol in which the hydrogen of the hydroxy group has been substituted by a 3-(4-methoxyphenyl)propyl group.	3.61	9	0	ether; imidazoles; monomethoxybenzene	TRP channel blocker
chlorethylclonidine chlorethylclonidine: RN refers to 2-chloroethyl derivative	2.4	2	0
sr 48968 SR 48968: structure given in first source; neurokinin A antagonist; tachykinin receptor antagonist; SR 48965 is the inactive R-enantiomer of SR 48968	1.98	1	0
fluo-3 Fluo-3: fluorescent Ca(2+) indicator; permits continuous monitoring of Ca without interference with use of UV-sensitive caged compounds	3.28	6	0	xanthene dye	fluorochrome
indolactam v indolactam V: only the (-)-isomer of indolactam V showed carcinogenic activity; structure given in first source	2.9	4	0	indoles
paxilline paxilline: structure given in first source; RN given refers to (2R-(2alpha,4bbeta,6aalpha,12bbeta,12calpha,14abeta))-isomer. paxilline : An indole diterpene alkaloid with formula C27H33NO4 isolated from Penicillium paxilli. It is a potent inhibitor of large conductance Ca2(+)- and voltage-activated K(+) (BK)-type channels.	3.1	5	0	diterpene alkaloid; enone; organic heterohexacyclic compound; terpenoid indole alkaloid; tertiary alcohol	anticonvulsant; Aspergillus metabolite; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; genotoxin; geroprotector; mycotoxin; Penicillium metabolite; potassium channel blocker
prolinedithiocarbamate prolinedithiocarbamate: do not confuse with pyrrolidine dithiocarbamate which is also abbreviated PDTC	2.4	2	0
fructose 2,6-diphosphate fructose 2,6-diphosphate: phosphofructokinase activator synthesized via Mg-ATP & fructose-6-P. beta-D-fructofuranose 2,6-bisphosphate : A D-fructofuranose 2,6-bisphosphate with a beta-configuration at the anomeric centre.	2.38	2	0	D-fructofuranose 2,6-bisphosphate	human metabolite; mouse metabolite
dihydrorhodamine 123 dihydrorhodamine 123: uncharged & nonfluorescent derivative of the laser dye rhodamine 123; flow cytometric indicator for respiratory burst activity in neutrophil granulocytes	2.91	4	0
bradykinin, des-arg(9)- bradykinin, des-Arg(9)-: RN given refers to parent cpd	2.38	2	0	oligopeptide	bradykinin receptor B2 agonist
(3h)2-carbomethoxy-3-(4-fluorophenyl)tropane (1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester: RN given refers to (1R-(exo,exo))-isomer	1.99	1	0
indo-1 indo-1: structure given in first source	2.38	2	0	indoles	fluorochrome
pregnenolone sulfate pregnenolone sulfate: RN given refers to (3 beta)-isomer	2.42	2	0	steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite
fura-2-am fura-2-am: pentaester precursor of fura-2	3.09	5	0
12-deoxyphorbolphenylacetate 12-deoxyphorbolphenylacetate: RN given refers to (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9aalpha))-isomer	2.38	2	0
u 69593 U 69593: selective ligand for opioid K-receptor. U69593 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of phenylacetic acid and the secodary amino group of (5R,7S,8S)-N-methyl-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-amine.	2.4	2	0	monocarboxylic acid amide; N-alkylpyrrolidine; organic heterobicyclic compound; oxaspiro compound	anti-inflammatory agent; diuretic; kappa-opioid receptor agonist
3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate 3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate: a surfactant; structure given in first source	2	1	0	1,1-diunsubstituted alkanesulfonate
cv 3988 CV 3988: platelet activating factor antagonist; structure given in first source	2.39	2	0
bremazocine bremazocine: potent, log-acting opiate kappa-agonist & centrally acting analgesic; RN given refers to (2R)-isomer; structure given in first source	2	1	0
cgp 35348 CGP 35348: antagonizes both GABA-A and GABA-B receptors	1.99	1	0
22-hydroxycholesterol [no description available]	2.01	1	0	cholanoid
inositol-1,3,4,5-tetrakisphosphate inositol-1,3,4,5-tetrakisphosphate: for cpd without numerical locants of phosphate groups, index INOSITOL PHOSPHATES. 1D-myo-inositol 1,3,4,5-tetrakisphosphate : A myo-inositol tetrakisphosphate having the four phosphates placed in the 1-, 3-, 4- and 5-positions.	1.98	1	0	inositol phosphate
methoctramine methoctramine: structure given in first source. methoctramine : A tetramine that is N,N'-bis(6-aminohexyl)octane-1,8-diamine where the primary amino groups both carry 2-methoxybenzyl substituents.. methoctramine tetrahydrochloride : A hydrochloride obtained by combining methoctramine with four molar equivalents of hydrochloric acid.	1.99	1	0	hydrochloride	muscarinic antagonist
arginyl-glycyl-aspartyl-serine arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets	2.69	3	0
phorbol-12-myristate [no description available]	2.05	1	0
dihydrokainate [no description available]	1.99	1	0	dicarboxylic acid
epicatechin gallate epicatechin gallate: a steroid 5alpha-reductase inhibitor; RN given refers to the (cis)-isomer; structure given in first source; isolated from green tea. (-)-epicatechin-3-O-gallate : A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3R)-hydroxy group of epicatechin. A natural product found in Parapiptadenia rigida.	2.08	1	0	catechin; gallate ester; polyphenol	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; metabolite
2'-5'-oligoadenylate trimer 2',5'-oligoadenylate: inhibits protein synthesis in cell-free systems	2.69	3	0
ecopipam ecopipam: structure given in first source	2.1	1	0	benzazepine
deguelin deguelin: a natural product from Mundulea sericea; RN refers to (7aS-cis)-isomer; structure given in first source. deguelin : A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.	2.08	1	0	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite
1,9-dideoxyforskolin [no description available]	2.67	3	0	acetate ester; labdane diterpenoid; organic heterotricyclic compound	plant metabolite
fk 888 FK 888: structure given in first source; a potent NK(1) receptor antagonist	1.99	1	0	peptide
fingolimod hydrochloride Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.. fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).	2.02	1	0	hydrochloride	immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
3,5-dihydroxyphenylglycine 3,5-dihydroxyphenylglycine: a potent agonst of metabotropic glutamate receptors	2.92	4	0	alpha-amino acid
ml 9 [no description available]	3.38	7	0
asiaticoside [no description available]	2	1	0
parthenolide [no description available]	2.44	2	0	germacranolide
benzamil [no description available]	2	1	0	guanidines; pyrazines
dynorphin (1-8) dynorphin (1-8): opioid octapeptide from porcine hypothalamus; comprises the N-terminal eight residues of dynorphin	2	1	0
sch 28080 Sch 28080: not related structurally to other known anti-ulcer agents; inhibits histamine-stimulated gastric secretion; prevents gastric lesions induced by aspirin, indomethacin & ethanol	1.99	1	0	imidazopyridine
carboxyamido-triazole carboxyamido-triazole: structure given in first source; coccidiostat; U.S. patent No. 4,590,201	2	1	0
kt 6149 KW 2149: derivative of mitomycin C; structure in first source	3.09	1	0
kt 5823 KT 5823: indolocarbazole; activates human neutrophils & fails to inhibit cGMP-dependent protein kinase phosphorylation of vimentin. KT 5823 : An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of methyl (3R)-3-methoxy-2-methyltetrahydrofuran-3-carboxylate (the 2S,3R,5R product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1-methyl-1,5-dihydro-2H-pyrrol-2-one.	3.7	10	0	gamma-lactam; hemiaminal; indolocarbazole; methyl ester; organic heterooctacyclic compound	EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor
1-hexadecyl-2-acetyl-glycero-3-phosphocholine Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.	5.16	47	0	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	4.56	25	0
leucinol leucinol: RN given for (L)-isomer	2	1	0
st 587 St 587: clonidine derivative which is selective alpha(1)-adrenoceptor stimulator with lipophilic properties; structure in first source	1.97	1	0
indolo(3,2-b)carbazole indolo(3,2-b)carbazole: potent inducer of cytochrome P-4501A1-dependent monooxygenase	3.53	2	0
homoorientin homoorientin: isolated from Swertia japonica; structure given in first source	2.13	1	0	flavone C-glycoside; tetrahydroxyflavone	antineoplastic agent; radical scavenger
u 73343 U 73343: an inactive analog of U 73122	2.41	2	0
n-(1-methyl-2-phenylethyl)adenosine N-(1-methyl-2-phenylethyl)adenosine: RN given refers to cpd without isomeric designation; structure given in first source	2.02	1	0
pd 123177 PD 123177: nonpeptide angiotensin AII-2 inhibitor	1.98	1	0	diarylmethane
opc 21268 OPC 21268: structure given in first source; vasopressin V1 receptor antagonist	2	1	0
tanshinone tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent	2.04	1	0	abietane diterpenoid	anticoronaviral agent
bn 50739 BN 50739: platelet activating factor antagonist; structure given in first source	1.99	1	0
monobutyryl cyclic amp monobutyryl cyclic AMP: RN given refers to parent cpd. N(6)-butyryl-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the exocyclic amino group on the purine fragment is carrying a butyryl substituent.	1.97	1	0	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; butanamides	protein kinase agonist
10-n-nonylacridinium orange 10-N-nonylacridinium orange: stains mitochondria of living HeLa-cells	2.03	1	0
icrf 193 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione: structure given in first source; RN given refers to cpd without isomeric designation. ICRF-193 : An N-alkylpiperazine that is butane which is substituted by a 3,5-dioxopiperazin-1-yl group at positions 2 and 3. The meso isomer.	1.99	1	0
phenylalanyl-prolyl-arginine-chloromethyl ketone phenylalanyl-prolyl-arginine-chloromethyl ketone: do not confuse with Pro-Phe-Arg-CH2-Cl or with Phe-Phe-Arg-CH2-Cl, both sometimes also referred to as PPACK	1.99	1	0
brassinolide brassinolide: plant growth promoting steroidal lactone from rape pollen; RN given refers to (2alpha,3alpha,5alpha,22R,23R,24S)-isomer; structure in first source	2.41	2	0	22-hydroxy steroid; 23-hydroxy steroid; 2alpha-hydroxy steroid; 3alpha-hydroxy steroid; brassinosteroid	plant growth stimulator; plant hormone
3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate: purinergic receptors agonist; structure given in first source	3.1	5	0	purine ribonucleoside triphosphate
4-bromo-a-23187 4-bromo-A-23187: ionophore with enhanced calcium ion transport specificity	1.97	1	0
nitroaspirin nitroaspirin: a nitric oxide donor	2.01	1	0	carbonyl compound
clofarabine [no description available]	3.82	3	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
morphiceptin morphiceptin: synthetic tetrapeptide with morphinelike activities, highly specific for morphine receptors, but not for enkephalin receptors; is the amide of a fragment of the milk protein beta casein; deproceptin is the D-Pro(4)-isomer; see also related heptapeptide beta-casomorphin; RN given refers to parent cpd(L-Tyr-L-Pro-L-Phe-L-Pro)-isomer	1.99	1	0	oligopeptide
ginsenoside rh2 ginsenoside Rh2: from leaves of Panax ginseng C; structure given in first source. (20S)-ginsenoside Rh2 : A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.	2.4	2	0	12beta-hydroxy steroid; 20-hydroxy steroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	antineoplastic agent; apoptosis inducer; bone density conservation agent; cardioprotective agent; hepatoprotective agent; plant metabolite
muricholic acid muricholic acid: internal standard in analysis of fecal bile acids; RN given refers to (3 alpha,5 beta)-isomer	2.01	1	0	3alpha-hydroxy steroid; 6-hydroxy steroid; 7-hydroxy steroid; bile acid; C24-steroid; trihydroxy-5beta-cholanic acid
trapoxin a trapoxin A: from Helicoma ambiens; structure given in first source. trapoxin A : A homodetic cyclic tetrapeptide constructed from L-phenylalanyl (x2), D-pipecolinyl and L-2-amino-8-oxo-9,10-epoxydecanoyl residues.	2.91	1	0	epoxide; homodetic cyclic peptide; ketone	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor; fungal metabolite
inositol-3,4,5,6-tetrakisphosphate inositol-3,4,5,6-tetrakisphosphate: for cpd without numerical locants of phosphate groups, index INOSITOL PHOSPHATES. 1D-myo-inositol 3,4,5,6-tetrakisphosphate : A myo-inositol tetrakisphosphate having the four phosphate groups placed at the 3-, 4-, 5- and 6-positions.	1.98	1	0	myo-inositol tetrakisphosphate	mouse metabolite
rges peptide [no description available]	2.01	1	0
beta-(5-hydroxy-2-pyridyl)alanine beta-(5-hydroxy-2-pyridyl)alanine: from Streptomyces; RN given refers to (+-)-isomer	2.38	2	0
2-n-(4-(1-azitrifluoroethyl)benzoyl)-1,3-bis-(mannos-4-yloxy)-2-propylamine 2-N-(4-(1-azitrifluoroethyl)benzoyl)-1,3-bis-(mannos-4-yloxy)-2-propylamine: an azi-ethyl-benzoyl-propylamine with mannose attached at two locations of the propylamine	1.99	1	0
phytosphingosine phytosphingosine: differ with an additional hydroxyl at C-4 & no double bond between C-4 & C-5	2.1	1	0	amino alcohol; sphingoid; triol	mouse metabolite; Saccharomyces cerevisiae metabolite
celastrol [no description available]	2.05	1	0	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
chaetoglobosins chaetoglobosins: like CYTOCHALASINS but with an indoyl in place of a phenyl ring at C10; chaetoglobosins A-J; metabolites of Chaetomium species; RN given refers to chaetoglobosin A; structure. chaetoglobosin A : A cytochalasan alkaloid isolated from Chaetomium globosum and Calonectria morganii.	3.19	1	0
aaptamine aaptamine: natural product from sea sponge Aaptos aaptos; structure given in first source; RN from CA Index Guide 1984	3.18	1	0
peroxynitrous acid Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES).	2.47	2	0	nitrogen oxoacid
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	7.09	27	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	3.89	4	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
ici 89406 ICI 89406: RN given refers to parent cpd	1.97	1	0	ureas
5,5'-dimethyl-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetate 5,5'-dimethyl-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetate: calcium chelator; do not confuse with calcium specific chelator (MAPTAM buffer). 5,5'-dimethyl-BAPTA : A polyamino carboxylic acid, the structure of which is that of BAPTA carrying methyl substituents at C-5 and C-5'.	1.97	1	0	polyamino carboxylic acid	chelator
4-carboxyfluorescein [no description available]	2.08	1	0	monocarboxylic acid	fluorochrome
substance p, methyl ester- substance P, methyl ester-: COOH-terminal amide of substance P replaced with methyl ester	1.98	1	0
phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide: endogenous opioid antagonist octapeptide from bovine brain	2.03	1	0
cyclic adp-ribose Cyclic ADP-Ribose: A pyridine nucleotide that mobilizes CALCIUM. It is synthesized from nicotinamide adenine dinucleotide (NAD) by ADP RIBOSE CYCLASE.	2.07	1	0	cyclic purine nucleotide; nucleotide-sugar	metabolite; ryanodine receptor agonist
f-chemotactic peptide F-chemotactic peptide: potent chemoattractant for human neutrophils	1.97	1	0
1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone 1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone: structure given in first source. 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one : A differentiation-inducing factor that is hexaphenone bearing two chloro substituents at positions 3 and 5, two hydroxy substituents at positions 2 and 6 as well as a single methoxy substituent at position 4. A secreted, chlorinated molecule that controls cell fate during development of Dictyostelium cells.	3.25	6	0	dichlorobenzene; differentiation-inducing factor; monomethoxybenzene; resorcinols	eukaryotic metabolite; signalling molecule
rmi 12330a RMI 12330A: adenyl cyclase inhibitor in rat liver; RN given refers to (cis)-isomer; NM refers to HCl, (cis)-isomer; structure	2.01	1	0
neurokinin a (4-10), beta-ala(8)- neurokinin A (4-10), beta-Ala(8)-: selective NK-2 tachykinin receptor	1.99	1	0
27-hydroxycholesterol (25R)-cholest-5-ene-3beta,26-diol : A 26-hydroxycholesterol in which the 25-position has R-configuration.	2.07	1	0	26-hydroxycholesterol	apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent
gluconamide [no description available]	2.02	1	0
n-(6-phenylhexyl)-5-chloro-1-naphthalenesulfonamide N-(6-phenylhexyl)-5-chloro-1-naphthalenesulfonamide: protein kinase C activator; RN & structure given in first source	2.9	4	0	naphthalenes; sulfonic acid derivative
2,3-dibenzylbutane-1,4-diol 2,3-dibenzylbutane-1,4-diol: RN given refers to parent cpd	1.97	1	0
glycerophosphoinositol 4,5-bisphosphate glycerophosphoinositol 4,5-bisphosphate: do not confuse with phosphatidylinositols which have fatty acids esterified at the C-1 and C-2 hydroxyl groups of glycerol	3.78	11	0
cl 277082 CL 277082: structure given in first source	1.98	1	0
sna 8073-a fujianmycin B: the isomer SNA-8073-B inhibits prolyl endopeptidase; from Streptomyces; structure given in first source	3.09	1	0
cp 46665 CP 46665: immunomodulator; RN given refers to di-HCl	2.38	2	0
lestaurtinib [no description available]	7.76	25	0	indolocarbazole
gyki 53655 GYKI 53655: an AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) receptor antagonist	2	1	0
methotrexate [no description available]	3.62	9	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
porphycene porphycene: photodynamic therapy agent; structure given in first source	2	1	0
ro 32-0432 [no description available]	2.92	4	0
pseudomonas aeruginosa autoinducer Pseudomonas aeruginosa autoinducer: autoinducer required for expression of Pseudomonas aeruginosa virulence genes; structure given in first source. N-(3-oxododecanoyl)homoserine lactone : A N-acyl homoserine lactone that is the monocarboxylic acid amide arising from formal condensation of homoserine lactone with 3-oxododecanoic acid.	2.05	1	0	N-acyl homoserine lactone
vb 20b7 2-(1-(4-piperonyl)piperazinyl)benzothiazole: a 5-HT3 receptor antagonist and 5-HT4 receptor agonist; structure in first source	2.01	1	0	N-arylpiperazine
alanyl-alanyl-phenylalanine chloromethyl ketone [no description available]	2	1	0
dihydroethidium dihydroethidium: RN given is for the (+-)-isomer	1.99	1	0
cki 7 N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide: casein kinase I inhibitor; structure given in first source. N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide : A member of the class of isoquinolines that is isoquinoline-8-sulfonamide which is substituted by chlorine at position 5 and in which the sulfonamide nitrogen is substituted by a 2-aminoethyl group. It is an inhibitor of casein kinase I.	1.99	1	0	isoquinolines; organochlorine compound; primary amino compound; sulfonamide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
na 0345 NA 0345: structure given in first source; SF 2370 derivative	7.38	2	0
ro 31-4639 Ro 31-4639: structure given in first source	1.98	1	0
kn 04 KN 04: structure given in first source	1.99	1	0
n-(2-chloroethyl)-4-piperidinyl diphenylacetate N-(2-chloroethyl)-4-piperidinyl diphenylacetate: structure given in first source; forms an aziridinium ion that binds irreversibly to muscarinic receptors; do not confuse this cpd with 4-DAMP (4-diphenylacetoxy-1,1-dimethylpiperidinium)	1.99	1	0
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide 4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide: increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol	2.03	1	0
n-ethoxycarbonyl-7-oxostaurosporine N-ethoxycarbonyl-7-oxostaurosporine: structure given in first source	3.6	9	0
thrombin receptor peptide sfllrnp thrombin receptor peptide SFLLRNP: a synthetic peptide that induces early events of T cell activation and synergizes with TCR cross-linking for CD69 expression & interleukin-2 production; thrombin receptor agonist; do not confuse with TRAP peptide	1.98	1	0
omega-n-methylarginine omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.	3.69	10	0	amino acid zwitterion; arginine derivative; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid
neuropeptide df2 neuropeptide DF2: an FMRFamide-related neuropeptide from crayfish, Procambarus clarkii	1.99	1	0
fim 1 fim 1: fluorescein-conjugated bis(indole)maleimide inhibitor of protein kinase C; can serve as useful fluorescent probe for protein kinase C	2.03	1	0
5'-(4-fluorosulfonylbenzoyl)adenosine 5'-(4-fluorosulfonylbenzoyl)adenosine: affinity label of the inhibitory DPNH site of bovine liver dehydrogenase; adenosylhomocysteinase antagonist; structure	2.39	2	0
8-chloroadenosine-3',5'-cyclic monophosphorothioate 8-chloroadenosine-3',5'-cyclic monophosphorothioate: inhibits growth of human cancer cells; the Rp-isomer is more potent than the Sp-isomer; RN given refers to the (S)- isomer	1.98	1	0
antibiotic 4181-a antibiotic 4181-A: isolated from Streptomyces grieseus; MF C29-H21-N-O9	2.1	1	0
1-(2,3-bis((4-methoxyphenyl)methoxy)propyl)-1h-imidazole 1-(2,3-bis((4-methoxyphenyl)methoxy)propyl)-1H-imidazole: structure given in first source	1.98	1	0
cystathionine ketimine cystathionine ketimine: structure given in first source. cystathionine ketimine : A 1-thia-4-azacyclohepta-3-ene-3,5-dicarboxylic acid that has R-configuration. It is cyclic sulfur-containing imino acid detected in bovine brain extracts.	2	1	0	1-thia-4-azacyclohepta-3-ene-3,5-dicarboxylic acid; sulfur-containing amino acid	human urinary metabolite; mammalian metabolite; rat metabolite; reactive oxygen species generator
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	3.5	8	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	3.09	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
perifosine [no description available]	5.06	3	1	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
tariquidar [no description available]	2.42	2	0	benzamides
peptide elongation factor 2 Peptide Elongation Factor 2: Peptide Elongation Factor 2 catalyzes the translocation of peptidyl-tRNA from the A site to the P site of eukaryotic ribosomes by a process linked to the hydrolysis of GTP to GDP.	2.4	2	0
1,3-dicapryloylglycerol 1,3-dioctanoylglycerol : A 1,3-diglyceride in which both acyl groups are specified as octanoyl.	1.98	1	0	1,3-diglyceride	Brassica napus metabolite; excipient
dx 8951 [no description available]	3.09	1	0	pyranoindolizinoquinoline
vatalanib [no description available]	4.06	4	0	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
evodiamine [no description available]	2.43	2	0	beta-carbolines
1,2-dihexanoylglycerol 1,2-dihexanoylglycerol: functions as bioregulator of protein kinase C in human platelets; RN given refers to cpd without isomeric designation	2.38	2	0	1,2-diglyceride
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	3.46	1	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
cyc 682 sapacitabine: structure in first source. sapacitabine : A nucleoside analogue resulting from the formal condensation of the carboxy group of hexadecanoic acid with the amino group of CNDAC. It is the prodrug of CNDAC and is currently in clinical development for the treatment of acute myeloid leukemia (AML).	3.18	1	0	nitrile; nucleoside analogue; secondary carboxamide	antimetabolite; antineoplastic agent; DNA synthesis inhibitor; prodrug
ruboxistaurin ruboxistaurin: inhibits protein kinase C beta; structure in first source	2	1	0
phorbols Phorbols: The parent alcohol of the tumor promoting compounds from CROTON OIL (Croton tiglium).	3.86	12	0	diterpene; terpenoid fundamental parent
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.92	4	0	oxygen hydride; oxygen radical; reactive oxygen species
nps-568 N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine: NPS-568 is the ((R), HCl salt)-isomer; calcimimetic compound and calcium-sensing receptor agonist	2.03	1	0
tipifarnib [no description available]	3.13	5	0	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
singlet oxygen Singlet Oxygen: An excited state of molecular oxygen generated photochemically or chemically. Singlet oxygen reacts with a variety of biological molecules such as NUCLEIC ACIDS; PROTEINS; and LIPIDS; causing oxidative damages.	2	1	0	chalcogen; monoatomic oxygen; nonmetal atom	macronutrient
fenton's reagent Fenton's reagent: used for oxidizing sugars & alcohols	2.05	1	0
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	5.71	8	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
dihydrosterculic acid dihydrosterculic acid: RN given refers to cpd without isomeric designation	1.99	1	0
2-phenyl-4-oxohydroquinoline 2-phenyl-4-oxohydroquinoline: structure given in first source	1.99	1	0
pinusolide pinusolide: RN given for (1S-(1alpha,4aalpha,5a,8abeta))-isomer; structure in first source	7.03	1	0	diterpene lactone	metabolite
dihydroguaiaretic acid dihydroguaiaretic acid: lignan extracted form Larrea divaricata; inhibitory to beef heart mitochondrial succinoxidase & NADH-oxidase; RN given refers to cpd without isomeric designation	7.03	1	0
8-aminohexylamino camp [no description available]	2.44	2	0
conopressin g conopressin G: amino acid sequence given in first source; molluscan vasopressin-like peptides	2	1	0
4-(3-(biotinylaminohexamethylenaminocarbonyl)propanoylaminomethyl)-2-methyl-1,3-dithiolane-2-yl-(ala(7))phalloidin 4-(3-(biotinylaminohexamethylenaminocarbonyl)propanoylaminomethyl)-2-methyl-1,3-dithiolane-2-yl-(Ala(7))phalloidin: structure given in first source	1.99	1	0
ly 300164 talampanel: AMPA receptor antagonist	2	1	0	benzodioxoles
enniatin b enniatins: cyclohexadepsipeptides containing valine, isoleucine & valeric acid from Fusarian; form complexes with cations & cellular membranes; there are at least three different enniatins H, B & C; minor descriptor (76-86); on-line & INDEX MEDICUS search PEPTIDES, CYCLIC (76-86); see also record for enniatin D, E, F. enniatin B : An enniatin obtained from formal cyclocondensation of three N-[(2R)-2-hydroxy-3-methylbutanoyl]-N-methyl-L-valine units.	2.06	1	0	enniatin	antimicrobial agent
histidinol L-histidinol : An amino alcohol that is propanol substituted by 1H-imidazol-4-yl group at position 3 and an amino group at position 2 (the 2S stereoisomer).	2	1	0	amino alcohol; imidazoles	EC 2.3.1.97 (glycylpeptide N-tetradecanoyltransferase) inhibitor; Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
nardosinone nardosinone: sesquiterpene peroxide; structure	7.01	1	0
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	3.61	9	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	10.65	77	0	amino acid zwitterion; angiotensin II	human metabolite
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	4.18	17	0
lignin Lignin: The most abundant natural aromatic organic polymer found in all vascular plants. Lignin together with cellulose and hemicellulose are the major cell wall components of the fibers of all wood and grass species. Lignin is composed of coniferyl, p-coumaryl, and sinapyl alcohols in varying ratios in different plant species. (From Merck Index, 11th ed). lignin : A polyphenylpropanoid derived from three monolignol monomers: trans-p-coumaryl alcohol, coniferol and trans-sinapyl alcohol. There is extensive cross-linking and no defined primary structure.	2.41	2	0
argipressin,(1-mercaptocyclohexaneacetic acid)(1)-o-ethyl-tyr(2)- argipressin,(1-mercaptocyclohexaneacetic acid)(1)-O-ethyl-Tyr(2)-: argipressin antagonist; RN given refers to all (L)-isomer	2	1	0
sb 203580 [no description available]	4.77	30	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
enzastaurin [no description available]	3.18	1	0	indoles; maleimides
zm 241385 ZM 241385: a high affinity radioligand selective for the A2a adenosine receptor	2.03	1	0	diamino-1,3,5-triazine
erlotinib hydrochloride [no description available]	3	4	0	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
homocysteic acid homocysteic acid: promotes growth in hypophysectomized rats; RN given refers to parent cpd. homocysteic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group has benn oxidised to the corresponding sulfonic acid.. L-homocysteic acid : A homocysteic acid with L-configuration.	1.97	1	0	homocysteic acid	NMDA receptor agonist
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	2.04	1	0	divalent inorganic anion; phosphite ion
ly 231617 LY 231617: structure given in first source; LY 231617 is the HCl salt; RN given refers to the parent compound	1.99	1	0
3-(piperidine-1-yl)propyl 4-amino-5-chloro-2-methoxybenzoate hydrochloride 3-(piperidine-1-yl)propyl 4-amino-5-chloro-2-methoxybenzoate hydrochloride: structure given in first source; a 5-HT(4) receptor antagonist	2.01	1	0
cgp 42700 CGP 42700: staurosporine derivative	7.9	4	0
repinotan hydrochloride repinotan hydrochloride: 5-HT(1A) receptor agonist; structure in first source	2.4	2	0
lapatinib [no description available]	3.66	3	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
arimoclomol arimoclomol: a coinducer of heat shock proteins, delays disease progression in ALS mice	2.05	1	0
bmy 7378 [no description available]	2	1	0
eglumetad eglumetad: LY-354740 is the active isomer, LY-366563 is the inactive isomer, and LY 314582 is the racemate; structure given in first source	2.96	4	0	L-alpha-amino acid
sorafenib [no description available]	7.75	26	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide [no description available]	3.55	2	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide: structure in first source. indisulam : A chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group at position 7. It is a carbonic anhydrase inhibitor and a potential anti-cancer agent currently in clinical development.	3.12	1	0	chloroindole; organochlorine compound; sulfonamide	antineoplastic agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
demecolcine Demecolcine: An alkaloid isolated from Colchicum autumnale L. and used as an antineoplastic.. (-)-demecolcine : A secondary amino compound that is (S)-colchicine in which the N-acetyl group is replaced by an N-methyl group. Isolable from the autumn crocus, Colchicum autumnale, it is less toxic than colchicine and is used as an antineoplastic.	8.1	5	0	alkaloid; secondary amino compound	antineoplastic agent; microtubule-destabilising agent
2-methylthioadenosine [no description available]	2	1	0
2-hydroxyestradiol 2-hydroxyestradiol: catechol estrogen; RN given refers to (17 beta)-isomer. 2-hydroxy-17beta-estradiol : A 2-hydroxy steroid that consists of 17beta-estradiol having an additional hydroxy group at position 2.	2.06	1	0	17beta-hydroxy steroid; 2-hydroxy steroid	carcinogenic agent; human metabolite; metabolite; mouse metabolite; prodrug
mibolerone mibolerone: prevents estrus in animals & prevents experimental lymphoid leukosis; minor descriptor (80-83); on-line & Index Medicus search NANDROLONE/AA (80-83); RN given refers to (7alpha,17beta)-isomer; structure. mibolerone : An androgen that is nalandrone carrying two methyl substituents at positions 7alpha and 17.	1.98	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid	anabolic agent; androgen
pheophorbide a pheophorbide a: split product of chlorophyll obtained by saponification of pheophytin	2.02	1	0
anisomycin Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.	3.8	11	0	monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic	anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.66	3	0
withaferin a withaferin A: an antiestrogen and phytogenic antineoplastic agent isolated from leaves of Withania somnifera Dun.; structure. withaferin A : A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 27 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Physalis longifolia, it exhibits cytotoxic activity.	2.03	1	0	27-hydroxy steroid; 4-hydroxy steroid; delta-lactone; enone; epoxy steroid; ergostanoid; primary alcohol; secondary alcohol; withanolide	antineoplastic agent; apoptosis inducer
wortmannin [no description available]	7.46	84	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
withanolides Withanolides: Ergostane derivatives of 28 carbons with oxygens at C1, C22, and C26 positions and the side chain cyclized. They are found in WITHANIA plant genus and have cytotoxic and other effects.	2.03	1	0
taiwanin c taiwanin C: were isolated from the root of Acanthopanax chiisanensis; structure in first source. taiwanin C : A furonaphthodioxole that is furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one substituted by a 1,3-benzodioxol-5-yl group at position 5. It is a naturally occurring lignan extracted from Taiwania cryptomerioides and found to be a potential inhibitor of COX2 expression.	2.01	1	0	benzodioxoles; furonaphthodioxole; lignan	antineoplastic agent; plant metabolite; platelet aggregation inhibitor
acylfulvene acylfulvene: an antineoplastic agent; structure given in first source; an analog of illudin	2.08	1	0
o-(chloroacetylcarbamoyl)fumagillol O-(Chloroacetylcarbamoyl)fumagillol: Semisynthetic analog of fumagillin (a cyclohexane-sesquiterpene antibiotic isolated from ASPERGILLUS FUMIGATUS) that inhibits angiogenesis.. O-(chloroacetylcarbamoyl)fumagillol : A carbamate ester that is fumagillol in which the hydroxy group has been converted to the corresponding N-(chloroacetyl)carbamate derivative.	2	1	0	carbamate ester; organochlorine compound; semisynthetic derivative; sesquiterpenoid; spiro-epoxide	angiogenesis inhibitor; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; methionine aminopeptidase 2 inhibitor; retinoic acid receptor alpha antagonist
tris(2-pyridylmethyl)amine tris(2-pyridylmethyl)amine: structure in first source	2.02	1	0
taurochenodeoxycholic acid Taurochenodeoxycholic Acid: A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic.. taurochenodeoxycholate : An organosulfonate oxoanion that is the conjugate base of taurochenodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. taurochenodeoxycholic acid : A bile acid taurine conjugate of chenodeoxycholic acid.	2.44	2	0	bile acid taurine conjugate	human metabolite; mouse metabolite
bortezomib [no description available]	4.97	4	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
calcein am calcein AM: a non-fluorescent compound cleaved to a fluorescent compound by non-specific intracellular esterases. calcein am : An organic heteropentacyclic compound that is calcein in which all four carboxy group hydrogens have been substituted by (acetyloxy)methoxy groups and the hyrodgens of the two hydroxy groups have been substituted by acetyl groups. It is a a non-fluorescent probe cleaved to a fluorescent probe by non-specific intracellular esterases.	2.48	2	0	2-benzofurans; acetate ester; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; xanthene dye	fluorochrome
bardoxolone methyl methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source	2.05	1	0	cyclohexenones
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	3.69	10	0
leupeptins Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.	4.41	21	0
carboplatin [no description available]	9.35	4	1
lithium chloride Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.	8.9	12	0	inorganic chloride; lithium salt	antimanic drug; geroprotector
leptomycin b [no description available]	4.35	6	0
s-adenosylhomocysteine S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions.. S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine.	2.41	2	0	adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide	cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite
5'-methylthioadenosine 5'-methylthioadenosine: structure. 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group.	1.98	1	0	thioadenosine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycogen glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.	7.68	3	0
n-acetylneuraminic acid N-Acetylneuraminic Acid: An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518). N-acetylneuraminic acid : An N-acylneuraminic acid where the N-acyl group is specified as acetyl.	2.43	2	0	N-acetylneuraminic acids	antioxidant; bacterial metabolite; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; human metabolite; mouse metabolite
fibrin Fibrin: A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.	2.41	2	0	peptide
bradykinin [no description available]	10.14	46	0	oligopeptide	human blood serum metabolite; vasodilator agent
glucosamine D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.	7.41	2	0	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
elastin [no description available]	1.99	1	0	oligopeptide
carnosine polaprezinc: stimulates bone growth	2.68	3	0	amino acid zwitterion; dipeptide	anticonvulsant; antineoplastic agent; antioxidant; Daphnia magna metabolite; geroprotector; human metabolite; mouse metabolite; neuroprotective agent
mevalonic acid Mevalonic Acid: A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.. mevalonic acid : A racemate composed of equimolar amounts of (R)- and (S)-mevalonic acid.. (R)-mevalonic acid : The (R)-enantiomer of mevalonic acid.	2	1	0	3,5-dihydroxy-3-methylpentanoic acid
diaminopimelic acid Diaminopimelic Acid: A diamino derivative of heptanedioic acid with amino groups at C-2 and C-6 and the general formula (COOH)CH(NH2)CH2CH2CH2CH(NH2)(COOH).. LL-2,6-diaminopimelic acid : A 2,6-diaminopimelic acid in which both chiral centres have S configuration. It is a component of bacterial cell wall.	2.07	1	0	2,6-diaminopimelic acid; amino acid zwitterion	Escherichia coli metabolite
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	3.37	7	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
inositol 1,4,5-trisphosphate Inositol 1,4,5-Trisphosphate: Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.	10.45	63	0	myo-inositol trisphosphate	mouse metabolite
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	4.53	24	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
puromycin [no description available]	2.41	2	0	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
tosylphenylalanyl chloromethyl ketone Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.	2.4	2	0	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor
taurolithocholic acid Taurolithocholic Acid: A bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. It is a cholagogue and choleretic.. taurolithocholic acid : The bile acid taurine conjugate of lithocholic acid.	2.01	1	0	bile acid taurine conjugate; monocarboxylic acid amide	human metabolite
nitroarginine Nitroarginine: An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6). N(gamma)-nitro-L-arginine : An L-arginine derivative that is L-arginine in which the terminal nitrogen of the guanidyl group is replaced by a nitro group.	2.69	3	0	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid
mannosamine mannosamine: RN given refers to parent cpd without isomeric designation. D-mannosamine : The D-enantiomer of mannosamine.. 2-amino-2-deoxy-D-mannopyranose : A D-mannosamine in cyclic pyranose form.	2	1	0	D-mannosamine
inositol 3-phosphate inositol 3-phosphate: RN given refers to (myo)-isomer	2.04	1	0
adenosine 5'-o-(3-thiotriphosphate) adenosine 5'-O-(3-thiotriphosphate): RN given refers to cpd with unspecified locant for thio group; see also records for 1-thio & 2-thio-isomers. adenosine 5'-[gamma-thio]triphosphate : A nucleoside triphosphate analogue that is ATP in which one of the oxygens attached to 3-phosphate group is replaced by sulfur.	3.69	10	0	nucleoside triphosphate analogue
dehydroascorbic acid Dehydroascorbic Acid: The reversibly oxidized form of ascorbic acid. It is the lactone of 2,3-DIKETOGULONIC ACID and has antiscorbutic activity in man on oral ingestion.. L-dehydroascorbate : An organic anion and the conjugate base of L-dehydroascorbic acid, arising from deprotonation of the acidic C2-position.. L-dehydroascorbic acid : Dehydroascorbic acid having the L-configuration.	2	1	0	dehydroascorbic acid; vitamin C	coenzyme; mouse metabolite
cortodoxone Cortodoxone: 17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.. 11-deoxycortisol : A deoxycortisol that is cortisol in which the hydroxy group at position 11 has been replaced by a hydrogen.	2.01	1	0	deoxycortisol; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
strychnine Strychnine: An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison.. strychnine : A monoterpenoid indole alkaloid that is strychnidine bearing a keto substituent at the 10-position.	2.93	4	0	monoterpenoid indole alkaloid; organic heteroheptacyclic compound	avicide; cholinergic antagonist; glycine receptor antagonist; neurotransmitter agent; rodenticide
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.7	3	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
monensin Monensin: An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies.. monensin A : A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle.	3.38	7	0	cyclic hemiketal; monocarboxylic acid; polyether antibiotic; spiroketal	antifungal agent; coccidiostat; ionophore
hyperforin hyperforin: a prenylated acylphloroglucinol derivative; antibiotic component of novoimanine; psychoactive agent in St. John's wort; Russian; structure;. hyperforin : A cyclic terpene ketone that is a prenylated carbobicyclic acylphloroglucinol derivative produced by St. John's Wort, Hypericum perforatum.	2.01	1	0
phalloidine Phalloidine: Very toxic polypeptide isolated mainly from AMANITA phalloides (Agaricaceae) or death cup; causes fatal liver, kidney and CNS damage in mushroom poisoning; used in the study of liver damage.. phalloidin : A homodetic bicyclic heptapeptide having a sulfide bridge.	3.52	8	0	homodetic cyclic peptide
ryanodine Ryanodine: A methylpyrrole-carboxylate from RYANIA that disrupts the RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL to modify CALCIUM release from SARCOPLASMIC RETICULUM resulting in alteration of MUSCLE CONTRACTION. It was previously used in INSECTICIDES. It is used experimentally in conjunction with THAPSIGARGIN and other inhibitors of CALCIUM ATPASE uptake of calcium into SARCOPLASMIC RETICULUM.. ryanodine : An insecticide alkaloid isolated from South American plant Ryania speciosa.	3.78	11	0
ingenol [no description available]	2.02	1	0	cyclic terpene ketone; tetracyclic diterpenoid
phorbol phorbol: RN given refers to (1aR-(1a alpha,1b beta,4a beta,7a alpha,7b alpha,8 alpha,9 beta,9b beta))-isomer; synonym isophorbol refers to (4a alpha)-isomer; structure in Merck Index, 9th ed, #7143. phorbol : A diterpenoid with the structure of tigliane hydroxylated at C-4, -9, -12(beta), -13 and -20, with an oxo group at C-3 and unsaturation at the 1- and 6-positions.	8.78	11	0	cyclic ketone; enone; tertiary alcohol; tertiary alpha-hydroxy ketone; tetracyclic diterpenoid
naringin [no description available]	1.99	1	0	(2S)-flavan-4-one; 4'-hydroxyflavanones; dihydroxyflavanone; disaccharide derivative; neohesperidoside	anti-inflammatory agent; antineoplastic agent; metabolite
lignans Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	4.36	6	0
acetylleucyl-leucyl-norleucinal acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.	2.7	3	0	aldehyde; tripeptide	cysteine protease inhibitor
bq 485 BQ 485: an endothelin ET(A)receptor antagonist; structure given in first source	1.99	1	0	peptide
bq 123 cyclo(Trp-Asp-Pro-Val-Leu): derived from the modification of a natural lead of BE-18257B, an endothelin A receptor antagonist; has neuroprotective activity; amino acid sequence given in first source	3.5	8	0	cyclic peptide
n-formylmethionine leucyl-phenylalanine N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.	5.82	92	0	tripeptide
devazepide Devazepide: A derivative of benzodiazepine that acts on the cholecystokinin A (CCKA) receptor to antagonize CCK-8's (SINCALIDE) physiological and behavioral effects, such as pancreatic stimulation and inhibition of feeding.. devazepide : An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders.	2.38	2	0	1,4-benzodiazepinone; indolecarboxamide	antineoplastic agent; apoptosis inducer; cholecystokinin antagonist; gastrointestinal drug
teprotide Teprotide: A synthetic nonapeptide (Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) which is identical to the peptide from the venom of the snake, Bothrops jararaca. It inhibits kininase II and ANGIOTENSIN I and has been proposed as an antihypertensive agent.	2	1	0	peptide
diprenorphine Diprenorphine: A narcotic antagonist similar in action to NALOXONE. It is used to remobilize animals after ETORPHINE neuroleptanalgesia and is considered a specific antagonist to etorphine.	2	1	0	morphinane alkaloid
sodium arsenite sodium arsenite : An inoganic sodium salt with formula with formula NaAsO2.	2.69	3	0	arsenic molecular entity; inorganic sodium salt	antibacterial agent; antifungal agent; antineoplastic agent; carcinogenic agent; herbicide; insecticide; rodenticide
vinpocetine vinpocetine: whole issue of Arzneim Forsch (23 articles) discuss this drug; Arzneim Forsch 26(10a);1976; RN given refers to parent cpd with unspecified isomeric designation	2	1	0	alkaloid	geroprotector
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.94	4	0	cyclodextrin
maleic acid maleic acid: RN given refers to parent cpd(Z)-isomer which is maleic acid; all RR's given refer to (Z)-isomer; (E)-isomer is fumaric acid. maleic acid : A butenedioic acid in which the double bond has cis- (Z)-configuration.	1.98	1	0	butenedioic acid	algal metabolite; mouse metabolite; plant metabolite
e-z cinnamic acid cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid	1.99	1	0	cinnamic acid	plant metabolite
ergosterol [no description available]	2.03	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; ergostanoid; phytosterols	fungal metabolite; Saccharomyces cerevisiae metabolite
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	4.33	7	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	9.22	53	1	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
aurovertin b [no description available]	2.01	1	0
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	6.86	104	0	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
prostaglandin h2 Prostaglandin H2: A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins.	2.01	1	0	olefinic compound; oxylipin; prostaglandins H; secondary alcohol	mouse metabolite
farnesol Farnesol: A colorless liquid extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose. It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). (2-trans,6-trans)-farnesol : The (2-trans,6-trans)-stereoisomer of farnesol.. farnesol : A farnesane sesquiterpenoid that is dodeca-2,6,10-triene substituted by methyl groups at positions 3, 7 and 11 and a hydroxy group at position 1.	1.99	1	0	farnesol	plant metabolite
phosphoramidon phosphoramidon: a membrane metallo-endopeptidase & endothelin-converting enzyme inhibitor; thermolysin inhibitor from culture filtrate of Streptomyces tanashiensis; structure. phosphoramidon : A dipeptide isolated from the cultures of Streptomyces tanashiensis.	1.99	1	0	deoxyaldohexose phosphate; dipeptide	bacterial metabolite; EC 3.4.24.11 (neprilysin) inhibitor; EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.46	2	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
retinol Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).	2.4	2	0	retinol; vitamin A	human metabolite; mouse metabolite; plant metabolite
latrunculin a latrunculin A: 16-membered macrolide attached to 2-thiazolidinone moiety; from Red Sea sponge Latrunculia magnifica; see also latrunculin B; structure given in first source. latrunculin A : A bicyclic macrolide natural product consisting of a 16-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica and from the Fiji Islands sponge Cacospongia mycofijiensis. Latrunculin A inhibits actin polymerisation, microfilament organsation and microfilament-mediated processes.	2.93	4	0	cyclic hemiketal; macrolide; oxabicycloalkane; thiazolidinone	actin polymerisation inhibitor; metabolite; toxin
cyanoginosin lr cyanoginosin LR: cyclic heptapeptide from cyanobacterium Microcystis aeruginosa. microcystin-LR : A microcystin consisting of D-alanyl, L-leucyl, (3S)-3-methyl-D-beta-aspartyl,L-arginyl, 2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl, D-gamma-glutamyl, and 2,3-didehydro-N-methylalanyl residues joined into a 25-membered macrocycle. Produced by the cyanobacterium Microcystis aeruginosa, it is the most studied of the microcystins.	3.38	7	0	microcystin	bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; environmental contaminant; xenobiotic
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	2.68	3	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	4.09	15	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.93	4	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
alpha-methyl-4-carboxyphenylglycine alpha-methyl-4-carboxyphenylglycine: glutamate receptor antagonist. (S)-alpha-methyl-4-carboxyphenylglycine : A non-proteinogenic alpha-amino acid that is alanine in which the alpha-hydrogen is replaced by a 4-carboxyphenyl group (the S-enantiomer). It is a non-selective group I/group II metabotropic glutamate receptor (mGluR) antagonist.	2.4	2	0	non-proteinogenic alpha-amino acid	metabotropic glutamate receptor antagonist
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	6.01	109	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.03	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	2.08	1	0
keratan sulfate Keratan Sulfate: A sulfated mucopolysaccharide initially isolated from bovine cornea. At least two types are known. Type I, found mostly in the cornea, contains D-galactose and D-glucosamine-6-O-sulfate as the repeating unit; type II, found in skeletal tissues, contains D-galactose and D-galactosamine-6-O-sulfate as the repeating unit.. keratan sulfate : A sulfated glycosaminoglycan, a linear polymer that consists of the repeating disaccharide [3)-beta-Gal-(1->4)-beta-GlcNAc-(1->] and containing sulfo groups located at random positions.. keratan 6'-sulfate : A keratan sulfate with random sulfation at the 6'-position.	2.52	2	0
pd 173955 PD 173955: inhibits src family-selective tyrosine kinase; structure in first source	2.01	1	0	aryl sulfide; dichlorobenzene; methyl sulfide; pyridopyrimidine	tyrosine kinase inhibitor
y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.	3.83	11	0	aromatic amide
adenosine-5'-(n-ethylcarboxamide) Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.	3.08	5	0	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
prostaglandin d2 Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).	2.68	3	0	prostaglandins D	human metabolite; mouse metabolite
zeatin Zeatin: An aminopurine factor in plant extracts that induces cell division. (Grant & Hackh's Chemical Dict, 5th ed)	2.02	1	0	zeatin	plant metabolite
alitretinoin Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA.	2.02	1	0	retinoic acid	antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	5.53	67	0	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
afimoxifene afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.	2.42	2	0	phenols; tertiary amino compound	antineoplastic agent; estrogen receptor antagonist; metabolite
acid fuchsin acid fuchsin: RN refers to disodium salt. acid fuchsin : An organic sodium salt that is the disodium salt of 2-amino-5-[(4-amino-3-sulfophenyl)(4-imino-3-sulfocyclohexa-2,5-dien-1-ylidene)methyl]-3-methylbenzene-1-sulfonic acid. It is used in the Van Gieson method in conjunction with picric acid to demonstrate collagen fibres red, and in Masson's trichrome to colour smooth muscle in contrast to collagen.	2.03	1	0
decitabine [no description available]	6.81	7	1	2'-deoxyribonucleoside
phorbol-12,13-didecanoate phorbol-12,13-didecanoate: RN given refers to (1aR-(1a alpha,1b beta,4a beta,7a alpha,7b alpha,8 alpha,9 beta,9a alpha))-isomer	4.75	31	0
cladribine triphosphate [no description available]	2.01	1	0	purine deoxyribonucleoside triphosphate
troxacitabine troxacitabine: shows good anti-HIV activity without cytotoxicity	3.11	1	0	carbohydrate derivative; nucleobase-containing molecular entity
kt 5720 KT 5720: indolocarbazole; synthetic derivative of K 252a. KT 5720 : An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of hexyl (3S)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2R,3S,5S product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.	5.9	32	0	carboxylic ester; gamma-lactam; hemiaminal; indolocarbazole; organic heterooctacyclic compound; semisynthetic derivative; tertiary alcohol	EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.03	1	0	purvalanol
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	5.7	80	0	actinomycin	mutagen
tiazofurin tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).	2	1	0	1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide	antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug
aphidicolin Aphidicolin: An antiviral antibiotic produced by Cephalosporium aphidicola and other fungi. It inhibits the growth of eukaryotic cells and certain animal viruses by selectively inhibiting the cellular replication of DNA polymerase II or the viral-induced DNA polymerases. The drug may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells.. aphidicolin : A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication.	3.87	12	0	tetracyclic diterpenoid	antimicrobial agent; antimitotic; antineoplastic agent; antiviral drug; apoptosis inducer; Aspergillus metabolite; DNA synthesis inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; fungal metabolite
3-(1-deoxyribofuranosyl)benzamide 3-(1-deoxyribofuranosyl)benzamide: structure given in first source	3.79	3	0
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.42	2	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
enkephalin, leucine Enkephalin, Leucine: One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.. Leu-enkephalin : A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-leucine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide produced in vertebrate species, including rodents, primates and humans that results from decomposition of proenkephalin or dynorphin and exhibits antinociceptive properties.	3.38	7	0	pentapeptide; peptide zwitterion	analgesic; delta-opioid receptor agonist; human metabolite; mu-opioid receptor agonist; neurotransmitter; rat metabolite
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	4.21	17	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
posaconazole [no description available]	4.57	3	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
5-ethynyl-2'-deoxyuridine 5-ethynyl-2'-deoxyuridine: structure in first source	2.06	1	0
terameprocol [no description available]	2.13	1	0	lignan
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	2.13	1	0	antibiotic antifungal drug; echinocandin	antiinfective agent
oxanosine oxanosine: from Streptomyces capreolus MG265-CF3; has weak anti-bacterial action; structure in first source	3.08	1	0
riboflavin vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).	2.05	1	0	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite
bromochloroacetic acid Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.. bromochloroacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by bromine while a second is replaced by chlorine. A low-melting (27.5-31.5degreeC), hygroscopic crystalline solid, it can be formed during the disinfection (by chlorination) of water that contains bromide ions and organic matter, so can occur in drinking water as a byproduct of the disinfection process.	3.89	12	0	2-bromocarboxylic acid; monocarboxylic acid; organochlorine compound
camalexin camalexin : An indole phytoalexin that is indole substituted at position 3 by a 1,3-thiazol-2-yl group.	3.55	2	0	1,3-thiazoles; indole phytoalexin	metabolite
dimethyl fumarate [no description available]	1.99	1	0	diester; enoate ester; methyl ester	antipsoriatic; immunomodulator
glycosides [no description available]	2.69	3	0
chalcone trans-chalcone : The trans-isomer of chalcone.	2.6	1	0	chalcone	EC 3.2.1.1 (alpha-amylase) inhibitor
isomethyleugenol Methylation: Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed)	3.41	7	0	isomethyleugenol
retinol acetate retinol acetate: structure given in first source	1.99	1	0	acetate ester
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	3.45	7	0	stilbene
phenyl-n-tert-butylnitrone phenyl-N-tert-butylnitrone: a spin-trapping agent	2	1	0
citraconic acid citraconic acid: was MH 1975-92 (see under MALEATES 1975-90); METHYLMALEIC ACID was see CITRACONIC ACID 1975-92; use MALEATES to search CITRACONIC ACID 1975-92; RN refers to (Z)-isomer; SO refers to (E)-isomer. citraconic acid : A dicarboxylic acid consisting of maleic acid having a methyl substituent at the 2-position.	1.99	1	0	dicarboxylic acid; dicarboxylic fatty acid	human metabolite
flavin-adenine dinucleotide Flavin-Adenine Dinucleotide: A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)	2.98	4	0	flavin adenine dinucleotide; vitamin B2	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; prosthetic group
lypressin Lypressin: The porcine antidiuretic hormone (VASOPRESSINS). It is a cyclic nonapeptide that differs from ARG-VASOPRESSIN by one amino acid, containing a LYSINE at residue 8 instead of an ARGININE. Lys-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.	1.99	1	0	cyclic peptide
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	4.82	33	0	vasopressin	cardiovascular drug; hematologic agent; mitogen
pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.	1.98	1	0	diphosphate ion
palmitoyl coenzyme a Palmitoyl Coenzyme A: A fatty acid coenzyme derivative which plays a key role in fatty acid oxidation and biosynthesis.. palmitoyl-CoA : A long-chain fatty acyl-CoA resulting from the formal condensation of the carboxy group of hexadecanoic acid with the thiol group of coenzyme A.	2	1	0	11,12-saturated fatty acyl-CoA; 3-substituted propionyl-CoA; long-chain fatty acyl-CoA; palmitoyl bioconjugate	Escherichia coli metabolite; mouse metabolite
gw9662 2-chloro-5-nitrobenzanilide: pretreatment of peroxisome proliferator activated receptors with GW9662 results in the irreversible loss of ligand binding	2.02	1	0	benzamides
s 1033 [no description available]	5.79	11	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
acetyl-aspartyl-glutamyl-valyl-aspartal acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor. Ac-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7.	3.09	5	0	tetrapeptide	protease inhibitor
azidopine azidopine: structure given in first source	3.23	6	0	benzamides
tropisetron Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.	1.97	1	0	indolyl carboxylic acid
xe 991, anthracenone 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone: neurotransmitter release enhancer and potassium channel blocker; structure given in first source	2	1	0	anthracenes
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	1.98	1	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
fludarabine [no description available]	8.52	8	0	purine nucleoside
n(6)-cyclopentyladenosine [no description available]	2.03	1	0
sesquiterpenes [no description available]	4.82	10	0
etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.	2.03	1	0	ethyl ester; imidazoles	intravenous anaesthetic; sedative
sb 366791 N-(3-methoxyphenyl)-4-chlorocinnamanilide: a TRPV1 antagonist; structure in first source	2.59	2	0
ag-213 tyrphostin 47: inhibits protein-tyrosine kinase activity of EGF-R both in vitro and in living cells;	4.06	15	0
3,3',4,5'-tetrahydroxystilbene 3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.	2.47	2	0	catechols; polyphenol; resorcinols; stilbenol	antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor
thioinosine Thioinosine: Sulfhydryl analog of INOSINE that inhibits nucleoside transport across erythrocyte plasma membranes, and has immunosuppressive properties. It has been used similarly to MERCAPTOPURINE in the treatment of leukemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p503)	2.42	2	0
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	3.72	10	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
rhodanine 2-mercaptothiazolinone: metabolite in urine from persons exposed to CS2; structure	2	1	0	thiazolidinone
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	3.38	7	0	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
epalrestat epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.	2	1	0	monocarboxylic acid; thiazolidines	EC 1.1.1.21 (aldehyde reductase) inhibitor
oxazolone Oxazolone: Immunologic adjuvant and sensitizing agent.	1.98	1	0
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	2.4	2	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
digitoxose [no description available]	2.02	1	0
1,3-dimethylthiourea [no description available]	2	1	0
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2	1	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
capsazepine capsazepine: modified capsaicin molecule; a capsaicin receptor antagonist. capsazepine : A benzazepine that is 2,3,4,5-tetrahydro-1H-2-benzazepine which is substituted by hydroxy groups at positions 7 and 8 and on the nitrogen atom by a 2-(p-chlorophenyl)ethylaminothiocarbonyl group. A synthetic analogue of capsaicin, it was the first reported capsaicin receptor antagonist.	2.72	3	0	benzazepine; catechols; monochlorobenzenes; thioureas	capsaicin receptor antagonist
fumonisin b1 fumonisin B1: isolated from Fusarium moniliforme MRC 826; structure given in first source; has cancer-promoting activity; inhibits ceramide synthase. fumonisin B1 : A diester that results from the condensation of the 1-carboxy groups of two molecules of propane-1,2,3-tricarboxylic acid with hydroxy groups at positions 14 and 15 of (2S,3S,5R,10R,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol.	2.73	3	0	diester; fumonisin; primary amino compound; triol	carcinogenic agent; metabolite
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole: intermediate in the synthesis of imidazolineoxyl N-oxides; partial structure given in first source	2	1	0	benzoic acid; imidazolines; organic radical	apoptosis inhibitor; radical scavenger
2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide: partial structure given in first source; endothelium-derived relaxing factor antagonist	2	1	0
tamoxifen [no description available]	4.7	29	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
sodium taurodeoxycholate Taurodeoxycholic Acid: A bile salt formed in the liver by conjugation of deoxycholate with taurine, usually as the sodium salt. It is used as a cholagogue and choleretic, also industrially as a fat emulsifier.. taurodeoxycholic acid : A bile acid taurine conjugate of deoxycholic acid.. taurodeoxycholate : An organosulfonate oxoanion that is the conjugate base of taurodeoxycholic acid.	2.03	1	0	bile acid taurine conjugate	human metabolite
nadp [no description available]	3.55	8	0
1,1-diphenyl-2-picrylhydrazyl 1,1-diphenyl-2-picrylhydrazyl: A diphenyl picrate; the ability to decolorize this stable radical indicates reactivity of tested compounds (Banda, Anal Chem 46:1772-7 1974)	2.08	1	0
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium: structure given in first source	2.06	1	0
methyl-thiohydantoin-tryptophan methyl-thiohydantoin-tryptophan: structure in first source	2.47	2	0	organonitrogen compound; organooxygen compound
monastrol monastrol: stops mitosis by fostering formation of monopolar spindles; structure in first source. (S)-monastrol : An ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate that has S configuration.. monastrol : A racemate comprising equimolar amounts of R- and S-monastrol.. ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate : A member of the class of thioureas that is 3,4-dihydropyrimidine-2(1)-thione substituted by a 3-hydroxyphenyl group at position 4, an ethoxycarbonyl group at position 5, and a methyl group at position 6.	2.07	1	0	enoate ester; ethyl ester; phenols; racemate; thioureas	antileishmanial agent; antimitotic; antineoplastic agent; EC 3.5.1.5 (urease) inhibitor
valinomycin Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.	3.81	11	0	cyclodepsipeptide; macrocycle	antimicrobial agent; antiviral agent; bacterial metabolite; potassium ionophore
thiopental Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.03	1	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
ranitidine Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.	2.42	2	0	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
toremifene Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.	2	1	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	4.47	22	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
laccase Laccase: A copper-containing oxidoreductase enzyme that catalyzes the oxidation of 4-benzenediol to 4-benzosemiquinone. It also has activity towards a variety of O-quinols and P-quinols. It primarily found in FUNGI and is involved in LIGNIN degradation, pigment biosynthesis and detoxification of lignin-derived products.	2.02	1	0
6-methyl-2-(phenylethynyl)pyridine 6-methyl-2-(phenylethynyl)pyridine: an mGlu5 antagonist. 2-methyl-6-(phenylethynyl)pyridine : A methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.	2.41	2	0	acetylenic compound; methylpyridines	anxiolytic drug; metabotropic glutamate receptor antagonist
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	3.58	2	0	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
lithium Lithium: An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER.	3.61	9	0	alkali metal atom
cobaltous chloride cobaltous chloride: RN given refers to unlabeled cpd; RN in Chemline for cobalt trichloride: 10241-04-0; RN for 60-labeled cpd: 14543-09-0; RN for 57-labeled cpd: 164113-89-1; RN for 58-labeled cpd: 29377-09-1; structure. cobalt dichloride : A cobalt salt in which the cobalt metal is in the +2 oxidation state and the counter-anion is chloride. It is used as an indicator for water in desiccants.	2.94	4	0	cobalt salt; inorganic chloride	allergen; calcium channel blocker; sensitiser; two-colour indicator
raclopride Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.	1.98	1	0	salicylamides
bn 50730 BN 50730: platelet activating factor antagonist; structure given in first source	1.99	1	0
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester [no description available]	4.35	20	0
12-deoxyphorbolphenylacetate-20-acetate [no description available]	1.99	1	0
12-deoxyphorbol-13-isobutyrate-20-acetate 12-deoxyphorbol-13-isobutyrate-20-acetate: RN given refers to (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9aalpha))-isomer	2.39	2	0
boc-tyr(s03)-nle-gly-trp-nle-asp-2-phenylethyl ester JMV 180: distinguishes high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors; RN given refers to (S)-isomer	2.39	2	0
rtki cpd RTKI cpd: preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors	2	1	0
2'-cyano-2'-deoxyarabinofuranosylcytosine 2'-cyano-2'-deoxyarabinofuranosylcytosine: structure given in first source; RN given is for mono HCl	2.02	1	0
6-thioguanosine 5'-diphosphate [no description available]	1.97	1	0
3-deoxy-3-fluoroinositol 1,4,5-trisphosphate [no description available]	1.99	1	0
8-bromoguanosino-3',5'-cyclic monophosphorothioate [no description available]	2.41	2	0
neurokinin a (3-10), lysyl(3)-glycyl(8)-r-lactam-leucine(9)- neurokinin A (3-10), lysyl(3)-glycyl(8)-R-lactam-leucine(9)-: neurokinin receptor agonist	1.98	1	0
methyl-n-dansylgalactosaminide methyl-N-dansylgalactosaminide: probe for the combining sites of N-acetyl-D-galactosamine-specific lectins; RN given refers to the (alpha-D-Galacto)-isomer	2.03	1	0
cystine [no description available]	2.41	1	0
u-50488 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer: A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21). U50488 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of 3,4-dichlorophenylacetic acid and the secondary amino group of (1R,2R)-N-methyl-2-(pyrrolidin-1-yl)cyclohexanamine	2.69	3	0	dichlorobenzene; monocarboxylic acid amide; N-alkylpyrrolidine	analgesic; antitussive; calcium channel blocker; diuretic; kappa-opioid receptor agonist
acth (11-24) [no description available]	1.99	1	0
biricodar biricodar: a non-macrocyclic ligand for FKBP12; structure in first source	2	1	0	alpha-amino acid ester
tandutinib [no description available]	5.82	7	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
safingol safingol: RN given refers to the (R-(R,S))-isomer	4.98	7	0	amino alcohol
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	10.87	17	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
ly 303070 GYKI 53784: a 2,3-benzodiazepine cpd	2	1	0
carbonyl 3-chlorophenylhydrazone carbonyl 3-chlorophenylhydrazone: inhibitor of ATP synthesis; inhibits iron-containing nitrile hydratases	2.15	1	0
7-deoxy-13-dihydroadriamycinone 7-deoxy-13-dihydroadriamycinone: a metabolite of epidoxorubicin	2.02	1	0
laromustine laromustine: has antineoplastic activity	2.04	1	0
dynorphin a, destyr(1)-destrp(14)-desasp(15)-desasn(16)-desglu(17)- dynorphin A, desTyr(1)-desTrp(14)-desAsp(15)-desAsn(16)-desGlu(17)-: antagonizes morphine analgesia	2	1	0
amanitins Amanitins: Cyclic peptides extracted from carpophores of various mushroom species. They are potent inhibitors of RNA polymerases in most eukaryotic species, blocking the production of mRNA and protein synthesis. These peptides are important in the study of transcription. Alpha-amanitin is the main toxin from the species Amanitia phalloides, poisonous if ingested by humans or animals.	2.39	2	0
ginsenosides ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.	2.4	2	0
phosphothreonine Phosphothreonine: The phosphoric acid ester of threonine. Used as an identifier in the analysis of peptides, proteins, and enzymes.. O-phospho-L-threonine : A L-threonine derivative phosphorylated at the side-chain hydroxy function.	4.08	15	0	L-threonine derivative; non-proteinogenic L-alpha-amino acid; O-phosphoamino acid	Escherichia coli metabolite
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline: structure given in first source; neuroprotectant for cerebral ischemia; AMPA receptor antagonist	2	1	0	naphthalenes; sulfonic acid derivative
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.9	4	0
anthraquinone sulfonate anthraquinone sulfonate: RN given refers to cpd with unspecified acid locant	2.08	1	0
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	1.99	1	0	organic sodium salt	detergent; protein denaturant
blister blebbistatin: structure in first source. blebbistatin : A pyrroloquinoline that is 1,2,3,3a-tetrahydro-H-pyrrolo[2,3-b]quinolin-4-one substituted by a hydroxy group at position 3a, a methyl group at position 6 and a phenyl group at position 1. It acts as an inhibitor of ATPase activity of non-muscle myosin II.	2.44	2	0	cyclic ketone; pyrroloquinoline; tertiary alcohol; tertiary alpha-hydroxy ketone	inhibitor
mtt formazan MTT formazan: a blue MEM-insoluble mitochondrial byproduct; used to determine viability of cells with active mitochondrial dehydrogenase enzymes	2.44	2	0
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2.42	2	0	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
6-cyano-7-nitroquinoxaline-2,3-dione 6-Cyano-7-nitroquinoxaline-2,3-dione: A potent excitatory amino acid antagonist with a preference for non-NMDA iontropic receptors. It is used primarily as a research tool.	3.38	7	0	quinoxaline derivative
fg 9041 FG 9041: structure given in first source	2.01	1	0	quinoxaline derivative
alizarin red s Alizarin Red S: RN given refers to parent cpd; structure. alizarin red S : An organic sodium salt having 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate as the counterion. It is commonly used to stain embryo skeletons in cleared whole mounts, usually of small mammals.	2.01	1	0	organic sodium salt; organosulfonate salt	histological dye
alpha-chymotrypsin Chymotrypsin: A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side.	2.03	1	0
nvp 231 [no description available]	2.1	1	0
sb 415286 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source	2.42	2	0	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
minoxidil sulfate ester minoxidil sulfate ester: metabolite of minoxidil; structure given in first source	1.98	1	0
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.69	3	0
d 609 [no description available]	3.38	7	0
2',3'-dialdehyde atp 2',3'-dialdehyde ATP: RN given refers to (R-(R,R))-isomer; OATP also stands for organic anion-transporting polypeptides	1.99	1	0
cathepsin g Cathepsin G: A serine protease found in the azurophil granules of NEUTROPHILS. It has an enzyme specificity similar to that of chymotrypsin C.	1.98	1	0
rhodamine 123 Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.	8.79	11	0	organic cation; xanthene dye	fluorochrome
myelin basic protein Myelin Basic Protein: An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.	8.86	12	0
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.01	1	0	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
diethyl maleate diethyl maleate : A maleate ester resulting from the formal condensation of both carboxy groups of maleic acid with ethanol. A colourless liquid at room temperature (m.p. -10degreeC) with boiling point 220degreeC at 1 atm., it is commonly used as a dienophile for Diels-Alder-type cycloaddition reactions in organic synthesis.	2.4	2	0	ethyl ester; maleate ester	glutathione depleting agent
ku 55933 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source	2.49	2	0
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	7.79	131	0	sphing-4-enine	human metabolite; mouse metabolite
quercetin [no description available]	4.13	16	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	5.58	72	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	4.66	28	0	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
leukotriene a4 Leukotriene A4: (2S-(2 alpha,3 beta(1E,3E,5Z,8Z)))-3-(1,3,5,8-Tetradecatetraenyl)oxiranebutanoic acid. An unstable allylic epoxide, formed from the immediate precursor 5-HPETE via the stereospecific removal of a proton at C-10 and dehydration. Its biological actions are determined primarily by its metabolites, i.e., LEUKOTRIENE B4 and cysteinyl-leukotrienes. Alternatively, leukotriene A4 is converted into LEUKOTRIENE C4 by glutathione-S-transferase or into 5,6-di-HETE by the epoxide-hydrolase. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene A4 : A leukotriene that is the (5S,6S)-epoxy derivative of (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid.	1.98	1	0	epoxy fatty acid; leukotriene; long-chain fatty acid; oxylipin; polyunsaturated fatty acid	human metabolite; mouse metabolite; plant metabolite
arachidonyltrifluoromethane arachidonyltrifluoromethane: structure given in first source; inhibits 85-kDa phospholipase A2. AACOCF3 : A fatty acid derivative that is arachidonic acid in which the OH part of the carboxy group has been replaced by a trifluoromethyl group	3.39	7	0	fatty acid derivative; ketone; olefinic compound; organofluorine compound	EC 3.1.1.4 (phospholipase A2) inhibitor
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.42	2	0	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	2.13	1	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2.38	2	0	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	5.47	25	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
psychosine [no description available]	1.98	1	0	glycosylsphingoid	human metabolite
vitamin k semiquinone radical vitamin K semiquinone radical: found in active preparations of vitamin K-dependent carboxylase. vitamin K : Any member of a group of fat-soluble 2-methyl-1,4-napthoquinones that exhibit biological activity against vitamin K deficiency. Vitamin K is required for the synthesis of prothrombin and certain other blood coagulation factors.	2.91	4	0
beta carotene beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.	2.05	1	0	carotenoid beta-end derivative; cyclic carotene	antioxidant; biological pigment; cofactor; ferroptosis inhibitor; human metabolite; mouse metabolite; plant metabolite; provitamin A
11-cis-retinal Rhodopsin: A purplish-red, light-sensitive pigment found in RETINAL ROD CELLS of most vertebrates. It is a complex consisting of a molecule of ROD OPSIN and a molecule of 11-cis retinal (RETINALDEHYDE). Rhodopsin exhibits peak absorption wavelength at about 500 nm.. 11-cis-retinal : A retinal having 2E,4Z,6E,8E-double bond geometry.	2.91	4	0	retinal	chromophore; human metabolite; mouse metabolite
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	4.33	20	0	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
leukotriene c4 Leukotriene C4: The conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some VASCULAR SMOOTH MUSCLE. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene C4 : A leukotriene that is (5S,7E,9E,11Z,14Z)-5-hydroxyicosa-7,9,11,14-tetraenoic acid in which a glutathionyl group is attached at position 6 via a sulfide linkage.	3.38	7	0	leukotriene	bronchoconstrictor agent; human metabolite; mouse metabolite
thromboxane a2 Thromboxane A2: An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).. thromboxane A2 : A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.	4.01	14	0	epoxy monocarboxylic acid; thromboxanes A	mouse metabolite
15-keto-13,14-dihydroprostaglandin e2 15-keto-13,14-dihydroprostaglandin E2: RN given refers to (5Z,11alpha)-isomer; structure in first source. 13,14-dihydro-15-oxo-prostaglandin E2 : The 13,14-dihydro derivative of 15-oxo-prostaglandin E2.	1.99	1	0	prostaglandins E
alprostadil [no description available]	3.24	6	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
5-hydroxy-6,8,11,14-eicosatetraenoic acid 5(S)-HETE : A HETE having a (5S)-hydroxy group and (6E)-, (8Z)-, (11Z)- and (14Z)-double bonds.. 5-HETE : A HETE having a 5-hydroxy group and (6E)-, (8Z)-, (11Z)- and (14Z)-double bonds.	1.99	1	0	HETE	human metabolite; mouse metabolite
cholecalciferol Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.	3.09	5	0	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol; steroid hormone	geroprotector; human metabolite
kaempferol [no description available]	2.7	3	0	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
leukotriene d4 Leukotriene D4: One of the biologically active principles of SRS-A. It is generated from LEUKOTRIENE C4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene D4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R).	2.39	2	0	dipeptide; leukotriene; organic sulfide	bronchoconstrictor agent; human metabolite; mouse metabolite
6-ketoprostaglandin f1 alpha 6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.	3.08	5	0	prostaglandins Falpha	human metabolite; mouse metabolite
zeaxanthin Zeaxanthins: Carotenoids found in fruits and vegetables. Zeaxanthin accumulates in the MACULA LUTEA.	2.05	1	0	carotenol	antioxidant; bacterial metabolite; cofactor
lipoxin a4 lipoxin A4: an antifibrolytic agent; structure given in first source; a role in ASPIRIN antiinflammatory activity. lipoxin A4 : A C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.	2.05	1	0	hydroxy polyunsaturated fatty acid; lipoxin; long-chain fatty acid	human metabolite; metabolite
alpha-linolenic acid linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.. linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid.	2.41	1	0	linolenic acid; omega-3 fatty acid	micronutrient; mouse metabolite; nutraceutical
genistein [no description available]	6.75	232	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.46	2	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	2	1	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
montelukast montelukast: a leukotriene D4 receptor antagonist	2.05	1	0	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
jasmonic acid jasmonic acid: a derivative of alpha-linolenic acid that has a role in plant response to herbivory analogous to the role of prostanoids in inflammation in mammals;. jasmonic acid : An oxo monocarboxylic acid that is (3-oxocyclopentyl)acetic acid substituted by a (2Z)-pent-2-en-1-yl group at position 2 of the cyclopentane ring.	3.1	5	0	oxo monocarboxylic acid	jasmonates; plant metabolite
geranylgeraniol (E,E,E)-geranylgeraniol : A geranylgeraniol in which all four double bonds have E- (trans-) geometry.	2.4	2	0	geranylgeraniol
mezerein mezerein: toxic component of plant Daphne mezereum with anti-leukemic activity against P-388 & P-1210 in mice; can act as a tumor promoter; RN given refers to (12beta(E,E))-isomer; structure	4.23	18	0	diterpenoid
zearalenone Zearalenone: (S-(E))-3,4,5,6,8,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione. One of a group of compounds known under the general designation of resorcylic acid lactones. Cis, trans, dextro and levo forms have been isolated from the fungus Gibberella zeae (formerly Fusarium graminearum). They have estrogenic activity, cause toxicity in livestock as feed contaminant, and have been used as anabolic or estrogen substitutes.. zearalenone : A macrolide comprising a fourteen-membered lactone fused to 1,3-dihydroxybenzene; a potent estrogenic metabolite produced by some Giberella species.	2.21	1	0	macrolide; resorcinols	fungal metabolite; mycoestrogen
amentoflavone [no description available]	1.99	1	0	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	2.04	1	0	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
fisetin [no description available]	2.42	2	0	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
euxanthone euxanthone : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1 and 7 and an oxo group at position 9. It has been isolated from Cratoxylum cochinchinense.	2	1	0	phenols; xanthones	metabolite; plant metabolite
norathyriol norathyriol: from Gentinanaceae; has vasorelaxing action on rat thoracic aorta; structure given in first source. norathyriol : A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 6 and 7. Isolated from Garcinia mangostana and Maclura pomifera, it exhibits inhibitory activity against protein kinase C.	1.99	1	0	polyphenol; xanthones	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor; plant metabolite
myricetin [no description available]	7.41	2	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
daidzein [no description available]	2.39	2	0	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
rosmarinic acid rosmarinic acid: RN given refers to parent cpd; promote OT project. (R)-rosmarinic acid : A stereoisomer of rosmarinic acid having (R)-configuration.. rosmarinic acid : The 1-carboxy-2-(2,4-dihydroxyphenyl)ethyl ester of trans-caffeic acid.	2.31	1	0	rosmarinic acid	geroprotector; plant metabolite
maytansine Maytansine: An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.. maytansine : An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines.	2.05	1	0	alpha-amino acid ester; carbamate ester; epoxide; maytansinoid; organic heterotetracyclic compound; organochlorine compound	antimicrobial agent; antimitotic; antineoplastic agent; plant metabolite; tubulin modulator
rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.	9.32	19	0	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	2	1	0	homodetic cyclic peptide
rutamycin Rutamycin: A macrolide antibiotic of the oligomycin group, obtained from Streptomyces rutgersensis. It is used in cytochemistry as a tool to inhibit various ATPases and to uncouple oxidative phosphorylation from electron transport and also clinically as an antifungal agent.. oligomycin D : An oligomycin with formula C44H72O11 that is oligomycin A in which the methyl substituent adjacent to the spirocyclic centre has been replaced by a hydrogen.	2.1	1	0
anandamide anandamide : An N-acylethanolamine 20:4 resulting from the formal condensation of carboxy group of arachidonic acid with the amino group of ethanolamine.	2.7	3	0	endocannabinoid; N-acylethanolamine 20:4	human blood serum metabolite; neurotransmitter; vasodilator agent
arachidonyl dopamine arachidonyl dopamine: a ligand for the vanilloid receptor VR1	2.02	1	0	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid: A non-penetrating amino reagent (commonly called SITS) which acts as an inhibitor of anion transport in erythrocytes and other cells.	4.37	6	0	stilbenoid
n,n-dimethylsphingenine N,N-dimethylsphingosine: a sphingosine kinase inhibitor. N,N-dimethylsphingosine : A sphingoid that is sphingosine in which the two amino hydrogens are replaced by methyl groups.	2.91	4	0	aminodiol; sphingoid; tertiary amino compound	EC 2.7.1.91 (sphingosine kinase) inhibitor; metabolite
tocotrienol, alpha alpha-tocotrienol : A tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2, 5, 7 and 8 and a farnesyl chain at position 2. It has been found in palm oil derived from Elaeis guineensis.	2.02	1	0	tocotrienol; vitamin E	ferroptosis inhibitor; human metabolite; neuroprotective agent; plant metabolite
etretinate retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.	1.98	1	0	enoate ester; ethyl ester; retinoid	keratolytic drug
isotretinoin Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.	2.01	1	0	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
ozagrel ozagrel: RN refers to (E)-isomer	2	1	0	cinnamic acids
15-keto-13,14-dihydroprostaglandin f2alpha 15-keto-13,14-dihydroprostaglandin F2alpha: main metabolite of PGF2alpha in plasma after allergen provoked asthma; RN given refers to (5Z,9alpha,11alpha)-isomer; structure. 13,14-dihydro-15-keto-PGF2alpha : A prostaglandin Falpha obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin F2alpha.	1.99	1	0	ketone; prostaglandins Falpha	metabolite
thromboxane b2 Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.	3.49	8	0	thromboxanes B	human metabolite; mouse metabolite
20-hydroxy-5,8,11,14-eicosatetraenoic acid 20-hydroxy-5,8,11,14-eicosatetraenoic acid: stimulator of renal sodium, potassium atpase; RN given is for the (all-Z) isomer. 20-HETE : A HETE that consists of arachidonic acid bearing a hydroxy substituent at position 20.	2.42	2	0	HETE; hydroxy monocarboxylic acid	human metabolite; mouse metabolite
arachidonic acid 5-hydroperoxide arachidonic acid 5-hydroperoxide: 5-HPETE is used inconsistently in literature as syn for cpds with various tetraene locants; RN given refers to (6,8,11,14)-isomer; RN in CA Vol 91 Form Index for (E,Z,Z,Z)-isomer: 70968-82-0; RN for (5,8,11,13)-isomer: 71133-12-5; in Merck, arachidonic acid is the (5,8,11,14)-isomer. 5-HPETE : A HPETE that consists of (6E,8Z,11Z,14Z)-icosatetraenoic acid in which the hydroperoxy group is located at position 5.	2.01	1	0	HPETE	human xenobiotic metabolite
4-hydroxy-2-nonenal 4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.	2.4	2	0	4-hydroxynon-2-enal; 4-hydroxynonenal
n-arachidonylglycine N-arachidonylglycine: structure in first source. N-arachidonoylglycine : Biologically active derivative of anandamide	2.03	1	0	fatty amide; N-acylglycine
linoleoyl ethanolamide linoleoyl ethanolamide: RN given for (Z,Z)-isomer. linoleoyl ethanolamide : An N-acylethanolamine 18:2 that is the ethanolamide of linoleic acid.	1.99	1	0	N-acylethanolamine 18:2	EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor
n-oleoylethanolamine N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.	1.99	1	0	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
1-monooleoyl-rac-glycerol Peceol: lipid excipient containing readily dispersible mixture of mono- & diglycerides of oleic acid. 1-oleoylglycerol : A 1-monoglyceride where the acyl group is oleoyl.. monooleoylglycerol : A monoglyceride in which the acyl group is oleoyl with the position of acylation unspecified.	2.67	3	0	1-acylglycerol 18:1; monooleoylglycerol	plant metabolite
menaquinone 6 menaquinone 6: RN given refers to (all-E)-isomer	2.44	2	0
sphingosine 1-phosphate sphingosine 1-phosphate: RN given refers to (R-(R,S-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1	3.62	9	0	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
n-palmitoylsphingosine N-palmitoylsphingosine: structure given in first source; RN given refers to (R,S-(E))-isomer. N-hexadecanoylsphingosine : A N-acylsphingosine in which the ceramide N-acyl group is specified as hexadecanoyl (palmitoyl).	2.1	1	0	Cer(d34:1); N-acylsphingosine; N-palmitoyl-sphingoid base	human blood serum metabolite; Mycoplasma genitalium metabolite
3-ketolithocholic acid 3-ketolithocholic acid: structure in first source	2.03	1	0	oxo-5beta-cholanic acid
acitretin Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.	2.31	1	0	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	3.11	5	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	5.57	22	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
menaquinone 7 menaquinone-7 : A menaquinone whose side-chain contains seven isoprene units in an all-trans-configutation.	2	1	0	menaquinone	bone density conservation agent; cofactor; Escherichia coli metabolite; human blood serum metabolite; Mycoplasma genitalium metabolite
brefeldin a [no description available]	4.14	16	0	macrolide antibiotic	Penicillium metabolite
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	9.39	22	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fenretinide Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.	2.41	2	0	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	3.11	5	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
su 5402 SU 5402: structure given in first source. SU5402 : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 3-(2-carboxyethyl)-4-methyl-1H-pyrrol-2-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.	3.1	1	0
su 9516 [no description available]	2.03	1	0
2-methylthio-atp 2-methylthio-ATP: purinergic receptors agonist; relaxes mammalian gut preparations; structure given in first source	2.39	2	0
arachidonyl-2-chloroethylamide arachidonyl-2-chloroethylamide: a potent and selective agonist of the neuronal cannabinoid receptor; structure in first source. arachidonyl-2'-chloroethylamide : A fatty amide obtained by the formal condensation of arachidonic acid with 2-chloroethanamine. It is a potent agonist of the CB1 receptor (Ki = 1.4 nM) and also has a low affinity for the CB2 receptor (Ki = 3100 nM).	2.02	1	0	fatty amide; organochlorine compound; secondary carboxamide; synthetic cannabinoid	CB1 receptor agonist; CB2 receptor agonist; neuroprotective agent
bibp 3226 BIBP 3226: a selective non-peptide neuropeptide Y Y1 receptor antagonist; structure given in first source; BIBP-3435 is the S-enantiomer	2.08	1	0
dexmedetomidine [no description available]	3.85	2	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
herbimycin herbimycin: herbicidal antibiotic produced by Streptomyces sp.; see also herbimycin B; structure for herbimycin A in second source. herbimycin : A 19-membered macrocyle incorporating a benzoquinone ring and a lactam functionality. It is an ansamycin antibiotic that induces apoptosis and displays antitumour effects.	6.46	57	0	1,4-benzoquinones; lactam; macrocycle	antimicrobial agent; apoptosis inducer; herbicide; Hsp90 inhibitor; tyrosine kinase inhibitor
l 365260 L 365260: a CCK-B antagonist; structure given in first source; potent & selective CCK-B & gastrin receptor ligand; L 365260 and L 365346 are (R)- and (S)-stereoisomers, respectively	1.98	1	0	benzodiazepine
ono-di-004 [no description available]	2.02	1	0
ono-ae1-329 ONO-AE1-329: a 16-(m-methoxymethyl)phenyl derivative	2.02	1	0
lysophosphatidic acid lysophosphatidic acid: RN given refers to parent cpd. 1-oleoyl-sn-glycerol 3-phosphate : A 1-acyl-sn-glycerol 3-phosphate having oleoyl as the 1-O-acyl group.. lysophosphatidic acid : A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class.	2.47	2	0	1-acyl-sn-glycerol 3-phosphate
lysophosphatidylcholines lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.	3.7	10	0	1-O-acyl-sn-glycero-3-phosphocholine
mdl 100907 Serotonin 5-HT2 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.	2.46	2	0
cytochalasin b Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.	4.82	33	0	cytochalasin; lactam; lactone; organic heterotricyclic compound	actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor
neurokinin a Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI.	2.68	3	0
ono 3708 ONO 3708: structure given in first source; thromboxane A2 antagonist	2	1	0
pd 123319 PD123319 : An imidazopyridine consisting of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine having 4-(dimethylamino)-3-methylbenzyl, diphenylacetyl and carboxy and groups at positions 1, 5 and 6 respectively	2.41	2	0	imidazopyridine	angiotensin receptor antagonist; endothelin receptor antagonist; vasoconstrictor agent
calyculin a calyculin A: RN given refers to (5S-(5alpha(2R(1S,3S,4S,5R,6R,7E,9E,11E,13Z),3R),7beta(E(S)),*beta,9alpha))-isomer	6.51	60	0
sq 29548 SQ 29548: SQ-26538 is the ((1S-1alpha,2beta(5Z),3beta(1E,3R*),4alpha))-isomer; thromboxane A2 antagonist; thromboxane receptor antagonist	2.4	2	0
kn 93 KN 93: reduces dopamine content in PC12h cells. KN-93 : A sulfonamide resulting from the formal condensation of p-methoxybenzenesulfonic acid with the anilino nitrogen of 2-(aminomethyl)-N-(2-hydroxyethyl)aniline in which the hydrogens of the primary amino group have been replaced by methyl and p-chlorocinnamyl groups. KN-93 is a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II.	3.63	9	0	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector
kn 62 KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II	4.6	26	0	piperazines
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.46	2	0
sulprostone sulprostone: structure	1.98	1	0	prostanoid
cycloheterophyllin cycloheterophyllin: RN refers to ((+)-)-isomer; structure given in first source	1.99	1	0	extended flavonoid
3'-methoxypuerarin 3'-methoxypuerarin: inhibits formation of advanced glycation end products; isolated from Pueraria lobata; structure in first source	2.13	1	0
casein kinase ii Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.	3.51	8	0
arcyriaflavin a arcyriaflavin A: from marine ascidian, Eudistoma sp.; structure given in first source	2.46	2	0	indolocarbazole
erbstatin erbstatin: from actinomycetes; an inhibitor of EGF-receptor kinase & other protein-tyrosine kinases; structure in first source	3.6	9	0
ag 99 tyrphostin A46: epidermal growth factor-urogastrone receptor antagonist	2.69	3	0
tyrphostin ag-494 AG 494: tyrphostin that blocks Cdk2 activation; structure in first source	2	1	0
tyrphostin b44 tyrphostin B44: inhibits protein kinases; an analog of tyrphostin B46; B44(+) is B50, and is the stereoisomer of B44(-)	1.99	1	0
ag-490 [no description available]	2.72	3	0	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
ag 127 AG 127: structure given in first source	1.99	1	0
bosutinib 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile: a Src kinase inhibitor; structure in first source	2.06	1	0	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	4.06	2	0	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
su 11248 [no description available]	6.32	12	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
lead Lead: A soft, grayish metal with poisonous salts; atomic number 82, atomic weight 207.2, symbol Pb.	2.7	3	0	carbon group element atom; elemental lead; metal atom	neurotoxin
12-hydroxy-5,8,10,14-eicosatetraenoic acid 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51)	2.67	3	0
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.75	3	0	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
methyl 2,5-dihydroxycinnamate methyl 2,5-dihydroxycinnamate: structure given in first source. 2,5-dihydroxycinnamic acid methyl ester : A cinnamate ester that is the methyl ester of 2,5-dihydroxycinnamic acid.	2.9	4	0	cinnamate ester; hydroquinones; methyl ester	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; geroprotector; human urinary metabolite; plant metabolite
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine: structure given in first source. 1,1',3,3'-tetraethyl-5,5',6,6'-tetrachloroimidacarbocyanine : The cationic form of a C3 cyanine dye having 1,3-diethyl-5,6-dichloroindoleinine units at each end.	2.48	2	0	cyanine dye; indolium ion	fluorochrome
diamide Diamide: A sulfhydryl reagent which oxidizes sulfhydryl groups to the disulfide form. It is a radiation-sensitizing agent of anoxic bacterial and mammalian cells.	2.39	2	0	1,1'-azobis(N,N-dimethylformamide)
psi-tectorigenin psi-tectorigenin: structure given in first source; isolated from Streptomyces	1.97	1	0
su 4984 SU 4984: structure given in first source	3.1	1	0
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid: A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)	4.07	15	0
antimony Antimony: A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.	2.07	1	0	metalloid atom; pnictogen
cesium Cesium: A member of the alkali metals. It has an atomic symbol Cs, atomic number 50, and atomic weight 132.91. Cesium has many industrial applications, including the construction of atomic clocks based on its atomic vibrational frequency.	2.42	2	0	alkali metal atom
barium Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous.	3.93	13	0	alkaline earth metal atom; elemental barium
rubidium Rubidium: An element that is an alkali metal. It has an atomic symbol Rb, atomic number 37, and atomic weight 85.47. It is used as a chemical reagent and in the manufacture of photoelectric cells.	4.25	18	0	alkali metal atom
aluminum Aluminum: A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.	3.37	7	0	boron group element atom; elemental aluminium; metal atom
thallium Thallium: A heavy, bluish white metal, atomic number 81, atomic weight [204.382; 204.385], symbol Tl.. thallium : A metallic element first identified and named from the brilliant green line in its flame spectrum (from Greek thetaalphalambdalambdaomicronsigma, a green shoot).	2.05	1	0	boron group element atom
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	3.62	9	0	metalloid atom; pnictogen	micronutrient
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	2.04	1	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
morphine-6-glucuronide morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer	2.02	1	0	morphinane alkaloid
batimastat batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor. batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor.	2.01	1	0	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor
sulfur Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.	2	1	0	chalcogen; nonmetal atom	macronutrient
geldanamycin [no description available]	3.1	5	0
alloocimene alloocimene: representative of carotenoid polyenes; RN given refers to cpd without isomeric designation. (4E,6E)-2,6-dimethylocta-2,4,6-triene : An ocimene that consists of octa-2,4,6-triene bearing methyl substituents at positions 2 and 6 (the 4E,6E-isomer).	2.02	1	0	ocimene	semiochemical
4-phenyl-3-butenoic acid 4-phenyl-3-butenoic acid: an inhibitor of peptidyl glycine hydroxylase (peptide amidating enzyme); RN given refers to cpd without isomeric designation	2.1	1	0
enalapril Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).	2	1	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
cytochalasin a [no description available]	2.39	2	0	cytochalasin
cytochalasin e cytochalasin E: structure	1.98	1	0	cytochalasan alkaloid	metabolite
dimyristoylphosphatidylcholine 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).. dimyristoyl phosphatidylcholine : A phosphatidylcholine where the phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).	2.01	1	0	1,2-diacyl-sn-glycero-3-phosphocholine; phosphatidylcholine 28:0; tetradecanoate ester	antigen; mouse metabolite
deoxyribose [no description available]	2.02	1	0	deoxypentose	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
fumarates Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)	1.99	1	0	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	4.02	14	0	cysteinium	fundamental metabolite
silicon Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].	2.07	1	0	carbon group element atom; metalloid atom; nonmetal atom
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	1.97	1	0	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
enalaprilat anhydrous Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.	2.02	1	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
s-trans,trans-farnesylthiosalicylic acid farnesylthiosalicylic acid: structure in first source	1.99	1	0	sesquiterpenoid
pepstatin pepstatin: inhibits the aspartic protease endothiapepsin	2.7	3	0	pentapeptide; secondary carboxamide	bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor
ici 118551 ICI 118551: RN given refers to (R,R)-(+-)-isomer; structure in first source; ICI 111581 is hydrochloride of ICI 118551. ICI 118551 : An indane substituted at position 7 by a methyl group and at position 4 by a 3-(isopropylamino)-2-hydroxybutoxy group (the 2R,3S-diastereomer).	2.91	4	0	aromatic ether; indanes; secondary alcohol; secondary amino compound	beta-adrenergic antagonist
enkephalin, ala(2)-mephe(4)-gly(5)- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-: An enkephalin analog that selectively binds to the MU OPIOID RECEPTOR. It is used as a model for drug permeability experiments.	2.92	4	0
3,3'-dipropyl-2,2'-thiadicarbocyanine 3,3'-dipropyl-2,2'-thiadicarbocyanine: potent inhibitor of endogenous respiration of Ehrlich ascites tumor cells; RN given refers to iodide; RN for parent cpd not in Chemline 10/24/83; structure	1.99	1	0
phenylalanylalanine phenylalanylalanine: RN given refers to (L)-isomer. Phe-Ala : A dipeptide formed from L-phenylalanine and L-alanine residues.	2	1	0	dipeptide zwitterion; dipeptide	metabolite
guanylin guanylin: from rat jejunum; contains 15 amino acids; activator of intestinal guanylate cyclase; stimulates this enzyme through the same receptor binding region as the heat-stable enterotoxins; amino acid sequence given in first source; GenBank Z73607 (pig)	1.98	1	0
ophiocordin ophiocordin: metabolite of Cordyceps ophioglossoides	2.02	1	0
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one: a janus-activated kinase inhibitor. 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one : An organic heterotetracyclic compound that is 1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one bearing additional tert-butyl and fluoro substituents at positions 2 and 9 respectively.	2.1	1	0	organic heterotetracyclic compound; organofluorine compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
6-mercapto-7-methylguanosine 6-mercapto-7-methylguanosine: structure given in first source	2.05	1	0
n-acetylsphingosine N-acetylsphingosine: inhibits phospholipase D. N-acetylsphingosine : A N-acylsphingosine that has an acetamido group at position 2.	4.5	23	0	N-acylsphingosine
z-val-ala-asp(ome)-fluoromethylketone z-Val-Ala-Asp(Ome)-fluoromethylketone: confuse with Z-VAD-FMK. Z-Val-Ala-Asp(OMe)-CH2F : A tripeptide consisting of Z-Val-Ala-Asp(OMe) in which the C-terminal OH group has been replaced by a fluoromethyl group. An irreversible pan-caspase inhibitor.	2.73	3	0	carbamate ester; organofluorine compound; tripeptide	apoptosis inhibitor; protease inhibitor
docosapentaenoic acid docosapentaenoic acid : Any straight-chain, C22 fatty acid having five C=C double bonds.. (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid : The all-cis-isomer of a C22 polyunsaturated fatty acid having five double bonds in the 7-, 10-, 13-, 16- and 19-positions.	2.01	1	0	docosapentaenoic acid; omega-3 fatty acid	algal metabolite; human metabolite
naltrindole naltrindole: delta opioid receptor antagonist	2.04	1	0	isoquinolines
bafilomycin a [no description available]	2.71	3	0
resiniferatoxin resiniferatoxin: phorbol related diterpene ester; potent agonist of vanilloid TRPV1 receptors. resiniferatoxin : A heteropentacyclic compound found in Euphorbia poissonii with molecular formula C37H40O9. It is an agonist of the transient receptor potential cation channel subfamily V member 1 (TrpV1).	2.67	3	0	carboxylic ester; diterpenoid; enone; monomethoxybenzene; organic heteropentacyclic compound; ortho ester; phenols; tertiary alpha-hydroxy ketone	analgesic; neurotoxin; plant metabolite; TRPV1 agonist
abscisic acid Abscisic Acid: Abscission-accelerating plant growth substance isolated from young cotton fruit, leaves of sycamore, birch, and other plants, and from potatoes, lemons, avocados, and other fruits.. (S)-2-trans-abscisic acid : A 2-trans-abscisic acid with (S)-configuration at the chiral centre.. (+)-abscisic acid : The naturally occurring (1'S)-(+) enantiomer of abscisic acid. It is an important sesquiterpenoid plant hormone which acts as a regulator of plant responses to environmental stresses such as drought and cold.	3.71	10	0	2-trans-abscisic acid
n-caproylsphingosine N-(hexanoyl)sphing-4-enine : An N-acylsphingosine consisting of sphing-4-enine bearing a hexanoyl group on nitrogen.	2.72	3	0	N-acylsphingosine
3,3'-dihexyl-2,2'-oxacarbocyanine 3,3'-dihexyl-2,2'-oxacarbocyanine: a fluorescent probe	2.11	1	0
carbocyanines Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.	2.96	4	0	cyanine dye; organic iodide salt	fluorochrome
syntide-2 syntide-2: amino acid sequence given in first source	2.42	2	0
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one: structure given in first source; potent irreversible, mechanism-based inhibitor of myocardial calcium-independent phospholipase A2	2.71	3	0	naphthalenes
st 638 [no description available]	2.9	4	0
ammonium sulfate Ammonium Sulfate: Sulfuric acid diammonium salt. It is used in CHEMICAL FRACTIONATION of proteins.. ammonium sulfate : An inorganic sulfate salt obtained by reaction of sulfuric acid with two equivalents of ammonia. A high-melting (decomposes above 280degreeC) white solid which is very soluble in water (70.6 g/100 g water at 0degreeC; 103.8 g/100 g water at 100degreeC), it is widely used as a fertilizer for alkaline soils.	2	1	0	ammonium salt; inorganic sulfate salt	fertilizer
c.i. fluorescent brightening agent 28 4,4'-bis({4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl}amino)stilbene-2,2'-disulfonic acid : An organosulfonic acid comprising stilbene having 4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl}amino groups at the 4 and 4'-positions and sulfo groups at the 2- and 2'-positions.	2.42	2	0
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid: An inhibitor of anion conductance including band 3-mediated anion transport.	5.2	15	0
12-o-retinoylphorbol-13-acetate [no description available]	2.05	1	0
menaquinone 9 menaquinone-9 : A menaquinone whose side-chain contains 9 isoprene units in an all-trans-configuration.	2.07	1	0	menaquinone	Escherichia coli metabolite
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	2	1	0	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
iodoresiniferatoxin iodoresiniferatoxin: a vanilloid receptor 1 antagonist	2.02	1	0
mastoparan [no description available]	3.48	8	0	mastoparans; peptidyl amide	antimicrobial agent
saralasin Saralasin: An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION.	1.99	1	0	oligopeptide
tetrodotoxin Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.	4.2	17	0	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker
jatrophone jatrophone: RN refers to (2R-(2R,3aR,9E,12Z))-isomer; structure	1.98	1	0	oxolanes
selenium Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.	2.02	1	0	chalcogen; nonmetal atom	micronutrient
tellurium Tellurium: An element that is a member of the chalcogen family. It has the atomic symbol Te, atomic number 52, and atomic weight 127.60. It has been used as a coloring agent and in the manufacture of electrical equipment. Exposure may cause nausea, vomiting, and CNS depression.	2.21	1	0	chalcogen; metalloid atom
diacetylmonoxime diacetylmonoxime: used diagnostically for determining urea in blood; structure; myosin ATPase antagonist. diacetylmonoxime : A ketoxime obtained via formal condensation of butane-2,3-dione with hydroxylamine. It is a reversible myosin ATPase inhibitor.	3.1	5	0
fk 409 FK 409: structure given in first source; from Streptomyces griseoporeus	2.05	1	0
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	3.81	11	0	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
antimycin a Antimycin A: An antibiotic substance produced by Streptomyces species. It inhibits mitochondrial respiration and may deplete cellular levels of ATP. Antimycin A1 has been used as a fungicide, insecticide, and miticide. (From Merck Index, 12th ed). antimycin A : A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison.	3.61	9	0	amidobenzoic acid
beta-aminopropionitrile fumarate beta-aminopropionitrile fumarate: RN given refers to unspecified fumarate	2.21	1	0
bongkrekic acid Bongkrekic Acid: An antibiotic produced by Pseudomonas cocovenenans. It is an inhibitor of MITOCHONDRIAL ADP, ATP TRANSLOCASES. Specifically, it blocks adenine nucleotide efflux from mitochondria by enhancing membrane binding.. bongkrekic acid : A tricarboxylic acid that is docosa-2,4,8,10,14,18,20-heptaenedioic acid substituted at positions 2 ,5 and 17 by methyl groups, at positions 6 by a methoxy group and at position 20 by a carboxymethyl group. It is produced by the bacterium Burkholderia gladioli and implicated in outbreaks of food-borne illness involving coconut and corn-based products in Indonesia and China.	3.26	6	0	ether; olefinic compound; tricarboxylic acid	apoptosis inhibitor; ATP/ADP translocase inhibitor; bacterial metabolite; EC 2.5.1.18 (glutathione transferase) inhibitor; toxin
ascofuranone ascofuranone: structure. ascofuranone : A dihydroxybenzaldehyde that is 2,4-dihydroxybenzaldehyde which is substituted by a (2E,6E)-7-[(2S)-5,5-dimethyl-4-oxotetrahydrofuran-2-yl]-3-methylocta-2,6-dien-1-yl group at position 3, chlorine at position 5, and a methyl group at position 6. A meroterpenoid produced by the soil fungus, Acremonium sclerotigenum. It is a promising drug candidate against the tropical disease, African trypanosomiasis.	3.08	1	0	dihydroxybenzaldehyde; meroterpenoid; monochlorobenzenes; olefinic compound; resorcinols; sesquiterpenoid; tetrahydrofuranone	angiogenesis inhibitor; antilipemic drug; antineoplastic agent; antiprotozoal drug; fungal metabolite
latrunculin b latrunculin B: 14-membered macrolide attached to 2-thiazolidinone moiety; from Red Sea sponge Latrunculia magnifica; see also latrunculin A; structure given in first source. latrunculin B : A macrolide consisting of a 14-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica.	2.41	2	0	cyclic hemiketal; macrolide; oxabicycloalkane; thiazolidinone	actin polymerisation inhibitor; metabolite; toxin
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	3.39	7	0	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
1-oleoyl-2-acetylglycerol [no description available]	4.98	39	0	1,2-diglyceride
involucrin involucrin: soluble precursor protein of cross-linked envelope characteristic of epidermal s. corneum synthesized by keratinocytes in natural & cultured human epithelia; see also related records for prekeratin & stratum corneum basic protein precursor	1.98	1	0
myxothiazol myxothiazol: strobilurin analogue; methoxyacrylamide derivative; antifungal antibiotic from Myxococcus fulvus; structure given in first source. myxothiazol : A 2,4'-bi-1,3-thiazole substituted at the 4-position with a (1E,3S,4R,5E)-7-amino-3,5-dimethoxy-4-methyl-7-oxohepta-1,5-dien-1-yl] group and at the 2'-position with a (2S,3E,5E)-7-methylocta-3,5-dien-2-yl group. It is an inhibitor of coenzyme Q - cytochrome c reductase.	2.01	1	0
12-o-tetradeca-2,4,6,8-tetranoylphorbol-13-acetate [no description available]	1.98	1	0
manoalide manoalide: phospholipase A2 inhibitor; sesterterpene from marine sponge L. variabilis; structure given in first source. manoalide : A sesterterpenoid isolated from the marine sponge Luffariella variabilis and which has been shown to exhibit inhibitory activity towards phospholipase A2.	2.9	4	0	butenolide; lactol; sesterterpenoid	EC 3.1.1.4 (phospholipase A2) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; metabolite
1,2-dioleoyloxy-3-(trimethylammonium)propane 1,2-dioleoyloxy-3-(trimethylammonium)propane: fluorescent probe for phospholipids; RN & structure given in first source	2.03	1	0
ly 53857 LY 53857: RN given refers to maleate[1:1](8beta)-isomer	2.02	1	0
sphingosine phosphorylcholine sphingosine phosphorylcholine: a wound healing agent	2.91	4	0
concanamycin a concanamycin A: from Streptomyces diastatochromogenes S-45; inhibits vacuolar H+ ATPase. concanamycin A : A concanamycin in which the lactone ring contains 4 double bonds and is substituted by 4 methyl groups, 2 hydroxy groups, 2 methoxy groups and an ethyl group.	2.01	1	0	carbamate ester; concanamycin	antifungal agent; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; metabolite
manumycin manumycin: an NSAID; RN given for (1S-(1alpha,3(2E,4E,6S*),5alpha,5(1E,3E,5E),6alpha))-isomer; a farnesyl protein transferase inhibitor; from Streptomyces parvulus; MF C31-H38-N2-O7; structure given in first source. manumycin A : A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties.	1.99	1	0	enamide; epoxide; organic heterobicyclic compound; polyketide; secondary carboxamide; tertiary alcohol	antiatherosclerotic agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; marine metabolite
s-farnesylcysteine S-farnesylcysteine: structural component of Saccharomyces cerevisiae mating hormone a-factor. S-[(2E,6E)-farnesyl]-L-cysteine : An S-farnesyl-L-cysteine where the C=C double bonds at the 2- and 6-positions both have (E)-configuration.	1.99	1	0	amino acid zwitterion; S-farnesyl-L-cysteine; S-polyprenyl-L-cysteine zwitterion
2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid 2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid: phospholipase A2 inhibitor	1.98	1	0
2,3,5,4'-tetrahydroxystilbene 2-o-glucopyranoside 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside: isolated from dried root tubers of Polygonum multiflorum; structure in first source	2.55	2	0
st 271 [no description available]	2.39	2	0
tei 3356 TEI 3356: a prostaglandin E receptor agonist; inhibits endothelin-induced DNA synthesis in cultured vascular smooth muscle cells; structure given in first source	2	1	0
n-(n-(7-nitro-2,1,3-benzoxadiazol-4-yl)-epsilon-aminohexanoyl)sphingosylphosphorylcholine [no description available]	1.99	1	0
krn 5500 KRN 5500: a derivative of spicamycin with a wide range of antitumor activity against human cancer cell lines; structure given in first source	3.09	1	0
picroside i picroside I: RN given for (1aS-(1aalpha,1bbeta,2beta(E),5abeta,6beta,6aalpha))-isomer; hepatoprotective agent; structure in first source	2.01	1	0
4-o-methylascochlorin 4-O-methylascochlorin: causes unusual concentration of urine & prevents polydipsia in DOCA hypertensive rats; structure given in first source	2.02	1	0
everolimus [no description available]	3.13	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
emerin emerin: a serine-rich protein; responsible for Emery-Dreifuss muscular dystrophy (EDMD)	7.44	2	0
laq824 LAQ824: Histone deacetylase inhibitor	2.02	1	0
ekb 569 EKB 569: an EGF receptor kinase inhibitor	2.04	1	0	aminoquinoline; monocarboxylic acid amide; monochlorobenzenes; nitrile	protein kinase inhibitor
u 75302 U 75302: RN refers to (R-(R,S-(E,Z)))-isomer; leukotriene B4 antagonist	2.02	1	0
trisialoganglioside gt1 [no description available]	1.99	1	0
zy 17617b CGS 9343B: calmodulin antagonist; structure given in first source; RN given refers to parent cpd	1.98	1	0
cx 614 2H,3H,6aH-pyrrolidino(2'',1''-3',2')1,3-oxazino(6',5'-5,4)benzo(e)1, 4-dioxan-10-one: an ampakine (AMPA receptor modulator); structure in first source	2.17	1	0
l 744832 L 744832: a CaaX peptidomimetic; a specific farnesyl-protein transferase inhibitor; structure given in first source. L-744,832 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 2-{[(2S,3S)-2-{[(2R)-2-amino-3-sulfanylpropyl]amino}-3-methylpentyl]oxy}-3-phenylpropanoic acid with the amino group of propan-2-yl (2S)-2-amino-4-(methylsulfonyl)butanoate. It is a farnesyltransferase inhibitor that exhibits anticancer properties.	2.43	2	0	benzenes; ether; isopropyl ester; secondary carboxamide; sulfone; thiol	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; geroprotector
beta-escin Escin: Pentacyclic triterpene saponins, biosynthesized from protoaescigenin and barringtogenol, occurring in the seeds of AESCULUS. It inhibits edema formation and decreases vascular fragility.	2.4	2	0	triterpenoid saponin
6-benzylthioinosine 6-benzylthioinosine: a subversive substrate of T gondii adenosine kinase; structure in first source	2.07	1	0
tanespimycin CP 127374: analog of herbimycin A	2.42	2	0	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
fm1 43 FM1 43: labels motor nerve terminals in an activity-dependent fashion that involves dye uptake by synaptic vesicles that are recycling; structure given in second source	3.38	7	0	organic bromide salt; pyridinium salt; quaternary ammonium salt; tertiary amine	fluorochrome
su 5614 SU 5614: inhibits the mast cell growth factor receptor known as kit protein; a tyrosine kinase inhibitor. SU5614 : A member of the class of oxindoles that is 5-chlorooxindole in which the two hydrogens at position 3 are replaced by a (3,5-dimethylpyrrol-2-yl)methylidene group.	2.95	4	0	organochlorine compound; oxindoles; pyrroles	vascular endothelial growth factor receptor antagonist
beta-escin [no description available]	3.39	7	0
l-165041 4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid: a PPAR-delta agonist has regulatory effects on a variety of adipokines, and these effects might explain some of their metabolic function.	2.06	1	0	aromatic ketone
s-nitroso-n-acetylpenicillamine S-Nitroso-N-Acetylpenicillamine: A sulfur-containing alkyl thionitrite that is one of the NITRIC OXIDE DONORS.	3.27	6	0	nitroso compound; nitrosothio compound	nitric oxide donor; vasodilator agent
lactacystin [no description available]	10.18	15	0	lactam; S-substituted L-cysteine
ca 074 methyl ester [no description available]	2.44	2	0
6 beta-hydroxycortisol 6 beta-hydroxycortisol: RN given refers to the (6beta,11beta)-isomer; see also record for 6 alpha-hydrocortisol. 6beta-hydroxycortisol : A C21-steroid that is cortisol bearing an additional hydroxy substituent at the 6beta-position. In humans, it is produced as a metabolite of cortisol by cytochrome p450-3A4 (CYP3A4, an important enzyme involved in the metabolism of a variety of exogenous and endogenous compounds) and can be used to detect moderate and potent CYP3A4 inhibition in vivo.	3.48	1	1	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; 6beta-hydroxy steroid; C21-steroid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mammalian metabolite; probe
gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)	2.52	2	0	gadolinium coordination entity	MRI contrast agent
ergoline Ergolines: A series of structurally-related alkaloids that contain the ergoline backbone structure.. ergoline : An indole alkaloid whose structural skeleton is found in many naturally occurring and synthetic ergolines which are known to bind to neurotransmitter receptors, such as dopamine, noradrenaline and serotonin receptors and function as unselective agonists or antagonists at these receptors.	2.68	3	0	diamine; ergoline alkaloid; indole alkaloid fundamental parent; indole alkaloid; organic heterotetracyclic compound
adenosine-3',5'-cyclic phosphorothioate adenosine-3',5'-cyclic phosphorothioate: RP-cAMP-S is a protein kinase A inhibitor; SP-cAMP-S is a protein kinase A agonist. (Sp)-cAMPS : A nucleoside 3',5'-cyclic phosphorothioate having adenine as the nucleobase (the Sp-stereoisomer).. (Rp)-cAMPS : A nucleoside 3',5'-cyclic phosphorothioate having adenine as the nucleobase (the Rp-stereoisomer).	4.39	21	0	nucleoside 3',5'-cyclic phosphorothioate
sq-23377 Ionomycin: A divalent calcium ionophore that is widely used as a tool to investigate the role of intracellular calcium in cellular processes.. ionomycin : A very long-chain fatty acid that is docosa-10,16-dienoic acid which is substituted by methyl groups at positions 4, 6, 8, 12, 14, 18 and 20, by hydroxy groups at positions 11, 19 and 21, and by a (2',5-dimethyloctahydro-2,2'-bifuran-5-yl)ethanol group at position 21. An ionophore produced by Streptomyces conglobatus, it is used in research to raise the intracellular level of Ca(2+) and as a research tool to understand Ca(2+) transport across biological membranes.	5.54	69	0	cyclic ether; enol; polyunsaturated fatty acid; very long-chain fatty acid	calcium ionophore; metabolite
fostriecin fostriecin: compound contains a conjugated triene and an unsaturated lactone; from Streptomyces pulveraceus; structure given in second source. fostriecin : A structurally unique, naturally-occurring phosphate monoester isolated from the soil bacterium Streptomyces pulveraceus. It inhibits DNA topoisomerase II as well as several protein phosphatase including PP2A and PPA4, and exhibits potent antitumor activity against several cancer cell lines.	2.68	3	0	2-pyranones; olefinic compound; phosphate monoester; polyketide; primary allylic alcohol; secondary allylic alcohol; triol	antineoplastic agent; apoptosis inhibitor; bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; topoisomerase II inhibitor
enkephalin, leucine-2-alanine Enkephalin, Leucine-2-Alanine: A delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.	2.41	2	0
montirelin montirelin: structure given in first source	2.05	1	0	oligopeptide
morpholinoanthracycline mx2 morpholinoanthracycline MX2: structure given in first source	1.99	1	0
etoposide phosphate [no description available]	2.03	1	0	furonaphthodioxole
dexniguldipine niguldipine: structure given in first source; clinical modulator of multidrug resistance	1.99	1	0	diarylmethane
perfosfamide [no description available]	3.1	5	0
pki 166 [no description available]	2.02	1	0
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	3.28	6	0	aminobenzoic acid
isavuconazole isavuconazole : A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis.	2.21	1	0	1,3-thiazoles; conazole antifungal drug; difluorobenzene; nitrile; tertiary alcohol; triazole antifungal drug	EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; ergosterol biosynthesis inhibitor; orphan drug
panobinostat Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.	2.52	2	0	cinnamamides; hydroxamic acid; methylindole; secondary amino compound	angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
bromopyruvate [no description available]	2.1	1	0	2-oxo monocarboxylic acid anion
bufalin bufalin: cardiotonic; powerful anesthetic & one of the active constituents of the Chinese drug ch'an su(senso); in Japan prepared from skin of Bufo bufo garfarizans; RN given refers to (3beta,5beta)-isomer. bufalin : A 14beta-hydroxy steroid that is bufan-20,22-dienolide having hydroxy substituents at the 5beta- and 14beta-positions. It has been isolated from the skin of the toad Bufo bufo.	2.05	1	0	14beta-hydroxy steroid; 3beta-hydroxy steroid	animal metabolite; anti-inflammatory agent; antineoplastic agent; cardiotonic drug
hypericum Hypericum: Genus of perennial plants in the family CLUSIACEAE (sometimes classified as Hypericaceae). Herbal and homeopathic preparations are used for depression, neuralgias, and a variety of other conditions. Hypericum contains flavonoids; GLYCOSIDES; mucilage, TANNINS; volatile oils (OILS, ESSENTIAL), hypericin and hyperforin.. 6-formamidopenicillanic acid : A penicillanic acid having a (6R)-formamido substituent.	2.01	1	0	penicillanic acids
formazans Formazans: Colored azo compounds formed by the reduction of tetrazolium salts. Employing this reaction, oxidoreductase activity can be determined quantitatively in tissue sections by allowing the enzymes to act on their specific substrates in the presence of tetrazolium salts.	2.44	2	0
3-aminopyridine-2-carboxaldehyde thiosemicarbazone 3-aminopyridine-2-carboxaldehyde thiosemicarbazone: a neuroprotective agent; structure given in first source	2.02	1	0
s-nitrosocysteine S-nitrosocysteine: A sulfur-containing alkyl thionitrite that is a nitric oxide donor.. S-nitroso-L-cysteine : An L-cysteine derivative in which the sulfur atom carries a nitroso substituent. A cell-permeable low-molecular-weight nitrosothiol and nitric oxide donor.	2.4	2	0	L-cysteine derivative; nitrosothio compound	hematologic agent; platelet aggregation inhibitor; vasodilator agent
plitidepsin plitidepsin: a cyclodepsipeptide isolated from Aplidium albicans; has a pyruvoyl-proline residue instead of the lactyl-proline residue found in the linear peptide moiety of didemnin B. plitidepsin : A didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans.	3.18	1	0	didemnin	anticoronaviral agent; antineoplastic agent; marine metabolite
variolin b variolin B: from Antartic sponge, Kirkpatrickia variolosa; structure in first source	3.18	1	0
euk-134 EUK-134: antioxidant; structure in first source	2	1	0
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	20.73	435	40	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
dmp 728 DMP 728: structure in first source; RN given refers to the monomethane sulfate	1.99	1	0
jasplakinolide jasplakinolide: cyclodepsipeptide isolated from marine sponge Jaspis; active against Candida; RN refers to 2S-(2R,4E,6S,8R*)-isomer; structure in first source. jaspamide : A cyclodepsipeptide isolated from Jaspis splendens and has been shown to exhibit antineoplastic activity. It is an actin polymerization and stabilization inducer.	4.05	4	0	cyclodepsipeptide; phenols	actin polymerisation inducer; animal metabolite; antifungal agent; antineoplastic agent; apoptosis inducer; marine metabolite; neuroprotective agent
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	4.06	15	0	oligopeptide
vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(o- methyl-l-tyrosine)-8-l-arginine- vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-: highly potent antagonist of vasopressor response to arginine-vasopressin; structure in first source	2	1	0
pd 150606 PD 150606: a calpain inhibitor; structure given in first source. (Z)-3-(4-iodophenyl)-2-mercaptoacrylic acid : An organoiodine compound that is acrylic acid in which the vinylic hydrogens at positions 2 and 3 are replaced by mercapto and 4-iodophenyl groups respectively (the Z geoisomer).	2.04	1	0	cinnamic acids; organoiodine compound; thioenol	apoptosis inhibitor; calpain inhibitor
etomoxir [no description available]	2.04	1	0	aromatic ether
n(6)-cyclohexyladenosine N(6)-cyclohexyladenosine: structure given in first source; receptors, purinergic P1 agonist	2.03	1	0
muromonab-cd3 xestospongin C: was indexed to xestospongin A; from Xestospongia sponge; empties the ER calcium store but does not inhibit InsP3-induced Ca2+ release. xestospongin C : An organic heteropentacyclic compound that is isolated from the marine sponge Xestospongia exigua.	2.21	1	0	alkaloid; macrocycle; organic heteropentacyclic compound; organonitrogen heterocyclic compound; oxacycle; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; IP3 receptor antagonist; marine metabolite
ursodoxicoltaurine tauroursodeoxycholate : An organosulfonate oxoanion that is the conjugate base of tauroursodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. tauroursodeoxycholic acid : A bile acid taurine conjugate derived from ursoodeoxycholic acid.	2.44	2	0	bile acid taurine conjugate	anti-inflammatory agent; apoptosis inhibitor; bone density conservation agent; cardioprotective agent; human metabolite; neuroprotective agent
l 163491 L 163491: structure given in first source	1.98	1	0
flag peptide FLAG peptide: engineered as a tag for immunoaffinity purification of genetically-engineered proteins; amino acid sequence given in first source; a polar octapeptide. FLAG peptide : An eight amino acid peptide consisting of L-aspartic acid, L-tyrosine, L-lysine, four L-aspartic acid residues, and L-lysine joined in sequence by peptide linkages. It is widely used as a fusion tag for the purification and detection of a wide variety of recombinant proteins.	2	1	0	peptide
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.92	4	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
alloin alloin: isolated from various species of aloe; structure	2.08	1	0	diastereoisomeric mixture	EC 1.14.18.1 (tyrosinase) inhibitor; laxative
17-hydroxywortmannin 17-hydroxywortmannin: inhibits secretion of human neutrophils	1.98	1	0
carbobenzoxy-leucyl-leucyl-norvalinal carbobenzoxy-leucyl-leucyl-norvalinal: structure given in first source	2.03	1	0	peptide
yf 476 YF 476: gastrin and CCK-B receptor antagonist; structure in first source	2.03	1	0
1,3-bis(bis(pyridin-2-ylmethyl)amino)propan-2-ol 1,3-bis(bis(pyridin-2-ylmethyl)amino)propan-2-ol: structure in first source	2.05	1	0
lipid a Lipid A: Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.. lipid A : The glycolipid moiety of bacterial lipopolysaccharide (R can be either hydrogen or a fatty acyl group).	7.91	4	0	dodecanoate ester; lipid A; tetradecanoate ester	Escherichia coli metabolite
ro 31-9790 Ro 31-9790: hydroxamic acid derivative	2	1	0
nb 506 NB 506: an indolocarbazole antitumor agent; structure given in first source; a DNA topoisomerase I inhibitor	3.5	2	0
hypothemycin hypothemycin: a resorcylic acid lactone antibiotic; antifungal metabolite from Hypomyces trichothecoides. hypothemycin : A macrolide that is isolated from the cultured broth of Hypomyces subiculosus and shows antifungal activity and inhibits the growth of some human cancer cells.	2.21	1	0	aromatic ether; diol; enone; epoxide; macrolide; phenols; polyketide; secondary alpha-hydroxy ketone	antifungal agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; fungal metabolite
tocotrienols tocotrienol : A tocol in which the hydrocarbon chain at position 2 contains three double bonds.	2.02	1	0	diterpenoid
cediranib [no description available]	3.16	1	0	aromatic ether
eht 1864 [no description available]	2.31	1	0
neuromedin n neuromedin N: peptide from porcine spinal cord with amino acid sequence homologous to COOH-terminal sequence of neurotensin	6.97	1	0
vosaroxin vosaroxin: has antineoplastic activity; vosaroxin was formerly voreloxin; structure in first source	3.18	1	0
u 18666a 3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one: inhibits cycloartenol synthase. 3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride : A hydrochloride obtained by reaction of 3beta-(2-diethylaminoethoxy)androst-5-en-17-one with one equivalent of hydrochloric acid. It is a cholesterol synthesis and transport inhibitor.	2.48	2	0	hydrochloride	antiviral agent; EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor; Hedgehog signaling pathway inhibitor; nicotinic antagonist; sterol biosynthesis inhibitor
cgp 55845a CGP 55845A: GABA-B receptor antagonist; RN refers to cpd with no isomeric designation; CGP 55845 is the (1S,2S)-isomer	2.02	1	0
g(m1) ganglioside G(M1) Ganglioside: A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis.. ganglioside GM1 : A sialotetraosylceramide consisting of a branched pentasaccharide made up from one sialyl residue, two galactose residues, one N-acetylgalactosamine residue and a glucose residue at the reducing end attached to N-stearoylsphingosine via a beta-linkage.	2.68	3	0	alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine; sialotetraosylceramide
osu 03012 OSU 03012: a PDK-1 inhibitor; structure in first source	2.48	2	0	antibiotic antifungal drug; aromatic amide; glycine derivative; organofluorine compound; phenanthrenes; pyrazoles	antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
ly 389795 LY 389795: a group II metabotropic glutamate receptor agonist; structure in first source	2	1	0
masitinib [no description available]	3.89	3	0	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor
bx795 BX795: structure in first source	2.15	1	0	ureas
fmrfamide FMRFamide: A molluscan neuroactive peptide which induces a fast excitatory depolarizing response due to direct activation of amiloride-sensitive SODIUM CHANNELS. (From Nature 1995; 378(6558): 730-3)	1.99	1	0
cystathionine Cystathionine: Sulfur-containing amino acid formed as an intermediate in the conversion of METHIONINE to CYSTEINE.. cystathionine : A modified amino acid generated by enzymic means from homocysteine and serine.	2	1	0	cysteine derivative
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	2.07	1	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
azd 6244 AZD 6244: a MEK inhibitor	2.07	1	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ly 379268 LY 379268: group II metabotropic glutamate receptor agonist; structure in first source. LY 379268 : An organic heterobicyclic compound that is (1R,5S)-2-oxabicyclo[3.1.0]hexane carrying amino, carboxy, and carboxy groups at positions 4R, 4R and 6R, respectively. It is a potent agonist of group II metabotropic glutamate receptors mGluR2 and mGluR3 (EC50 = 2.69 nM and 4.48 nM, respectively) that exhibits antipsychotic-like action in animal models of schizophrenia.	2	1	0	amino dicarboxylic acid; bridged compound; organic heterobicyclic compound	antipsychotic agent; anxiolytic drug; metabotropic glutamate receptor agonist; neuroprotective agent
aee 788 AEE 788: structure in first source	3.66	3	0	6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist; trypanocidal drug
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	3.54	8	0
7-aminoactinomycin d 7-aminoactinomycin D: staining reagent used in flow cytometry	2.43	2	0
crenolanib [no description available]	5.24	5	0	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.95	4	0
4'-demethylamino-4'-hydroxystaurosporine 4'-demethylamino-4'-hydroxystaurosporine: structure given in first source; produced by Streptomyces sp. RK-286	2.89	4	0
olivose olivose: RN given for (D)-isomer	2.02	1	0	hexose
ucn 1028 c calphostin C: structure given in first source; isolated from Cladosporium cladosporioides	8.08	175	0
ribose ribopyranose : The pyranose form of ribose.	2.4	2	0	D-ribose; ribopyranose
acebutolol alpha-D-glucosyl-(1->4)-alpha-D-mannose : An alpha-D-glucosyl-(1->4)-D-mannopyranose in which the anomeric hydroxy group has alpha configuration.	2.05	1	0	alpha-D-glucosyl-(1->4)-D-mannopyranose
lactulose Lactulose: A synthetic disaccharide used in the treatment of constipation and hepatic encephalopathy. It has also been used in the diagnosis of gastrointestinal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p887). lactulose : A synthetic galactosylfructose disaccharide used in the treatment of constipation and hepatic encephalopathy.	2	1	0
palytoxin palytoxin: coelenterate toxin; composed of substituted N-3-hydroxypropyl-trans-3-amidoacrylamides. palytoxin : A polyol marine coelenterate toxin composed of substituted N-3-hydroxypropyl-trans-3-amidoacrylamides and produced by species of Palythoa and Zoanthus soft corals (collectively called zoantharians), either as a defence mechanism or to assist them in capturing prey. An ionophore that forms cation channels through Na+/K+-ATPase, it is a potent vasoconstrictor useful in evaluation of anti-angina agents. It is considered to be one of the most poisonous non-protein substances known, second only to maitotoxin in terms of toxicity in mice.	1.97	1	0	polyol	toxin
15-methoxypinusolidic acid 15-methoxypinusolidic acid: structure in first source	7.03	1	0
regorafenib [no description available]	2.15	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
abt-737 [no description available]	2.79	3	0	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
brimonidine tartrate Brimonidine Tartrate: A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.	2.4	2	0
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	2.39	2	0	nystatins
bi 2536 [no description available]	2.25	1	0
inno-406 [no description available]	2.41	1	0	biaryl
nvp-ast487 NVP-AST487: antineoplastic; a RET kinase inhibitor that blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells	2.04	1	0
kw 2449 KW 2449: has both multikinase inhibitory activity and antineoplastic activity; structure in first source	3.85	3	0
nutlin-3a nutlin 3: an MDM2 antagonist; structure in first source	3.36	2	0	stilbenoid
nvp-aew541 [no description available]	2.07	1	0
lbw242 LBW242: proapoptotic IAP inhibitor; low MW Smac (Second mitochondria-derived activator of caspases) mimetic; structure in first source	2.03	1	0
ro 31-8425 Ro 31-8425: structure given in first source	2.9	4	0
talaumidin talaumidin: a neolignan from Aristolochia arcuata; structure in first source	7.17	1	0
veratridine Veratridine: A benzoate-cevane found in VERATRUM and Schoenocaulon. It activates SODIUM CHANNELS to stay open longer than normal.	4.01	5	0
tak 285 N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide: also inhibits HER2; structure in first source	2.13	1	0
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	2.11	1	0	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	2.1	1	0	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
liphagal liphagal: selective inhibitor of PI3 kinase alpha isolated from the sponge akacoralliphaga; structure in first source. liphagal : A meroterpenoid isolated from the marine sponge Aka coralliphaga and has been shown to exhibit inhibitory activity against phosphatidylinositol-3-OH kinase.	3.18	1	0	aldehyde; cyclic ether; meroterpenoid; organic heterotetracyclic compound; polyphenol	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; metabolite
n,n'-dibenzhydrylethane-1,2-diamine dihydrochloride N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride: selective metabotropic glutamate receptor 7 agonist; structure in first source. AMN082 dihydrochloride : A hydrochloride obtained by combining N,N'-bis(diphenylmethyl)ethane-1,2-diamine with two molar equivalent of hydrochloric acid.	2.55	2	0	hydrochloride	geroprotector; metabotropic glutamate receptor agonist; neuroprotective agent
trametinib [no description available]	2.59	2	0	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
sauchinone sauchinone: isolated from Saururus chinensis; structure in first source	7.01	1	0
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	4.35	20	0
palmitoylcarnitine Palmitoylcarnitine: A long-chain fatty acid ester of carnitine which facilitates the transfer of long-chain fatty acids from cytoplasm into mitochondria during the oxidation of fatty acids.. O-palmitoyl-L-carnitine : An O-acyl-L-carnitine in which the acyl group is specified as palmitoyl (hexadecanoyl).	3.24	6	0	O-palmitoylcarnitine; saturated fatty acyl-L-carnitine	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; human metabolite; mouse metabolite
calcimycin Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.	7.18	144	0	benzoxazole
veliparib [no description available]	2.06	1	0	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
sepharose agarose : A linear polysaccharide made up from alternating D-galactose and 3,6-anhydro-alpha-L-galactopyranose residues joined by alpha-(1->3)- and beta-(1->4)-linkages.	2.42	2	0
pituitrin Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).	4.28	19	0
24-hydroxycholesterol 24-hydroxycholesterol : An oxysterol that is cholesterol which is substituted by a hydroxy group at position 24.	7.07	1	0	24-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol
arenobufagin arenobufagin: structure given in first source	2.11	1	0	steroid lactone
dihydrotachysterol Dihydrotachysterol: A VITAMIN D that can be regarded as a reduction product of vitamin D2.. dihydrotachysterol : A hydroxy seco-steroid that is 9,10-secoergosta-5,7,22-triene substituted by a hydroxy group at position 3. A synthetic analogue of vitamin D that acts a bone density conservation agent.	2.4	2	0
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	3.08	5	0
erythrosine Erythrosine: A tetraiodofluorescein used as a red coloring in some foods (cherries, fish), as a disclosure of DENTAL PLAQUE, and as a stain of some cell types. It has structural similarity to THYROXINE.. erythrosin B : An organic sodium salt that is the disodium salt of 2-(2,4,5,7-tetraiodo-6-oxido-3-oxo-8a,10a-dihydroxanthen-9-yl)benzoic acid.	2	1	0
kamebakaurin kamebakaurin: isolated from leaves and stems of Radbosia serra (Maxim) Hara; structure given in first source	2.43	2	0
yessotoxin yessotoxin: produced by dinoflagellates and accumulated in invertebrates (e.g., Patinopecten gessoensis also known as YESSO SCALLOP) that feed on them. RN given refers to parent compound	2.06	1	0	ciguatoxin
nodularin nodularin: cyclic pentapeptide toxin from NODULARIA SPUMIGENA	2.05	1	0	ether
kt 5926 KT 5926: indolocarbazole; structure given in first source. KT 5926 : An organic heterooctacyclic compound that is 5-propoxy-1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of methyl (3R)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2S,3R,5R product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.	3.69	10	0	gamma-lactam; hemiaminal; indolocarbazole; methyl ester; organic heterooctacyclic compound; tertiary alcohol	EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
icatibant icatibant: a potent bradykinin (B2) receptor antagonist; WIN 65365 is an L-Tic(7) stereoisomer. icatibant : A ten-membered synthetic oligopeptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequrence. A bradykinin receptor antagonist used as its acetate salt for the treatment of acute attacks of hereditary angioedema in adult patients.	2	1	0
hmr 1098 HMR 1098: KATP channel blocker; structure in first source	2.01	1	0
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.	3.88	12	0	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
n-(6-(biotinamido)hexyl)-3'-(2'-pyridyldithio)propionamide N-(6-(biotinamido)hexyl)-3'-(2'-pyridyldithio)propionamide: structure in first source	2.06	1	0
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	6.09	115	0
gw 4869 GW 4869: inhibits neutral sphingomyelinase; structure in first source	2.03	1	0
cosyntropin Cosyntropin: A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of ADRENOCORTICOTROPIC HORMONE. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of CORTICOSTEROIDS in the ADRENAL CORTEX.. cosyntropin : A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of adrenocorticotropic hormone (corticotropin). A segment similar in all species, it contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. It is used diagnostically to investigate adrenocortical insufficiency.	2.4	2	0
melitten Melitten: Basic polypeptide from the venom of the honey bee (Apis mellifera). It contains 26 amino acids, has cytolytic properties, causes contracture of muscle, releases histamine, and disrupts surface tension, probably due to lysis of cell and mitochondrial membranes.	2.9	4	0
cholecystokinin Cholecystokinin: A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.	9.06	15	0
ceruletide Ceruletide: A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.. ceruletide : A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction.	2.38	2	0	oligopeptide	diagnostic agent; gastrointestinal drug
motilin Motilin: A peptide of about 22-amino acids isolated from the DUODENUM. At low pH it inhibits gastric motor activity, whereas at high pH it has a stimulating effect.	2.21	1	0
dynorphins Dynorphins: A class of opioid peptides including dynorphin A, dynorphin B, and smaller fragments of these peptides. Dynorphins prefer kappa-opioid receptors (RECEPTORS, OPIOID, KAPPA) and have been shown to play a role as central nervous system transmitters.	2.68	3	0
atrial natriuretic factor Atrial Natriuretic Factor: A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS.	5.39	23	0	polypeptide
iturelix iturelix: a gonadotropin-releasing hormone antagonist	2.05	1	0
endothelin 1, ala(1,3,11,15)- endothelin 1, Ala(1,3,11,15)-: alanyl residues substituted for cysteinyl in endothelin-1; RN given refers to (all-L)-isomer; has been used as a radioligand, highly selective for ET(B) receptor	2.04	1	0
thrombin receptor peptide (42-55) thrombin receptor peptide (42-55): tethered ligand exposed by cleavage of platelet thrombin receptor by thrombin, activates platelets and induces platelet activation; amino acid sequence given in first source; do not confuse with other TRAP (CD40L, MtrB, TRAP protocol, or thrombospondin related anonymous protein)	2.9	4	0
humanin humanin: suppresses neuronal cell death induced by the Swedish mutant of amyloid precursor protein; suppresses neuronal cell death induced by three different types of FAD genes and amyloid beta; amino acid sequence in first source	2.05	1	0
nociceptin [no description available]	2	1	0	organic molecular entity; polypeptide	human metabolite; rat metabolite
alamethicin Alamethicin: A cyclic nonadecapeptide antibiotic that can act as an ionophore and is produced by strains of Trichoderma viride. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	2.02	1	0
protein kinase inhibitor peptide protein kinase inhibitor peptide: 18 amino acid residues given in first source; corresponds to the inhibitory domain of the heat-stable protein kinase inhibitor	1.98	1	0
omega-conotoxin (conus magus) Conus magus toxin: from marine mollusk Conus magus; 25-27 amino acid peptide; MW 3 kDa	2.67	3	0
glucagon-like peptide 1 (7-36)amide glucagon-like peptide 1 (7-36)amide: potent stimulator of insulin released in perfused mammalian pancreas	1.97	1	0
gastrins Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.	2.69	3	0
gramicidin a Gramicidin: A group of peptide antibiotics from BACILLUS brevis. Gramicidin C or S is a cyclic, ten-amino acid polypeptide and gramicidins A, B, D are linear. Gramicidin is one of the two principal components of TYROTHRICIN.	2.93	4	0
glucagon Glucagon: A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511). glucagon : A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.	3.77	11	0	peptide hormone
beta-endorphin beta-Endorphin: A 31-amino acid peptide that is the C-terminal fragment of BETA-LIPOTROPIN. It acts on OPIOID RECEPTORS and is an analgesic. Its first four amino acids at the N-terminal are identical to the tetrapeptide sequence of METHIONINE ENKEPHALIN and LEUCINE ENKEPHALIN.. beta-endorphin : A polypeptide consisting of 31 amino acid residues in the sequence Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu. It is an endogenous opioid peptide neurotransmitter found in the neurons of both the central and peripheral nervous system and results from processing of the precursor protein proopiomelanocortin (POMC).	2.38	2	0
sauvagine sauvagine: isolated from skin of South American hylid frog, Phyllomedusa sauvagei; has hypotensive & antidiuretic effect; potent stimulating action on secretion of ACTH & corticosterone; inhibitory effect on secretion of PRL, GH, & TSH; consists of straight chain of 40 amino acid residues	2.02	1	0
thymosin beta(4) thymosin beta(4): biological active peptide present in thymosin fractions 5 & 5A; participates in the regulation, differentiation & function of thymus-derived lymphocytes & may also act directly or indirectly on macrophages & other cells involved in cell-mediated immunity	2.03	1	0
neuropeptide y Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.	8.5	8	0
conotoxin gv conotoxin GV: NMDA antagonist from Conus geographus	2.42	2	0
peptide phi Peptide PHI: A 27-amino acid peptide with histidine at the N-terminal and isoleucine amide at the C-terminal. The exact amino acid composition of the peptide is species dependent. The peptide is secreted in the intestine, but is found in the nervous system, many organs, and in the majority of peripheral tissues. It has a wide range of biological actions, affecting the cardiovascular, gastrointestinal, respiratory, and central nervous systems.	1.97	1	0
pancreastatin pancreastatin: A 49 residue post-translational fragment of chromogranin A that inhibits insulin secretion; amino acid sequence given in first source; the 49-amino acid peptide is from pig; human pancreastatin has 52 amino acids (hCgA 250-310) ; see also record for human pancreastatin	2	1	0
s6c sarafotoxin sarafotoxins s6: several isotoxins from Atractaspis engaddensis; has strong cardiotoxic activity; all contain 21 amino acid residues; see also endothelium-derived vasoconstrictor factor	2.41	2	0
iberiotoxin [no description available]	2.42	2	0
angiotensinogen Angiotensinogen: An alpha-globulin of about 453 amino acids, depending on the species. It is produced by the liver in response to lowered blood pressure and secreted into blood circulation. Angiotensinogen is the inactive precursor of the ANGIOTENSINS produced in the body by successive enzyme cleavages. Cleavage of angiotensinogen by RENIN yields the decapeptide ANGIOTENSIN I. Further cleavage of angiotensin I (by ANGIOTENSIN CONVERTING ENZYME) yields the potent vasoconstrictor octapeptide ANGIOTENSIN II; and then, via other enzymes, other angiotensins also involved in the hemodynamic-regulating RENIN-ANGIOTENSIN SYSTEM.	1.98	1	0
bq 3020 [no description available]	1.99	1	0
tannins Tannins: Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). The two main types are HYDROLYZABLE TANNINS and CONDENSED TANNINS. Historically, the term has applied to many compounds and plant extracts able to render skin COLLAGEN impervious to degradation. The word tannin derives from the Celtic word for OAK TREE which was used for leather processing.	3.1	1	0
oligonucleotides [no description available]	5.12	8	0
complestatin complestatin: compound extracted from Streptomyces lavendulae mycelia; on acid hydrolysis yields D-4-hydroxyphenylglycine & D-3,5-dichloro-4-hydroxyphenylglycine & acidic chromophore; inhibits gp120-CD4 binding. isocomplestatin : A heterodetic cyclic peptide which is a atropisomer of complestatin. It is isolated from the culture broth of Streptomyces and has anti-HIV-1 activity.. chloropeptin II : A heterodetic cyclic peptide consisting of N-acylated trytophan, 3,5-dichloro-4-hydroxyphenylglycine, 4-hydroxyphenylglycine, 3,5-dichloro-4-hydroxyphenylglycyl, tyrosine and 4-hydroxyphenylglycine residues joined in sequence and in which the side-chain of the central 4-hydroxyphenylglycine residue is attached to the side-chain of the tryptophan via a C3-C6 bond and to the side-chain of the tyrosine via an ether bond from C5. It is isolated from the culture broth of Streptomyces and has anti-HIV-1 activity.	2.01	1	0	cyclic ether; heterodetic cyclic peptide; indoles; organic heterobicyclic compound; organochlorine compound; peptide antibiotic; polyphenol	anti-HIV-1 agent; antimicrobial agent; HIV-1 integrase inhibitor; metabolite
glucagon-like peptide 1 Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.	3.63	9	0
incretins Incretins: Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially.	2.47	2	0
natriuretic peptide, c-type Natriuretic Peptide, C-Type: A PEPTIDE of 22 amino acids, derived mainly from cells of VASCULAR ENDOTHELIUM. It is also found in the BRAIN, major endocrine glands, and other tissues. It shares structural homology with ATRIAL NATRIURETIC FACTOR. It has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. Several high molecular weight forms containing the 22 amino acids have been identified.	2.91	4	0
ristocetin Ristocetin: An antibiotic mixture of two components, A and B, obtained from Nocardia lurida (or the same substance produced by any other means). It is no longer used clinically because of its toxicity. It causes platelet agglutination and blood coagulation and is used to assay those functions in vitro.. ristocetin : A heterodetic cyclic peptide that is produced by species of Amycolatopsis and Nocardia.	1.98	1	0	glycopeptide; heterodetic cyclic peptide; macrocycle; tetrasaccharide derivative	antibacterial drug; antimicrobial agent; bacterial metabolite; platelet-activating factor receptor agonist
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	4.64	27	0
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	4.82	33	0	1,2-diacyl-sn-glycero-3-phosphocholine
atractyloside Atractyloside: A glycoside of a kaurene type diterpene that is found in some plants including Atractylis gummifera (ATRACTYLIS); COFFEE; XANTHIUM, and CALLILEPIS. Toxicity is due to inhibition of ADENINE NUCLEOTIDE TRANSLOCASE.	2.4	2	0
n-(7-(4-nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine N-(7-(4-nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine: fluorescent ceramide analog; structure given in first source. N-{6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoyl}sphingosine : An N-acylsphingosine that is sphingosine with the amino nitrogen converted into a 6-{[N-(7-nitrobenzo-2,1,3-oxadiazol-4-yl)amino]}hexananamido group.	1.99	1	0	N-acylsphingosine	fluorescent probe
mk-8776 MK-8776: a checkpoint kinase 1 (CHK1) inhibitor; SCH900776 was renamed MK-8776; structure in first source	2.07	1	0	pyrazolopyrimidine
chlorophyll a Chlorophyll: Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.. chlorophyll : A family of magnesium porphyrins, defined by the presence of a fifth ring beyond the four pyrrole-like rings. The rings can have various side chains which usually include a long phytol chain.	2.69	3	0	chlorophyll; methyl ester	cofactor
thimerosal Thimerosal: An ethylmercury-sulfidobenzoate that has been used as a preservative in VACCINES; ANTIVENINS; and OINTMENTS. It was formerly used as a topical antiseptic. It degrades to ethylmercury and thiosalicylate.. thimerosal : An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent.	2	1	0	alkylmercury compound	antifungal drug; antiseptic drug; disinfectant; drug allergen
azd5438 [no description available]	2.1	1	0	sulfonamide
dihydroceramide dihydroceramide: lacks the 4-5 trans double bond of the sphingosine moiety of ceramides; structure in first source. N-acylsphinganine : A ceramide consisting of sphinganine in which one of the amino hydrogens is substituted by a fatty acyl group.. dihydroceramide : An N-acylsphingoid obtained by formal condensation of the carboxy group of any fatty acid with the amino group of any dihydrosphingoid base.	2	1	0
nsc 23766 NSC 23766 trihydrochloride : A hydrochloride resulting from the formal reaction of NSC 23766 with 3 mol eq. of hydrogen chloride. An inhibitor of the signalling G-protein known as RAC1 (Ras-related C3 botulinum toxin substrate 1).. Rac1 inhibitor : Any inhibitor of Rac1.	2.46	2	0	hydrochloride	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist
hoe 33342 bisbenzimide ethoxide trihydrochloride: benzimidazole fluorescent dye	3.96	13	0
sodium salicylate [no description available]	2	1	0	organic molecular entity
sphingosine kinase [no description available]	4.73	9	0
ubiquinone Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.	4.02	4	0
ono ae 248 ONO AE 248: structure in first source	2.02	1	0
dinophysistoxin 1 dinophysistoxin 1: from toxic dinoflagellate Dinophysis fortii; RN given for (35R)-isomer; structure given in first source. dinophysistoxin 1 : A ketal that is a marine toxin structurally related to okadaic acid. Produced by dinoflagellates it is known to accumulate in shellfish and cause diarrhoeic shellfish poisoning. It is an inhibitor of serine/threonine protein phosphatases 1 (PP1) and PP2A and has been shown to promote cancer cell growth in tumour cell lines and animal models.	1.98	1	0	ketal	animal metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; marine metabolite; toxin
calpain Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.	4.83	32	0
lucifer yellow lucifer yellow: RN given refers to di-Li salt	2.4	2	0	organic lithium salt	fluorochrome
pyrazolopyridine pyrazolopyridine: act as competitive antagonists of brain adenosine A1 receptors	3.25	1	0
chitosan [no description available]	2.8	3	0
technetium tc 99m sestamibi Technetium Tc 99m Sestamibi: A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack.	2.02	1	0
2-fluoro-araatp [no description available]	2	1	0
9-(tetrahydro-2-furyl)-adenine [no description available]	2.69	3	0
s-nitro-n-acetylpenicillamine S-nitro-N-acetylpenicillamine: a NO donor	3.62	9	0
bucladesine Bucladesine: A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed). bucladesine : A 3',5'-cyclic purine nucleotide that is the 2'-butanoate ester and 6-N-butanoyl derivative of 3',5'-cyclic AMP.	5.85	95	0	3',5'-cyclic purine nucleotide
sarkosyl sarkosyl: RN given is for sarkosyl L, the parent cpd; structure	1.98	1	0
xk 469 XK 469: structure in first source	2	1	0
merocyanine dye merocyanine dye: fluorescent dye used for studying axons 2 position on pyrimidine ring may be S or O; RN given refers to Na salt; structure	2	1	0
arginine Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.. teniposide : A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.	2.39	2	0
borrelidin treponemycin: isolated from Streptomyces albovinaceous; active against Treponema hyodysenteriae. borrelidin : A macrolide that is isolated from several Streptomyces species and displays antibiotic, antineoplastic and antimalarial properties.	2.15	1	0	aliphatic nitrile; diol; macrolide; monocarboxylic acid; secondary alcohol	antifungal agent; antimalarial; antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite
echinomycin Echinomycin: A cytotoxic polypeptide quinoxaline antibiotic isolated from Streptomyces echinatus that binds to DNA and inhibits RNA synthesis.	1.98	1	0	cyclodepsipeptide
hygromycin b [no description available]	1.98	1	0
methyl jasmonate [no description available]	2.07	1	0
phosphatidylinositol 4-phosphate phosphatidylinositol 4-phosphate : A phosphatidylinositol monophosphate carrying the phosphate group at the 4-position.	2.38	2	0
mln 8237 MLN 8237: an aurora kinase A inhibitor	2.13	1	0	benzazepine
gdc 0449 HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity	2.17	1	0	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent
picrotoxin Picrotoxin: A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the GAMMA-AMINOBUTYRIC ACID-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates.. picrotoxin : A mixture consisting of equimolar amounts of picrotoxinin and picrotin found in the climbing plant Anamirta cocculus.	1.99	1	0
ponatinib [no description available]	4.84	5	0	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor
quizartinib [no description available]	9.6	20	1	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor
pervanadate pervanadate: from a mixture of orthovanadate and hydrogen peroxide	8.7	10	0
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	2.4	2	0
rimorphin rimorphin: tridecapeptide NH2-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-COOH from bovine posterior pituitary gland; major leucine enkephalin containing peptide in tissue that contains dynorphin & alpha-neo-endorphin	1.98	1	0
dynorphins dynorphin (1-13): potent opioid peptide; see also record for dynorphin & D-Ala(2)-dynorphin (1-11)	2	1	0
neurotensin neurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91	7.92	4	0	peptide hormone	human metabolite; mitogen; neurotransmitter; vulnerary
atrial natriuretic factor (4-23)nh2, de-gln(18)-de-ser(19)-de-gly(20,22)-de-leu(21)- [no description available]	2	1	0
protein kinase c [no description available]	2.4	2	0
adrenocorticotropic hormone [no description available]	1.99	1	0
incb-018424 [no description available]	2.25	1	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
entrectinib entrectinib: inhibits TRK, ROS1, and ALK receptor tyrosine kinases; structure in first source. entrectinib : A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours.	3.27	1	0	benzamides; difluorobenzene; indazoles; N-methylpiperazine; oxanes; secondary amino compound; secondary carboxamide	antibacterial agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
mannans [no description available]	2.02	1	0
alexa fluor 546 Alexa fluor 546: a fluorescent dye	2.1	1	0	organic heteropentacyclic compound	fluorochrome
glasdegib glasdegib: a smoothened inhibitor. glasdegib : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a (2R,4S)-4-{[(4-cyanophenyl)carbamoyl]amino}-1-methylpiperidin-2-yl group at position 2. It is a hedgehog signalling pathway inhibitor that acts by binding to Smoothened (SMO) receptors and blocking signal transduction (IC50 = 5 nM). It is used in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients (aged >= 75 years), or who have medical conditions that prevent the use of standard chemotherapy.	5.36	4	0	benzimidazoles; nitrile; phenylureas; piperidines	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist
to-pro-3 TO-PRO-3: a cyanine nucleic acid dye; a membrane-impermeant modification of the dye thiazole orange; excited by a 647-nm laser beam and fluoresces in the far red of the spectrum. To-Pro-3 : An unsymmetrical C3 cyanine dye having benzothiazolium-2-yl and quinolinium-4-yl substituents.	2.11	1	0	cyanine dye; organic iodide salt	fluorochrome
gsk 1363089 GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source	2.21	1	0	aromatic ether
ganglioside, gd1a [no description available]	2.69	3	0
phenylalanyl-leucyl-leucyl-arginyl-asparagine phenylalanyl-leucyl-leucyl-arginyl-asparagine: a pentapeptide; an inhibitor of TRP-mediated platelet aggregation	1.98	1	0
glycolipids [no description available]	4.02	14	0
pretubulysin pretubulysin: from myxobacteria; structure in first source	2.1	1	0
piperidines Piperidines: A family of hexahydropyridines.	10.4	50	0
bryostatin 1 bryostatin 1: a protein kinase C activator; macrocyclic lactone from marine Bryozoan Bugula neritina; RN given refers to (1S-(1R,3R,5Z,7S,8E,11R,12R(2E,4E),13E,15R,17S(S),21S,23S,25R))-isomer; structure given in first source; activates protein kinase c. bryostatin 1 : A member of the class of bryostatins that is (17E)-2-oxooxacyclohexacos-17-ene which is substituted by hydroxy groups at positions 4, 10, and 20; an acetoxy group at position 8; methyl groups at positions 9, 9, 18, and 19; 2-methoxy-2-oxoethylidene groups at positions 14 and 24; an (E,E)-octa-2,4-dienoyloxy group at position 21; and with oxygen bridges linking positions 6 to 10, 12 to 16, and 20 to 24. It is one of the most abundant member of the class of bryostatins.	11.44	18	0
thymosin Thymosin: Thymosin. A family of heat-stable, polypeptide hormones secreted by the thymus gland. Their biological activities include lymphocytopoiesis, restoration of immunological competence and enhancement of expression of T-cell characteristics and function. They have therapeutic potential in patients having primary or secondary immunodeficiency diseases, cancer or diseases related to aging.	2.44	2	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	4.43	22	0
kahalalide f kahalalide F: a cyclodepsipeptide toxin; isolated from a mollusk, Elysia rubefescens; exhibits antitumoral activity against cell lines of colon cancer and prostatic cancer; structure given in first source	3.18	1	0
thiopental sodium [no description available]	2.08	1	0	organochlorine compound; piperazines; pyrimidines	antineoplastic agent; tyrosine kinase inhibitor
hydroxocobalamin Hydroxocobalamin: Injectable form of VITAMIN B 12 that has been used therapeutically to treat VITAMIN B 12 DEFICIENCY.	2.1	1	0
exenatide Exenatide: A synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exenatide increases CYCLIC AMP levels in pancreatic acinar cells and acts as a GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist and incretin mimetic, enhancing insulin secretion in response to increased glucose levels; it also suppresses inappropriate glucagon secretion and slows gastric emptying. It is used an anti-diabetic and anti-obesity agent.	2.07	1	0
3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol 3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol: inhibits ALK2 protein; structure in first source	2.17	1	0
aplysiatoxin aplysiatoxin: structure. aplysiatoxin : The parent member of the class of aplysiatoxins. It is a cyanotoxin produced by several species of freshwater and marine cyanobacteria, as well as algae and molluscs.	1.98	1	0	aplysiatoxins; bromophenol; cyclic hemiketal; ether; organic heterotricyclic compound; secondary alcohol; spiroketal	algal metabolite; carcinogenic agent; cyanotoxin; marine metabolite; protein kinase C agonist
gsk 2334470 GSK 2334470: a PDK1 inhibitor; structure in first source	2.1	1	0	indazoles
englerin a [no description available]	2.07	1	0	cinnamate ester; glycolate ester; guaiane sesquiterpenoid	antineoplastic agent; metabolite
chymostatin [no description available]	2.02	1	0
gilteritinib gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor. gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.	8.94	23	0	aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	7.02	13	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
butyrolactone i butyrolactone I: selective inhibitor of cdk2 & cdc2 kinase; structure given in first source	3.08	1	0	butenolide
pf-4708671 [no description available]	2.1	1	0
nvp-cgm097 NVP-CGM097: an MDM2 and HDM2 inhibitor; structure in first source	2.11	1	0
vasoactive intestinal peptide Vasoactive Intestinal Peptide: A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).	3.37	7	0
natriuretic peptide, brain Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.	4	5	0	polypeptide
heme Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.	2.42	2	0
leukotoxin leukotoxin: do not confuse with leukotoxin which is 9,10-epoxy-12-octadecenoate	2.39	2	0
heparitin sulfate Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.	2.02	1	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.7	3	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	2.41	2	0
chlortetracycline Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.	1.98	1	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	3.13	5	0
salicylates Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.	2.94	4	0	monohydroxybenzoate	plant metabolite
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	4.9	11	0	benzenes; hydroxycoumarin; methyl ketone
antimycin [no description available]	2.44	2	0
betalains Betalains: Compounds derived from TYROSINE via betalamic acid, including BETAXANTHINS and BETACYANINS. They are found in the Caryophyllales order of PLANTS and some BASIDIOMYCETES.	3.1	1	0
omega-agatoxin iva omega-Agatoxin IVA: A neuropeptide toxin from the venom of the funnel web spider, Agelenopsis aperta. It inhibits CALCIUM CHANNELS, P-TYPE by altering the voltage-dependent gating so that very large depolarizations are needed for channel opening. It also inhibits CALCIUM CHANNELS, Q-TYPE.	2	1	0
snx 230 omega-conotoxin-MVIIC: isolated from Conus magus; amino acid sequence given in first source	2.4	2	0
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	5.57	71	0
microcystin microcystin: microcystins have the general structure cyclo(D-Ala-L-X-D-erythro--methylisoasp-L-Y-Adda-D-isoGlu-N-methyldehydroAla) where X and Y are variable L-amino acids;. microcystin : A family of cyclic heptapeptide hepatotoxins produced by a number of cyanobacteria, the most notable of which is Microcystis, from which the name of the family is derived. Microcystins consist of a heptapeptide macrocycle made up of five non-protein amino acids and two protein amino acids.	3.1	5	0	peptide
charybdotoxin [no description available]	2.92	4	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	6.27	56	0
phytoestrogens Phytoestrogens: Compounds derived from plants, primarily ISOFLAVONES that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS.	2.43	2	0
okadaic acid Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.	6.44	169	0	ketal
phosphatidylethanol phosphatidylethanol: formed in rat brain by phospholipase D. phosphatidylethanol : A glycerophospholipid that is the monoethyl ester of any phosphatidic acid.	4.12	16	0
ceritinib ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.	2.13	1	0	aminopyrimidine; aromatic ether; organochlorine compound; piperidines; secondary amino compound; sulfone	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
pyrethrins [no description available]	2.4	2	0
debio 1347 CH5183284: a fibroblast growth factor receptor antagonist; structure in first source	2.17	1	0
maitotoxin [no description available]	3.4	7	0
agar Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.	2.41	1	0
ivosidenib ivosidenib: an inhibitor of isocitrate dehydrogenase 1 (IDH1) for treatment of acute myeloid leukemia (AML). ivosidenib : A tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation.	5.68	6	0	cyanopyridine; monochlorobenzenes; organofluorine compound; pyrrolidin-2-ones; secondary carboxamide; tertiary carboxamide	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
hirudin Hirudin: A 65-residue polypeptide from LEECHES.	2.67	3	0
formycin triphosphate formycin triphosphate: formycin ATP analog	1.98	1	0
imetelstat [no description available]	4.05	2	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	8.96	13	0
caseins Caseins: A mixture of related phosphoproteins occurring in milk and cheese. The group is characterized as one of the most nutritive milk proteins, containing all of the common amino acids and rich in the essential ones.	3.09	5	0
ly 355703 cryptophycin 52: an antimitotic antitumor agent; structure in first source	2.01	1	0
ap20187 AP20187: a nontoxic, cell-permeable analog, a wholly synthesized, cell-permeable dimeric FK506 derivative. AP20187 : A tertiary amino compound that is 2-(aminomethyl)-N,N-dimethylpropane-1,3-diamine in which the primary ammino groups have each been acylated by condensation with the carboxy group of 2-{3-[(1R)-3-(3,4-dimethoxyphenyl)-1-hydroxypropyl]phenoxy}acetic acid, the hydroxy groups of which have been esterified by condensation with the carboxy group of L-pipecolic acid, the nitrogen of which has been acylated by condensation with (2S)-2-(3,4,5-trimethoxyphenyl)butyric acid. It is a synthetic, cell-permeable ligand that can be used to induce homodimerization of fusion proteins containing the DmrB domain.	2.05	1	0	aromatic ether; carboxylic ester; N-acylpiperidine; tertiary amino compound	ligand
oligomycins Oligomycins: A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X).	3.71	10	0
asbestos, crocidolite Asbestos, Crocidolite: A lavender, acid-resistant asbestos.	1.99	1	0
carubicin Carubicin: A very toxic anthracycline-type antineoplastic related to DAUNORUBICIN, obtained from Actinomadura carminata.. carminomycin(1+) : An anthracyline cation that is the conjugate acid of carminomycin, obtained by protonation of the amino group.	1.99	1	0	anthracycline cation
g(m3) ganglioside G(M3) Ganglioside: A ganglioside present in abnormally large amounts in the brain and liver due to a deficient biosynthetic enzyme, G(M3):UDP-N-acetylgalactosaminyltransferase. Deficiency of this enzyme prevents the formation of G(M2) ganglioside from G(M3) ganglioside and is the cause of an anabolic sphingolipidosis.. alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/24:1(15Z)) : A sialotriaosylceramide consisting of beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc attached to the primary hydroxy function of ceramide(d18:1/24:1(15Z)).	2	1	0	alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide; sialodiosylceramide; sialotriaosylceramide	mouse metabolite
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	6.69	85	0
s-nitroglutathione S-nitroglutathione: structure in first source	2	1	0
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.79	3	0
bassianolide bassianolide: cyclodepsipeptide from mycelia of Beauveria bassiana; inhibits isotonic contractions induced by acetylcholine. bassianolide : A cyclodepsipeptide consisting of a cyclic tetramer of the depsipeptide D-Hiv-N-methyl-L-leucine (where D-Hiv = D-alpha-hydroxyisovaleric acid). Found in the fungal species Beauveria bassiana and Verticillium lecanii, it has insecticidal properties and is used as a commercial biopesticide to control of insects of agricultural, veterinary and medical significance. For elucidation of the structure, see Suzuki et al., Tetrahedron Lett. 1977 v25, 2167-2170.	1.99	1	0	cyclodepsipeptide; cyclooctadepsipeptide	antineoplastic agent; fungal metabolite; insecticide
enasidenib [no description available]	6.1	8	0	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
calpastatin calpastatin: large mol wt, heat-stable calpain inhibitor; not based on sequestering Ca++ from medium, but binding to calpain does require Ca++. calpastatin peptide Ac 184-210 : A 27-membered polypeptide comprising the sequence Ac-Asp-Pro-Met-Ser-Ser-Thr-Tyr-Ile-Glu-Glu-Leu-Gly-Lys-Arg-Glu-Val-Thr-Ile-Pro-Pro-Lys-Tyr-Arg-Glu-Leu-Leu-Ala-NH2. An acetylated synthetic peptide from human calpastatin that strongly inhibits both calpains I and II but not papain (a cysteine protease) or trypsin (a serine protease).	2.71	3	0	polypeptide	EC 3.4.22.52 (calpain-1) inhibitor; EC 3.4.22.53 (calpain-2) inhibitor
angiotensin i Angiotensin I: A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.. angiotensin I : A ten amino acid peptide formed by renin cleavage of angiotensinogen. Angiotensin I has no direct biological function except that high levels can stimulate catecholamine production. It is metabolized to its biologically active byproduct angiotensin II, a potent vasoconstrictor, by angiotensin converting enzyme (ACE) through cleavage of the two terminal amino acids.. angiotensin I dizwitterion : A peptide zwitterion that is the dizwitterionic form of angiotensin I having both carboxy groups deprotonated and the aspartyl amino group and arginine side-chain protonated. It is the major species at pH 7.3.	2.4	2	0	angiotensin; peptide zwitterion	human metabolite; neurotransmitter agent
hyaluronoglucosaminidase Hyaluronoglucosaminidase: An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS.	3.1	5	0
adrenomedullin Adrenomedullin: A 52-amino acid peptide with multi-functions. It was originally isolated from PHEOCHROMOCYTOMA and ADRENAL MEDULLA but is widely distributed throughout the body including lung and kidney tissues. Besides controlling fluid-electrolyte homeostasis, adrenomedullin is a potent vasodilator and can inhibit pituitary ACTH secretion.	7.69	3	0
protein kinase c [no description available]	2.9	1	0
lipofectamine Lipofectamine: mediates gene transfer; a polycationic lipid reagent	2.05	1	0
sta 2 STA 2: thromboxane A2 agonist; structure given in first source	2.38	2	0
7-oxostaurosporine 7-oxostaurosporine: structure given in first source; isolated from Streptomyces platensis malvinus; inhibits the cell cycle progression at G2 phase of human chronic erythroleukemia cells K-562	3.11	5	0
oridonin [no description available]	2.02	1	0
gibberellins [no description available]	2.7	3	0
quinomycin quinomycin: RN given refers to cpd with unknown MF; see also echinomycin for quinomycin A: 512-64-1; structure	1.98	1	0
oblimersen oblimersen: targets the Bcl-2 oncogene good efficacy with low toxicity tumour regressions	3.11	1	0
aprinocarsen ISIS 3521: 20-nucleotide phosphorothioate antisense molecule that targets protein kinase C-alpha isoenzyme	3.11	1	0
oxyntomodulin Glucagon-Like Peptides: Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.	1.97	1	0
transforming growth factor alpha Transforming Growth Factor alpha: An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.	3.08	5	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	4.97	38	0
cytochalasin d Cytochalasin D: A fungal metabolite that blocks cytoplasmic cleavage by blocking formation of contractile microfilament structures resulting in multinucleated cell formation, reversible inhibition of cell movement, and the induction of cellular extrusion. Additional reported effects include the inhibition of actin polymerization, DNA synthesis, sperm motility, glucose transport, thyroid secretion, and growth hormone release.. cytochalasin D : An organic heterotricyclic compound that is a mycotoxin produced by Helminthosporium and other moulds which is cell permeable and a potent inhibitor of actin polymerisation and DNA synthesis.	9.95	37	0
apicidin apicidin: structure in first source	2.03	1	0
lactoferrin Lactoferrin: An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.	2.91	4	0
digitonin Digitonin: A glycoside obtained from Digitalis purpurea; the aglycone is digitogenin which is bound to five sugars. Digitonin solubilizes lipids, especially in membranes and is used as a tool in cellular biochemistry, and reagent for precipitating cholesterol. It has no cardiac effects.. digitonin : A spirostanyl glycoside that is digitogenin in which the 3-hydroxy group is substituted by a beta-D-glucopyranosyl-(1->3)-beta-D-galactopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->3)]-beta-D-glucopyranosyl-(1->4)-beta-D-galactopyranosyl group. It is a steroidal saponin isolated from the foxglove plant, Digitalis purpurea. It is used extensively as a mild non-ionic detergent for extracting proteins from membranes for structure and function studies.	8.87	12	0
o-methyl-serine dodecylamide hydrochloride O-methyl-serine dodecylamide hydrochloride: a lysosomotropic detergent	2.06	1	0
rs100642 RS100642: sodium channel blocker, neuroprotectant and anti-seizure agent in a rat model of transient middle cerebral artery occlusion	2.01	1	0
thromboplastin Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.	4.08	15	0
muramidase Muramidase: A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17.	3.36	7	0
amyloid beta-peptides amyloid beta-protein (1-40): although acutely neurotoxic in both rat & monkey cerebral cortex, neuronal degeneration in primates resembles more closely to that found in Alzheimer's disease; amino acid sequence has been determined	2.73	3	0
plicamycin mithramycin A: structure given in first source	2.08	1	0
tautomycin tautomycin: an inhibitor of protein phosphatases 1 and 2A; isolated from Streptomyces spiroverticillatus; MF: C42-H70-O12; exists as a tautomeric mixture in solution	3.09	5	0
euk-189 EUK-189: a salen Mn compound that mimics the action of catalase; structure in first source	2	1	0
8-oxodeoxyguanosine triphosphate 8-oxodeoxyguanosine triphosphate: mutagenic nucleotide; hydrolyzed by 8-oxodGTPase to 8-oxodGMP. 8-oxo-dGTP : A purine 2'-deoxyribonucleoside 5'-triphosphate having 8-oxo-7,8-dihydroguanine as the nucleobase.	2.01	1	0	purine 2'-deoxyribonucleoside 5'-triphosphate	mutagen
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	5.11	44	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
deoxyguanosine [no description available]	2.04	1	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
7,8-dihydroneopterin 7,8-dihydroneopterin: an antioxidant. 7,8-dihydroneopterin : A neopterin where positions C-7 and C-8 have been hydrogenated.	2.01	1	0	dihydropterin; neopterins	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanosine diphosphate Guanosine Diphosphate: A guanine nucleotide containing two phosphate groups esterified to the sugar moiety.	4.13	16	0	guanosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	5.49	21	0	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanine [no description available]	3.26	6	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose.	2.41	2	0	guanosines; purines D-ribonucleoside	fundamental metabolite
hypoxanthine [no description available]	1.98	1	0	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite
inosinic acid Inosine Monophosphate: Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.	2.38	2	0	inosine phosphate; purine ribonucleoside 5'-monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
inosine triphosphate Inosine Triphosphate: Inosine 5'-(tetrahydrogen triphosphate). An inosine nucleotide containing three phosphate groups esterified to the sugar moiety. Synonym: IRPPP.	2.68	3	0	inosine phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	2.72	3	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
3-methyladenine N3-methyladenine: structure in first source	2.05	1	0
queuine [no description available]	2.39	2	0	pyrrolopyrimidine	Escherichia coli metabolite
guanosine 5'-o-(3-thiotriphosphate) Guanosine 5'-O-(3-Thiotriphosphate): Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.	5.14	46	0	nucleoside triphosphate analogue
neopterin [no description available]	2.01	1	0
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	4.93	4	2	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.44	2	0	dacarbazine
ganciclovir [no description available]	2.41	2	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
zaprinast zaprinast: anaphylaxis inhibitor; structure	1.99	1	0	triazolopyrimidines
chir-124 [no description available]	2.06	1	0
2-methyl-6-(4-methoxyphenyl)-3,7-dihydroimidazo(1,2-alpha)pyrazin-3-one 2-methyl-6-(4-methoxyphenyl)-3,7-dihydroimidazo(1,2-alpha)pyrazin-3-one: cypridina luciferin analog	2.01	1	0
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	3.26	6	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
guanylyl imidodiphosphate Guanylyl Imidodiphosphate: A non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+. The nucleotide is a potent stimulator of ADENYLYL CYCLASES.. guanosine 5'-[beta,gamma-imido]triphosphate : A nucleoside triphosphate analogue that is GTP in which the oxygen atom bridging the beta- to the gamma- phosphate is replaced by a nitrogen atom A non-hydrolyzable analog of GTP, it binds tightly to G-protein in the presence of Mg(2+).	3.08	5	0	nucleoside triphosphate analogue
guanosine 5'-o-(2-thiodiphosphate) [no description available]	3.69	10	0	nucleoside diphosphate analogue
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	2.05	1	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
loxoribine [no description available]	1.97	1	0
hymenialdisine [no description available]	3.25	1	0
isogranulatimide isogranulatimide: G2 checkpoint inhibitor; structure in first source	1.99	1	0
xav939 XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source. XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.	2.17	1	0	(trifluoromethyl)benzenes; thiopyranopyrimidine	tankyrase inhibitor
8-bromocyclic gmp 8-bromo-3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic GMP bearing an additional bromo substituent at position 8 on the guanine ring. A membrane permeable cGMP analogue that activates protein kinase G (PKG). It is 4.3-fold more potent than cGMP in activating PKG1alpha and promotes relaxation of tracheal and vascular smooth muscle tissue in vitro.	3.59	9	0	3',5'-cyclic purine nucleotide; organobromine compound	muscle relaxant; protein kinase G agonist
trypan blue Trypan Blue: A diazo-naphthalene sulfonate that is widely used as a stain.. trypan blue : An organosulfonate salt that is the tetrasodium salt of 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonic acid).	2.93	4	0
nintedanib nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.	2.17	1	0
7-methyl-8-oxoguanosine [no description available]	1.97	1	0
methylnitronitrosoguanidine Methylnitronitrosoguanidine: A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties.. N-methyl-N'-nitro-N-nitrosoguanidine : An N-nitroguanidine compound having nitroso and methyl substituents at the N'-position	3.12	5	0	nitroso compound	alkylating agent
8-hydroxy-2'-deoxyguanosine 8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.	2.04	1	0	guanosines	biomarker
bms 536924 BMS 536924: inhibits insulin-like growth factor I receptor kinase; structure in first source	2.17	1	0
8-((4-chlorophenyl)thio)cyclic-3',5'-gmp 8-(4-chlorophenylthio)-cGMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic GMP in which the hydrogen at position 2 on the purine fragment is replaced by a 4-chlorophenylthio group.	1.99	1	0	3',5'-cyclic purine nucleotide; aryl sulfide; organochlorine compound; ribonucleotide	protein kinase agonist
debromohymenialdisine [no description available]	2.01	1	0
prodigiosin Prodigiosin: 4-Methoxy-5-((5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl)- 2,2'-bi-1H-pyrrole. A toxic, bright red tripyrrole pigment from Serratia marcescens and others. It has antibacterial, anticoccidial, antimalarial, and antifungal activities, but is used mainly as a biochemical tool.. prodigiosin : A member of the class of tripyrroles that is a red-coloured pigment with antibiotic properties produced by Serratia marcescens.	2.5	2	0
8-nitroguanosine 3',5'-cyclic monophosphate 8-nitroguanosine 3',5'-cyclic monophosphate: a signal for protein S-guanylation; structure in first source. 8-nitroguanosine 3',5'-cyclic monophosphate : A 3',5'-cyclic purine nucleotide that is guanosine 3',5'-cyclic monophosphate in which the hydrogen at position 8 on the purine fragment has been replaced by a nitro group.	2.06	1	0	3',5'-cyclic purine nucleotide; C-nitro compound	biomarker; Brassica napus metabolite; human metabolite; signalling molecule
formycins Formycins: Pyrazolopyrimidine ribonucleosides isolated from Nocardia interforma. They are antineoplastic antibiotics with cytostatic properties.	1.98	1	0
undecylprodigiosin prodigiosin 25C: red pigment produced by Streptomyces hiroshimensis; potent immunosuppressive agent with its primary effect on functions of T cells; structure given in first source. undecylprodigiosin : A member of the class of tripyrroles that is 1H-pyrrole substituted by (4'-methoxy-1H,5'H-[2,2'-bipyrrol]-5'-ylidene)methyl and undecyl groups at positions 2 and 5, respectively. It is a pigment produced by Stveptomyces coelicolor.	2.25	1	0	alkaloid; aromatic ether; tripyrrole	antibacterial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; biological pigment; immunosuppressive agent; radiosensitizing agent
nucleoside q Nucleoside Q: A modified nucleoside which is present in the first position of the anticodon of tRNA-tyrosine, tRNA-histidine, tRNA-asparagine and tRNA-aspartic acid of many organisms. It is believed to play a role in the regulatory function of tRNA. Nucleoside Q can be further modified to nucleoside Q*, which has a mannose or galactose moiety linked to position 4 of its cyclopentenediol moiety.. queuosine : A nucleoside found in tRNA that has an additional cyclopentenyl ring added via an NH group to the methyl group of 7-methyl-7-deazaguanosine. The cyclopentenyl ring may carry other substituents.	2	1	0	7-deazaguanine ribonucleoside
guanosine 5'-o-(1-thiotriphosphate) [no description available]	1.99	1	0
pf-477736 PF 00477736: a Chk1 inhibitor; structure in first source. PF-00477736 : A diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1).	2.05	1	0
dibutyryl cyclic gmp Dibutyryl Cyclic GMP: N-(1-Oxobutyl)-cyclic 3',5'-(hydrogen phosphate)-2'-butanoate guanosine. A derivative of cyclic GMP. It has a higher resistance to extracellular and intracellular phosphodiesterase than cyclic GMP.	3.08	5	0
3-cyano-5-(4-pyridyl)-6-hydrazonomethyl-2-pyridone 3-cyano-5-(4-pyridyl)-6-hydrazonomethyl-2-pyridone: inhibits DNA-activated protein kinase (DNA-PK); structure in first source	2	1	0
eye [no description available]	1.98	1	0
goadsporin goadsporin: structure in first source	3.14	1	0
picroside ii picroside II: RN given for (1aS-(1aalpha,1bbeta,2beta,5abeta,6beta,6abeta))-isomer; structure in first source	2.01	1	0
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	4.98	15	0
metallothionein Metallothionein: A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals.	2.69	3	0
yo-pro 1 YO-PRO 1: a generally membrane impermeable fluorescent dye	2.71	3	0
nk314 NK314: a benzo[c]phenanthridine that inhibits topoisomerase IIalpha and G2 cell cycle arrest; structure in first source	2.03	1	0
biphenylylacetic acid biphenylylacetic acid: metabolite of BHD 7538; RN given refers to cpd with unspecified locants for acetic acid moities	2.05	1	0
2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein [no description available]	3.08	5	0
phosphorus radioisotopes Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.	4.07	15	0
phosphatidylbutanol [no description available]	2.39	2	0
preproenkephalin preproenkephalin: initial enkephalin precursor	1.98	1	0
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	3.94	13	0
tetrafluoroaluminate tetrafluoroaluminate: induces inositol phosphate formation	2.9	4	0
filipin Filipin: A complex of polyene antibiotics obtained from Streptomyces filipinensis. Filipin III alters membrane function by interfering with membrane sterols, inhibits mitochondrial respiration, and is proposed as an antifungal agent. Filipins I, II, and IV are less important.	2.41	2	0
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	2.92	4	0

staurosporine

Description

Cross-References

Synonyms (101)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (3)

Pathways (4)

Protein Targets (537)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (2953)

Molecular Functions (482)

Ceullar Components (394)

Bioassays (4260)

Research

Studies (6,488)

Market Indicators

Research Demand Index: 52.42

Study Types

Clinical Trials (10)

Trial Overview

Trial Outcomes

Duration of Response

Maximum Tolerated Dose of Midostaurin in Combination With Azacitidine in Patients With Acute Myelogenous Leukemia (Phase I)

Number of Participants With Hematologic Improvement (Phase I)

Overall Survival (Phase II)

Toxicity Profile (Phase II)

Complete Remission (CR) Rate

Median Duration of Response (DoR)

Overall Response Rate (ORR)

Overall Survival (OS)

Progression-free Survival (PFS)

staurosporine

Description

Cross-References

Synonyms (101)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (3)

Pathways (4)

Protein Targets (537)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (2953)

Molecular Functions (482)

Ceullar Components (394)

Bioassays (4260)

Research

Studies (6,488)

Market Indicators

Research Demand Index: 52.42

Study Types

Clinical Trials (10)

Trial Overview

Trial Outcomes

Duration of Response

Maximum Tolerated Dose of Midostaurin in Combination With Azacitidine in Patients With Acute Myelogenous Leukemia (Phase I)

Number of Participants With Hematologic Improvement (Phase I)

Overall Survival (Phase II)

Toxicity Profile (Phase II)

Complete Remission (CR) Rate

Median Duration of Response (DoR)

Overall Response Rate (ORR)

Overall Survival (OS)

Progression-free Survival (PFS)

Related Drugs (3,426)

Related Conditions (933)